<SEC-DOCUMENT>0001558370-23-003650.txt : 20230314
<SEC-HEADER>0001558370-23-003650.hdr.sgml : 20230314
<ACCEPTANCE-DATETIME>20230314093039
ACCESSION NUMBER:		0001558370-23-003650
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230314
DATE AS OF CHANGE:		20230314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Virios Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001818844
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				854314201
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39811
		FILM NUMBER:		23729376

	BUSINESS ADDRESS:	
		STREET 1:		44 MILTON AVENUE
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30009
		BUSINESS PHONE:		8666208655

	MAIL ADDRESS:	
		STREET 1:		44 MILTON AVENUE
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Virios Therapeutics, LLC
		DATE OF NAME CHANGE:	20200721
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tmb-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/13/2023 10:39:15 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: e4827c70-80d6-4a11-804c-092681e3a5a7 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:viri="http://www.virios.com/20221231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" xs:nil="true" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_lZFub5RiNEaT10GhfCSmMg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" xs:nil="true" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_nSxxnShqC0ms8I3lL-ScrA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" xs:nil="true" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" name="us-gaap:PreferredStockValue" id="Hidden_g98_LEx6m0iGYU0oez53mQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" xs:nil="true" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" name="us-gaap:PreferredStockValue" id="Hidden_H490oChYRUiWywnG5LXpSQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Hidden_fShwsexZgUqxezn77bjtyQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Hidden_P2p0tDP4lU2AYmbbheUymA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_MhJuUiG5jEG0ZWPo8EvG4A">1.11</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_WF2qwdt_CEm6Zk4VcPToSw">1.92</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_8OtyTsZAIU6iOHmtIfjT1A">11070116</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_pJLaGSLK5USc2kdWUT-cdg">8329310</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityCentralIndexKey" id="Tc_5_Xy6zwY8k-0WrAHtohZrw_2_1">0001818844</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:DocumentFiscalYearFocus" id="Tc_DVUl0Fm3QUWkMcjaIWjbbQ_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:DocumentFiscalPeriodFocus" id="Tc_L8mugFSx0UeKqnknKgsZ1w_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:AmendmentFlag" id="Tc_LHPwOb2JFkuKkvTGNL1fIg_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityRegistrantName" id="Hidden_DaqBv8HmyEyA7xikWYGzsw">Virios Therapeutics, Inc.</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:SecurityExchangeName" id="Hidden_Q5qZWOLpJUCZAh_89hTyVw">NASDAQ</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_oHnHAxEtjkSEk0DF-WTqiA">18330390</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_JxC-36GfvUKSaH-OXfQG3A">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_sdXhQbgcvUWsTh4eEyGrAg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Hidden_VfwIj3Fs2EKwWsM1T_o8Qw">0.0001</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_VYcd50m3f0yVEciBOooblw">8330390</ix:nonFraction><ix:nonNumeric contextRef="Duration_6_16_2022_To_6_16_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_p9GEDysUj0yLr6kbN6USkA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_zpYbTwNkCEuu23buIe0eJQ">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_21_2021_UH5_wupqpEWPUP_czHBCeA" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_qp_BKBo_iESKd88pDgZH3g">P5Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tmb-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_S_a8HrS8Ike_exmqyqXIMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_LDUdwdZQkU2vEFN0QuBgEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_xfm2EfLia0i3nez_VARJng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_07boxe2rbUysaeH7Ihz82A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">viri:ChiefMedicalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_VicePresidentOperationsAndFinanceMember_X9NqiprFVkeF2f-E51b3HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">viri:VicePresidentOperationsAndFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_9Fj9-utpbkORtVRzg81GPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2020_To_9_10_2020_RVDodrV4eECIJMPDAPhQBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-10</xbrli:startDate><xbrli:endDate>2020-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">viri:ChiefMedicalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2012_To_12_31_2012_us-gaap_TypeOfArrangementAxis_viri_KnowHowLicenseAgreementMember_v_HMShg6JkeIz5pkc4ARKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">viri:KnowHowLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_ujddVzlF9kmGOtaxPWQprg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_19_2022_To_9_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FjS6TDESSkSjA8g43D0JKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-19</xbrli:startDate><xbrli:endDate>2022-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mTuQdj48xkSPPkeT8q6HWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4-H-oXcCNESU_xrftuaLnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZScAQIaW_km0W4UmK9ailg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_585XaE_Qb06wg3yY8VCAnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9rd8UeAZvkiyb61_0b58xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TTmYcU_i-kGxQDW5uKyINw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xSxWfKQTuEmBuKVtKLpaYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_na0T6F0WK0iSAkJB4vdliQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m9xCbfrpkkuZH2FpqooItA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bmANR8woWk2jfaAekf9q_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_f6XxsTWSbk6n_wNrDUfYkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_HfIQGNlGO0GfJuvJzN6shA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_PSW_ICNFWUWC815QcUkHTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_16_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_EKNzGamAM0e5Uudfko5Mbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_16_2022_To_6_16_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Sy6PBJsphU-CRbISsoIF6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-16</xbrli:startDate><xbrli:endDate>2022-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_16_2022_To_6_16_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_kJHmoKVpsEyo6AaXVE_bJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-16</xbrli:startDate><xbrli:endDate>2022-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ikj9w2rCj0izLrRvksWE6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_qgz0o95s_0aPxtVxKLV_Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ClZ-Zp5G-kmzZkhdCCktbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_jfwr1MSSHkK724vOCV_g2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_16_2022_To_6_16_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_p9GEDysUj0yLr6kbN6USkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-16</xbrli:startDate><xbrli:endDate>2022-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">viri:NonQualifiedStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yFCbkitpnUybTr1oZGQIXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_iX6ZkNMhbEeXsuVhLuePbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_epi_lHMtoEOuSGGUHTT6cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iwzJfTl-OUiIleLyhau04g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_Qf178jUjQ0m0mIlYgP4eGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_npYg-xxOqkqKwXBoOxfd0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_X5Y3MAAZ80-3sQBqUVtS-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">viri:GendreauConsultingLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_uEjU9DNz10qTagf5uNcBwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">viri:GendreauConsultingLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-19</xbrli:startDate><xbrli:endDate>2022-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_20_2021_To_12_20_2021_srt_LitigationCaseAxis_viri_TorreyaCapitalLlcMember_593RpFikOES1pICvYkGC7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">viri:TorreyaCapitalLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aWecVCFl10-XycTsN-tb1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nhUquGnkwkWL4lFfC9GfAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_26_2021_To_8_26_2021_srt_LitigationCaseAxis_viri_TorreyaCapitalLlcMember_U8Q3TkmcJkCKXKS_Ao-Drw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">viri:TorreyaCapitalLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-26</xbrli:startDate><xbrli:endDate>2021-08-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_viri_NorthriverPharmLlcMember_5EL1vFgplUm9u---06s8UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">viri:NorthriverPharmLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_5tEhIARsaEiYoR53c54ELg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">viri:NonQualifiedStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_IXFyCqWULkiAGzccCCWCsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_fA7tndkyWEeG7RdGqTIrYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_21_2021_UH5_wupqpEWPUP_czHBCeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_tCm4u3HF1ESoDqVBr91eXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_J7UBwLt2s02a0dmSAvm0Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_zVHuNo8JJUOL740CgoX5UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_tuCBnQCdJkqjINAChtpNqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aPhBzRC3h0y-kExu1oDuMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_bzvM8doJ10mkpUYJYD_rTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_E57glfgKCUSq3eMsl6w6qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fp9m85ab_kqv2G63PG8esw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_13Xq7gMuT0mkNLo5wF0tow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_VktHnKz5PUWL5c7XiyyBUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">viri:GendreauConsultingLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_XAqJzIFAPEimuSHD-_p6Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">viri:GendreauConsultingLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_6pKaPRrEBEueDT3pVVSG6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_10_2023_gDWxuz6Fxk2oZ4xGHfj6UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818844</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_wR6KQv_y_U6N2ZwjlZ-M-Q"><xbrli:measure>viri:item</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_9e58b28d_7286_4e26_9361_570a5ce7ec05"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:DocumentType" id="Narr_gbct8qp7i0-A4LI14cFoGw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:DocumentAnnualReport" id="Narr_uZ2UOly8v0aO2A0qW_7qhg"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT</b><b style="font-size:6pt;font-weight:bold;"> </b><b style="font-size:9pt;font-weight:bold;">TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:DocumentPeriodEndDate" id="Narr_BUyQLcbick-CmN7OPJNeBw"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:CurrentFiscalYearEndDate" id="Narr_ldpqV8MhKkezda36-GXwWA"><b style="font-size:9pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, 2022</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:DocumentTransitionReport" id="Narr_OLF2kxDHBkGoX1691aACfw"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityFileNumber" id="Narr_3rT7g5MEaUiv_oPODjC15Q"><b style="font-size:9pt;font-weight:bold;">001-39811</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_DaqBv8HmyEyA7xikWYGzsw;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">VIRIOS THERAPEUTICS,&#160;INC.</b></span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_89318a21_7011_49b5_aedb_c3e8aef08abc"></a><a id="Tc_qsQXHP2oTEKHf1xs1V86oA_2_0"></a><a id="Tc_8fHaaN8WG0usU56kyZIu1w_2_1"></a><a id="Tc_u5y7gqA-p0SIT7HaC9rw_Q_4_0"></a><a id="Tc_-pZ0PcgGDUS-eYXHM_Il9w_5_0"></a><a id="Tc_OAAOrbHFh0idCyjLgYU4qg_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityIncorporationStateCountryCode" id="Tc_m9Z7_WSSEkq_r6BZuSvZtw_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityTaxIdentificationNumber" id="Tc_R2tqBK0PB0eBGynG158ffQ_1_1"><b style="font-size:8pt;font-weight:bold;">85-4314201</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(State of Other Jurisdiction of incorporation or Organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityAddressAddressLine1" id="Narr_w0h8kTvOYEiNjDzSeOZ2rQ"><b style="font-size:8pt;font-weight:bold;">44 Milton Avenue</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityAddressCityOrTown" id="Narr_t5avwlTq2kKPp8JavpsEBA"><b style="font-size:8pt;font-weight:bold;">Alpharetta</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityAddressStateOrProvince" id="Narr_2q6Wi1QSU02OO70G05FWVw"><b style="font-size:8pt;font-weight:bold;">GA</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityAddressPostalZipCode" id="Tc_ozGofd8x9k-9c2wRUQBVlw_4_1"><b style="font-size:8pt;font-weight:bold;">30009</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:CityAreaCode" id="Narr_fZSNkIyFRkq4FkD_T0k9PQ"><b style="font-size:8pt;font-weight:bold;">866</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:LocalPhoneNumber" id="Narr_WEDj40NKDkehIROcpjDpDA"><b style="font-size:8pt;font-weight:bold;">620-8655</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_11eb4b0c_1ed8_49b8_9968_9424bf904143"></a><a id="Tc_h5ieSVFi80etZEPXzS-1bQ_1_4"></a><a id="Tc_1gDVCQLWX0q33Xbnk_K69Q_2_0"></a><a id="Tc_oUK04-b950uOvC9o_4WX_Q_2_2"></a><a id="Tc_-WwXbsgUMkODhLcp1mTxlQ_2_4"></a><a id="Tc_LxORtZgPGEu2I-mkEJ7cvA_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name Of Each Exchange</b></p></td></tr><tr><td style="vertical-align:top;width:36.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:top;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:28.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:28.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">On Which Registered</b></p></td></tr><tr><td style="vertical-align:top;width:36.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:Security12bTitle" id="Tc_TDxuqVevZEWMPTpFOImpxw_3_0"><span style="font-size:8pt;">Common Stock, $0.0001 Par Value per Share</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:TradingSymbol" id="Tc_luiKQtU0HUC821X2r7oFKw_3_2"><span style="font-size:8pt;">VIRI</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.52%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Q5qZWOLpJUCZAh_89hTyVw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">Nasdaq</span></span><span style="font-size:8pt;"> Capital Market</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(g)&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">of the Act:  None</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;white-space:pre-wrap;">  </span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_P0mp9CHw-kKXMw7tNu-2Pg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityVoluntaryFilers" id="Narr_lxuImP4xiUSTimITbYWX6A"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityCurrentReportingStatus" id="Narr_c7KNyOmzvU6TmD0XecpoJQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;white-space:pre-wrap;">   No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant has submitted electronically; every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.0405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityInteractiveDataCurrent" id="Narr_QgEmPknhwkqPs-A3pdeEzw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;white-space:pre-wrap;">   No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-indent:0pt;margin:0pt;">Large accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityFilerCategory" id="Narr_l77-gqvJTU24Yga_JlYgfg"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntitySmallBusiness" id="Narr_rnahE-OcX0KZA1errctwTA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityEmergingGrowthCompany" id="Narr_BEJD6L1u_0CT0IcJy7CQbA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityExTransitionPeriod" id="Narr_dzSv5vdVFEKGFrBayhXzkw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:IcfrAuditorAttestationFlag" id="Narr_ttw9KJnN9EiLo9OR1UE-IA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to Section 240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:EntityShellCompany" id="Narr_QBH-kAz-H0K-oklN3avkUA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">As of June 30, 2022, the last business day of the Registrant&#39;s most recently completed second fiscal quarter, the aggregate market value of the Registrant&#8217;s common stock held by non-affiliates of the registrant was $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2022_6pKaPRrEBEueDT3pVVSG6w" decimals="2" name="dei:EntityPublicFloat" id="Narr_1gnbtabwYEu0oaSkWRe9Sg">31,229,227.08</ix:nonFraction> based on the closing sale price as reported on the Nasdaq Capital Market.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">The number of outstanding shares of the Registrant&#8217;s Common Stock as of March 10, 2023 was <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_10_2023_gDWxuz6Fxk2oZ4xGHfj6UA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_iBQJRVkhgE618CJFURdzeA">18,330,390</ix:nonFraction>.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Documents Incorporated by Reference</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Part III incorporates certain information by reference from the definitive proxy statement to be filed by the registrant in connection with the 2023 Annual Meeting of Stockholders (the &quot;Proxy Statement&quot;) with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the year ended December 31, 2022, provided that if such Proxy Statement is not filed within such period, such information will be included in an amendment to this Annual Report on Form 10-K to be filed within such 120-day period</span>.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:14.4pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_1ef431bf_1e7d_4c00_9801_1ce7c32755a3"></a><a id="TOC"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTI_44399"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_673316"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1. Business</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_188664"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1A. Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">41</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_457500"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1B. Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_573127"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">2. Properties</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_628469"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">3. Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_646555"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTII_565441"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">5. Market for Registrant</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8217;</span><span style="font-style:normal;font-weight:normal;">s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_858223"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">6. Selected Financial Data</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">7. Management</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8217;</span><span style="font-style:normal;font-weight:normal;">s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">8. Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_878602"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9A. Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_810311"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9B. Other Information</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIII_541444"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10pt;"><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">10. Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_533479"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">11. Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">13. Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantsFeesandService"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">14. Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PartIV_188453"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">15. Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_375667"><span style="font-style:normal;font-weight:normal;">Item&#160;16. Form 10 K Summary</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">110</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_f0e427b8_acb3_41e5_88b9_bd01c5bc98ca"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K, including &quot;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&quot; in Item&#160;7, contains forward-looking statements. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report on Form&#160;10-K are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form&#160;10-K and are subject to a number of risks, uncertainties and assumptions described under the sections in this Annual Report on Form&#160;10-K titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report on Form&#160;10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_71850eba_2d52_44af_b73a_6fdcf2fbd1dc"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">SUMMARY OF RISK FACTORS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">The following is a summary of the principal risks described below in Part I, Item 1A &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. We believe that the risks described in the &#8220;Risk Factors&#8221; section are material to investors, but other factors not presently known to us or that we currently believe are immaterial may also adversely affect us. The following summary should not be considered an exhaustive summary of the material risks facing us, and it should be read in conjunction with the &#8220;Risk Factors&#8221; section and the other information contained in this Annual Report on Form 10-K.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require additional capital to fund our operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history and no history of commercializing pharmaceutical products.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are heavily dependent on the success of IMC-1, our lead candidate, which is still under clinical development, and if this candidate does not receive regulatory approval or, if approved, our commercialization efforts are unsuccessful, our business may be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We may face future business disruption and related risks from the spread of infectious disease, including coronavirus 2019 variants, which could have a material adverse effect on our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are ultimately unable to obtain regulatory approval for any of our product candidates, our business will be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The market opportunities for IMC-1, if approved, may be smaller than we anticipate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We may never obtain approval for or commercialize IMC-1 or any other development candidate in any other jurisdiction, which would limit our ability to realize their full global market potential.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Commercialization</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if IMC-1 or any other candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing IMC-1, if approved.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Dependence on Third Parties</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of IMC-1 and intend to rely on CMOs for the production of commercial supply of IMC-1, if approved.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We intend to rely on third parties to conduct, supervise and monitor our clinical trials.</span></td></tr></table><div style="margin-top:6pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our development candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If we become profitable, our ability to use our net operating loss carryforwards and other tax attributes to offset future taxable income or taxes may be subject to limitations.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our patents may be challenged in courts or in patent offices.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We enjoy only limited geographical protection with respect to certain patents.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Employees, Managing Our Growth and Our Operations</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Common Stock</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to maintain listing of our common stock on the Nasdaq Capital Market or another national stock exchange, it may be more difficult for our stockholders to sell their shares of common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price of our common stock is highly volatile.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our principal stockholders and management own a significant&#160;percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></td></tr></table><div style="margin-top:6pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:147.16pt;"><a id="_726ed54e_7762_4aab_93c6_66150cd48d11"></a><a id="PARTI_44399"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_673316"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Business</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Company</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We were incorporated under the laws of the State of Delaware on December 16, 2020 through a corporate conversion just prior to the Company&#8217;s initial public offering (&#8220;IPO&#8221;). The Company was originally formed on February&#160;28, 2012 as a limited liability company under the laws of the State of Alabama as Innovative Med Concepts, LLC. On July&#160;23, 2020, the Company changed its name from Innovative Med Concepts, LLC to Virios Therapeutics,&#160;LLC.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (&#8220;FM&#8221;). Overactive immune response related to activation of tissue resident herpes virus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (&#8220;IBS&#8221;), chronic fatigue syndrome and other functional somatic syndromes, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of the herpes virus is triggered by some form of environmental and/or health stressor. Our lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IMC-1 combines two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication, thereby keeping the herpes virus in a latent (dormant) state or &#8220;down-regulating&#8221; the virus from a lytic (active) state back to latency. The famciclovir component of IMC-1 inhibits viral DNA replication. The celecoxib component of IMC-1 inhibits cyclooxegenase-2 (&#8220;COX-2&#8221;) and to a lesser degree COX-1 enzymes, used by the herpes virus to amplify or accelerate its own replication. We are unaware of any other antivirals in development for the treatment of FM. We believe this novel approach was a germane consideration in the U.S. Food and Drug Administration (&#8220;FDA&#8221;) designating IMC-1 for fast-track review status for the treatment of FM. Furthermore, IMC-1 has been granted a synergy patent based on the fact that neither antivirals nor NSAIDS/COX-2 inhibitors (the individual components of IMC-1) has proven effective in the management of FM when used as a monotherapy, yet the dual mechanism combination therapy generated a result in preliminary studies that appears to be greater than the sum of its parts.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Dormant Herpes Virus is Reactivated by External Triggers and Amplifies</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Its Own Replication via Cyclooxygenase (COX 1 and COX 2) Enzymes</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k001.jpg" alt="Graphic" style="display:inline-block;height:147.16pt;width:473.3pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:188.1pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">IMC-1&#8217;s Novel, Synergistic Antiviral Mechanism Suppresses Viral Replication,</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Demonstrates FM Treatment Effect</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k002.jpg" alt="Graphic" style="display:inline-block;height:155.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:401.36pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The potential of IMC-1 in FM was demonstrated by statistically significant improvement versus placebo in the primary endpoint of pain reduction in our double-blinded, placebo-controlled, randomized Phase 2a proof-of-concept study in FM patients. This proof-of-concept study generated statistically significant clinical data on the effects of IMC-1 on both primary pain assessment and secondary measures of pain reduction, reduction in fatigue and improvement in the global health status in patients diagnosed with FM. A result is considered to be statistically significant when the probability of the result occurring by random chance, rather than from the efficacy of the treatment, is sufficiently low. The conventional method for measuring the statistical significance of a result is known as the &#8220;p-value,&#8221; which represents the probability that random chance caused the result (e.g., a p-value = 0.001 means that there is a 0.1% or less probability that the difference between the control group and the treatment group is purely due to random chance). Generally, a p-value less than 0.05 is considered statistically significant and may be supportive of a finding of efficacy by regulatory authorities. However, regulatory authorities, including the FDA and EMA, do not rely on strict statistical significance thresholds as criteria for marketing approval and maintain the flexibility to evaluate the overall risks and benefits of a new treatment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below demonstrates the significant differences observed in the proof-of-concept study between IMC-1 and placebo in change from baseline using both the Numerical Rating Scale (NRS) 24-hour recall pain data and the Revised Fibromyalgia Impact Questionnaire (FIQ-R) with LOCF/BOCF imputation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k003.jpg" alt="Graphic" style="display:inline-block;height:188.1pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:274.25pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IMC-1 also exhibited consistent improvement across several secondary FM treatment outcomes, including 50% responder analysis, improved functional assessments, lower chronic fatigue, increased time to rescue medication and improvements in FM patient&#8217;s overall global health status. One key secondary measure assessing a 30% pain reduction analysis was approaching but did not meet statistical significance (p = 0.052). In the Phase 2a study, IMC-1 demonstrated a lower discontinuation rate due to adverse events as compared with placebo.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There were no deaths during the study and only three serious adverse events (&#8220;SAEs&#8221;) were reported. The two SAEs in the IMC-1 group were a non-ST segment elevation myocardial infarction and a facial cellulitis and the one SAE in the placebo group was a right breast micro-metastatic ductal carcinoma. One of the 3 SAEs was considered possibly related to study treatment&#160;&#8212; the non-ST segment elevation myocardial infarction that occurred early in the study in a 47-year- old patient treated with IMC-1. The causal relationship of this SAE to treatment with IMC-1 cannot be ruled out and as such was determined to be &#8220;possibly related&#8221; to IMC-1; however, the patient&#8217;s underlying coronary artery disease and strong family history of premature cardiac disease suggest that other causal factors might also have been involved.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the significant unmet need in treating FM and the aforementioned Phase 2a FM data, IMC-1 has been granted FDA designation for fast-track review status. In addition, the novel mechanism of IMC-1 has enabled us to secure composition of matter intellectual property (patent) protection to 2033.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following on from our successful Phase 2a study, we held an end of Phase 2 meeting with the FDA. In the meeting, we agreed to initiate either a Phase 2b study or a Phase 3 program after we provide animal toxicology study data, to conduct a human PK study and a clinical trial protocol that includes monitoring renal function through standard safety labs to the FDA. A human PK study with the combined tablet of IMC-1 was completed and performed as expected, with no drug-drug interactions and no adverse events. Multiple dose PK of IMC-1 was well characterized and provides additional data to better understand the PK profile of IMC-1. As a result, we have progressed development of IMC-1 from Phase 2a proof-of-concept to a larger scale Phase 2b study, known as FORTRESS, (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1), for the treatment of FM. The Phase 2b and chronic toxicology studies are planned components of the registration package supporting Phase 3 requirements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2022, we announced the top line results from our FORTRESS study in FM. Overall, the FORTRESS study did not achieve statistical significance on the prespecified primary efficacy endpoint of change from baseline to Week 14 in the weekly average of daily self-reported average pain severity scores comparing IMC-1 to placebo (p=0.302). However, analysis of the data showed a bifurcation of response based on the timing of patient enrollment in the FORTRESS study. During the first half of the trial from June 2021 to November 2021, for the patients who were enrolled (n=208) (Cohort 1) when the Delta variant of COVID-19 was the dominant strain in the U.S., full vaccination rates were below 50% and some form of quarantining was still in place in most geographies, IMC-1 demonstrated no improvement versus placebo-treated patients. Conversely, during the second half of the trial from November 2021 to April 2022, for the patients who were enrolled (n=214) (Cohort 2) when vaccination rates improved, the Omicron variant of COVID-19 became the dominant U.S. strain and quarantining restrictions were less, IMC-1-treated patients demonstrated a statistically significant improvement on the primary pain reduction endpoint (p=0.03) at Week 14, as well as a statistically significant improvement in the key secondary PROMIS Fatigue assessment (p=0.006) and the Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms domain score (p=0.015). See the figure below. We believe the likelihood of such a differential response based on the timing of patient enrollment is highly unlikely due to chance or a random occurrence, thus further analysis of the data was warranted, particularly in the context of our previous IMC-1 Phase 2a study success.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:229.5pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k004.jpg" alt="Graphic" style="display:inline-block;height:229.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:479.5pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Importantly, IMC-1 displayed a first in class safety profile with excellent tolerability and with only 4.6% of IMC-1 treated patients dropping out due to adverse events, as compared with 8.1% of placebo treated patients. No adverse event category in the IMC-1 group exceeded a 4% rate with the exception of COVID-19 infection. Overall discontinuations were 18.5% in the IMC-1 treated group versus 23% in the placebo treated group. Patients in the FORTRESS trial were randomized one-to-one to either IMC-1 or placebo and patient background demographics and baseline pain scores were well matched.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition to potential COVID pandemic related impacts, a number of factors differed between those patients recruited during the first half versus the second half of the FORTRESS study.  For example, 70% of the patients enrolled in the first half of the study were &#8220;Prior&#8221; patients who had previous relationships with their respective FORTRESS research sites and/or were participants in prior FM clinical trials. In contrast, over 50% of the FORTRESS subjects enrolled later in the study were &#8220;New&#8221;, community based patients who had not participated in prior FM clinical trials.  These New patients were generally recruited through social media advertising. Based on this demographic understanding, the team assessed how New patients versus Prior treated patients responded to IMC-1 treatment, in both cases versus placebo. Encouragingly, New patients demonstrated statistically significant improvement on the primary endpoint of reduction in FM related pain versus placebo, irrespective of when they enrolled in the study. In addition, New patients demonstrated statistical improvement in key secondary measures, including reduction in fatigue, improvement on the FIQR total scores and reductions in depression, the latter of which is believed to be important given depression is associated with the increased rate of suicide amongst FM patients. Conversely, Prior patients did not show improvement in FM related pain when compared with placebo. In addition to the difference in response between Prior and New patients, we also observed differences within these groups based on timing of recruitment.  We believe that recruitment early in the FORTRESS study was much more strongly impacted by pandemic related issues, as opposed to those recruited in 2022. Factors such as staffing levels, training, rates of absenteeism, and supply related issues all improved at the site level as we moved into 2022. The figure below shows the statistically significant primary endpoint result when analyzing the New patient population. </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:305pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k005.jpg" alt="Graphic" style="display:inline-block;height:305pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:366.9pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the analysis of the FORTRESS data, we believe focusing the forward development of IMC-1 on New FM patients represents a viable and manageable path forward. The Company is scheduled to meet with the FDA in March 2023 to discuss the most appropriate next steps in advancing IMC-1 development as a treatment for FM. If alignment can be reached, management will consider raising additional capital to fund future research and/or seek a partner to develop or co-develop IMC-1 as a treatment for FM.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the Phase 3 program, we intend to run two qualifying pivotal trials demonstrating the safety and efficacy of IMC-1 treating patients with FM. The first Phase 3 study is planned to be a four-arm, multifactorial design to demonstrate the relative safety and efficacy of IMC-1 as compared to celecoxib alone, famciclovir alone and placebo. The second Phase 3 study is planned to be a two-arm study comparing IMC-1 to placebo. All patients from the Phase 3 program will be offered the opportunity to enroll into an open label safety follow-on extension study in which all patients will be treated with IMC-1, which is the third key component of the Phase 3 program proposal.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Background of Fibromyalgia (FM)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">FM is a widespread chronic pain disorder including severe symptoms of fatigue lasting 3&#160;months or longer in duration. FM is also characterized by generalized aching, muscle stiffness, non-restorative sleep, chronic fatigue, depression, cognitive impairment and disturbances in bowel function. Researchers estimate that FM affects 2% to 8% of the US population and is the second most common &#8220;rheumatic disorder,&#8221; second to osteoarthritis. The National Fibromyalgia&#160;&amp; Chronic Pain Association estimates that 10 million Americans have FM.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">We estimate that there are approximately 3.6 million patients in the U.S. that have been diagnosed with FM, with approximately 2 million being treated. Because there are no specific clinical or laboratory tests available to diagnose FM, diagnosis is established by demonstrating that a patient has widespread chronic pain in 7 or more of the 19 bodily locations for at least 3&#160;months in duration. Additionally, these patients may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">also have non-restorative sleep, life altering fatigue, and cognitive impairment. The underlying cause of FM has remained elusive and frustrated treating physicians and the scientific community alike. To date, the three products approved by the FDA for the treatment of FM have the potential to cause troublesome side effects and/or deliver limited efficacy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The American College of Rheumatology (&#8220;ACR&#8221;) has provided working definitions for the diagnosis of FM. ACR published its 1990 criteria and 2010 criteria to assist physicians in making this diagnosis. The 1990 criteria require that patients have widespread chronic pain in all four quadrants of the body for at least 3&#160;months duration and at least 11 out of 18 predefined tender point sites are painful. The 2010 criteria revision introduced the concepts of a widespread pain index (&#8220;WPI&#8221;) and symptom severity scale score (&#8220;SSS&#8221;) for at least 3&#160;months and no other explanation for the chronic symptoms. In 2016, the ACR developed a revision of the 2010/2011 FM criteria. FM may now be diagnosed in adults when all of the following criteria are met:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">WPI &#8805; 7 and SSS score &#8805; 5 OR WPI = 4-6 and SSS score &#8805; 9;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Generalized pain, defined as pain in at least 4 of 5 regions, is present; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Symptoms have been present at a similar level for at least 3&#160;months.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A diagnosis of FM is valid irrespective of other diagnoses and does not exclude the presence of other clinically important illnesses.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fibromyalgia: A Serious Condition with Unmet Medical Need</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">FM is associated with increased mortality due to suicide or accident. Researchers evaluating over 8,186 patients with FM across three different sites in the United States between 1974 and 2009 found that individuals with FM were more than three times as likely (odds ratio (&#8220;OR&#8221;) = 3.31) to die from suicide compared to the general population and were at increased risk of death due to accidents (OR = 1.45, 95% confidence interval (&#8220;CI&#8221;); 1.02-2.06). This led the authors to speculate that some of the deaths that were classified as accidents may actually have been suicides, suggesting an even higher rate of suicide among these patients. This increased risk of mortality associated with the diagnosis of FM suggests that FM is a serious disease and that treatment of FM represents a significant unmet medical need.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2018, the FDA conducted a Patient-Focused Drug Development (&#8220;PFDD&#8221;) meeting with over 400 individuals or caregivers of individuals who experience chronic pain. Based on input from that meeting, the FDA reported that despite patient use of FDA approved and off-label therapies, the majority of FM patients continue to experience worsening pain, fatigue, cognitive impairment and other symptoms over time that requires increasing utilization of significant healthcare resources. In a 2001 study of 100 cases of FM in Ontario, Canada, patients reported spending most of at least one day in bed over the previous two weeks because of their health, and they spent more total&#160;days in bed compared to pain control and general control groups. Such unresolved morbidity significantly impacts the day-to-day functioning of patients suffering from FM.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the fifth authorization of the Prescription Drug User Fee Act, from 2013-2018, the FDA conducted 24 disease specific PFDD meetings to better understand patients&#8217; perspectives on their condition and the available therapies to treat their conditions. On March&#160;26, 2014, the FDA held a public meeting with patients suffering from FM. The meeting was chaired by 5 panelists from the FDA who interviewed 10 patients with FM who expressed FM to be a condition with an unmet medical need. Patients described the impact of FM on their daily lives, and their experiences with currently available therapies. During FDA&#8217;s meeting on the diagnosis, symptoms and treatment options for FM, the FDA acknowledged that: &#8220;There is a continuing need for treatments to better manage symptoms and treat the underlying condition.&#8221; Patients described prescription drugs as having widely varying degrees of effectiveness, with many participants noting limited benefits or decreased benefit over time. Additionally, even when treatment was effective, many FM patients described </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">that they could not adhere to treatment regimens because they were unable to tolerate treatment side effects including, but not limited to, cognitive issues, mood disruptions, nausea, high blood pressure, and, in certain cases, severe withdrawal symptoms. The following complaints, summarized from patient comments from the PFDD meeting and public comments submitted to the meeting docket, demonstrate the significant limitations of the three drugs approved by FDA for the management of FM.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 19pt;">Lyrica (pregabalin)&#160;&#8212; FDA Approved June&#160;2007</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Discontinuation of Lyrica after a few weeks due to negative side effects, most notably drowsiness, cognitive issues, dizziness, effects on mood, and weight gain. Other side effects noted included depression and swelling of the mouth and tongue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Loss of effectiveness over time.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Withdrawal symptoms after discontinuing Lyrica.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">Cymbalta (duloxetine)&#160;&#8212; FDA Approved June&#160;2008</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Negative side effects such as headache, vertigo, sleep issues, fatigue, mood disruptions, loss of libido, nausea, cognitive issues, weight gain, swelling of the mouth and tongue, vision problems and suicidal thoughts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Severe withdrawal symptoms after discontinuing Cymbalta.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">Savella (milnacipran)&#160;&#8212; FDA Approved January&#160;2009</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Discontinuation of Savella due to side effects, such as nausea, vomiting, high blood pressure, excessive sweating, and mood disruptions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Ineffective or intolerable side effects.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of the three drugs approved by the FDA for the management of FM, Lyrica, Cymbalta and Savella, modify central pain processing; pregabalin via modulation of voltage-gated calcium channels, and duloxetine and milnacipran via serotonin and norepinephrine reuptake inhibition (&#8220;SNRI&#8221;). Current treatments, including FDA approved therapies, prescription drugs used off-label and other non-prescription treatments are generally ineffective in managing FM for most patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below shows the&#160;percentage use of different therapies for FM based on data from a 2012 study lead by Dr.&#160;Rebecca Robinson, a FM researcher, and her colleagues. The study evaluated the burden of illness and treatment patterns for patients with FM from July&#160;2008 through May&#160;2010 in 58 care settings in the United States, including Puerto Rico. A majority of the 91 physicians participating were either rheumatologists or primary care physicians. There were 1,700 patients with FM who were mostly female and white with a mean age of 50.4&#160;years and duration of illness of 5.6&#160;years. The study shows the burden of illness is high, patients were taking on average 2.6 medications concurrently to treat their FM and the treatments with the most evidence to support their use were not always the treatments most frequently chosen. Opioids were one of the most commonly used treatments, even though there is no evidence opioids are effective in treating FM </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:273pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">related pain. The FDA issued a statement in February&#160;2019 indicating the agency will be pushing for increased research and development of non-addictive, non-opioid chronic pain treatments.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k006.jpg" alt="Graphic" style="display:inline-block;height:272.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:155.67pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The chart below comes from an observational study in 2013 led by Dr.&#160;Rebecca Robinson. Researchers assessed the 12-month treatment patterns and outcomes for patients starting a new medication for FM in actual clinical practice. Data from 1,700 patients was collected at baseline and 1, 3, 6, and 12&#160;months using a regression model. Patients were started on 145 unique drugs and over 75% took two or more medications concurrently for FM at each time point assessed. The most common reason for discontinuation was adverse events (63.4%) followed by lack of efficacy (30.3%). This study shows that adverse events can have a detrimental impact on adhering to medications used chronically to treat FM.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k007.jpg" alt="Graphic" style="display:inline-block;height:174.7pt;width:189.33pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The polypharmacy (both indicated and off-label medications) utilized by patients to manage their FM symptoms, along with a demonstrated lack of adherence to currently approved FDA treatments, reflect side </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">effects and/or lack of efficacy of currently available drugs and treatments. It also indicates a very significant unmet medical need, with associated cost burden to payers and loss of productivity of patients. With the exception of IMC-1, we are not aware of any drugs currently in development and directed at the management of FM that deploy an antiviral mechanism(s)&#160;of action. Current products are used to ameliorate FM symptoms rather than address an underlying cause(s)&#160;of the disease. In contrast, the mechanism of action of IMC-1 targets a potential underlying, root cause of FM- herpes virus reactivation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials are conducted under widely varying conditions. As a result, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. However, generally speaking, in clinical trials the discontinuation rate for the three central nervous system-mediated, FDA approved drugs, is approximately twice that of patients treated with placebo. This is important as inability to tolerate a medicine can lead to discontinuation of therapy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Novel Mechanism of Action (&#8220;MOA&#8221;)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Scientists and clinicians agree that patients with FM have a problem with central pain processing. The exact causality of the heightened pain sensitivity in FM is poorly understood. What is generally agreed is that the central sensitization seen in FM is secondary to a combination of genetic and environmental factors that render the patient susceptible to developing the widespread chronic pain and related symptoms seen in FM. We believe that, when FM patients are exposed to significant life stressors, be they physical or emotional, it results in an abnormal stress or herpes virus mediated-immune response. Herpes viruses are unique in that they remain in a dormant state (latency) in neuronal nuclei as nonintegrated, circular DNA associated with nucleosomes, with recurrent reactivations for the life of the host. We believe it is likely that nerve resident viral herpetic reactivation is necessary for the nociceptive response seen in FM. This cyclical process of virus reactivation and lytic infection is postulated to perpetuate FM symptoms in these patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our novel therapeutic is directed at interrupting the ongoing immune response by suppressing the herpes virus, which suppresses the abnormal stress response, thereby alleviating the central pain processing abnormality and other FM symptoms. Studies have shown that neither antivirals nor COX-2/NSAIDS taken alone result in a meaningful clinical benefit. However, when administered in combination, the synergistic response was unexpected and promising. This IMC-1 synergistic response resulted from a combination of famciclovir inhibiting viral DNA polymerase and celecoxib inhibiting upregulation of COX-2 (and to a lesser extent COX-1). There have been multiple published studies using NSAIDS/COX-2&#8217;s in the treatment of FM. According to a 2017 review published in the Cochrane Database of Systemic Reviews, NSAIDs/COX-2&#8217;s alone were shown to be no more effective than placebo in treating pain associated with FM. Products included in the review were ibuprofen 2400mg daily, naproxen 1000mg daily, tenoxicam 20mg daily and COX-2 etoricoxib 90mg daily. Antiviral monotherapy treatment of FM was studied by Dr.&#160;Sally A. Kendall and her colleagues and published in 2004 in the Journal of Rheumatology. Dr.&#160;Kendall evaluated valacyclovir 1 gram three times a day vs placebo in 60 patients with FM. The results showed no difference in change of pain between valacyclovir and placebo.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Virally induced upregulation of COX enzymes is important for efficient viral replication. An article published by Dr.&#160;Lynn W. Enquist, a professor at Princeton University, and his colleagues in the Journal of Virology (2004), demonstrated that many herpes viruses significantly up-regulate COX-2 and to a lesser degree COX-1. In an article published by Yuehong Liu and colleagues in 2014 in The Scientific World Journal, they estimated 14-fold increase in COX-2, 1.8-fold increase in COX-1 during herpes virus infection.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Celecoxib inhibits COX-2 and to a lesser degree COX-1, both of which are critical to the replication and growth of live virions. In general, COX-2 inhibition is regarded as more important than COX-1 inhibition for the suppression of herpes virus reactivation. COX-2 activation is involved in the induction of herpetic recurrences, and COX-2 inhibition is accompanied not only by a reduction of viral shedding, but also a reduction of viral DNA in nerve ganglia.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The anti-herpes virus MOA of the nucleoside analogs (which include famciclovir) is well characterized, and this drug class has been used to treat viruses over decades. In its active state famciclovir is initially phosphorylated to a monophosphate form, after which it is converted to penciclovir triphosphate by cellular kinases within virus-infected cells. Penciclovir triphosphate, the active moiety, competitively inhibits viral DNA polymerase, reducing viral DNA synthesis and replication. The specificity of penciclovir for viral DNA polymerase is an important contributor to its benign safety profile. Famciclovir interrupts DNA polymerase and, in combination with celecoxib, results in synergistic viral suppression. If definitively demonstrated through pivotal clinical trials, the efficacy, safety and tolerability, along with the combined MOA, would, we believe, differentiate IMC-1 from current standard of care and near-term pipeline drugs, while providing new opportunities in the treatment of other chronic pain conditions within the Somatic Symptom Disorders.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Discovery and Development</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initial clinical evidence supporting the development of an antiviral plus COX-2/NSAID combination to address FM was first derived through clinical observation in patients with IBS. IBS patients treated with famciclovir, who were serendipitously also placed on celecoxib to treat their arthritis, showed significant improvement not only in their IBS, but also FM, fatigue, and headaches. In particular, FM patients conveyed that they felt noticeably better when placed on the combination of famciclovir and celecoxib. We believe that stress and other environmental factors reactivate a persistent (indolent) herpes infection, resulting in a continuous nociceptive stimulation and immune response. The cyclical process of virus reactivation and lytic infection of herpes virus perpetuates FM symptoms. To interrupt and reverse viral reactivation and immune response, and resultant continuous nociceptive stimulation requires the suppression of the herpes virus, reverting it into a dormant (latency) status. We believe the coaction (synergy) of therapeutic agents with different antiviral properties is required to suppress herpes virus and reverse the symptoms of FM. Famciclovir, a nucleoside analog DNA inhibitor, inhibits the replication of viral DNA. The herpes virus upregulates COX-2, and to a lesser degree COX-1, and this upregulation of COX enzymes is critical for efficient viral replication. Celecoxib effectively blocks virally induced upregulation of COX enzymes, hence the combined activity of Famciclovir and Celecoxib results in the reversion of the herpes virus to latency.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IMC-1 interrupts the chronic dysfunctional immune response to the herpes virus infection by suppressing viral replication and re-emergence from latency. This results in the suppression of the abnormal stress response seen in IBS and FM, thereby alleviating the central pain processing abnormality. Multiple published clinical studies have confirmed that neither antivirals (such as famciclovir) nor COX-2/NSAIDs (such as celecoxib) administered singly deliver any meaningful clinical benefit. Based on Phase 2a study results, the synergy of the fixed-dose combination of famciclovir and celecoxib (IMC-1) has potential as a FM therapy. If approved, this could differentiate IMC-1 from current standard of care and pipeline products and, we believe, alter treatment outcomes in FM, and potentially a number of other chronic pain conditions in the Somatic Symptom Disorders where herpes viruses may play a role.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:175.52pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 18.7pt;">Biomarker&#160;&#8212; Gastrointestinal Tissue Study to see if Herpes Simplex Type 1 (&#8220;HSV-1&#8221;) is present in IBS/FM</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k008.jpg" alt="Graphic" style="display:inline-block;height:153.73pt;width:206.22pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The stomach of FM patients is one of the few sites that presents an opportunity for biopsy of tissue to determine if FM patients are burdened with herpes virus infection, where active FM is resultant upon reactivation of herpes virus infection. We have postulated that herpes virus infected nerve tissue located in the gastric mucosa provides a site for biopsy and represents an excellent site to confirm active herpes virus infection in patients with recurrent active FM<i style="font-style:italic;">.</i> To test this hypothesis, we engaged the University of Alabama to analyze GI biopsy tissue to search for active HSV-1 virus. Thirty patients with documented FM with chronic GI complaints had their stomach biopsied with samples sent to the University of Alabama for analysis by Carol Duffy PhD, University of Alabama virologist. Fifteen controls without chronic pain or FM and without chronic GI conditions were studied as the comparator arm to the open study. The GI biopsies were evaluated for HSV-1 infection by Immunoblot analysis for viral non-structural protein (ICP8) with PCR used to detect herpesvirus DNA sequence. ICP8 is only found during an active HSV-1 infection. A summary of this data is presented below.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k009.jpg" alt="Graphic" style="display:inline-block;height:175.47pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:302.96pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The study found that 83% of patients with FM and chronic GI conditions had ICP8, a protein only found in active HSV-1 infections as demonstrated in the GI biopsy. While only 9% of control patients had ICP8 (p = 0.0001). The study also analyzed patients suffering from symptoms of IBS and demonstrates a strong correlation with HSV-1 (p = 0.0005) as well, when compared to controls. The correlation of HSV-1 activation to FM (and IBS) was shown and we believe corroborates the underlying mechanistic rationale for IMC-1. The study is not required to be submitted to the IND.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PRID-201 Phase 2a Study of IMC-1 In Patients with Fibromyalgia (NCT01850420)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 19pt;">PRID-201 Phase 2a Study Design</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The PRID-201 study represents the first placebo-controlled study evaluating the safety and efficacy of IMC-1. The Phase 2a clinical study involved 143 FM patients and a 16&#160;-week, multicenter, double blind, randomized, placebo-controlled, Phase 2a proof of concept trial conducted under IND 114827. Randomized patients received either IMC-1 or placebo in a 1:1 ratio. The primary objective of the study was to evaluate the safety and efficacy of IMC-1, as a single treatment for patients with primary FM. The primary efficacy outcome measure was a change from baseline in FM pain. FM pain was assessed using the 24-hour recall average pain score as recorded on the 11-point Numerical Rating Scale (&#8220;NRS&#8221;) measure during clinic visits, as well as with the 7-day recall average pain score recorded on the Revised Fibromyalgia Impact Questionnaire (&#8220;FIQ-R&#8221;). The safety and tolerability of treatment with IMC-1 was compared to placebo by analysis of vital signs, laboratory parameters, treatment-emergent adverse events (&#8220;TEAEs&#8221;), and discontinuation due to adverse events. A complete description of the study, including secondary and exploratory objectives, and results can be found in the PRID-201 Clinical Study Report submitted to the Investigational New Drug (&#8220;IND&#8221;) on December&#160;11, 2014 (Serial No.&#160;0009).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 12pt 1pt;">Patients completed the NRS for pain, revised FIQ-R, Beck Depression Inventory (&#8220;BDI-II&#8221;), Multidimensional Fatigue Inventory (&#8220;MFI&#8221;), and the National Institutes of Health (&#8220;NIH&#8221;) Patient-Reported Outcomes Measurement Information System (&#8220;PROMIS&#8221;) fatigue questionnaire at Baseline and Weeks 6, 12, and 16 (or early termination (&#8220;ET&#8221;)). Patients also completed a Patient Global Impression of Change (&#8220;PGIC&#8221;) questionnaire at Weeks 6, 12, and 16 (or ET).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 12pt 1pt;">IMC-1 demonstrated statistically significant improvement in the chronic pain of the studied FM patients when measured by either metrics utilized in the study: the 24-hour recall data, or the 7-day pain recall. Additionally, in this proof-of-concept study, IMC-1 treated subjects reported significant improvements on overall global impression of change at the 12 and 16-week visits. Significant improvement in fatigue (PROMIS fatigue scale) and mood (BDI-II scale) were noted at endpoint.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 12pt 1pt;">The primary outcome measure was based on change in patient-reported pain scores from baseline to week 16 of the study. IMC-1 treated subjects reported statistically significant better scores compared to placebo subjects, as summarized below. The two pain scales are very similar. The NRS scale measures pain over the last 24 hours on an 11-point numerical rating scale (from 0 = no pain to 10 = worst imaginable pain) that was recorded during clinic visits. The FIQ-R is a disease specific instrument designed to assess the impact of FM on various aspects of the patient&#8217;s well-being. The symptom section of the FIQ-R asks the patient to rate their level of pain over the past 7&#160;days using an 11-point numerical scale (from 0 = No Pain to 10 = Unbearable Pain).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 20.15pt;">PRID-201 Phase 2a Primary Endpoint Analysis</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Placebo&#160;LS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">IMC-1&#160;LS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change&#160;@</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change&#160;@</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Pain Analysis</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Endpoint&#160;(SE)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Endpoint&#160;(SE)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contrast&#160;(SE)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">P-&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">NRS 24-hour recall, MMRM LOCF/BOCF Imputation @ 16 weeks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">-1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.28)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">-1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.28)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">-0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.37)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.031</p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">FIQ-R 7-days recall, MMRM LOCF/BOCF Imputation @ 16 weeks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">-0.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.30)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">-2.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.30)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">-1.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.38)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.001</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 12pt 1pt;">If the estimated change from baseline for a patient&#8217;s pain scores met or exceeded 50%, they were considered a 50% pain responder. In the pain responder analysis, a generalized linear regression curve fit was applied to an individual patient&#8217;s pain data. The high hurdle of 50% pain reduction from baseline is statistically significant at endpoint, pain outcome measures by 50% responder analysis are summarized below.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 20.15pt;">PRID-201 Phase 2a Secondary Endpoint 50% Reduction of Pain Analyses with Curve Fit</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IMC-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IMC-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">50% Pain Responder Analysis</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Measure</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">P</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Week 16 Visit, 50% Reduction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">NRS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (15.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 62</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(84.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (30.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 46</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (69.7)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.009</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Week 16 Visit, 50% Reduction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">FIQ&#8209;R&#160;Pain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16.9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(83.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (37.9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (62.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.001</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As shown in the chart below, the same analysis was performed for a 30% reduction in pain, and the results were statistically significant for the responders with 7-day recall but were not statistically significant for the 24-hour NRS.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 18pt;">PRID-201 Phase 2a Secondary Endpoint 30% Reduction of Pain Analyses with Curve Fit</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IMC-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IMC-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">30%&#160;Pain&#160;Responder&#160;Analysis</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Measure</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">P-Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Week 16 Visit, 30% Reduction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">NRS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (31.5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (68.5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (42.4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 38</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (57.6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.052</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Week 16 Visit, 30% Reduction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">FIQ-R Pain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (28.2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 51</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (71.8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (43.9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 37</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (56.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.012</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Past studies of FM treatment have indicated that the Patient Global Interpretation Change (PGIC) scale is a sensitive measure for detecting therapeutic benefit. While it tends to correlate most closely with pain results, the PGIC can be viewed as a patient&#8217;s assessment of overall therapeutic benefit of the therapy in question. The PGIC outcome measure was pre-specified as a key secondary endpoint. The PGIC responder analysis (see below) was significant at the 6, 12, and 16-week visits.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt;">PRID-201 Phase 2a Secondary Endpoint Patient Global Impression of Change Result</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IMC-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IMC-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PGIC&#160;Analysis</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">Responders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">P-&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Week 6 Visit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (19.2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (80.8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 26</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (37.7)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 43</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (62.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.040</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Week 12 Visit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17.8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 60</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (82.2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 26</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (37.7)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 43</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (62.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.005</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Week 16 Visit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (19.2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (80.8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (33.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 46</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (66.6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.040</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">FIQ-R total score change was significant as was the PROMIS Fatigue inventory, both of which evidence that IMC-1 does more than just modify the perception of pain. The FIQ-R total score is a composite of all questions from all three domains (Functional, Overall Impact and Symptoms). Fatigue was assessed in both the PROMIS fatigue score and the MFI total score. In the statistical analyses, the reductions from Baseline to Week 16 were numerically greater in the IMC-1 group than in the placebo group and reached statistical significance for the reduction in fatigue score in the PROMIS assessment (LS mean change of&#160;-2.68 vs.&#160;-6.65, p=0.001) but not in the MFI total score assessment (LS mean change&#160;-3.69 vs.&#160;-6.90, p=0.107).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt;">PRID-201 Phase 2a Secondary Endpoint Fibromyalgia Impact Questionnaire-Revised&#160;&amp; PROMIS Fatigue Results</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:13.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IMC</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placebo&#160;LS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IMC</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">1&#160;LS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outcomes&#160;Measure</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Method</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Baseline</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Baseline</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change&#160;(SE)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change&#160;(SE)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contrast&#160;(SE)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">P</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">&#160;Value</b></p></td></tr><tr><td style="vertical-align:middle;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">FIQ-R</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Week&#160;16&#160;MMRM<br />&#160;LOCF/BOCF</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 56.81</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (73)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 54.28</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (69)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-7.87</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.33)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-17.54</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.40)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-9.67</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3.05)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.002</span></p></td></tr><tr><td style="vertical-align:middle;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">PROMIS Fatigue</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:13.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Week&#160;16&#160;MMRM<br />&#160;LOCF/BOCF</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65.83</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (73)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65.55</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (69)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-2.68</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (0.93)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-6.65</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (0.96)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-3.96</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.22)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.001</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FIQ-R demonstrated statistical significance in all 3 domains (see below).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt;">Analysis of FIQ-R Domain Scores with LOCF/BOCF Imputation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Week&#160;16</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LS&#160;Mean&#160;(SE)&#160;Change&#160;from&#160;Baseline</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FIQ-R&#160;Analysis</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IMC</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOCF/BOCF&#160;Imputation)*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">N&#160;=&#160;71</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">N&#160;=&#160;66</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contrast&#160;(SE)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">P-&#160;Value**</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Functional Domain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-5.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.32)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-14.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.40)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-8.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3.03)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.004</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Overall Impact Domain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-1.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (0.61)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-4.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (0.63)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-2.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (0.79)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.003</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Symptoms Domain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-7.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.33)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-16.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.40)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-8.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3.06)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.004</span></p></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">*&#160;&#160;&#160;&#160;&#160;LOCF/BOCF imputation = BOCF for missing data due to withdrawals related to adverse events or lack of efficacy or LOCF for missing data unrelated to efficacy or adverse events.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">**&#160;&#160;&#160;&#160;Obtained from MMRM model with treatment as the main effect, and investigative site and Baseline score as covariates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Rescue Medication</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tramadol use was prospectively identified as the only rescue therapy to be used in this study. The proportion of patients taking tramadol for FM rescue was defined as all tramadol usage from the concomitant medication logs. The proportion of patients who took rescue therapy for FM was summarized by treatment group. The use of tramadol was significantly higher in the placebo group compared to the IMC-1 group.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:198pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">IMC-1 exhibited consistent improvement across several secondary FM treatment outcomes, including functional assessments, lower fatigue, increased time to rescue medication and improvements in FM patient&#8217;s global health status, as reflected in the table below.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k011.jpg" alt="Graphic" style="display:inline-block;height:197.3pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:227.5pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PRID-201 Phase 2a Safety</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tolerability of IMC-1 was better than placebo in Study PRID-201 (P2a). As shown below, many of the treatment-emergent adverse event categories, including gastrointestinal, were reported more frequently in the placebo group and are actually symptoms of FM. No serious unexpected adverse events were noted in this study. There were no deaths during the study and only three serious adverse events (&#8220;SAEs&#8221;) were reported. The two SAEs in the IMC-1 group were a Non-ST Segment Elevation Myocardial Infarction and a Facial Cellulitis and the one placebo group SAE was a right breast micro-metastatic ductal carcinoma. One of the three SAEs was considered possibly related to study treatment&#160;&#8212; the non-ST segment elevation myocardial infarction that occurred early in the study in a 47-year-old patient treated with IMC-1. The causal relationship of this SAE to treatment with IMC-1 cannot be ruled out; however, the patient&#8217;s underlying coronary artery disease and strong family history of premature cardiac disease suggest that other causal factors were also involved.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PRID-201 Phase 2a Adverse Event Report</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;">Adverse Events Reported for &#8805;5% of the Patients in Either Treatment Group</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;text-indent:18pt;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IMC</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adverse&#160;Event</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">N=73</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">N=69</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Any Event</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 57</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (78.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (72.5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Headache</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13.7)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (11.6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Urinary Tract Infection</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5.5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (8.7)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Blood Lactate Dehydrogenase Increased</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5.8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nasopharyngitis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5.8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Diarrhea</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nausea</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17.8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fibromyalgia</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5.5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vomiting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6.8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:173.2pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;">Adverse Events Reported for &#8805;5% of the Patients in Either Treatment Group</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;text-indent:18pt;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placebo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IMC</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">1</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adverse&#160;Event</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">N=73</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">N=69</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Constipation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (8.2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gastroesophageal Reflux Disease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5.5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Alopecia</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5.5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oropharyngeal Pain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5.5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">In PRID-201 Phase 2a, as seen in the chart below, more patients in the placebo group (16.2%; n=12) discontinued therapy due to adverse events than on IMC-1 (5.8%; n=4). Increased treatment adherence in actual clinical practice is important in any chronic therapy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k012.jpg" alt="Graphic" style="display:inline-block;height:173.2pt;width:348.65pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The lack of adherence to currently available treatments is indicative of the significant need for more effective and better tolerated therapies. Patients and physicians suggest that an ideal treatment would have fewer side effects and address the pervasive symptoms of FM including chronic fatigue; chronic fatigue was one of the three key factors of an ideal FM product that was discussed at the FM PFDD meeting. The preliminary clinical evidence reported suggests the potential for IMC-1 to address an unmet medical need by first treating an underlying cause, and thereby the symptoms of FM. IMC-1 also has the potential to improve safety and tolerability through more manageable rates of adverse reactions and consequently improving efficacy through improved adherence by FM patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 20pt;">IMC-1 Phase 2a End of Study Blinded Questionnaire</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An end of study questionnaire analysis was included as an exploratory instrument in this Phase 2a study. It simply asked the patients whether they had suffered any conditions listed below which are commonly associated with FM, and if so, how their symptoms were now relative to baseline. The likelihood of improvement versus placebo was measured for patients on IMC-1 in the blinded &#8220;End of PRID-201 Phase 2a Trial&#8221; Questionnaire; data listed below:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">FM and Chronic Fatigue: 2.2 times (improvement vs placebo)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">IBS: 2.8 times</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Brain Fog (cognitive impairment): 2.1 times</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Headache: 2.5 times</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#0000ff;">Temporomandibular joint</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">: 5 times</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Insomnia: 1.7 times</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Neck and back pain: 2.3 times</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Anxiety: 2.8 times</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Depression: 1.6 times</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This information was gathered as exploratory data to inform future research. For example, patients who were on IMC-1 and had IBS symptoms were 2.8 times more likely to be improved compared to placebo. IBS is one of the indications we may explore for future IMC-1 clinical trials.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PRID-202 Phase 2b FORTRESS Study of IMC-1 In Patients with Fibromyalgia (NCT04748705)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 19pt;">PRID-202 Phase 2b FORTRESS Study Design</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May 2021, we began screening patients in our Phase 2b study known as the FORTRESS study (an abbreviation that stands for Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Virus) and in June 2021, we announced the dosing of our first patient in the FORTRESS study. The study participants were randomized to receive either IMC-<span style="white-space:pre-wrap;">1 or placebo in a 1:1 ratio.  FORTRESS was a double-blinded, randomized, placebo-controlled, trial of IMC-1 for the treatment of FM. A total of 425 female FM patients ages 18 to 65 were randomized in a 1:1 ratio to treatment with either IMC-1 or placebo at 42 U.S. sites. The primary endpoint for our FORTRESS study was reduction in pain over time. Patients were dosed with IMC-1 (675 mg famciclovir and 180 mg celecoxib) or matching placebo on a BID basis for 14 weeks. At the Week 14 primary endpoint visit, all patients were switched to placebo on a blinded basis. Previous experience with chronic pain trials has indicated that efficacy outcome measures recorded at the final study visit may be confounded by psychological factors relating to patients exiting a study. Therefore, it was critical that the patient was unaware of this potential change in her assigned study drug during the Week 14 and Week 16 interval. The primary objective of the study was to evaluate the safety and efficacy of IMC-1, as a single treatment for patients with primary FM. The primary efficacy outcome measure was pain reduction. The patient&#8217;s self-reported 24-hour recall pain intensity score was evaluated on the 11-point Numerical Rating Scale (&#8220;NRS&#8221;) measure collected daily on an e-diary. Weekly mean scores were calculated from averaging the available daily scores recorded for that week. The safety and tolerability of treatment with IMC-1 was compared to placebo by analysis of vital signs, laboratory parameters, treatment-emergent adverse events (&#8220;TEAEs&#8221;), and discontinuation due to adverse events. A complete description of the study, including secondary and exploratory objectives, and results can be found in the PRID-202 Clinical Study Report that will be submitted to the Investigational New Drug (&#8220;IND&#8221;) in Q2 of 2023.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pain reduction was measured daily on the NRS 24-hour recall scale via an electronic diary that the patient used at home. In addition to assessing the FM patient&#8217;s pain reduction, we also assessed IMC-1&#8217;s ability to improve symptoms of fatigue, sleep disturbance, overall global health status and patient function. In parallel to the FORTRESS study, our chronic toxicology studies in two species were completed. These studies are required by regulatory authorities to support chronic administration of IMC-1 in future clinical development.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 12pt 1pt;">Patients completed the NRS for pain daily on an electronic diary, the revised FIQ-R, the Beck Depression Inventory (&#8220;BDI-II&#8221;), the National Institutes of Health (&#8220;NIH&#8221;) Patient-Reported Outcomes Measurement Information System (&#8220;PROMIS&#8221;) fatigue and sleep questionnaires and the Hospital Anxiety and Depression Scale (&#8220;HADS&#8221;) at Baseline and Weeks 6, 12, 14 and 16 (or early termination (&#8220;ET&#8221;)) during clinic visits. Patients completed a Patient Global Impression of Change (&#8220;PGIC&#8221;) questionnaire at Weeks 6, 12, 14 and 16 (or ET) during clinic visits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:235.5pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 12pt 1pt;"><span style="font-style:italic;font-weight:bold;">PRID-202 Phase 2b FORTRESS Study Results</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 12pt 1pt;">In this study, IMC-1 had a greater reduction in FM related pain at each study visit but did not achieve statistically significant improvements compared to placebo at the Week 14 primary endpoint. The graph below shows the primary endpoint result, p=0.30:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:20.15pt;margin:0pt 0pt 12pt 0.7pt;"><img src="tmb-20221231x10k013.jpg" alt="Graphic" style="display:inline-block;height:235.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:357.87pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 12pt 1pt;">However, an anomalous bifurcation of results was noted when comparing the patients enrolled during the first half of the study (&#8220;Cohort 1&#8221;) with results from patients enrolled during the second half of the study (&#8220;Cohort 2&#8221;). More specifically, there were no statistically significant differences between treatment with IMC-1 versus placebo for Cohort 1 patients on any of the outcome measures of interest. Conversely, there were statistically significant differences in multiple outcomes of interest including the primary endpoint of reduction in pain at Week 14 as compared to placebo, p=0.030. The graph below compares Cohort 1 to Cohort 2 on the primary endpoint:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:19.95pt;margin:0pt 0pt 12pt 1pt;"><img src="tmb-20221231x10k014.jpg" alt="Graphic" style="display:inline-block;height:214.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:448.12pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 12pt 1pt;"><span style="white-space:pre-wrap;"> Other outcomes that were statistically significant in Cohort 2 included fatigue (p=0.006), PGIC mean score change (p=0.027), FIQ-R symptoms (p=0.015), and FIQ-R total score change (p=0.019).  It is highly unlikely that the differences between the first half and second half study results could be a random finding.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:19.95pt;margin:0pt 0pt 12pt 1pt;">In addition to the Cohort 1 vs Cohort 2 finding, there was a subpopulation recruited through social media advertising (who were consequently new to the staff at the treatment sites and who were not prior FM trial participants), who also showed statistically significant results on both the primary endpoint and multiple secondary endpoints, independent of Cohort timing. The Table below summarizes the clinical results for the 175 patients included in this advertising subpopulation:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:69.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr style="height:34.25pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:68.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-size:10pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advertising Population Outcomes Analysis</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.27%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">P Value</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect Size</b></p></th></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:68.61%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">PGIC mean score change</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.27%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.005</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.21%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.43</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:68.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">PROMIS fatigue</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.27%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.001</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.49</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:68.61%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">FIQ-R symptoms domain</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.27%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.006</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.21%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.42</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:68.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">FIQ-R total score</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.27%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.005</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.43</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:68.61%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">Pain interference</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.27%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.031</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.21%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.33</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:68.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">PROMIS sleep</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.27%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.077</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.27</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:68.61%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">HADS depression</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.27%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.002</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.21%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.48</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:68.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">HADS anxiety</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.27%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.011</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.39</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:68.61%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">BDI-II</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.27%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.010</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.21%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">0.39</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">While the overall efficacy results from FORTRESS did not achieve statistical significance, the safety results were consistent with the excellent results previously seen in the Phase 2a study.  As was seen previously, dropout rates on drug were less than placebo, and all adverse event categories other than COVID-19 infection were less than 5%.  The Table below compares adverse event rates between IMC-1 and placebo:</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:26.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:25.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr style="height:16.3pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adverse Event</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:26.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Placebo</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N=208</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:25.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IMC-1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N=216</b></p></th></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">COVID-19 infection</p></td><td style="vertical-align:top;width:26.06%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">  17 (8.2%)</span></p></td><td style="vertical-align:top;width:25.02%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">  20 (9.3%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Headache</p></td><td style="vertical-align:top;width:26.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">  12 (5.8%)</span></p></td><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   8 (3.7%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Nausea</p></td><td style="vertical-align:top;width:26.06%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   4 (1.9%)</span></p></td><td style="vertical-align:top;width:25.02%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   8 (3.7%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Urinary tract infection</p></td><td style="vertical-align:top;width:26.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">  10 (4.8%)</span></p></td><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   7 (3.2%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sinusitis</p></td><td style="vertical-align:top;width:26.06%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   7 (3.4%)</span></p></td><td style="vertical-align:top;width:25.02%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   7 (3.2%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Diarrhea</p></td><td style="vertical-align:top;width:26.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   7 (3.4%)</span></p></td><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   7 (3.2%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Upper respiratory tract infection</p></td><td style="vertical-align:top;width:26.06%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   1 (0.5%)</span></p></td><td style="vertical-align:top;width:25.02%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   7 (3.2%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Dyspepsia</p></td><td style="vertical-align:top;width:26.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   3 (1.4%)</span></p></td><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   5 (2.3%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Depression</p></td><td style="vertical-align:top;width:26.06%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   2 (1.0%)</span></p></td><td style="vertical-align:top;width:25.02%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   5 (2.3%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Constipation</p></td><td style="vertical-align:top;width:26.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   2 (1.0%)</span></p></td><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   4 (1.9%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cough</p></td><td style="vertical-align:top;width:26.06%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   2 (1.0%)</span></p></td><td style="vertical-align:top;width:25.02%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   4 (1.9%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Urine protein/creatinine ratio increased</p></td><td style="vertical-align:top;width:26.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   1 (0.5%)</span></p></td><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   4 (1.9%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Anxiety</p></td><td style="vertical-align:top;width:26.06%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   1 (0.5%)</span></p></td><td style="vertical-align:top;width:25.02%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   4 (1.9%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Glomerular filtration rate decreased</p></td><td style="vertical-align:top;width:26.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   3 (1.4%)</span></p></td><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   3 (1.4%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Fatigue</p></td><td style="vertical-align:top;width:26.06%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   1 (0.5%)</span></p></td><td style="vertical-align:top;width:25.02%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   3 (1.4%)</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:48.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Alanine aminotransferase increased</p></td><td style="vertical-align:top;width:26.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   0 (0.0%)</span></p></td><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">   3 (1.4%)</span></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.89%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the analysis of the FORTRESS data, we believe focusing the forward development of IMC-1 on New FM patients represents a viable and manageable path forward. We are scheduled to meet with the FDA in March 2023 to discuss the most appropriate next steps in advancing IMC-1 development as a treatment for FM. If alignment can be reached, management will consider raising additional capital to fund future research and/or seek a partner to develop or co-develop IMC-1 as a treatment for FM.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulatory and Development Timeline</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have regularly engaged the FDA on IMC-1 for the treatment of FM. The FDA has provided the following guidance with respect to the development of IMC-1 for the treatment of FM. Since we are combining proprietary doses of two previously approved drugs, our fixed dose combination product candidate is eligible for submission to the FDA for approval under Section&#160;505(b)(2)&#160;of the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;). Section&#160;505(b)(2)&#160;permits the submission of an NDA where at least some of the information required for approval comes from studies that were not conducted by, or for, the applicant and on which the applicant has not obtained a right of reference. The 505(b)(2)&#160;application enables us to reference published literature and/or the FDA&#8217;s previous findings of safety and effectiveness for previously approved drugs with the same active ingredient. Under Section&#160;505(b)(2), we plan to rely upon FDA&#8217;s previous findings of safety and effectiveness, and extensively reference several sections of the US Prescribing Information for Famvir (famciclovir), from Novartis, and Celebrex (celecoxib), from Pfizer, the reference drugs for our program. The 505(b)(2)&#160;NDA filing will rely on portions of the development programs conducted by the sponsors of the reference drugs, as described in the FDA-approved US Prescribing Information. The FDA has agreed to our (b)(2) filing plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the conclusion of our Phase 2a clinical study in 2017 we held an end-of-phase 2 meeting with the FDA and conducted a subsequent conference call with the FDA in November&#160;2017. As a result of those meetings the FDA has provided us with a defined path forward to Phase 3, including agreement to initiate a Phase 2b study and/or Phase 3 trial after we provide animal toxicology study data, conduct a human PK study with celecoxib and famciclovir combined in one tablet (which has been completed) and submit the Phase 2b clinical trial protocol that includes monitoring renal function through standard safety labs to the FDA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The human PK study on the new tablet, using a three-way crossover study design, has been successfully completed. IMC-1 performed as expected in the human PK study, with no drug-drug interactions and no reported adverse events. Multiple dose PK of IMC-1 has been well characterized and provides additional data to better understand the PK profile of IMC-1.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have also successfully completed the required 90-day sub-chronic toxicology studies with the oral combination of IMC-1 that we believe support the optimal dosing used in our FORTRESS study and to be used in our Phase 3 trials. This GLP 13-week general toxicology study with toxicokinetics and a recovery period has been completed, as has a 13-week GLP study of embryo-fetal development in rats, including using higher famciclovir doses. There were no unexpected toxicities from IMC-1 (all toxicities shown were consistent with the known toxicities of the individual reference drugs&#160;&#8211; celecoxib and famciclovir). Based on its review of prior 90-day and chronic toxicology studies, the FDA is requesting that we assess long term testicular and kidney toxicity in our chronic toxicology studies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to support chronic long-term dosing with IMC-1, we conducted the required chronic toxicology studies in parallel to the FORTRESS study. These studies consisted of a six-month rat and a nine-month dog study. Consistent with earlier studies, there were no unexpected toxicities from IMC-1. All toxicities shown were consistent with known toxicities in celecoxib and famciclovir. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development of the IMC-1 tablet formulation and manufacture was completed at Frontida (Aurora, IL) along with the ongoing stability data (18-month stability data completed). The IMC-1 prototype tablet, completed at Catalent, had excellent 24-month stability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In September 2022, we announced the top line results from our FORTRESS Phase 2b FM study.  Analysis of the study data revealed:</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">New FM patients treated with IMC-1, who were recruited into our FORTRESS study through social media advertising, demonstrated statistically significant reductions in FM related pain, fatigue, anxiety and depressive symptoms and showed an overall improvement in their global health status.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Prior FM patients, who had previously enrolled in FM studies and/or who had a prior relationship with the FORTRESS study sites, did not exhibit meaningful treatment benefits.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">New patients treated with IMC-1 also exhibited a lower discontinuation rate due to adverse events as compared with New patients receiving placebo.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">All patients treated with IMC-1 demonstrated exemplary safety and tolerability in the FORTRESS study.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe the safety and efficacy results from the FORTRESS study support progression of IMC-1 to Phase 3 development for New patients, who represent the vast majority of the FM patient community.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are scheduled to meet with the FDA in March 2023 to discuss advancing IMC-1 into Phase 3 development as a treatment for FM. At this meeting, we will discuss plans for a Phase 3 program that would support submission of a NDA for IMC-1 for the treatment of FM.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market and Competition</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The three pharmaceutical agents currently approved for the treatment of FM, pregabalin (Lyrica), duloxetine (Cymbalta) and milnacipran (Savella), are all associated with significant adverse events and limited clinical efficacy. Despite this, Lyrica and Cymbalta together had peak sales of approximately $10 billion across all of their approved indications, with Lyrica achieving sales of $3.6 billion in the United States in 2018, including sales related to FM. Reflecting the need for more effective and better tolerated treatments, a large number of additional products are also prescribed that are not indicated for FM. The American Academy of Rheumatology and FDA strongly recommends avoiding opioid narcotic medications for treating FM. Evidence shows these drugs are not helpful to most people with FM and will cause greater pain sensitivity or make pain persist. Despite that, research shows that FM patients are prescribed opioids as part of their treatment regimen.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the National Fibromyalgia&#160;&amp; Chronic Pain Association, approximately 10 million Americans and 3%&#160;&#8211; 6% of people worldwide are afflicted with FM. Common chronic pain conditions affect approximately 116 million adults in the United States at a cost of $560&#160;&#8211; $635 billion annually in direct medical treatment costs and lost productivity. This estimate combines the incremental cost of health care ($261-$300 billion) and the cost of lost productivity ($299&#160;&#8211; $335 billion), more than heart disease or cancer. Competitive late-stage FM pipeline products are not disruptive to the current standard of care, nor do they appear to address the root cause of the disease.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We conducted a commercial opportunity assessment in each of 2014 and 2020 to better understand the medical needs existing in the FM treatment market and to quantify the addressable market opportunity for a potential new FDA approved FM treatment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our 2014 assessment reviewed the competitive landscape for the treatment of FM, including physician demographic information, patient demographic information, current&#160;&amp; potential future treatment projections, and obtained information from high prescribing physicians and primary research with six healthcare payors as well as conducted a revenue forecast.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our 2020 assessment provided an updated disease review, forecast and valuation for FM and IBS for the U.S. and Ex-U.S. markets. Both assessments show that significant unmet medical needs exist in the FM treatment armamentarium, as well as the IBS treatment armamentarium, highlighting the commercial potential for a new medicine that proves to be safe and effective as determined by the FDA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:165.02pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 19pt;">Primary Research Background</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In our 2014 assessment 75 physicians were surveyed, targeting high volume prescribers in key geographies and practice settings (rheumatologists, pain specialists, neurologists, primary care) across the United States. Also, eight high prescribing key opinion leader physicians (&#8220;KOLs&#8221;) were interviewed to gain qualitative insights into the treatment paradigm for FM and related disorders. Additionally, six payors were interviewed to determine their receptivity to IMC-1 as a first line treatment, how price sensitive these payors would be, how likely they would be to reimburse IMC-1, and whether Medicare would cover IMC-1.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This primary research confirmed the large unmet medical need in the treatment of FM. The researchers found that physicians and patients, express a need for additional, safer and more efficacious FM therapy options. The 2014 assessment found that only 15% of the 75 physicians surveyed expressed satisfaction with their current FM treatment options and none responded as being &#8220;very satisfied&#8221;. Ninety five&#160;percent of physicians surveyed indicated the available standard of care treatments only manage symptoms and did not treat the cause of the disease.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 18pt;">Physician Satisfaction with Available FM Therapies (n=75)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20221231x10k015.jpg" alt="Graphic" style="display:inline-block;height:164.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:329.95pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Physicians paralleled the concerns described by the patients at FDA&#8217;s PFDD meeting indicating that the currently FDA approved therapies have many of the associated adverse events such as dizziness, nausea or vomiting, weight gain, dry mouth, sleeplessness, restlessness, peripheral edema, chronic headaches, IBS symptoms and suicidal thoughts or actions. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The six payors interviewed confirmed FM to be a serious disease with patients routinely consuming substantial healthcare resources. IMC-1, with proprietary dosing (dosing cannot be replicated by generic products) and a unique antiviral MOA with Fast Track status, can be expected to receive favorable pricing and formulary coverage and a high level of unmet need exists because the underlying cause is not well understood and treatment is patchwork.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Secondary Research: FM Pipeline</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Both of our 2014 and 2020 assessments analyzed historical markets for FM and related disorders and identified key players and trends. They also created competitive intelligence on all in-line and pipeline FM treatments, including ongoing U.S. clinical trials. It is worth noting that the mechanistic approach for all of these potential new treatment candidates is complementary to the antiviral IMC-1 mechanistic approach, thus not true competitors to IMC-1, presuming continued success.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other Market Opportunities</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of the 2014 and 2020 assessment confirmed that FM represents an unmet medical need with a large market opportunity and that IMC-1 is a differentiated product. Overall, the assessment found that physicians are not satisfied with current FM treatments, that the etiology and cause of FM remains poorly understood, and that current products only manage the symptoms of FM. We believe our paradigm changing discovery that herpes virus could play an important role in the pathogenesis of FM. If successfully proven, we believe that IMC-1 can be disruptive to the market and can change the way FM is treated. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, there is increasing recognition in the scientific community of the potential role of activated viruses, triggering a wide range of morbidities, including FM, IBS, fatigue related disorders and potentially dementia and even long Covid (&#8220;Long-COVID&#8221;) symptoms. The Company provided the Bateman Horne Center (&#8220;BHC&#8221;) with an unrestricted grant for an investigator-sponsored study to explore the therapeutic potential of combination antiviral therapy with Virios&#8217; second development candidate, IMC-2, a combination of valacyclovir and celecoxib. The study is evaluating changes in common Long-COVID symptoms such as fatigue, sleep, attention, pain, autonomic function and anxiety and commenced dosing in the third quarter of 2022. The study is fully enrolled with data expected in mid-2023. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the development and implementation of our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, our portfolio of owned patents totaled 21 issued patents in the United States and abroad. This includes three Composition of Matter patents, including a Synergistic Patent, and two Method of Use patents in the United States, all of which relate to IMC-1. Exclusivity with all patents extends to 2033.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Issued US IMC-1 Patents</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. &#8220;Composition of Matter&#8221; Patents (US 8,809,351&#160;&amp; US 10,034,846) Drug-combination of famciclovir and celecoxib</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. &#8220;Method-of-Use&#8221; Patent (US 9,040,546) Famciclovir + celecoxib for the treatment of FM (fibromyalgia), CFS or IBS</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. &#8220;Method-of-Use&#8221; Patent (US 9,173,863) Method of dispensing famciclovir + celecoxib in a regimen to treat Functional Somatic Syndrome conditions</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. &#8220;Composition of Matter&#8221; Synergistic Patent (US 10,251,853) Synergistic combination for total daily dose of famciclovir and celecoxib</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Issued Foreign IMC-1 Patents</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">European Patent (EP 2 811 833&#160;&amp; 2 965 759 &#8211; validated in 18 countries)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Japan (JP 5855770&#160;&amp; 6422848)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Australia (AU 2013217110)</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">China (CN 104144606)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Korea (KR 10-1485748)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Canada (2,863,812)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">U.S. Patents Covering Other Anti-Viral Combinations</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. 9,682,051 (acyclovir/meloxicam)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. 8,623,882 (acyclovir/diclofenac)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. 9,259,405 (famciclovir/diclofenac)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. 9,642,824 (valacyclovir/diclofenac)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. 9,980,932 (valacyclovir/meloxicam)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. 10,543,184 (acyclovir/celecoxib)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. 10,632,087 (famciclovir/meloxicam)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. 11,096,912 (valacyclovir/celecoxib)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20&#160;years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five&#160;years and the total patent term including the restoration period must not exceed 14&#160;years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20&#160;years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and selected consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have also been granted additional U.S. and EU patents, representing all possible combinations of targeted antivirals and non-steroidal anti-inflammatory drugs (NSAIDs/COX-2s) containing appropriate COX-2&#160;&amp; COX-1 inhibition. At present, we are developing only IMC-1 (famciclovir/celecoxib) with the other </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">patents being obtained to increase the therapeutic combinations that we may explore in the future to treat other virally medicated illnesses.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our drugs or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have an adverse impact on us. If third parties have prepared and filed patent applications prior to March&#160;16, 2013 in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO, to determine priority of invention. For more information, please see &#8220;Risk Factors&#160;&#8212; Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Material Agreements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2012, we entered into a Know-How License Agreement (the &#8220;License Agreement&#8221;) with the University of Alabama. In consideration for the License Agreement, the University of Alabama received membership interests in the Company representing 10% of the issued membership interests at that time. The License Agreement is in effect for 25&#160;years and will terminate on June&#160;1, 2037. Under the License Agreement, we were granted a non-exclusive, worldwide, royalty-free license to utilize, including the right to sublicense and sell products incorporating, the know-how, technical information, and data related and pertaining to the herpesvirus biology, including herpesvirus replication mechanisms, modes of action of anti-herpesvirus medications, and sensitivity and accuracy of herpesvirus diagnostic tests, any of which were developed by the University of Alabama under the direction of Dr.&#160;Carol Duffy before the effective date of the License Agreement, all of which is defined as the Technical Information. The University of Alabama reserved the right to use the Technical Information for educational, research, clinical, and other non-commercial purposes. We may assign the license to any purchaser or transferee of substantially all of our assets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales and Marketing</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If IMC-1 is approved, we plan to enter into sales and marketing agreements with one or several pharmaceutical companies to sell to neurologists, geriatric specialists and to primary care physicians.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on third-party contractors for manufacturing clinical supplies and plan to do so for commercial amounts also. Presently we are working with an overseas supplier for the manufacture of the cGMP API and with a local supplier for the storage stability, encapsulating, blister packing, blinding and distribution of the capsules or pills to the clinical sites.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. Government Regulation of Drug Products</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the United States, the FDA regulates drugs under the FDCA and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) regulations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an IND, which must become effective before human clinical trials may begin.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Approval by an independent institutional review board (&#8220;IRB&#8221;) at each clinical site before each trial may be initiated.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety and efficacy of the proposed drug product for each indication.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an NDA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA advisory committee review, if applicable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;) requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of user fees and securing FDA approval of the NDA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) and the potential requirement to conduct post-approval studies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical Studies</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to initiate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Trials</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it initiates at that institution. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on their www.clinicaltrials.gov website.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 studies or trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketing Approval</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), guidelines that are currently in effect, the FDA has a goal of ten&#160;months from the date of &#8220;filing&#8221; of a standard NDA, for a new molecular entity to review and act on the submission. This review typically takes twelve&#160;months from the date the NDA is submitted to FDA because the FDA has approximately two&#160;months to make a &#8220;filing&#8221; decision.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, under the Pediatric Research Equity Act of 2003, as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA also may require submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA conducts a preliminary review of all NDAs within the first 60&#160;days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Special FDA Expedited Review and Approval Programs</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has various programs, including fast track designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may give a priority review designation to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six&#160;months, rather than the standard review of ten&#160;months under current PDUFA guidelines. Under the current PDUFA agreement, these six- and ten-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two&#160;months to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, products tested for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM) that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on IMM or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act passed in July&#160;2012, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accelerated Approval Pathway</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may grant accelerated approval to a drug for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the drug influences a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a drug.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Orphan Drug Designation and Exclusivity</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven&#160;years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease if the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There are continuing, annual program user fee requirements for any marketed products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments and list their marketed drug products with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once an approval of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Fines, warning letters or holds on post-approval clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Product seizure or detention, or refusal to permit the import or export of products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs or devices may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. Coverage and Reimbursement</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Significant uncertainty exists as to the coverage and reimbursement status of our product candidate, IMC-1, or any other development candidate for which we may seek regulatory approval. Sales in the U.S. will </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">depend in part on the availability of adequate financial coverage and reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by payors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list or formulary, which might not include all the FDA-approved products for a particular indication. Also, third-party payors may refuse to include a branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or another alternative is available. Medicare Part&#160;D, Medicare&#8217;s outpatient prescription drug benefit, contains protections to ensure coverage and reimbursement for oral oncology products, and all Part&#160;D prescription drug plans are required to cover substantially all oral anti-cancer agents. However, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Sales of IMC-1 or any other candidates will therefore depend substantially on the extent to which the costs of our products will be paid by third-party payors. Achieving favorable coverage and reimbursement from the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) and/or the Medicare Administrative Contractors is typically a significant gating issue for successful introduction of a new product.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate&#160;percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our operations include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims and civil monetary penalties laws, including the federal civil False Claims Act, which prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provisions of the </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#0000ff;">Health Insurance Portability and Accountability Act of 1996 (&#8220;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA&#8221;), which created federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program or making false statements in connection with the delivery of or payment for healthcare benefits, items or services. In addition, HIPAA, as amended by the </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Health Information Technology for Economic and Clinical Health Act and its implementing regulations, impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payment Sunshine Act requirements, under the Patient Protection and Affordable Care Act, which require manufacturers of certain drugs and biologics to track and report to CMS payments and other transfers of value they make to U.S. physicians and teaching hospitals as well as physician ownership and investment interests in the manufacturer. Many states have their own Sunshine laws governing the tracking and reporting of payments to healthcare providers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The Hatch-Waxman Amendments and Generic Competition</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Section&#160;505(b)(2)&#160;NDAs</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA, an applicant may submit an NDA under Section&#160;505(b)(2)&#160;of the FDCA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;505(b)(2)&#160;was enacted as part of the <span style="text-decoration-color:#0000ff;">Drug Price Competition and Patent Term Restoration Act of 1984, referred to as &#8220;the </span>Hatch-Waxman Amendments&#8221; to the FDCA and enables the applicant to rely, in part, on the FDA&#8217;s previous approval of a similar product, or published literature, in support of its application. Section&#160;505(b)(2)&#160;permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the Section&#160;505(b)(2)&#160;applicant can establish that reliance on FDA&#8217;s previous findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved reference drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the reference drug has been approved or for any new indication sought by the Section&#160;505(b)(2)&#160;applicant.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">ANDA Approval Process</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Hatch-Waxman Amendments also established an abbreviated FDA approval process for drugs that are shown to be bioequivalent to drugs previously approved by the FDA through the NDA process. Approval to market and distribute these drugs is obtained by filing an abbreviated new drug application (&#8220;ANDA&#8221;) with the FDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are termed abbreviated because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to the innovator drug. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Orange Book Listing</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">In seeking approval for a drug through an NDA, including a 505(b)(2)&#160;NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant&#8217;s product. Upon approval, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a Section&#160;505(b)(2)&#160;NDA referencing a drug listed in the Orange Book must certify to the FDA, as applicable, that (1)&#160;no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2)&#160;such patent has expired; (3)&#160;the date on which such patent expires; or (4)&#160;such patent is invalid or will not be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. A notice of the paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the ANDA or Section&#160;505(b)(2)&#160;application refers. The applicant may also elect to submit a &#8220;section viii&#8221; statement certifying that its proposed label does not contain (or carves out) any language regarding a patented method-of-use that is approved for the reference drug, rather than certify to a listed method-of-use patent.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If within 45&#160;days of receipt of a Paragraph IV Notification the NDA holder for the reference drug and/or patent owners initiates a patent infringement lawsuit against the ANDA or 505(b)(2)&#160;applicant, the FDA is prohibited from approving the application until the earlier of 30&#160;months from the receipt of the paragraph IV certification (the 30-Month Stay), expiration of the patent, settlement of the lawsuit with a finding of patent invalidity or non-infringement, or a decision in the infringement case that is favorable to the applicant.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ANDA or Section&#160;505(b)(2)&#160;application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the reference drug has expired as described in further detail below.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Non-Patent Exclusivity</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to patent exclusivity, the holder of the NDA for the listed drug may be entitled to a period of non-patent exclusivity, during which the FDA cannot approve an ANDA or Section&#160;505(b)(2)&#160;application that relies on the listed drug. For example, a pharmaceutical manufacturer may obtain five&#160;years of non-patent exclusivity upon NDA approval of a new chemical entity, or NCE, which is a drug that contains an active moiety that has not been approved by the FDA in any other NDA. A fixed combination drug product may receive NCE exclusivity if one of its active ingredients is an NCE, but not if all of its active ingredients have previously been approved. An &#8220;active moiety&#8221; is defined as the molecule or ion responsible for the drug substance&#8217;s physiological or pharmacologic action. During the five&#160;year exclusivity period, the FDA cannot accept for filing any ANDA seeking approval of a generic version of that drug or any Section&#160;505(b)(2)&#160;NDA for the same active moiety and that relies on the FDA&#8217;s findings regarding that drug, except that the FDA may accept such an application for filing after four&#160;years if the application includes a paragraph IV certification to a listed patent. In the case of such applications accepted for filing between four and five&#160;years after approval of the reference drug, a 30-Month Stay of approval triggered by a timely patent infringement lawsuit is extended by the amount of time necessary to extend the stay until 7-1/2&#160;years after the approval of the reference drug NDA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A drug, including one approved under Section&#160;505(b)(2), may obtain a three-year period of exclusivity for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability studies) was essential to the approval of the application and was conducted/sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or Section&#160;505(b)(2)&#160;application for the protected modification until after that three-year exclusivity period has run. However, unlike NCE exclusivity, the FDA can accept an application and begin the review process during the exclusivity period.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulation Outside the United States</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">To market our future products in the EEA (which is comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein) and many other foreign jurisdictions, we must obtain separate regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;). There are two types of marketing authorizations:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency (&#8220;EMA&#8221;), and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the member countries of the EEA assess the risk-benefit balance of the product based on scientific criteria concerning its quality, safety and efficacy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Data and Marketing Exclusivity</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EEA, new products authorized for marketing, or reference products, qualify for eight&#160;years of data exclusivity and an additional two&#160;years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight&#160;years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10&#160;years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period can be extended to a maximum of eleven&#160;years if, during the first eight&#160;years of those 10&#160;years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Orphan Drug Designation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EEA, a medicinal product can be designated as an orphan drug if its sponsor can establish that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment in development. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the EEA, an application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, the EMA or the member state </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_208"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">competent authorities, cannot accept another application for a marketing authorization, or grant a marketing authorization, for a similar medicinal product for the same indication. The period of market exclusivity is extended by two&#160;years for medicines that have also complied with an agreed <span style="text-decoration-color:#0000ff;">pediatric investigation plan</span>.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This period may, however, be reduced to six&#160;years if, at the end of the fifth&#160;year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of &#8220;clinical superiority&#8221; by a similar medicinal product, or, after a review by the Committee for Orphan Medicinal Products, requested by a member state in the fifth&#160;year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs are eligible for incentives made available by the EU and its Member States to support research into, and the development and availability of, orphan drugs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Capital Resources</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had four full-time employees. Accordingly, a high percentage of our work performed for our development projects is outsourced to qualified independent contractors. All employees and contractors are subject to contractual agreements that specify requirements for confidentiality, ownership of newly developed intellectual property and restrictions on working for competitors as well as other matters.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Facilities</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#0000ff;">We do not own or lease any offices at this time other than a &#8220;virtual office&#8221; at the address set forth on the cover page of this Annual Report.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Website</p><a id="_cp_text_1_215"></a><a id="_cp_field_47_216"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration-color:#0000ff;">Our internet address is</span><span style="text-decoration-color:#0000ff;"> </span><span style="text-decoration-color:#0000ff;">https://www.virios.com</span><span style="text-decoration-color:#0000ff;">.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e0f38ba1_6007_43e8_8ff9_3472aaf7a82b"></a><a id="Item1ARiskFactors_188664"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An investment in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below and the other information contained in the Annual Report on Form 10-K. Our business, financial condition, results of operations or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline.</p><a id="Verdatum"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Need for Additional Capital</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a development-stage biotechnology company with a limited operating history and have incurred losses since our formation. We incurred net losses of $12,247,834 and $15,960,268 for each of the&#160;years ended December&#160;31, 2022 and 2021. As of December&#160;31, 2022, we had an accumulated deficit of $56,173,207. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to research and development, including our preclinical and clinical work, and to intellectual property.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">We expect to incur significant additional operating losses for the next several&#160;years, at least, as we advance IMC-1 and any other candidates through clinical development, complete clinical trials, seek regulatory approval and commercialize the drug or any other candidates, if approved. The costs of advancing candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any of our candidates to marketing approval in even a single </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">jurisdiction will be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any products or achieve or maintain profitability. Our expenses will also increase substantially if and as we:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct our Phase 3 FM studies or conduct clinical trials for any other indications or other candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establish sales, marketing, distribution, and compliance infrastructures to commercialize IMC-1, if approved, and for any other candidates for which we may obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, scientific and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our development and planned future commercialization efforts, as well as to support </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our transition to a public reporting company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license or invent other candidates or assets.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, our ability to successfully develop, commercialize and license any candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described below under &#8220;&#8212; Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval&#8221; and &#8220;&#8212; Risks Related to Commercialization.&#8221; As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our common stock will be materially and adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of IMC-1.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to advance the clinical development of IMC-1 and launch and commercialize IMC-1, if we receive regulatory approval. We will require additional capital for the further development and potential commercialization of IMC-1 and may also need to raise additional funds sooner to pursue a more accelerated development of IMC-1. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our cash on hand of $7,030,992 as of December&#160;<span style="white-space:pre-wrap;">31, 2022 is sufficient to fund our operations and capital requirements for at least the next 12 months subsequent to the filing date of the Company&#8217;s Annual Report on Form 10-K.  Currently, there are no planned research and development activities for 2023 other than minimal carryover costs associated with completing the final reports for the FORTRESS study and the chronic toxicology program, regulatory consulting to prepare for the meeting with the FDA, the on-going grant to BHC for the fully funded investigator-sponsored study in Long-COVID and purchase of active pharmaceutical ingredients (&#8220;API&#8221;) to support the start of a potential Phase 3 study for IMC-1. We are scheduled to meet with the FDA in March 2023 to discuss the most appropriate next steps in advancing IMC-1 development as a </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">treatment for FM. Additional capital will need to be raised before initiating additional research and development activities. We have based this estimate on assumptions that may prove to be wrong, and we could deploy our available capital resources sooner or for other purposes than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to the:</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for IMC-1 or any other future candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical development plans we establish for IMC-1 and any other future candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obligation to make royalty and non-royalty sublicense receipt payments to third-party licensors, if any, under our licensing agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">number and characteristics of candidates that we discover or in-license and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">outcome, timing and cost of regulatory review by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">effects of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs and timing of the implementation of commercial-scale manufacturing activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to become profitable will be compromised.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our common stockholder&#8217;s rights as common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate candidate development or future commercialization efforts.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Unstable global market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty about economic stability. For example, the current&#160;conflict&#160;between&#160;Ukraine&#160;and Russia has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We were established and began operations in 2012. Our operations to date have been limited to financing and staffing our company, licensing candidates, conducting preclinical and clinical studies of IMC-1. We have further tested IMC-1 in clinical trials for safety and proof-of-concept. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product, arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and&#160;year to&#160;year due to a variety of factors, many of which are beyond our control. Accordingly, the results of any particular quarterly or annual period should not be relied upon as indications of future operating performance.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are heavily dependent on the success of IMC-1, our lead candidate, which is still under clinical development, and if this candidate does not receive regulatory approval or, if approved, our commercialization efforts are unsuccessful, our business may be harmed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">We do not have any products that have been granted regulatory approval. Currently, our lead development-stage candidate is IMC-1. As a result, our business is dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize IMC-1 in a timely manner. We cannot commercialize IMC-1 in the United States without first obtaining regulatory approval from the FDA; similarly, we cannot commercialize IMC-1 outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of IMC-1 for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials and, with respect to approval in the United States, to the satisfaction of the FDA, that IMC-1 is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate. In our most recent clinical trial involving IMC-1, the Phase 2b FORTRESS study, IMC-1 did not achieve statistically significant efficacy outcomes. Even if IMC-1 were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for IMC-1 in one or more jurisdictions, or any approval we receive contains significant limitations or requirements, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other candidate that we may in-license, develop or acquire in the future. Furthermore, even if we obtain regulatory approval for IMC-1, we will still need to develop a commercial organization, establish commercially viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize IMC-1, we may not be able to earn sufficient revenue to continue our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may face future business disruption and related risks resulting from the spread of infectious disease, including coronavirus 2019 variants (COVID-19), which could have a material adverse effect on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development of our drug candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver components or raw materials on a timely basis or materially and adversely affect our collaborators and out-license partners&#8217; ability to perform preclinical studies and clinical trials. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response to the spread of an infectious disease. Such events may result in a period of business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The <span style="text-decoration-color:#0000ff;">ultimate extent of the impact of any epidemic, pandemic or other health crisis, including COVID-19, on our ability to advance the development of our drug candidates, including delays in starting or completing clinical trials, or to raise financing to support the development of our drug candidates</span>, will depend on future developments, which are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning the severity of such <span style="text-decoration-color:#0000ff;">epidemic, pandemic or other health crisis and</span> actions taken to contain or prevent their further spread, among others.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical testing is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, IMC-1 and our other compounds may not have favorable results in later preclinical and clinical studies or receive regulatory approval. We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory approval to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining Institutional Review Board, or IRB, approval at each site, or Independent Ethics Committee, or IEC, approval at sites outside the United States;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">having patients complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of a clinical hold by regulatory authorities or IRBs, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements or follow trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites deviating from trial protocol, committing fraud or other violations of regulatory requirements, or dropping out of a trial, which can render data from that site unusable in support of regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing patient safety concerns that arise during the course of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adding a sufficient number of clinical trial sites; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of IMC-1 for use in clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board, or DSMB, for such trial or the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in &#8220;Risks Related to Our Dependence on Third Parties.&#8221;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for IMC-1 or any other candidates, our business will be substantially harmed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for IMC-1 or any other candidates. We are not permitted to market any of our product candidates in the United States until we receive regulatory approval from the FDA.</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a candidate is safe and effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">serious and unexpected treatment-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our candidates, or other products containing the active ingredient in our candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our development candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign authorities may disagree regarding the formulation, labeling and/or the specifications of our candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may inspect and find deficiencies at the clinical trial sites we use to conduct our clinical studies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to obtaining approval to commercialize a candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the adequacy of the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our safety interpretation of our drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our efficacy interpretation of our drug; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may regard our CMC package as inadequate, and more particularly:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if our NDA does not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if the results of such tests show that such drug is unsafe for use under such conditions or do not show that such drug is safe for use under such conditions;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such drug are inadequate to preserve its identity, strength, quality, and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if FDA determines that it has insufficient information to determine whether such drug is safe for use under such conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if based on information we submit and any other information before the FDA, the FDA determines there is a lack of substantial evidence that the drug will have the effect it purports or </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">is represented to have under the conditions of use prescribed, recommended, or suggested in the proposed labeling thereof; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if FDA determines that our labeling is false or misleading in any particular way.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of the large number of drugs in development, only a small&#160;percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market IMC-1 or another candidate, which would significantly harm our business, results of operations and prospects.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than we originally requested, the FDA or applicable foreign regulatory agency may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate, or may require warnings, other safety-related labeling information, or impose post-market safety requirements, including distribution restrictions, that negatively impact the commercial potential of the drug. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature of the trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the existing body of safety and efficacy data with respect to the product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">competing clinical trials being conducted by other companies or institutions;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain patient consents; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect when implemented in prospective clinical trials. Even if our clinical trials for IMC-1 are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publish interim &#8220;top-line&#8221; or preliminary data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Serious adverse events or undesirable side effects caused by IMC-1 or any other candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Patients treated with IMC-1 in our Phase 2a and Phase 2b studies discontinued due to adverse events at a rate lower than patients treated with placebo. The most common adverse events IMC-1 patients experienced (other than COVID-19 infection) were gastrointestinal events and headache at rates less than 5%. There were three serious adverse events observed in the Phase 2a study, two on patients treated with IMC-1, and one for a placebo treated patient. In the larger Phase 2b study, there were three serious adverse events that occurred in two patients, both of whom were treated with placebo.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If unacceptable side effects arise in the development of our candidates, we, the FDA or the IRBs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our development candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such product;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the product may become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market opportunities for IMC-1, if approved, may be smaller than we anticipate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect to initially seek approval for IMC-1 for FM in the United States. Our estimates of market potential have been derived from a variety of sources, including scientific literature, patient foundations and primary and secondary market research, and may prove to be incorrect. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have never obtained marketing approval for a development candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our development candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our development candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our development candidates. If the FDA does not accept or approve our NDAs for our development candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our development candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain FDA approval for IMC-1 or any other candidates in the United States, we may never obtain approval for or commercialize IMC-1 or any other development candidate in any other jurisdiction, which would limit our ability to realize their full global market potential.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for IMC-1 or any development candidate, we will still face extensive and ongoing regulatory requirements and obligations and any development candidates, if approved, may face future development and regulatory difficulties.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and Good Clinical Practice, or GCP, requirements for any clinical trials that we conduct post-approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS.&#160;If any of our product candidates receive marketing approval, the accompanying label may limit the approved indicated use of the product candidate, which could limit sales of the product candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on manufacturing such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, the FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current presidential administration may impact our business and industry. Namely, the current presidential administration has taken several executive actions, including the issuance of a number of executive orders, which could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek a Breakthrough Therapy designation for IMC-1 from the FDA. However, we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may seek a Breakthrough Therapy designation for IMC-1 or one or more of our other candidates. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to the FDA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation for a product candidate may not result in a faster development or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The use of IMC-1 or any other candidates we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of our business reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of participants from our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">distraction of management&#8217;s attention from our primary business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to commercialize IMC-1 or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased market demand for any product; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The product liability insurance coverage we plan to acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. In connection with our Phase 1 clinical studies, we carried insurance for product liability claims in the United States. We intend to acquire insurance coverage to include larger clinical studies, different countries and sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect the results of our operations and business, including preventing or limiting the commercialization of any product candidates we develop.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Commercialization</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">IMC-1 is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies in the United States and other jurisdictions. These organizations may have significantly greater resources than we do and may conduct similar research; seek patent protection; and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">Our competitors may, among other things:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">have significantly greater name recognition, financial, manufacturing, marketing, drug development, technical, and human resources than we do, and future mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain quicker regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">implement more effective approaches to sales and marketing; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">form more advantageous strategic alliances.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel; establishing clinical trial sites and patient registration; and in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, or are more convenient or are less expensive than IMC-1. Our competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for IMC-1, which could result in our competitors establishing or strengthening their market position before we are able to enter the market.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may face early generic competition for IMC-1 or our other products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pharmaceutical companies developing novel products face intense competition from generic drug manufacturers who aggressively seek to challenge patents and non-patent exclusivities for branded products, and who are able to use much less-onerous product development and FDA approval pathways for their generic products. Both of the active ingredients of IMC-1, famciclovir and celecoxib, are marketed in numerous FDA-approved single-ingredient generic products that copy the original brand name products containing those active ingredients, indicating that numerous potential generic competitors have successfully developed formulation and manufacturing processes to make finished drug products of the individual components of IMC-1 using these ingredients. Such generic competitors could apply those processes to develop equivalent generic versions of IMC-1. Under FDA&#8217;s generic drug approval processes, described in more detail in the section titled &#8220;Hatch-Waxman and Generic Competition,&#8221; we do not believe that IMC-1 would be eligible for the 5-year NCE Exclusivity period, because both active ingredients have previously been approved by FDA in other branded drug products, although ICM-1 may qualify for a 3-year exclusivity period during which no generic version could be approved. As discussed elsewhere herein, we have procured several patents that we believe cover IMC-1 and would be eligible for listing in FDA&#8217;s Orange Book, and as such would require any proposed generic competitor to IMC-1 seeking FDA approval prior to the expiration of such patents to submit a Paragraph IV Certification alleging that our patent(s)&#160;are invalid, unenforceable, or would not be infringed by the marketing of the proposed generic product. Such a Paragraph IV ANDA could be submitted to FDA at any time after approval of the IMC-1 NDA, but if we file a patent infringement action against such a generic challenger within 45&#160;days of receiving the required notification of such Paragraph IV </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">filing, FDA would be barred from approving the generic version for 30&#160;months from the date of our receipt of the notification. This 30-Month Stay, however, may be shortened if the court earlier decides that our patents are in fact invalid, unenforceable, or would not be infringed. Even if the litigation is not concluded at the end of the 30-Month Stay, FDA may still grant final approval of the generic application, and the applicant would be able to choose to launch its product, absent a court-ordered injunction, but at the risk of becoming liable to us for monetary infringement damages, including potentially treble damages, if we ultimately prevail in the litigation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IMC-1 uses novel dosage strengths of both famciclovir and celecoxib, neither of which dosage strengths have been approved by FDA for other products. Thus, there are no currently-approved single-ingredient generic products that could readily be prescribed in combination as a direct equivalent substitute for IMC-1. However, physicians are lawfully able to prescribe drugs for unapproved uses and in unapproved strengths, and it is possible that some physicians could seek to prescribe separately approved generic versions of these two drugs in combination as a treatment for FM or other proposed indications for IMC-1, in an attempt to lower the costs to their patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The successful commercialization of IMC-1 and any other candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as IMC-1, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our drug and any other product candidates we develop. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and offer to reimburse patients only for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&#160;and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules&#160;and regulations are likely.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if IMC-1 or any other candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If IMC-1 or any other candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on a number of factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of our sales and marketing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments, including any similar generic treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to offer our products for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of any restrictions on the use of our product together with other medications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing IMC-1, if approved.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not have any infrastructure for the sales, marketing or distribution of IMC-1, or compliance functions related to such activities, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market and successfully commercialize our drug or any product candidate we develop, if approved, we must build our sales, distribution, marketing, managerial, compliance, and other non-technical capabilities or make arrangements with third parties to perform these services. We expect to build a focused sales, distribution and marketing infrastructure to market IMC-1, if approved, in the United States and Europe. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, oversee the compliance of sales and marketing functions, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing, distribution and compliance capabilities could delay any product launch, which would adversely impact the commercialization of that product. For example, if the commercial launch of IMC-1 for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to physicians or attain adequate numbers of physicians to prescribe our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of our product candidates, if approved, in certain markets overseas. Therefore, our future success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in a product and such collaborator&#8217;s ability to successfully market and sell the product. We intend to pursue collaborative arrangements regarding the sale and marketing of IMC-1, if approved, for certain markets overseas; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of IMC-1, we may be forced to delay the potential commercialization of the drug or reduce </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the scope of our sales or marketing activities. If we need to increase our expenditures to fund commercialization activities for IMC-1 we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We may also have to enter into collaborative arrangements for IMC-1 at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to it or otherwise agree to terms unfavorable to us. Any of these occurrences may have an adverse effect on our business, operating results and prospects.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates and may never become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A variety of risks associated with operating internationally could materially adversely affect our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently have no international operations, but our business strategy includes potentially expanding internationally if any of our product candidates receive regulatory approval. Doing business internationally involves a number of risks, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties maintaining compliance with multiple, conflicting and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">additional potentially relevant third-party patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">limits in our ability to penetrate international markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">certain expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Dependence on Third Parties</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees and independent contractors, including principal investigators, clinical trial sites, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our employees and independent contractors, including principal investigators, clinical trial sites, consultants, vendors and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless or negligent conduct or unauthorized activities that violate: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse and other healthcare laws and regulations; or laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of IMC-1 and intend to rely on CMOs for the production of commercial supply of IMC-1, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials and commercial quantities of IMC-1 and any candidates we develop, if approved. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. We intend to have manufactured a sufficient clinical supply of IMC-1 drug substance to enable us to complete our clinical trials, and we have also engaged a CMO to provide clinical and commercial supply of the drug product.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be essentially dependent on, our CMOs for </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacture of our product candidates or that obtained approvals could be revoked. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We do not and will not have control over the process or timing of the acquisition of these raw materials by our CMOs. Moreover, we currently do not have any agreements for the production of these raw materials. Supplies of raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also impair our ability to cost effectively manufacture our product candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a possible disruption of the manufacture of our product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finding new CMOs or third-party suppliers involves additional cost and requires our management&#8217;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we generally have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely, and will continue to rely, on CROs, CRO-contracted vendors and clinical trial sites to ensure the proper and timely conduct of our clinical trials. Our reliance on CROs for clinical development activities limits our control over these activities, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We and our CROs will be required to comply with the Good Laboratory Practice requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our relationship with any CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the loss of, or a disruption in our relationship with, any one or more collaborators could harm our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under such collaborations. If we do not receive the funding we expect under these agreements, our continued development of our product candidates could be delayed, and we may need additional resources to develop additional product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of any collaborators and there can be no assurance that our collaborations will produce positive results or successful products on a timely basis or at all.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination or otherwise changes its business priorities, the collaborator might deemphasize or terminate the development or commercialization of our product candidates. If a collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of our business and our stock price could be adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may in the future collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our programs, and our business may be materially and adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our development candidates, if approved, and may affect the prices we may set.</p><a id="_cp_text_1_270"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March&#160;2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, was passed, which substantially changed the way healthcare is financed by both the government and private insurers and<span style="text-decoration-color:#0000ff;"> continues to significantly impact the U.S. pharmaceutical industry. Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA. </span>Other legislative changes have been proposed and adopted in the United States since the ACA was enacted.<span style="text-decoration-color:#0000ff;"> It is unclear how future litigation or healthcare </span>initiatives at the U.S. federal and state levels<span style="text-decoration-color:#0000ff;"> will impact our business, financial condition and results of operations. Complying with any new legislation or changes in healthcare regulation could be time consuming and expensive, resulting in a material adverse effect on our business.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, or FCA, which, among other things, impose criminal and civil penalties, including through civil whistleblower or </span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">qui tam</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">does </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with physicians and other healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">compliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General Data Protection Regulation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we conduct clinical trial programs or enter into research collaborations in the European Economic Area, we may be subject to the General Data Protection regulation, or GDPR. The GDPR applies extraterritorially and implements stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data, robust disclosures to individuals, a comprehensive individual data rights regime, data export restrictions governing transfers of data from the European Union, or EU, to other jurisdictions, short timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to health data, other special categories of personal data and coded data and additional obligations if we contract third-party processors in connection with the processing of personal data. The GDPR provides that EU member states may establish their own laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to &#8364;20 million or up to 4% of our total worldwide annual turnover of the preceding financial&#160;year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we become profitable, our ability to use our net operating loss carryforwards and other tax attributes to offset future taxable income or taxes may be subject to limitations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2022, we had federal and state net operating loss carry forwards, or NOLs, of approximately $22.2 million. These net operating losses can be carried forward and applied against future </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">taxable income, if any. A full allowance for the value of the NOLs is provided for in our audited financial statements for the year of December 31, 2022 included in this Annual Report on Form 10-K. We cannot guarantee what the ultimate outcome or amount of the benefit we may receive from the NOLs, if any, will be. If we become profitable in the future, our ability to use net operating loss carryforwards and other tax attributes to offset future taxable income or reduce taxes may be subject to limitations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our patents may be challenged in courts or in patent offices which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is no assurance that all the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents further cover IMC-1 or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period during which we could market a product candidate under patent protection could be reduced.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#160;years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. However, in certain instances, the laws of the United States are more restrictive than those of foreign countries. For example, a recent series of U.S. Supreme Court cases has narrowed the types of subject matter considered eligible for patenting. Accordingly, certain diagnostic methods are considered ineligible for patenting because they are directed to a &#8220;law of nature.&#8221; Further, publications of discoveries in scientific literature often lag the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated, held unenforceable, in whole or in part, or reduced in term. Such a result could limit our ability to stop others from using or commercializing similar or identical technology and products. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20&#160;years after it is filed. While various extensions may be available, the life of a patent is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become subject to third parties&#8217; claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly, time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical and biotechnology industries is common, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous U.S., EU and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may be subject to third-party claims including infringement, interference or derivation proceedings, post-grant review and <i style="font-style:italic;">inter partes</i> review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if we believe third party infringement claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Proceedings challenging our patents or those that we license may also result in our patent claims being invalidated or narrowed in scope. Similarly, if our patents or patent applications are challenged during interference or derivation proceedings, a court may hold that a third-party is entitled to certain patent ownership rights instead of us. Further, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, methods of manufacture, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. In addition, defending such claims would cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages, if we are found to be infringing a third party&#8217;s patent rights. If we are found to have infringed such rights willfully, the damages may be enhanced and may include attorneys&#8217; fees. Further, if a patent infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require us to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if a license can be obtained on acceptable terms, the rights may be nonexclusive, which could give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. Modifying our product candidates to design around third-party intellectual property rights may result in significant cost or delay to us and could prove to be technically infeasible. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. In addition, if the breadth or strength of protection </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">provided the patents and patent applications we own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of eligibility, lack of novelty, obviousness or non-enablement. Third parties might allege unenforceability of our patents because someone connected with prosecution of the patent withheld relevant information, or made a misleading statement, during prosecution. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Furthermore, our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing on our patents or other intellectual property rights.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finally, even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, in the United States, certain filed applications that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, EU and elsewhere are published approximately 18&#160;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our future product candidates, or their manufacture or use may currently be unpublished. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the EU or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may identify patents or applications in the same general area as our products and product candidates. We may determine these third-party patents are irrelevant to our business based on various factors including our interpretation of the scope of the patent claims and our interpretation of when the patent expires. If the patents are asserted against us, however, a court may disagree with our determinations. Further, while we may determine that the scope of claims that will issue from a patent application does not present a risk, it is difficult to accurately predict the scope of claims that will issue from a patent application, our determination may be incorrect, and the issuing patent may be asserted against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing our product candidates. We might, if possible, also be forced to redesign our product candidates so that we no longer infringe on the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical and pharmaceutical industries involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical and pharmaceutical patents is costly, time-consuming and inherently uncertain.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The U.S. has in recent years enacted and implemented wide ranging patent reform legislation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent&#160;years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the U.S. federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent&#160;years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and European and other patent agencies over the lifetime of a patent. In addition, the USPTO and European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">means in accordance with the applicable rules, there are situations in which such noncompliance will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our product candidates in any indication for which they are approved.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the EU. These products may compete with our product candidates, and our and our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we may decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules&#160;and regulations in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, we may be able to extend the term of a patent covering each product candidate under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five&#160;years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. The total patent term including the extension cannot exceed 14&#160;years following regulatory approval. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, under certain circumstances, patent terms covering our products or product candidates may be extended for time spent during the pendency of the patent application in the USPTO (referred to as Patent Term Adjustment, or PTA). The laws and regulations underlying how the USPTO calculates the PTA is subject to change and any such PTA granted by the USPTO could be challenged by a third-party. If we do not prevail under such a challenge, the PTA may be reduced or eliminated, resulting in a shorter patent term, which may negatively impact our ability to exclude competitors. Because PTA added to the term of patents covering pharmaceutical products has particular value, our business may be adversely affected if the PTA is successfully challenged by a third party and our ability to exclude competitors is reduced or eliminated.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not address all potential threats to our competitive advantage.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are similar to IMC-1 or our future product candidates but that are not covered by the claims of the patents that we own or license from others;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we or any of our collaborators might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we or any of our collaborators might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">ownership of our patents or patent applications may be challenged by third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We consider proprietary trade secrets or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. Because we expect to rely on third parties to manufacture IMC-1 and any future product candidates, and we expect to collaborate with third parties on the development of IMC-1 and any future product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. However, trade secrets or confidential know-how can be difficult to maintain as confidential.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is expensive, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A third party may hold intellectual property, including patent rights that are important or necessary to the development or commercialization of IMC-1 or our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize IMC-1 or our product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, which could materially harm our business. At this time, we are unaware of any intellectual property that interferes with ours or is complementary and needed to commercialize IMC-1.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership or right to use. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our proprietary information may be lost, or we may suffer security breaches.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, disruption of our operations, damage to our reputation and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay our clinical development of our product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Employees, Managing Our Growth and Our Operations</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the development, regulatory, commercialization and business development expertise of the executive team, as well as the other principal members of our management, scientific and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop product candidates, gain regulatory approval, and commercialize new products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize product candidates will be limited.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the&#160;percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business and operations would suffer in the event of system failures.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including hurricanes), terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of IMC-1 or any other product candidate could be delayed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to maintain listing of our common stock on the Nasdaq Capital Market or another national stock exchange, it may be more difficult for our stockholders to sell their shares of common stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nasdaq requires issuers to comply with certain standards to remain listed on its exchange. We have received a delisting notice from Nasdaq as a result of the closing bid price of our common stock being below $1.00 per share for 30 consecutive business days. Our common stock may be involuntarily delisted from Nasdaq if we fail to regain compliance with the minimum closing bid price requirement of $1.00 per share. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to maintain our listing on Nasdaq, it may become more difficult for our stockholders to sell our common stock in the public market, and the price of our common stock may be adversely affected due to the likelihood of decreasing liquidity resulting from delisting. In addition, it may inhibit or preclude our ability to raise additional funding. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market price of our common stock is highly volatile, which could result in substantial losses for holders of our common stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market price of our common stock is highly volatile and is subject to wide fluctuations in response to a variety of factors, including the following:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in submitting an NDA and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of that NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to successfully develop and commercialize IMC-1 or any future candidate;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries applicable to IMC-1 or any other candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain adequate product supply for IMC-1 or any other candidate, or the inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of new products, services or technologies by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial projections we provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed the estimates and projections of the investment community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of companies similar to ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors, and the issuance of new or changed securities analysts&#8217; reports or recommendations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us or our shareholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political, regulatory and market conditions, may negatively affect the market price of our common stock, regardless of our actual operating performance.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We could be subject to securities class action litigation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology companies have experienced significant share price volatility in recent&#160;years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts may publish about us or our business. We do not have any control over these analysts. If our financial performance fails to meet analyst estimates or one or more of the analysts who cover us downgrade our common stock or change their opinion of our common stock, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock would be our stockholder&#8217;s sole source of gain on an investment in our common stock for the foreseeable future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our principal stockholders and management own a significant&#160;percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially own approximately 16% of our outstanding voting stock. Therefore, these stockholders may be able to significantly influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. The interests of this group of stockholders may not always coincide the interests of our public market investors and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a public company, and particularly after we no longer qualify as an emerging growth company, we incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;), the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules&#160;and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules&#160;and regulations may make it more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. In addition, these rules&#160;and regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. Pursuant to Section 404 of SOX, we are required to furnish a report by our senior management on our internal control over financial reporting. While we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To comply with Section&#160;404, we are required to engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and maintain a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be reevaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In connection with our initial public offering, we began the process of documenting, reviewing and improving our internal controls and procedures for compliance with Section&#160;404 of SOX, which requires annual management assessment of the effectiveness of our internal control over financial reporting.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls and any failure to maintain that adequacy or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our common share price and make it more difficult for us to effectively market and sell our service to new and existing customers.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; and a &#8220;smaller reporting company&#8221; and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including exemption from compliance with the auditor attestation requirements of Section&#160;404, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal&#160;year (a)&#160;following the fifth anniversary of the closing of our IPO, (b)&#160;in which we have total annual gross revenue of at least $1.07 billion or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the end of our prior second fiscal quarter, and (2)&#160;the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 and reduced disclosure obligations regarding executive compensation. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the extended transition period for adopting new or revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Provisions in our certificate of incorporation and bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Advance notice bylaw provisions for proposals from stockholders for presentation at annual meetings; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Forum selection bylaw provisions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three&#160;years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our certificate of incorporation and our bylaws will contain exclusive forum provisions for certain claims, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our certificate of incorporation and our bylaws, to the fullest extent permitted by law, provide that the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the General Corporation Law of the State of Delaware, our certificate of incorporation, or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Moreover, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules&#160;and regulations thereunder and our bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. Section&#160;27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules&#160;and regulations thereunder and neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules&#160;and regulations thereunder must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit our stockholders&#8217; ability to bring a claim in a judicial forum they find favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation and/or bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5d576ba7_6eac_4b3e_b469_27e09519de1c"></a><a id="Item1BUnresolvedStaffComments_457500"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. Unresolved Staff Comments</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e606fafd_aee7_4067_b109_49bae36eeee8"></a><a id="Item2Properties_573127"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Properties</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">We do not own or lease any real property. We run a virtual model and have a mailing address in Alpharetta, Georgia.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4a7ff20a_a557_45fb_be50_aacc44ab7d56"></a><a id="Item3LegalProceedings_628469"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, we may be involved in claims that arise during the ordinary course of business. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management&#8217;s attention from important business matters and initiatives, negatively impacting our overall operations. we do not currently have any pending litigation to which we are a party or to which our property is subject that we believe to be material. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management&#8217;s attention from important business matters and initiatives, negatively impacting our overall operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e884204f_a70b_4b0b_86b8_4d148ea86074"></a><a id="Item4MineSafetyDisclosures_646555"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Not applicable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_97cf1ba1_7a72_442a_a302_753e223915b8"></a><a id="PARTII_565441"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our common stock has been listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;VIRI&#8221; since our initial public offering on December 16, 2020.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On November 1, 2022, Virios Therapeutics, Inc.  (the &#8220;Company&#8221;) received a letter (the &#8220;Notice&#8221;) from the Listing Qualifications Department (the &#8220;Staff&#8221;) of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company&#8217;s common stock </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price Requirement&#8221;). The Notice has no effect at this time on the Company&#8217;s common stock, which continues to trade on The Nasdaq Capital Market under the symbol &#8220;VIRI&#8221;.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until May 1, 2023 (the &#8220;Compliance Date&#8221;), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the bid price for the Company&#8217;s common stock closes at $1.00 or more for a minimum of 10 consecutive business days, the Staff will provide written notification to the Company that it has regained compliance with the Bid Price Requirement, unless the Staff exercises its discretion to extend this 10-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Company is not in compliance with the Bid Price Requirement by the Compliance Date, the Company may qualify for a second 180 calendar day compliance period. If the Company does not qualify for or fails to regain compliance during the second compliance period, then the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff&#8217;s delisting determination to the Nasdaq Listing Qualifications Panel. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination that such an appeal would be successful.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Holders of Record</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of February 28, 2023, there were approximately 139 holders of record of shares of our common stock. This number does not reflect the beneficial holders of our common stock who hold shares in street name through brokerage accounts or other nominees.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Dividend Policy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Issuer Purchases of Equity Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not repurchase any of our equity securities during the year ended December 31, 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;text-indent:18pt;margin:0pt;">We did not issue any equity securities during the year ended December 31, 2022 that were not registered under the Securities Act and that have not otherwise been described in a Quarterly Report on Form 10-Q or a Periodic Report on Form 8-K.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6b3710f5_4d50_4be4_bb23_c11bb8f53b80"></a><a id="Item6SelectedFinancialData_858223"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6. Selected Financial Data</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">This item is not required.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_06bdb22f_565e_4356_bf09_f2cd6ed0e950"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties, including those set forth under &#8220;Cautionary Statement About Forward-Looking Statements.&#8221; Actual results and experience could differ materially from the anticipated results and other expectations expressed in our forward-looking statements as a result of a number of factors, including but not limited to those discussed in this Item and in Item 1A - &#8220;Risk Factors.&#8221; Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as FM. Overactive immune response related to activation of tissue resident herpes virus has been postulated to be a potential root cause of chronic illnesses such as FM, IBS, chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of the herpes virus is triggered by some form of environmental and/or health stressor. Our lead product candidate, which we have named IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IMC-1 combines two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication, thereby keeping the herpes virus in a latent (dormant) state or &#8220;down-regulating&#8221; the herpes virus from a lytic (active) state back to latency. The famciclovir component of IMC-1 inhibits viral DNA replication. The celecoxib component of IMC-1 inhibits cyclooxegenase-2 (&#8220;COX-2&#8221;) and to a lesser degree cyclooxegenase-1 (&#8220;COX-1&#8221;), enzymes used by the herpes virus to amplify or accelerate its own replication. We are unaware of any other antivirals in development for the treatment of FM. We believe this novel approach was a germane consideration in the U.S. Food and Drug Administration (&#8220;FDA&#8221;) designating IMC-1 for fast-track review status for the treatment of FM. IMC-1 has also been granted a synergy patent based on the fact that neither of the individual components has proven effective in the management of FM, yet the combination therapy generated a result that is greater than the sum of its parts. IMC-1 was the focus of our Phase 2b FORTRESS study.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2022, we announced the top line results from our FORTRESS study in FM. Overall, the FORTRESS study did not achieve statistical significance on the prespecified primary efficacy endpoint of change from baseline to Week 14 in the weekly average of daily self-reported average pain severity scores comparing IMC-1 to placebo (p=0.302). However, based on the analysis of the FORTRESS data, community based patients who have not participated in prior FM clinical trials demonstrated statistically significant improvement on the primary endpoint of reduction in FM related pain versus placebo, irrespective of when they enrolled in the study. We believe focusing the forward development of IMC-1 on these &#8220;new&#8221; patients represents a viable and manageable path forward. The Company is scheduled to meet with the FDA in March 2023 to discuss the most appropriate next steps in advancing IMC-1 development as a treatment for FM and hopefully agree on a Phase 3 program. If alignment can be reached, management will consider raising additional capital to fund future research and/or seek a partner to develop or co-develop IMC-1 as a treatment for FM. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">For the Phase 3 program, we intend to run two qualifying pivotal trials demonstrating the safety and efficacy of IMC-1 treating patients with FM. The first Phase 3 study is planned to be a four-arm, multifactorial design to demonstrate the relative safety and efficacy of IMC-<span style="white-space:pre-wrap;">1 as compared to celecoxib alone, famciclovir alone and placebo. The second Phase 3 study is planned to be a two-arm study comparing IMC-1 to placebo.  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">All patients from the Phase 3 program will be offered the opportunity to enroll into an open label safety follow-on extension study with all on IMC-1, which is the third key component of the Phase 3 program proposal.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not generated revenues and have incurred losses since inception. Our net losses were $12,247,834 and $15,960,268 for the&#160;years ended December&#160;31, 2022 and 2021, respectively, and our accumulated deficit at December 31, 2022 was $56,173,207. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue to develop and seek regulatory approvals for our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty about economic stability. For example, the current conflict between Ukraine and Russia has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, if at all. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Operations Overview</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses consist of expenses incurred in development and clinical studies relating to our product candidates, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">payments to third-party contract research organizations, or CROs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">payments to third-party contract development and manufacturing organizations, or CMOs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expenses, such as salaries, benefits and stock compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">payments to contract laboratories and independent consultants.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expense all research and development costs as incurred. Clinical development expenses for our product candidates are a significant component of our current research and development expenses. Products in later stage clinical development generally have higher research and development expenses than those in earlier stages of development, primarily due to increased size and duration of the clinical trials. We track and record information regarding research and development expenses for each study or trial we conduct. We use third-party CROs, CMOs, contractor laboratories and independent contractors. We recognize the expenses associated with third parties performing services for us in our clinical studies based on the&#160;percentage of each study completed at the end of each reporting period.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our research and development expenses in 2022 primarily related to our FORTRESS study which completed in August 2022 and two long-term animal toxicology studies, a 26-week study in rats, which completed in the first quarter of 2022 and a 39-week study in dogs, which completed in the second quarter of 2022. Once we initiate our Phase 3 program in FM, we expect our research and development expenses to increase. These expenditures are subject to numerous uncertainties regarding timing and cost to completion. Completion of our clinical development and clinical trials may take several&#160;years or more. Because of the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration and completion costs of the current or future studies and clinical trials or if, when, or to what extent we will generate revenues from the commercialization and sale of our product candidates. We may never succeed in achieving regulatory approval for our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment in, and completion of, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of Investigational New Drug-enabling activities, including for IMC-1 for indications other than FM;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">making arrangements with third-party manufacturers or establishing our own commercial manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection and non-patent exclusivity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of IMC-1, if approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of IMC-1, if approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies and treatment options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile following approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">enforcing and defending intellectual property and proprietary rights and claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">achieving desirable medicinal properties for the intended indications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future product candidates. For example, if the FDA, or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. We expect our research and development expenses to increase for the foreseeable future as we continue the development of IMC-1 and other potential product candidates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries, benefits and other related personnel costs, including equity and stock-based compensation, for personnel serving in our executive, finance and administrative functions. General and administrative expenses also include public company costs, directors&#8217; and officers&#8217; insurance, professional fees for legal, including patent related expenses, consulting, auditing and tax services.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We anticipate that our general and administrative expenses will increase in the future to support continued research and development activities and potential commercialization of our product candidates and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (Expense), Net</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2022, other income (expense), net consists of interest income earned on cash in a money market account. In 2021, other income (expense), net primarily consists of the cost associated with the Release and Settlement Agreement with Torreya Capital LLC. See Note 8 to the Financial Statements included in this Annual Report on Form 10-K.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Parties</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company uses Gendreau Consulting, LLC (&#8220;Gendreau&#8221;), a consulting firm, for drug development, clinical trial design, and planning, implementation and execution of contracted activities with CROs. Gendreau&#8217;s managing member became the Company&#8217;s Chief Medical Officer (&#8220;CMO&#8221;) effective January 1, 2021. The Company has and will continue to contract the services of the CMO&#8217;s spouse through Gendreau to perform certain activities in connection with the Company&#8217;s clinical programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a full discussion of related party transactions see Note 7 to the Financial Statements included in this Annual Report on Form 10-K. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> As of December 31, 2022, the Company has U.S. federal and state net operating loss carryforwards of approximately $22,168,000. These net operating losses can be carried forward and applied against future taxable income, if any. These losses currently have no expiration date and may be carried forward indefinitely. As the Company was incorporated in December 2020, all tax years of the Company remain open to examination by tax authorities.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a full valuation allowance against its net deferred tax assets as of December&#160;31, 2022 and 2021 because the Company has determined that it is more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which these temporary differences become deductible.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Use of Estimates</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates&#160;&#8212; which also would have been reasonable&#160;&#8212; could have been used. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be most critical to the judgments and estimates used in the preparation of our financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development costs are expensed as incurred. The Company arranges and contracts with third-party contract research organizations (&#8220;CROs&#8221;), contract development and manufacturing organizations </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(&#8220;CMOs&#8221;), contractor laboratories and independent consultants. As part of the process of preparing its financial statements, the Company may be required to estimate some of its expenses resulting from its obligations under these arrangements and contracts. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided. The Company&#8217;s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are rendered. The Company determines any accrual estimates based on account discussions with applicable personnel and outside service providers as to the progress or state of completion. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company&#8217;s estimates are dependent upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record prepaid or accrued expenses related to these costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity and Share-Based Compensation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense relating to equity-based payments based on the fair value of the equity or liability instrument issued. For equity-based instruments, the expense is based upon the grant date fair value and recognized over the service period. For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and warrants granted using an options pricing model. Expense is recognized within general and administrative expenses and forfeitures are recognized as they are incurred.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18.7pt;">Operating expenses and other (expense) income were comprised of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18.7pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 8,069,628</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,795,688</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,245,681</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,845,252</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total operating expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 12,315,309</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,640,940</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other income (expense):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 67,475</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,672</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (325,000)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total other income (expense)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 67,475</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (319,328)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (12,247,834)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (15,960,268)</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Years Ended December&#160;31, 2022 and 2021</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development expenses decreased by $2.7 million to $8.1 million for the&#160;year ended December&#160;31, 2022 from $10.8 million for the&#160;year ended December&#160;31, 2021. The decrease was primarily due to decreases in expenses for clinical trials of $1.5 million, toxicology studies of $1.1 million and drug </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">development and manufacturing costs of $0.4 million partially offset by increases in salaries and related personnel costs of $0.2 million and amortization of research grant of $0.1 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses decreased by $0.6 million to $4.2 million for the&#160;year ended December&#160;31, 2022 from $4.8 million for the&#160;year ended December&#160;31, 2021. This decrease was primarily due to decreases in expenses for salaries and related costs of $0.2 million, costs associated with being a public company of $0.2 million and accounting and legal fees of $0.2 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Income (Expense)</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other income (expense) increased by $0.4 million to $0.1 million in income for the year ended December 31, 2022 from an expense of $0.3 million for the year ended December 31, 2021. The increase in other income was mainly due to an increase in interest income of $0.1 million from 2021 to 2022 and a decrease in expense of $0.3 million related to the Release and Settlement Agreement with Torreya Capital LLC in 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have financed our operations through public offerings of common stock and proceeds from private placements of membership interests and convertible promissory notes. To date, we have not generated any revenue from the sale of products and we do not anticipate generating any revenue from the sales of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of December 31, 2022, our principal source of liquidity was our cash, which totaled $7.0 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Financings</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 22, 2022, we closed an underwritten public offering raising gross proceeds of $5.0 million and net proceeds of approximately $4.5 million, after deducting underwriting discounts, commissions and offering expenses. There were no equity financings during the year ended December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Debt Financings</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There were no debt financings during the years ended December 31, 2022 and 2021. There was no debt outstanding at December&#160;31, 2022 and 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Capital Requirements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We estimate our current cash of $7.0 million at December 31, 2022 is sufficient to fund operations and capital requirements for at least the next 12 months subsequent to the filing date of the Company&#8217;s Annual Report on Form 10-K. Currently, there are no planned research and development activities for 2023 other than minimal carryover costs associated with completing the final reports the FORTRESS study and the chronic toxicology program, regulatory consulting to prepare for the FDA meeting, the on-going grant to BHC for the fully funded investigator-sponsored study in Long-COVID and purchase of API to support the start of a potential Phase 3 study for IMC-1. Additional capital will need to be raised before initiating additional research and development activities. We completed our FORTRESS study in August 2022 and are scheduled to meet with the FDA in March 2023 to discuss the most appropriate next steps in advancing IMC-1 development as a treatment for FM. If alignment on a Phase 3 program can be reached, management will consider raising additional capital to fund future research and/or seek a partner to develop or co-develop IMC-1 as a treatment for FM. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">We will need to raise additional capital before we exhaust our current cash in order to continue to fund our research and development, including, subject to consultation with the FDA, any plans for a Phase 3 trial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and any new product development, as well as to fund operations generally. We will need to finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. To the extent that we raise additional funds by issuing equity or equity-linked securities, our shareholders will experience dilution. We can give no assurances that we will be able to secure such additional sources of funds to support our operations, or, if such funds are available to us, that such additional financing will be sufficient to meet our needs. Failure to secure the necessary financing in a timely manner and on favorable terms could have a material adverse effect on the Company&#8217;s strategy and value and could require the delay of product development and clinical trial plans.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18.7pt;">The following table summarizes our cash flows from operating, investing and financing activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18.7pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Statement of Cash Flows Data:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (11,467,797)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (15,689,578)</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,490,605</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (97,604)</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Decrease in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (6,977,192)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (15,787,182)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Years ended December&#160;31, 2022 and 2021</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the year ended December&#160;31, 2022, net cash used in operations was $11.5 million and consisted of a net loss of $12.3 million offset by a net change in operating assets and liabilities of $0.2 million attributable to a decrease in prepaid expenses of $0.4 million and an increase in accounts payable of $0.2 million offset by a decrease in accrued expenses of $0.4 million and non-cash items of $0.6 million attributable to share-based compensation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, net cash used in operations was $15.7 million and consisted of a net loss of $15.9 million and a net change in operating assets and liabilities of $0.1 million attributable to an increase in prepaid expenses offset by non-cash items of $0.3 million attributable to share-based compensation. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities during the year ended December 31, 2022 was $4.5 million and was attributable to cash proceeds from our public offering in September 2022, net of costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used by financing activities for the year ended December 31, 2021 was $0.1 million and was attributable to $0.2 million in proceeds received from the exercise of warrants offset by the payment of $0.3 million in carryover offering costs from the Company&#8217;s IPO in December 2020.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not have any off-balance sheet arrangements or relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See Note 2 &#8211; Summary of Significant Accounting Policies in the accompanying notes to the financial statements elsewhere in this report for details of recently issued accounting pronouncements and their expected impact on our financial statements. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">JOBS Act</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;5, 2012, the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;), was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an &#8220;emerging growth company.&#8221; As an &#8220;emerging growth company,&#8221; we are electing to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Subject to certain conditions set forth in the JOBS Act, as an &#8220;emerging growth company,&#8221; we are not required to, among other things, (i)&#160;provide an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section&#160;404, (ii)&#160;provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii)&#160;comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis), and (iv)&#160;disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer&#8217;s compensation to median employee compensation. These exemptions will apply until the fifth anniversary of the completion of our initial public offering or until we no longer meet the requirements for being an &#8220;emerging growth company,&#8221; whichever occurs first.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_af61130f_a461_4cc7_9b85_c337cacef6fa"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This item is not required.</p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_9d727289_c935_43e9_be1b_cb9b70615a1d"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8. Financial Statements and Supplementary Data</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Index to Financial Statements</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#ReportofAccountingFirm"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#BalanceSheet"><span style="font-style:normal;font-weight:normal;">Balance Sheets as of December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#StateofOperations"><span style="font-style:normal;font-weight:normal;">Statements of Operations for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#StatementofChangesinEquity"><span style="font-style:normal;font-weight:normal;">Statements of Changes in Shareholders&#39; Equity for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">94</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#StatementofCashFlows"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">95</p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#NotestoFinancialStatements"><span style="font-style:normal;font-weight:normal;">Notes to Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">96</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_9e0b36a0_43c2_4127_9f34_ba1e7ac36d9b"></a><a id="ReportofAccountingFirm"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 0pt;">Shareholders and the Board of Directors </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 0pt;">Virios Therapeutics, Inc.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 36pt 0pt 0pt;">We have audited the accompanying balance sheets of Virios Therapeutics, Inc. (the &quot;Company&quot;) as of December 31, 2022 and 2021, the related statements of operations, stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31, 2022, and the related notes (collectively referred to as the &quot;financial statements&quot;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 36pt 0pt 0pt;"><span style="font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 36pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 36pt 12pt 0pt;">These financial statements are the responsibility of the Company&#39;s management. Our responsibility is to express an opinion on the Company&#39;s financial statements based on our audits. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 36pt 0pt 0pt;">We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&quot;PCAOB&quot;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 36pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 36pt 0pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 36pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 36pt 0pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 0pt;"><span style="font-variant:small-caps;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk65783700"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:AuditorName" id="Narr_AIlfJljf1kan1ADGr1-cuA">FORVIS, LLP (Formerly, Dixon Hughes Goodman LLP)</ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 0pt;">We have served as the Company&#39;s auditor since 2020. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 0pt;"><span style="font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:AuditorLocation" id="Narr_xHnzDFZvWE-smkwc-5fiDw"><b style="font-weight:bold;">Atlanta, Georgia</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 0pt;"><b style="font-weight:bold;">March 14, 2023</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_ba126fa6_bf3e_47f4_9af3_f63ee9f0c56f"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VIRIOS THERAPEUTICS, INC.</b></p><a id="BalanceSheet"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BALANCE SHEETS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_7238f437_2858_4c39_abe9_2283ae10472a"></a><a id="Tc_6x4jQB_f7kC9jdQZfQcxSA_1_2"></a><a id="Tc_6eARtgC3f0CuzUc2F4xEUw_1_5"></a><a id="Tc_MerCliRZUEGzk43hifeQuw_2_2"></a><a id="Tc_gL_PMM7Y7EeY5AgDF1jdlg_2_5"></a><a id="Tc_eZtY6bNGQEi0mfoYs_2czQ_3_0"></a><a id="Tc_9X6UB-wmFUiNOhNwH9TWaA_4_0"></a><a id="Tc_RT3S9okBB0my94LJRPEUCQ_5_0"></a><a id="Tc_0gKQJN8bMkupyS2LhofYBg_5_2"></a><a id="Tc_dqqXkE18DUC6-5AgtI6s3w_5_5"></a><a id="Tc_FYI9lPmJL0aIgYgjF83fcQ_6_0"></a><a id="Tc_SJ87TVbtm0ybvu_pyaMEFA_7_0"></a><a id="Tc_wucqDl7p20qikGY_ejiJew_8_0"></a><a id="Tc_2vKedk06SkGJvUJQgDHcrw_8_2"></a><a id="Tc_heVzixTrJ0az63Io6wRWLQ_8_5"></a><a id="Tc_tUUdFrF6oUGwyMtygvYpZA_9_0"></a><a id="Tc_LDRJpEiEkkqy_aQibJIanw_10_0"></a><a id="Tc_njHhJybKfEOaI0CR-vrxUw_11_0"></a><a id="Tc_OQ8qZfWuSkySqW--jPWg4w_11_2"></a><a id="Tc_HBnml-oWpEay0_BVv3XYRA_11_5"></a><a id="Tc_WgvN3IIQDUGVKBOEPoiPEQ_12_0"></a><a id="Tc_B2XR7JTxPUu5a4bc5qdPlg_13_0"></a><a id="Tc_dSwgzxe3zkqSVr7TTZ6pNA_14_0"></a><a id="Tc_zmH7bL0HtkCymG-imwqojw_15_0"></a><a id="Tc_kYtATYS-h0es12xj7IjEeg_16_0"></a><a id="Tc_9wCuMM4RqEWAmj0MpTKMPA_17_0"></a><a id="Tc_9RzDFNv-5U-eMMxV8mmr5A_18_0"></a><a id="_5536328e_0e67_4707_9962_3cf05249db64"></a><a id="_5536328e_0e67_4707_9962_3cf05249db64_2"></a><a id="_5536328e_0e67_4707_9962_3cf05249db64_3"></a><a id="Tc_CmM9UChp00--MA1XXMi_Vg_19_0"></a><a id="Tc_l9Bb16GBfkKAo5XoKolzMw_20_0"></a><a id="Tc_V5bRkiQgiUePUdTcn-hfLA_21_0"></a><a id="Tc_8yGgXSp3hkSZ8nYojqmS6A_22_0"></a><a id="Tc_akTifLWFeE6n7YXBzqPzAA_22_2"></a><a id="Tc_jYKeQWUNF0WcPyEuhi33qA_22_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_XYZPwqmI80CrOj1oolnMUg_5_3">7,030,992</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_hDVQrRVCUE-ul2iilTSZUw_5_6">14,008,184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Prepaid expenses and other current assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_3JX0vflhvkGONL9SpS41Bg_6_3">1,338,764</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_zPOHtVF2vUCwnpNj9E6tXQ_6_6">1,768,503</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_XBOfVVttuEiP7GvbsbR2Uw_7_3">8,369,756</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_eRAn66-NUEu0QU2bzV31Pw_7_6">15,776,687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_ulR25h4D3U-iqN7C1qhhqA_8_3">8,369,756</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_Zv9sLAElIk2II168uxlpDQ_8_6">15,776,687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#39; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_AKgcEM6gvky-CwzM3z6yqg_11_3">573,164</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_cAatySCcd0Cxv992iOKvMg_11_6">353,863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_UmoU1MSlDUu_u_HRmqRxhg_12_3">470,098</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_uCc9nV3Q_kGadoCrEDhzXQ_12_6">921,760</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_1VGzqo4iEUWu1mNkSinLKQ_13_3">1,043,262</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_9tHMQyKR_kK7FSqE9kJ2HQ_13_6">1,275,623</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_lCURV5faV0iDV9Ug4rqRRA_14_3">1,043,262</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_gipTcHKLykaM4tEnB6gzYA_14_6">1,275,623</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Commitments and contingencies (Note 8)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Stockholders&#39; equity:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_rZSg5I0p5ECFPTSTY21e8Q"><ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_P6AURPlJmUiz4lz2jG4Ogg">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_swwPA3zUYkuI7-Z9fN3yVA"><ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_qz_CDTeR8EuHq2yqJkt_OQ">43,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_RGn1Znqk7ke1zXdhicv7mw">18,330,390</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_X_bRSqU1p0-nJIkEQFxajg">8,330,390</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_oHnHAxEtjkSEk0DF-WTqiA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_VYcd50m3f0yVEciBOooblw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_wFButRb3HUqoVBodVK5-CQ_17_3">1,833</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_4qTSOcYkv0muxcd2_EzY5g_17_6">833</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_RREj4tHHCUyupnpg0nYdHQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_lz4Uws_Vqky4f1ZUmqzzgw">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_T3hLjyqe_0CjqqY6brkD7g"><ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_lvNk53GT_UacmDM-h7tgSw">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_7qhALSuM8U2MMbkwR9czaQ"><ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_O7wkVMVAg0CdZ_KMSOjH2Q">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_g98_LEx6m0iGYU0oez53mQ;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> &#8212;</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_H490oChYRUiWywnG5LXpSQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_KwTO8TeYk02J4fjoFEXzZg_19_3">63,497,868</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_Spbs4hzCW0Kl2lFh9HEB4Q_19_6">58,425,604</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_o35ctKZ10UWjnsjSnbYrBA_20_3">56,173,207</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_oyxD2liKFkG1KWFhw0tWMw_20_6">43,925,373</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stockholders&#39; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_E7YgM21RXEKBKMr_5qPI0Q_21_3">7,326,494</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_EOFu5V0aLUKAjKiVG6oYsA_21_6">14,501,064</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total liabilities and stockholders&#39; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_S4x8wHr4ykydgFRXnOX3lw_22_3">8,369,756</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_sGLOogTtKkuv_oukt467hQ_22_6">15,776,687</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to the financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_ee505a4b_0985_4134_afd6_438284f905b7"></a><a id="_contentSection_d8ac545e_5ac8_49f4_b0b6_"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">VIRIOS THERAPEUTICS, INC.</p><a id="StateofOperations"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF OPERATIONS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cdcb71d2_3ed4_4d40_8ed7_2c1b3492dd20"></a><a id="Tc_NNfBJyq_x0GCOi0VuS_O1w_1_2"></a><a id="Tc_z5w9sMwMoEK5-D704vyMyg_2_2"></a><a id="Tc_iGJINNXNMkWq9INy5F4Djw_2_5"></a><a id="Tc_86gk5v-qI0iaFXz7b4u0Pg_3_2"></a><a id="Tc_jaLvjBGdHkqdYUwKHGROMg_3_5"></a><a id="Tc_YrZOi_upbk6FI7Zhq-4ahQ_4_0"></a><a id="Tc_pF78GFobjE6n8YQs4aki2g_4_2"></a><a id="Tc_x83bGV_LT0-nmqrrk2MmIA_4_5"></a><a id="Tc_Xm16HAUJFUK8UkwGJuSptg_6_0"></a><a id="Tc_5NpTyRM_PE-8x37cHsRZzA_7_0"></a><a id="Tc_iZVD8FAe8ESM08pwc4g35w_8_0"></a><a id="Tc_8_FV-Gl_iEGMTku53YwYaA_9_0"></a><a id="Tc_1zChN2zPq0yqPjdaC6K5GQ_11_0"></a><a id="Tc_gaN-aI9exE6i_WlTuyJtuQ_13_0"></a><a id="Tc_018WaqNmUkavq3KU2rm3jQ_14_0"></a><a id="Tc_mlgnv14PZEePx8j_Re9DJQ_15_0"></a><a id="Tc_c9taIMjlGU2FVuNAlumkDQ_15_3"></a><a id="Tc_l42R5ky6LUaRfkZq0empVw_16_0"></a><a id="Tc_9Ch7LKXZmEGnlCP7xGS5Rw_18_0"></a><a id="Tc_Z9lcY89LW0ObQkDxn3h5yQ_19_0"></a><a id="Tc_GWXS_anLIkigPkr5ryEmmQ_19_3"></a><a id="Tc_ubzxhfKHwUaEdtpZQ5V0mg_19_6"></a><a id="Tc_NQNTI--6s0CZ3bnJMUREiA_21_0"></a><a id="Tc_bAF6PkGb0UeDxYbV3fKCAA_21_2"></a><a id="Tc_PN5slffl2UuoFbz4ytVPXw_21_5"></a><a id="Tc_4W9PDaNN5EWvEKjevoMDzA_22_0"></a><a id="Tc_l0W-t91FiESf0m0MrdlcYw_23_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_fShwsexZgUqxezn77bjtyQ;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> &#8212;</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_P2p0tDP4lU2AYmbbheUymA;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> &#8212;</b></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_HXwEnAVT0EqOdMZsrvcgTQ_7_3">8,069,628</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_8cb3g2A3HUiZhWtf7xdpCA_7_6">10,795,688</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_Ymo3jREfO0eJc3A63bw2AA_8_3">4,245,681</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_ZAIkBb43t0iqSDsI14zIxA_8_6">4,845,252</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_LS1Aqz0CmUWL32MoKIXfeA_9_3">12,315,309</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_4WBHHRCvx0u1V4sr5hjFQg_9_6">15,640,940</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_5cStOpNEY0u0aJVpv59N1g_11_3">12,315,309</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_oBWNCxOe5Ume7g9lfJrByA_11_6">15,640,940</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" id="Tc_e1hoSmpnwk2pO7kQF66vBg_14_3">67,475</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" id="Tc_H10yYDBuyEqrA3mBlLlQMg_14_6">5,672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="0" id="Tc_AxIJU_pt-ECOWW4cZENN0w_15_6">325,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="Tc_zD70wdW2f0ue6uaCf3QFyA_16_3">67,475</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="0" id="Tc_nhk1xRiEdkioHQyeflWHBw_16_6">319,328</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_EM0lrNSBg0OhBrL3QaiRww_18_3">12,247,834</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_eAAknUXXSk6DgaazeBuQ3g_18_6">15,960,268</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_9pd7FtIaCkC8L_sBJSXOzQ_21_3">12,247,834</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_WzaP-FOLL0KaAEYKcKIqVQ_21_6">15,960,268</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_MhJuUiG5jEG0ZWPo8EvG4A;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">$</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_F78nKKOWBka4UIG7ILGMuQ_22_3">1.11</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_WF2qwdt_CEm6Zk4VcPToSw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_UVX2VbFrsUmbOgEAmGca7g_22_6">1.92</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted average number of shares outstanding &#8211; basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_jyOkpiWlMUSjSbWluZApoA_23_3">11,070,116</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_GiRR1PoZgk28c6sBjmuuxw_23_6">8,329,310</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 38.95pt;">See accompanying notes to the financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_a12db6bf_d33d_42c4_b6ca_37ca07f59219"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">VIRIOS THERAPEUTICS, INC.</p><a id="StatementofChangesinEquity"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a4d73de5_0f21_41b9_8960_9f8a5185cb85"></a><a id="Tc_S6__fzyYekulWzN5JGgEnw_2_13"></a><a id="Tc_TeETSPX6lUOn-heYlZdGYg_3_2"></a><a id="Tc_7O5G1lnn-UW-OiPYcCBTww_3_7"></a><a id="Tc_vuQb7O70tUC9sBI99qByPg_3_10"></a><a id="Tc__Oz5o6ng4Ee4UHUObCZMAQ_3_13"></a><a id="Tc_7JfyuHGlfEKgjuV_WLCwog_4_2"></a><a id="Tc_Mc0YIvdP7kqzp7gIA_4cAQ_4_4"></a><a id="Tc_758dg4PrNkWvPUOTzfJA1g_4_7"></a><a id="Tc_gpMhVVNk6kij1GGyuUkuyQ_4_10"></a><a id="Tc_bTJuDrMcskeQEoPKuKELvw_4_13"></a><a id="Tc_E_d5iNCoRUqZK71OEomqww_5_0"></a><a id="Tc_dKoaJrx8ak6vcR21EX8W6w_5_4"></a><a id="Tc_hEzYy62i906zJ9XrCy9wdA_5_7"></a><a id="Tc_nZct1OsFHEiMXLFpcbWgAw_5_10"></a><a id="Tc_E1n2FrH_iUiddoktYo3UVg_5_13"></a><a id="Tc_LzGrMLoM00SDsJI61vyDaw_6_0"></a><a id="Tc_eyyAJ0KiHkiWeGzUIRm45Q_6_2"></a><a id="Tc_emJh9PuBKU2s0SO1JAk38A_6_5"></a><a id="Tc_w-nQ2fiZqUqIak3dKqT2dw_6_11"></a><a id="Tc_26Ds2gPjg02u2l9scDTWEg_7_0"></a><a id="Tc_XsRka7-ka0mAUxdeZ_CYbQ_7_11"></a><a id="Tc_8z1yjcwscUitW8A5k67XrA_8_0"></a><a id="Tc_V51VKEhd60CBG_Pn3nh9aQ_8_2"></a><a id="Tc_hgy80wqmEEquYUSG7ual1g_8_5"></a><a id="Tc_X6JkfQdzjE-qatgEkXqNog_8_8"></a><a id="Tc_ioQkSg0JCkul9ss65QhMtw_9_0"></a><a id="Tc_QCJl75uBa0CPumMQbfq9cw_9_4"></a><a id="Tc_zsMnkDhgXU2RLUtCLsAaDw_9_7"></a><a id="Tc_V9BSeGlBnUathxYHEGYubw_9_10"></a><a id="Tc_uPHBUU9SpU--p4nx6P6Q9A_9_13"></a><a id="Tc_mi7-nd3cP061_nTWAmq1WQ_10_0"></a><a id="Tc_oaAbndpYhEirLkq_hAUdBg_10_11"></a><a id="Tc_qkxTKmnVc06ZYlYCLpqT-g_11_0"></a><a id="Tc_hXqgN0DbGUe4jciZOeTjFw_11_2"></a><a id="Tc_9HY0LhKCI06uBSw-oF4olg_11_5"></a><a id="Tc_wsTSOj_-KU-2LqxMYDQ0Fw_11_11"></a><a id="Tc_gpEpZECiFkuxkMrVuwSRcQ_12_0"></a><a id="Tc_8VnZKVBevkyxwsP4xJ739w_12_2"></a><a id="Tc_YR6ocVTpUUKBhTIFhx3xqg_12_5"></a><a id="Tc_oYEGT5xfJUiMUzwgf82F4w_12_8"></a><a id="Tc_WjBFuiZOi0eAmIZg-qNf_A_13_0"></a><a id="Tc_xa7X_jWTtE2fnG68L7Qgkg_13_4"></a><a id="Tc_O3iHYSD6c0eHPfhgPaUVTw_13_7"></a><a id="Tc_KHX8dX0dLke1OIDUASLlEg_13_10"></a><a id="Tc_PkSlIUrGHEi2jJJ8uUnHEw_13_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#39;</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Par</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bmANR8woWk2jfaAekf9q_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_MR9JANizikWVcYQS1zEB8Q_5_2">8,305,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bmANR8woWk2jfaAekf9q_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_YLplOO4cekSHqBHLv9k0HQ_5_5">830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xSxWfKQTuEmBuKVtKLpaYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_TWj0pAUDrkiNWfs1yKJ4rg_5_8">57,905,164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TTmYcU_i-kGxQDW5uKyINw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_EQPeH3nfEE2i7RuSPRauJQ_5_11">27,965,105</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2020_tCm4u3HF1ESoDqVBr91eXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_U25HiZAn6Eae5Yli8pFnuw_5_14">29,940,889</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_13Xq7gMuT0mkNLo5wF0tow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_Qa0nIZNurUiVDd53eKl_5A_6_8">322,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_TxQyl6uxrkiY2N04K5rPZg_6_14">322,881</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_S_a8HrS8Ike_exmqyqXIMA" decimals="INF" format="ixt:numdotdecimal" name="viri:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_5S9-n67FPESXnriadTi8zA_7_2">25,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_S_a8HrS8Ike_exmqyqXIMA" decimals="0" format="ixt:numdotdecimal" name="viri:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_1KXbd0JNwUGA7eF9HM65cg_7_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_13Xq7gMuT0mkNLo5wF0tow" decimals="0" format="ixt:numdotdecimal" name="viri:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_wXSd_AbhPU-5wDxFkQ6Srw_7_8">197,559</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="viri:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_fbflZTJhDECa2cebKp445w_7_14">197,562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nhUquGnkwkWL4lFfC9GfAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_7XA8z7sqh0SAm8iKKTlhIg_8_11">15,960,268</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_e7JJnUONVkyFLH0yc_YCnw_8_14">15,960,268</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m9xCbfrpkkuZH2FpqooItA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_KnhNz4nM0U-GM3kbJ0NQAw_9_2">8,330,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m9xCbfrpkkuZH2FpqooItA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Xrg6008BLEutH1tl66orGg_9_5">833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9rd8UeAZvkiyb61_0b58xQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_4sgSqovgKUSb_gGA0D9vPQ_9_8">58,425,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_585XaE_Qb06wg3yY8VCAnw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_7-syKa8gUUCluFOvtKorYw_9_11">43,925,373</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_0u_yxRqBtkSarcbcJng20A_9_14">14,501,064</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Issuance of common shares in public offering, net of costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mTuQdj48xkSPPkeT8q6HWw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_UACgrMPar0-M3VroH-CZpw_10_2">10,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mTuQdj48xkSPPkeT8q6HWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_VXGMFYs5TE-Zt7ZIkNLdXQ_10_5">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fp9m85ab_kqv2G63PG8esw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_iZ1-0lK_xkSEPX2DBmmV7A_10_8">4,489,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_mqzjoehbcEaAKjWGtD4v_g_10_14">4,490,605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fp9m85ab_kqv2G63PG8esw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_8WWTOJUWn0OLKShw07KKAQ_11_8">582,659</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_69-dofRcmUGuXahJ8mxtYw_11_14">582,659</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aWecVCFl10-XycTsN-tb1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Y3jRrNPfJ0WDjg5v3mYKiw_12_11">12,247,834</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_dMgh6byj70aVOHmU03RjhQ_12_14">12,247,834</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:38.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_na0T6F0WK0iSAkJB4vdliQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_c5wvUb5Ex0iigK88NKG61A_13_2">18,330,390</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_na0T6F0WK0iSAkJB4vdliQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_R_io_gAsMUGo0AFECmoB7w_13_5">1,833</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZScAQIaW_km0W4UmK9ailg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Gzt8msg96k68Jyti4miEVw_13_8">63,497,868</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4-H-oXcCNESU_xrftuaLnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_yjfyFvRgW0uxrkIJHcoG3A_13_11">56,173,207</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_vZe8L4XjkE61ZegBnv7dng_13_14">7,326,494</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 38.95pt;">See accompanying notes to the financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_011705fd_dd1d_4f37_a500_25e2515a36fe"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">VIRIOS THERAPEUTICS, INC.</p><a id="StatementofCashFlows"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF CASH FLOWS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8eacd34d_5aa7_4724_a784_16e70976bf09"></a><a id="Tc_XQxI50zp70mIup-9lgn0qw_1_2"></a><a id="Tc_Uzzd7qw030uoJikj5hDGmA_2_2"></a><a id="Tc_9YOQXw8RZEC2E3xQ8SDVGA_2_5"></a><a id="Tc_fppbQeB5OU2UXBh7YaAJjw_3_2"></a><a id="Tc_xK3EiHsJzUSYEqDQOUx9Rg_3_5"></a><a id="Tc__t9ycjOl50S1z5ni5NjgRg_4_0"></a><a id="Tc_JcsmEcPAZUuKnVlUOf_9Yg_5_0"></a><a id="Tc_3ubzciEc_UOwG1RS1osTjw_5_2"></a><a id="Tc_U0OMbGnlbkKzgLWs-lXTEQ_5_5"></a><a id="Tc_R2PdPhPKhUOdkdrnxoYGuw_6_0"></a><a id="Tc__-ogJn7IBkW809hrYS8U2g_7_0"></a><a id="Tc_IcBVRjqszUqPiyTzSebRcg_8_0"></a><a id="Tc_li1PBkZxh0C3ZcYDMugJEw_9_0"></a><a id="Tc_oYRAOs2bt0Wm8tCStW3sRA_10_0"></a><a id="Tc_AHFFk5fw_0eykA_OElLmXA_11_0"></a><a id="Tc_OA_VAWezRkylye2PtpH96A_12_0"></a><a id="Tc_IXyNjAHM20-6HPxGxh8WQQ_12_3"></a><a id="Tc_Mtibx4nFa0uykwGWxxIscA_13_0"></a><a id="Tc_SSV4QCWf5EmHAlUzVuJ3uQ_14_0"></a><a id="Tc_29xI5aPC7Eaphr6D_QVr1A_15_0"></a><a id="Tc_yKGQz6LFvE6krWyzvn8SqQ_16_0"></a><a id="Tc_IvftJ3vyeU2j_rYSr79G5A_16_3"></a><a id="Tc_8pOtvBEz7Uahw1l6S7UehA_17_0"></a><a id="Tc_Ny40ilCdK0m-FKORrowQQg_18_0"></a><a id="Tc_YEIaZkTWTUmNmIaa7FobFQ_19_0"></a><a id="Tc_UB016L5K3U2H4WPF86HR8A_20_0"></a><a id="Tc_pPh0-tKe6kOCfyxLUaiEXQ_20_2"></a><a id="Tc_DUtyuJR0bkKWdHBrCpt1Sg_20_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_RAUpIdOTNkyxKeVBhpx0fA_5_3">12,247,834</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_X0c7SjdEHky5tbtNhla6Pg_5_6">15,960,268</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Share-based and equity compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_FN6X7fS90kyRMyq4eLVMdQ_7_3">582,659</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_IlNeM8HRzUqrQvHQUyUZAw_7_6">322,881</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Decrease (increase) in prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_bQz_Y6B1G0yL9CAJHstQSg_9_3">429,739</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_eya_Zy4X7kysxDwhnZZ14A_9_6">91,138</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Increase in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_Vka134VeHEKL7negIIG0-A_10_3">219,301</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_2YuTgSLW3Uy1Mrc7MM9fug_10_6">270,007</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">(Decrease) increase in accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_8MUo4T5Uzk6OUfpPO9OSfQ_11_3">451,662</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_t_VaXrkxDEeNBt-fTfcUpw_11_6">147,773</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Decrease in accrued salaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedSalaries" sign="-" scale="0" id="Tc_z1gqYwGWyECTS-rBCjrwig_12_6">378,833</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_xXkkeavaa0ei1b_Kct5rpQ_13_3">11,467,797</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_ddEx60sV0EG5-WTZTYuzQQ_13_6">15,689,578</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from initial public offering, net of costs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="Tc_nAxssqAPqE6v7lLkbMKgjw_15_3">4,490,605</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" sign="-" scale="0" id="Tc_Se-h7Om-PkqBn6UYGqb_Yg_15_6">295,166</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from the exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_pojKn03tY0Wky5cOjo-aNA_16_6">197,562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Net cash provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_7Qef1Ofb80a7r7UaWED65g_17_3">4,490,605</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="0" id="Tc_3nqeGdWeIUieKurN6-OkXQ_17_6">97,604</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_9D9i1E2NBkmMRwXHqc8cqA_18_3">6,977,192</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_VgCmrvSD40SnhwxjRqU3zQ_18_6">15,787,182</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash, beginning of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_RkorXC64r0iBPCNen0Bv6A_19_3">14,008,184</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2020_tCm4u3HF1ESoDqVBr91eXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_2HOnP9iDRk-PYkJVjAxMOg_19_6">29,795,366</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash, end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_KpQmDAAVS0K8ExZoEJK_WQ_20_3">7,030,992</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_R89ZzOi-hEeb-gd8dsDAhg_20_6">14,008,184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">See accompanying notes to the financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_0764f8ce_96e1_4a7c_ad2c_aced7fe44cd5"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">VIRIOS THERAPEUTICS,&#160;INC.</p><a id="NotestoFinancialStatements"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_sbT_04F9u06UtASDlg2s5g" continuedAt="Tb_sbT_04F9u06UtASDlg2s5g_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;Background and Organization</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Virios Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the State of Delaware on December 16, 2020 through a corporate conversion (the &#8220;Corporate Conversion&#8221;) just prior to the Company&#8217;s initial public offering (&#8220;IPO&#8221;). The Company was originally formed on February&#160;28, 2012 as a limited liability company (&#8220;LLC&#8221;) under the laws of the State of Alabama as Innovative Med Concepts, LLC. On July&#160;23, 2020, the Company changed its name from Innovative Med Concepts, LLC to Virios Therapeutics,&#160;LLC. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company operates in one segment as a pre-revenue, development-stage biotechnology company focused on advancing novel combination antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The Company is developing its initial product candidate, IMC-1, for people who are suffering from fibromyalgia (&#8220;FM&#8221;). Research has shown that the herpes virus could be a potential root cause of FM. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib, both of which are drugs approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for other indications. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication, thereby converting activated herpes virus back to dormancy and/or by keeping the herpes virus in a latent or dormant state. The famciclovir component of IMC-1 inhibits viral DNA replication, thus inhibiting upregulation of the herpes virus. The celecoxib component of IMC-1 inhibits cyclooxegenase-2 (&#8220;COX-2&#8221;) enzymes used by the herpes virus to amplify or accelerate its own replication. IMC-1&#8217;s synergistic antiviral mechanism represents a first-in-class medicine designed specifically to inhibit both herpes virus activation and subsequent replication, with the goal of keeping tissue resident herpes virus in a latent state.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Public Offering</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On September 19, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with ThinkEquity LLC (the &#8220;Underwriter&#8221;) in connection with the issuance and sale by the Company in a public offering of </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_9_19_2022_To_9_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FjS6TDESSkSjA8g43D0JKQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_iofUl-bh5U2AaPEjD-w7Hw">10,000,000</ix:nonFraction></span><span style="font-weight:normal;"> shares of its common stock at a public offering price of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_-1wVCgH_70aGrk02hPH6Nw">0.50</ix:nonFraction></span><span style="font-weight:normal;"> per share (the &#8220;Offering&#8221;), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-263700). The Offering closed on September 22, 2022 and the gross proceeds from the Offering were </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_1fMOHVhNGUOjUvCYpTl0MQ">5,000,000</ix:nonFraction></span><span style="font-weight:normal;">. The net proceeds of the Offering were approximately </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="Narr_V208XluLyEWj2WQkqIsbpw">4,490,605</ix:nonFraction></span><span style="font-weight:normal;white-space:pre-wrap;"> after deducting underwriting discounts, commissions and offering expenses payable by the Company.  In conjunction with the Offering, the Company granted to the Underwriter </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_4ZaEHX1kVEWukng2VCdHEg">500,000</ix:nonFraction></span><span style="font-weight:normal;"> warrants to purchase shares of the Company&#8217;s common stock at an exercise price of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_fqfqGGlLqEC4WTajr6pavg">0.625</ix:nonFraction></span><span style="font-weight:normal;"> per share, which was </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg" decimals="2" format="ixt:numdotdecimal" name="viri:WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice" scale="-2" id="Narr_agErT73GREyj6PXa3drd9A">125</ix:nonFraction>%</span><span style="font-weight:normal;"> of the Offering price.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Material Uncertainty</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its founding, the Company has been engaged in research and development activities as well as organizational activities, including raising capital. The Company has not generated any revenues to date. As such, the Company is subject to all of the risks associated with any development-stage biotechnology company that has substantial expenditures for research and development. Since inception, the Company has incurred losses and negative cash flows from operating activities. The Company has funded its losses primarily through issuance of members&#8217; interests, convertible debt instruments and issuance of equity securities. For the years ended December 31, 2022 and 2021, the Company incurred net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Narr_Bq996NVPY02z4NLqYvcJDQ">12,247,834</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Narr_I4-P5z00okOeGLSXe-GUPQ">15,960,268</ix:nonFraction>, respectively, and had net cash flows used in operating activities of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Narr_L2xC1nj25kyFSTQ5ilRXLg">11,467,797</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Narr_IYrDMraJpEmsie-tWIvycg">15,689,578</ix:nonFraction>, respectively. As of December&#160;31, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Narr_enUBt7pbZUeJnd_K2jkimg">56,173,207</ix:nonFraction>.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of the date these financial statements are issued, based on reasonable estimates, current cash is sufficient to fund operating expenses and obligations for at least 12 months. Currently, there are no planned research and development activities for 2023 other than minimal carryover costs associated with completing the final reports for the Company&#8217;s FORTRESS, (Fibromyalgia Outcome Research Trial Evaluating </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_sbT_04F9u06UtASDlg2s5g_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Synergistic Suppression of HSV-1), study for the treatment of FM and the chronic toxicology program, regulatory consulting to prepare for the meeting with the FDA, the on-going grant to the Bateman Horne Center for the fully funded investigator-sponsored study in Long-COVID and the purchase of active pharmaceutical ingredients to support the start of a potential Phase 3 program for IMC-1.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses in 2022 primarily related to our FORTRESS study for IMC-1, the Company&#8217;s lead candidate, which was completed in August 2022 and two long-term animal toxicology studies; a 26-week study in rats, which was completed in the first quarter of 2022 and a 39-week study in dogs, which was completed in the second quarter of 2022. Overall, the study for IMC-1, did not achieve statistical significance on the prespecified primary efficacy endpoint of change from baseline to Week 14 in the weekly average of daily self-reported average pain severity scores comparing IMC-1 to placebo (p=0.302). However, management observed a differential response based on the timing of patient enrollment and believe it is highly unlikely due to chance or a random occurrence, thus further analysis of the data was warranted, particularly in the context of the previous IMC-1 Phase 2a study success. Based on the analysis of the data, management believes focusing the forward development of IMC-1 on new fibromyalgia patients remains a viable and manageable path forward. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is scheduled to meet with the FDA in March 2023 to discuss the most appropriate next steps in advancing IMC-1 development as a treatment for FM and hopefully agree on a Phase 3 program. If alignment can be reached, management will consider raising additional capital to fund future research and/or seek a partner to develop or co-develop IMC-1 as a treatment for FM.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company will need to raise additional capital within the next <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_LDUdwdZQkU2vEFN0QuBgEQ" format="ixt-sec:durmonth" name="viri:PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment" id="Narr_Fd588vvUj0eYDo_aQr3Ljw">13</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_xfm2EfLia0i3nez_VARJng" format="ixt-sec:durwordsen" name="viri:PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment" id="Narr_3vO7V3a8EE-IXlZBXQdpeQ">18 months</ix:nonNumeric> to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms. The financial statements do not include any adjustments to reflect this uncertainty.</p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_7DCnA2ZllEO3Nz2iddq-1Q" continuedAt="Tb_7DCnA2ZllEO3Nz2iddq-1Q_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_v1HHbe2ejkWP5oAv7vRTYg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Basis of Presentation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:UseOfEstimates" id="Tb_yyMmUWHuOkOZ0nvJMP3VSw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company&#39;s significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_ICfjdY7DTkWRCFuTK1gGXQ" continuedAt="Tb_ICfjdY7DTkWRCFuTK1gGXQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentrations of Credit Risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash is potentially subject to concentrations of credit risk. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_7DCnA2ZllEO3Nz2iddq-1Q_cont1" continuedAt="Tb_7DCnA2ZllEO3Nz2iddq-1Q_cont2"><ix:continuation id="Tb_ICfjdY7DTkWRCFuTK1gGXQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_9KY8LbfMC0KfCIAAGDyTgA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i>, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8212; Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8212; Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amount of the Company&#8217;s financial instruments, including cash, accounts payable and accrued expenses approximate their fair values.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_oRtdRs3FxUC13yy7SEhtxg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cash</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash is maintained in bank deposit accounts, which exceed the federally insured limits of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashFDICInsuredAmount" scale="0" id="Narr_mUEOQHRXgEqifw9HbDxcZw">250,000</ix:nonFraction>. The Company does not have any cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="Tb_tn8y24CdEkC-Srgv5V_tOQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Variable Interest Entities</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When determining whether a legal entity should be consolidated, the Company first determines whether it has a variable interest in the legal entity. If a variable interest exists, the Company determines whether the legal entity is a variable interest entity (&#8220;VIE&#8221;) due to either: 1) a lack of sufficient equity to finance its activities, 2) its equity holders lacking the characteristics of a controlling financial interest, or 3) the legal entity being structured with non-substantive voting rights. If the Company concludes that the legal entity is a VIE, the Company next determines whether it is the primary beneficiary due to it possessing both: 1) the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, and 2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE which could be significant to the VIE. If the Company concludes that it is the primary beneficiary, it consolidates the entity.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:EquityMethodInvestmentsPolicy" id="Tb_kEyfkaEOI0-Eoi_t2P_KjA" continuedAt="Tb_kEyfkaEOI0-Eoi_t2P_KjA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Equity Method Investment</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2017, the Company purchased a <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_viri_NorthriverPharmLlcMember_5EL1vFgplUm9u---06s8UQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_TQCIt0TUF0Kt7muI3eTQJg">25</ix:nonFraction>% ownership in Northriver Pharm, LLC (&#8220;NRP&#8221;) in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_viri_NorthriverPharmLlcMember_5EL1vFgplUm9u---06s8UQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="Narr_rAjVzQHxYEK2LekNMExVLQ">125,000</ix:nonFraction> from existing investors of NRP. NRP is an entity with common ownership with the Company&#8217;s former Chief Executive Officer and Founder, who is also the Founder and sole voting member of NRP. The Company evaluated the ownership under VIE guidance and has determined that the Company does not have the power and economics to control the entity and are not the entity most closely associated with NRP.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company previously accounted for the investment under the equity method of accounting. However, consistent with equity method accounting guidance, the Company has now discontinued applying the equity method accounting as the investment has been reduced to zero and the Company has not committed to provide further financial support and there is no expected return to profitable operations by NRP.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk66200019"></a><ix:continuation id="Tb_7DCnA2ZllEO3Nz2iddq-1Q_cont2" continuedAt="Tb_7DCnA2ZllEO3Nz2iddq-1Q_cont3"><ix:continuation id="Tb_kEyfkaEOI0-Eoi_t2P_KjA_cont1"></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"> <span style="font-style:italic;">Income Taxes</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_brpo-ZcUvE6isq2q3S-dQA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company operated as an Alabama limited liability company until its Corporate Conversion. Therefore, the Company passed through all income and losses to its members until this point. As of December 31, 2022 and 2021, the Company had a full valuation allowance against deferred tax assets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, <i style="font-style:italic;">Income Taxes</i>. Under ASC 740, consideration is given to the recognition and measurement of tax positions that meet a &#8220;more-likely-than-not&#8221; threshold. A tax position is a position taken in a previously filed tax return or a position expected to be taken in a future that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions include the Company&#8217;s status as a pass-through entity until December 16, 2020 and as a corporation thereafter. The recognition and measurement of tax positions taken for various jurisdictions consider the amounts and probabilities of outcomes that could be realized upon settlement using the facts, circumstances, and information available at the reporting date. The Company has determined that it does not have any material unrecognized tax benefits or obligations as of December&#160;31, 2022 and 2021. The Company recognizes interest and penalties related to uncertain tax positions, if any, in income tax expense. The Company is not currently under examination by the Internal Revenue Service or by state tax authorities and the Company&#8217;s tax year remains subject to examination by the tax authorities.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_rUIYudLUAk2GcvhFhcMOPA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Basic and Diluted Net Income (Loss) per Share</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share (&#8220;EPS&#8221;) is computed in accordance with U.S. GAAP. Basic EPS is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted EPS reflects potential dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if all potential common shares had been issued and were dilutive. However, potentially dilutive securities are excluded from the computation of diluted EPS to the extent that their effect is anti-dilutive. For the&#160;years ended December&#160;31, 2022 and 2021, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_zVHuNo8JJUOL740CgoX5UA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_QXMWpSs4xkeqgtHCN7tyQg">1,924,397</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aPhBzRC3h0y-kExu1oDuMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_w_gnMCn2TEOBnBQrkNz_wg">1,041,647</ix:nonFraction> options, respectively, and <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_J7UBwLt2s02a0dmSAvm0Hg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_fbrJXfTOFEyZQ0P3u1cblA">672,500</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_tuCBnQCdJkqjINAChtpNqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_GdM8JsVf3UqwhtocXzWcsw">172,500</ix:nonFraction> warrants, respectively, to purchase common shares outstanding that were anti-dilutive. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_nnR3q444eUaIA7vQhG6DmQ" continuedAt="Tb_nnR3q444eUaIA7vQhG6DmQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development costs are expensed as incurred. The Company arranges and contracts with third-party contract research organizations (&#8220;CROs&#8221;), contract development and manufacturing organizations (&#8220;CMOs&#8221;), contractor laboratories and independent consultants. As part of the process of preparing its financial statements, the Company may be required to estimate some of its expenses resulting from its obligations under these arrangements and contracts. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided. The Company&#8217;s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are rendered. The Company determines any accrual estimates based on account discussions with applicable personnel and outside service providers as to the progress or state of completion. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company&#8217;s estimates are dependent upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk66200315"></a><ix:continuation id="Tb_7DCnA2ZllEO3Nz2iddq-1Q_cont3"><ix:continuation id="Tb_nnR3q444eUaIA7vQhG6DmQ_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record prepaid or accrued expenses related to these costs.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_CmNdkZOXgkuE8t6vYV3fuQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Share-Based Compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense relating to share-based awards to employees and directors with a performance condition over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and warrants granted using an options pricing model, see Note 9. Expense is recognized within both research and development and general and administrative expenses and forfeitures are recognized as they are incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="viri:StatusOfCompanyPolicyTextBlock" id="Tb_QeL_sLfDCkmCPFhuJhZ2Ww" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided by the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_R45bmCCzkEKTMQUZz0WF6g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recent Accounting Pronouncements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes</i>. The standard eliminates the need for an organization to analyze whether the following apply in a given period: (1) the exception to the incremental approach for intraperiod tax allocation; (2) the exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (3) the exception in interim periods income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also is designed to improve financial statement preparers&#8217; application of income tax-related guidance and simplify U.S. GAAP for (1) franchise taxes that are partially based on income, (2) transactions with a government that result in a step-up in the tax basis of goodwill, (3) separate financial statements of legal entities that are not subject to tax, (4) enacted changes in tax laws in interim periods and (5) certain income tax accounting for employee stock ownership plans and affordable housing projects. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">In August 2020, the FASB issued ASU 2020-06, <i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. Early adoption is permitted. ASU 2020-06 allows companies to adopt the guidance through either a modified retrospective method of transition or a fully retrospective method of transition. The Company is continuing to evaluate the impacts that ASU 2020-06 will have on its financial statements.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_contentSection_71eaaaec_832d_422a_af20_"></a><a id="Tc_l3W5poCCWEiErRpmoIub5A_1_2"></a><a id="Tc_0j4hXnk6y063ngvCpyiDbw_1_5"></a><a id="Tc_en6zS3APEU-NRrZQsMHNoA_2_2"></a><a id="Tc_kaqvip1VeESVIMlxUFOFhA_2_5"></a><a id="Tc_kz9GgnYNNkmsbqm199SuZw_3_0"></a><a id="Tc_MqxScqR3d0eXk7k26xpruA_3_2"></a><a id="Tc_AurSOQ5qOkqCX_PAH5cD3w_3_5"></a><a id="Tc_6qbr_dfFDEufSwq_pIZmbg_4_0"></a><a id="Tc_6nJrOglol0uuTQWLsKb9wg_5_0"></a><a id="Tc_kfCHFNJjN0mFETJ1mzzjBA_6_0"></a><a id="Tc_5Tt3X96BIECCl-h83eDsiA_7_2"></a><a id="Tc_esKUwFLTXUSWm6vZyLvrHg_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="viri:PrepaidExpenseAndOtherAssetsCurrentTextBlock" id="Tb_1lzxCRoWf0mQ5MrVr_8Ugg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;Prepaid Expenses and Other Current Assets</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18.7pt;">Prepaid expenses and other current assets consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="viri:PrepaidExpenseAndOtherAssetsCurrentTableTextBlock" id="Tb_A93SbGaJbEec9fsRT7nWQg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_DBhf1XwVNEOJpMiUtIf-7w_3_3">1,165,634</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_oAIq56JaNUmAFYz-JJHXLw_3_6">1,329,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid clinical research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="viri:PrepaidClinicalResearchCosts" scale="0" id="Tc_FwGPFdessEykyS97znj4Mw_4_3">154,510</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="viri:PrepaidClinicalResearchCosts" scale="0" id="Tc_Y-yhfmflFUKKDAiFCruI_Q_4_6">422,591</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="viri:PrepaidServices" scale="0" id="Tc_OLXc4Pgt3kuSHCbgHN_w3w_5_3">11,329</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="viri:PrepaidServices" scale="0" id="Tc_09vWMQYjdkWZhedO30LlRQ_5_6">15,664</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other miscellaneous current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="0" id="Tc_IIfb7HxWP0Wf5hxDIep7KA_6_3">7,291</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="0" id="Tc_Gi2iEhJD5USkB3DasdY0bQ_6_6">863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_xseEqjeLZUiz-14akJ2hbQ_7_3">1,338,764</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_GB4nNs_Z00eYATcSpGJWEg_7_6">1,768,503</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_oZs6fzJFR0eOeRxVVIJ_8g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;License Agreement</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company entered into a Know-How License Agreement (the &#8220;Agreement&#8221;) with the University of Alabama (&#8220;UA&#8221;) in 2012. In consideration for the Agreement, UA received a <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2012_To_12_31_2012_us-gaap_TypeOfArrangementAxis_viri_KnowHowLicenseAgreementMember_v_HMShg6JkeIz5pkc4ARKw" decimals="2" format="ixt:numdotdecimal" name="viri:CollaborativeArrangementPercentageOfNonVotingMembershipInterest" scale="-2" id="Narr_NGENaWDRjk-ABWTg2EhBiA">10</ix:nonFraction>% non-voting membership interest in the Company. Upon the adoption of the May 1, 2020 Second Amended and Restated Operating Agreement, the non-voting membership interest converted to a voting membership interest. Upon the Corporate Conversion, voting membership interest was converted into shares of common stock. The Agreement is in effect for <ix:nonNumeric contextRef="Duration_1_1_2012_To_12_31_2012_us-gaap_TypeOfArrangementAxis_viri_KnowHowLicenseAgreementMember_v_HMShg6JkeIz5pkc4ARKw" format="ixt-sec:durwordsen" name="viri:LicenseAgreementExpirationPeriod" id="Narr_-czADAp2XUChjzWLEMfTsg">25&#160;years</ix:nonNumeric> and will terminate on June&#160;1, 2037.</p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_contentSection_4aec0257_5eab_4a6d_bd65_"></a><a id="Tc_FsbevYY1sUKOsykgd8jrgg_1_2"></a><a id="Tc_qkJ48r9OvkKjcg5P7oc5Tw_1_5"></a><a id="Tc_QxuA7wxrNkS_IOkwOLK4eQ_2_2"></a><a id="Tc_0s49Qia1BUOqXmIWNKPUGg_2_5"></a><a id="Tc_3liPnw2F-Uev6dQ6FTJz1w_3_0"></a><a id="Tc_26Bmyej1ZUGtswhiJqBFBg_3_2"></a><a id="Tc_DH06jTMbj0a0AKpXzmgdMA_3_5"></a><a id="Tc_gqiExo3FPUuUBTR6hKxZ7A_4_0"></a><a id="Tc_pgrCzIpFlU2rGNUd0SZ4dg_5_0"></a><a id="Tc_whMegwbzcE-OccTEEo9BSQ_6_0"></a><a id="Tc_NQ4fmSfRj0mfNW9QI5jpjA_7_0"></a><a id="Tc_k9HzDAw70kWEPWvlDOAF7Q_8_0"></a><a id="Tc_nwV-ZzygxEG17HfPsmWFmw_9_2"></a><a id="Tc_Y-XZH_c5MUaxjt5L7ambVQ_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_H10zK1LjI0Ge4nWfe-1MWg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.&#160;&#160;&#160;&#160;Accrued Expenses</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18.7pt;">Accrued expenses consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_zH1unIr4ZEuZtsvxNww2_g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_LJ98zD3mokelwEn7MTe99w_3_3">159,704</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_JvD6kNzaA0egbpeTHoaWcg_3_6">532,678</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest on preferred members&#8217; interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="viri:AccruedInterestOnPreferredMembersInterest" scale="0" id="Tc_nrSJITKs_EGaS8kHSlN3Gw_4_3">188,085</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="viri:AccruedInterestOnPreferredMembersInterest" scale="0" id="Tc_IPksdf2CUEinXrvtQl8A9g_4_6">188,085</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="viri:AccruedResearchAndDevelopmentCosts" scale="0" id="Tc_K2UnRgzkik2xh02rB8HGDQ_5_3">78,349</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="viri:AccruedResearchAndDevelopmentCosts" scale="0" id="Tc_ndxi_ViSOkeFkymwE-xkVQ_5_6">138,522</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued director fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="viri:AccruedDirectorFeesCurrent" scale="0" id="Tc_J9UwS45rzkC1UkgKWk_t8g_6_3">31,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="viri:AccruedDirectorFeesCurrent" scale="0" id="Tc_SZy0uKtmEkyp2F9zrrHqTg_6_6">31,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_bBI07w4acEGlY0mFfoAO6Q_7_3">11,600</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_ANsb6ri_Y0uBLy9Y52lExg_7_6">24,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other miscellaneous accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_1n4gSKm8OUq96sWg9S58qw_8_3">1,360</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_3vOv4uTO0kyZEogVr6KZWQ_8_6">7,375</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_PmrK0J3dyEq5Il8m1ymTig_9_3">470,098</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_WtPtkEb0OU-24YDzzEBZZA_9_6">921,760</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_O_CHQ_h3DkWcWRkxFCvtdA" continuedAt="Tb_O_CHQ_h3DkWcWRkxFCvtdA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6.</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Stockholders&#8217; Equity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s certificate of incorporation adopted on December 16, 2020, authorizes the issuance of two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock&#8221;. The total number of shares which the Company is authorized to issue is <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg" decimals="INF" format="ixt:numdotdecimal" name="viri:CommonAndPreferredStockSharesAuthorized" scale="0" id="Narr_E_vPegy0xkqv18IL4eQD2g">45,000,000</ix:nonFraction>, each with a <span style="-sec-ix-hidden:Hidden_VfwIj3Fs2EKwWsM1T_o8Qw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">par value</span></span> of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_VYZHQiZuAE6P0agZgXqqeQ">0.0001</ix:nonFraction> per share. Of these shares, <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_sbh3RDE7wEqskBk1Svd8Rw">43,000,000</ix:nonFraction> shall be Common Stock and <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_lpCz7mMRPkSlyQVHv85ILw">2,000,000</ix:nonFraction> shall be Preferred Stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividends</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of the Common Stock are entitled to receive dividends when and as declared by the Board.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O_CHQ_h3DkWcWRkxFCvtdA_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to the holders of Common Stock as to liquidation, upon liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of the Common Stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Voting</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the Common Stock are entitled to <ix:nonFraction unitRef="Unit_Standard_item_wR6KQv_y_U6N2ZwjlZ-M-Q" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="INF" format="ixt-sec:numwordsen" name="viri:NumberOfVotesPerCommonStock" scale="0" id="Narr_hQb6DGl0h0aoXeCvdCGJIQ">one</ix:nonFraction> vote for each share of Common Stock held. There is no cumulative voting.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preferred Stock may be issued from time to time by the Board in one or more series.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_8Yve63CYb0m92I3GxXpdPA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">7</span>.&#160;&#160;&#160;&#160;Related Parties</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company uses Gendreau Consulting, LLC, a consulting firm (&#8220;Gendreau&#8221;), for drug development, clinical trial design, and planning, implementation and execution of contracted activities with CROs. Gendreau&#8217;s managing member became the Company&#8217;s Chief Medical Officer (&#8220;CMO&#8221;) effective January 1, 2021. The Company has and will continue to contract the services of the CMO&#8217;s spouse through the firm to perform certain activities in connect with the Company&#8217;s ongoing clinical development of product candidates. During the years ended December 31, 2022 and 2021, the Company paid Gendreau $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_X5Y3MAAZ80-3sQBqUVtS-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_1Bb9892rvkyO44M8FALsZg">356,088</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_uEjU9DNz10qTagf5uNcBwQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_33iI7HGr-Eq32AyTlm3nCw">326,416</ix:nonFraction>, respectively, and had accounts payable of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_VktHnKz5PUWL5c7XiyyBUQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" scale="0" id="Narr_r4gQrkvmD0-OID0ExOsHXw">21,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_XAqJzIFAPEimuSHD-_p6Hg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" scale="0" id="Narr_arVFGeXCWE-HMX-OpndERA">24,840</ix:nonFraction> to Gendreau as of December 31, 2022 and 2021, respectively.</p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_9PZWmV4D4U-5-kjEXkgxag" continuedAt="Tb_9PZWmV4D4U-5-kjEXkgxag_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">8</span>.&#160;&#160;&#160;&#160;Commitments and Contingencies</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Litigation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#8217;s liquidity, financial condition and cash flows.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 26, 2021, Torreya Capital LLC (&#8220;Torreya&#8221;) filed a demand for arbitration with the American Arbitration Association in New York, New York in connection with a claim by Torreya that it is entitled to a transaction fee of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_8_26_2021_To_8_26_2021_srt_LitigationCaseAxis_viri_TorreyaCapitalLlcMember_U8Q3TkmcJkCKXKS_Ao-Drw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="0" id="Narr_qkFJ2ixoNkGoksWaCIogJA">1,035,000</ix:nonFraction> in connection with the Company&#8217;s IPO, plus the costs of arbitration, based on services Torreya alleged it provided for the Company as a financial advisor to the Company prior to the IPO.&#160;<span style="white-space:pre-wrap;">  On December 20, 2021, in order to avoid the risk, inconvenience and expense of a continued dispute, the Company entered into a release and settlement agreement with Torreya, whereby the Company agreed to pay Torreya </span>$<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_12_20_2021_To_12_20_2021_srt_LitigationCaseAxis_viri_TorreyaCapitalLlcMember_593RpFikOES1pICvYkGC7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="0" id="Narr_pjaYy48ZcEigXnrUA1TSug">325,000</ix:nonFraction> for the release and discharge of any and all claims, liabilities and costs related to the arbitration. The Company paid the obligation prior to December 31, 2021, the cost of which is included in other expense in the accompanying statements of operations.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_9PZWmV4D4U-5-kjEXkgxag_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreement and Deferred Compensation Plan</p><p style="font-family:'Garamond';font-size:11pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">The Company has employment agreements with its CEO, SVP of Operations, and SVP of Finance (the &#8220;Executives&#8221;), as well as its CMO. Per the terms of the agreements, each Executive and the CMO are entitled to receive a cash bonus with a target amount of no less than </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_9Fj9-utpbkORtVRzg81GPA" decimals="2" format="ixt:numdotdecimal" name="viri:PercentageOfCashBonusOnSalary" scale="-2" id="Narr_Wyz-ri6dB0qJrIl-ogypRA">50</ix:nonFraction>%</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> for the CEO, </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_07boxe2rbUysaeH7Ihz82A" decimals="2" format="ixt:numdotdecimal" name="viri:PercentageOfCashBonusOnSalary" scale="-2" id="Narr_keQAqX15HEqpR9wjZ6KEHw">35</ix:nonFraction>%</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> for the CMO and </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_VicePresidentOperationsAndFinanceMember_X9NqiprFVkeF2f-E51b3HA" decimals="2" format="ixt:numdotdecimal" name="viri:PercentageOfCashBonusOnSalary" scale="-2" id="Narr_Gp2Aw282JEi_RiERrg4zVQ">20</ix:nonFraction>%</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> for the SVP of Operations and the SVP of Finance, of the then-current base salary. The bonuses are subject to achievement of annual bonus metrics set by the Board. The employment agreements will continue in effect until terminated by either party pursuant to its terms. Upon termination of the agreement by the Company for any reason other than for cause, death or disability or by one of the Executives or CMO for good reason, the Company shall pay to an Executive a &#8220;Severance Payment&#8221; equal to the aggregate of the Executive&#8217;s then-current annual base salary plus an amount equal to a prorated portion of the Executive&#8217;s cash bonus for the year in which the termination occurs. &#160;The Severance Payment to an Executive is payable in cash over a period of </span><ix:nonNumeric contextRef="Duration_9_10_2020_To_9_10_2020_RVDodrV4eECIJMPDAPhQBA" format="ixt-sec:durwordsen" name="viri:EmploymentAgreementSeverancePaymentPaymentPeriod" id="Narr_Z_46h5VCWkuE-K0zBqqDLw"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">one year</span></ix:nonNumeric><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. The Company shall pay to the CMO a Severance Payment equal to </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw" decimals="2" format="ixt:numdotdecimal" name="viri:EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary" scale="-2" id="Narr_aWKKzO7RvUGUzOWsOMZHQQ">25</ix:nonFraction>%</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> of the then-current annual base salary plus a prorated portion of the CMO&#8217;s cash bonus for the year in which the termination occurs over a period of </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw" format="ixt-sec:durwordsen" name="viri:EmploymentAgreementThresholdTerminationPeriod" id="Narr_e2tGHS22M0W0k30SZBIDew"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">three months</span></ix:nonNumeric><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> and health benefits for a period of </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw" format="ixt-sec:durwordsen" name="viri:EmploymentAgreementHealthBenefitOfferedPeriodOnTermination" id="Narr_5JsSVCHEVEqabvnoU4r1eg"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">12 months</span></ix:nonNumeric><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> unless the CMO becomes eligible for health benefits under another employer. If the termination of the agreement is related to a change of control, the Company shall pay to the Executives and the CMO a &#8220;Change of Control Termination Payment&#8221; equal to the aggregate of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw" decimals="0" format="ixt:numdotdecimal" name="viri:EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary" scale="0" id="Narr_HcIgylwRX0m2Ej9oGevcmQ">1.0</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> times the then-current annual base salary plus an amount equal to </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw" decimals="0" format="ixt:numdotdecimal" name="viri:EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus" scale="0" id="Narr_rQpqe1JT-EyUcRZn1oSllA">1.0</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> times the Executives&#8217; and CMO&#8217;s cash bonus for year in which the termination occurs. The Change of Control Termination Payments are payable in a single cash lump sum no later than </span><ix:nonNumeric contextRef="Duration_9_10_2020_To_9_10_2020_RVDodrV4eECIJMPDAPhQBA" format="ixt-sec:durwordsen" name="viri:EmploymentAgreementChangeOfControlTerminationPaymentPeriod" id="Narr_0hOzF7tnok26xF70FB4QOA"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">45 days</span></ix:nonNumeric><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> after the triggering event. </span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_7yovymnxq0GMf7ncFFAIxg_1_7"></a><a id="Tc_J05KP4opLEC_QIwIUJ9nrQ_2_7"></a><a id="Tc_cdwt3WSKFkSlYxj5a5Msqg_3_4"></a><a id="Tc_mru-O2v9HEKHM2y35u_avg_3_7"></a><a id="Tc_wCS_cb3DrUy3sI4GQNcBmQ_4_4"></a><a id="Tc_47NmTSrXiUuZ6ys2AQQIRA_4_7"></a><a id="Tc_uoEsWGYock-koYc1PM7BtQ_5_2"></a><a id="Tc_L05p7mE8GkiVRPtn7Ye_Fw_5_4"></a><a id="Tc_2dKTpBiQxUKq9hjzXKfVIQ_5_7"></a><a id="Tc_XjgL4g74WEG6hWyIiiBQ6w_6_2"></a><a id="Tc_WEiPuEIFqEaLQS43ha7QEA_6_4"></a><a id="Tc_0YwDnIoq6UOjDPT3zl-qFg_6_7"></a><a id="Tc_4L-q60yaAk-jU2E-DMPZqg_7_0"></a><a id="Tc_mAgR8VcITEyLngY8jzyEOw_7_4"></a><a id="Tc_U_7FXFGjgUS3t9fqej5ahg_8_0"></a><a id="Tc_NKLJIagLXk6gndBamRqWtg_8_7"></a><a id="Tc_1nbW768HekeaBzZZwpJVBA_9_0"></a><a id="Tc_PXF1TQrZ6EKt3oZjYaXXtg_9_4"></a><a id="Tc_X1sAum_Cy0CdxsUZcOuhVw_10_0"></a><a id="Tc_swyFTApQtUqN7AVvrjnK3A_10_7"></a><a id="Tc_4yEhqon_G0iNDotMDPhXaw_11_0"></a><a id="Tc_7Kal6Gm1Y0qxtuqx-ECIcQ_11_7"></a><a id="Tc_w2Vpewe82ky1sGohFlGV3w_12_0"></a><a id="Tc_6EgRMmtLXkGTjA5Fs_Qwzg_12_4"></a><a id="Tc_LMr7AF-Ey0K-CTSb4UA3VA_13_0"></a><a id="Tc_DDulKaXmrkioV82OeWRHrg_13_4"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_LPCBZ8JrR0W6uuZGipbM4g" continuedAt="Tb_LPCBZ8JrR0W6uuZGipbM4g_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;Share-Based Compensation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Equity Incentive Plan</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 16, 2022, the stockholders of the Company approved the Amended and Restated 2020 Equity Incentive Plan (the &#8220;Plan&#8221;) to increase the total number of shares of common stock reserved for issuance under the Plan by <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_6_16_2022_To_6_16_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_p9GEDysUj0yLr6kbN6USkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_SwRZ00xA3UGkSV2I0k5HGw">1,250,000</ix:nonFraction> shares to <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_6_16_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_EKNzGamAM0e5Uudfko5Mbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_5OKnbshnaUK8bGQZwAU8vg">2,062,500</ix:nonFraction> total shares issuable under the Plan. As of December&#160;31, 2022 and 2021, <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_TTQfQ2Zo-UOaPmeepnu9YA">430,603</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_PSW_ICNFWUWC815QcUkHTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_iKfppuR8hUSiYdh_qQWF5Q">63,353</ix:nonFraction> shares, respectively, were available for future grants.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock awards, options, and other equity-based awards. The amount and terms of grants are determined by the Board. Stock options have a maximum term of <span style="-sec-ix-hidden:Hidden_zpYbTwNkCEuu23buIe0eJQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">10&#160;years</span></span> after date of grant and are exercisable in cash or as otherwise determined by the Board. The maximum aggregate number of shares subject to grant under the Plan to any individual, with the exception of any non-employee director, during any calendar year is limited to <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_6_16_2022_To_6_16_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_kJHmoKVpsEyo6AaXVE_bJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="Narr_oiNfXKdBt0W0sRwK8hu5Jg">500,000</ix:nonFraction> shares. With respect to any non-employee director, the maximum aggregate number of shares subject to grant under the Plan to any individual during any calendar year is limited to <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_6_16_2022_To_6_16_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Sy6PBJsphU-CRbISsoIF6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="Narr_NO_wNTH1SECMBr1qCgSjqg">200,000</ix:nonFraction> shares.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below sets forth the outstanding options to purchase common shares under the Plan:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_KyVlE7MiLk-I9GDNp8R44w" continuedAt="Tb_KyVlE7MiLk-I9GDNp8R44w_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_HfIQGNlGO0GfJuvJzN6shA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_MbhmHjPY6UukTZMK3B7x5w_7_2">519,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_HfIQGNlGO0GfJuvJzN6shA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_84oC1AcNLEynXDnX2C3A8Q_7_5">10.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_f6XxsTWSbk6n_wNrDUfYkg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_OuKtyQlQjECTKE43haveKA_7_7"> 9.98</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_Poo-qM78aUa8UimXm6aQ1Q_8_2">229,984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_88R82zynkEe_35vcmFEozQ_8_5">6.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_PSW_ICNFWUWC815QcUkHTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_IyjwlvRxRU6JOL7HinCUIA_9_2">749,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_PSW_ICNFWUWC815QcUkHTQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_HGOBqAfMLEG7QYwRp9OTTA_9_5">9.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_h1eRzm0HRESJmKfp79uiiw_9_7"> 9.09</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_7m8A100IQ0OO4AZ3MVmsSA_10_2">912,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_8odWfNuJ6EKRqZiS13sxxQ_10_5">1.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_737bJJIR9ku9J6vWYuWA9A_11_2">29,750</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_XfSLeMSi40KinM2K7MlmuQ_11_5">4.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_akhSqBmagkCfV_jlT30ruA_12_2">1,631,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_NT9VJO6GFUWGwAQke6pTXA_12_5">4.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_bsvQaBN80k--671Vxxroxg_12_7"> 9.04</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_QX69vOiyz0iaL4UgQW77NA_13_2">665,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_FbHOgD2TREyimEbeDrDUiw_13_5">9.30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_bXBHzfk_mkK7z6EmABfaJQ_13_7"> 8.06</ix:nonNumeric></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_LPCBZ8JrR0W6uuZGipbM4g_cont1" continuedAt="Tb_LPCBZ8JrR0W6uuZGipbM4g_cont2"><ix:continuation id="Tb_KyVlE7MiLk-I9GDNp8R44w_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022 and 2021, the aggregate intrinsic value of options outstanding and exercisable was $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_PSW_ICNFWUWC815QcUkHTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Narr_f99qLZ67REOZdLoKj_eEQw"><ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Narr_Vtzzok8CX0O7nJpTY5C6rg">0</ix:nonFraction></ix:nonFraction>.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, the Company granted certain individuals options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_bj4uYiNTGUyHOO8q-9eFtg">912,500</ix:nonFraction> shares of the Company&#8217;s common stock with an average exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_GXGtf31fCk-e3OuXDETPrA">1.42</ix:nonFraction> per share, contractual terms of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_0QM-WdqzGUqQOotgMg4QOA">10 years</ix:nonNumeric> and vesting periods ranging from <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_epi_lHMtoEOuSGGUHTT6cQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_8HszjneaAUmie03X7FQ6Ww">100</ix:nonFraction>% vesting after one year to <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yFCbkitpnUybTr1oZGQIXA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_LZACE7R67EidCrRcSAo2Dg">33.333</ix:nonFraction>% vesting after one year with the remaining <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_iX6ZkNMhbEeXsuVhLuePbw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_G6z0Rk09h0qKTEWhg12ovw">66.667</ix:nonFraction>% vesting in 24 monthly installments, thereafter. The options had an aggregate grant date fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew" decimals="0" format="ixt:numdotdecimal" name="viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" scale="0" id="Narr__ElvBkcWl0G4AXPzncc8Sw">980,075</ix:nonFraction> as calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option pricing model include: (1) discount rates ranging from <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ikj9w2rCj0izLrRvksWE6Q" decimals="5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_BRIW5Xo68kqWRU5v16pfsQ">3.145</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_qgz0o95s_0aPxtVxKLV_Pw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_eTwyms9L4k6zomMweKESrQ">3.765</ix:nonFraction>% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected lives ranging from <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ikj9w2rCj0izLrRvksWE6Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_HByU-K_ozkCpIDdKXJ_5BA">5.5</ix:nonNumeric> years to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_qgz0o95s_0aPxtVxKLV_Pw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_DKgLpdoyHEeGx7DZdzFUxA">6.0</ix:nonNumeric> years based on the simplified method (vesting plus contractual term divided by two), (3) expected volatility ranging from <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ikj9w2rCj0izLrRvksWE6Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_3v7w0tloxUK1hPb2zSwkEg">90.62</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_qgz0o95s_0aPxtVxKLV_Pw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_i94HgyOAZkasvh1DQ70omA">93.66</ix:nonFraction>% based on the average historical volatility of comparable companies&#39; stock, (4) <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" scale="0" id="Narr_sBTUQjMivEq5SjB_WT7d4Q">no</ix:nonFraction> expected dividends and (5) fair market value of the Company&#39;s stock ranging from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ikj9w2rCj0izLrRvksWE6Q" decimals="4" format="ixt:numdotdecimal" name="viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="Narr_zHDJoqgZKEuWp39ZOrZi1g">0.2789</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_qgz0o95s_0aPxtVxKLV_Pw" decimals="2" format="ixt:numdotdecimal" name="viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="Narr_mmJp5NrmG0q4ar349ma8Fw">4.23</ix:nonFraction> per share.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, the Company granted certain individuals options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_uIv--Ahink6X19cTvqCN3w">229,984</ix:nonFraction> shares of the Company&#8217;s common stock with an average exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_FDtmqP8tRUOkZ_1ffy26Lw">6.85</ix:nonFraction> per share, contractual terms of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_i53kdZFHMUa7HVMSAW17gg">10 years</ix:nonNumeric> and vesting periods ranging from <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_npYg-xxOqkqKwXBoOxfd0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_eI9if_wrhEWqNNJoc6BPng">8.33</ix:nonFraction>% monthly over one year to <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iwzJfTl-OUiIleLyhau04g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_3kkLLLzOk0-92HODKydqLQ">33.333</ix:nonFraction>% vesting after one year with the remaining <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_Qf178jUjQ0m0mIlYgP4eGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_GiTaQokJa0GYBYmG0yPx7Q">66.667</ix:nonFraction>% vesting in 24 monthly installments, thereafter. The options had an aggregate grant date fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g" decimals="0" format="ixt:numdotdecimal" name="viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" scale="0" id="Narr_TWnIz6GaHE2OrNoi2FJzcQ">1,150,284</ix:nonFraction> as calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option pricing model include: (1) discount rates ranging from <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ClZ-Zp5G-kmzZkhdCCktbA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_1XDWAlRRrE6zYSXvui8m5A">0.505</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_jfwr1MSSHkK724vOCV_g2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_0pDr-q0c3EO_L26lRdRKXQ">1.075</ix:nonFraction>% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected lives ranging from <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ClZ-Zp5G-kmzZkhdCCktbA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_Nii4RmZsYk-DKSO77PVkIw">5.27</ix:nonNumeric> years to <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_jfwr1MSSHkK724vOCV_g2A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_IwSbSEzKSkeZCYrHvnPn9w">6.0</ix:nonNumeric> years based on the simplified method (vesting plus contractual term divided by two), (3) expected volatility ranging from <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ClZ-Zp5G-kmzZkhdCCktbA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_J_pmuZlM9UWo3f_yRCcDbA">89.04</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_jfwr1MSSHkK724vOCV_g2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_iLB7NXkA7ku5R2Kr14tGSg">90.16</ix:nonFraction>% based on the average historical volatility of comparable companies&#39; stock, (4) <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" scale="0" id="Narr_vxxKNvTSiE-Ie3NAwS9tGg">no</ix:nonFraction> expected dividends and (5) fair market value of the Company&#39;s stock ranging from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ClZ-Zp5G-kmzZkhdCCktbA" decimals="INF" format="ixt:numdotdecimal" name="viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="Narr_LiongCwnwESBlra8UJ6Wzw">6.50</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_jfwr1MSSHkK724vOCV_g2A" decimals="INF" format="ixt:numdotdecimal" name="viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="Narr_o3tlML9f106okZWbA-9PUQ">7.51</ix:nonFraction> per share.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2022 and 2021, the Company recognized share-based compensation expense related to stock options of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_bzvM8doJ10mkpUYJYD_rTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_hXAqVJLMaEGudZIerXQUbA">582,659</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_E57glfgKCUSq3eMsl6w6qQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_t-tN7roVVUqDf9iq--Jbaw">322,881</ix:nonFraction>, respectively. The unrecognized compensation expense for stock options at December 31, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_IXFyCqWULkiAGzccCCWCsQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" id="Narr_1O0BVckgAEuwRJI-daIcMA">1,114,073</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_fA7tndkyWEeG7RdGqTIrYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" id="Narr_oHPwJlPqOUWZ4J1FGgdWuQ">827,402</ix:nonFraction>, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock Options for Unregistered Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the stock options issued under the Plan, on December 16, 2020, the Company granted non-qualified stock options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_M4fezxbNZkuxe4pgWMkDqg">292,500</ix:nonFraction> shares of common stock as provided for in the employment agreement of the Company&#8217;s President at the time of and in conjunction with the Company&#8217;s IPO (the &#8220;President Options&#8221;). The President Options are exercisable within <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="Narr_32iQEr7wU0eN7Di1wnMwmg">10 years</ix:nonNumeric> of the date of grant at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_OJWlFWr3HEyxm7WBhrKNAw">10.00</ix:nonFraction> per share, were <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_D0V76e45EkevYozd_a1SnA">100</ix:nonFraction>% vested at the grant date and have a remaining contractual term of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_4gF90tgd1kWuhYEDXe5DwQ">7.96</ix:nonNumeric> years. As of December 31, 2022, there was <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_5tEhIARsaEiYoR53c54ELg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" id="Narr_KeKGgt_Mz0GTMkyQlvc9ww">no</ix:nonFraction> unrecognized compensation expense related to these options as they were <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_Vn4phYpmqE-NwCB3AjRluw">100</ix:nonFraction>% vested upon issuance. The shares of common stock issuable upon exercise of the President Options will be unregistered, and the option agreement does not include any obligation on the part of the Company to register such shares of common stock. Consequently, the Company has not recognized a contingent liability associated with registering the securities for the arrangement. As of December 31, 2022, the aggregate intrinsic value of the President Options was $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_5tEhIARsaEiYoR53c54ELg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Narr_iDNqyqvCK06212zuNY9gvw">0</ix:nonFraction>.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Underwriters Warrants</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In conjunction with the IPO, the Company granted the underwriters warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_21_2021_UH5_wupqpEWPUP_czHBCeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_TPcpDUPFjUynvxWCaivgSw">172,500</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_21_2021_UH5_wupqpEWPUP_czHBCeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_so3-9-Ro0EGpiPJsb7Axeg">12.50</ix:nonFraction> per share. The warrants have a <span style="-sec-ix-hidden:Hidden_qp_BKBo_iESKd88pDgZH3g;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">five-year</span></span> contractual term and were not exercisable prior to December 21, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">In conjunction with the Offering in September 2022, the Company granted the Underwriter warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_phhOuEzKPUO2GyzKUa7eLA">500,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_urIM6Ai8oEOoq3W3lJg1_Q">0.625</ix:nonFraction> per share. The warrants have a </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_j3gEbl_FT0agcQNFULxKdQ_1_7"></a><a id="Tc_qpyRZdgN_06hTN8WNDe4KA_2_7"></a><a id="Tc_0laOreCEM0eyT1wGgRCz1Q_3_4"></a><a id="Tc_TgDApHLNIkeLr7Oj7qcYCQ_3_7"></a><a id="Tc_2GnMJDUsBkeTLV-SZQhkUg_4_4"></a><a id="Tc_gSRVJ9QH8EKYTDdYHtpV0Q_4_7"></a><a id="Tc_DJDgB1hvOEG6RvkkvTsCKQ_5_2"></a><a id="Tc_CRd2FSJejkC_WXlrJlpzGw_5_4"></a><a id="Tc_H7qqC_quR0qeCCFwO5xr_w_5_7"></a><a id="Tc_qOWKk8_MPE2lu99HuT8pSg_6_2"></a><a id="Tc_im3QSvFFwU239V5B-qlhyQ_6_4"></a><a id="Tc_P8KyHvYloUCmTs-7cVkRvg_6_7"></a><a id="Tc__NttIXaBRkqFrBdrA3IuaA_7_0"></a><a id="Tc_ymxb0GjhnkG53NmJarpirQ_7_4"></a><a id="Tc_jF5sOcVOiE2WqTiLb7yU5g_8_0"></a><a id="Tc_MPw_cdrMKk-Xpx1GgvGe5Q_8_2"></a><a id="Tc_L4tnqBuFnE-JjW8D8-Kr9g_8_5"></a><a id="Tc_P6X62nDV6k2-nc52uUtsew_8_7"></a><a id="Tc_rsSmO2NJfUWCTd3bEzJJjw_9_0"></a><a id="Tc_2RAxTBJsCkuUnrkm3I6cZw_9_4"></a><a id="Tc_8IEn9pl_hEGnjyVDCOJUTA_10_0"></a><a id="Tc_Sno-aIOJ_UWbSx2PI0AziQ_10_7"></a><a id="Tc_EJAOSCXFnkaCZ67n_BW4cA_11_0"></a><a id="Tc_WD2HTLuHlkGBAkmEdP1CcA_11_4"></a><a id="Tc_Tpev2QrBc0Kf5e6p8uBNlg_12_0"></a><a id="Tc_76PoDTm93kiEu3imMOE9Mw_12_4"></a><ix:continuation id="Tb_LPCBZ8JrR0W6uuZGipbM4g_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_o101VY_9HUqeJHBrSUxJyA">five-year</ix:nonNumeric> contractual term and are not exercisable prior to March 18, 2023. The Company has accounted for the warrants as equity-based awards issued to a non-employee. The warrants had an aggregate grant date fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g" decimals="0" format="ixt:numdotdecimal" name="viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" scale="0" id="Narr_jLtYIFWVs0yW1tD42ykSOg">178,462</ix:nonFraction> that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option pricing model include: (1) discount rate of <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_rkUQzEXN60qdl3F8WWSa_g">3.69</ix:nonFraction>% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected life of <ix:nonNumeric contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_KXBN-3jX-0GTE5yRPPjmsw">5.0</ix:nonNumeric> years, (3) expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_e24_NDqwXEumsMInfZEdug">96.46</ix:nonFraction>% based on the average historical volatility of comparable companies&#39; stock, (4) <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" scale="0" id="Narr_whcuwFpC60WxwpmhLWnTUg">no</ix:nonFraction> expected dividends and (5) fair market value (Offering price) of the Company&#39;s stock of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_VDhLPCYL_ESaTwYdTWgdrA">0.50</ix:nonFraction> per share.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There was no net impact recognized by the Company in the accompanying financial statements as the warrants were equity-based awards issued for services rendered by the Underwriter for the Offering that was offset by the Company recognizing the fair value of the warrants as a direct and incremental costs associated with the Offering by reducing paid-in capital for the same amount. There is <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" id="Narr__Pep5TIWpUeO05Iydi7WCw">no</ix:nonFraction> unrecognized compensation expense for these awards as of December 31, 2022. The table below sets forth the outstanding warrants to purchase common shares:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_IYHt-HROUEikv7EDoRwKcg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2020_tCm4u3HF1ESoDqVBr91eXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_wTLkP4rzo0OIL-orGDea8Q_7_2">172,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_31_2020_tCm4u3HF1ESoDqVBr91eXw" decimals="2" format="ixt:numdotdecimal" name="viri:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_mWqyX0ZIBkWTmvvRjD5gaA_7_5">12.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_ujddVzlF9kmGOtaxPWQprg" format="ixt-sec:duryear" name="viri:ClassOfWarrantOrRightRemainingTerm" id="Tc_Cig-NEiQOUmxUGLGGeBH0g_7_7"> 4.96</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Ljh5xUTk6EuHV6FcLSwsPw_9_2">172,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="2" format="ixt:numdotdecimal" name="viri:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_MMu7DHuSEEuAZYxL2L1v4A_9_5">12.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" format="ixt-sec:duryear" name="viri:ClassOfWarrantOrRightRemainingTerm" id="Tc_BIxpXZOrrkW1mqwi9xpUug_9_7"> 3.96</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="INF" format="ixt:numdotdecimal" name="viri:ClassOfWarrantOrRightGranted" scale="0" id="Tc_Su3Cp8eOLk6NECkaFseVSg_10_2">500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="2" format="ixt:numdotdecimal" name="viri:ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" scale="0" id="Tc_gYwsT3jIXk-SI9F3xAypzA_10_5">0.63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_pyWQGsnRWUmQSdNA_cdKRA_11_2">672,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="2" format="ixt:numdotdecimal" name="viri:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_9g8OuAWnokiz3MOMCmIHoA_11_5">3.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" format="ixt-sec:duryear" name="viri:ClassOfWarrantOrRightRemainingTerm" id="Tc_pfIOYRzVmUmYywhaZIypMw_11_7"> 4.27</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="INF" format="ixt:numdotdecimal" name="viri:ClassOfWarrantOrRightExercisable" scale="0" id="Tc_zu8o_XOAsEao-MKe-ZEZnw_12_2">172,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="2" format="ixt:numdotdecimal" name="viri:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" scale="0" id="Tc_Boffg-W9DE2nAsbsPyGkfg_12_5">12.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" format="ixt-sec:duryear" name="viri:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" id="Tc_lZavUJRYP0iA3p5jBmtmeg_12_7"> 2.96</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">As of December 31, 2022, the aggregate intrinsic value of the warrants outstanding was $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="INF" format="ixt:numdotdecimal" name="viri:AggregateIntrinsicValueOfWarrantsOutstanding" scale="0" id="Narr__DJsghm2LkCnNmzO7BHLIQ">0</ix:nonFraction>.</p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_yXi-DUWHMkyP0_v6_vLHQw_1_2"></a><a id="Tc_xbHIu-xOTUKFYHeVv9y6dA_2_2"></a><a id="Tc_b_YZ_BUCEEeoJN87k1N5XQ_3_2"></a><a id="Tc_d7FkUX8cbEqQLmNJOEIumA_3_4"></a><a id="Tc_IArSzmt3UUKDr2lQF7VoOA_4_0"></a><a id="Tc_SoXBZ-W2AkiM3U79kGC1zQ_4_3"></a><a id="Tc_Pb3C0zU7P0OmOhBq3DmbAg_4_5"></a><a id="Tc_F_yJYI50IEexjeNpSvg7Iw_5_0"></a><a id="Tc_VQEWU8VETU6OfiVjRpTHTQ_5_3"></a><a id="Tc_YETwqM9L-EuL0MStI68LIA_5_5"></a><a id="Tc_VH9sxUvYrESXaOJ6YgK0NA_6_0"></a><a id="Tc_uPivfGPEGEGTy1OqMFZmXw_6_3"></a><a id="Tc_AD7uQbnT-ke4_GBFtmq4ZQ_6_5"></a><a id="Tc_TxFS3vctM0Ol-_75b5GX3w_7_0"></a><a id="Tc_zP_YNa0tc0usxtJz50Viyw_7_2"></a><a id="Tc_HHxSU6jSd0mRvRHVUGOOAw_7_3"></a><a id="Tc_g3YKlaD6CkaiXLsT7vmMXQ_7_5"></a><a id="Tc_nJppsICoY02rnmcent__sw_8_0"></a><a id="Tc_ZTMkx59Ab067RnaZ_Ujrmw_8_3"></a><a id="Tc_l_uB9SDf5UqEIXyw2o0bBA_8_5"></a><a id="Tc_NtDzrt6EMU2pfw2ocbUtVQ_9_0"></a><a id="Tc_DR0vsJ3Yc0e-KHSkj9XHhw_9_3"></a><a id="Tc_d-zfJIlWJUSuDCYusRITdA_9_5"></a><a id="Tc_RVQ6ZsAKsEGxJW0O6RZW0w_10_0"></a><a id="Tc_IkccwlLStUGIqi9Zlj4kCw_10_3"></a><a id="Tc_SsKhG6M3Okq6UyuSyVS-JQ_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_OUrwLZ9nXUCahssMNtTETg" continuedAt="Tb_OUrwLZ9nXUCahssMNtTETg_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company has U.S. federal and state net operating loss carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_TOu55wB-V0yVmkZLUgzdYQ">22,168,000</ix:nonFraction>, which have an indefinite carryforward. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">A reconciliation of the U.S. federal income tax rate to the Company&#8217;s effective tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_YwSkWMq-WUOFgcHGKO9rFw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_7xKbeAs-dUCl9q1GgBuQCQ_4_2">21.00</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_9QlQY0CnUkWGhwe-OA1uQw_4_4">21.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="4" format="ixt:numdotdecimal" name="viri:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_biaQoKBD1kKk_pxkR3hnTw_5_2">0.57</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="4" format="ixt:numdotdecimal" name="viri:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_saUEOxEn8kKH_zL3A1ogog_5_4">0.33</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_fBD6SVu55kW9HCZDuX2peA_6_2">4.83</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_6bdp_-D49kmr6FHXlrslYQ_6_4">4.47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax true-ups</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="4" format="ixt:numdotdecimal" name="viri:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent" sign="-" scale="-2" id="Tc_QO-JJsU-PEyonS_4I7CVpQ_7_4">1.82</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_4ikNKaWBeUeTvXodMBWZqw_8_2">0.06</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_LRSkWZD1vUKMO_2byB96ug_8_4">0.15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_IVFdcym7Tk6_hcsG1PeTIw_9_2">25.32</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_T4lgGjV7mEKh8HlM8sR3aA_9_4">23.47</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective Income Tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_UJK8kBs1S0uQwZNpbe4CQA_10_2">&#8212;</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_7KAcAPzvNkOKFyPLQXEIrA_10_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_BKnWNpfy-EScBVc2nssKRQ_1_2"></a><a id="Tc_m7uPT5c8n02GIeI2UK172g_2_2"></a><a id="Tc_IU7rSkJB1UWYwPVjHFeL8Q_2_5"></a><a id="Tc_rXaKcTZXxkGrljz3YZmfow_3_0"></a><a id="Tc_pJWayOfCAkOAYBGQgFFeeQ_4_0"></a><a id="Tc_HyAxsuygRkKZGO1Hpx2XHA_4_2"></a><a id="Tc_v_GFTaptHkiRbD-Q7oEwyw_4_5"></a><a id="Tc_p17As7c7R0K8N-eYxsh8Fg_5_0"></a><a id="Tc_t0fO0HOhak6hAXymZJ7emg_5_6"></a><a id="Tc_zCRD07zxSE24E-XdIDs5ww_6_0"></a><a id="Tc_kOvJo-cTHki1rv0MXRgz9Q_7_0"></a><a id="Tc_q9NmR8W5pkKjHBugYiXwQQ_8_0"></a><a id="Tc_a5hAgHfqTUmyduCZ0wJdLg_9_0"></a><a id="Tc_Z4-5JXLaQEybhaM9Vcd2HA_10_0"></a><a id="Tc_wkrRMTbh-kW7KxGSGBKupA_11_0"></a><a id="Tc_yIbYgw7SAkWKYV6YWfj_0A_13_0"></a><a id="Tc_qRE0wwiodkyGTBHi_qY9Tw_14_0"></a><a id="Tc_sJTvGIKR3Ee2K4Jm65xpdA_15_0"></a><a id="Tc_74BCVjrspkamlWLFg1o1Ug_17_0"></a><a id="Tc_eDmqeG9nqUKwC4aj5gdpcA_17_2"></a><a id="Tc_pndHaLp5mkWQIPHzTzTtGA_17_5"></a><ix:continuation id="Tb_OUrwLZ9nXUCahssMNtTETg_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets are comprised of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_OCHRYnzKmU2QkSh9Pnd5xA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_0ZLTXUKQ_kmSNczqpgHW9g_4_3">5,692,533</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_4Eav5LwsyE68TiYDAhwS-A_4_6">4,586,488</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="viri:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" scale="0" id="Tc_ueh13h5fHUGLRR-qEHpmpA_5_3">1,873,211</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_rP9xob1L1UiXZfc2eCIjqw_6_3">1,411,624</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_-tsSBnIyx0WmnUhax4kzBw_6_6">1,338,234</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Investment in partnership</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="viri:DeferredTaxAssetsInvestmentInPartnership" scale="0" id="Tc_8AV6y0W7jEOtB8miJxTGAA_7_3">30,771</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="viri:DeferredTaxAssetsInvestmentInPartnership" scale="0" id="Tc_-6pTGGwVm021YgGWBR22eA_7_6">30,593</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="viri:DeferredTaxAssetsAmortization" scale="0" id="Tc_LDmN3Tjq3EKPhdLT51RsNg_8_3">15,223</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="viri:DeferredTaxAssetsAmortization" scale="0" id="Tc_LNjzUQtNHEukL5zCK6SYSw_8_6">16,299</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_K0CF6ONJXUydNVXL3A0xzg_9_3">9,023,362</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_pDLyB3vZqEuOq1be3PjLZg_9_6">5,971,614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_-yvxZ27JEkKXZiNv-s8Hsw_10_3">8,682,497</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_PUvCqFXFD0mYJxjrsuNcDA_10_6">5,581,599</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_hjO64A_SCUKKd0BCj7yaYw_11_3">340,865</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_hXV8luS9VUiNaQKZM-iX8Q_11_6">390,015</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="0" id="Tc_iIryC39zx0SZhs8plGSnZg_14_3">340,865</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="0" id="Tc_NTEzS0PV0EmxGFHZnQ_X0w_14_6">390,015</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="Tc_2qnUcK3-aECCyxLWHE74yw_15_3">340,865</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="Tc_XAic98WwSk6s2NtHOc5ZhQ_15_6">390,015</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="Tc_eSHO9UiWIUSjnv7jJGjgKw_17_3">&#8212;</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="Tc_dB2FoGTqvUyaFj2PG3GStw_17_6">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For tax years beginning on or after January 1, 2022, the 2017 Tax Cuts and Jobs Act amended Section 174 of the code to eliminate current-year deductibility of research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and fifteen years for research activities performed outside of the United States. For the 2022 tax year, the Company has capitalized $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="viri:CapitalizedResearchAndDevelopmentExpense" scale="0" id="Narr_UdmFeKsa10iAhPKcU025NA">8,099,702</ix:nonFraction><span style="white-space:pre-wrap;"> of research and development expenses.  This has resulted in an increase in the deferred tax asset associated with capitalized research and development by </span>$<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ" decimals="0" format="ixt:numdotdecimal" name="viri:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" scale="0" id="Narr_pRkT8lKqSE6ggYSYCs3f_A">1,873,211</ix:nonFraction>.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company has not generated sufficient positive evidence for future earnings to support a position that it will be able to realize its net deferred tax asset. The Company has significant negative evidence to overcome in the form of cumulative pre-tax losses from continuing operations since its formation, as well as projected losses for the current year. Therefore, it will continue to maintain a full valuation allowance on its U.S. federal and state net deferred tax asset. The change in the valuation allowance offset the income tax benefit related to the pre-tax loss for the year ended December 31, 2022. The Company does not have any material unrecognized tax benefits as of December 31, 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company experienced a net change in valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr__ck3upPZykCxbC1f6mM_1g">3,100,898</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA" contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_7BylGIHc3Uqmd7AZd6Z6hg">3,745,299</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively.</p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_c010451a_9471_4264_8973_bd3b461d7fd1"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_10a51ca9_2342_4436_b2bf_368134e87a11"></a><a id="Item9AControlsandProcedures_878602"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our Chief Executive Officer and SVP of Finance, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) as of the end of the period covered by this Annual Report on Form&#160;10-K. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on such evaluation, our Chief Executive Officer and SVP of Finance have concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in rules, regulations and forms of the SEC, including ensuring that such material information is accumulated by and communicated to our management, including our Chief Executive Officer and SVP of Finance, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Report on Internal Control Over Financial Reporting</b>&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management utilized the criteria established in the Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) to conduct an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2022. Based on the assessment, management has concluded that, as of December 31, 2022, our internal control over financial reporting was effective.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As an emerging growth company, management&#8217;s assessment of internal control over financial reporting was not subject to attestation by our independent registered public accounting firm.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control Over Financial Reporting</b>&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">There has been no change in our internal control over financial reporting identified in connection with the evaluation required by Rule&#160;13a-15(d)&#160;and 15d-15(f)&#160;of the Exchange Act that occurred during the quarter ended December&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_becc5de6_c0e7_4ee9_b378_3bd1251a3072"></a><a id="Item9BOtherInformation_810311"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_0bcb27c7_03d4_4807_80a6_f8b1b9c335dc"></a><a id="PARTIII_541444"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10. Directors, Executive Officers, and Corporate Governance</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item 10 by reference to the definitive proxy statement for our 2023 annual meeting of shareholders, to be filed with the SEC. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a list of our executive officers as of the date of this Annual Report.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:84.93%;background:#ffffff;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.55%;background:#ffffff;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#ffffff;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#ffffff;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:46.6%;background:#ffffff;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:14.05pt;"><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#0000ff;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#0000ff;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Position</b></p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:bottom;width:46.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;">Greg Duncan</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;">Chairman and Chief Executive Officer</span></p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;">R. Michael Gendreau, M.D., Ph.D.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;">Chief Medical Officer</span></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:bottom;width:46.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;">Ralph Grosswald</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;">Senior Vice President of Operations</span></p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;">Angela Walsh</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#0000ff;">Senior Vice President of Finance</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_609f75e4_5bac_4b8b_b5c3_a3c01276281f"></a><a id="Item11ExecutiveCompensation_533479"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11. Executive Compensation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">We incorporate the information required by this Item 11 by reference to the definitive proxy statement for our 2023 annual meeting of shareholders, to be filed with the SEC.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_14341009_e8d7_4c83_839e_5fd7b26b673d"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">We incorporate the information required by this Item 12 by reference to the definitive proxy statement for our 2023 annual meeting of shareholders, to be filed with the SEC.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_72da0a0a_abd8_455f_acd9_889146585312"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">We incorporate the information required by this Item 13 by reference to the definitive proxy statement for our 2023 annual meeting of shareholders, to be filed with the SEC.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cc36ecd6_89c9_4a9f_8243_94c9807e7f25"></a><a id="Item14PrincipalAccountantsFeesandService"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14. Principal Accountant&#8217;s Fees and Services</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Independent Registered Public Accounting Firm is FORVIS, LLP (PCAOB Firm ID No. <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA" name="dei:AuditorFirmId" id="Narr_t_lh695HvUe3bx9yDHWVHg">686</ix:nonNumeric>) located in Atlanta, Georgia. We incorporate the remaining information required by this Item 14 by reference to the definitive proxy statement for our 2023 annual meeting of shareholders, to be filed with the SEC.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f69f2f33_28b4_4089_81b9_8238fe285a27"></a><a id="PartIV_188453"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Part&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15. Exhibits and Financial Statement Schedules</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The following documents are filed or furnished as part of this Annual Report on Form 10-K:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statements</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">Reference is made to the Index to Financial Statements under Item 8, Part II hereof.</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The Financial Statement Schedules have been omitted because they are not applicable, not required, or the information is shown in the financial statements or related notes.</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2c4f2b87_5508_4c55_ae19_7bf4614ddd83"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">EXHIBIT&#160;INDEX</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:88.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:88.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920099726/tm2025286d5_ex2-1.htm"><span style="font-style:normal;font-weight:normal;">Plan of Conversion (incorporated by reference herein from Exhibit 2.1 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on August 28, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2.2</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920099726/tm2025286d5_ex2-2.htm"><span style="font-style:normal;font-weight:normal;">Certificate of Conversion of Virios Therapeutics, LLC (incorporated by reference herein from Exhibit 2.2 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on August 28, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920099726/tm2025286d5_ex3-1.htm"><span style="font-style:normal;font-weight:normal;">Certificate of Incorporation of Virios Therapeutics, Inc. (incorporated by reference herein from Exhibit 3.1 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on August 28, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920099726/tm2025286d5_ex3-2.htm"><span style="font-style:normal;font-weight:normal;">Bylaws of Virios Therapeutics, Inc. (incorporated by reference herein from Exhibit 3.2 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on August 28, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920115438/tm2025286d15_ex4-1.htm"><span style="font-style:normal;font-weight:normal;">Specimen Certificate evidencing shares of the Registrant&#8217;s common stock. (incorporated by reference herein from Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on October 16, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000155837021003366/tmb-20201231xex4d2.htm"><span style="font-style:normal;font-weight:normal;">Description of Registrant&#8217;s Securities (incorporated by reference herein from Exhibit 4.2 to the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on March 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.1+</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920099726/tm2025286d5_ex10-2.htm"><span style="font-style:normal;font-weight:normal;">Employment Agreement, dated March&#160;3, 2015, by and between Richard Burch and Innovative Med Concepts, LLC, as amended. (incorporated by reference herein from Exhibit 10.2 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on August 28, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.2+</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920099726/tm2025286d5_ex10-3.htm"><span style="font-style:normal;font-weight:normal;">Employment Agreement, dated April&#160;5, 2020, by and between Greg Duncan and Innovative Med Concepts, LLC, as amended. (incorporated by reference herein from Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on August 28, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.3+</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920099726/tm2025286d5_ex10-4.htm"><span style="font-style:normal;font-weight:normal;">Employment Agreement, dated April&#160;5, 2020, by and between Angela Walsh and Innovative Med Concepts, LLC, as amended. (incorporated by reference herein from Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on August 28, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.4+</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920099726/tm2025286d5_ex10-5.htm"><span style="font-style:normal;font-weight:normal;">Employment Agreement, dated April 5, 2020, by and between Ralph Grosswald and Innovative Med Concepts, LLC, as amended. (incorporated by reference herein from Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on August 28, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.5+</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000155837022010085/tmb-20220616xex10d1.htm"><span style="font-style:normal;font-weight:normal;">Virios Therapeutics, Inc. Amended and Restated 2020 Equity Incentive Plan. (incorporated by reference herein from Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed June 17, 2022)</span></a> </p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.6+*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20221231xex10d6.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Award Agreement*</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920099726/tm2025286d5_ex10-7.htm"><span style="font-style:normal;font-weight:normal;">University of Alabama Know-How License Agreement, dated June 1, 2012, by and between The Board of Trustees of The University of Alabama for and on behalf of its component institution The University of Alabama and Innovative Med Concepts, LLC.</span><b style="font-style:normal;font-weight:bold;"> </b><span style="font-style:normal;font-weight:normal;">(incorporated by reference herein from Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on August 28, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.8+</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920105402/tm2025286d7_ex10-8.htm"><span style="font-style:normal;font-weight:normal;">Employment Agreement, dated September 10, 2020, by and between R. Michael Gendreau and Virios Therapeutics, LLC. (incorporated by reference herein from Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on September 16, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.9+</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:-54.69pt;"></span><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1818844/000110465920131043/tm2025286d19_ex10-9.htm"><span style="font-style:normal;font-weight:normal;">Agreement, dated July 15, 2020, by and between William L. Pridgen and Innovative Med Concepts, LLC. (incorporated by reference herein from Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on December 1, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">23.1*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20221231xex23d1.htm"><span style="font-style:normal;font-weight:normal;">Consent of FORVIS, LLP</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">31.1*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20221231xex31d1.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to Rule</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">13a-15(e) or Rule</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">15d-15(e)</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><sup style="font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">*</sup></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">31.2*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20221231xex31d2.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to Rule</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">13a-15(e) or Rule</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">15d-15(e)</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><sup style="font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">*</sup></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">32*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20221231xex32.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Executive Officer and Chief Financial Officer of Periodic Report Pursuant to 18 U.S.C. Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1350 </span><sup style="font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">*</sup></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:9.28%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">101.INS*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">XBRL Schema Document.</p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">XBRL Calculation Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">XBRL Definition Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">XBRL Label Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">XBRL Presentation Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">104*</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</p></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">Filed with this Annual Report on Form&#160;10-K.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Indicates management contract or compensatory plan.</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_df9bafae_dda4_4bae_b9ac_b7d1248e4990"></a><a id="Item16Form10KSummary_375667"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16. Form&#160;10-K Summary</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_9cb43213_9cf4_48fc_841d_ec792ef941b1"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 14, 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:24.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:24.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">VIRIOS THERAPEUTICS,<span style="font-family:'Times New Roman','Times','serif';">&#160;</span>INC.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Greg Duncan</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Greg Duncan</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Chairman of the Board of Directors, and </i></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer </i></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 14, 2023 by the following persons on behalf of the registrant and in the capacities indicated:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:47.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:50.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Greg Duncan</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Chairman of the Board of Directors, and</p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Greg Duncan</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Chief Executive Officer </p></td></tr><tr style="height:7.75pt;"><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Angela Walsh</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Senior Vice President of Finance, Corporate Secretary</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">and Treasurer</p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Angela Walsh</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Richard Burch</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Richard Burch</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Abel De La Rosa</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Abel De La Rosa</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ David Keefer</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">David Keefer</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ William L. Pridgen, MD</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">William L. Pridgen, M.D.</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ John C. Thomas, Jr.</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">John C. Thomas, Jr.</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Richard J. Whitley, MD</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:47.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Richard J. Whitley, M.D.</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>tmb-20221231xex10d6.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/13/2023 10:39:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title>_</title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:right;margin:0pt;">Exhibit 10.6</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">VIRIOS THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;text-transform:uppercase;">AMENDED AND RESTATED 2020 Equity INCENTIVE Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FORM OF STOCK OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:normal;">The Board of Directors of Virios Therapeutics, Inc. (the &#8220;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-weight:normal;">&#8221;) has decided to grant to you an option to purchase shares of the common stock of the Company under the Virios Therapeutics, Inc. Amended and Restated 2020 Equity Incentive Plan. &#160;The terms of the grant are set forth in the Stock Option Grant provided to you (the &#8220;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant</u><font style="font-weight:normal;">&#8221;). &#160;The following provides a summary of the key terms of the Grant; however, you should read the entire Grant, along with the terms of the Plan, to fully understand the Grant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SUMMARY OF STOCK OPTION GRANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Grantee:</b></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>______________________ </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Date of Grant:</b></font><font style="display:inline-block;width:36pt;"></font><b style="font-weight:bold;white-space:pre-wrap;">            ______________________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Exercisability/Vesting Schedule:<font style="display:inline-block;width:14.34pt;"></font>As set forth in Section 2 below.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:180pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Exercise Price Per Share:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">$_____________________</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Total Number of Shares Granted:<font style="display:inline-block;width:6.01pt;"></font>______________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Term/Expiration Date:<font style="display:inline-block;width:25.69pt;"></font><font style="display:inline-block;width:36pt;"></font>______________________</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:28.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.1pt;text-align:center;margin:0pt;">1</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.1pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:none;">VIRIOS THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:none;">AMENDED AND RESTATE 2020 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:none;">STOCK OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:normal;">This STOCK OPTION GRANT, dated as of __________ (the &#8220;Grant Date&#8221;), is delivered by Virios Therapeutics, Inc. (the &#8220;Company&#8221;) to _____________ (the &#8220;Grantee&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RECITALS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">A.</font></font><font style="font-weight:normal;">The Virios Therapeutics, Inc. Amended and Restated 2020 Equity Incentive Plan (the &#8220;Plan&#8221;) provides for the grant of options to purchase shares of common stock of the Company. The Board of Directors of the Company (the &#8220;Board&#8221;) has decided to make a stock option grant as an inducement for the Grantee to promote the best interests of the Company and its stockholders. &#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">B.</font></font><font style="font-weight:normal;">The Board is authorized to appoint a committee to administer the Plan. &#160;If a committee is appointed, all references in this Agreement to the &#8220;Board&#8221; shall be deemed to refer to the committee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:normal;">NOW, THEREFORE, the parties to this Agreement, intending to be legally bound hereby, agree as follows:</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant of Option</u><font style="white-space:pre-wrap;">.  Subject to the terms and conditions set forth in this Agreement and in the Plan, the Company hereby grants to the Grantee a stock option (the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option</u>&#8221;) to purchase __________ shares of common stock of the Company (&#8220;Shares&#8221;) at an exercise price of $_________ per Share, which represents the fair market value on the date of grant. </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>It is understood and intended that this Option is intended to qualify as an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code to the extent permitted under applicable law. &#160;Accordingly, the Grantee understands that in order to obtain the benefits of an incentive stock option under Section&#160;422 of the Code, no sale or other disposition may be made of Shares for which incentive stock option treatment is desired within the one-year period beginning on the day after the day of the transfer of such Shares to him or her, nor within the two-year period beginning on the day after Grant Date of this Option and further that this Option must be exercised within three months after termination of employment as an employee (or 12 months in the case of death or disability) to qualify as an incentive stock option. &#160;If the Grantee disposes (whether by sale, gift, transfer or otherwise) of any such Shares within either of these periods, he or she will notify the Company within 30 days after such disposition. &#160;The Grantee also agrees to provide the Company with any information concerning any such dispositions required by the Company for tax purposes. &#160;Further, to the extent this Option and any other incentive stock options of the Grantee having an aggregate Fair Market Value in excess of $100,000 (determined as of the Grant Date) first become exercisable in any year, such options will not qualify as incentive stock options. </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercisability of Option</u>. &#160;The Option shall become exercisable subject to the following dates and/or criteria set forth below, if the Grantee is employed by the Company on such dates or dates:</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:28.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.1pt;text-align:center;margin:0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date/Conditions</u><font style="display:inline-block;width:29.34pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares for Which the Option is Exercisable</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">_____________</font></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-weight:normal;">_____________________</font><font style="display:inline-block;width:18pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;text-align:justify;margin:0pt;"><font style="font-size:12pt;font-weight:normal;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The exercisability of the Option is cumulative, but shall not exceed 100% of the Shares subject to the Option. &#160;If the foregoing schedule would produce fractional Shares, the number of Shares for which the Option becomes exercisable shall be rounded down to the nearest whole Share. &#160; &#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term of Option</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>The Option shall have a term of ten (10) years from the Date of Grant and shall terminate at the expiration of that period, unless it is terminated at an earlier date pursuant to the provisions of this Agreement or the Plan.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>The Option shall automatically terminate upon the happening of the first of the following events:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>Subject to clause (iii) below, the expiration of the ninety (90) day period after the Grantee ceases to be employed by, or provide service to, the Company, if the termination is for any reason other than Cause (as defined in the Plan).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>The expiration of the one (1) year period after the Grantee ceases to be employed by, or provide service to, the Company on account of the Grantee&#8217;s Disability.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font>The expiration of the one (1) year period after the Grantee ceases to be employed by, or provide service to, the Company, if the Grantee dies either while employed by, or providing service to, the Company or within (90) days after the date Grantee ceases to be employed by, or provide service to, the Company, if the termination is for any reason other than Cause (as defined in the Plan).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font>The date on which the Grantee ceases to be employed by, or provide service to, the Company, for Cause. &#160;In addition, notwithstanding the prior provisions of this Paragraph 3, if the Grantee engages in conduct that constitutes Cause after the Grantee&#8217;s employment or service terminates, the Option shall immediately terminate.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, in no event may the Option be exercised after the date that is immediately before the tenth anniversary of the Date of Grant. &#160;Any portion of the Option that is not exercisable at the time the Grantee ceases to be employed by, or provide service to, the Company shall immediately terminate.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Procedures</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Subject to the provisions of Paragraphs 2 and 3 above, the Grantee may exercise part or all of the exercisable Option by giving the Board written notice of intent to exercise in the manner provided in this Agreement, specifying the number of Shares as to which the Option is to be exercised. &#160;On the delivery date, the Grantee shall pay the exercise price (i) in cash, (ii) by </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:28.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.1pt;text-align:center;margin:0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">certified check, bank cashier&#8217;s check, personal check or wire transfer, (iii) with the approval of the Board, by delivering Shares of the Company, of previously owned Common Stock, which have been previously owned for more than six months, which shall be valued at their fair market value on the date of delivery, or by attestation (on a form prescribed by the Board) to ownership of Shares having a fair market value on the date of exercise equal to the exercise price, or (iv) by such other method as the Board may approve. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>The obligation of the Company to deliver Shares upon exercise of the Option shall be subject to all applicable laws, rules, and regulations and such approvals by governmental agencies as may be deemed appropriate by the Board, including such actions as Company counsel shall deem necessary or appropriate to comply with relevant securities laws and regulations. &#160;The Company may require that the Grantee (or other person exercising the Option after the Grantee&#8217;s death) represent that the Grantee is purchasing Shares for the Grantee&#8217;s own account and not with a view to or for sale in connection with any distribution of the Shares, or such other representation as the Board deems appropriate. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>All obligations of the Company under this Agreement shall be subject to the rights of the Company as set forth in the Plan to withhold amounts required to be withheld for any taxes, if applicable. &#160;Subject to Board approval, the Grantee may elect to satisfy any tax withholding obligation of the Company with respect to the Option by having Shares withheld up to an amount that does not exceed the minimum applicable withholding tax rate for federal (including FICA), state and local tax liabilities.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">5.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions on Exercise/Transfer</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Except as the Board may otherwise permit pursuant to the Plan, only the Grantee may exercise the Option during the Grantee&#8217;s lifetime and, after the Grantee&#8217;s death, the Option shall be exercisable (subject to the limitations specified in the Plan) solely by the legal representatives of the Grantee, or by the person who acquires the right to exercise the Option by will or by the laws of descent and distribution, to the extent that the Option is exercisable pursuant to this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>The Option or any part thereof shall not be transferable, and no interest therein may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution. Subject to the foregoing and the terms of the Plan, the terms of this Award Agreement shall be binding upon your executors, administrators, heirs, transferees, successors and assigns.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>The Company, within the limits of applicable law, shall be entitled to ignore any attempted assignment or alienation or any creditor&#8217;s process not permitted under this Section 6.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">6.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant Subject to Plan Provisions</u>. &#160;This grant is made pursuant to the Plan, the terms of which are incorporated herein by reference, and in all respects shall be interpreted in accordance with the Plan. &#160;The grant and exercise of the Option are subject to interpretations, regulations and determinations concerning the Plan established from time to time by the Board in accordance with the provisions of the Plan, including, but not limited to, provisions pertaining to (i) rights and </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:28.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.1pt;text-align:center;margin:0pt;">4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">obligations with respect to withholding taxes, (ii) the registration, qualification or listing of the Shares, (iii) changes in capitalization of the Company and (iv) other requirements of applicable law. &#160;The Board shall have the authority to interpret and construe the Option pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions arising hereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">7.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>You acknowledge receipt of a copy of the Plan.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>You represent and warrant that you understand the Federal, state and local income tax consequences of the granting of the Option to you, the acquisition of rights to exercise the Option with respect to any Option Shares, the exercise of the Option and purchase of Option Shares and the subsequent sale or other disposition of any Option Shares. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>You acknowledge the Options are intended to be exempt from the requirements of Section 409A of the Code, and, to the extent that further guidance is issued under Section 409A of the Code after the date of this Agreement, you hereby authorize the Company to make any changes to this Agreement as are necessary to bring this Agreement into compliance with the applicable exemptions under Section 409A of the Code and the Treasury regulations issued thereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">8.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Employment or Other Rights</u>. &#160;The grant of the Option shall not confer upon the Grantee any right to be retained by or in the employ or service of the Company and shall not interfere in any way with the right of the Company to terminate the Grantee&#8217;s employment or service at any time. The right of the Company to terminate at will the Grantee&#8217;s employment or service at any time for any reason is specifically reserved.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">9.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Stockholder Rights</u>. &#160;Neither the Grantee, nor any person entitled to exercise the Grantee&#8217;s rights in the event of the Grantee&#8217;s death, shall have any of the rights and privileges of a stockholder with respect to the Shares subject to the Option, until certificates for Shares have been issued upon the exercise of the Option.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">10.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment and Transfers</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Except as the Board may otherwise permit pursuant to the Plan, the Option and Grantee&#8217;s rights and interest under this Agreement may not be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of by Grantee, other than by will or the laws of descent and distribution (in which case, such transferee shall succeed to the rights and obligations of Grantee hereunder) and is exercisable during Grantee&#8217;s lifetime only by Grantee, except that (i) Grantee may designate in writing a beneficiary to exercise the Option after Grantee&#8217;s death (provided the designation has been received by the Company prior to Grantee&#8217;s death) and (ii) Grantee may transfer the Option to any family member (as defined in Rule 701 under the Securities Act of 1933, as amended) subject to the requirement that Grantee will cause any entity included in such definition to convey the Option held by it to another family member prior to the occurrence of any event which would cause such family member to cease to qualify as a family member. &#160;If Grantee or anyone claiming under or through Grantee attempts to violate this Paragraph 10, such attempted violation shall be null and void and without effect, and the Company&#8217;s obligation hereunder shall terminate. &#160;If at the time of Grantee&#8217;s death, the Option has not been fully </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:28.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.1pt;text-align:center;margin:0pt;">5</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">exercised, Grantee&#8217;s estate or any person who acquires the right to exercise the Option by bequest or inheritance or by reason of Grantee&#8217;s death may exercise the Option in accordance with and with respect to the number of shares set forth in Paragraph 1 above. &#160;The applicable requirements of Paragraph 4 above must be satisfied in full at the time of any exercise.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>In the event of any attempt by the Grantee to alienate, assign, pledge, hypothecate, or otherwise dispose of the Option or any right hereunder, except as provided for in this Agreement, or in the event of the levy or any attachment, execution or similar process upon the rights or interests hereby conferred, the Company may terminate the Option by notice to the Grantee, and the Option and all rights hereunder shall thereupon become null and void. &#160;The rights and protections of the Company hereunder shall extend to any successors or assigns of the Company and to the Company&#8217;s parents, subsidiaries, and affiliates. &#160;This Agreement may be assigned by the Company without the Grantee&#8217;s consent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustments; Reorganization, Reclassification, Consolidation, Merger or Sale</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>In the event that, after the date hereof, the outstanding shares of Common Stock shall be increased or decreased or changed into or exchanged for a different number or kind of shares of stock or other securities of the Company or of another corporation in each such case through reorganization, merger or consolidation, recapitalization, reclassification, stock split, split-up, combination or exchange of shares or declaration of any dividends payable in Common Stock, the Board shall, in good faith, appropriately adjust the number of shares of Common Stock (and the option price per share) subject to the unexercised portion of the Option (to the nearest possible full share), and such adjustment shall be effective and binding for all purposes of this Option Agreement and the Plan.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>If any capital reorganization or reclassification of the capital stock of the Company or any consolidation or merger of the Company with another corporation, or the sale of all or substantially all its assets to another corporation, shall be effected after the date hereof in such a way that holders of Common Stock shall be entitled to receive stock, securities or assets with respect to or in exchange for Common Stock, then you shall thereafter have the right to receive, in lieu of the shares of Common Stock immediately theretofore receivable upon the exercise of the Option, such shares of stock, securities or assets (including cash) as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Common Stock equal to the number of shares of such stock immediately theretofore so receivable had such reorganization, reclassification, consolidation, merger or sale not taken place.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>In the event that the Board shall determine that any event not specifically provided for in Sections 11(a) and (b) affects the shares of Common Stock such that an adjustment is determined by the Board to be appropriate to prevent dilution or enlargement of participants&#8217; rights under the Plan, then the Board shall, in such manner as it may deem equitable, adjust any or all of (i) the number and kind of shares which may thereafter be issued under the Plan; (ii) the number and kind of shares issued or issuable in respect of outstanding grants under the Plan; and (iii) the exercise price, grant price or purchase price relating to any grants under the Plan or, if deemed appropriate, make provision for a cash payment with respect to any outstanding grants under the Plan.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:28.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.1pt;text-align:center;margin:0pt;">6</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">12.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan Documents</u>. &#160;This Agreement is qualified in its entirety by reference to the provisions of the Plan, and any current or future amendments thereto, which are hereby incorporated herein by reference. &#160;Pursuant to the Plan, the Board is authorized to adopt rules and regulations concerning the administration of this Award Agreement and the Option granted hereunder that are not inconsistent with the Plan as it shall deem appropriate and proper. &#160;A copy of the Plan in its present form is available for inspection during business hours by you or the persons entitled to exercise the Option at the Company&#8217;s principal office. Notwithstanding the foregoing, this Agreement shall control in the event of any conflict with any terms of the Plan. &#160;Capitalized terms not explicitly defined in this Grant but defined in the Plan will have the same definitions as in the Plan.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">13.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Provisions</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>This Award Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. &#160;If any one or more provisions of this Award Agreement shall be found to be illegal or unenforceable in any respect, the validity and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>This Award Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>(c)<font style="display:inline-block;width:22.68pt;"></font>Any notice to the Company under this Award shall be made in care of the Board at the Company&#8217;s main office. &#160;All notices under this Award shall be deemed to have been given when hand-delivered, delivered by overnight courier, or mailed first class postage prepaid, and shall be irrevocable once given.</p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:28.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.1pt;text-align:center;margin:0pt;">7</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the Company has caused its duly authorized officers to execute and attest this Agreement, and the Grantee has executed this Agreement, effective as of the Date of Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 180pt;">VIRIOS THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 180pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 180pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 180pt;">By:<font style="display:inline-block;width:18.66pt;"></font>_______________________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 180pt;"><font style="display:inline-block;width:36pt;"></font><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;font-weight:normal;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;font-weight:normal;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:normal;">I hereby accept the Option described in this Agreement, and I agree to be bound by the terms of the Plan and this Agreement. I hereby further agree that all the decisions and determinations of the Board shall be final and binding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;font-weight:normal;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:normal;">Grantee:</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:27.69pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;font-weight:normal;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;font-weight:normal;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:normal;">Date:</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:7.01pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;font-weight:normal;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';font-size:16pt;font-weight:bold;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:normal;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:28.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.1pt;text-align:center;margin:0pt;">8</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:14.71%;padding-right:14.71%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">VIRIOS THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">OPTION EXERCISE FORM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">I, [___________], a participant under the Virios Therapeutics, Inc. Amended and Restated 2020 Equity Incentive Plan (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u><font style="white-space:pre-wrap;">&#8221;) or a person otherwise entitled to exercise the Option, do hereby exercise the right to purchase ___________ shares of Common Stock, $0.0001 par value, of Virios Therapeutics, Inc. pursuant to the Option granted to me on [    ] under the Plan.  Enclosed herewith is $</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">_________</u><font style="white-space:pre-wrap;">, an amount equal to the total exercise price for the shares of Common Stock being purchased pursuant to this Option Exercise Form.  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:39.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Date:</font></font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td><td style="vertical-align:top;width:60.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><u style="font-size:12pt;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:12pt;font-weight:normal;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><font style="font-size:12pt;font-weight:normal;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="clear:right;float:right;margin-right:calc(50% - 0pt);"><div style="left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.1pt;text-align:justify;width:100%;margin:0pt;">9</p></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;margin:0pt;"><font style="font-weight:normal;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:14.71%;margin-right:14.71%;margin-top:30pt;page-break-after:avoid;width:70.59%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tmb-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/13/2023 10:39:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">We consent to the incorporation by reference in the Registration Statement on Forms S-3 and S-8 (Nos. 333-263700, 333-265757, 333-251544) of Virios Therapeutics, Inc. of our report dated March 14, 2023, with respect to the financial statements of Virios Therapeutics, Inc. included in this Annual Report on Form 10-K for the year ended December 31, 2022. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ FORVIS, LLP (Formerly, Dixon Hughes Goodman LLP)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Atlanta, Georgia</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">March&#160;14, 2023</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>tmb-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/13/2023 10:39:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CERTIFICATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Greg Duncan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I have reviewed this annual report on Form 10-K of Virios Therapeutics, Inc.;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Date: &#160;March 14, 2023</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">/s/Greg Duncan  </font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Greg Duncan</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chairman of the Board of Directors,</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>tmb-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/13/2023 10:39:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CERTIFICATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Angela Walsh, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I have reviewed this annual report on Form 10-K of Virios Therapeutics, Inc.;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Date:  March 14, 2023</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/Angela Walsh</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Angela Walsh</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President of Finance, Corporate Secretary and Treasurer </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>tmb-20221231xex32.htm
<DESCRIPTION>EX-32
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/13/2023 10:39:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS REQUIRED BY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Annual Report of Virios Therapeutics, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ending December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify that to the best of our knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:32.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 14, 2023</p></td><td style="vertical-align:top;width:32.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ </i>Greg Duncan</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Chairman of the Board</p></td></tr><tr><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:32.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Greg Duncan</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 14, 2023</p></td><td style="vertical-align:top;width:32.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/</i> Angela Walsh</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President of Finance, Corporate Secretary and Treasurer (Principal Financial and Accounting Officer) </p></td></tr><tr><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:32.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Angela Walsh</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section&#160;906 has been provided to Virios Therapeutics, Inc. and will be retained by Virios Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tmb-20221231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $G [0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !6?K^I/HVB7]]';M=26T#S+"IP7*J3M_'%:%-= ZE6
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M5*G23LG^*$I2?0[K0/C;X,\26FJ7%MK!MTTR$7-VNHVLUF\4)Z2;)D5BA[,
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M):1:C;7$<8#7" *Y!4C@,N<C'&:S=)JVNY2G>^AZ+62/%6F?VU>Z6T[QW5E
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M5EW97Y23M'(X/:DJ.G,W_5@<];'TE[TM(.E+7,:B48Q2T4 )C%+110 4444
M%%%% !1110 5PWQJ_P"2=:G]8O\ T8M=S7#?&K_DG6I_6+_T8M7#XD3+9G96
M/_'E!_US7^5>5_'%OBC/<:?8^!-+\,ZCHUW;7$>K/XEEE2*,;?EXB^=@>1@#
M\17JEC_QY0?]<U_E3Y_,\B3R=OG;3LWYV[L<9QVS1&7+*]@:NK'X1:S?7<GC
M*#P2?"N@:]'%KYN@GAFQ82WP+8:WAE(WF+ ("D<'-=#\:-=^$_C'XPS+!X0U
MGX5Z!9Z>UM<Z=9VD;7/VY%^4/$6VJ,\$]3UK[HU_]C+QA\8-9U;QIXKU"U\*
M>/X-0CBT670[AUL["RC;.^'9AC*X).9 <'L:\R^ 7['7@WXB?%[QO)K7B:;Q
M3J?ASQ Z70U.#[4FHVS)_P M-P WELY<9(QP!7TJQ5*W-?9=//\  \QTI[=S
MT[]CO]GW4]7\$>#/$?B7Q!\0+&_T*Y6>TTW5=6233I8]G'DPKD",@C&237VM
M7E7P3^!7_"E;G7+>Q\2:G?>&[B4?V5H%S(7MM)AZF.,L2QR?4\#@"O5J^?KU
M/:3;OH>C3CRQL%%%%<YH%%%% !1110 445C>*_&&B>!]'FU77]4M=)TZ$9>X
MNI B_09ZGV'--)O1!L3^)-?L_"N@:AK&H2K#964#SRNQP JC->1?LI:9=W7@
M[5_&.HQM'?>+-1EU/:XPRPDXB'_?(%<7J.K:Y^V!J=OINE65WHGPDMYQ)>:G
M=(8IM:*G(CB4\B+/4GK7TW86,&F64%I:Q+#;P((XXT& J@8 %;R7LX<KW?X&
M2?-*_0L4445SFIY[XV_Y*7X%_P!ZZ_\ 0%KT$=*\^\;?\E+\"_[UU_Z M>@C
MI6DMH_UU)6[%HHHK,H**** "BBB@ HHKQ+]I;]K/P;^S/H2RZS*=3\0W2%K'
M0;1QY\_;>QZ1QY_C/X GBKA"522C%79,I**NSVN218D9W8(BC+,QP /4UX9\
M2/VW?@Q\+YIK;5/&MG?:A%PUEHZM>R@^A\L%5/\ O,*_*GX\_MC_ !*_: NI
MXM8UA]*\/LW[O0=*=HK8+V\P@[I3[N<>@%>'@ #   ]!7NT<KTO5E\D<$\7T
M@C]5]:_X*T?#:TE9=-\*^)]20='>."#/X-(35?3/^"MOP^N)@M]X.\364>>7
MC-O-C\ XK\L**[?[.P_;\3#ZS4/VO^'_ /P4"^"/Q!FCMXO%JZ%>2$!;?7H&
ML\D]MYS'_P"/5]"6.H6VJ6<-W9W$5W:S+OCG@<.CCU5AP1]*_G,[$=C7IOP8
M_:1^(7P$U)+GPCX@N+6TW;I=*N"9K*?U#1$X!_VEPWO7)5RM6O2E]YM#%O[:
M/WNHKYC_ &4_VZ/"G[1D<6C7R)X:\<*F6TJ63,5U@<M;N?O>I0_,/<<U].5X
M-2G.E+EFK,]",E-7B%%%%9E&7XIU"32O#6JWL-W:6,UO:RRI=7X)MX2JDAY
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M@&3(.DA'W2X[,1D>M)JGP4\":UXF'B&^\*:7=:OO61KF2 $NZ_==E^ZS#LS
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MI7T1R-=UH/PS?6/@]XP\=&>;9H5_86 MH8PP)N"Y,DI_A10@ (ZLX%=#XJ^
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M!5$4O&8R@VL-X)X^]4GP?^!MIX>\/ZA_;VA:982W^L1ZS#H^G2,\&GM$L:P
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M%/[IF5@=A],US?QVO-"MM<\2Z9IMMH7AR[\,V445F^L:O>K?2G:61K"VB<#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU)6:/0BTTFBT>E?/G[,F;7Q]\8;/IY?B$OC_ 'D!KZ#-?/OP'(MOCU\:+4<
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M&8\)+W3Z-V]Q[US/Q*^ ?Q!^$-O#<^+?"]WI=C-)Y45^KQSVKOC.P2Q,R;L
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M\T>^GLK^UGL;R!MDMM=1-%)&WHRL 0?J*^JI8?VG+.MK)>CNCR)U.6\8;/\
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M#XH@MKG6I8?-8 #YH,#[N5YW'ICBOU^%>3C)J@W"$%:7W_\  .NC'VB4FW=
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MQN[FU/MMD(KH6M%^3,_MKT.X\;?\E+\"_P"]=?\ H"UZ".E>?>-O^2E^!?\
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MS\1OA3\/->\-_$6875U;ZU/)8W*W/GK/"X5V=">0A<N0" 02>!7Y2^./V?\
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M_@#'_A7TY^SC\0-:^(W@>74M<GCN+M;EHPT40C&T>PKS'_A4/P#_ .AMC_\
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M_9"LWTG0_&^EN"HLO$EV@4]@6S_6O>+.[BO[2&Y@<20S()$=>C*1D&N6\"^
MQX,U+Q/<K,DB:SJ3WX101LW  @_E77&24)1[V/*:]Y,S/&W_ "4OP+_O77_H
M"UZ".E>?>-O^2E^!?]ZZ_P#0%KT$=*4MH_UU!;L6BBBLR@HHHH *0C(I:* /
MPD_:V^%NH_"/X_>,-+OK.2TL;K49K[39I%VQSVTKET*-T.-Q4XZ%37C^#7]$
M7B?P;H/C6R%GX@T73];M021#J%JDZ GJ0&!Q^%>>7'[)'P7NG+2?##PL6)R<
M:9&/Y"OH*>:144IQU/-EA&W>+/PAP?0TF,5^[7_#'WP3_P"B7>%__!<G^%?G
MK_P4U^"_A?X3^-O!4_A'P]8>'=,U'3YXY8-.@$4;S1R*=Q [[7QGVKMH8^%>
M:II-&-3#RIQYFSXOHHHKTSD"BBB@#M/@I="Q^,?@:X8X$6N63D_2=*_H&'2O
MYV/"]\=,\3:/> [3;WL$V?3;(I_I7]$=K.MU;13)]R10X^A&?ZU\[FJU@_4]
M/![2):SO$.@V7BC1+W2M0A$]E=Q-%+&>X(_GW%:-%>#L>@?FE\2_ 5[\-?&-
M_H5X"PA;=!,1@31'[CC\.#[@URU?=W[3GPD_X6'X..HV$._7=*5I80H^::/J
M\?Z9'N/>OA+I[5[U&K[6%^IYU2'(SZV_8;_Y WB[_KYM_P#T!Z^GZ^8/V&_^
M0-XN_P"OFW_] >OHCQ=?:OIOAG4[K0--CUC6HK=VL[&:X$"3RX^56D(.T$]3
MBO*Q"O5:.RG\"->DSSBOD3PI^W+%X8^%'B:_^(]I"OQ$\,ZD]IK'A?36BMY(
M5:3$3Q>=+^]CVD'>I)/]VO.O#W[1?P\\2?M@>)O'!\;:G8>%-"\,0W316NJS
M/9WUV&"RA8 2)0B. 51>2A;G&3:PM1WNMOZ_4EUHZ'Z ,P523T%?)?Q5_P""
MD/PJ\&^&M:.D7=QKOBJRN9K*/0VM)(6\^-RNYW9=JQ[ESN!)/89KWW5?C5X)
MT73/"NHWWB&UM]/\43QVNDW3[A'<R2*61<X^7('\6.>.M>$:Y^P7H<W[46D?
M%;2KJT33#=M?:KX?OK8R1R7&P@2Q'. 2VUBK C(R.N*5"-)-NNGY>=N@ZCFU
M^[/SL\3_  .^.GQNC\1_%?4_!>JWD-T3?W%TT A:5. /(@)#NBJ !A3\J]Z[
M3]EKQ7^SKH7PB\96OQ6TA+OQ9,SFT>>TDFDEA\L!$MF48CD#[LDD=0<X%?J!
M^T+\&9_CC\.+GP[9^)]4\):AO$UOJ6F3.A#@$;9%5@7C8$@KD>O45\%_M#_L
M3Z-\$?V07U?5K73;CQ[HMZB-K6D/,B7EO+<  2HYPS!7(SCC P:]BGBX8B*I
MS=KM))'%*BZ;YEKIU/@=L9.T$+G@,<G';/O71>"?B/XK^&U]/>>%/$>I^'+J
MXC\F:73;EH3(G]UL<$?7IVKZ&^&W[%$WBW]F34OBG>GQ'>:E*95T;0/#]BEQ
M)=!3L61\@L$+YR5Z*I->X_LW?L*:'\5/@3J-AXW^'&K_  _\7 @6WB6[O&:X
MN'Y(=;9L>7&/E!1A\W4'T[ZF*HQ3YM4G9G/"C-M6/'_@Q^S!\8-6\#^'/BO\
M//$MP_BGQ)J<UC)+:2HTEI:N&66YGG<DJVY2" "V".<FOUH\+Z%+HWA+2M(U
M"\DU>>ULHK6>[NCN>Y94"L[YZEB"3GUK\T_V<_VCKC]A#Q7XP^$OQ.L;Z^TZ
MUNOM-G/I$8F*R,HP51F'R2KM8<Y5@01UK].-%U1-<T:PU&.&:WCNX([A8;E-
MDL8=0P5U[,,X([&O"QTJCDN;X>C[K_@'H8=12TWZC-%T'3?#.D6^F:186VEZ
M=;+LAM+.)8HHQG.%50 .237'_!7_ )%G4O\ L,7_ /Z/:N_;[IK@/@K_ ,BS
MJ7_88O\ _P!'M7G+6+.GJCT"BBBLR@K-\1Z0FOZ!J&FR?ZN[@>%OHRD5I44U
MIJ!^>G[5OPMU#XN?LNVDMG ]QXK^&]W)#>6B#,CVX!5R!W^3:X]=AKX/^$GQ
MY\;_  1N[V7PAK LXK]0EU9W%NES;7 'W2\3@J2,\'KS7[1_$+P9K'A[Q*?&
M_A"V6]O&C\G5M&8X74(1W7MY@'3UZ5\7_%K]C3P)\3-3NO'?PSUFW\.W=M(;
MW5_!^IH8_+*G=)Y2]8SP?EP5ST*U]!A<3#D<*B]U_P!6?Z'G5:4N;FCN>->'
M]*_:,\:>*O\ A;L-Q-=ZW#:R0)=SV?F100,A4QK&L9CC7:QX[9R:\,7XB>-O
M GA#Q/\ #IK^2TT/5YDDU'3945PTB$,'1C]W.!DK]X8K]QO@E806?PD\,0PQ
MJD3V*.5 QDMR2?Q-?"7BC]C30/BE\7?$OB[Q1XJL_"G@?3=0EM9K>+BZN&5R
MVQ">%&&QD!CZ"JHXR$I24XI)?IL3.C)).+U9P/\ P38^&#Q>+=;^+6LQFW\.
M^&;25(+B0866Y=""%]=JD_BRU^C/P TBYM/!#ZM?1F*^UV[EU.1&ZJLA^0'_
M ("!^=<!X&\#6OCS2]&T#P_HC>%_A'HQ4P6K(8Y=5=3D$@\^7GDD\L?T^B8X
MUBC5$4(B@!548 'H*\S%UW5DV^OX(ZJ,.1#J***\\Z0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH P+GX?^%[VXDGN/#>D3SR,6>66QB9F/J25R37.^._
MA[X6M?!FM2P^&M(AE2TD99([")64[3R"%XKT&L/QQ:S7W@_6;>WB::>6UD1(
MT&68E3@"M(R=UJ2TK'YJ: BRZWIZ.H=&GC!5AD$;AP:_2"W^&_A)H(R?"^BD
ME1R=/B]/]VOA70O@MX\M]:L)9?".K)&DZ,S&V.  PYK]#8 5AC!&"%&1^%=V
M+G\/*SGHQWNC)T[P3X=T>[2ZL-!TRRN4SMFM[..-USUP0 :VJ**\YMO<ZM@H
MHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8_M'Z7>
M:S\(]:M;"TGO;IPFV&WC,CM\W8#DU\/'X8^,,_\ (JZU_P""^7_XFOTOI,5U
MTL0Z4>5(QG34W>Y^:'_"L/&'_0JZU_X+Y?\ XFC_ (5AXP_Z%76O_!?+_P#$
MU^E^*,5M]=EV(]@NY^:'_"L/&'_0JZU_X+Y?_B:^P_V3M#U'0?AS-;ZG87.G
MS_:W;RKJ%HVQZX8 U[9BEK*KB75CRM%PI*#O<****XS8*^9_VI/^2D_#K_KX
M_P#9Q7TQ7S/^U)_R4GX=?]?'_LXKIP_\3[S.I\)]+CI2T@Z4M<QH%<-\:O\
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M%0&P>2.,U!X0^*7@;XC^='8W<*WUS%Y<]AJ5LUI=LA'W6BE56(P?<5Y-<_\
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M-?'WQJD'Q5L_$?Q(\2LS6EC=:N7GTS288X?,0[LX25RC@' /R9ZDFOU.
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M?J=6';?-=BT445Y9UA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'GW@G_DJ?Q#^MA_Z):L;XL_LR>"_C+XZ\(>*_$-F;F_\.3,R0.JO;W<
M9Y\J:-@0RA\./0CT)%7=6U&/X;?$JZU?428/#WB"&&&6^8?N[6ZBR$\P_P *
M.K8#'@%>>M>D07$5S$LL,B2QL,JZ,&!'L16SE*#4HNVGZ6,[)JS/AC_@H%\
MO &E>"O%OQ'U[6)$UA],BTW0=.NIECAMKE6!5;<*%.&7=NC;<N,GBL7X7_\
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MW-%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?#[R%HHHKRCL"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[\SG"_@.I]A7FFO_ +'W@#QO9V4WB.RGN]=3Y[K5;:X:&:YD)RV\C@C/ !'
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M4U-\.OV=M*@^';Z/XGTBUM99]4DU>*TTFZEB_LV0X"+%.A5]P"\N",DGK3_
M_P"TWI6N_#VP\0ZSI&KZ5>7DYMK?3UTR=I;R7>P"6R8W2\+R1PO.2,5WG@7X
MGZ-X_DOK:S2]L-4L"HN]+U2U>UNH WW69&'*G!PPR#ZU<G5C&S5K>I*4&[E#
M2/@9X(T.RNK6TT0+'=W4-]<-)<S2237$1S'*[LY9F'J3SWS5*3]G/P!+J<E[
M)HLCE[K[<+8W]Q]FCN-VXRI#YGEHY/.545;\:?&C1_ NIR6M_I>OSP0(LEUJ
M%EI$\UI:J>C/*%QCUVYQWQ2_&76Y(?@UXCU72KUXG_LXSV]W:R%6 (!5E8<]
M#U%9IU+K5ZE6CVV)K_X+^$=4UC6-2N=.F>;6$"7\*WLZP3D8PS1!PF_@?-C/
MO5?Q-\"/!?BW59M1O],G2ZN(UBNC97]Q:I=HO19TBD590/\ ;!XXZ5E#XX:-
MX=LM/T^:VUO7;Z"P@GU"32--FO5M%:,'=,Z @$\G'+8R<5;U7]H'PI8:A;6E
MHNJ:]YMO%>23:+ILUW';0R'$<DI0':#SQR>#D<4TJJ>EPO ZW2? V@Z%JB:C
MIVF0V5VEFNGHT.55;=3E8PH.T $#H*L>'O"^E^%-/>QTJT6TM6EDG,89F!=V
M+.>2>I)-<E#\<?#UUXK;0[:VUBZ$=P+.74X-+F>QBGP#Y3S!<*<$9)X&>2*K
MV_[0'A>XU=+81:NFG27'V2/79-,F737FSMV"X(V_>XW?=SQFHY*CW3'>)(O[
M/?@-=:_M(:*__'S]M^PF\G^P^?G/F_9=_D[L\YV=>>M=EI?AC3-&U35-1LK1
M8+W4W1[N4,Q,K(-JD@G P#VQ7,^%/C%H7C;Q)>Z-HT&IWDEC-);W=Y]@D2U@
ME3K&TK #<<\ 9IGB_P",^B>$=:DTHV>LZS?01B:ZCT73);S[)&>C2E!A<X)Q
MRQ X%-JI)\KN"Y5JC0\;?"WP[X_FM+K5+6:/4K//V74M/NI;2[@SU"31,K '
MNN<'TJMX=^#?A/PW8ZK;QZ8=1?5D\O4;K5IY+ZXO%QC;)),69E]%S@>E5#\>
M/!:--YNK>1$FG?VK'/-"Z1SV^<%HV(^<J>"H^8$X(KGM/_:(@O\ XGQ^&?\
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M9;6%IYHMK=!''YTSS/@>KN2S'W))JY116184444 %%%% !1110 5\^?MQ?\
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MC>7T][I<)2S,";WMX@.0H / R>34N@_$?Q7X>MY;72=<O;6&5S*T46&!<]6
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M^PNG_HMZ_3$=*X\?]CT_4WP^\A:***\H[ HHHH **** "BBB@ HHHH ****
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MBI&%%%% !1110 4444 %?/G[<7_)%(_^PM:?^A&OH.OGS]N+_DBD?_86M/\
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M'N*P_&]YHMEX2U6;Q#-#!HJ6[_:I)SA0F.:^&/ W[6_Q \6_%/PWX/\ "=S
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MGLEVI;OIYA*,"@'#$LV[.[FOM&33[66\BNWMH7NHE*1SM&"Z*>H#=0#63<^
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MT(KVJH+.PMM/C:.UMXK:-F+LL*! 6/4D#N?6IZPG+GE<TBK*P4445!04444
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M 3V))/Y5^A=<./>L%Y?J;X?[3%HHHKRSL"BBB@ HHHH **** "BBB@ HHHH
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MFJTTW>Y'LH732"D Q2T5RFP4444 %%%% !1110 4444 %%%% !1110 4444
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M/_(7LZG\OY?YGR?17UA_PP3HW_0_>)O^_=G_ /&*/^&"=&_Z'[Q-_P!^[/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tmb-20221231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $Y R@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K#\;>,=,^'_A35/$.L3>1ING0-<3.!D[0.@'<GH![UN5X/\ MQ,5
M_9B\9D$@^5#T_P"NT=:THJ<XQ?5B?D?(GB__ (*6>/\ 4-:G?P_I&BZ5I88B
M&&[MWN9MO8NV]1GZ#%8G_#QWXM?\\_#O_@M;_P".U\M'K17C/,*_V;)?X8_J
MF_O/UV/#66Q24H-OOS2U^YI?<CZE_P"'COQ:_P">?AW_ ,%K?_':/^'COQ:_
MYY^'?_!:W_QVOEJBC^T,1W7_ (#'_(K_ %<RO_GT_P#P*?\ \D?4O_#QWXM?
M\\_#O_@M;_X[1_P\=^+7_//P[_X+6_\ CM?+5%']H8CNO_ 8_P"0?ZN97_SZ
M?_@4_P#Y(^I?^'COQ:_YY^'?_!:W_P =I&_X*/\ Q8499?#BCU.FL/\ VK7R
MW7O_ .R)JFEZ)JOCS4[K3)[O4M.\,WE[:74%TL+0; -VS=&X#G(P_P##SP<U
M4<=B).UU_P" Q_R.?$9#EE"DZBHMVZ<\O_DCIA_P4>^+)&0GATC_ +!K?_':
M/^'COQ:_YY^'?_!:W_QVK/A']G71/B!I<5UJ&A>)+"[U32Y]3/B35M9M;9I;
MDH\H$6GX,DT7&/,R"W+8 K+\%_!7X;ZRW@31M2M?$0U?Q)X:EUN;4;74HUBM
M6C$IVI"8COW>7CEAM[9S6GUO%=U_X#'_ .1.)Y=DJO\ NGIO:4GW_O>3\_(M
M_P##QWXM?\\_#O\ X+6_^.T'_@H_\65ZKX<&>.=-;_X[6'I'P7\#>-+3P?XB
MT^/6]!\.WUKJEWJ=E+>QWER([)5?]U)Y: ,X8#!4A3R,U#\.-'\&>+/^$@O/
M"=OXI\+R1>&M3DN[6YO$N8I-B*4"W'E+N# D/'M!'&&I?7,3W7_@,?\ (T>5
M919M49:;^]+35K7WO)[7_$Z+_AX[\6O[GAW_ ,%K?_':!_P4>^+)&0GAPCU&
MFM_\=KC_ !3X&^'?@'5(_"=Y9^);CQ3#IUM>'6K2=);8W,B+*(OLFP$0@-@R
M;\CDXKM_COX'\(Z#XK\8>-_%6GZEK%O=Z]%I%EI6CWJ6(C*V4,DDKR&-\\$!
M5 &3DDT?7,3;=?\ @,?\B?[*RGFC%4)>\KKWI:[6M[W6]]6MB#_AX[\6O^>?
MAW_P6M_\=H_X>/\ Q9W8V^',]<?V:V?_ $;6!XE_9RTAUUS3?#,]]>ZW9W.E
MWELES(I+Z;?* NY ,>9'(ZAF!P0>@KKT^#?A+4XM%\.66I:S<>&V\>G0Y8Q>
M(4D*6G[V9/DRK%PP!R0%P,=Z:Q>*[K_P&/\ D2\MR5)-4G_X%/LG_-]QGG_@
MH]\61U3PX/KIK?\ QVC_ (>._%K_ )Y^'?\ P6M_\=KE_#R^#?#NC^-=>M=&
MU"QT)I8/#"1WFH+<7$IEF)N94?RU"'R(VX"G;NZFCQ-\ ='\'KXD>_.J744V
MOVNE>'/L'[R:YAE43-*$P/-(A90!\H+-UJ?KF)M=-?\ @,?\C7^R<H4N65%K
M_MZ7E?[72ZN=1_P\=^+(_@\._P#@M;_X[0/^"CWQ9(R$\.D>HTUO_CM7+S]G
MW0]#TXZ]:^']4\+7^C:UIX2VU7Q!:ZA-=V\EP(RTUO$H-L_0X)(ZC)Q4VH?!
MC1/&/Q(\;7]]X5US5ED\47%K)>IK%KHNG6D0(Y224,9Y,G[@   '/-5];Q7=
M?^ Q_P#D3G67Y*]52=O\<O+^_;KW\MS-_P"'COQ:_P">?AW_ ,%K?_':/^'C
MOQ:_YY^'?_!:W_QVN>\6?"+P'\(K;4;WQ/!KOB.&7Q%<Z-86^G7R6;0P0!6>
M:1C&^]_F "  '&214?A_X$>&_'L/AJ\\.RZM%IAUR?3M;?42$G@ME3SHYRF,
M1$Q+(#U&5SGM2^N8J]KJ_P#AC_D;K*LFY>?V3Y>_-.W_ *5\O4Z7_AX[\6O^
M>?AW_P %K?\ QV@?\%'OBR>B>'#CTTUO_CM<AK'@WX6^$+#P])JNG>*-2/B=
M)[ZUFTV^0'3[3S6C@Q&8S]HD.W<P+(.<"NR\6^ O#NH^$?#7B'Q!%?7.C>'/
M!D4[V&GNMI<7DCW;1QJTA5O+'.6.TD8Q1]<Q/=?^ Q_R$\JRE./[B5F[?%+\
M/>[Z:V[[#/\ AX[\6O\ GGX=_P#!:W_QV@_\%'OBR" 5\. GH#IK<_\ D6L!
M?@9X3\2:19:CH0U2T?Q'H5Y?Z)IUW=+-)#>6K#S87<(OFJZYVG"D&M72OA'H
M^A^&O$&D)?:I#JD?AW3[S6HHKE1%)+<7"%82I3("QLI(SG<?PH^N8KNO_ 8_
MY">5Y,MJ3O?;FGWM_-WT]?O+7_#QWXM?\\_#O_@M;_X[1_P\=^+7_//P[_X+
M6_\ CM>4?M!^'?"/@GXAZKX8\*:9JEHFD73VT]WJ>HBY-R<*0501J(P,D=6S
M[5YC6;Q^(B[77_@,?\CNI9!E=6"J*DTGKK*7_P D?4O_  \=^+7_ #S\._\
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M 'T* )**C\^/^^O_ 'T*//C_ +Z_]]"@"2BH_/C_ +Z_]]"CSX_[Z_\ ?0H
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MQ=<^(KF*U=!&898!"L49;G>H Y( ./>OT8_X9J^%G_0@Z!_X!+1_PS5\+/\
MH0= _P# ):?L*/=_A_D1_;=U9TEUZOKOUZGX[3:K'HWC+^UO#QOHH+:\%U9/
M>JHN%PP9=^S*Y!]*]QOOVGM,N_C+H?BJ'PY>6'A_3+"[A32[<IO-S<K(9Y1D
M[<-))GKG:H^E?HQ_PS5\+/\ H0= _P# ):/^&:OA9_T(.@?^ 2U*PU&.S?X&
MU7B"5:W/23T:Z]='U/S!M?C7HL?Q"^'>OWOAN?4M/\-:+;Z7<V=R(R99(_,_
M>Q@Y7@R!E#]UY%=\_P"UWH20Z!#-)XQ\1R:7K\.L->:]=6I=HT1U,,<41$<0
M&X8QUYSCBOT%MOV<_AA9SI-%X#T!9$.5/V%#@_B*ZU?!F@*H5=$TY5 P +2/
M _\ ':I4**V;_ YJN=.HU>BG;S?G_G_5D?C3\)?B=IWP^^,MEXQO;:XNK"&[
MGN&MK9T\XK)OP!N(7(W>O:NDMOBC\/O EEXDN_!5AXEN_$VLVL]DM]XAFM$A
MLHIL^8T<<))=R"0"Q &:_7/_ (0[0?\ H"Z=_P" D?\ \31_PAV@_P#0%T[_
M ,!(_P#XFI6&H)6N_P #6?$-:I+FE26R6[U2VN?D=%^T7'I'Q \(>(-,L'>Q
MTO0+70=2TV]=&COX8U*RH0"1M8'C/((!K<\6?M4Q17'C'4O T-_X>USQ)JT-
MS->W(MI/+LHH0J0 '>-Q<9)(Q@#'-?JK_P (=H/_ $!=._\  2/_ .)H_P"$
M.T'_ * NG?\ @)'_ /$U7U>EW?X&;SR3:;H1T5MWJKWU[ZGXY?%'XSGXM^$/
M#*:]Y]UXQTAIK>752(DCNK1CN16"8PZ-G&%Q@U[!\1?B9X-^&WC?PSXBM[#5
M+[QK9^$[&.V,=W!_9ID>W*K)(/\ 6!D!/R#@\9(K]+?^$.T'_H"Z=_X"1_\
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MIW_@)'_\31_PAV@_] 73O_ 2/_XFLWA:$G=M_@=]+B:O1CR0I1MZL_"/<O\
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M)!))!'KQFO.K5\14J*A0>I]KE&7Y?0PKS3,U>'-RQBNK[O5:?/H[WV? ^&?
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M=9-P.QB<,Y"@ G-=C\.?^"7?B26:TD\5^(],T>Q#@RV>DJ]Q,5[@2,%52?4
MU]Z?#'X5>&/@_P"&8M"\+:9'IUDAW.1\TDS=WD<\LWN:\>,*^(2A5?N)]=_)
M=_Z^[U\=F>59;.=? 13Q$HV;C=03>[6MK]K7OU>]^M10BA0, < 4ZDW#W_*C
M(KUC\L%HHHH **** "BBB@ HI,UB^*?&N@^"-.>^U[5K32K5!DR7,H7/T'4_
M04TF]$&QMU\W>+K_ /X7!^TUX?\ #UBWGZ-X.!U#495Y07)&$3/J/2K&L?&_
MQ9\8UET;X1Z%=1V<N8YO&.LPM;VD"]"T*, TK>G&*]+^#?P?TSX/>&3I]I+)
M?ZC<N;C4-3N.9KN8_>=CZ>@[5T)>Q3<M^QDWSZ+8[T4M%%<QJ%>9ZC_R7O2/
M^P7-_,5Z97F>H_\ )>](_P"P7-_,5I#KZ$R/3****S*"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBFR.$C9CT R: /SO_X*9^,M%G\5
M>'O#MG:QMKL%N9[Z]4_,L+']W"?7)#-ST[=37C/PM^#/A/5/"MU:^/Y=4\(:
M[K4*7/AW6KF,BP"<\R#NKGC=V'/%8WB_41\=OVG]0FOKQ(+'5=<\EKB:0*D-
MJC[,ECT C0FOM?QM\09_C[8'X>_"_P (6FK:#:(MM)X@U:#%K:JHVJ8<_=(
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MNI-2TFTOGF6-F*F-I4/DD;V48RNW:,?*#7M]%'MI]PY(]AD42P1)&@"H@"@
M8  I]%%8EA1110 4444 %9>N>)](\,PI+JVI6NG(YPAN953<?0 ]?PK2=MJD
M^@S7%?#[38=4:[\37B+<:I=W$L:32#)@A1RBQIG[H^4DXZD\U22W8F^B)_\
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MUSPOI=_/CSY[='DQT+8Y/YT-*UT/R9L4445 PHHHH **** "BBB@ KS32?\
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MOEU@S]!BZ/$5"TK1Q$5\G_P/Q7H?<'[0-M=? [XS:'\6-/B\[2KXKI^L6ZD
MMQC('?*C\T'K4Z?"KPC\-_&6K_&Y[E9_"OV,:GI]FD9WK<RCDXQT.05'8N<X
MQ7FW@KXEQ_ML_%;P\+^U.F^'/#ME]NU'3'DW*TP/SG/=&.U03R%W9ZUT7AK]
MI5_&/QLOM'U: 2?#?6RVA6EO(F(%*\*X[98G!'967TKZ&G)U*:<'?37T[>I^
M?5Z,\-5E2K*S3Z]_\CE7\&WWC?X#_&#XJ>(@HOM?L9ELH\AO*A1@>/3E%4>R
MGUKD/^"85V\?Q2\5P#_5RZ0&(]Q,F/YFIOBGXGN/@)X-^+GPINYY)=/O8T?1
MRYR0)77(!]TSGWC]ZTO^"7?A^23Q-XVUPH?)BM(;,,1QN=]Y_1*\C&:XN-NV
MGH?9Y;[N18ARZO\ '0^\_%GA'3/&NDG3]4B=XA(DT<D,K12PRJ=R21R*0R,I
M&00:YJZ^">@7<%INNM;2]@1XCJ,>L7"W<T;D,\<DH?+(2 =IX&/EQ5CXL>-+
M[P9HNGMIPM(KS4=0@T]+S4 QMK4R-CS) ""0.@&X9) R,YKR_5?CIXMT;4=5
M\/*NE:UJL&L6NDP7^E6S,JF6!Y6,D#3J/,^3:$\T#++SSBNZ$9M>ZSXR3BGJ
M>A:U\ _!NMQQ0R6-S:V:V4>GR65E?36\$\$9)C21$8!]I9B">?F.<YK%T/X%
M6-[KGBB^U^*\,.HZP;L646HRBUO(EBB6,S0JVUL%#P1R ,Y%9.G_ !,^(>NW
M.G:5';:1H5^UMJ%Q<7&H6QE+K;O$L;+#%<$)N\PAE:0E=IZ\"H8/C7XG\2:5
M=ZEITF@Z)'I6B6NKW4&II))]K:579E1Q(OEQ#85WD.<GIQS:55+<F\>QZ'J7
MP<\.7ZAHEOM-NUN9KI;S3;^6WG5Y2/- =&!VM@97IP#C(!I]U\)-!O=2TR[N
M)-4GCL/*,=G-JEQ);.\1W12/&SD.ZGG<>20"<X%>;3_&'QQJGVK4M+BT.RTZ
M/4=.L(K&_MYFG_TJ*%BTCK( #&TP^4+\VTC*]:;JWQJ\8:=+!X=BL[:^U\ZO
M<Z<VHV-@9(F2*!)@5MWN$P[!\8\TXVL>>E+DJ=Q\T>Q[#KO@71/$FN:-K&HV
M2W&H:0\CV<I=AY9=2K< X.0>_?!ZUF:'\(_"OANSTVUT[3!;V^GO<R6Z"5R%
M,^[S<Y/.0Y'/08QC KGM5\6>*-7^ NK:WMA\.>)$L;A@Y43)&R%@' 20XR%R
M!O.TG!SBN<MOB3XQ:RN+:/5O#]O<:'H=MJEY<ZE;2#^T#(K'Y )AY2 )AI,O
M\S#@=*E1FU:_]?TQMQOL>A:#\(_#WAZS:VMXKJ9#9-IH:ZNY)F6V+9$0+'(4
M=!Z#BMC4/!>D:KX0;PQ=6GG:*UH+(VY=L^4%"@;LYS@#G.:Y'Q3\3-0@\$>$
M]2TRWM]/OO$DUI!')J89H;(S*&S( 5+$?= RNYB!D9KF_$/Q.\8^&=2O+5Y]
M$U:+1]'GU:]DL;23S+HQR;1#&OFD1DC[Q);!Z#G@49RUN%XH[^Y^%'AF[L+>
MRDT\_9H+ :9&BRN,0;D;;P>3F-3GKQUYJIX@^#/AKQ+K]QJUY%>B6Y,3W-O!
M?316]P\1S$\D:L%9E/0D?7-><Z7\;/%]OH-_=ZW9P62RV=O<6%Z=.!W33.J)
M MNEV[3!MPVONC!QSC-4M,^)_CCQ1?>&1]OL]&EM?$-UI>H6\ECDW2I:F5=R
M)<,$.#C:';D YZK5*%1?:)YHOH>]Z%X>L?#=O<0V$)ACGN)+J0%BV9';<QY]
M3VK2KP[X8_&+Q?XV\1Z=)<:$(O#^I2W,:Y@2%K01EP#YAN&,QRF&41*5SZ Y
MF^(_Q0\8Z#K7BH:*-#&G>'[2TN3#?0RM+=-*SAD+JX$8 4$-M8Y[5FZ4N;E>
MY?.K7/:Z*\0O/BIXMTG5;CPQ=3:(^LOJEK80ZN;>2.UB2:-WR\)D)+#RRJC>
M Q9>G-1P_%?QA>:[!X;@DT1[^'5)["ZU5+:1X94CMO/W11"3B3HK*7(!.<]J
M/92#G1[G17A_PK^,'B_QOK^FR7>AB/0=3-QM8P)";01E@OSFX9IB2N& C0J3
MZ Y]PJ)P<'9C34E=!1114%!1110 R;_5/]#7+?"__D3[?_KXN?\ T>]=3-_J
MG^AKEOA?_P B?;_]?%S_ .CWJU\+%U.LHHHJ!A1110 4E+7A_P"USX"^('C[
MX5WUKX!\8R^$[VWC>XG6VB(EO4521"LRL&BR>XY[5<(J4E%NQ,G97L>X51U'
M6].TB2!+Z_MK-YVV1+<3+&9&]%!(R?I7Q=\(/VU/#W@G]D;3=<M[.Y\1:[X>
M"V.K:/=ZO''>+)N.Z4O.Q9U/7Y0QZC'%<!^UU\5?!_[4-S\&/!%E%8OK^M:C
M#<WDME=Q7DFE1/\ *T/G1Y7>V>0.F.1Q77'"3<^66BUU]#%UH\MUN?H]17*?
M#'1="\+>#[+P_P"'M4?5=.T@&R66:_\ MDJ%3RDDA).X=,'ITKJJXFK/0W0M
M%%%(93UG_D$7O_7%_P#T$UC?#;_D1-#_ .O5/Y5LZS_R"+W_ *XO_P"@FL;X
M;?\ (B:'_P!>J?RJ_LD]3I:***@H**** "BBB@ HHHH *\TTG_DO&L?]@J/_
M -#KTNO--)_Y+QK'_8*C_P#0ZTAU]")=#TNBBBLRPIKH)$*L 5(P0>].HH _
M+S]HWX0Z]^S)\:&\8:=+K<'@;5;WSWN- OWLI4W-N>W:1?NG.2I(P>E>,_'.
MR3Q=XC77_AKXGUC59=: LFT6;6;N\UJ<;<MYZL!A >-NYE/45^SFLZ+8>(=-
MN-.U2R@U"PN$*2VUS&)(Y%/4%3P:^2?B9_P35\$>)KF2\\):O?>#YV);[*%^
MU6@/^RK$.@^C8]JQH5,1@)N5%<T7]E_H?7U,3EV=THPS)NG5BK>T2NFO[RWO
MZ?>EH? 'B?Q!J^E_!OP=X+TO7U\3R2W$C'0G\+O'=Z9.#\T4-T1F3)X(7-4_
M#?A#Q#X4M=%^(&I^$U?1HKSR6EO;2*YA,BG#1R1N&"/UQO7K7UJ__!-[XI:=
M)9+IGQ$THP6,IFM"TMW ;=SU>-1N"$]R"*W=%_X)H^(];NXY/&WQ+:Z@!W-%
M8Q2SN3WP\SX'UVU&*Q,\0U4I47"I_,G^>B3/7RV&"R^G*AB<=&KAW]AP;^[W
MFXZ^7GO9KS_XS?&[P_\ ''3M*^'OP=\$+IMYKS0G4WATZ*UEG=.D>(^"JGDO
MTQTK] O@A\-T^$OPL\.^%@XEEL+8+-(!]Z4_,Y_,G\JRO@S^SAX%^!-DR>&=
M*VWTJA9]4NV\VZF'H7/0?[*@#VKT^HHTIJ3JU7>3/G\TS'#5:,<#@(<M&+OK
MNWW_ ,OZ2^8?B+'_ ,++_:Z\)>&KC]]I7AVS;5983]UI3PI/TKZ= P/2OF7P
M?\O[;_BT/]XZ)'LSZ9KZ;KU*VG*O)'RE/J_,****YS4**** "BBB@!B;^=^.
MO&WTKYO^+>K2?\-9_"^P1CA;>>0CZ\5])U\L>+S_ &K^W1X4AZBSTB1\>E=-
M!:OT9E4V7JCZFKS34?\ DO>D?]@N;^8KTRO,]1_Y+WI'_8+F_F*RAU]"Y'IE
M%%%9E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-=UB1G=@JJ
M,EB< "N+F\8:AXME>T\(QQM; E)=>N5)MD[$0KP9FZ\C"#N3TJDFQ-V.P:\M
MTNDMFGC6X=2ZPEQO91U('4@9'/O4IY%8/AKP;8^&WEN5:6^U2X&+C4KQM\\W
MMG^%1V50%'I6_2=N@(_)[]M_X<W?PH_:%NM:LE:WL]:==6LYEX"S CS #ZAP
M&_X$*]J\<_$;X8?%?P!X;\5Z:+ZU^+%Y"H$7AM<7(NU^5O. XP6&01\Y!&*[
M/]LS3)_C]XBT_P"%OA72(=1\2::#J<VHS/L6S&W_ %>[MN!&<^J]^GQW^S[\
M:]5_9?\ B7>OJ.AI< %K+4+*[CVSV[ X+(V,JP[@?>'X&N6#>!KJ4OAE_6O]
M;'W#@L_RQ0I_QJ6GJO\ @K\4?07B^7XAN_AQ?CB?$L7@8HOF?V>L?)_A^T;?
MXO7=\V.G-?:?PEC\%1^#+/\ X0,6/]@D?(;'NW??_%O]=W-<!HGQ;\1_$;PQ
M#J&F^"[+7]!U"+*R)<K)%*AZ@@_D5(R.]>-ZAX$\??"7Q%<>-/ 'A>ZT"T1?
M-U'0A-YUK.@Y;"DY QG@<C^$CI7M-^WC:Z7H]#X#E=*3NG\]S[6K@_C+\&O#
MGQO\&W&@>(K7S$.7M[J, 36LN.)(V['VZ$<&K_PL^(VG_%7P/IOB/3@8XKI,
M20,<M#(.'0_0]^XP:ZQONFO.E'>,D==*K*G)5*;LULS\1]5A\0? [XA:I#I.
MJ3VMU87-Q8K?V^4$Z LC CIA@#E37T!IGCWPKXC_ &7_  _;:;<+;^+M UQ;
MB[M&^63]X2/,3^\F @R.A7GMGNH]+\):MI?[0>B^*VLHYQ>2W5A'>.$E$RM+
ML>+/.X%EZ==W/!KXKUWP[J?@:]T^:21(WN8?M5M)%*K-LW%<LH.5.0>#U'/2
MH:GEU3GCK3NOR/M*<Z'$U#V56T<1%:/HU_6ZZ;KJCVW]MWXI:;\2OB-ICZ=%
M-%-::;%%?"8 $S<L!P>P;]:^WOV%?A9)\-/@3ITUY"8=3UQSJ<ZL,,J, (E/
M_  #_P "K\^/V9/A^OQD^.V@VNO>??V,]V;B]=B6:;:"Y#'T.T9]J_8R&)((
MDCC18XT 5548  Z "N:DI5)NO);[>AEG%2G@L-3RNB[N.LGY[_\ !^XPO'/A
MNX\6>'+C3+>\M[-YL;C=V,=Y Z@\I)$^ RD<$9!]"*YCP7\%-&\/:-K%CJMM
MIFL)JTJ27-M'ID=O9*J#$:1V^6"@<G)))))STQ-\:M=U/0/#%I-8W<^EV<M_
M!#J6J6L0DELK1FQ)*H*L!C@;BI"@EL<5YIJGC:..ZL;67XCZU:>$1932V6OQ
MQQ>9?7:R8\EI?(*N$7E5"YDR>6VUZL(S<='H?$2:3U/=M+\*Z+H<%O!I^DV-
MC#;QM#"EO;I&(T8@LJ@#@$@$CN1S63<^#_!/B*_BMY]&T/4;S1@@2)[:*22R
M#<H ,90'&0.!QGM7@Z?$O6;W4I8?%WC?5?!][#H-E>6UE9V*()KIS."6#1.6
M=@D9^S]>3QQQ8\0?$7XA6^B3RW(?27=])74YRGV86"2PR-.PD\F4I\X12Q5]
MFX],9JO8SON+G78^CGT/39&E9K"U8RS+<2$Q*=\BXVN>.6&T8/48'I5+6?!/
MA[Q#8W%GJ>B:=?VL\HGEAN;5'5Y   Y!'+8 &>O%?..L_$+Q9I?AG0M0N?&$
M5S:"XNC%!I5T5N[^-&C$8CGEL_+N77+KY>Q!(""&.TUZQ\7O$E]IL/AH/JEY
MX8\.WMP5U35[>-1-:KY1:-&8JPB#/M4N1QTR,YJ'3E%K7^D5S)W.LU35?#?@
MZUTO0IH8;:"^;['9Z9:69=7&"2HBC4@(!DDD!0.IJ.7X6^#KBVTVVE\+:/)!
MIN?L<;V,96W!.2$!'RC/.!QFO%O"8UOQ9\0_ VJ7>M:S>:?:7FI0V-ZT*0K?
M6JQ*4EE'EC.XEDW#;O"@@<YKLOB'XA\6Z/XZBT#2[BX,'B5(8M/NDMPZZ=)&
M_P#I+$[< &(EAOS\R8'6FX--)/47,FKM'I-Q#H?C32;JSF2QUO36=K>X@<)/
M$64X9&!R,@]0>AJA)8>%/ASHK70L-.T33;:+R2T%LJ*B,WW<*.A8Y(]>:\KL
M=;\4ZQXFL[>?5M6M--@GU>>>'3[6-)+E8)HQ FXIZ$],%O6O.(?'?B'QEHWB
M>U>]O-4TNYTR*^2":;[7+;3_ &E 8G9+>)8W"M\T*[]N.O<N-%OKH)S2Z'O^
MOZ%\,?AYHEU%JVF>&]"TO5I/)FCGMH8H[M^6"L,?.>"<?4TD0^%TG@B.^C7P
MO_PBEO<I*MPH@^R13@A5;=]U7!VC/7I6?\9-:LO#GB3X>ZGJ5RMEI]OJ\GFW
M,@.R/-K,!N('&20.?6O+?'MA;>/;WQ5K.C:9)-X1U'^S+.Y=K5DBU.X%XI:1
M4*@NJQDJ9,8.0,G;PX1YDFV_Z=@;MLCWVV\.>#]#\5K?0:9H]CXCU(.5N(X(
MTNKG R^& W-QR?IS5N$^'-?O]8M(AINH7D1C@U&%0DCJ<;D64=>AR WKQ7S_
M *IJFK?"[XBZ%I>J6M]J6G:!9ZC>:5J$<+R":T,!"0,P!_>QL0@!Y92IY(-3
M?#>Q\6_#OQCX>U;7O#1TV+Q!YEKK=W#>K<F2ZF?S('9%0%0C'RLDG"D>E)TM
M+WZ:!S:VL?06J>%=%UNVO;?4-)LKV"]"BYCN+='6;;]W>"/FQVSTHTKPIHNA
MV]G!IVD6-C#9[OLT=O;H@AW##% !P3DYQUS6K17-=[&MD8>G>!O#ND:Y<ZS8
MZ%IMGJUSGSKZ"T1)I,]=S@9.>_K6Y110VWN,****0!1110 R;_5/]#7+?"__
M )$^W_Z^+G_T>]=3-_JG^AKEOA?_ ,B?;_\ 7Q<_^CWJU\+%U.LHHHJ!A111
M0!\]_M#_ +9'AC]G7X@>#O#NO0D6VLEY+W4"QVV, X#[%!+DL1P.@R:^=?VK
M_P!K2;5/$O@_5/@_\4M)UT&7[)'X5LHY&-S-*"OFW#94;%!&U6XW'FON;Q-X
M#\+ZQ=S:WJOAS3=6U&&SDMQ-=VJ2R&$_,T8+ \$@<5^(G[1>J>&=2^(46L^#
M/!M_\/["YC9VT^8L(_M"3.C26Y_N?*/NX ;(QQ7M8&G2JR6FJWVLSAKRE!;[
MF!\:?A+XN^#_ (YFT;QQ816>NSI]N/E2)*CB1B2RLO ^;/ QBO3_ -D[X.^!
MOB):^+-8\3_$=_ .K:# MUIAM[B*WD+@$^;N?E@I &U,'GK57]EW2-"^.W[1
M6B6GQ:UVZU2QN8V4R:I?/NNG1?W4#2L<A2>, C/3O75?\%"_A!\-/A%\2]'L
M? "6UB;BT:74-)@G,L=JP(",-Q)0L,_+GMFO8E4;DJ#=I-;I:'$HV3J=#7_9
M7_; ?X12Z]!I_@S6?'OQ$\2WI4W2:HRP7[$_([0;3B3CJHR0>2*^U_V3O#7Q
MXT#QSXKU#XH0VT>@^(5_M.WM(-1^T#3K@D#R%4Y*C;U )&1US7Y<?LU7WB:T
M^,F@+X.UNP\/^(;HR6UIJ.I8\B-G0KS]<X!]<5^X7PML_$6G?#OP[:^+;A;K
MQ+#911ZA,CAP\P7#'<  <^O>O+S!1I.T4O>^_P"78Z\,W/=['54445X)Z!3U
MG_D$7O\ UQ?_ -!-8WPV_P"1$T/_ *]4_E6SK/\ R"+W_KB__H)K&^&W_(B:
M'_UZI_*K^R3U.EHHHJ"@HHHH **** "BBB@ KS32?^2\:Q_V"H__ $.O2Z\T
MTG_DO&L?]@J/_P!#K2'7T(ET/2Z**JZGJMGHMA/?:A=0V5G ADEN+B0(D:CJ
M68\ 5GL:).3LMQU]?VNEVDEU>7$5I;1#<\T[A$0>I)X%<;X=^.WPZ\6^(1H6
MB>.- U;63DBQLM1BEE..N%4DG'M7Q[^UK^V%\(_B+X?NO"$7ANZ^(5LCEA<B
M\DL;)9!P&#J=\F/]W:?6OBSX1?%?6O@'K.HZKX-NK#2[R\79YMS9Q73PIG(6
M-I 2ON>]<SQF%C%W;<NEDK?>V?68;A7-<3KR*"_O-W^<8J37S2/W.S39)4A1
MGD=41>2S' %?D/;_ /!0/XTV\Q<^-[:8'G9-I5J5'Y(#^M=#K'[?_C/QMX&U
M?POXKT#P_P"([+4+9H&FC$MK(K$<-A693@\\ ?6N>..I.24DU]S_ "9VU>#L
MQA!SA*,O_ E^,HQ7XGZK0SQW$:R1.LB-T9#D'\14E?EW_P $Z_"Y'B:&YC^,
M]WH.KI.=_@HH7AO8?K*VUC_N#<*_4.O4DZ3?[J?,CXVOAL1A)^SQ5-PEV?YK
MNO-:"T445!SGS+_R"_VZ?07WA\?B0U?35?,GCL'3_P!MCP--T%WI<T/UQS7T
MT.E=%;:+\C*'7U//)O'5SH_QGA\,WTH^PZI8&>QR /WJ'YUS].:]$KQK]IOP
MAJ.I^$K/Q1H"D^(_#%P-1M54<RHO^LC]\KGBNZ^&'Q!T_P"*'@C2_$6FN&AN
MX@SIGF.3^)#[@YJ91O!37H4GJTSJZ***Q+"BBB@ KY9ME^T_MZ2[O^6&A\?C
M7U-7RS:M]F_;TG#\>?H?R^^*Z:'VO1F53IZGU*.E>::C_P E[TC_ +!<W\Q7
MI8Z5YIJ/_)>](_[!<W\Q64.OH7(],HHHK,H**** "BBB@ HHHH **** "BBB
M@ HHHH ***9+*D,;22,$1069F.  .I)H ?6'XE\8Z?X86&.<R7-_<<6VGVJ^
M9<3G_93T]6.%'<BL27Q;J7C"1K;PDB)9 E)=?N4W0+V/D)QYS>_"#U/2MKPU
MX.L/#1FGC\V\U*X'^DZC=MYEQ/\ 5NRCLJX4=A5V4?B)O?8Q$\*:GXS<7'BQ
MEAT_.8_#]M)F+V-PX_UI_P!D80?[76NUAA2WB2*)%CC0!51!@*!T '84^BDV
MV-*P4445(SE=#^&F@^'O&FN>*K*V>/6=92-+N5I696"# VJ>%Z#..N*\,_:Q
M_8TTWXY0R>(?#[0Z3XUBCQYCC;#?J!PDN.C#H'[=#D=/IVBIJ1556GJ=6%Q-
M7!U%5H.S7]:GXZ>$/B/\5?V0O&ESIH2ZT2??NNM%U*,O:W0'\0&<-GM(AS[]
MJ^P/A[_P4H\#>(K);7QIH]_X:NW79)+;(;NU;/!.5PZCV*GZU]2^//AIX6^)
MVD'3/%.A66MV7\*740)0^J-]Y#[J17RKXZ_X)C^#]7FDG\+>)=3\.ELD6UTB
MWD(/H"2K@?5C7#[*M2_ANZ/K7F&5YFKXZFX3_F7_  /U3]3T/X8?M _L^_#_
M ,-MI?AOQSIMI8//)=&.[FE#[W.3]]<]@,>U6_$W[>'P8\.0,\?BDZS*/^6&
ME6DLS'\2H7\S7S!=?\$OO&BS$6WC3098NS36\Z-^0S_.M?P]_P $N-5EF7^W
MO'UI!$.JZ;I[R,?8%V 'Y53JXF3UCK_7F9K!9%#5XAM=OZB>.?M*?M,>'OC!
MKTM_X:\%)H%RY EUBYG)N9P. 3&I\M3CC)W-[T[]G/\ 8Y\7?'?4(-5U*.?0
M?"18-+JERA$MR/[L"MRV?[Y^4>_2ON;X6?L+_"SX93P7KZ5)XFU6(AEN]<83
M*K#NL0 0?B":^@XXUB1410JJ,!0, #TI^RJ5;.O*Z7053.,+@H.EE=+E;WD]
M_P#-_/[CS7X3_LZ>!/@N[R^&=(,%VR>6;NYF::7;W +=,XYQC->F445W7N?'
M2DY-RD[MA28I:*0C%T[PM;Z;XGU?6XYI6N-2A@AEC8C8HBW[2.,Y/F'.?05L
MTM%-NX"8HI:*0"4M%% !28I:* $ZT8Q2T4 )2T44 %%%% !17%3_ !+BA^*=
MMX+^P.99K,W?VSS!M &?EVXSVZYKM:IQ:W$G<****D845Q7@#XEQ>/-7\26,
M=A)9G1;O[(SO(&$IY^8 #CI7:TVG%V8D[[#)O]4_T-<M\+_^1/M_^OBY_P#1
M[UU,W^J?Z&N6^%__ ")]O_U\7/\ Z/>J7PL.IUE%<1\8/C#X=^!_@NX\3^)I
MIX].BD2();1>9+(['"JJ\>O4D #DUXI^UA^T9X0TOX5WVG6WB_4M U35]%EU
M/1M7TB8PQS,@!6-+D95F8D#8I)QUQUJZ=*=1JRW)E-1O<^HJ*^1_A)^W7\.9
M/ 5M9W6N7)N=(\.P7MYJ>K7 D\RXV[6A)9O-DEWC^%3D$8->[_ SXAZ[\4/A
MWI^O^(O"=UX.U&Y&[[#<R+)OC/*2H1R%8$'# ,.A%.I1G3OS*PHSC+8XO]JO
M]I2\_9GT'0];7PC-XHTV^NS9W!M[D0M [*?+ZJ0=S8'..M?G[^U7\+/C7\4=
M,G^*WC^P\/>$=+M[?&F>'7U&*.Y2 G>51,?._P#$P+;CV7M7ZT:YH&F>)M-D
MT_5]/M=4L9,%[:\A66-B#D95@1P1FN6^+7PD\&_%WP>^B>,],@O=(A9;A'=S
M$ULZ<B1) 04(]<].O%=.'Q,:#34=>K\C.I2=2]WH?C_\3-;^ EY^S?X2L_"&
ME7,/Q1C=/[3N6CE!.,^:9'8[&4_PA>1QTYKS#X.^.=,^&_Q*T3Q+K7AVW\6:
M=8S^;/I5V1MG&,<[@02.HW CBOLY/V>?!W[57[87C./1YH)O OA_3H%GFTB=
M8A?7(3:H$J C).-S@'[IK3\-_P#!,V6;X9^.(_$^GZ?H/B-)9+C0=3L]:FO/
M+B7)$4R,B(5P "^-QR>F*]M8BC"/)-O7OOJ>?[*<G>*V_0\@^%'PB\'_ +3/
M[0.J1^)?#OB3P#;>)T.HZ#I.@VB+%'".&G>1UVK'E3T7!8\5]A_"#]E#XB?"
M_P#:#T:ZN?B#KOBCX::)I\C6*:O?;G29P4\GRP<$ '.X@#L*M_L!?'?0OB?X
M&L_#CZ=,OC7PS8C3M1OQ:;HGBC<K&!<@8(]$)[9Q7UO7DXG$U(S=.UE:UM_F
MCMI4HN*D%%11W4,LTD*2HTL>-Z*P++]1VJ6O*.LIZS_R"+W_ *XO_P"@FL;X
M;?\ (B:'_P!>J?RK9UG_ )!%[_UQ?_T$UC?#;_D1-#_Z]4_E5_9)ZG2T445!
M04444 %%%% !1110 5YII/\ R7C6/^P5'_Z'7I=>::3_ ,EXUC_L%1_^AUI#
MKZ$2Z'B?[=$_QQU^#2O"WPGTZ^M=.N(I+C4]<M+E+;RU7D1^:Q&P=SCDU\'?
M%C]I[QS\2/!NC>'/$^HI#I>D1""2WM96=;V5#CS97))D/''..]?JA^U5K%UH
M7[/GCF\LB5N4TV0*R]5R,$_D:_(G1'U72OAKX\O[3PMI^M::UG%8W.J7CH9-
M-WN-KQ1D$EFQC<,8]:XZTI8NK2P*LDWJ^K_I+[['WF0TZ678+$9U-<TH:17;
M;[KN2UW2O;<XNUUBWOG_ -'GQ*OW2\8Q_P!\MD5S^I:=-%J*3Z@\MS;M(#-(
MF-Y3/..P..G:O>_A?^QW:_$#X$W_ ,1F^)NA:-<6J22+I,X!9-G\,K[P48]@
M%->->$)[[Q-J]MH<%L;Z]N6,<$:$9D;T&<9)[>M=_P!5K974E7P7OQ7Q)K7\
MOQ7S3+AFV!XFH0P6:?NJGV9)^[=^KLK]I:/I*-['U9\4;K]CQ_V?BGA2W(\;
M_9%^S>0EP+X7.!GSBWR;<YSV]*^*+>XEML&.1D/?::]<\+^$_!":A?Z3XWL-
M9TJ5B8UU&PD(FL)1VEMG&'7/4#:P[9KS>#PV]]XOBT&SNX)FGO!:07DI,4+Y
M;"N2WW5/7GI7LX#%X7'TY0NWU:EK_P !H^/S3*<RX?K*HO=6RG"Z_P FGY/Y
M76II>'O%D\-Y 6E:WN8V#Q7,3%&5AT((Z&OTS_99_;ST2X\$W>G?%7Q%:Z5J
M>DQAH=4O'V_;XNP/K*/;KUKXM_:/_8G\2_LW>#M*\1ZIXET;6;:]=8C!9[HY
M$<C(VAO]8ON*A_9=T32O%OQG\!Z9K>EV^MZ9=WR13VEY'OC=2.Z]\5\YC\/0
MP=:G7P[]R3LTOTO_ $O1GVN6XRKQ%EM?"XU7JTES1E\GO;KI9_S)W>JN?I'^
MS/\ MO\ AC]I'Q?KWARQTZ;2;ZP9I+1I)1(E];@X\Q> 5/JI_.OI.O,_"7[-
MOPV\!^.CXO\ #GA*PT/7#;FU,NGIY,>P]?W:_+GWQFO3*Z:KIN5Z2LC\[@I)
M>]N?,WQZ/]F?M-_!^_Z"1YX"?J*^F*^9OVND.F>-/A/KAX2WUM(&;T#5],(P
M=0PY!Y%74UA!^7ZDQ^*02(LD;(ZAD8$$'H17Q-\,_BQ9_!K]HGQ7X>@AFM_A
M]J>I_9UF<YBM+YAD@'^$,>U?:\\HA@DD/1%+?D*^/?@9\,]/^-'@?XM6VIKE
M-4UV?R)OXHI%^XZGU!JZ'*HRY]M!5+W5MS[%5@ZAE((/(([TM>$?LN_$C4M4
MTW4_ ?BEB/%OA:3[+,S];F <1RCUR,5[O7-.#A+E9I&2DKH****@H*^6/B;_
M ,4W^VG\/]1'RIJ5C):$^IKZGKY:_;)C.@^+?A=XI0;6LM86)W]%;BNG#ZSY
M>Z9E5^&Y]2"O--1_Y+WI'_8+F_F*](@D$L*.#D,H(/X5YOJ/_)>](_[!<W\Q
M64.OH7+H>F4445F4%%%% !1110 4444 %%%>#?%[XUV>D:1K6IWGB ^$_ NC
M2&WOM=A&ZZOKC_GULQS\V>"P!.>!C!-:0@YNR)E)15V>V7^MZ=I; 7M_;6A/
M03S*F?S-36E[;W\0EMIX[B(]'B<,OYBOR:\4?\%!M%LM4E'A#X1Z%=68)'V[
MQA*]_>7'^VW.%)]-QKKOA#^W7X'\1:[;VOB;PX?A3JDSA8O$OA2X;['&QZ?:
M+=AC9ZG#?AUKT'E]51YK?E_F<RQ$&[7/T^HK@_A]XZNM4NY-!UTVQUJ&!;J"
M\LSFVU*V;[MQ$?RW+DX)XX(KO*\V47%V9U)WU,?Q)XFM_#5K$\D%S>7,[^5;
MVEI$9)9GQG '0< DEB  .36!'X2U+QA(MSXM=$L@=T>@6KY@'<>>_'G-_L\(
M/1NM=O10I6V"U]QL<:0QK'&JHB@*JJ,  = !3J**D84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!X=??\ )V.E_P#8%?\ ]FKW&O#K[_D['2_^P*__ +-7N-;U?L^AG'=A1116
M!H>'?L\?\CA\3O\ L,G_ -FKW&O#OV>/^1P^)W_89/\ [-7N-;5OC^[\C.'P
MC)O]4_T-<M\+_P#D3[?_ *^+G_T>]=3-_JG^AKEOA?\ \B?;_P#7Q<_^CWJ%
M\++ZG-?&CXP>&?!6AZUI5SXD\,:9XF737NK6R\37BP02#E07SR5SP0N3[5^,
M/BCPG%XUUC3[W0M6T WOB'69K2W\+Z5-*%TXEP X\P86)VY7IP1^'[8^._@K
MX+\<ZH^O:SX;T?4]=BL7L[>^U:S2Z2%"=WW'RO! .<9Z\\U^0?CKX&6OA#XX
MWT.IW]UJG@[3;Z ^(-?\&Z:RV^G2RL28H!\PR/EPJY(SC'%>WETH)2L]3@Q*
MD[7V'_M2>%/BKX*\<>#O"_C:#2[[5]#TJ-=(?P]:AP\"G.6PNYF4J,Y4#C/<
MFOM3]F3]L?5;GX:>'X]4\->/?&FHWVIQVUYKDVD+'I]IYCA2$G3Y61.PV@C.
M"1C-?!UGK'CO6/CA<:AX"\3^(+^\-XVCZ9X@\07'DSF-P52&66?Y49EW#8V"
M?3-?I!^PEJ.A>$=%OOA[<7'B33_'MBBSZOX<U]I)5LB"09(' \L12,Q88/))
M]*VQ:2HI22;7;3_AC.C=S;3L?6=1W-M%>6\D$\:30R*4>.10RLIX((/45+17
MS9ZAY;\./V9/AO\ "+Q?J/B7P?X<30-2OXS%.MI<S" J3N($)?8O/HO';%>F
M7=I!?VTMO<PI<6\JE)(I5#*ZG@@@]14U%5*<I.\G=B225D8_A?P=H7@C3!IW
MA[1K#0[ '<+;3K9((\^NU !FO*?VF?CCJWP"TS3?$PCTB[\-QF1+^RFN?+U&
M=BOR?958A9-OWF3.X@8%>W5\>?MS?";Q;>^!-=\4:;X\U)8[6YAOK329I;:W
MM+$QCEU9HFED8D A589/8UO049U4IO<SJ-QB^4^6O"/[?&KZ'XC\8>/;>U\,
M:?>7]S9K=Z$J/'>ZDJ;U+QMM947!4MEB1MX)K] OV6/'S^//A-I6LW_B6XU^
M\U.:699;VV^S;2?F:& $!I(X\E0YR3M.37Y.ZGXLU^'X<^'_  =?V&D>(Y[O
M69=:U+2KC3)[?5()MPS'=3G: K[LY7& >2,U]_?L(?"KP;I.FSW%WHEE8?$+
M1KF1[BR^S7$5UI*S XA9GD99%*_==>&7GKS7K8RE3C3YDK/^D<="<G*USZ^U
MG_D$7O\ UQ?_ -!-8WPV_P"1$T/_ *]4_E6SK/\ R"+W_KB__H)K&^&W_(B:
M'_UZI_*O#^R=_4Z6BBL'QSX=N_%GA74-*L=6GT.ZN8RD=_;Y\R$_WAAE/ZBI
M5F]1LW<T9KYN_P"&6/&O_1:O$'Y3?_)%'_#+'C7_ *+5X@_*;_Y(KJ]E2_Y^
M?@S'GG_+^*/I'-&:^;O^&6/&O_1:O$'Y3?\ R11_PRQXU_Z+5X@_*;_Y(H]E
M2_Y^?@PYY_R_BCW77_'.@^%M0T^RU?5+?3;B_)6V%RVQ9&'4!CQGV)K<5@ZA
ME(((R".]?%/Q5_99\?SWNCV=MXFU+QT9V8-)J)9(K,8^\6>1\9]N:]_^ WP@
MUSX5:-]GU?Q9=ZSN7"Z>#FUM_P#<+ O^H'M3J4J48*49W81G-R:<;'K%>9Z3
M_P EWUC_ +!4?_H=>F5YII/_ "7C6/\ L%1_^AUSPZ^AI+H?('[4/Q:^/.C_
M !UUGX9Z9H]EXA\,>,(!:Z3:7UIB(*5PY692N&').XGZ5\6_$CX=^*/AWJ^H
M>#_$'GZ)?Q[%N[=9&:&9>JO\O$B]P?:OW9:)'969%9E.5)&2/I7DO[07[-'A
M7]H30EM]6C-AK-NI^Q:Q;*/.@/H<_?0]U/X8-<V*YJCIU:"49PZ]_P"O\^Y]
M5D.8T<&JN$QOO4:N_ET];/K;5636JL_PJU33?[+OYK5WBGVGB6(Y20=B/_K\
MBC3+2ZO]3L[:Q1Y+Z:9([=8CAS(3A<'L<]Z^C?VC_P!E[Q!^S_>0IXG?3[[2
M;N4QV>I6DZCSC[Q$[T/X$>]>*2>&XK*YCEBNI+*=&$D98['4CD$9P?QKUZ/$
M$%%1Q4'&7X?Y_=?U-:_!,Z]ZV55HU*?F]5Y72<?OY7_=1]!?%O\ 91^/?@_P
M0OCOQE/:ZY:6=NIN5^W">]MHNWF$H"^/]YB*^?@UCXCA&<)-C\:]*\8?'[XH
M^/?!R>%O$/Q#OM0T *$:V?RT,JCH)'4!G'U-</X2\ S>)-=M-*T.SN=:U>X;
M;!:6:F21S[ ?SKP<7BL'5_>TFU5Z.*LOG>WWK7U/L,ERW.<+'ZMCE&6'M9J3
MYFEY64E;^[+3LXO4P[S2]5U*YAM[V]N;RWB&V,SSO($7T4,3C\*^A_V0OB%\
M/OA7\9=-USQ]JDVDV5E YLIOLDDL33D8RS*"1@>QYKW+X#_\$X]?UR[MM3^)
M,JZ%I2,&_L:VE$EU./[KN"5C'K@D_2OLOXF?LV>"_B5\*CX!ETV'2-'2-8[5
M[&",26H'0QEE.#[]ZJG.MCJL)XU^['Y/UM^>U[;'C9AB\NR;#5L)E"7/4^)W
MYDEM9/T;22;M=MR;M:?X+_M%^"?C\NL/X+OKC4;;2Y1#-<R6KPQN2,@H6 +#
M\!7IU<#\%?@CX6^ G@JW\,^%+1X+-#OEGG;?-<2'J\C=R?RKOJ[JG)S/DV\S
M\ZC>WO;GSY^V[H\MW\&_[6@!,VC7T%ZN.H 89_2O:?!6LQ>(?".CZE"VZ*ZM
M(Y0?7*BJ_P 0_"L7C;P1K6AS*&2^M9(>1G!(.#^=>2?L:^+)M1^&DWAC4&*Z
MQX7NI--N(W/S!5/R''IBM?BH^C_,C:?J>[7L)N;.>$'!DC9 ?J,5\W?L972:
M&OCSP?=_N=7TS6I99(FX+1N<JX]C7TQ7S+^T5HMW\(?'ND?&/0(F\J%EL_$%
MM&.)[9CCS"/5:*7O)T^_YA/1J78C^,4?_"L?VF_ /C"V_<VVN[M(O\='/\!/
MTKZ=!R,U\M_M@:O::]X.^'6LZ?*LT<^M6LUM(ISE6(KZ@MB3;Q$]=H_E15UA
M!O?5?<$/BDD2T445S&H5\_?MNZ&VI_!&YO(TS+IMY!=AAU4*XS7T!FN=^(7@
MZ'Q_X,U7P_<2>5%?0F(R8SM]\5I2ER34NQ$US1:+'@F[-_X/T6Y8Y:6SB<GZ
MH*X[4?\ DO>D?]@N;^8KN_#FD#0-!T_31)YHM($@#XQNVC&:X34?^2]Z1_V"
MYOYBG'=V\P>R/3****R+"BBB@ HHHH **** .6^*&OR^&/A]KVIVY(N(+1_*
M([.?E4_F17Y7?\% -=U+4_BQX4^$VE!Y+/P]8VD$5HC?\?%_= ,TA]6.Y1D]
M,MZU^J/Q0T"7Q1\/M>TRW&;B>T?R@.[CYE'Y@5^5W_!0'0M2TWXK^$_BUI1>
M*S\0V-K-%=H/^/?4+4 -&?1AM4X/7:WI7L9=;VGGK]_]7.+$WY3S;Q)^RU%I
ML&J0Z)X^TGQ/K/AZ_MM/\2Z;:6<\1TUIIE@\R.1_EN(TE8(Y7&#[56^*W[*/
MB/X/Q>/I=;OH/+\,7%A'!)'"VS5(;J22-)HFSA0IC8,IR0P([9/8Z5\6?$GQ
M;?61X ^%%AIVNZW?VNI>*-1TVYGE.HM#,L_EHCY%NCR*'=4SD^U<Y\5?VD?&
MFM>%?'?P^\2Z0EI;:SXA.NPP32,9-*+3-,\$9(^>)F.1G&#N(ZD#V8RK<R5_
M7:_3M\_EYG$U3M<^K?V%OB;?^(?@=ILEY*TM[X#\06]G!.[98V%UA3"?4 DX
M],+Z5^B K\\/V%_AC?\ A[X':;'>1/%>^//$$%Y! ZX8:?:X8S$=@2#CUROK
M7Z'BOG<;R^U?+W?]??<]*A?D5Q:***X#H"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFNZQ
MH7=@J@9+,< 4 >(7W_)V.E_]@5__ &:O<:\-OB/^&L-+.>/[%?\ ]FKW".19
M4#(P=3T*G(K>K]GT,X[L=1137D2,J&8*6. "<9/M6!H>(?L\?\CA\3O^PR?_
M &:O<:\,_9\D6+Q;\3V=@BC6#DL<#^*O<ZVK?']WY&</A&3?ZI_H:Y;X7_\
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MUG&?*F0Y1U(Z$&MZBFFT[H#SK5O@OIE_\1M"\5VLL6F?V<ERLUA;6,/EWIF
M#M*Q7.?E'(ZX&:[^&T@MY))(H8XY)""[(H!<C@9/>IJ*;DY;B22V*>L_\@B]
M_P"N+_\ H)K&^&W_ "(FA_\ 7JG\JV=9_P"01>_]<7_]!-8WPV_Y$30_^O5/
MY4_LBZG2T445!04444 %%%% !1110 5YII/_ "7C6/\ L%1_^AUZ77FFD_\
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MC4Q>$O%^VPU/ PD%S_RSD/IFOJ"N5^)WP]TWXH>"M2\.ZF@:"ZC(63'S1/\
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MT+/]I7G_ #^W7_?]_P#&C^TKS_G]NO\ O^_^-5J*T(N6/[1O#UO+DC_KN_\
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M(4.=H'4DGBM:5N=<VQ$[\KL6_P!F'PZ_A?X%^$K*5-DIM%E8'U;YOZU/J/\
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M\<L3!D<'H01P12<6AIW)J***D8445#=W<-A;2W%S*D%O$I>265@JHH&223P
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MQIG[Q^E'/#N@Y9',?\)=KW_0=U3_ ,#I?_BJ/^$NU[_H.ZI_X'2__%5T^D?
M_P 6:Q#?RBUM;%+*=K63^T+M("TH&2B9^\?I3/A'X)TOQWXNET'5;BXM9I8)
M?LK6[*,SJ#A6R#D'';'UH<HV;[!:1S?_  EVO?\ 0=U3_P #I?\ XJC_ (2W
M7A_S'=4_\#I?_BJ[CPG\,[(^%M8UO6UG>:SU&/3K2Q258EN)B^&5R03M^F,9
MJ]KOP1USQ+XQ\1QZ#HFGZ)9Z9+&DUG)J0,=MN7.?,8<CN3VI<\+V#ED><_\
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M<]L2O96UW&^:^AQ.F_M1V]OX:TBYU[0VTW6=0$\JV+ZA9PKY,4A0R;Y)@O7
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MVHS720P'.0TCDNR],]J^;O\ A%M:_P"@+J/_ (!2_P#Q-'_"+ZU_T!M2_P#
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M,#6JR7%S-.T,3##)$9';RE(XPF.*U3X1\.!-%T\:?9H-&*SZ= @"FUV#8&C
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MSM]2BM?L=[(+J0_;(MNT#H/+QU!&36MK?P.\.Z9JGC>*.6]>VTS1HM4L1),
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M184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)?D?3T^&,?."DW&-^C;NO6T6OQ/W=W#W_*C</?\ *OPB_P"$LUS_ *#6I?\
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M?A'_ ,)5KN,_VSJ6/^OR7_XJD_X2O7,9_MK4L?\ 7Y+_ /%4?6\+WE_X"O\
MY(/]5L=_/#[Y?_(G[N[A[_E1N'O^5?A%_P )7KG_ $&M2_\  R7_ .*I1XKU
MT_\ ,9U+_P #)?\ XJCZWA>\O_ 5_P#)!_JMCOYX??+_ .1/W<W#W_*C</?\
MJ_"+_A+-<_Z#6I?^!DO_ ,51_P )9KG_ $&M2_\  R7_ .*H^MX7O+_P%?\
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MT^"__)6O!_\ V%;?_P!#%?M\O2OQ!^"__)6O!_\ V%;?_P!#%?M\O2O>PO\
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M*7 XX''M7;?\*2^('_0F:S_X#?\ UZ/^%)?$#_H3-9_\!O\ Z]'/'N'*^QQ
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A%&!Z"EHH 3 ]!1@>@I:* $P/04M%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tmb-20221231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Y B4# 2(  A$! Q$!_\0
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M7_[Z-']FX;L_O#ZY6[GZP?\ #USX9_\ 0L^*/_ >+_XY1_P]<^&?_0L^*/\
MP'B_^.5^3_VF;_GJ_P#WT:/M,W_/5_\ OHT?V;ANS^\/KE;N?K!_P]<^&?\
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M3-_SU?\ [Z-']FX;L_O#ZY6[GZP?\/7/AG_T+/BC_P !XO\ XY1_P]<^&?\
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MZP?\/7/AG_T+/BC_ ,!XO_CE'_#USX9_]"SXH_\  >+_ ..5^3_VF;_GJ_\
MWT:/M,W_ #U?_OHT?V;ANS^\/KE;N?K!_P /7/AG_P!"SXH_\!XO_CE'_#US
MX9_]"SXH_P# >+_XY7Y/_:9O^>K_ /?1H^TS?\]7_P"^C1_9N&[/[P^N5NY^
ML'_#USX9_P#0L^*/_ >+_P".4?\ #USX9_\ 0L^*/_ >+_XY7Y/_ &F;_GJ_
M_?1H^TS?\]7_ .^C1_9N&[/[P^N5NY^L'_#USX9_]"SXH_\  >+_ ..4?\/7
M/AG_ -"SXH_\!XO_ (Y7Y/\ VF;_ )ZO_P!]&C[3-_SU?_OHT?V;ANS^\/KE
M;N?K!_P]<^&?_0L^*/\ P'B_^.4?\/7/AG_T+/BC_P !XO\ XY7Y/_:9O^>K
M_P#?1H^TS?\ /5_^^C1_9N&[/[P^N5NY^L'_  ]<^&?_ $+/BC_P'B_^.4?\
M/7/AG_T+/BC_ ,!XO_CE?D_]IF_YZO\ ]]&C[3-_SU?_ +Z-']FX;L_O#ZY6
M[GZP?\/7/AG_ -"SXH_\!XO_ (Y1_P /7/AG_P!"SXH_\!XO_CE?D_\ :9O^
M>K_]]&C[3-_SU?\ [Z-']FX;L_O#ZY6[GZP?\/7/AG_T+/BC_P !XO\ XY1_
MP]<^&?\ T+/BC_P'B_\ CE?D_P#:9O\ GJ__ 'T:/M,W_/5_^^C1_9N&[/[P
M^N5NY^L'_#USX9_]"SXH_P# >+_XY1_P]<^&?_0L^*/_  'B_P#CE?D_]IF_
MYZO_ -]&C[3-_P ]7_[Z-']FX;L_O#ZY6[GZP?\ #USX9_\ 0L^*/_ >+_XY
M1_P]<^&?_0L^*/\ P'B_^.5^3_VF;_GJ_P#WT:/M,W_/5_\ OHT?V;ANS^\/
MKE;N?K!_P]<^&?\ T+/BC_P'B_\ CE'_  ]<^&?_ $+/BC_P'B_^.5^3_P!I
MF_YZO_WT:/M,W_/5_P#OHT?V;ANS^\/KE;N?K!_P]<^&?_0L^*/_  'B_P#C
ME'_#USX9_P#0L^*/_ >+_P".5^3_ -IF_P">K_\ ?1H^TS?\]7_[Z-']FX;L
M_O#ZY6[GZP?\/7/AG_T+/BC_ ,!XO_CE'_#USX9_]"SXH_\  >+_ ..5^3_V
MF;_GJ_\ WT:/M,W_ #U?_OHT?V;ANS^\/KE;N?K!_P /7/AG_P!"SXH_\!XO
M_CE'_#USX9C_ )EGQ1_X#Q?_ !ROR?\ M,W_ #U?_OHU/8W$K7D(,KD;AP6-
M"RW#/H_O#ZY6[G] OPH^)&G_ !>^'>A>,=*@GMM.U>#[1#%= "15W%<, 2,\
M'O76UX5^PU_R:9\-/^P9_P"U7KW6OE:L5&<HKHV>[!N4$V%%%%9EA1110!\T
M_P#!1;_DTCQC_O6O_I0E?C!J/_']-_O&OV?_ ."BW_)I'C'_ 'K7_P!*$K\8
M-1_X_IO]XU]3E?\  ?K^AX6._BKT*U%%%>N>>%%6=,C674K1'4,C2HK*>X)%
M?HQ^T7XJ^ 7[-_Q$TCPIJGP&TO6;:ZTZ&^FU*VN/+>,.6! B*G<1MS]\=:YZ
MM;V<E%1;;_0VA3YTY-VL?F]17UC^UG^RK::!\5?!$7PITVXOM&\?6:W>DZ>I
M),<F%+(&8\+M=6^8_*,Y.!7!_%3]C+XC?"3PC>>)-3BTO4]+T^58=1;1[];I
M[!VP )E'*<D#VR,T0Q%.:B[VN*5*<6U;8\*HKW[X;?L1?$OXG>$M,\164.DZ
M38ZLQ&F1ZQJ"VTU_@$YB0\L#@XZ9'/3FJOP]_8O^)WQ(UCQAI&G:;:VFK>%)
MTM]2LK^Y$3J[[MNTX*L,*3G.,8.:;KTE?WEH+V4W;3<\+HKW?1OV-/'OB3QY
MJ_AC2+G0-3.D6J7>HZO:ZHCZ=:H^2H>?IN^4\#.,<US_ ,1?V8?B!\-/&F@>
M&=1TN*]O?$&S^R9]-G6>WO=Q 'ER#CC(SG& <].::K4V[*2N#IS2O8\HHKZ/
M\7?L#?%+PCX;US5Y!H>J'1(#<ZCI^F:FD]W;1A=Q+1@9X )QU..,UF?#C]BG
MXB_$KP?I7B6V?1-&TS5V*Z;_ &UJ26TE[@D?ND.2<D''KUZ4OK%*W-S*P_95
M+VL>!T5ZSH_[+7Q(UOXP7WPS@T%D\46(,EVDDBB""' (F:7[NPAEP>^0!SQ2
M_&7]F+QM\#M+TW5]<BL-0T+4':&#5M&O%N[8RC.8RZ]&X/4<X..AJO:TVU'F
M5V3R2LW8\EHKVS]D;P3JOC[XJ2Z9H_A3P[XQNQITTQT[Q/)(EJ%4KEP4YWC/
M'U-6/ '[(7C_ .+?A6_\6:#%I$.C6^IRV%PUS?"!;9EY=V+# C4$<D_A2E6A
M%M2=K?J-4Y22:1X717I_QQ_9S\9?L^WNDQ>*;>U:UU:%I[&_T^X$]M<*N-P5
MQW&Y3CT8'O7N/_!/GP!X-\8)\3M1\8>%;+Q7#H>D+?6]K> _>7>2%/;.T#.#
M4SK1C3]JM5Y#C3E*?(]&?']%?HEX#\*_!_\ :R^$/Q&FTSX/+\,-2\/V+75M
MK$,S21&0([ >9M0'!3YEP>#UKYO^''[#WQ)^)?A#1?$5H=$TFSUO/]F0ZOJ2
MV\]X!WC0@DY[=^_2HCB8._/[K7<J5&6G+K<^?:*^EO@K\#/&&G^(OBEX<N_
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M;QYXG=2K>)=992,$'49B"/\ OJLV?5K^YL(;&:^N9K*$EHK629FBC)SDJA.
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M?]"G=?\ @UN?_BZ/[3P_G]W_  0^HU?(_%ZBOVA_X=N? 3_H4[K_ ,&MS_\
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M_#CZ(****Q-0HHHH ^:O^"BO_)I7C#_?M?\ TH2N&_X)1?\ )M.J?]C+=?\
MHBVKN?\ @HK_ ,FE>,/]^U_]*$KAO^"47_)M.J?]C+=?^B+:O4C_ +B_\1PO
M_>EZ'V=1117EG<%%%86F^.?#VLZY=:-8ZW8W>JVN?.LX9U:6/!P<J#G@D9]*
M -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KX"_X*]?\DY^'G_88G_]$&OOVO@+
M_@KU_P DY^'G_88G_P#1!KNP/^\0_KH<N*_@R/HG]AS_ )--^&G_ &#/_:KU
M[I7A?[#G_)IOPT_[!G_M5Z]TKGK_ ,67J_S-:7\./H@HHHK$U"BBB@#YJ_X*
M*_\ )I7C#_?M?_2A*X;_ ()1?\FTZI_V,MU_Z(MJ[G_@HK_R:5XP_P!^U_\
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M&X/ O_/MJW_@*O\ \77PD.@HKZ#ZA1\SR_K-0^[?^&X/ O\ S[:M_P" J_\
MQ='_  W!X%_Y]M6_\!5_^+KX2HH^H4?,/K-0^[?^&X/ O_/MJW_@*O\ \71_
MPW!X%_Y]M6_\!5_^+KX2HH^H4?,/K-0_0/PG^UUX1\9>)-.T/3[?45O;^80Q
M&:W"IN/J0YP/PKUC1O$#:Y'*]ND6(W:,Y8]0<'M[5^<GP _Y+3X._P"P@G]:
M^^?A2<V=_P#]?<W_ *&:\K&484))0.VA4E43<CM-UW_<A_[Z/^%&Z[_N0_\
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MW_@NC_\ CU'_  ]8^$'_ #Y>)O\ P71__'J_)"BC^S:'G]X?7:OD?M#\(_\
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M:(R%?W@4-_LG(I]% !1110 4444 %%%% !1110 5\!?\%>O^2<_#S_L,3_\
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MJFJ?]A6P_P#1M=6%_CP]485_X4O0_'BBBBOMCYD**** "BBB@#Z-_P""?/\
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M?]@S_P!JO7NE<]?^++U?YFM+^''T04445B:A1110!\U?\%%?^32O&'^_:_\
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M=Z)_SYQ_]\BO7_M2MV7]?,\_ZC3[L_%O2?V0OBG;ZK92R>'X5CCG1V/]HV_
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M3_QYW_\ U]S?^AFO S'XX^AZ>%^%G?4445Y)VA1110 5\D?\%/\ _DU35/\
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M*+_DVG5/^QENO_1%M7<_\%%?^32O&'^_:_\ I0E<-_P2B_Y-IU3_ +&6Z_\
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MX+B%RDD4@PR,#@@CUK?^&?\ R4CPI_V%K3_T<E*?PL%N?HI\/O\ D/\ B/\
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MVOK>ODC_ (*?_P#)JFJ?]A6P_P#1M=6%_CP]485_X4O0_'BBBBOMCYD****
M"BBB@#Z-_P""?/\ R=1X8_Z]-1_](IJ_8+X8_P#(K6?^X/Y5^/O_  3Y_P"3
MJ/#'_7IJ/_I%-7[!?#'_ )%:S_W!_*OF<S_B?)?J>U@?@^?^0_XJ_P#)-_%/
M_8*NO_1;5^6HZ"OU4^(6FW.L>"/$%A9Q^==W6G7$,,>0-SLA &3P.3WKX '[
M+?Q0P/\ BE7_ / RV_\ CE& J0A&7,TB\3&4FK(Y'P'I7A;5M0N8_%6N76A6
MBP[H9K6U-PSR9'RD#H,9.?:OID)Y>AVVO6]R)/!D7P]FT_[2?EC-SYK (1V<
M_+QUKQ3_ (9;^*'_ $*S_P#@;;?_ !RI?^&9/BL(#!_PC<_D$[C%]OM]F?7'
MFXKMJ.G4=_:+[T804X_9.L^#/A/6=,T;Q7X3UG0=2$>I6]CJ&=,>(WBJ),QL
MJ,PW(>Y!RO7'->@ZAX2N/&WQA\5^(OM6I2^#-"NH)YM/TIGE-]?Q1I\B(O#,
M"!EOISR<>*C]FOXMK*)1H%T)0NP2#48-P7TSYO3VI8/V;OBY:J5@T&[A4G<5
MCU*!03Z\2UG)0E)R51:_\#S\BES))<K.&^)6JW^N^/M>U#4[!]+O[F[>66RE
M0JT)/12#WQBCX9_\E(\*?]A:T_\ 1R5V<O[,'Q3GD:23PS+)(QR7>^MR3]29
M*V? G[-?Q(TCQOX>OKOPT\-I:ZC;SS2&[MSL195+' DR< 'I70ZM)0LI+;N9
M<DW*]F?9'P^_Y#_B/_K^E_F:[VN"^'W_ "'O$1[&^EP?Q-=[7RA[04444 %%
M%% !1110 4444 %%%% !7P%_P5Z_Y)S\//\ L,3_ /H@U]^U\!?\%>O^2<_#
MS_L,3_\ H@UW8'_>(?UT.7%?P9'T3^PY_P FF_#3_L&?^U7KW2O"_P!AS_DT
MWX:?]@S_ -JO7NE<]?\ BR]7^9K2_AQ]$%%%%8FH4444 ?-7_!17_DTKQA_O
MVO\ Z4)7#?\ !*+_ )-IU3_L9;K_ -$6U=S_ ,%%?^32O&'^_:_^E"5PW_!*
M+_DVG5/^QENO_1%M7J1_W%_XCA?^]+T/LZBBBO+.XH7VO:;I=U;VUYJ%K:7%
MP<0PSS*CRG.,*"<GDCI7#^$-6\47'Q7\266NSVR6*:?;SV5C:$LL*F69=S,0
M-SL$!..!P.V3VFI>&='UF\M;O4-*L;Z[M#NMY[FV222$Y!RC,"5Y /'I4,'A
MJ&#Q;>:^)I#<7-G%9-$<; L;NP([Y)D/Y"@#9HHHH **** /DC_@I_\ \FJ:
MI_V%;#_T;7X\5^P__!3_ /Y-4U3_ +"MA_Z-K\>*^JRS^!\_\CP<;_%^0444
M5ZQP!1110 5]'_\ !/?_ ).F\-_]>>H_^D<U?.%?1_\ P3W_ .3IO#?_ %YZ
MC_Z1S5SXG^#/T9K1_B1]4?L!\,/^14L_]P4[XK_\DW\4?]@JY_\ 19IOPP_Y
M%2S_ -P4[XK_ /)-_%'_ &"KG_T6:^,7\1>I]+]D_+8=!2JNY@!U)QS2 <"E
MQ7V!X1[3X$\%VGPM\>^'I_%=GI_B(ZA)&FGP6&H++'%*9$&^8#L Q(7N:Y'X
MY0)#\9?&*)'LA34Y1MC7 4;NW85QFFZA<:1J-K?6K>7<VTJS1.0#M93D'!]Q
M707/Q+\0WA\2F:[1SXB=9-2)@3,I4D@CCY>2?NXK!0DI\][Z?J:.2<>4]3^,
M-YH6J? 7P-=Z!HXT>P_M"ZA2-V#RN% &YV[L3D_C7@=;=[XPU;4/"VG>'9[@
M/I%A+)/;P>6H*._WCNQDY]ZQ<55*#A&S[L4Y<SN=_P# #_DM/@[_ +""?UK[
MX^%/_'G?_P#7W-_Z&:^!_@ /^+T^#O\ L()_6OOCX4_\>=__ -?<W_H9KQ<Q
M^./H>AA?A9WU%%%>2=H4444 %?)'_!3_ /Y-4U3_ +"MA_Z-KZWKY(_X*?\
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M*Q-0HHHH ^:O^"BO_)I7C#_?M?\ TH2N&_X)1?\ )M.J?]C+=?\ HBVKN?\
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M)=*T2XG0R11:A>1PLZ@X+ ,1D9XS4E'.?\(]XS_Z& _]^8__ (FC_A'O&?\
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MJFJ?]A6P_P#1M=6%_CP]485_X4O0_'BBBBOMCYD**** "BBB@#Z-_P""?/\
MR=1X8_Z]-1_](IJ_8+X8_P#(K6?^X/Y5^/O_  3Y_P"3J/#'_7IJ/_I%-7[!
M?#'_ )%:S_W!_*OF<S_B?)?J>U@?@^?^1U]%%%>*>F%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %? 7_!7K_DG/P\_P"PQ/\ ^B#7W[7P
M%_P5Z_Y)S\//^PQ/_P"B#7=@?]XA_70Y<5_!D?1/[#G_ ":;\-/^P9_[5>O=
M*\+_ &'/^33?AI_V#/\ VJ]>Z5SU_P"++U?YFM+^''T04445B:A1110!\U?\
M%%?^32O&'^_:_P#I0E<-_P $HO\ DVG5/^QENO\ T1;5W/\ P45_Y-*\8?[]
MK_Z4)7#?\$HO^3:=4_[&6Z_]$6U>I'_<7_B.%_[TO0^SJ***\L[@HHHH ***
M* "BBB@#Y(_X*?\ _)JFJ?\ 85L/_1M?CQ7[#_\ !3__ )-4U3_L*V'_ *-K
M\>*^JRS^!\_\CP<;_%^0445<TC1K_7[Y++3+*XU&\<%EM[6)I)& &20J@G@
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M  /\CR.OH_\ X)[_ /)TWAO_ *\]1_\ 2.:O,/\ AGGXJ_\ 1,?&?_A/W?\
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M_??]!N__ / A_P#&C_A7]]_T&[__ ,"'_P :[JBCG8<J.%_X5_??]!N__P#
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M *135^P7PQ_Y%:S_ -P?RKYO,_XGR7ZGLX'X/G_D=?1117BGIA1110 4444
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MUE%%%>2>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?
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M^:VZ*.9A9&)_PA^E_P#/LG_?-'_"'Z7_ ,^R?]\UMT4<S"R,4>$-,!R+9/\
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M +!G_M5Z]TKGK_Q9>K_,UI?PX^B"BBBL34**** /FK_@HK_R:5XP_P!^U_\
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M7=CU/ KXU_X>Z>!_^A&\0?\ ?Z#_ .*H_P"'NG@?_H1O$'_?Z#_XJCZEB/Y
M^LT?YC[R\M=^_:-^,;L<XIAMH2"#$A!.2-HY/K7PA_P]T\#_ /0C>(/^_P!!
M_P#%4?\ #W3P/_T(WB#_ +_0?_%4?4L1_('UFC_,?>+Q)*H5T5P.@89I'@CD
M(+1HQ P"5!XKX/\ ^'NG@?\ Z$;Q!_W^@_\ BJ/^'NG@?_H1O$'_ '^@_P#B
MJ/J6(_D#ZS1_F/O V\1!'EI@@ _*.0.E2=*^"_\ A[IX'_Z$;Q!_W^@_^*H_
MX>Z>!_\ H1O$'_?Z#_XJCZEB/Y ^LT?YC[THKX+_ .'NG@?_ *$;Q!_W^@_^
M*H_X>Z>!_P#H1O$'_?Z#_P"*H^I8C^0/K-'^8^]**^"_^'NG@?\ Z$;Q!_W^
M@_\ BJ/^'NG@?_H1O$'_ '^@_P#BJ/J6(_D#ZS1_F/O2BO@O_A[IX'_Z$;Q!
M_P!_H/\ XJC_ (>Z>!_^A&\0?]_H/_BJ/J6(_D#ZS1_F/O2BO@O_ (>Z>!_^
MA&\0?]_H/_BJ/^'NG@?_ *$;Q!_W^@_^*H^I8C^0/K-'^8^]**^"_P#A[IX'
M_P"A&\0?]_H/_BJ/^'NG@?\ Z$;Q!_W^@_\ BJ/J6(_D#ZS1_F/O2BO@O_A[
MIX'_ .A&\0?]_H/_ (JC_A[IX'_Z$;Q!_P!_H/\ XJCZEB/Y ^LT?YC[TKX"
M_P""O7_).?AY_P!AB?\ ]$&K/_#W3P/_ -"-X@_[_0?_ !5?-W[;7[:'A_\
M:C\+^&=+T;P_J6C2Z3?274DE\\;*ZM&4P-I/.:Z\)A:U.M&4HV1SXBO3G2<8
MO4_0?]A;3+:#]E[X?7\<6V[N=)2.63<?F5)9=@QG QO;IZU[]7A?[#G_ ":;
M\-/^P9_[5>O=*\VO_%EZL[:7\./H@HHHK U"BBB@#G?B!\/?#WQ2\*W?AOQ3
MIJ:MHEV5,UH\CH'VL&7E"#P0#P:\=_X=_P#P _Z)S:?^!]W_ /'J^A**UC5J
M05HR:^9$H0D[R5SY[_X=_P#P _Z)S:?^!]W_ /'J/^'?_P  /^B<VG_@?=__
M !ZOH2BJ^L5OYW][)]E3_E7W'SW_ ,.__@!_T3FT_P# ^[_^/4?\._\ X ?]
M$YM/_ ^[_P#CU?0E%'UBM_._O8>RI_RK[CY[_P"'?_P _P"B<VG_ ('W?_QZ
MC_AW_P# #_HG-I_X'W?_ ,>KZ$HH^L5OYW][#V5/^5?<?/?_  [_ /@!_P!$
MYM/_  /N_P#X]1_P[_\ @!_T3FT_\#[O_P"/5]"44?6*W\[^]A[*G_*ON/GO
M_AW_ / #_HG-I_X'W?\ \>H_X=__   _Z)S:?^!]W_\ 'J^A**/K%;^=_>P]
ME3_E7W'SW_P[_P#@!_T3FT_\#[O_ ./4?\.__@!_T3FT_P# ^[_^/5]"44?6
M*W\[^]A[*G_*ON/GO_AW_P# #_HG-I_X'W?_ ,>H_P"'?_P _P"B<VG_ ('W
M?_QZOH2BCZQ6_G?WL/94_P"5?<?/?_#O_P" '_1.;3_P/N__ (]1_P ._P#X
M ?\ 1.;3_P #[O\ ^/5]"44?6*W\[^]A[*G_ "K[CY[_ .'?_P  /^B<VG_@
M?=__ !ZC_AW_ / #_HG-I_X'W?\ \>KZ$HH^L5OYW][#V5/^5?<?/?\ P[_^
M '_1.;3_ ,#[O_X]1_P[_P#@!_T3FT_\#[O_ ./5]"44?6*W\[^]A[*G_*ON
M/GO_ (=__ #_ *)S:?\ @?=__'J/^'?_ , /^B<VG_@?=_\ QZOH2BCZQ6_G
M?WL/94_Y5]Q\]_\ #O\ ^ '_ $3FT_\  ^[_ /CU'_#O_P" '_1.;3_P/N__
M (]7T)11]8K?SO[V'LJ?\J^X^>_^'?\ \ /^B<VG_@?=_P#QZC_AW_\  #_H
MG-I_X'W?_P >KZ$HH^L5OYW][#V5/^5?<?/?_#O_ . '_1.;3_P/N_\ X]1_
MP[_^ '_1.;3_ ,#[O_X]7T)11]8K?SO[V'LJ?\J^X^>_^'?_ , /^B<VG_@?
M=_\ QZC_ (=__ #_ *)S:?\ @?=__'J^A**/K%;^=_>P]E3_ )5]Q\]_\.__
M ( ?]$YM/_ ^[_\ CU'_  [_ /@!_P!$YM/_  /N_P#X]7T)11]8K?SO[V'L
MJ?\ *ON/GO\ X=__   _Z)S:?^!]W_\ 'J/^'?\ \ /^B<VG_@?=_P#QZOH2
MBCZQ6_G?WL/94_Y5]Q\]_P##O_X ?]$YM/\ P/N__CU'_#O_ . '_1.;3_P/
MN_\ X]7T)11]8K?SO[V'LJ?\J^X^>_\ AW_\ /\ HG-I_P"!]W_\>H_X=_\
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IX<\.V*Z;HNG1^3:VB.SB),DXRQ)/)/4FMNBBL6VW=FB5M$%%%%(9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tmb-20221231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N \ # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M36SI'QV\":SX%U?QBGB"*R\/:,\L6IW&JP2V$EA)&</'/#.B21."1\KJ"<C
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M,DUI!*YZL\8)_,BK-% %+^Q=._Y\+7_ORO\ A1_8NG?\^%K_ -^5_P *NT4
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MXOU#X=>#-/3P;I&AWOC77-4M])T>VU> M;-*[%G:149&*K$DAX9><9/8\KX
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MW^%=BL,_G.DTHE4_\LVW?=_+!_&NR=*"I*<7J<T:DG4<&CU.BBBN,Z0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S
MWX]?";_A=WPRU#PA_:O]B_:[BUG^V?9_/V^3<1S8V;USN\O;G/&<\XQ7H5%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!'<01W4$D,R"2*12CHPR&4C!!KYY^$TTGPK^+NL>"[ER+"^8O9LYZ]2
MGXE<CZK7T57AG[3/AJX@M-*\8::3%?:5,H>1.H7=E&_!OYUU4&FW3>S_ #Z&
M%562FNA[G16'X)\4P>-/"VG:S;X"W409T!^X_1E_ @UN5S--.S-D[JZ"BBBD
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(H8# 8#J&_.O2O[3!^<7^#.2W)7]4?:-%4O[)@_YZ77_ (%R_P#Q5']DP?\
M/2Z_\"Y?_BJ\TZR[15+^R8/^>EU_X%R__%4?V3!_STNO_ N7_P"*H NT52_L
MF#_GI=?^!<O_ ,51_9,'_/2Z_P# N7_XJ@"[15+^R8/^>EU_X%R__%4?V3!_
MSTNO_ N7_P"*H NT52_LF#_GI=?^!<O_ ,51_9,'_/2Z_P# N7_XJ@"[15+^
MR8/^>EU_X%R__%4?V3!_STNO_ N7_P"*H NT52_LF#_GI=?^!<O_ ,51_9,'
M_/2Z_P# N7_XJ@"[15+^R8/^>EU_X%R__%4?V3!_STNO_ N7_P"*H NT52_L
MF#_GI=?^!<O_ ,51_9,'_/2Z_P# N7_XJ@"[15+^R8/^>EU_X%R__%4?V3!_
MSTNO_ N7_P"*H NT52_LF#_GI=?^!<O_ ,51_9,'_/2Z_P# N7_XJ@"[15+^
MR8/^>EU_X%R__%4?V3!_STNO_ N7_P"*H NT52_LF#_GI=?^!<O_ ,51_9,'
M_/2Z_P# N7_XJ@"[15+^R8/^>EU_X%R__%4?V3!_STNO_ N7_P"*H NT52_L
MF#_GI=?^!<O_ ,51_9,'_/2Z_P# N7_XJ@"[15+^R8/^>EU_X%R__%4?V3!_
MSTNO_ N7_P"*H NT52_LF#_GI=?^!<O_ ,51_9,'_/2Z_P# N7_XJ@"[15+^
MR8/^>EU_X%R__%4?V3!_STNO_ N7_P"*H NT52_LF#_GI=?^!<O_ ,51_9,'
M_/2Z_P# N7_XJ@"[15+^R8/^>EU_X%R__%4?V3!_STNO_ N7_P"*H NT52_L
MF#_GI=?^!<O_ ,51_9,'_/2Z_P# N7_XJ@"[15+^R8/^>EU_X%R__%4?V3!_
MSTNO_ N7_P"*H NT52_LF#_GI=?^!<O_ ,51_9,'_/2Z_P# N7_XJ@"[15+^
MR8/^>EU_X%R__%4?V3!_STNO_ N7_P"*H NT4V.,11JBEB , LQ8_F>33J "
MBBB@ HHHH XWQGX]N="U[2/#VC:6FL^(-362:."XN3;00PQCYY990CD#)50%
M1B2>PR:Z71Y=0GTV!]5M;:RU @^;!9W+7$2')QMD:.,MQ@\H.<CW/B?Q4L='
MT_XXZ)JOBK5[C0O#USH\UJE_'JDNFQK.L@8(]Q&Z$$KDA=P!QR#@5V/[/UYK
M%_\ #:VGU:YO;V-[FX.G76I9^U3V/F'[/)+N^8LR8.3R00><YH ](HHJM-:2
MRR%EO9X1_<18R!^:DT ?EO\ \%&/BAXSA^/4F@C5=0TO1-.M8);&WMIWB20L
M,M+P1EMV1GMMK[/_ &1==UGXQ?LMZ._C.2:^N+R*>S:\N"3+<Q*Q59"QZMVW
M=RN>M._:[^ FC_%3X0^);RYLUO\ Q)I>FS7.FW;Q1B9&C7S-@95!(;:1@G'-
M<G_P3K\62^+_ -G+3[ ZA/'-H=U-8F-!&<(6\Q#RI/\ &1U[5[%2I&I@X\JL
MXM?\/\S@C!PKOF>C1UG[.^KW/A/Q)KW@+4WQ/;2M+!G@,1PV/8C:PKZ KYW^
M/NAWO@?Q3HGCS39I9)HY5BN'(4$D=,X4#E=R\@U[=HMPNOZ19ZE9ZK=26MU$
MLT;;8LX(SS\G6N&NN:U5=?S.BE[MX/I^1M452^P3_P#02NO^^8O_ (BC[!/_
M -!*Z_[YB_\ B*Y3<NT52^P3_P#02NO^^8O_ (BC[!/_ -!*Z_[YB_\ B* +
MM%4OL$__ $$KK_OF+_XBC[!/_P!!*Z_[YB_^(H NT52^P3_]!*Z_[YB_^(H^
MP3_]!*Z_[YB_^(H NT52^P3_ /02NO\ OF+_ .(H^P3_ /02NO\ OF+_ .(H
M NT52^P3_P#02NO^^8O_ (BC[!/_ -!*Z_[YB_\ B* +M%4OL$__ $$KK_OF
M+_XBC[!/_P!!*Z_[YB_^(H NT52^P3_]!*Z_[YB_^(H^P3_]!*Z_[YB_^(H
MNT52^P3_ /02NO\ OF+_ .(H^P3_ /02NO\ OF+_ .(H NT52^P3_P#02NO^
M^8O_ (BC[!/_ -!*Z_[YB_\ B* +M%4OL$__ $$KK_OF+_XBC[!/_P!!*Z_[
MYB_^(H NT52^P3_]!*Z_[YB_^(H^P3_]!*Z_[YB_^(H NT52^P3_ /02NO\
MOF+_ .(H^P3_ /02NO\ OF+_ .(H NT52^P3_P#02NO^^8O_ (BC[!/_ -!*
MZ_[YB_\ B* +M%4OL$__ $$KK_OF+_XBC[!/_P!!*Z_[YB_^(H NT52^P3_]
M!*Z_[YB_^(H^P3_]!*Z_[YB_^(H NT52^P3_ /02NO\ OF+_ .(H^P3_ /02
MNO\ OF+_ .(H NT52^P3_P#02NO^^8O_ (BC[!/_ -!*Z_[YB_\ B* +M%4O
ML$__ $$KK_OF+_XBC[!/_P!!*Z_[YB_^(H NT52^P3_]!*Z_[YB_^(H^P3_]
M!*Z_[YB_^(H NT52^P3_ /02NO\ OF+_ .(H^P3_ /02NO\ OF+_ .(H NT5
M2^P3_P#02NO^^8O_ (BC[!/_ -!*Z_[YB_\ B* +M%4OL$__ $$KK_OF+_XB
MC[!/_P!!*Z_[YB_^(H NT56AM)8I S7L\P_N.L8!_)0:LT %%%% !1110 44
M44 %%%% !7P#^QP5^$W[8?Q8^'9_<VES+--9Q,>B+)YD?X^7(OY5]_5^>G[0
MTC_"/_@H%X+\51#9;:U% ),<>8W,+#\?W8KT<'[ZJ4NZ_%:G+7]WEGV?YGZ%
MT4R&9+B&.6-@\<BAE8="#R#3Z\XZ@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)
M&LJ,CJ'1@0RL,@CT-?!W[!!;X7_'KXN_"Z5BD-M=/-:(3]Y8Y"JM^,;(?QK[
MSKX,^) _X5#_ ,%(O"6N#]S8^+H([69NF^1U\G'_ 'VL->AA??C4I=U?YK4Y
M:WNN,^S_ #/M;QOX5@\:^%=1T:?"BYB*HY'W''*M^! _6O*/V:?%%Q:1:IX+
MU0&*_P!+E=HXWZA=V'4?1N?QKW2ODOXV>)G\&?&Q]5T'_1-1@B0SLR@I(Y7G
M([@K@'Z5G03J*5+Y_,=5\C50^M**Y/X7>-6^('@RRUB6%;>XDW)-&F=H=3@[
M<]NAKK*Y9)Q;3.A-25T%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BL#QMX^\-?#;0I-:\5Z]IWAS2(V"->ZI=);Q!
MCT7<Q R>PZUJ66KV.I3WD-I>074UE+Y%S'#(&:"3:K;' ^ZVUE.#SA@>] %N
MBBB@ HHHH **** "OA7_ (*C>'I;30O ?C.T7%SI>H- 9,?=SAT_\>0U]U5X
M#^W7X-_X3+]F+Q>B)YD^FQIJ<0QG'E,"Y_!"]=F$GR5X/S_/0PKQYJ<D=]\#
M/%T7C'X<:3>1/N40IM.<_(RAD/\ WR0/PKT"OCC_ ()]^/?[1^'FBV,TF=T+
M6G)Z/$3M'_?&/RK['J,33]E5E$=&7/!,****YC8**** "BBB@ HHHH ****
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M44T[:H#\R?V+;N_\*1>+M E/EZMX9U<,\8_A(8HV1Z;X\5^E6CZI#K6EVM_
M<Q7$8D'MGJ/P/'X5^;/Q'GNO@O\ MJ^.K"V AL_%]IYZ CO)MD+#WWI+S[U[
MU^S/XIU6W\?1:4MU++I]U$YE@=R4! R& /0]OQKV\72]LO;+JK_@>;0J>S?L
MWZ'UQ1117AGI!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!XU^T%%X?UW6O 7ACQ3;Z>NB:K?SL^H7MS+:RV\L<),:6UQ%)&\4[EN
M&#9VHXQSPG[/L'A_0-;\>^&?"T-A+H>EW\#IJ%G<2W4LTLD(,L=S<2R2/-,A
M3)=FSB1 1QD\C^TEXZU'[+X\TI[#P_K&D:9I=E:VNA:[IBWB:EJ=_-Y-JS!F
MP8XWQN0+EMQY&*[/]GW3;OP*_B'X>W%QIM]!X<^RO;W>EZ3!ID12=&8Q_9X
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MCBV^)]O+<>'[:Z\*^']7U3Q1:WD%_&;G5;JXC80P>4^T1NGF2)O=MN!'R.<
M'7_#[P<=8_9TO]+T[7-.UR\\1V>I7)U.TB:"R:YO7FD?8GS,D:R2E<'+87YO
MFS5[X=^*-8\*ZEX>^'OB;1[.RO(](3[%?Z;J#74-R(%2-PP>*)D;H<888/7B
MK7PP\#ZO:_"NYTO7VET'6-7NM0U"XCTFZ_>:<]U<RSA(Y1P7C\P L 59@QP5
M.*N6WPDA^VW^HZAXEU[5]9N;"33H=3N)8(9K*)Q\Q@$$,:(V<-N*DY4<\8H
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M='V^?_H&W7_?47_Q=7:* *7V^?\ Z!MU_P!]1?\ Q='V^?\ Z!MU_P!]1?\
MQ=7:* *7V^?_ *!MU_WU%_\ %T?;Y_\ H&W7_?47_P 75VB@"M#=RRR!6LIX
M1_?=HR!^3$U9HHH XSQ1\*_!'BGQAHWB77-$L;SQ!I!\ZQO)R0\17D-C(#;2
M206!VDY&#5SP'X>\+Z/::E?>%Q;S0ZO>RW]W>071NOM$[MEF,C,Q('0*#M0
M*H  %?//[1W@W5?$WCO7-%@\*:IJUYXOT^Q\/Z?K]K9-+;Z58/.?[4$DXX@#
M0\\D;R% SC%>F_ OP_8:'XI^('_".^'#X7\(B]AL[*R33C80RW$"O'<S11%5
MRC,$42 ;7\O*DC!(![!1110 4444 %%%% !1110!X7^VMX*\1^/_ -G7Q+I/
MA>*:[U(^5,UG; F2YB1PS1J!]X]#COMQUK\^O^"?RW?AS]JK1+._FET6>6VN
M87MKI6B:<["1%M(ZY&[G^[7Z\U\8?\%"O@YJLNGZ/\8/",DEKXC\*,CW$EN/
MWGD*VY91_N-U_P!DG/ ->O@ZZY'AI;2Z^;.&O2]Y5ET/L^N,^*W@I/&/@_4H
M8+9)-56!C:R='W#G;GWZ8/'-<O\ LS_M!Z1^T/\ #BTUNT:.#6(%6'5=/!YM
MY\<D#^XW53Z<=0:];KS6I49V>C1UWC4CILSX:^'%KJ'A;XAZ1=7UM=Z>EG<@
MW#/$RE5Z,"#[9&*^X+6ZAO;:.XMY%FAD4,DB'(8'N*H>(_#EEXITN2QO8]R-
MRKC[T;=F!]:\LT?6=2^$.M?V5JVZYT69LQ3J"0H_O*/YK714G]9U6C1A"/L=
M.A[/145K=0WMO'/!(LT,BADD0Y# ]Q4M<1U!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7@_B;X]>*S?_ -G>&?#.E7%UJ7B&3P]H
MDNI:C(B3- DC7EQ.J1$QQH8F10I8L<$[017O%?)6L^)_A=X.^+VO^(+[7_&.
MA16TFH6UMK-];AO#NFZDT):Z:V9XSFXQ&20VY"RLJ@L6! /HKX8^,;GQSX1B
MU"_LHM.U2&YN;"^M8)3+%'<03/#)Y;E5+(6C+*2 =K#(!R!U=><_L]QV,?PG
MT<Z;8:[8V<K3SJ_B6/R]1NVDF>1[J=,#:TSLTN"%QO VK]T>C4 %%%% !111
M0 4444 5[^PM]4L+FRNXEGM;F-H98FZ.C A@?J":^%O^">MW/\,_BK\4_A+?
MR,7T^\::WW]9!&YC+#V92C?B*^\:_/SX^:M:?L[?M[^%/'4US'::-XA@1-3;
M/W$(\F1V YP,1MT_@->CA?WD:E'NKKU1RUO=<:G9_F?H'1573-3L]:T^WO\
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M-HK/3;G3IK"2)58@[H9E60$G)RPRV<Y.<UWM !1110 4444 %%%% !7Y4?\
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M0/\ WB1U_&D\(_$/0O'?AK3]?T.YEU#2K^(307$5M(0RGM]W@@Y!'8@BM?\
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M)?\ XF@"[15+^UH/^>=U_P" DO\ \31_:T'_ #SNO_ 27_XF@"[15+^UH/\
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M-']M:=_S_P!K_P!_E_QH NT52_MK3O\ G_M?^_R_XT?VUIW_ #_VO_?Y?\:
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M!J5X.R/)T_:\TL_?\/7B_P"[.A_H*K>(/VM;:71YET;2)X-3; C>\VM$OJ<
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M6MM#95(O2YWE%%%8F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?Q>U/]@3XH^(OAOX^2^U#P5,[76GW=K$';G[DJ*2!A@,,H/#+WK[^^&?Q/\
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MXLUGE?5H",DGLRL%]!2^I.IK0DI+[G]P_K"C_$31^D=%>/\ [+_[0UG^T?\
M#D>(8K#^RM0MYC:WMD)/,5)  =RM@95@<C/(Y'N?8*\^<)4Y.$EJCIC)27,M
M@HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P */[%T[_GPM?\ ORO^% %VBJ7]BZ=_SX6O_?E?\*/[%T[_ )\+7_ORO^%
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M%1ZK\#="O"S6<MSI['HJMYB#\&Y_6NY_L73O^?"U_P"_*_X4?V+IW_/A:_\
M?E?\*U]K-=3/V<>QY7_PJ'Q+I'_()\1;0.@\R2']%R*^==?^'GBR/QG<Z;<:
M;>7>JS7#,)E1G$Q+9\P/CD'KD_C7V]_8NG?\^%K_ -^5_P */[%T[_GPM?\
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M>Q8_6O,?'6I>"_$NGZ=<^+?AUJNL-<Z:+JW2?PO)?SPAUR;<F-)#!*,@$,5
M/1N,C>^"&BZYX>^%F@:?XB\U=5@B8/'/+YLD2%V,<;/D[BJ%5SGM0!W5%%5I
MM/BN)"[/.">R7$B#\@P% %FBJ7]DP?\ /2Z_\"Y?_BJ/[)@_YZ77_@7+_P#%
M4 7:*I?V3!_STNO_  +E_P#BJ/[)@_YZ77_@7+_\50!=HJE_9,'_ #TNO_ N
M7_XJC^R8/^>EU_X%R_\ Q5 %VBJ7]DP?\]+K_P "Y?\ XJC^R8/^>EU_X%R_
M_%4 7:*I?V3!_P ]+K_P+E_^*H_LF#_GI=?^!<O_ ,50!=HJE_9,'_/2Z_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEY6H_P#/U:_^ S?_ !RCRM1_Y^K7_P !F_\ CE7:* *7E:C_ ,_5K_X#-_\
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MH\K4?^?JU_\  9O_ (Y5VB@"EY6H_P#/U:_^ S?_ !RCRM1_Y^K7_P !F_\
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M_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\
MGUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC
M_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\
MGUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC
M_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\
MGUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC
M_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\
MGUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC
M_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\
MGUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC
M_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\
MGUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC
M_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\
MGUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC
M_P ^MK_X$M_\;H\W4?\ GUM?_ EO_C=7:* *7FZC_P ^MK_X$M_\;H\W4?\
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M0PB-I1<12Q1QL5W$#+%@0W':@#W2BBHKE96MI5A8),4(1FZ!L<'\Z ./\/\
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M<]D106;J,X!QWKIJ\@_:GTBQF^#?B/49+*W?4(888HKMHE,L:-<PEE5\9 )
MR <' H ]?HHHH YOQ=\0]#\#F(:M/="22-YA%96%Q>2+&GWI&6%'*H/[S #W
MK6T/6[#Q+I%IJFEW<5]I]W&)H+B%LK(IZ$5S_P 3O'\?P_\ #C7$-NVHZW=M
M]ETG2X_OWETP^1!R,+GEFZ*H)I/A'X'D^&WPWT'PW/<)=7%C;[9I8@0C2,Q=
M]N?X=S''MCI0!U]<]XI\?:-X-DMXM2ENFGG5GCM["PN+V8HOWG,<".P49'S$
M >]=#6'XML_$-]IIC\-ZKI^D7A# SZAI[W:].-JK-'@@\Y.X>QH M^'?$6F^
M+=#L=9T>\CO],O8A-;W$7W74_7D'L0<$$$$ BM&O,/V;YX!\*;'3H;62SETF
MZNM.N4>X$X:XCG?S760*H968EAA0!G&.*]/H H:[KMAX9T:]U;5+I++3K*%I
M[BXD^ZB*,D\<GZ#D]JK^$_%>E>./#MCKNB77VW2KU#);W'EO'O7)&=K@,.0>
MH%>>_&34_M?B+PUH5_I^KS>&O-&HZC+I^CW5^DYB8&&W80Q/P7 <AN"$ [U!
M^R9JD.H? ?PS%$ERC6T3QN9[66%2?-<_(74!QSU7(SQG(H ]@KG?%WC_ $7P
M.^GQZM-=";4)&BM8+*PN+R69E7<P6.%';@<]*Z*N(^(7@+4O%>L^&-7TC6+7
M2;_0KB6>/[;8-=Q2^9&8R"JS1$8!)SNH Z?0];M_$.G)>VL=Y%"Y("WUE-:2
M\>L<R*X_$<UH5Q'PG\;:CXTT74QJ]O;0ZMI.I7&EW3V.[[/,\1 \R,-D@$$?
M*22"",UV] &1XH\5Z5X,TEM2UF\6SM ZQ*=C.\CL<*B(H+.Y/ 502>PI_A[Q
M':>)[)KJSAOX8E<H5U'3KBRDS_N3HC$>^,5Y?\:XM5O/B1\+[739K*V=KZ[D
MCGU"!KB%)5MR5)B5T+D#=@;UP3G/&#T_PP\::OXCO_%.D:XMC)J.@WXM&O--
MC>*"X5HUD5@CNY1@&PPW'GO0!WM8WB3Q79>%(89;V#4IUF8JHTW2KJ^8$?WE
M@C<J/<X%;-8WC+Q39^"/"FK:_?MBSTVVDN9.<%@JD[1[DX ]S0!5\(?$#1?'
M+:BFDRW33:=*L-W#>V%Q9RPNRA@"DR(W*D'IW%='7G7P%\/7FB_#JTO=64KK
MNN2/K&HYQD33G?MXZ;5*KCMBO1: ,?Q3XNTGP9IRWNKW1MX9)4@B2.)YIII&
M.%2.*,,\C'^ZJD]3T!J+PGXVT?QO:W,^D7,DWV68V]Q#<6\MM-!( #M>*55=
M#@@\J,UY[^T0MW=P^$;'0?D\9S:LLFB32N%MHI$0M*T^0<Q^7O!"C=R,4SX"
M75['KGCBQ\21*GC=;])]4EMGW6<R,@$!MQ@%4" +M?+9!))SP >Q5C^*?%NE
M>"]+&H:Q=?9;=I4MXPD3RR32N<)''&@+R.3T503UXXK8K@_BEX)U3Q1<>&=4
MT1K)]3T'41>QVNHNT<%PI0HZEU5RAPQ(;8V"!Q0!T'A3QKH_C:UN)](N7F%M
M*8+B&>WDMYX)!SMDBE570X(/S*,UN5XU\&Y-7O/BG\3+K4X;.U8S6<4L&GW3
M7,*2K#R!(R1ECM*Y^1<9QVR?9: .9E^)7AB'QM!X0.L6[^)9HFG73H\NZHH!
M)<J"$X((#$$]LU2U3XP^$=&U\Z-=ZJT=VL\=K)(MI,]M#,_W(I+A4,4;GLK.
M#R..17&^*M'L-+_:'\"S6=C;6DMW;W\UQ)!"J-,^Q!N<@?,<#&3S7GFM@R?L
MO?%@7))OCKVHA\\L9_MJ^6/KG9C\,4 ?5%<S=_$KPQ9>-+/PC+K%O_PDEU&T
ML>G)N>0*!DEMH(3CIN(SVS70VRRK;1+,P>8( [+T+8Y/YUY%X[TBQT_X\?#J
MYM;*WMKF\EO9+F:&)4>=A;A0SD#+$  9/88H [R[^)7ABR\:6?A&76+?_A)+
MJ-I8].3<\@4#)+;00G'3<1GMFNFKQWQWI%CI_P >/AU<VME;VUS>2WLES-#$
MJ/.PMPH9R!EB  ,GL,5[%0!S6H_$CPUI7C+3O"=SJ\">(]01I+?3E#/(R@$E
MFV@A!A3@MC.#C-4]6^+OA70M>_LB_P!0FMKD7$=HTS6-P;5)W *1/<B/R5<@
MCY6<'D>HKD_B-I%C8_&'X9W=M96]O=7FHW;W,\42J\[+:,%+L!EB!P,]!2_&
MQCX_O-.^&NG*)KJ_E@OM4G !%C91RJ^XGL[L@5!W^8] : /7*YK5?B/X:T7Q
M=I7A:\U>"+Q#JF[[)IZ[GE<*I8DA0=@PK8+8!Q@9-=+7D/Q-T>PL_BS\,+ZW
ML;:"]N]7G^T7,<*K)-MLI0N]@,M@=,]* .LUWXO>%/#>LMIFHZC-;SI+%;RS
MBQN'M89),;$EN%C,4;'(X=P<$'N*[*O&_P!IBSUH_#[5;YKJQN?"=DD5UJ.C
MB!H;N[BC<.R+=%V5 2%X\K)P0&&<CUS3[U-2L+:[B#+%<1+*H<88!@",CUYH
M P==^)7ACPUXETCP]J.L6]OK>K/Y=G8#<\LAP3DJH.U>#\S8''6G>./B-X<^
M&]E:7?B/4TTV"[N%M("8WD:25NBA4!/XXP.Y%>??&C1["U\=_#;4(;&VBO[G
MQ!&D]U'"JRRA89-H9@,L!VR>*\O_ &D=8&KW?B*\U;3M:MTTF>RL-)5M%NV@
M?-Q$\\XG$1C^; 11NR=IQU H ^M:YGQ%\2O#'A37M(T35=8M[75]6E$-E9?,
M\LK'I\J@E5_VFP/>MW3K^+5+""[A6=(ID#JMS \$@!_O1R!64^S &O)OCII%
MC#XA^'VHQV5NFH3>)K**6[6)1+(BB0JK/C) ). 3@9- '9:U\5_#N@^()]#F
M?4[O5+>))YK?3-&O;[RD?.TL8(7 S@\$YKKD<2(K#(##(W @_D>E>1>/?#GB
M3P'K'B_XCZ!JVDR(-,26YTG5+"0[X[=6=@EPDR["R[L$QL <9XKTSPQK:^)?
M#>DZND+VZ:A:17:PR?>02(&VGW&<4 9OB?XD>&O!NKZ-I6LZO!9:EK$ZVUC:
M$,\L[L=HPJ@D+D@;CA1W-.\3_$'0_"%Y:66H3W,E_=(TD-EI]C/>W#(N-S^5
M CN%!(&XC&3C-<-\>=(L8I?!>I)96Z:C+XITN&2[6)1,\8E8A"^,E022!G'-
M<Y>3>*T^-OQ%O=$OM'L;FQT>U:(:Q92SK+$%D8*"DT6Q2^[+G=].* />;.Z2
M^M(+F-9%CFC615FB:)P",C<C ,IYY5@".A -35S'PQ\9-\0OA]H'B1[0V+ZG
M9I<-;DYV,1R >XST/IBNGH **** "BBB@ HHHH **** ,3PWX'\.>#5F7P_X
M?TO0A.091IME';^9CINV*,_C6W110!%=VD%_:S6US#'<6TR-'+#*H9)$(P58
M'@@@D$&N=T+X7>#/"VH+?Z+X1T+2+Y5*K=6&FPP2@'J RJ#@UT]% !4%]8VV
MIV5Q9WEO%=VEQ&T4UO.@>.5&&&5E/!!!((/!!J>B@#EM#^%?@KPSJ,>H:/X0
MT'2;^,$)=6.F00RJ",'#*H(S74T44 ,EB2>)XY$62-P59&&0P/4$=Q6)X;\!
M>&?!KS/X?\.:3H3S@"5M-L8K<R = VQ1G\:WJ* "BBB@"H^E64NI1:B]G;OJ
M$4;0QW;1*940D$J'QD D D9QQ5NBB@ KG_#GP\\*^#KB6?0/#.CZ'/*NR273
M;"*W9UZX)102/:N@HH **** ,2R\$>'-,UZXURST#2[36KC(FU*"SC2YESC.
MZ0+N.<#J>U;=%% !5.PT:PTJ6ZDLK&VLY+N4S7#V\*H9I#P7<@?,WN>:N44
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M"7P/#I4VEQ^#/#Z:9-*LTMDNEP"&2100KLFS!8 D D9&37644 8WAOP9X?\
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M-.IR<B4MG)]37;44 16EI!86L-M;0QV]M"BQQ0Q*%2- ,!5 X     J6BB@
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tmb-20221231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )B MX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1_PDFG_\]S_W[?\ PH TZ*S/^$DT_P#Y[G_OV_\ A1_PDFG_ //<_P#?M_\
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M1_PDFG_\]S_W[?\ PH TZ*S/^$DT_P#Y[G_OV_\ A1_PDFG_ //<_P#?M_\
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M6B@!,48I:* ,WQ'QH=[_ -<S6E6;XC_Y =[_ -<S6E0 4444 %%%% !1110
M4444 %9EC_R&]2_W8?Y-6G698_\ (;U+_=A_DU &G1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2Z_T ?O64$1XZ_(#G/4FO%O">K:;XX\8ZY;_ !A^(_B_P3XVCO&2UV3M;VD
M[#H0F&SC[JX ()R3525I<J_K_,F/P\S/TAHK/\/6WV/0--@-\VIF*VB3[:Y!
M:XP@'F$C.2W7\:T*35G8:U5PHHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-\1_\@.]_ZYFM*LWQ'_R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S?$?_(#O
M?^N9K2K-\1_\@.]_ZYFM*@ HHHH **** "BBB@ HHHH *S+'_D-ZE_NP_P F
MK3K,L?\ D-ZE_NP_R:@#RC]K[4;BS^"M[;6Z/*-2O['3Y8T<(9(I;A%=-QX
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M[S_R'_\ %4?VM/\ ] N\_P#(?_Q5:.*,4 9W]K3_ /0+O/\ R'_\51_:T_\
MT"[S_P A_P#Q5:.*,4 9W]K3_P#0+O/_ "'_ /%4?VM/_P! N\_\A_\ Q5:.
M*,4 9W]K3_\ 0+O/_(?_ ,51_:T__0+O/_(?_P 56CBC% &=_:T__0+O/_(?
M_P 51_:T_P#T"[S_ ,A__%5HXHQ0!G?VM/\ ] N\_P#(?_Q5']K3_P#0+O/_
M "'_ /%5HXHQ0!G?VM/_ - N\_\ (?\ \51_:T__ $"[S_R'_P#%5HXHQ0!G
M?VM/_P! N\_\A_\ Q5']K3_] N\_\A__ !5:.*,4 9W]K3_] N\_\A__ !5'
M]K3_ /0+O/\ R'_\56CBC% &=_:T_P#T"[S_ ,A__%4?VM/_ - N\_\ (?\
M\56CBC% &=_:T_\ T"[S_P A_P#Q5']K3_\ 0+O/_(?_ ,56CBC% &=_:T__
M $"[S_R'_P#%4?VM/_T"[S_R'_\ %5HXHQ0!G?VM/_T"[S_R'_\ %4?VM/\
M] N\_P#(?_Q5:.*,4 9W]K3_ /0+O/\ R'_\51_:T_\ T"[S_P A_P#Q5:.*
M,4 9W]K3_P#0+O/_ "'_ /%4?VM/_P! N\_\A_\ Q5:.*,4 9W]K3_\ 0+O/
M_(?_ ,51_:T__0+O/_(?_P 56CBC% &=_:T__0+O/_(?_P 51_:T_P#T"[S_
M ,A__%5HXHQ0!G?VM/\ ] N\_P#(?_Q5']K3_P#0+O/_ "'_ /%5HXHQ0!G?
MVM/_ - N\_\ (?\ \51_:T__ $"[S_R'_P#%5HXHQ0!G?VM/_P! N\_\A_\
MQ5']K3_] N\_\A__ !5:.*,4 9W]K3_] N\_\A__ !5']K3_ /0+O/\ R'_\
M56CBC% &=_:T_P#T"[S_ ,A__%4?VM/_ - N\_\ (?\ \56CBC% &=_:T_\
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MHH **** "BBB@ HHHH *S+'_ )#>I?[L/\FK3K,L?^0WJ7^[#_)J -.BBB@
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M_D7 SCJ8P,\?QU^H5?$?_!4_P"-9^%'AOQ5&F9=%U(VTS <B"X7;D_21(_\
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M^_!H TZ*S/[;_P"G&]_[\&C^V_\ IQO?^_!H TZ*S/[;_P"G&]_[\&C^V_\
MIQO?^_!H TZ*S/[;_P"G&]_[\&C^V_\ IQO?^_!H TZ*S/[;_P"G&]_[\&C^
MV_\ IQO?^_!H TZ*S/[;_P"G&]_[\&C^V_\ IQO?^_!H TZ*S/[;_P"G&]_[
M\&C^V_\ IQO?^_!H TZ*S/[;_P"G&]_[\&C^V_\ IQO?^_!H TZ*S/[;_P"G
M&]_[\&C^V_\ IQO?^_!H TZ*S/[;_P"G&]_[\&C^V_\ IQO?^_!H TZ*S/[;
M_P"G&]_[\&C^V_\ IQO?^_!H TZ*S/[;_P"G&]_[\&C^V_\ IQO?^_!H TZ*
MS/[;_P"G&]_[\&C^V_\ IQO?^_!H TZ*S/[;_P"G&]_[\&C^V_\ IQO?^_!H
M TZ*S/[;_P"G&]_[\&C^V_\ IQO?^_!H TZ*S/[;_P"G&]_[\&C^V_\ IQO?
M^_!H TZ*S/[;_P"G&]_[\&C^V_\ IQO?^_!H TZ*S5UG<P'V*\&3C)A-:5 &
M;XC_ .0'>_\ 7,UI5F^(_P#D!WO_ %S-:5 !1110 4444 <7\:AXF;X1^,AX
M,W?\)6=(NO[+V8W_ &GRF\O;GC=GIGC.*^*O.^%4NF^&D^#G_"0GXXB_TXGS
M9+\W^[S8_M?]IB4[?+\KSM^_C^[SBOM7XT:IXCT3X2>,;_PA;FZ\46VDW,NF
M0A-Y:X6-B@"_Q'/1>YP.]?,?B?XXZ!JGPT^'5K\.?BI?>)_B58WUBEMI2W2R
M7FJ-++&MU'J%L%RJ",S,2P7R]N0>.9I_Q?G#\W^'?Y&=7X->TO39;^?;YGV>
M.E+2#IS2U1H%9EC_ ,AO4O\ =A_DU:=9EC_R&]2_W8?Y-0!%XJDUV+26?P]#
M8W&HJZD0ZA*\4;I_$-RJQ4^AP17F=SX#\8_$[QEX6U7QC;Z5H.C>'+PZE!IN
MFW;W<MS=!2L;/(40*B[B=H!)->R44+1W#I8Y2)/&'_"P[YI)-,_X0[^SD%JH
M#?:Q>;CN+]MFW'3FN'\7:9\5O'/AW4?"TMCX<T2WU"!K2YUN"_EN&$3C;(8X
M#$OS%20-SX!ZU['12LFK,=VG=&3X2\-6G@WPOI.@V.[[%IMK%:0[SEBB*%!/
MOQ6M115-MN[)2LK(****0PHHHH *R?%OARU\8>%M7T*]&;34[26SF&/X)$*G
M^=:U(>133L[H#\U?^":OB2Z^'7QO\<_#/5&,4UQ$^(V&/])LY"C@9[E&)^BU
M^E=?F!^T@C?LX?M]:'XWA5K?2M4N;;5I"O *2?Z/=C_T)C_O5^GD4BRQJZ,'
M1@"K Y!'8UZ6/7-*-9?:7X]3DPVB=-]&/HHHKS#K"L[Q!H-GXFT:\TN_B$UI
M=1F-U/7![CT(ZCW%:-%-.VJ#<^2?!.MWW[/WQ1NM$U9V.CW+JDLA'RLA_P!7
M./IT/X^E?6D<BS1JZ,'1@"K*<@CUKS/X[?"Q?B)X:\^SC']MV 9[8]Y5_BB/
MU[>_U-<9^S=\5VN8E\':S(4O+<%;%Y>"ZCK$<_Q+V]N.U=M1>WA[5;K?_,Y(
M/V4N1[/8^@:***X3K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S?$?_(#O
M?^N9K2K-\1_\@.]_ZYFM*@ HHHH **** /%?B'XJ\2:I^T)X(\#Z3KH\-Z/'
MIEQXDU298$DEU".&>&);12_"*3(6=A\V H&,YKP ^,_&)\):E^T78>*6L[*?
MQ*MGIWA6*PMEM-0TDZ@MFH=]GG-/*"TJOOP"5&"*^I_BY\"/!WQLM]/3Q18W
M$L^GLYM;RQO9;.XB60!9$$L3*VQP &7.#@>E4]1_9T\$:IJG@F>:QN%TWP=&
MB:/H45RZ:;"Z8\J5H!\LDB8^5FSCKUYI4URM-]'^%[O\$HI;;WW(FG*Z77]%
M;\VY-[[=CTT'(I:**985F6/_ "&]2_W8?Y-6G698_P#(;U+_ '8?Y-0!IT44
M4 %%%% !1110 4444 %%%% !1110!\3?\%2?AI_PD/PHT/QA!$&GT"^\BY91
MS]FN $.3Z"18_P#OJO;?V-?B9_PM3]G7PAJDTHDU"UMO[,O3W\Z#]V2?=E"M
M_P "KFO^"@GCV#P/^S/K\$UBE^^O21Z-$DN=D;298R''=5C)'^UMK\RO@E^T
MKXY^ .I1S>&]5?\ LG[1]IN]&G :VNN &R,95BJ@;E((P.M>[1P\\5A.5;Q>
MAYU2K&C7N^JU/W&HK,\,:[%XH\-Z5K,"LD&HVD5W&K]0LB!P#[X-:=>%L>B%
M%%% !7SE^T+\)[C3[T^-O#JO%-&XFO(X.&1P>)UQ_P"/?GZU]&TUT65&1U#(
MPP5(R"/2M:51TI<R,YP4U9GF7P3^,-O\1M)%I>.D.OVJ#SXN@F7_ )Z(/0]Q
MV/MBO3Z^8_BU\&-1\":N/%G@OS8K>)_.>"VY>U;NRCNGJ.WTIL?[6^HQZ5:1
MG0X)M048N)6F*QO[JH!(S[UTRH>T]^CL_P #"-7D]VIN?3U%<#\+_B[IOQ(T
M2XNPG]G75H0MS;RN"$R,A@W=3@_D:R/'?[17ACPDDD-E,-;U%>!#:-E%/^U)
MT'X9-<RI3<N1+4W]I'EYKZ'JA8*,D@#WKR#XM_M V?@.6*PTF*#5M3==[GS?
MW4 S@;L<ECZ5Y4=2^)?QZN&6U#V6CDX(B8P6RCW;JY]N?I57QO\ LU>(O"VG
MVMSIQ_M[<"+B.TC(:)NV%ZL/?]*[*="G&2566O8YIU9RC>FOF>K?!_\ :$_X
M3[6AHNJV4=CJ$JL\$D#$QRX&2N#R#C)[YQ7M-?%OA7X%^.]1@EU*SLI=*GMB
M&A-Q(8)9&_V.XQZG KK_  Q\?O%7P^U,:1XTL)[N.,@,\J;+E!Z@]''^<TZN
M'C)MT6O0*=9Q7[S[SZCHK&\*^+])\::8E_I%['=P-UVGYD/HR]0?8ULUYS33
MLSL33U04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)-WLQ:***DH**** "BBB@ HHHH S?$?_ " [W_KF:TJS?$?_ " [W_KF:TJ
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M=\9O#7[4O@?P7X:\&VT_P8.EHNH:V\9+P,J2#'F;@%*[(@%*G=N/X?1P4#H
M*,#.<<UIS:W\[OS=K$6TMY67EU/SP\1_#CXQ?LB?M9?$#XE_#[X=S?%'P;X\
M7S;BPL+GRKBUN"V\[@%8C#F3!VD%7Z@BO1/V'_V?_'WA;QU\3_C1\3].BTGQ
MGXXGW0Z%!,)#9VX8N$9@2,G$:@9R G."<#[+(!ZC-+41]R*2Z*R\D5+WG=]7
M=^;1^4'[0/B'X^?&CX^?"SXA+^SEXFTM? 5X;A;$2M-]N F23&\1#9]S&<-U
MKV_]JOX1_$O]L']GCP%XUTSP7+X-^)OAC5GU.'PMJ5RID*!]I42,$&X^7%(
M0.,CKBON[8O]T?E2X &,<4+2*BNCNO6]_P! >LW/NK?+56_$_-SQIX.^._[=
M_CSX::?XR^%C?"CP?X3U)=3U2_O[KS);J4;<B%2JM@A2  " 6R6XK](P,"@
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M-N_^@G/_ -\)_A1_9MW_ -!.?_OA/\* -*BLW^S;O_H)S_\ ?"?X4?V;=_\
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M#)&+<LJMZ!LY(_"@_LD:F>#XCM\'K^X?_&OHC^S;O_H)S_\ ?"?X4?V;=_\
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M/_WPG^%<MVS>R-*BLY=.N@P)U*<@'H43G]*T:0S-\1_\@.]_ZYFM*LWQ'_R
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M+>3=(?0QM@_B,BN#%8.=";Y4W'N=-&NJD5=ZGJM%(&# $'(/I2UYQU!1110
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MF?RWTZ>8+:H,<R>< 25S@8VY^G6L9X";=Z/O1?7_ #-(XF*TJ:,^XO[=M_\
MGG<_^ [_ .%']NV__/.Y_P# =_\ "ODG]E[_ (*#6?QJ\:0>$?$VB1^'=8O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^12_99TRYTC]GSP+;W:-'-_9R2%'&"JNS.H_)A7JM,BB2"-8XT6.- %55&
M.@ I]:2?-)LB*LDF%9GEZM_SWM?^_;?XUIT5(S,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\
MO5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\
MO5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\
MO5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\
MO5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\
MO5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\
MO5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\
MO5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\
MO5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\
MO5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\
MO5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\
MO5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;
M_GO:_P#?MO\ &M.B@#,\O5O^>]K_ -^V_P :/+U;_GO:_P#?MO\ &M.B@#-6
M/5=PS-:D9Y_=MT_.M*BB@#-\1_\ (#O?^N9K2K-\1_\ (#O?^N9K2H ****
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M-8D@^S/J%E#=-"3GRRZ!BOX9H6JN#T9L457U"::WL;F6V@-U<)&S1P!@ID8
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M7$_VF=(U62;9M\Q@.6QVR><5/2&9OB/_ ) =[_US-:59OB/_ ) =[_US-:5
M!1110 4444 %%%% !1110 5F6/\ R&]2_P!V'^35IUF6/_(;U+_=A_DU &G1
M110 4444 %%%% !1110!XG\<IE\.?%'X2^*KS]UHUCJ-W8W=TW"0&X@V1LY[
M*67&3ZBH?'%[:^.?V@OAC8Z3.E]_8 OM6U"2W8.L"-#Y408CH69C@>QKVG4=
M-M-7LI;.^MH;RUE&V2">,.CCT*G@U1\.>$-#\(6SV^AZ18Z1 YW/'8VZ1!CZ
MG:!FB.G]?UUU!Z_=;^OEH:PX%+110 UW6-&=V"JHR6)P *\(TK7],_X:WUNX
M_M"U\AO"-M&LGG+M+?:GX!SU]J]UN;>*\MY8)XUFAE4H\;C*LI&"".X(KC(_
M@C\/HF5D\%: I4AE(TZ+@CH1\M)?$GV_R:_4'K%K^MT_T.WHI.E+3 *^>/B/
MXH@^.OBN[^'NGZG#8^#].F5?$NIF94-PP(;[#"2>2<?.W8<=:^AZXNY^"_@*
M\N))Y_!NA33RN9'D?3XBS,3DDG'4DYI=1]#J=*6S33;9-/,7V*.,1PB$@H$4
M8 &.PQBK=4M'T6P\/:;!I^F6<&GV$ VQ6UM&(XT&<X"C@<DU=JGN2M KR_Q_
MHGPX^(U]?V'B*^A>^TR,P7$0U*2W:!6 ?YD5P#P006!KU"N?U_X>^&/%5TEU
MK/A[2]4N4QMFO+..5QCIR1FI:N4G8\V_91UK4]6^'NHQ7=R^H:3I^KW5CHNH
M21A&NK&,@1OP #_$-P'.*]IJ*UM8;*WC@MXD@@C4*D<2A54>@ X J6J;N2E8
M*\<^-.A>+M>\9^$7TWPX/$/AC2I&U&YM5OHH#->+Q &$A&43)?W;;Z5['12Z
MIC[H^;?@9KOB&[_:%^*@O?##V"W4VGM?$WL,GV)EM#Y8.T_/OZ_+G'>OI*J5
MGHFGZ?J%]?6UE!;WE\4:ZN(XPKSE1M4N1RV!P,]JNT=$@>K;"L/QE%X?O-#>
MR\3+92:5=NL+0ZAM\J5L[E4AN"<KD?2MRJ6KZ)I_B"Q>RU.QMM1M'^]!=1+(
MA_!@128T?.NOZ)X>\*_'7X;V_P -DM['4+FYF_MNRTE_]';3Q$<O,BG:"'VA
M6ZYKZ6'2L;PYX*\/^#TD30]$T_1UD^^+&V2+=]=H&:VJJ^EA=;A63XLTZ76/
M"^KV$)Q-=6<T"'_:9&4?J:UJ*F2YDT-/E:9\9>&?#WPYC_92%[J5O;VOBW3M
M+EM'E,S#4+?48]R*D?.]6\P+A5P.1QS7U1\-#JS?#SPR=>W?VT=-M_MN_P"]
MYWEKOS[YSGWJ63X?^&9M?_MQ_#VEOK&=WV]K.,SY]=^,Y]ZZ"K<KW;Z_\'_/
M\B+6MY?\#_(****DH\1_:8U"?Q';>'/AGITA2_\ &-Z(+IH_O1:?'A[E_;*@
M+_P(U[-I]C!IEC;V=K$L-M;QK%%&HP%11A0/H *@DT+3IM9AU9[&W?5(86MX
M[QH@94C)R4#=0"><5?H6BM_7]?YL'J_Z_K_A@HHHH ^=_BO:Z?\ $WXXV7@?
MQ;<QZ7X9T[34UBUY$4M_<F0J0DQY01@ D(03GGBK?[.[-X4\<>,_ 6CWPUGP
M9HJ6]Q8WN%+V\LQ8R6SR*,2$8#9///->S>(O"&A^+K=(-;TBQU>%#N5+VW24
M*?4;@<5/HF@:9X;L5LM)T^UTVT7E8+2%8D'X* *(Z+[_ .OD$M?P_KY_J:%%
M%% '%?%7PCX=\9:'9VGB&\.F&&\CN+"^BG$$UO<KDHT;'^+&>.<C->.)X977
MOC_X&M[/Q3J?C&7PZ+G4M3O+J2-H;16B,<,0$2*H=V8GUVKZ5]#Z]X=TKQ1I
M[6.L:=:ZI9,0QM[R%94)'0X8$9IN@^&=)\+67V31M,M-*M<Y\FS@6),^N% H
M6CN#U5C2I:** /"OVK]6LE\)^&[<W< N(_%6DN\1D&Y5$X))&>!BNX^)/AWP
MK\0?#]C'J^J+9K#>K/I^I6MTL4L%TF=K1OTW8W9'.1FM/6OA5X-\1ZE-J.J>
M%M'U&_FQYES<V4<DCX&!EB,G@ 58_P"%<^%O^$>&A?\ ".:6=%#F4:>;1/(#
MDY+!,8SGO1]FWG?\O\@^U?RM^?\ F>%0>&5U[]H/P1#9^*=3\8R>'$NM0U2]
MNI(VAM0\1CAB C15#L6)]=JU]+UFZ#X:TGPM9"ST?3+32[4'/DV<"Q)GUPH%
M:5/I876YYA^TIJ5I;? _QU;S7,,4\NB77EQ.X#/^[/0=ZZ+X5ZE:7GPZ\-B"
MYBF,.EVHD\MPVP^2O!QTZ5<\2?#WPQXPN8;C7/#^FZO/"GEQRWMJDK(N<X!8
M' S4OA[P-X=\)0W46B:'I^DQ76//2RMDB$N 0-P4#/!/7UJ5I?SM^%_\QO6W
ME?\ &W^1Y#?Z_IA_:XTFX_M"U\@>#YT,GG+M#?:UXSGK7O((8 @Y!Y!%<1_P
MH[X>G_F2= _\%T7_ ,37;1QK$BHBA44 !0, #TJE\*7:_P"+;_45M6^_^27Z
M$5[?6^GP^;=3QV\60-\KA1GTR:\3_97U6S?1O&ENMW T\GB_572,2 LR^:#D
M#N/>O8/$'AK2?%>GFPUG3;75;(N)/L]Y"LJ;AT.UAC(K)T3X6^#O#6I1:AI/
MA?2--OX@0ES:V4<<B@C! 8#(R.*E;W\K?D_T&]4EYW_-?J>/>.O$EK^T#XMN
M/!5KJ4%GX#TBY7^W[]I@IU"9"&%G%SRH(&]OPKZ"L&MFLH?L9C:U" 1&(@IM
M' QCM7)3?!3P!<2O++X+T&21V+,S:?$223DG[OK75:3I-EH6G6^GZ=:0V-C;
MKLAMK>,)'&OHJC@"FM%8'J[EEW6-&=B%51DDG  KPC3]?TS_ (:YU2X_M"U\
MAO!\""3SEVEOM;<9SU]J]UN+>*[@D@FC66&12CQN,JRD8(([@BN,3X(?#Z,J
M5\$Z I4@@C3HN".G\-)?$GV_R:_4'K%K^M&G^AG^/=+^'WC_ %*?1O$=[#)?
MZ=$=]L-1DMGC210<E4=0P(QU!''UKE/V5=4O;C1/%FEI=-J7A72-:EL= U!U
M ,UJH!P&4 .%8D!N]>I^(? 'AKQ9+')K7A_3-6DCQL>\M$E9<>A89K8LK&WT
MVUCMK2"*UMHAM2&% B(/0 <"FM+_ -?/^NX/6Q/7@_QEUO3S\;O@R?MUMBWU
M+4/./FK^[_T0CYN>.>.:]XKC;SX->!-0NY[JY\':'<7,[F2662PB9G8G)8DC
MDD]Z.J?835TT<?\ &_1O$_B^[\(1:+H:>)/"\%U_:.I6\5]%";EH\&WCRY 9
M-_SGUV 5Q'PLU_Q+=_M2^.VO?"KV,ESIVF)>J;Z%_L:*DNQSM/S[CQA<D=Z^
MD--TRTT:PM[&PMHK.SMT$<-O @1(U'15 X ]JBM]$T^UU2ZU*&RMXM0NT1)[
MI(P))53.P,W4@9.,],TXOE?WC>JMZ?G<O5XS^USJ5I%^S_XVM'N84NGL04A9
MP';]XG0=3T->S5S?B'X;^%?%M\M[K7AS2]6NU01K/>6B2N%!)"@L,XY/'O4-
M75AK0JR7WAK5? T<&LW&GW6CS0Q6UPMS(C0L6"@(V3CDXXKQ/Q[X?\+^$_B;
M\-5^&T=MIWB2YUE%O;31FQ%-IVUO/:=%.W:.,,1G)XKWC3OAUX6TC2;K2[+P
M[I=KIMTX>>TBLXUBE8  %EQ@G@<GTJ7PYX$\.>#S(=#T'3M(:3AVLK5(BWU*
M@9Z5I?W^;Y_\#^NA"5H<IN57OM0M=.B$EU<16T9.T-*X4$^F35FLGQ'X4T7Q
M?9I::YI5GJ]JCB58;V!945@"-P# \X)Y]ZAE'C7[)UW:WOP<FL([N$W4FIZK
MB-9 7 -U+@XZXY%>:?#+PG\-[7]G.]7Q5:VEOXET2*\L[V2YF87EM<1O($\K
M)W(3\A4)C.1ZU]0:!\,_"7A74/M^C>&M*TN]V&/[19V:12;3C(W 9P<#\JFO
M?A_X9U'6TUFZ\/:7<ZLF-M]+9QM,,=#O(SQ0U=6\DON!.WWW,7X%MK;_  >\
M'-XC,IULZ9 ;HS_ZS=M_B_VL8S[YKNJ**N3YI-DQ7*DC-\1_\@.]_P"N9K2K
M-\1_\@.]_P"N9K2J2@HHHH **** "BBB@ HHHH *S+'_ )#>I?[L/\FK3K,L
M?^0WJ7^[#_)J -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-\1_\@.]_P"N
M9K2K-\1_\@.]_P"N9K2H **** "BBB@ HHHH **** "LRQ_Y#>I?[L/\FK3K
M,L?^0WJ7^[#_ ":@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHKA_C'XTU/P%X+EU;2K1+NX2:-&$BDJB$G+$#
M\!^-5&+DU%";45=G<54N]6LK!T2YNH8&<X59'"D_G7RO_P -4>,/^@?IW_?M
M_P#&O*/$WB34/%NLW.IZG.UQ=3.6.2<(.RJ.P'I7?#!3;]YV..6*BOA1^A*L
M'4,I# ]"*#Q7QAX+^/WBKP;HB:9;+!?V\;$QM=AW= ?X00>@[?6O0_AM^T/X
MF\5^-=,TB\TNVDMKMS&YM4</&,9W\D\#'-9SPE2-WT1<<1"5D;>N?M&ZM#X\
M\2^&] ^'FM>)VT&:.&ZNK&2(*&>,..&8'H3^5;>B_'O3?&?PQ\7>(M%MYK;5
M?#UM<FZTK4HS'-;SQQLX21?0[>H]Z\D\,_$^;X>?'SXS1P^$]?\ $[WFH61!
MT6T\Y8BMN  YR-N<\?0UK^'/ _B#3?A]\<?&OB73QHFH>++.YN(])WAFMH8[
M5U3>1QO.<FO/;_=M_P!V_P ]/^"=L5^\2\[?(]O^%'BRY\=?#3PQXAO8XX+O
M4]/ANI8X<[%9U!(&><5U>0:^;+"^TW3_ -E3X=3:MXUO/!%B-/M!)=6 7S[G
M,1 A3()R2<_*,_+7)?!?XEKI_P ==!\-Z!XJ\3^(?#^L6EU]I@\46[K)#-&F
M]'B=U4D$ @@<5O)+VDHKNS&+M34GV1]@9Q2U\X+;Z_\ M _%7QSII\5ZKX7\
M+>%+J/38K?176*:YN"F]Y'D()P,@ 5#\9O&7B/X#?##0=!E\576I:IK&KFQ3
M7WL_-N;>TY=F$:C]Y(JC:..<YK+HGWM^)I;6W;]#Z4R#7FOAOXEZAK'QV\8>
M"Y;>!-.T?3;*\AF7/F,TV=P;M@8&*^<?#?Q2_P"$4\<>%G\)^*_&WB>.^U*&
MTU73?$6GR>4T,AVM+&Y0;"I(./\ "NQO/"6L^-/VL_B%INF^(KCPW8MHVFF_
MN+%!]JE3#;4C8Y"<Y);!/ Q5):KY_D+H_E^:1]3]:,@=Z^</ OB;7/@]\6/%
M7@;6==O?$^@V_A\^(=.N=0(:ZB5"1)$S@?-T."?:J'PW\ ^+OCMX'L_'NL?$
M/7-#O]8#W6GV&C.L=K91%B(U92/WAP 3DTMU=;?\.OT?W!Y/^M$_U1]/T5Y)
M^S1\0-:\=>!+Z+Q'(EQKVA:I<Z-=W,:[5G:)AB3'8D$9]Z];IL2"BOG?]M?]
MH#Q)^SQ\/=#USPS9V5Y>7NK+8RI?1NZB,P2OD!2#G*#]:^-C_P %/?BR1_R
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M8?Y-0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[!?_ /017_OP/\:/L%__ -!%?^_ _P : -*BLW[!?_\ 017_ +\#_&C[!?\
M_017_OP/\: -*BLW[!?_ /017_OP/\:/L%__ -!%?^_ _P : -*BLW[!?_\
M017_ +\#_&C[!?\ _017_OP/\: -*BLW[!?_ /017_OP/\:/L%__ -!%?^_
M_P : -*BLW[!?_\ 017_ +\#_&C[!?\ _017_OP/\: -*BLW[!?_ /017_OP
M/\:/L%__ -!%?^_ _P : -*BLW[!?_\ 017_ +\#_&C[!?\ _017_OP/\: -
M*BLW[!?_ /017_OP/\:/L%__ -!%?^_ _P : -*BLW[!?_\ 017_ +\#_&C[
M!?\ _017_OP/\: -*BLW[!?_ /017_OP/\:/L%__ -!%?^_ _P : -*BLW[!
M?_\ 017_ +\#_&C[!?\ _017_OP/\: -*BLW[!?_ /017_OP/\:/L%__ -!%
M?^_ _P : -*BLW[!?_\ 017_ +\#_&C[!?\ _017_OP/\: -*BLW[!?_ /01
M7_OP/\:/L%__ -!%?^_ _P : -*BLW[!?_\ 017_ +\#_&C[!?\ _017_OP/
M\: -*BLW[!?_ /017_OP/\:/L%__ -!%?^_ _P : -*BLW[!?_\ 017_ +\#
M_&C[!?\ _017_OP/\: -*BLW[!?_ /017_OP/\:/L%__ -!%?^_ _P : -*B
MLW[!?_\ 017_ +\#_&C[!?\ _017_OP/\: -*BLW[!?_ /017_OP/\:/L%__
M -!%?^_ _P : -*BLW[!?_\ 017_ +\#_&C[!?\ _017_OP/\: -*BLW[!?_
M /017_OP/\:/L%__ -!%?^_ _P : -*BLW[!?_\ 017_ +\#_&C[!?\ _017
M_OP/\: #Q'_R [W_ *YFM*LBYT>[O('AEU &-QM8"$ X_.M>@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tmb-20221231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %L , # 2(  A$! Q$!_\0
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MG_@H#^S[_P!!+XJ@_P#8;U'_ .2:0?\ !0#]GTMG^TOBJ?\ N-ZC_P#)-/\
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MQ[_Y<R^X/;4_YCZ.^/.J+<_M&?"&'7;NXT?0K3PUXCULSV3'S+>[2UCC+QL
M=SQPS3LHP3D;L<5\GZ#\3=)U+P]<W-C\1O%MM\*M0\;6#:QI\NK:C/JNC:0+
M.>,2W-US)%]INHT<QQ,0OR+GDBNKU+]M?]F/5]9T?5KZ/XEWFJ:,\DNG7DVK
M:BTMH\B&.1HV-SE2R$J<=02*U3_P4!_9])'_ !,OBK]/[;U'G_R9I?V3C_\
MGS+[@]M3_F/+X/&WQ'/AWPU'XA\3^.[;QQ_96C/\.K,S74?]JL^L3+.UPJ#;
M,_V-;8OY_(5B<9-=U\#?BIXZ3]J/QA-HT/B/QYJ$AUMO^$:O]8N+1H]M["L*
MWT=PIM;0)&)# 8,EUX;!K6_X> _L^GC^T_BKG_L-ZC_\DT?\/ /V?3_S$OBJ
M?^XWJ/\ \DT_[(S#_GS+[A>WI_S%OXL?$VZU3]IZRM/#/B7Q!X3^)6FZ7+=7
M^@7VJ7%Q87=_)IY^RZ/:0*HMY<2D/),0 ">&)("^:^&?B%<6_P %?B[=:?\
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M5(0%;L0-_!Z<]>E7BZ^%Q+E".(C'X;-2[<U^OF*G&<$KQ-WX;_#>SMOVQX_
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M\(GXT_\ "<N?\*J-.77\T+FB=EFC-<?_ ,+,B7KX3\:?^$Y<_P"%(?B;$?\
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MQ=#_ *AAP&!/Z"NM'Q*T,?\ +2YY_P"G63_"NRA":3NB&SJJ*Y7_ (67H?\
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MY)--O8XTPS,T#!0,]ZB=2'*[2+BG<['39A#H22;'<1H\FR/EFP6.%'KZ>]>
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M^E<I#X+\ 6UC;V<7@*QBL[:Y^VPP)H*+''/P/-5=F ^%4;NO ]*+(#F?B/\
M%K7?!MEX.\0?V<+#P?>Q1R:]>26?VR?3WEDMTABV">)P"9I0SJDA4H/DKF/
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MTLX8G\\2)N!VPL0#N/0USUUX7^&]\J+<>%;&0)8C3$W:?REH)1*(%/4() '
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M_P"%'_"=M_T)_C;_ ,)JY_\ B:.5_P!6_P PYD=1FHYP3$?J/YUS?_">,/\
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M5#HU/Y']PN:)N;F_O'\Z-Q]3^=8?_"9:9_>N/_ =_P#"C_A,=,_O7'_@._\
MA4^RJ?RO[D'-$W-Q_O'\Z-Q_O'\ZP_\ A,M,_O7'_@._^%'_  F.F'^*X_\
M =_\*/8S_D_!!S1+VLL?[/;D_P"LC_\ 0UKO@>M>4ZEXKT^YM"D9N"V]#C[.
MW0,">WH*ZP?$K0CG][<_^ LG^%==&G)+56$VCJL_6E_.N5_X65H7_/6Y_P#
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MZ^E6[7=E/+<6UP=*_>02RG,KHVW*LY)+,.3WHY7V'='H_P"=&:Y3_A9FA?\
M/6Y_\!9/\*/^%EZ%_P ]+G_P%D_PI<LNPKHZK-9/BP?\4WJ)[^2:R_\ A9FA
M#_EI<_\ @+)_A5#Q!\0='O\ 1+RWADN#++&44&V<9)]R*'&26P71Y^TFR&9]
MNXH78+NVYP2<9[?7M7SYI'[6AL+ 6OBGPS>KXTDO#:CPEH5I-+>PXA,K$AQB
M52JG9)$2LG8"OH5+>XEC<"PN)HV9^1 2K L<_45R:_!3P?\ 8C9CP#9K;_:%
MN]BV!!$P38L@;J"$)48/ ..E>I&M'EBE-;&?+N>1W'[6-H_Q%@M[>PFMO!T-
MAJQN+O4$2&:ZO;2>VA\J(%]R;7G9"'4%FQM]\G6?VQI=0M]>NM!T&XLM(TW1
M5U)]2O84DGM[A=0:SEB>W,J;EW(5#!@<MD\"O<[GX+>$+O4-0OI_ %C->:A&
MT5W.^F@O.C;=P8^^Q,^I53U%1?\ "B_!(T^&Q'P\T\6444D*6_\ 9@V".1_,
MD7'<,_SD'/S<]:?M8W^-":\CS27]LGPD+S^S[70?$-[JPNO[/;3X;53,MWYE
MRHMR Q_>%;260#NI3^\*[OP!\:]*^(7BG4] MM*U31[ZQLX+UHM:@%I-(DJ*
MWRPL=Y"%]C-C"NI4\XSMWOPC\,:A'J27/@FVF74KU=2O=VG_ #7%TH(6=R.3
M( 2-W7!-7-)^'^DZ%J\VJZ=X5%EJDT(MY+V*S(E>,;<(6ZX^5?KM&>E5[:-_
MC0K&U2Y'I2_9[L?\P^\/_; TOV>ZQ_QX79_[8FK=>G_,A<C&Y'I2<>E.^SW9
M_P"8?>#_ +8&E%M=_P#/A>?]^#4^WI_S(.1C<CTI#3S!=?\ /A>'Z0&D\BZ_
MZ!][_P!^#5>WI?S(.1C<^@Q1G-#I<1+N>QNT7(&XP'N<"K9T?4^,:3?_ /@.
MU-5J?<7+(J45:_LC5/\ H$WW_@,U+_8VJ?\ 0)OO_ 9J?M:?<.5E0'%)CZU<
M_L?5/^@3??\ @,U)_9.I8)&E7N!W\@T>UI]PY9%3'UI<^U6CI.I8S_9=]C_K
MW-']DZD>FEWQ_P"W<T>UI]PY9%4GC.*7(]*M?V/JA_YA%]_X#M1_8^IC_F$W
M_P#X#M1[6GW#E94R/2F7&/)/'<?SJ]_9&J?] B^'_;NU0W>F:A#;2/+IE[&B
MX)=X&"@9ZFIG4IN#UZ%*+NCM="&=-M@3@8.3Z?,:^;_"'[5VOKI;3^)?#7VZ
M\U".RDT6PTBW:.6Z,\ERA'$DWR 6S8<A68DCR@,&OH'2M7B@T^!#!>%EW?,E
MNY'WCT(%8L?@WP1%IU]I\?@JP2POG66ZMDT-!'.ZDE6==F&(.2">AKY%63=S
ML.*_X:9A36;FRN/"5]I5O"FQKO5[Z&U$5U_9XOVMYT.3"%B)!D.0&7&.:6/]
MINUA@TV?4?"NI:=!+!8S7^ZYCDEL?MAD^S*(@-T^Y8]S;,;0P!!(8#NYO#GA
M&YL#8S>$K6:R8!3;2:,K1D"/R@"I7!_=_N_]WY>G%%GX=\):==:=<VOA*VMK
MG34:.QFBT=5>U5B25B(7* EF.!CJ?6E[H'D>G?M1W'V_4M1U738M+T7;;S6=
MM)=12N(FTV6]#/*A.QI-B#:58J>,$$&M*']K&S.D0ZG<>$-3M[:*TU2[U2'[
M5&UUIBV+O'*7@*AF5W5$4\$M)C;\C8]%MO"/@JSM)[6#P78PVMP7::&/1$5)
M"Z%&+*$P259E.>H)'0FH[3P7X'L)[6:V\$6%O-:Q/!!)%HB*T4;[BZ*0G"L7
M?('!W-GJ:=X@>?7?[5?]EZ-#?ZG\/]<TMQ:W&HW-M?7,4#QV<+PJ\T?F!3-G
M[0FU0H)(89Z973/VH(OMZ6]YH-U<VB7@M[K5()(X5@$MU<P0 0%F=SFV.[!'
M4'U [)OAC\/GU+2;W_A";97TI)%L8%TD"W@+NCLZQ;=H?=&A#XR,5T,=CX>B
ME,J>'560R+,772P"75RZMG;]X.S,#U#,3U)H]U= /,= _:D77-!T;7)/ NMZ
M/HFJ7D,$>JZI*(+2."6/?'.TA3HQ(CQC&\@;^0:]R8%6(.00<<\5Q5OX.\$6
MGE^1X)L(!'<_;$$>B(H2?_GJ $X?_:ZUTO\ ;D/_ #[7Q]_LK_X5#MT OYHS
M5#^VX?\ GVO1_P!NK_X4?VW#_P ^UZ?^W5_\*0#M9/\ Q+V_ZZ1_^AK7?+WK
MS+5]9A>Q($%X/WD9^:V<#[X]J[8>)8<G%EJ/_@%)_A7;A]F1+<V:*Q_^$DB_
MY\M2_P# *3_"C_A)(O\ GRU+_P  I/\ "NI$FNV=IQC..,U\YZM\9_'>G_#>
M?Q"-/TJ;^Q]=U2TUZXTVU-REK96AG ECADN82[9CC!^?/+$)V'NI\20D8-CJ
M)'_7E)_A7'1?#WX=V]K]FB^'6G1VWGBZ\E/#R!/. P)-OEXW8)^;KS3 SOB3
M\2M4T.;P4_AVZTF^;7+N"%-,N8)&NKZ-WB,DD1#J(5B@::1G=6 (12 6&>*\
M#?M$>))_B@G@WQKIVG:!=B_>$SV\4DT<I94$,".CNBON<9D<KD-&-B,^%]1U
M3PIX)UN\BN]1\#V]_=12O/'/=:&)'21RI=PQ0D,Q1"2.NQ?05>-CX;:]LKP^
M%MUW932W%K.=(S);RRDF5T;;E6<DEB.6SSF@#L**Q_\ A)(O^?+4O_ *3_"C
M_A)(O^?+4O\ P"D_PH V*R/%I_XIK4O^N+4G_"21?\^6I?\ @%)_A67XFU^*
M?0;^/[)?KNB(R]HZC\\5,@,W0QNTRU7.W((SZ?,:\1\&?M;:)XDTZ*[U/1+_
M $2=;>ZGN+%7^U7";)[>*U$:(F9?M(NHF3'&=R\D$CVS0S_Q*K8C@X;D=OF:
MN+N?V>_A_=2"23PU'YJZ2NB+*L\JR)9K,)T0,&!!655=9/OJ0,,,5YFEW<U*
M%M^TCX-O-1M[!5UJ*[DN!:W$<VER)_9\INOLH2Y)XCS-A>-V0P;H<US6C?M=
M^$K?P=9ZEXI2^T3598H9?[/2S<_:5D>95>W+$>8G^CR9)(QMZ<C/:6'PE\ 6
M-^^E0:=$^I^7'?2Q2WDLEU(HNS<+/(S.6<FXRV]LDD8)QQ5"U^ ?PUTUUAAL
M/LETMQ +:5-8N$N;61/,>*.WD\W?#Q-,VQ",B1B00:%R]0)]-_:$\)ZSJ$EG
M81ZS>,L)FCG3376&<BU2[,4<CE09!!(KE3C'()!&*I0?M-^![B#3[EWUFSL;
MN*WE:_N]*E2WL_/5V@6X?GRS(J%E&#P\9)&]<]+JGP>\*:[8WEM>Z;+/%>M+
M)<N;N99)6DM5M9&+A]V6A4(3GWZDFN?MOAG\,;_Q@EB5BU/Q%80H9M.N=6GN
M7=(E(C>XA:0B4QI<@*T@)59$ P H![O8#!T?]J+3]1UO4Q-I%[8Z- 5>VFO(
M7M[R6'["+LR>4WR@$-QEDXYZ\5LV/[3G@6_TRQU-)=4CTF[M+V\&I2V#"WB2
MT)%R)'!.UD8!>F"60 DL*O0?LX?#Z'3'T_\ X1^2>V8!3]HOKF:3 A6%0':0
ML L:JJ@'Y0JXQ@4FD_LX^ =$DFDMM'NS]HM)["X2XU2[F2YAFEDEE657E(DW
M232.2V3D@YX&'[H&;;?M2^ [RTL;J&36)(+CS6DDCTQW6S2.6*&22<J2$0--
M%\P+##9['$FF_M*^$9[VWLKYKVQF<E9KL6LC6%J?-N8T62<A=I8VDV!M_A]"
M"9M=^!/@^\UW3-2UJ\U"[@TVQF@CL-4UF>2.2,S0SL\S22;I$1H4^1R8QDDB
MMRV^"W@J.)O+T"*2*>:*Y=7ED=)'CDFE0D%B& >YG.#P?,P<@#![H"_"[XQ>
M&/C'IM]?>%[JXN(+*5(IOM$!B/SH'1AR0593D$'/!! (KM,UA^#_  7IG@32
M$TO2/MBV,858H;R^GNO*55"JB&5V**   H( QTK<J':^@%+63_Q+V_ZZ1_\
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MO_\ /Q:_^ W_ -E1["KV%SQ/5OQK)\6?\BWJ/7_4FO/S\0->(_X^+;_P'_\
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MUXAS_P ^8_\ BJ[,/LR)&QGVHS[5C_8-8_Z"\?\ X!C_ .*H^P:Q_P!!>/\
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M^%5O\1+WQ7ILOBC5=4.A6VER.RW&FPV1NKIKIPJ3J=[Y2'805*JW!QVKL?\
MA([_ /Y[#_OA?\*0^)+_ /YZJ?\ @"_X4.[[ >5Z/8?&E/$45]>:QJDEB'CG
M;39+2R$#9U8Q-%N";PHL,2DABQ.&SD;3@M<?'6]\-W<.KOK.^ZNWBO8-'T:W
M%Q:H;>Y"BU>5F2: RBW#,5W*O.?F.WW,>)+_ !_KE_[X7_"E'B._/_+8?]\+
M_A32?9 >'?#+2/BAX0E\/:3J>F>(-/\ #L=O;1RG18;669KB.QL4"3EP^V#>
M+H,Z#.5/( &:&B+\:]?NH;GQ-:>*;.&PU=OLD%I#:[WBFTZ966; Q- EQY:%
M]JG#LP&-I7Z /B._'_+8?]\+_A2?\))?_P#/8?\ ?"_X46:Z(3/#FE^.MEX9
M:TTZTU.QUFWTGRH85M;5["-181^6T;'+M=BZWAD8[,#IC#5U^FO\4=*\;Z#9
MW4NM:WH<.KW5I<3-;VL(GLCY;17D\RIC"?O5$**C/D'<"/F]#'B*_/\ RV'_
M 'PO^%(?$=^/^6P_[X7_  HY7V0+8ZVC\#7)?\))?_\ /8?]\+_A1_PDE_\
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$Z __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tmb-20221231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #I .X# 2(  A$! Q$!_\0
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MZ8>_Z4 =?17(#7?&F1GPEIX^FM'U_P"N'XUJ^$?$$GB72&NI[/[!<17,]K-
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MN?&.W:5_M^?!7./]5#Z_E^%=J?SKB_AHVZX\8D8(_M^< A]^<10CK^'3MTH
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M< X(['D<59H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Y3X<\Z5JIX/_$YU'D#_ *>I/\_YP.KKE/AQ_P @G5/7^VM1_P#2N7_/^<T
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M,^D65Z3KL]W?1K=RP.)?*$AVMY@CC:(-AMS2#DD#<W5^'/$=UX-\1>+-)NM
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M?$F1YS%_PB'B96"AB39)CGISYF/7Z4 =I17"1_%5I+>VF'@WQ6JSG"*VG*K
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80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tmb-20221231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #- 1,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#\JJ*** "B
MBB@ HHHH **** "BBB@ HIR(TCJJJ69C@*.237>6?PL>#38+_6;S[#!)SY,4
M1>11_M?W3^=!I"$INT4<#17;:K8>%K*U*PQSSOC_ %J7 )_$8&/RKC)?+\QO
M++%.V[K2O<<Z;I[C****9D%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4 9HH'>@#UWX>Z./!/A1_%M
MTOFS7@:*SCCC5GB ;!?)Z$]!CGWKC?$/BB\GGD\R[>YED;=A^D7X'^+^5=MX
MZU6ZTWP9H-C;:?Y<-O9Q&.\E*AB64,2H!YY/4UY7IFGSZUJ<-K IEFF;].I)
M/H!DDT[Z'=4?LTJ<2JSM.Y9W+,3DEC4L.GSW! B3S2> $.2?PK0U[24TQX\$
MA9"S(O?;G@_EBJ-G=?9)T<$\'-2CGY;2M,74-*NM*D2.\A>WD=!(J.,$J>A^
MAJI7<?$34;76]&\,WMM*)&2V>TF&,,K(Y89'N'X^E</3,Y*SL@HHHH)"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ H%% H ],^(@>^T?2GC=FABM+:-HR.4<QX&,=<[3Q6E\&/ D6IV6KZQJ
M#RPQ6ZB)(4RID!&XY]B,?6L#P99+XNO;>PD>66>6VD*Q0MB0R01LT04^XXQ7
MHW@"^>'X5:A?2QO;E;V2+,C$G  PISZ$D5E)V/4II5*BD>'>))'DUJY+.S@.
M0NXYPN>!1X?MEGUJR21596E4%6^[U[^V<5)XH*2:BTZ<>;\Q [5'I.J/86UU
M';QH+F?:JSD LBC.0,],\<^U6MCDDDJK4ANIZ5=Z; WVF,1CSWB9>X=,9_#Y
MJS:[KXE:=?:';:58:B8I+N16NC-"VY958*%<'W"FN%JC*<>6304444&84444
M %%%% !1UKTWX*?L]>+?CIJ-T-$@M['1-/PVI^(=5E\C3M/4]#+*1RQ[(H+M
MV4U]0^%OA?\ "+X/(@TKPZ/BKXB4?-KOBF-HM,1N_P!GT]3EU'9IV.?[@KGJ
MUZ=!7FSMPV"KXQVHQO\ D?%OA;P+XD\<7?V7PYX?U37[G('E:99R7# GV137
MIMM^Q9\=[R+S(_A)XN"C_GII4J'\F -?4WB+XX_$:]A-@/$USHNC!=L&F:&B
M:=;*O8"* ( ,?6O(?$NIZK+++-)J-[+<.<M(UW(<_7YJ\YYG"]E$^IH\+UJG
MQU$O37_(\0\6?L[_ !1\"VYG\0?#OQ1H]N 29[O29TC&/]HKC]:\]*D=:^P?
M"WCSQSX4,4NA^,M>T9U&[=8ZG*JCVV[L'\16YK'Q5T_X@[K?XJ> M$\>*P"M
MK-K"NE:TO^T+F!0)"/25'![UO''4W\6AC7X9Q5/^%)2_!GQ%17TIX]_9%BU;
M1KSQ-\'M7N/&FD6L1N+[PY>PB'7M-C R6:%25N8QWEASC^)5KYL9=IYKT(R4
ME>+N?*5:52C-PJ1::Z,2BBBJ,@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ZGX6ZN="^(WAN^SA8K^(-_NLP5OT)KZ'\;WVGV%[K7@^_D2UCNKDSV<YP
M%$HSD'V;U]:^<?AWHD_B/QUH&FVZEI+B^A7CL-P+'\ "?PKUG]HB6+487N@5
M-PMXY+ \[23@?K64]6D>CAI<E.3/)O%VD3Z?J#JZDH,G=V-<\H^8?UKH5U+4
MHM+5KN)Y;69'2&9^I(ZX/?'O3/%/AY_#Z:/))(&DU"Q2^*!<",,S!5_)0?QJ
MHZ:&%97?/L6/B$ZQZXEDEPUPEC;0VP8ON52%RRIZ*&)XKF*5W:5V=R69CDD]
MS259SR?,[A11102%%%% !7KOP-^"]EXWM-6\8>,-0GT#X:>'F0:IJ4"!KB[G
M;F.QLU/#W$F._P L:Y=N  >2^$GPOUOXR?$/1?"&@1*^H:G-Y?FR<16\8&Z2
M>0_PQQH&=CV"FO6?VB/'NDW][H7@'P87B^'GA/?:Z6A&UKZ4D"?4)@.LL[#=
M_LH$48 K&I44-.K/0P>$EB6Y?9C:[]=E\SU"'XIR^/=/TS3M.TN#PIX*TJ0C
M1_#%@3]GME/_ "TD;K/.V,O,^6))Q@8%=_X)\+W?CK4_[.M;K3K )&9I+K4)
M5ABC4=RYY[]/\*\*\#O#;:7;Q2(X)7J.1TKI;O5YYF2*-=P3U'/X>E?*5GSU
M.:1^N4\'&-+V6'M&VQZ]=?!?4+J=FAU'1&MWF,:7,FIPQI(V-V%!;()7G# >
MG7BO.+OPO&CF,O%(0W)W##?2LQ+J>'<\K8W?>!';W%5IO$3OD-,3M'&[CO7-
M:[]T]3"T*T/CFI>BL= WAB&V3 !?/+ ,"15671K2W0;D1B6].@K/LM;9PSAV
M&>""W]:MS:J)@@3!8\;<UGK'1G?]6E?<U/#XN?#^LVNIZ/<S6&H6\@F@O+1S
M'+$PZ%6'(-3?&[X"V7[16BW_ (K\+:;#I?Q6LX7NM3T:QA$<'B.)1F2XMXQP
METHRSQJ,2 %E&[()%?B".(E#\N 1C&16YI_B"XMKZVO=/N)+.\MI%GMKB)ML
MD3J<AE/J"*Z,/BIX>::U75'B9KE%/,J?+:TEM+M_P#\]F4J2#V]J2OK']M?X
M46=TFG_%[PW90V>G:]<?9/$.GVB[8K#5MI8R*H^[%<*&D4= ZR#TKY./6OLX
M352*G'9GXC6HSP]25*HK-:,****LQ"BBB@ HHHH **** "BBB@ HHHH *=%$
MTTBHBEW8A551DDGH *[GX;?!?Q-\4&EETJU2#3(6VSZG>-Y=O&?3=C+-_LJ"
M?I7O7A;PEX.^"$ N(IXM>\68XU"90$MST_<H>G^\?F],5$I*)T4Z$JGDCFOA
MQ\.Y_@UX<NO%NO0^7XFN+=H=.TXCY[5'7#2R>CD$@+U )SR>/(/%FO7&H6TZ
M7.=[R \_C7N^I^,+#Q->%-8O3;.0=LS?,A^M<;X@^%^E^(59=*\1:;-<R#]V
MAEVEFSP/YUBI-N[/2=&T.2F'QOT*/P_\%_@U!&@CENM,N;R4]V+R!A^C5Y]\
M2;]-8&AWD7$0LA;+["-L8_45]&_MH?#75M(U;P7H-M"EU:>'/#,<<C1," V,
M$8_X *XWX-^!M*\<_#2[T#7+8EA<&XMKJ%P)K=R,'&>QP,CH<"M825C3,*7^
MT3A#9)+[DD?-]%>C^/O@9X@\%WH6*%]4M)"3');H3)@>J#)_+(KSIXS&S*P*
MLIP01@@UH>&XN.C&T444$A4]A97&I7UO:6EO+=75Q(L4,$*%WD=CA551R220
M !US4%?27@FVA_96^'EG\0-1CC;XK>);0R>$-/F4%M%LFRIU>13TE?E;8'_:
ME[)D ^C_  5\.]"_9,_9?\4N)H[KXL>))Y-"UB]B(*:7%'&DMS80N.K+OC29
MEX\QBF3Y=?!]U<_;?$J@#.&  Q[U]>?&ZTE\#_"[P!X1D+&72_"L%W=M(Y9G
MO+P_;+AF)ZG,RC/7Y17R!X=3[7K;.QY#$@UY"J>TJ5)=%H?HU+#?5<#A:2WJ
MOG?IT_ ]\L-8BL]/CRN9%7:$09).*DLI)[HI* (#Z/U-<7I=\S[(H]H0'."<
MM]:VFU61E"LY<Y^\.!7E3A9Z'U\+Q6AI^(-=^P0L0V]B.<GC-8T.MK<6@:0'
MY3D[>]8>JZF9U,3+\V[/!R*FL-/N?L#W7V6X-LH5FD$1,8#$A<GH,E3CUP::
MII(]S#M1BKFWI^M*UR%R0K=!BNGLKNVEF(4 MP1G@9KSW[2T9C*J'VGJ>U;]
MK>!X20I+D?,O^%9R@GN=U31'HL]QL*Y<%0N21U'M5SP_<I<709@5P<!<?SKA
M#J9%J4:96X'3M74^#[P3'S",X(P3UQ7#.+2L9J+5+4]@T#1K+QOHVN^ M3*+
MI?BVT_L_S'.5@NL[K2?V*3!,G^ZSCO7YJ:OI5WH6JWFG7\+6U]9SO;SPN,-'
M(C%64^X((K]#[*;"&2%F/.58<;2#FOEG]M+18[#X]:IJ\"+';^);6VUY57IY
MD\0,_P#Y'6:O=RFJW&5)]-3\@XJPBA5AB8KXM'\CPNBBBOH#X,**** "BBB@
M HHHH **** "NO\ A/\ #^?XF^/=*T"%S#%<2%[FX'_+&!1ND?\ !0<>^*Y"
MO?OV4U33H_'6MD8FMM-CMHW[KYKY./PCI-V1K2BIS46=?\;/B_:^#M/M_"WA
M:);#2K)/(MX(N  /XB>Y/4D]2:^:I_%6I7-PTTMRSLQR<FK?C[5&U3Q'<NS%
M@K;0:YRHC%6-ZU:7-:.R.JA\1?;K39,WSCC)K2^$V@OX@^+/A#3H07-SJUM'
MCU'F+G],UP8)'2O:/V.X%O?VD_ L4G*B]+CZK&Y'ZBDXVU1T82?ML13A+JU^
M9WO[3WBB_/[4'B_[-?-%Y<4=BBNWRL!&I QTZDC\:\06^U;2];6\@OG@96^8
M1L0,9]*[7XYZ?/X@^,OC-OM*/=?VM<J2A)P%DPH_+TKA]>T/4;?4@DS+YLD:
MER&R"V.?QJ(M)'9BWSUZDFMY,]\TG7K_ ,1^$9K:"Z)U.$"XMG+8+X^\A/N.
MGN*\V\0Z=#\28KA# L/BBW5BCJ-K7.T9,;CN2.AZYP.E6_A;?WUG/#!*?F1Q
MCGJ,UJ>-+"3PG\7M.N(5,<5T5G4C@?3\*T2V9S2C>/O'ST1@^E%='\1M,31_
M'.N6D0 B2Z=D [*QW ?@#75? CX/I\4M=U"]UK4#H'@3P];C4?$>O%-WV2V#
M8$<8_CGE;]W%'U9CZ*Q&AY+5G8Z;X&_#_0?#WAN[^+GQ#LQ=^$-)G-MI&ARG
M:?$FJ ;EMAW^SQY5YW'1=J#YG&/._%OC37/C1\3+C7_$MZ;[6=;O4,\H 55W
M$*J(HX1%7"JHX55 ' K9^.?QAD^+7B2T^PV/]@>#]$MQIWAWP]&^Z/3K-3D*
M3_'*YR\DAY=V)/& .)\,W*67B/2KB0A8X;N*1B>P#@F@1]N?MS:DL7Q0\5P*
M<103FSC'H(P(P/IA*^0_" 87KLJ[LYKZ>_;YN?(^+'BQ W^LU2>48YRK-E?T
M:OF#PS+Y&]UZ],UX5!6IR?=GZWC)QGB<)37V::_)'5JQAO$"N1(^1GTK7COF
MMX88Y>=I[&J6G0F94DD^1CV8<>U59[@,VQ1@*2.O6N:5F?08>TMS2EBCN)-Z
MX!/OR:]*\(1^')[V>VN9(K&R>#,MS)(\4>5555U0$MNW')7YLC. *\DBU%8I
M4P_ER@@AN^?6M77/%NEWE[&UK/.CO&C7'VUUDDDGQ^\8$ 84MD@=0#WI*+?0
M]2K5H2BH.21W?C&Z\+O9+::19E[Q)V<:D)FPT.2 C1L,YX#9R< X!ZBN6^W1
M^4&#*NP88KUK/M[L2HS!QAA]WN*CU36&NC$&$0*1K'^ZB$>X+W;'5O4GDUG:
M[9TN*IQC%.Z[LE?5&\PJ&X)[5ZO\/%:;2W9@,@<>]>+QA9W.T8)Y KU7P)J"
MVUO% 6^7(.TCC\:RJKW= JU.6GH>F6=_%&C( P; !'X5XM^VO8[XOAGJI4;Y
MM(N;(MW/DW<I'Y"85Z5=:E'#<. S9^\,CEJ\Q_;!U(77A?X5PDGS!8ZA<8/]
MUKLH/_11K?+$U6^7^1\#Q3%_4(S?\R_)GS/1117U)^2A1110 4444 %%%% !
M1110 5[C^S]/Y?@7XA+T^2S.?QEKPZO:_@2N/ 7Q!;'WELT!_&6HGK$Z</\
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M1XS\4?:;)XK1?+CCC):1@"20.U?+&I:A*FNR7:2L9XY0ZR$Y(8'(->R^)]:
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MKUK8>&A'I6BG7_#S0C3O$AMG^WQPQ2-)' 3O\IT&XK\T9)3Y<X&*[+P/^T7
MMSKAO_#_ (9T;1[?PYJ-II_AZVLIC8W-S=20>;O!D:0NZQCYMXVB)-NW:* .
M:N/V8O%/]I6UM87NE:M!>7NG6MI>6D[^3/%?+(UO= L@(A_<R*Q8!D9"&4&N
M6\"_"ZY\<7.MO_;.EZ-HNBQ":_UO47D%K$K2".,#RT9W9V("JJ$XR3@ D>G>
M%OVBY+.S\?:_>7=GIVJ7WAM/"VB>&M.LG%M;0DJ%EC=BPC\E5D(+,TC/+G/+
M&O+/AY\2[WX>G58$TS3M=TC5X%M[_2=7C=[:X57#QL=CHZLCJ"&5@>HY!((!
MZ?X@^#UI\-/@#XNN=8DT*X\7KXFM=)4;I9IDM3;FX66U=5\O;*&1]Y.3&,<$
MX/@!ZUW7C;XS>(O'^GZI9:K]C,%_JJ:LXM[<1^4\<'D1Q1@'"Q)%A0N. J\\
M5PNT^E !11C%% !1110 4444 %%%% !1110 Z.-I9%11EF(4#W->S_M1,EOX
MQM-/0X2SMHX%4= %15'\J\ET"(SZ]IL8&2]S&H'U85Z3^TW-Y_Q9U<XP%D*@
M?2H>Z.B&E.7R/*HP0KGMMKVS]FS1!(?$FLRC]U;VZVR9_ON<G]%_6O%XE)BD
M[]/YU] _#MU\._!R IA9M1N)KF0]\#Y%'_CI_.E4=HFN%CS5$^QYY\2K2":_
MEE!^8'CFO.CUKJ/&>I-/=NN<DL37+T4UH+$M<]D%%%%:'&;?ADNMTSH?ND''
MKBN]^.&B"#4-#\56HS;:K;IYA'\-Q$ K _5=I_.O//#MW]FOU4_=<%3^5>J7
M,O\ PD_P4UBW(\R32IXKR,GD@;MC_H_Z4FSLBE*EIT/.?B!:QP^)9KF$8MK^
M-+V+'I(H8C\&W#\*YRNCU=OM_A+1;K&7MFELG/L#O3_T)ORKG*9RRW"BBB@D
M]#_9X\-:1XP^-_@K1=>C6XTJ]U.**:V>3RUN>?EA+=A(VU,_[=>W>$[S7_C
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tmb-20221231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #J 90# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[=^$GPD\-
M>,? \&LZS!J%]J=W>WS37#ZO> N1=S*.!*         *['_AG[P-_P! V^_\
M'%[_ /'J/V?O^25:;_U]W_\ Z6SUZ+0!YU_PS]X&_P"@;??^#B]_^/4?\,_>
M!_\ H'7W_@XO?_CU>BT4 >=?\,_>!O\ H&WW_@XO?_CU'_#/W@?_ *!M]_X.
M+W_X]7HM?/\ ^T%^UQI_P%\?>%O#DWA^YUN"^C2^US48)Q&FA:>]U%:I=RC:
M=ZF:8+@$<*QSQ0!W?_#/W@;_ *!M]_X.+W_X]1_PS]X&_P"@;??^#B]_^/59
M\3?'7P!X-\7VOA76_%FF:;XANO*\NPGFP^9"PB5CT5I"K!%8@N1A037F>B_M
MJ^#/$FDZ;KUC-;67AI]9U32K^]UJX:SFMTL8)99)HH3&QF!6+=MRI5"2>05H
M ]#_ .&?O W_ $#;[_P<7O\ \>H_X9^\#?\ 0-OO_!Q>_P#QZIM7^/?P]T&&
MZEO_ !;IMO';6%KJ<K&7<%MKERELXP#GS6!"*,LQZ U8O?BUHEQ\)=9\?^';
MJW\2:38Z==W\1M9<+.8$<M$6P2C;D*$$94@@C(Q0!1_X9^\#?] V^_\ !Q>_
M_'J/^&?O _\ T#K[_P '%[_\>KRK_AN3PY/:^ )M.L;?7Y/$7A;4/$U_8Z)J
M4=W=Z6;2RCNC:F)1EY'\QHQG9RAX[#EO"W[>VM>(/A=XL\<M\-;6ZTC0]+AU
MH3Z!XJM]4A,!E19H)WCC#6]U'$S2^4RG(C8;AB@#W[_AG[P-_P! V^_\'%[_
M /'J/^&?O W_ $#;[_P<7O\ \>JKX:^-]OXQ^-FJ>!=%T];[3=*T"SUJ\UY+
MD%%DNG?[/;K&%Y+11M)NW#@KP<YK+MOVC(;W]I=?A%#X9U2,KI-SJ,GB"[C:
M"UD>)H,Q6^Y?WV!<+N=2 I^7DYP ;W_#/W@?_H&WW_@XO?\ X]1_PS]X&_Z!
MM]_X.+W_ ./5C>*/VD-"\"_%;Q)X6\3>1H>B:%X9L_$=SXANKG$2K/=RVPC9
M-O&&C!W9.=^,#&:Y'XD_MM^"_#NF^'?^$-NK#QKJ^M^([;PY':+=26T=K)*I
M?S9W$3LB[=I'R'?N!7(!( /1_P#AG[P-_P! V^_\'%[_ /'J/^&?O W_ $#;
M[_P<7O\ \>J;2_CW\/=9\0:OH=IXPTF75-(BGFOH?M 40I 0+AMYPK"(D!RI
M.P\-BN*\0?MI?"G2-"TW5;'Q)%KUO>ZU9Z'MTU'D>"6Y*F-Y5QN6/8V\-CY@
M/EW4 =?_ ,,_>!O^@;??^#B]_P#CU'_#/W@;_H&WW_@XO?\ X]6#%^U#X,T6
MSUZY\7Z]H?AV*P\07VAVXBU'[6\_V4*TC,BH&1U5MTB881C!+8-:?BO]I[X5
M>"+ZUM-<\=:/8375A#JL.Z8LKV<K;8[G<H*B)F&-Y.WD<\B@"W_PS]X'_P"@
M;??^#B]_^/4?\,_>!_\ H&WW_@XO?_CU=7X=\9Z)XLNM8MM(U*&_GT>[^P7Z
M0DDV\_EI)Y;>^R1&X[,*VJ /.O\ AG[P-_T#;[_P<7O_ ,>H_P"&?O __0-O
MO_!Q>_\ QZO1:* /+/@WH]OX:\7?$K1;!KE=,L]6M?L\%Q=2W'E;]/MG8*9&
M8@%B3C.,DGO7J+C*-]*\[^'7_)2_BM_V%K+_ --MK7HK?=/TH \*^#7P:\*^
M)OA)X,U?4[;4+O4K[1[2YN;B36;W=+*\2L[G]]U))/XUV/\ PS]X&_Z!M]_X
M.+W_ ./5+^SY_P D)^'O_8!LO_1"5Z!0!YU_PS]X'_Z!M]_X.+W_ ./4?\,_
M>!O^@;??^#B]_P#CU>BT4 >=?\,_>!O^@;??^#B]_P#CU'_#/W@;_H&WW_@X
MO?\ X]7HM>!?%3]K&T^&7QS\-> 3X<N=3TR[^R#7/$,4P6'1&O)G@L%D3:=W
MFRQLO5=HP><T =Q_PS]X&_Z!M]_X.+W_ ./4?\,_>!_^@;??^#B]_P#CU2:[
M\?\ X>>&O&$OA34O%VFVOB.(#?ISR$R*QC,JQG (\QHU+K']]@,A37FO@7]M
MKP7XZLK'7TGM=%\'3:+>ZO<7^K71AO+46]Y';?-;!#F(F1290^%+*I!R2 #T
M;_AG[P-_T#;[_P '%[_\>H_X9^\#?] V^_\ !Q>__'JG\1?'CP!X3GUB'5O%
M6GV<^D2VD%Y$SEGCDNE+6T8502SR*I957)(&<8K&^+G[0.D_#W]GO6?BQH26
M_C#1[.R2^MA9W82*[C:14RLH# 8W'L<8(.* -+_AG[P/_P! V^_\'%[_ /'J
M/^&?O __ $#;[_P<7O\ \>KSGQM^VEX:\,>)/&5EH]K#XTTSPSX,/BR>^\/:
MA'=&1Q<-#]EVID*0%#ERW"G.W R>6T']N/5KGX:ZMXUU?P'IT6A:5?:9'=:I
MH/BB#5]/^R74ZPRRK/%'Q+;EU:2%E7Y3G<!S0![?_P ,_>!O^@;??^#B]_\
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MCY0(RJD[P20OS4 >A?\ #/W@;_H&WW_@XO?_ (]1_P ,_>!_^@;??^#B]_\
MCU)I'[1?PRUV/7I++QQHL\6A6\EWJ,OVH+'!!&[(\VXX#1JZLI=25##&<\5S
M&H_MA?#*&Z\(0:;KJZX_B771X?@^P1NQMKGRS(1.I ,?&S 89/F*0-N6 !U'
M_#/W@?\ Z!M]_P"#B]_^/4?\,_>!O^@;??\ @XO?_CU<WH7[5G@>'P!X?\1^
M,/$>@>&Y=8%R\4-MJ?VV'RX)VB>42A%S&I5=[E55&;:3QD[_ (B_:2^&7A/Q
M1_PCNK^--+L-8_T?-O+(?D%QCR&9P-JJ^0%8D D@9YH E_X9^\#_ /0-OO\
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M_"/B"UU&\N]7T>[%C=WMU;B+R;)+H_ZH$222$#YF$> 1S7*VGQAU?X9WUO\
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M[D/=BQESQL  /KKP=I&M:+'J$&K7UC>VHG4:<+2U:%XK=8HU"S$NWF/O5SN
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MT#X!_#CPKI6FZ;HW@C0M*L--OTU6T@L[".)8;Q RI<#:/]8 [ ,>0&(KO:*
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M1NM>)M*T&VT+Q1J,:VKZ@DVFLINHK61TMIXVD0>='$_F*DL995)(!YY;X?\
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M_$;P-H?BBRM+6'Q7\/(?%,<-OAC;7<<T<<XW#JDB7$+@'E2I&37T?7E?@O\
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M>T*[FBU&2.UU,->P0SR3PG(D:19'!+$G&.>*^BZ\Q_:$_P"1-T/_ +&K0/\
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MLZ?M"6G[1.E>*M3L= U/P_:Z)K<FCI%JZ>5<7 6&&59FB(#1;EF&$;D#!/7
MY/X3?L._#_X=?"O1?!6L)<>,TTK6'UV'4=2E>*9KPX59&\MAG:BH@!R,*.*]
M+^%WPFM_AAJWCR^M]0FOSXL\02^()DE0*+>1X88O+7'50(0<GGDT =]1110
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M*</_ (?U/N#_ ((^_P#);?BM_P!@:Q_]&M7ZL5^4_P#P1]_Y+;\5O^P-8_\
MHUJ_5BOH*'\*/HC\'SG_ )&6(_QR_,****W/&"OFK_@H/\;_ !5^SU^SC?\
MC'P9=V]GKL.HVELDES;K.FR1R&&UN,X[U]*UG:[X=TKQ1I[6&LZ99ZO8LP8V
MU];I-&2.A*L",B@#\,O^'MO[1G_0P:/_ .":#_"OU4_8$^-/BC]H#]FC0_&?
MC&Z@N]=N[N\AEEMH%A0K'.R*-J\#@"O5?^%(_#K_ *$'PO\ ^":V_P#B*Z70
M_#^E^&-.33]'TVTTFP0EDM;&!88E).20J@ 9/- 'YX>+OC[\1O"WC'QO:S^(
M]5E\/:M\6[/PYHUU;RDMILD-W:-/8D]HI[:61E' !@<?Q"O=/V7_ -KS6_CK
M\1Y= U/2]%M[*]T2XUVUBTJ>22ZTE8K]K3['J 8D"=@ X("='&TXW'Z4E\(:
M#/&Z2Z)ITB278U!U>TC(:Y&,3D8YD&!\_7@<T_2_"^C:)>W]YIVD6.GWE^_F
MWEQ:VR1R7+_WI&4 N>3R<T ?G]\&_C[\7O$.G? Z#5H[VPT;4=2\0HOB^;5T
MO3K9BM=1:))K-%\S;$T:$*2<^2 .2*\]^''QP^(EYX/\976F?$_7O%?B7PYH
M-IXVD6UUF#5M-U&.WO%^TA6C2.6R$D)E4V,T>X?*V?DK]0K;PKHEE'81V^CV
M$$>GN\MFL=JBBV=@P9HP!\A(9LD8SN/J:BTOP3X=T,:@--T#3-/&H$F\^RV<
M<7VDG.3)M4;\Y/WL]30!\L_!WX[>+?%GA+6/%^GZ;XGUX?$;Q%?1>#;A=->[
MTS0;"'9;6L]Z@=6AB=P\S8Y8;NA%>B?L5^(/$WB'X2ZNWB_Q#+XIUZQ\5:UI
MTVIR+L$H@O98UV)D[$PORH"0HP.U>Y:9I5EHMA!8Z=9V]A90+LAMK6)8XXU]
M%50 !["DT[2K+1X9(K"SM[**25YW2VB6-6D<[G<@ 99B22>I)YH MT444 ><
M_#K_ )*7\5O^PM9?^FVUKT5ONGZ5YU\.?^2E_%;_ +"ME_Z;;6O16^Z?I0!P
M'[/G_)"?A[_V +'_ -$)7S]_P4(6+Q!I7@[P]J7A;QE>:*=1:\N-?\,/9+';
MJ;:>"2W<W,J /(DK*"2N ^58LNP_0/[/G_)"?A[_ -@&R_\ 1"5X=_P42;2+
M/X>>"]2U:?33_9_B1+FWL-6\/'7+>\86EPK*]MYD:[4C:24NS841Y'S8H ]'
M_9"M=.MO@Q ^D:)/X=TVZU74;JWTVXGMI6@CDNI'5<6S-%& " (U8[0!DDY-
M>U5Y%^RV+6W^$T=E;_\ "/JVGZG?V%PGAC1/['L4FBN9(Y%2VW,!\RG+!B&S
MN[UOZS\>_AWX>T[Q'?ZCXST:ULO#MS'9:M.]VI6SN' *1.1_&<CY1S[4 9_[
M0G_(FZ'_ -C7H'_ITMJ].KRCXY:C:ZQ\/?#-]8W$5Y9W/B;P]-!<0.'CEC;4
M[4JRL."""""*]7H 0'(R*6OY\/C@MS??'GXJ22ZGJ8V>+M6C"1WLB*JB[DP
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MHIX8=3\#W^OV\!C2X,LA:UD1ED)\D*$^91O)!5LK[_\ L^?\D)^'O_8!LO\
MT0E>2?M[:!HWBCX9^'M+UO5]9LX+K6?*ATSP_:7-U?:G,UG<K''#% 0SM&Q%
MQACLQ =W:@#K_P!CIB/@+HT TFST6VM;BZM[>UL-"FT6'RDG<*ZVD[O*F[&[
M+G<V=Q S7D7C#]BS7?M7CVY\'OX;TD7OC32?%NAZ;,LB6K&UM%AFCN"B$H9'
M:5]RA\D@GECCTO\ 89TJVT;]G/1+:VOHKP_;+YYXH;.XM!9S&YD,EJ8KDF96
MB;*'S"6RO4C%>_4 ?+?B3X&'X9_"+X0Z;)XGUFYE\*WOAC1FM;:Z,6GWC1ZA
M;H99(,'<<DD<\;5]*^I*\Q_:%_Y$W0_^QJT#_P!.EM7IU '\^?QE_P"2[?%;
M_L<=7_\ 2N2N3KK/C+_R77XK?]CCJ_\ Z5R5R=?+5_XLO4_I?(?^17AO\$?R
M/T)_X(T?\?\ \</^OK2?_1=U7Z7U^:'_  1H_P"/_P".'_7UI/\ Z+NJ_2^O
MI*/\./HC^>\T_P!_Q'^.7_I3"BBBM3S HHHH **** "OYP_VV?\ D[GXO?\
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M444 %%%>-^-?VQ/@O\./%-_X;\3?$71=&URP94NK&YE821,5# , O]U@?QH
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M"(/AQIFI0Z!JMQIR7DFIR(TRQN5#E1&0"<9QFOI*/\./HC^>\T_W_$?XY?\
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M@IF;33LSYJK]#?\ @B=_R<7XT_[%23_TLMJ_/*OT-_X(G?\ )Q?C3_L5)/\
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MP_\ 1LU?F/7Z<?\ !#W_ )'7XK_]@^P_]&S5J>8?KA129I: &APW3/Y4N:_
M+X[:SKD_Q]^*FWQ/X@MXHO%FJQ1PP:G*D<:"Z<*  W 'H*XC^U-<_P"AL\2?
M^#>?_&N&>,I0DXN^A]EA>$\QQ="&(I\O+))J[Z/Y']&F><5_.'^VS_R=S\7O
M^QEO?_1IK]'_ /@CKJ^I:C;_ !BAU#5;_5$MKS3%A-_=/.4!CG)P6)QD^GH/
M2OSA_;9_Y.Y^+W_8RWO_ *--=D9*24EU/E*]&6'JSHSWBVGZIV/$Z_3?_@A[
M_P CQ\5O^P=8?^C9J_,BOTW_ ."'IQXW^*V?^@=8?^C9:HP/UQHI"P'4@4M
M!1110!YM\&_^0I\2O^QLG_\ 26UHH^#?_(4^)7_8V3_^DMK10 []GK_DDVE_
M]?5]_P"EL]>CUYQ^SSS\)M*_Z^;[_P!+)Z]'H *\L_:5^%^K?%SX5SZ)H4]G
M#K-OJ6GZM:+J)86\TEI=Q7(BD902JOY6W< <9S@UZG10!\V^%_V0Y+GX'>$O
M WB/QKX@TTZ;;R"^M_"UZMM:7$LERUR?OQ,S!';:I^7(7)'.*ZC_ (9JO/\
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M\(==^,'@C0;;PU+IPUG0O$%GKT%MJS.EM=>3O!B=T5BF1(3NVMRHXYR/9J*
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M@E<ZA<> O&/CWPI/J")'=OI^KP@S*A)4-N@/0L?S-8W[//BKXJ^,OCKX:O\
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MT#_H.:;_ .!<?^-)_P )EX?_ .@YIO\ X%Q_XUB_\*6^'O\ T(?AG_P3V_\
M\11_PI;X>_\ 0A^&?_!/;_\ Q% &W_PF7A__ *#FF_\ @7'_ (TG_"8^'Q_S
M'--_\"X_\:Q1\%OAZ/\ F0_#/_@GM_\ XBC_ (4M\/?^A$\,_P#@GM__ (B@
M#;_X3'0/^@YIO_@7'_C1_P )EH'_ $'--_\  N/_ !K%_P"%+_#[_H1/#/\
MX)[?_P"(H_X4O\/O^A$\,_\ @GM__B* -K_A,M _Z#FF_P#@7'_C1_PF6@?]
M!S3?_ N/_&L7_A2_P]_Z$3PS_P"">W_^(H_X4O\ #[_H1/#/_@GM_P#XB@#:
M_P"$RT#_ *#FF_\ @7'_ (TG_"8^'_\ H.:;Q_T]Q_XUC?\ "E_A]_T(GAG_
M ,$]O_\ $4?\*7^'W_0B>&?_  3V_P#\10!L_P#"8^'_ /H.:;_X%Q_XT?\
M"8^'_P#H.:;_ .!<?^-8W_"E_A]_T(GAG_P3V_\ \12?\*6^'O\ T(GAG_P3
MV_\ \10!M?\ "8^'_P#H.:;_ .!<?^-+_P )EH'_ $'--_\  N/_ !K%_P"%
M+_#[_H1/#/\ X)[?_P"(H_X4O\/O^A$\,_\ @GM__B* -K_A,M _Z#FF_P#@
M7'_C1_PF6@?]!S3?_ N/_&L7_A2_P^_Z$3PS_P"">W_^(H_X4O\ #W_H1/#/
M_@GM_P#XB@#:_P"$RT#_ *#FF_\ @7'_ (T?\)EH'_0<TW_P+C_QK%_X4O\
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M_!/;_P#Q% "^%!X"\"Z6VF^'9/#^B6#3/<-;6$D,*-*YR[D*1EF/))Y-;/\
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<M;I8Z+IUII%D,N+:P@6",,3R=J@#)]:*0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tmb-20221231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &+ <<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z^*OVB?
M^"DT7P!^+^M>!6^'4VO'35A;[?'K"P"3S(U?[AA;&,XZGI7VK7XH_P#!1/\
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M(S#Y,J2 1CDJ*Y[]H/Q)\-?#/[26BZQX*TS0M7\/V"64NKV.G6ZR:5=7*_\
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MU;5['2[>X<1PRWMRD*R.1D*I8@$D=A39O%FAV\6HRRZSI\<6FE1>N]T@%J6
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ME!_\57[6T4?VCB._X!]3H]C\4O\ AW;\?/\ H3(O_!E!_P#%4?\ #NWX^?\
M0F1?^#*#_P"*K]EY_%NAVNMPZ--K.GPZQ,,QZ?)=1K<./58R=Q_ 5;U75[#0
MK"6^U*]M].LHAF2YNY5BC09QRS$ 4_[0Q/?\ ^IT3\7?^'=OQ\_Z$R+_ ,&4
M'_Q5'_#NWX^?]"9%_P"#*#_XJOV3N/&OAZST.+6I]>TR#1IL>7J,EY&MN^3@
M8D+;3T/0U+?^*]$TO28M5O=8T^TTR7:8[V>Z1(7W?=PY.TY[<\T?VAB>_P"
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MWN=7,'^CVA=7:)4ABB0[F1"S,K,=BC..*[&#2;&UB>*&SMXHG&UD2)55AZ$
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M!DGNUGW)"RJ&FWLD87(]\#)JO92M_7]=1>TB:W_#,?P]_P"@?JW_ (4.H_\
MQ^C_ (9C^'O_ $#]6_\ "AU'_P"/UD?$CX\#3_"%U>:-'J&G:OIFM:99ZAI]
MW8[KE(KBX1<"/YMV]"P4KGH>A%=E8_%W2]1M-2,&FZR^I:?<QVMQI L6-VCN
M@="5!*A2ISN+!>",YXJ?9R2O8?/%NQB?\,Q_#W_H'ZM_X4.H_P#Q^C_AF/X>
M_P#0/U;_ ,*'4?\ X_56'XQ_\)3XX^'$?A^Y=-%UF;5[;4+:X@"S+-:)M,;
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MKJQ6V9K"[M"MQ*+B7RH#&H)#;Y/E'(P>N*7LYOH'/'N5/^&8_A[_ - _5O\
MPH=1_P#C]'_#,?P]_P"@?JW_ (4.H_\ Q^MB\^,6DV5UIEF^F:TVI7T$MU]@
M2P8W$$,4GER22)UP&Z;=Q;@J"",Y.F_%JQT=]>2_U:[\0W?_  DDVD65A:::
M(YHW6&.3[,@#?O0BEG,K%>"<XQ1[.78.=#?^&8_A[_T#]6_\*'4?_C]'_#,?
MP]_Z!^K?^%#J/_Q^K=Q\??#,%EILH@U2:\O]2ETB/3(K%FNDNXT9VB=/X3M4
MG).W!!S@UT7ASXBZ)XE\)W/B*&=[33K1IX[O[;&8GM7A9EF213]TJ5;/TI.$
MDKM#4HO9G)?\,Q_#W_H'ZM_X4.H__'Z/^&8_A[_T#]6_\*'4?_C]2'X^:/=:
M;<R6FG:M%>R:5-JVFP7UD8?[1AC ):+)&<;D)4[6VMG'7&5X"^*MUH_[.A^(
M?BJ?5+^5--.K7"7EO! W^J5O*@6)5'EEN$+[F^;EC5>RE:]B>>)H_P##,?P]
M_P"@?JW_ (4.H_\ Q^C_ (9C^'O_ $#]6_\ "AU'_P"/US7Q"\9?%/P=\$O%
M_C*]U#PW#-!X?N-1M;73]/F6;3IQ'O16DDED2Y Z$^7%R,XYQ7:>%_C3I.N1
M7EI)::M%K-AIUOJ,MA-I[K/<0REE26*,<LK.C+VP1\V*'3E;F6H*:O9E#_AF
M/X>_] _5O_"AU'_X_1_PS'\/?^@?JW_A0ZC_ /'ZN7?QZ\.:?HUW?WEMJMK)
M:ZG#I$U@]DS72W,H4Q)L4G.X,I!!QS0WQ[\-K:+N@U-=5;5/[&71#:'[<UUY
M1FV"/.,>4#)NSMVC.>E+V<^P^>/<I_\ #,?P]_Z!^K?^%#J/_P ?H_X9C^'O
M_0/U;_PH=1_^/U-I/[07A[7M'T^^T[3]:O);[[28;"*RS<^7 _ES2,F["JK@
MIR<Y& *[KPOXET[QCX?L-:TF<7.G7L0FAEP02#V(/((.00>A!I.$H[H:DGLS
MS_\ X9C^'O\ T#]6_P#"AU'_ ./T?\,Q_#W_ *!^K?\ A0ZC_P#'Z]4HJ"CR
MO_AF/X>_] _5O_"AU'_X_1_PS'\/?^@?JW_A0ZC_ /'Z]4HH \K_ .&8_A[_
M - _5O\ PH=1_P#C]'_#,?P]_P"@?JW_ (4.H_\ Q^O5** /F'X3_L[>!K_Q
M?\48I['4V2T\1+#$%UV_4A?L5LW)$P+'+'DY/;H!7I7_  S'\/?^@?JW_A0Z
MC_\ 'Z/@U_R.OQ<_[&9?_2"UKU2@#RO_ (9C^'O_ $#]6_\ "AU'_P"/T?\
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MDBC:RDG^7IW[0GQAUWX<Q^#M$\(:=8:CXM\7:H-,T\ZLSK:6X"%Y)90A#,
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M%S_$/_H@7B[_ ,'6A_\ R=0!['17CG_"Y_B'_P!$"\7?^#K0_P#Y.H_X7/\
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M0_\ H@7B[_P=:'_\G4?\+G^(?_1 O%W_ (.M#_\ DZM?:SO>_D1R1['):_\
ML@7.M^+-:9/'=Q:^!=;U^+Q'J/A@::C/+=(ROA;G?E49T5BNP\CK6IXW_9J\
M1>-XK:[N?B7=)XBTCQ)+KWA_5&TJ-UTV)@5%HT6\"5 IQG*DX' Y%;/_  N?
MXA_]$"\7?^#K0_\ Y.H_X7/\0_\ H@7B[_P=:'_\G57MZFFNWDB?90['%Z-^
MPMX8BT^2YUKQ+K^H>+[B[OK^Z\0Z;>2::TT]T5\T^7$_"?(HV[CWYYK-\/\
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M;GA ;#7'R09QENF?O',&C:/XH@^,MIX!O)KZXT*]N8/'GFM*5:(+%LDLW)Y
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M1^7J:_:CMC5<#[0I\O@#>,KZU@?%[0M;\!>!_%]YIT&LZ99W/P[MKB]NC).
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M&'2)K^);N0'D;82V\_@*T/$'B/2?">E3:IKFJ66C:;#CS;S4+A((8\G W.Y
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MZ+_(GVJT74^GM?\ '7AOPI>V%GK?B'2M&O-0;99V^H7L4$ERV0,1J[ N<D#
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MPHHHH **** "LV+P[ID'B"XUQ+*)=7N+=+26\Q^\:%&9E3/H"[''J36E13N
M5R>L?"GPEK^L2ZIJ&AVUS?3%#,[;@LQ3[ID0':^,#[P/2NLHH3:V$TGN'2BB
MBD,*S?$7AW3/%NB7>CZQ91:CIEVGESVLXRDBYS@C\!6E11MJ@"BBB@ HHHH
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MX)/F;9V)65@HHHJ1GE?[,7_)&]._["&J?^G"XHH_9B_Y(WIW_80U3_TX7%%
M'JE>%>"_B+X5\)_%_P"+=KK?B32=(N7U.R98;Z]CA<C[##R S XKW6O&/A[X
M8T;6OBU\7)=0TFQOI5U2R4/<VR2,!]AAXR0: .P/QM^'9QGQUX;./^HK!_\
M%4?\+L^'.[=_PG/AO=Z_VI!G_P!"K8_X5_X7_P"A;TC_ , 8O_B:/^%?^%_^
MA;TC_P  8O\ XF@#&/QK^')SGQQX:.>O_$T@Y_\ 'J4?&SX=#&/'/AL8Z?\
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M>O#G_@U@_P#BJU_^%?\ A?\ Z%O2/_ &+_XFC_A7_A?_ *%O2/\ P!B_^)H
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M[_AW_P!#UX<_\&L'_P 56O\ \*_\+_\ 0MZ1_P" ,7_Q-'_"O_"__0MZ1_X
MQ?\ Q- &1_PN_P"'?_0]>'/_  :P?_%4?\+O^'?_ $/7AS_P:P?_ !5:_P#P
MK_PO_P!"WI'_ ( Q?_$T?\*_\+_]"WI'_@#%_P#$T 9'_"[_ (=_]#UX<_\
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ML_PI\=]8L+V7P9JUC_PDWC:WUJ?1K:6S"VD5]%# DYNI-Q*Q$12+O"Y&\X4
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M@9&#G+-;_:T\?:M\ 4M]'U*SL_B7:6VL7FHZK';1M'%:::TJM/Y3J4#3-$J
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M_P"Q1=#$X&,>HKZ.KROX5_\ )5?B]_V%;+_TAAH J>1\?/\ G]^''_@'?_\
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M235=)F=HUF5&0AU.&5E8!E8'J" :Z6H::=F4FFKH\@\CX^?\_OPX_P# ._\
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M-(/_ (NI^L/L/V2[GB\'@CPI%\6? ?B2V^'E];^'3:7]E;&ZT"65[2X-W%)
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M?Z];Z]X5@UJ_CCANK^._MQ-.B?<5WW9(7L#TK5_X6QX(_P"AR\/_ /@T@_\
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MP_\ ^#2#_P"+H_X6QX(_Z'+P_P#^#2#_ .+KBD^9MG4E96.KHKE/^%L>"/\
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M3Z'T]_PJ+P+_ -"5X=_\%4'_ ,11_P *B\"_]"5X=_\ !5!_\17AR_%#XC?
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M!R7_  J+P+_T)7AW_P %4'_Q%'_"HO O_0E>'?\ P50?_$5UM% ')?\ "HO
MO_0E>'?_  50?_$4?\*B\"_]"5X=_P#!5!_\176T4 <E_P *B\"_]"5X=_\
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M-&SXV?\ /7P+_P!^[S_&@#U6BO*MGQL_YZ^!?^_=Y_C1L^-G_/7P+_W[O/\
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ML"(]W]H7&=N><?6B@#UZO*_A7_R57XO?]A6R_P#2&&O5*\K^%?\ R57XO?\
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M&O>()[5+[1]5BBCOXD\W)N8!;D;%*;?+5E)V[MPSBN\\-?M?ZGK>J^%;VZ\
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M7AD8'YEWDD9Y&3@C-9WQU^(]_P"!]7\"6D&M1>'+'6;Z>"]O9;5;AHT2W>0
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MU*R4VVE_9_+8_8HOF/F1.<_C7T17E?PK_P"2J_%[_L*V7_I##0 ?\*8\0_\
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M1J]4I&944LQ"J!DDG  H \L_X4QXA_Z*WXR_\D?_ )&H_P"%,>(?^BM^,O\
MR1_^1J]'CUO3I;$WJ7]J]F#M-PLRF,'.,;LXZ\5=H \K_P"%,>(?^BM^,O\
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M]JLC1W32?\)2R1H2C\ +)$=LGS;FPYP< U[QX:^)/Q=U;1[Z];PC9S+/H?\
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M"@*5 *\XZFK:_LE^'8OAYX"\#)JM\WACPOJ:ZK-9S!9/[4E$C2XG)_A,CLQ
M'?'2K=2CI;OVZ?=]WZ$J%7KV[GH/P:OO%&J_"WPU?>,_)'B>ZLDGOD@B\I$=
MANV[>Q (!]\UV=%%><W=MG8E96"BBBD,\K_9B_Y(WIW_ &$-4_\ 3A<44?LQ
M?\D;T[_L(:I_Z<+BB@#U2O%4T3XE>#OB/XXU/0?#VA:SI.NW5O<PR7FKO;2I
MLMTB8,@A8=5/>O:J* /*O^$F^,/_ $(OAG_PH9/_ )&H_P"$F^,/_0B^&?\
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M^1J/^$F^,/\ T(OAG_PH9/\ Y&KU6B@#RK_A)OC#_P!"+X9_\*&3_P"1J/\
MA)OC#_T(OAG_ ,*&3_Y&KU6B@#RK_A)OC#_T(OAG_P *&3_Y&H_X2;XP_P#0
MB^&?_"AD_P#D:O5:* /*O^$F^,/_ $(OAG_PH9/_ )&H_P"$F^,/_0B^&?\
MPH9/_D:O5:* /*O^$F^,/_0B^&?_  H9/_D:C_A)OC#_ -"+X9_\*&3_ .1J
M]5HH ^?O!6G?&3PGKGC&_;P=X8G&O:H-15!X@D'E 6\46W_CWY_U6?QKK/\
MA)OC#_T(OAG_ ,*&3_Y&KU6B@#RK_A)OC#_T(OAG_P *&3_Y&H_X2;XP_P#0
MB^&?_"AD_P#D:O5:* /*O^$F^,/_ $(OAG_PH9/_ )&H_P"$F^,/_0B^&?\
MPH9/_D:O5:* /*O^$F^,/_0B^&?_  H9/_D:C_A)OC#_ -"+X9_\*&3_ .1J
M]5HH \J_X2;XP_\ 0B^&?_"AD_\ D:C_ (2;XP_]"+X9_P#"AD_^1J]5HH \
MJ_X2;XP_]"+X9_\ "AD_^1J/^$F^,/\ T(OAG_PH9/\ Y&KU6B@#RK_A)OC#
M_P!"+X9_\*&3_P"1J/\ A)OC#_T(OAG_ ,*&3_Y&KU6B@#S_ . _A'6? WPO
DTS2/$$=K#JZ3WD\\=E,98E,MU+*H5RJDX60=ASFBO0** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tmb-20221231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #G <$# 2(  A$! Q$!_\0
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MO[K?E3N.T3M?^%V^.O\ H9+O\E_PKH%\9_%"30(=8C\1^=93-Y<2Q7,+S.^
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M."/D7G)&&,UY^RI\.;VSO;1M(\116MXFH1R10O*H1+RX@N)E3Y>!OM8=O]T
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M3_GSM_\ ORO^%,_M'_ISO_\ P#D_PH_M'_ISO_\ P#D_PH ?_9]I_P ^=O\
M]^5_PH_L^T_Y\[;_ +\K_A3/[1_Z<[__ , Y/\*/[0_Z<[__ , Y/\* '_V=
M9_\ /G;?]^5_PH_LZS_Y\[?_ +\K_A3/[0_Z<[__ , Y/\*/[1_Z<[__ , Y
M/\*!W'_V=9_\^=M_WY7_  H_LZS_ .?.W_[\K_A3/[0_Z<[_ /\  23_  H_
MM#_ISO\ _P  Y/\ "C00_P#LZS_Y\[;_ +\K_A1_9UG_ ,^=M_WY7_"F?VC_
M -.=_P#^ <G^%']H_P#3G?\ _@')_A0.X_\ LZT_Y\[?_ORO^%']G6G_ #YV
M_P#WY7_"F?VC_P!.=_\ ^ <G^%']H_\ 3G?_ /@')_A0%REX@L+5=%NV%I;J
M0HP1$N?O#VK2?3K3<?\ 0[?K_P \5_PK+U^_W:-=+]DOAE1RUI(!]X>U:#:D
M"QQ9W_7_ )\Y/\*!#O[/M/\ GSMO^_*_X4?V?:?\^=O_ -^5_P *9_:/ _T.
M_P#_  #D_P */[1_Z<[_ /\  .3_  H ?_9]I_SYVW_?E?\ "N%^*OBRY\ :
M9876F^'=+UN:]OH--@L9KC[-+/<S2!(TCQ"X(QO=BQ4*J$\UV_\ :/\ TYW_
M /X!R?X5C:UHNGZ_JV@:C>V.J-<:'>/?V02WD51,T,D)9ACYL)*^ >A(/:@#
MG/!'Q+T?QW\1?&OA>PT=/(\,K:!M5:)/)O9)C.KB(;<E8W@9"W0L& ^[D]__
M &=9C_ESMO\ ORO^%<9X6^&_A/P3XLUCQ%H7ANXTO4=5MX+6Y%M9.D12)I&7
M:@7"DM,Y8]SCTKL#J/\ TY7_ /X!R?X4 /\ [/M/^?2W_P"_*_X4?V=:?\^=
MO_WY7_"F?VC_ -.=_P#^ <G^%']H_P#3E?\ _@')_A0 \:=9Y'^AV_\ WY7_
M  K/T*PM6L"3:VY/GS<F)?\ GHWM5T:C@C_0[_\ \ Y/\*H:'?[; C[)?']]
M,>+5S_RT;VH TO[.L_\ GSMO^_*_X4?V=9_\^=O_ -^5_P *9_:'_3G?_P#@
M')_A1_:/_3E?_P#@')_A0.X_^SK/_GSM_P#ORO\ A7)_%/QCI/PM\#7_ (CN
M],BNU@D@MXK=(E4RS3S)!$N0I(!>1<D D#. 3Q74_P!H_P#3G?\ _@')_A6/
MXMT73_&F@7.D:G8ZG]EF:.0/!;R)+%)'(LD4J-M^5T=%8'GE1D'I0%SR2V_:
M3T>36;*SF\/:?%"+BTM+ZX-V@*R7-]+91"WB:(/+MEBS*K"-XPZAEW9%>['3
MK,$_Z);<?],5_P *\RM/@EX1MM1TZ\>PUZZEL[PZDPND>1;F[,YG^T2C9]_S
M6W'9L!VH""$4#TK^T?\ ISO_ /P#D_PH$/\ [/M/^?.W_P"_*_X4?V=9_P#/
MG;?]^5_PIG]H_P#3G?\ _@')_A1_:/\ TYW_ /X!R?X4 /\ [.M!_P N=O\
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MNF0C_M[_ /L*+H#=P*,"L(Z[J/\ T#8/_ O_ .PIO]OZE_T"X?\ P+_^PHT
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M .PI5UW43UTR$?\ ;W_]A1= ;N!69&H_X22?_KTC_P#0WJK_ &[J'_0-A_\
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MC(L*<#"X58P,   >@%%T!VV!1@5@_P!O:C_T"X?_  +_ /L*/[>U'_H&0_\
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M$GS8\^WET]B8F *(V%!^7%?<=_87&F65Q=W?B#[-:0QM)-/-%&B1QJ"69F/
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MW]C<:78W-W>>(1:V<"--//-%&D<: 99V8\   DD] *YKQ'X[\-^$;*PNM?\
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M_P (]>_]!9O_  &2C_A'KW_H+-_X#)18!M%._P"$>O<_\A=O_ 9*0^';T_\
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ME+VY8JLR[7.8RP(#="01GBBX'H%%<G_9%L"3NN/_  )E_P#BJ/[*M_6X_P#
MF3_XJBX'645R?]DVW]ZX_P# J3_XJC^R;;UN?_ J3_XJBX&OXG'_ !)+O_='
M_H0K4 Q7"Z_I=NFBW;*9\A1UN)#_ !#_ &JT&TFW#$ W'7_GYD_^*HN!U=%<
MD-'MA_%<_P#@3)_\57*^-_&F@_#Z))]5@UI[01/<3W=HLTL%I$KHK23/N 49
MD7@98@,0I"G!<#U>O/?BIX1U#QS/X5TM$5M CUJ*^UI&?;YMO CRQ1[?XPUP
MMOD=U!SQ63X1\=^&?&^J75CI<FI>9"DDL<MRTL45U"DQA>6%BV&02*5)..QQ
M@@G!N_C9X%L;>SOKV;5[/1KR%YXM:N(ITLBBQ33?ZPMSF*WDD& 1MVYP64$N
M!J?"3PEK</C[Q%XD\0^'$\.7$L7]FZ996,T#6D%BD\DB_P"K;+32O(TKL54#
M<JC.&9O8J\>TCX@>']:\/:KJUO9>(%DTR2.&YTIX9_MZO(B/$HA5B3O66-@<
MXP3DKM;&!;?M ?#VXU4Z=]KU>*^03I-!(LVZ&>)IE>V;#G]\6MY@%7()48/S
M#)<#Z HKSVVU/2;GQ'=:%F^AU2VMHKQX)II5S#(S*KJ=V&PR,K8Z''J"=;^R
MK;UN#_V\R_\ Q5%P.LK,\/?\@T]OW\__ *->L==)MLCFX_\  J7_ .*K/T/2
MX&L"6:<'SIAQ<2#_ ):,/[U%P.[HKD_[)MC_ !7'_@5+_P#%53U@Z7H&E7>I
M7]Q-:V-I$TT\SW,I"(HR3@')^@R3VYHN!W%>>_'GP-??$7X9ZCHNG,_VIKFR
MNQ%'-Y+3K!=Q3O").B%UB*!CP"W/%<CIGQ@\):M:>&;VV@\0G3?$*6CVFHRP
M3QVZ-<LR6\<C,^5=F0C: 2N5W;=PJYXS^*/@KP%%K<FMWU];QZ,EL;UX3/+L
M>X)\F(!22TC ;MH'"D$D T7 RO WPP\4C7/!_P#PD<4;:)I-YJ^LBWDG266*
MZFF L4F(!\Z2.&6X+2Y)W[3EB-Q]X Q7E*^+-(/C^/P=)I^NPZK):S7J3R%O
MLQAB949RZRDJ"SA5W*-QR!T..<\4?'GX>>#M1\36%[J.HS7GAR2TBU*&T\Z4
MPO<12RH@.X L(X)'8=5 '<@47 ]ZHKRN+QKX:FMM-NDGO_L.HZF=(M;PO*(9
M;CY@,-N^XS*R*_0L,=Q74?V3;C^*X'_;S+_\51<#K*S(_P#D9)_^O2/_ -#>
ML;^R;8][@?\ ;U+_ /%50CTJW_MZ=<SX%K&1_I,F?OOWW47 [NBN3_LBV_O7
M/_@5)_\ %4C:5; =;G_P*E_^*HN!UM9^O:'8^)-(O-,U.V2]T^[B:&XMI1E)
M48896]01P17CWB/XU_#[PJ_C5-1U:]5O!T-O-K'D?:)?*,X9HHDVD^9(0ARB
MY(R,X[='XC\4:!X6L],N+QM2E.I%OLMO:&:>>0+"TSD1JQ)"QH2< GH.20"7
M \MB^!_B1_ 7PX\*R>&[.&71K?3UN]0@OXTC'D"5'AF4)O=421O),9(5Y"Q"
M[?F[G]G7X;^)/ T.M3^(O+MS<PZ?9VEFAB)BCM;8198Q#:23P#U*JI(3.Q<;
M4?CSX%T7S%U-=>TVZ@D=+RUN(9A+8J@MRTDP60@(!=V_W2Q_>=.&QT7C;Q[H
M?P\U/3K/5K'7=E_/]GAN[3?+"'$<DC[L2[P$CB=V(4@*,T7 ]>HKQ?P9\5O"
MGC_1Y=1T--;O(X;.6]EA"3>;&B' 5EWXWOR47)+ 'TKL-%DTGQ%H]CJNG7,M
MUI]] ES;SQW4A62-U#*P^;T(HN!W%9.O]=-_Z_8_ZUE?V3;>MQ_X$R?_ !55
MKC3X8;W2Y(_-R+R,?/.[#HW8DBB]P.PW44N312 \E^,/A*R^)G@GX@>"KG5X
MM'_MZU>P>Z=0[0K) B[]A(W8],CZUY[J_P"S!\.9M2\(OH0TGPKIFB#4C<66
MEP1HU[)>67V0R^9G*21K\RMAN@'%>ZZOXETCP3H_BOQ#KEU%8:1IF^\N[N52
M1%%' C,Q !)P > "3VKDO#/[1W@G6]$U75=8-[X$M-,E@BN6\:63:2!YR[H2
MKS81@XS@!B01@@'BG8#Y5T[_ ()V^&-.\.C2E\>6&_\ L[4-.-PFEKAEN-/6
MRBD8/.Q,D8!<D$ DX41@"KWBS]@S3?$3W\5O\3K?3M,N]3;4VT]-+C,<3F.Q
M53&5F7# V(SG*D2'Y=P#5];:O\<?AEX?O9[/4_'GA;3KN");B6WNM6MXY$C9
M597*EP0I5T(/0A@>]9_C+]HCX:^"--\27%YXITF\N_#UC+J.H:3I]U%<7T4$
M:AG;R%;?P&4].XHLP/F?Q!^Q2NKV&I:?9_%#3]/T[4#>6\\7]B1N[6<VJ+J:
MQ;Q./WB3!E\S&"A4;05R;OB/]B#PIXB3PEYWB^SW:-=:E+="2S!2]CO-1^VM
M\JS+ME4@1B1O,! !*9"X^A_&G[1OPS^'^CZCJ.L^*]*MX]-EM8;VVCG1[BU>
MX=5A$L8.Y,EP26   )/ -;LWQ?\ A]#8ZO>R>,_#:6>D2)%J-PVIP".S=SA%
ME;=A"QX ;&3Q19@?,/AC]F6/P[\:O!.J-JMG<^%_#UO>7U[=M<HIU6_>]N;B
MQ1K<9(^R_;+@B1F.XE< $&K/Q1_9&L/B/XS\1:O%X^LM,T_7+V75+BT?2XKB
MY2Z?2Y-..RY,BL(?+</Y6W&Y3S@C'OOA?]H'X>>)_A9H_P 17UVQT/PGJK,M
MK?Z[(EDKL)'CVYD(&28W(&>0,U#HG[0O@OQ#\2$\$6+W,VMO/>0(1:GR&:VA
MMII2),X*E+R$J?XLGTHLP/F_4?V'='U&^UR3_A8L%G;:EH\.GF&UTR-6DFB6
MU$<TY,I650UHIV*J%@Y5W;:#6MJ_[(UMXBUE-1U3X@:4'OS9?VVFG:#;V@G^
MR7\E[!]B*R9LR7D*R-^\9P,DACFOI#_A>'PTSJX/COPP#H^/[2!U6WS99D\H
M>=\_[O\ >?)\V/FXZUF>*OVC_A=X1\.:YK5WXTT.XMM%T]=4O8;&\BN;A+9P
MIC<1(2Q#[TV\<[U]119@?.>G_L4:1HNC>'X--\=:=!?Z-:Z9%%<2:3&\4T]G
MJ<]\)I8Q*-P?SS&5W< 9R<XJ7PU^Q3X>T'3-*M9/&UK=S6%QHDRW7V"-9=NG
MW%U,44^82OF_:BIP?EV X;.!]2:=\6_ 6JSW,%IXN\/SW-K8KJ5S FHP&2"U
M9 XF=0V5CVL&W'C!!SS3;?XO_#^]BT*6W\9>')H]>D:+2'34X"-0=6VLL!W?
MO"&X(7.#QUI68'QI??\ !/ZRUFSMH]5^*-GJ,^FV6F:;I@;2?*MTMK**YAC%
MQ''<J97,=T?F5DPR X*DK7?> /V2]'^&_P 2O#FOZ5XWLVT/1=0?5(M*FTZ+
M[2T[Z:M@Z_:Q)D0[8U=8PF%.1D@#'O\ HWQP\"ZK\.;/QU<ZS::#X9NI9($O
M=<=+)1(DSPE29" "7C; SSBM0_%+P*+ZZLO^$LT#[7:6/]IW$']HP;X;3:&^
MT.N[(CVLIWGC# YY%.S ^;F_9&\,7WQ$UWQ-?>+()X-6O]?O'M(K:..2$:I:
M6]LP27<<-$+<LK[>3(>!CGEQ^PUI%TL<VI?$*PN]06SDT\M;:/#;VWD#29M-
M@(@$I E19C(TF?F*A0$ &/KFT^*?@6_;0UM?%>@7+:[O_LH1:A"QO]IPWD8;
M]Y@@@[<X/%4#\<?AF-(?5CX[\+C2X[O[ ]Z=6M_)6YV[O)+[\!]O.WKCFBS
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M^5&#  J?>/@?X6UGX=Z7+X2U'Q!;:_I.@VEC8:?<%%2]8K /.>X520-SX*#
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MEL;BW6.6UF@NOLT\<A7@[F88ZC,3X)!%>NU@Z/X&T30-7GU+3[&.TN9;6&Q
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M,6J?MQV-QXNLM+T7PCJ:V%Q;V;2ZAJT/E&VN)=7_ +-DMY8D8E6217 8%@7
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M:7*_^7G<IT:,7RML]T'[/WPCBU;5=2@\*ZK9WFI&8SR6>H7,.PRR1RR-$%G
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M^J7_ (#+_P"3']3IG3?\)K:?\^MY_P!^U_\ BJ/^$TM/^?6\_&-?_BJYG(]
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M6_\ ?\@>$A>USL/^$UM/^?2\_P"_:_\ Q5*/&EH?^76\_P"_:_\ Q5<P1@]
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M]-_:%UF1O$S>'-:L_&J6;745P-/6!3?_ /"+O%ED/R-_IF$ 8%0Y  QBMJ7
MW#]":J4L/:2V:G->7\W9V%[>H^I]DZ'\,1X;TJVTS2DTVQL+9%2*&&-E
M)]3@#YCDGN:D;X<-(TSM'I;23[1*S6Y)E"G*;SCYMIY&>G:OGFP\6?'[QQXM
MEN-.M_%'AO0T-]<VEIJFC6]J;EX=+LVMK>8R(3'%+>FZ&<AB-P!7C'IO[(NK
M_%/6? 6IS?%5[Q]5%Z@M#J.EBPN!&84,JE %W(LI<*VT9YP6 #'%\ \.2DYR
MPVKW?/.[_P#)@^L5.YW0^',@%ROEZ9BZ):X7[.<3DC&9!CYSCN<UE:_\$--\
M365Y:ZCIVC3QWL1AN76W,<LJ'&Y3(N&P<8(SR.#Q7I]&.>GZ5I3X%X>I24Z>
M'L^ZG/\ ^2!XBH^IR!\':@  MQ9@#H C@"C_ (0[4O\ GYL_^^7KK\8[48QV
M_2N;_B'?"_\ T!K_ ,"E_P#)!]8J]SC_ /A#]2_Y^;/_ +Y>E_X0_4<<7-G_
M -\/77\?_JI:/^(=\+_] :_\"E_\D/ZS5[G'?\(?J7_/S9_]\O3AX/U''_'Q
M9_\ ?#UU^/;]*3\/TH_XAWPO_P! :_\  I?_ "0OK%7^8Y'_ (0_4<?\?-GG
M_=>D_P"$.U+_ )^;/_OEZZ^@C':C_B'?"_\ T!K_ ,"E_P#)#^LU?YCA-8\*
M:A;Z;.YN;0A0#@*_/(JX?!^I;CFYL^O]UZW_ !#C^Q+OM\H_]"%:3\.?K3?A
M[PRTH_5%9?WI?_)"^LU>YQO_  B&HC_EZL_^^7IK^"[Z?;YDUC)L(<9C9MI'
M((]"/7M799%>=_&;PU?Z_:^#Y=-?4C+I_B?3;N6WL)F2.2$7"^:TZK]^-$RV
M#P,9(.*2\.^%UMA%_P"!2_\ D@^L5?YBS:_#;^R9FFM+?2;"63[\MO:^47YS
MR0!GDYY]:ATCX6_V#96]G8K8P6MIO$$81V\@.22J$\J#G&!QC Z8KC_A7HUR
M/&WCK7-)T/5?#$+6TECI^DZM;W"G4)UFED.H3O*-K-)(^U%#,PBY;&0J\!/X
M/\5>(?!_PTUOPE=:S=:S/X+UNUN)ENW^SVVJRV8P\@) 69KLRKN;D%,97%;?
MZ@\-M.+PVC_O3_\ DO-C^L5>Y[D?A@BVPLS9Z1]GYQ;_ &/Y.3DX7&.2 3ZD
M9J6'X<265N(;>'3(+=0R"*.V*HH;[P  P W<=^]>7^#;.3PM\)_&-AJ?@_7=
M:T3STDTW2K33I[2]U-!!;"2-H%/[H>=N0GY1(JNQ#_,S\Q<_"+Q+IOA_2-?T
MNXUG4M9DM[[[5HD,$UO:VT#-<2O9PF0+(D1$X@C3;ERB.,; *3X X;>CPW_D
M\_\ Y(/;U.Y[=9?#!=.U*:^M!86\\T,5J62-U58H]VR-1T5068X7')K3_P"$
M0U'_ )^;/_OEZX;X7ZYKNO?$NVN=0T@Z%)<>%(Y=9TOYPMO<K>.EFP1N8VD@
M$[;6^8*$#<K7M(YI5/#_ (:JOFGA;O\ Q3_^2%]8JKJ<>/!^I9'^DV?_ 'R]
M4]*\*ZA-:%EN;0 22#E'[.P_I7>#J*SM"7.GG_KO-_Z,:H_XA[PPHN*PBL_[
MTO\ Y+S8?6:O<P3X/U$_\O-IG_=>F_\ "'ZE_P _-G_WR]=CC HQ[4O^(=\+
M_P#0&O\ P*7_ ,D/ZS5[G%2>"+R0!Y);)RARI,;':?4'L>3S[UFO\)8KO4[J
M_D@TV>>\2**?S87D241;O++*?E++O8!L9QQT KG_ (B^']3?XS:)KFF6=_J%
M[&NGVL4$VD1SZ<EO]ID:ZD%T3N@F5&#9^7.R,+OR0.<^(V@7?C35OB?H8L&U
M'7;J]T;3=/:6'S!IVF3HBR7D0/"E2]ZQ<='4 GY1C6' /#E._)A;7T^*>V_\
MW=7#ZQ5[GJ$OPW>Z*F:+2IS'+YX,EL6VR=-_(X;@?-UXITOP^G9E>5=.9EE%
MPK26[$K)C D!(X;'&[K7!?&;0+&_C\,>&-%\-ZNC0D6$.NPV-W-;Z%:Q/ S.
M@0'?<,$1(V[8<EP%96YFR\'^+OA/\2C+H.D:IXRT.\UIY7-^K*(IYE4O*NTX
M($;E/.?Y"PDR 0M+_4#AM)6PNW]Z?_R0>WJ=SUS0_AK-X=TR'3K![2"U@R%0
M^8S98EF)8DDDLQ))Y))-:'_"'ZA_S\6G_?#UE? ::2;P%<?O6N--CUK5(=)F
M8[M]@MY*MOM.3N0(,*3U4+7H?%*?A]PS5FYSPEV]6^:?_P D+ZQ574Y#_A#]
M2'_+S9_]\O51/">H?VQ+$+FT!$"-G8^,%F&/TKN\>U9\?_(P3_\ 7I'_ .AM
M4KP]X8CMA%K_ 'I?_)!]8J=SG_\ A#]1_P"?FT_[Y>@^#]1Q_P ?-F/^ O77
M\4'IQ2_XAWPO_P! :_\  I?_ "0_K-7^8XBX^'\]V)5N!ITZ7"A)5D@+B51T
M# _> ST/K5;4/ABVI_88[@61%A<1W5MM61#!(@(4KC&, L,="&(/%<+XU\&Z
MY97WQGO++2;WQ-/JEAILFCP:IFYMQ=[9H\0HPVJD)='*@>I.<YK<USPO:?#\
M?!_PI8R2P^%K/4_L4LIE.99DM)C:^8QZAYUW<G!<(.<@5K'@'AN#3CA;?]O3
M[6_F["^L5.YU(\"72< V"_/YV!"PPQ_C^O/WNO/6JR_"]/M,=VMGH_VF,C9<
M"S_>(1P,-C(QGUKR3PS\,?$FFV&ABX;Q-<2Z5\4KV[1;R[E?[1ISSR;;J?)_
M>)LQM+?* _ Z8E^)G@KQ+XP^,=H^C6^JV]CJLM@DVM>3-;R:;8K#=1W<<,F-
MB[MRDJX5R[J0'&UD2X X;6V%_P#)I_\ R0_K-3JSU'5?A5_:UE-9W46GM%-
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M_!CP=J'P^^%/A3PWJNH2ZKJ.EZ?%:SW<T[3L[*N#^\8!G Z!F ) &1FNTHT
MP_\ A&!_T$K_ /[[3_XFE_X1@?\ 02O_ /OM/_B:VZ*- ,0^&<]=3OS_ ,#3
M_P"(H_X1G_J)7_\ WVG_ ,36W11H!B?\(P/^@E?_ /?:?_$T?\(P/^@E?_\
M?:?_ !-;=%&@&)_PC(_Z"5__ -]I_P#$TG_",#/_ "$K_P#[[3_XFMRBC0#$
M_P"$8'_02O\ _OM/_B:#X8!/_(2O_P#OM/\ XFMNBC0#DO$/AP1Z-=G^T;YO
ME'#,F#R/]FM(^&0Q)_M*_P _[Z?_ !-3>)O^0)=_[H_]"%:@ZFC0#%_X1@?]
M!*__ .^T_P#B:3_A%Q_T$K__ +[3_P")K<I",BC0#D;)=)U75-2TVR\1S7=_
MIKI'>VT-Q&\ELSKN19 %^4E>0#SCFL_3]6\+7.HZ?IEGXL1[W4OM$MG:P7,.
M^Y$+[9W10OS!6X9AQGO5'P_\-;CP]XP^).HVWV73+7Q,;=[:2R3;(DJ6[1R2
MR *!N+D-G))QS7%>!?A/J4$WP@\0G2+:PU/PGH5UI&J1W*B.ZF?R(X4"NJG=
M&9(Y'!)QB3< 232T ]$\0Z[X8\*7SV>K^+FL+Q+&34FMY[F,2"V1TC:7;MSM
M#R1KGNS@#DT6NO\ AF_M!>6_BXS6A%L?M"7,90?:,?9_FVX_>;EV^NX>HKSC
M4/V<[_6/CM>^.M7O+?5]*U+0KK3KJPD5H;F)C-:2VL$4R$%8XVMW<.-K!V+8
M)8D<M>? WQ[X7\">,O#%A<6TWA[6-'%AIVFZ:N6M+Z80QK* R JD!$C>8TAS
M&L0V@IDF@'T='X3C5G9-0O0[GYW#1@MCID[.<>]2CPR /^0E?_\ ?:?_ !-:
MMJC1P(C.9&4!2[=6('7\:FIZ 8@\, ?\Q*__ .^T_P#B:S]!\.;[ G^T;Y/W
MTW"NF/\ 6-_LUU=9GA[_ )!I_P"N\_\ Z-:DT!7/AG/_ #$K_P#[[3_XFC_A
M&1C_ )"5_P#]]I_\36W13T P_P#A%QG/]I7^?]]/_B:8WA./S?-^WWOF[0N_
M='NQG.,[,XSVK?ILAPI.,XYQ1H!P^A:KX=\4:EJ&GZ3XJDO[VP;R[F""XC9H
MB&*G^'D!E9<C(#*PZ@BM[_A&!C']I7__ 'VG_P 37F?P?^$VO>"/$RW6JMIY
ML]/T^?2[.2T9FDNDEO7N?-D!4;"%*+MRV6+G.,"O:*- ,"'PC%;1)%%?WL42
M *J(8U50.@ "8 ]J?_PC _Z"5_\ ]]I_\36Y11H!B?\ ",C_ *"5_P#]]I_\
M36>GAW/B&=?[1OO^/6,[MR9^^_'W:ZNLR,_\5+/_ ->D?_H;TF!7/A@?]!*_
M_P"^T_\ B:3_ (1@?]!*_P#^^T_^)K<HIZ <CXACTKPEHM[J^M>(IM)TJRB,
MUS>WEQ'%%"@ZLS%< 5#JT.B:9:VDNI>();>WNI%2![B6,+(^TNN,IU"JS9[!
M2>,9I?B]X"C^(WPV\3Z!]FM+FZU#3KB"T%^@>&.X:-EBD.0<;7(8,!D8R.:\
M^^-/PSU;QA:^$].AC+6KZ=J>A7<R(TOV5[NP:".Z*CJBL"I/82Y]:- .PL/$
MOA?5_#<VOV/BJYO=(B?RY+BW82;6.W *B,MDAE(XZ,#T.:S=-^)G@#6#_H?C
M^.4_9IKS'VE%(AA9UE<Y08"F.0'//R-_=-4-#\&^.-+\/>-YH(M,TWQ+KULQ
MLS%>/);V=Q%8Q6UN6;RU9@S1F0D ;0%'S'FLCQ;^S=!-HGAZ'PY#:V&LZ3ID
M5E_:4\CMYGV>-A;JR<HQ,DCLTK*6 +#!#L*- /3+>QTG6;R]TV/6[BZN+5(W
MN;5I(R460%HRRE.C '&>/E/<&M3_ (1@9).IWY)]73_XFO,OA=X5\86GQ#&H
M^*7-S=6/AR+3;K40/EO)VNI9D52%42>3%M5I J@O(V .0/::- ,/_A&!_P!!
M*_\ ^^T_^)JGJ&B"QN=,E^VW<V+R/Y)64J>&]%%=163K_P#S#?\ K]C_ *T:
M :F#ZT4F**- .0;2[.[UG6))[6*:3[0HW.N3CRDI_P#8.FG_ )<8/^^!49U*
MWM=8UB.9G1OM"GB)F_Y9)W -2_VU9_\ /23_ +\2?_$U("?V#IIZV,!'^X*9
M/HFG0P22)IL4K(I81H@W-@9P/<]*E_MFS_YZ2?\ ?B3_ .)H76[16#"1\@Y'
M[F3_ .)I(#YQM/VT?A5?1J+?0M5GNGT*RUQ+-+2+S7%U<QVR6H!DQ]H5Y8RR
MYP%;.35B;]LKX.VM[:V=T'MIY18-*7BC,5NEV\J([2*Y4JGE N5)QYB ;CD"
MKHO[%OPYT&]TJ[@U/5'FT[QK/XUCW6_#22;<61^3_CW4I&0.N5SWJ;PU^R5X
M=\,:MX7N[;QIK4EIHG]E.]C-IR%;V;3I[B:VD=]FY#_I4JD+P?E/44QG5^)_
MVCOA#X:E\+P+K&F:O<^));1;"#3'25VAN'*)<L"1B(%6)/WL*V <&KFG_M"?
M!355T]K3QEX<G_M R?9"DAQ/L!+%25&1P<'H2"!D@BO+=$_8>\*^'+;3;.P\
M>>(8M/AGL[J]MFT^)QJ$]K+.]O(S&/='M6X="$(!"J3SG.G'^QYX674?AM<-
MXSUV>T\#66FV5II\]DLD%Q]CD=U=@4^0R"1EDV_> 7TP01Z9/\;/@_;V\D\G
MB[PVL,00NQN%PNZV^U+V[P?O!ZK[\5+X(^*O@#XC^*)M&\,_9M9C32(]974[
M55:TDA:XEMR@;.X.LD#A@0,8ZUX=HW_!/_X?>'&U";2/%_B73KZZTZ?3UNXH
MSYD1>Y65)1E>62)1:@=#%D'K7H7P0_9I\)? ]M3%CKNIZM#J&F2Z7-#=68B4
M1R7<]TY41H-IW7+J . H7O0 OBO]JCX.>'=)M+S3M1LO%LESK5OH,=IH)CFE
M^U3;MF2S*H3",=^=IP<$UWNL_$+X;>'O%Y\*:IKN@:=XD%L]ZVFW-PD<JPJK
M.SMG 4!4=L$@[5+8P,UY7X0_9-\->%M0\.7C^,M>U6;PY/I::4;BRCC$%AI_
MVC[-9$1QKO&;F0M*WSG"^^=[QI^SQH'C;Q+XSO+GQ5KECH7C.U$&O:!9VL?E
M7<BVIM4E$S1&6/$17Y4(!9 3P2" :-S^T9\#K/0+/6[CQOX8BTJ\DEAM[IIO
MED>((95QC(*B2-CD#Y7#=.:U[CXN_":SO/$%K/XG\/17/A^$3ZK&9US:(2H!
M;'7ET&%R<NHZD"O,9_V1/#NI_P!LWVL^-]=UC7]9T_4M.U#5I-.BB:5+NQ@L
M0RQ)&$0Q0VZ8P/F)8MG.*R]=_8=\$>(KS7)KSQ;KAM]2M8(DLX[")(HYH9+>
M1)I56,"Y(:V7 E!^5W4D\$(#U<?'+X-'4],T[_A+_#C7^I0QSV=NLN6G1P^P
MKQU;RW !YRI&,\5L_"3QOX,^-G@#3/&7A>W2?1M0#^49X/+D4JQ4JZ]B"/UK
MR;P]^R!X,\,PI%9^(M41?-T6XD$>GQQ*\FG7DUV"%2-502R7#A@!P ,<Y->K
M?!WP=8?"#X=Z5X/@UR]UJRTL/%:7%W9^7(D!8LD1V* =N<;NI[T: =H-"TT?
M\N%O_P!\"D_L#3#_ ,N$'_? IW]LV?\ STD_[\2?_$TG]M6?_/23_OQ)_P#$
MT: )_8.F_P#/A!_WP*/[ TS_ )\8#_P 4O\ ;5E_SUD_[\2?_$TO]M6?:20_
M]L)/_B:- &_V!IG_ #X0?]\"C^P-,_Y\(/\ O@4O]M67_/23/_7"3_XFC^VK
M+_GI)G_KA)_\31H G]@Z;_SXP?\ ? H_L#3#_P N$'_? IW]M6?_ #TD_P"_
M$G_Q-)_;5G_STD_[\2?_ !-&@&?KVAZ='HUTRV,"D*,$)_M"M!M TT,V+&#G
M_8JAK^L6;Z+=J)7W%1P87'\0_P!FM!M:LRQ_>2?]^)/_ (FC0!O]A::?^7&
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M .*K.T'Q!<IIQ"Z7,X\^8Y$T8_Y:-_M4".NHK"'B*Z_Z!$__ '^B_P#BJ/\
MA([G_H$S?]_HO_BJ+@<SXO\ %_B#1/BEX"T>S@L#X>UJ>[@OKB9W-T)([62:
M-8D VA<Q_,Q)/0 <DUQOQ0^+GBWP]H_Q/U+P]9Z7)'X3-I;1KJ+2#>[Q)-/*
M=O+!4FC5$X!8,2V.*]*O)X]0OK&\N?#QGNK&1I;65Y(BT#LA1F0[N"59E/L3
M6#<^%]-N]7\0WMSX>ENH=?A@AU*QN)H7M[CR@51RA/WMI"DYY"+QQ1H!@?M
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M))90:=%#'+"L5M;Q,[B.)01M#/([L2268Y/05UW_  D=U_T")_\ O]%_\55
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M ,B4O]F:V>^G?^1***+ )_9>M^NG?^1*/[+UOUT[_P B4446&*-,UL=]._\
M(E']F:WZZ=_Y$HHHL(/[,UL=]._\B4G]EZWZZ=_Y$HHHL O]F:WZZ=_Y$JNN
M@ZV+][KS-.)>)8MO[SC!)SG\:**+#N3_ -EZWZZ=_P"1*/[+US^]IW_D2BBB
MP@_LO7/[VG?^1*/[,UO/73L?]M***+ +_9FM]CIW_D2C^S-;]=._\B4446 3
M^R];[G3C_P!_*/[,USUT[_R)1118 _LO7#U;3O\ R)3#H>K3W-FT[V0B@G68
7B(/N.,\#/'>BBBP'2[3Z+111189__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tmb-20221231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ': M # 2(  A$! Q$!_\0
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MC5X^\=Z%I&MZ=\+5_LC4HXYXKA_$< 81L?O%#'G@<XKU/QI_R)VN_P#7A/\
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MX ==F>G&:X'X36,&F?M!?%ZSMHUAMK>WT:**-!@(JVF !] *L_LC?\D4LO\
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MTT7WF>;N\OY-^<[MF=N<\]*[VB@#*N_"^E7^O:?K5Q8Q2ZIIZ21VMT<[H5D
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MQ>7*YW3>6NU-WT'%+X;\,:7X0TI=-T:RCT^Q5WE6"+.T,[%W//JQ)_&M2B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *RO%/\
MR+]]_P!<S_,5JUE>*?\ D7[[_KF?YB@!GA'_ )%RQ_W/ZFMBL?PC_P BY8_[
MG]36Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !11TKRSQI^U+\)OAWXBNM!\2>/=&T?6+7;Y]E<W $D>1D9';@@_C5PA
M.H[05WY$N2CNSU.BOG/QS^WW\&/"WA+5-5TOQGI?B;4K:$M;:1I]P#/=R=%C
M7(P,DCGL,FO"?#W_  44\::'X@L[WQWX;\/P>$+BXCBNGTF287.G([!1(2Y*
MRA21NP%XSBO2HY7BZ\)3A!VCWT.6IBZ-*2C*6K/T"HKQ#_AMSX$_]%0\/_\
M@3_]:NP^&_Q[^'GQ?O;NS\&>+M,\175I&)9X;&;>T:$X#$>F>*X94*L%S2@T
MO1G2IP;LF=_17@/B7XW>+M/TF.ZTRQT^\N(_$^HZ?+;-"Y,MG:I+(53#\2E(
MCACD9_AK;^*7QIOM$7PX?"BV5Y'>&TO;RXN49TCLIIXX4VA6&'=I#M)R $;@
MU@6>QT5YWI_B3Q)XWU;7CH5W8:5INCW[Z:HO+-KA[N:,*9"2)%\M QVC )."
M?05VKZD6MYX[9[>ZU**(G[.)MH+@=">2HSQG'% %^BN"^$GBW7/%5IXC3Q M
M@E_I>LSZ=C3E<1;%1&'+DEB-^-W&<9P*XZQ^-NM0^,?&NF:G;646G6TUW;:'
M<QHP+SV\"RO#-EL%F#[UQMR%8=1F@#VZBOG_ %7XWZU"/#S3ZMI>A0W?A*/7
MIIIM-DN0]PS % !*NU.>^3[UT?BCXF^(=(T/P;=7UM!X7BU6V:;5-1N+=KR'
M3I1&K+$55EQN);YR<#;CJ: /7:*\^^(/C35?#OPAO-?TB[TR^U9881;W7EL]
MG([RI&'VA\E?FS@-^-<_KWQGU*/X46^I:=:VL?C*Y>6P^PW*LT5O=P!S<%U#
M!BB")VZ@D;>>: /8:*\KA^.5K9>&]%N;VSEO-1FT6WUB_CL0JK;1R)G=AW!.
M2'PH).%-=!XJ^*%CX9T6WUA;.ZU'2Y;7[<UU;; JP[=VX;F!8[>=JY..U ':
M45Y_K/QCT[3KJ]AM--U#5OL>FPZO/):1*56UD#D/EF&3B,G:.3V!KM]-U"#5
MM.M;ZU?S;:YB2:)_[R, 5/Y$4 6:*** "BN1O_BWX.TN]FM+KQ%8P7,+F.2-
MI>58=0:Y_P 7?M!^$O#_ (=O=0L=4MM6N8$++;029)]S["M52G+9&,ZU.E%S
MG))+<].HKYH^%?[8MMXQ\0O8:U8PZ9;[2XN5) 11W;)/'3\Z]A_X75X&_P"A
MGT__ +^U*@Y)2AJGU1R8+,<+F%+V^&FI1.VHKGM.\;Z1XCTG4+S0]1MM2^R(
MQ8PMN"MM) /UQ7D7AKXQ>)-3TO0;C^TM+UEM7T2>_NET^R:)M*D6V\U"Q,CJ
MRE_DPP!SCKR*EIK1GH)IZH]^HKRO3_B^^@_#7PSKFN6EW>_:-'M[_4+^%(U5
M-T:L[[<KG&22J X';I73-\1()_$<VDZ=IU[JOV4PB\N;55,=L90&0'+ D[2&
M(4' (SUI#.NHKS_3_C/HNH^(+73XXIQ:7EY)I]KJ)V>3-<)NR@&[=U1P"5 )
M4X/2L#X7?&*XU/P]X>/B&WO#+J=W-8QZL\")!+.)90D>%P1E8\!MN"1U)H ]
M?HK@=-^,.FZE<:?*+"]BT;4KK[%9:O(BB">4DA0/FW ,5(5B "<>HK'^,/Q0
MUSX?^)?"\.F65M>Z9-'=WNK(Z,T_V6$1[S#A@ RB0O@@Y"$<9H ]6HKQ#Q9\
M:]5L;+QI<Z9-I_V73-1TFVL;MH&F4PW2PEY& <;R!*2N".W6GP_%KQ,?"_BN
M\LK>V\0QZ7?6]K;ZK:6<B*R.5%P[6^\LQ@R20&&[CIS0![917+?#SQ$/$NAM
M=+KVG^(4$A47>GP&$#I\KH7;:PY[],<5Q'PU^,FH:OJWBFU\4)96=O927EWI
M]S;HR*]G!<20R!]S'+H8P21@$.O H ]@HKQ+P+\==1N=.\37WBJT@M1;W]K!
MIEC9QD3.ES"LL,3[FP9,.,GY0.>F*[O1OB99ZWHNJWEO8W1O-,G^S76G_(98
MY"JLO(;;M*LK;MV,'K0!V5%>=I\:](.D?:VL[T7*ZO'HLEDB+)*ES( R#Y6*
ME2&4[@2.?8UT7@_QI!XN74HQ:7&G7VFW/V6[L[H*'B<HKKRI((*LI!![T =%
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9
M7BG_ )%^^_ZYG^8K5K*\4_\ (OWW_7,_S% #/"/_ "+EC_N?U-;%8_A'_D7+
M'_<_J:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *Y+6_A+X+\2:G-J.J^%M(U"_FQYES<V4;R/@8&6(R> *ZVBJ4G'6
M+L)I/<\N\6?LR?#+QCX:U+1+SP=I4%M?0- \UG:1PS1Y'WD=1E6!Y!'<5X;X
M/_X)PZ%I/BBPO?$GC75?%VA6$ZW$&BW5G#"DK(<H)Y%R95&.1A<GKQQ7V'17
M92QV)HQE"G4:3W,)X>E4:E**;1PG_"B/AW_T).@_^"^+_P")K9\,_#OPQX,N
M)KC0?#^FZ1/,@222RM4B9U!S@E0,C-=%17*ZDVK-LVY4NAYUIGP>AT[4K"[_
M +3DE^RZ]?:YY;0@!S<QR(8CST7S3SWQTK)L?V>=/T[PYJNDPZM<L+S4K:[B
MFEC#-;6]O.LL-J@S]Q<, >OS>U>MT5F4<,OP_P!2T;6M5O/#FNKI5IJMP;N\
MLY[(7*B<A5:2([UV%@HR"&&><=0>AB\,VEC+=WEC!;V^K7$;*U\T(9F8_P 3
M ;=W(!(R,^U;%% '#?#KP'JW@J^UR:]URWU6'5;V34)(X]/^SE)W"*<-YK?+
MA!P1GGK67KGP/L=>\,>+M)GU&9)=<U.358+V.("2PG:-$5DYYV[.^,AB#Q7I
MM% 'GVB_!^RTR\L)+B[-_;6_AM/#<EM)" LT88$N>>"0,;>G/6I=-\!Z_H7A
M+1M$T_Q/&XL+8VCR:AIJW"SQCB,E1(I#*H"YW$'G*YZ=Y10!Y\?@_90_"A/
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MG_"2Z9_S]I^1_P */^$ETS_G[3\C_A0!IT5F?\)+IG_/VGY'_"C_ (273/\
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MF?\ /VGY'_"C_A)=,_Y^T_(_X4 :=%9G_"2Z9_S]I^1_PH_X273/^?M/R/\
MA0!IT5F?\)+IG_/VGY'_  H_X273/^?M/R/^% &G169_PDNF?\_:?D?\*/\
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MHV+_ '1^5.HH ;L7^Z/RK)\*J#H%GD _*?\ T(UL5D>%/^1?L_\ =/\ Z$:
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M_5_QH MT54_M6R_Y^X/^_J_XT?VK9?\ /W!_W]7_ !H MUD'_D:U_P"O(_\
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M=U+P#XO\-^*O&5SX8MM&U#3?%+)/+_:3LC6DWE")R0 ?,0A0VW(Y!'>O8Z*
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M_P *MT4 5/[)L?\ GSM_^_2_X5EZ?IUH^M:LC6T)1&BVJ8Q@93G%;]9&F_\
M(=UC_>A_] H N?V38_\ /G;_ /?I?\*/[)L?^?.W_P"_2_X5;HH J?V38_\
M/G;_ /?I?\*/[)L?^?.W_P"_2_X5;HH J?V38_\ /G;_ /?I?\*/[)L?^?.W
M_P"_2_X5;HH J?V38_\ /G;_ /?I?\*/[)L?^?.W_P"_2_X5;HH P;O3[5?$
M-A&+:$(T,Q*B,8)!3'%:?]DV/_/G;_\ ?I?\*IWG_(R:=_UPF_FE:] %3^R;
M'_GSM_\ OTO^%']DV/\ SYV__?I?\*MT4 5/[)L?^?.W_P"_2_X4?V38_P#/
MG;_]^E_PJW10!4_LFQ_Y\[?_ +]+_A1_9-C_ ,^=O_WZ7_"K=% %3^R;'_GS
MM_\ OTO^%9GB;3K2'0KMX[6%'"C#+& 1R*WJR?%?_(OWO^X/YB@"W_9-C_SY
MV_\ WZ7_  H_LFQ_Y\[?_OTO^%6Z* *G]DV/_/G;_P#?I?\ "C^R;'_GSM_^
M_2_X5;HH J?V38_\^=O_ -^E_P */[)L?^?.W_[]+_A5NB@"I_9-C_SYV_\
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M\C_Z,% $W_"/Z=_SZ1T?\(_IW_/I'6C10!G?\(_IW_/I'1_PC^G?\^D=:-%
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M\0]5,+Y3CTV.H_X":]#^)A/.#_"7_!7XG/\ #5]5^1]%?V$W_03O_P#OZ/\
M"JNJ^#;;7-.N+&^N[RYM)T*2122 A@?PK?HKS]M3H/#O",EY\,_%B^"M<U*\
M72+@EM$OQ*%4KG_4MD=1V_\ KBO7/[";_H)W_P#W]'^%9_C_ ,#6/Q \/3:;
M>9C?[]O<J/G@D'W7'^>17,?"CQS?3SW/A'Q/B'Q/I8VEFZ7</\,JGOQC/X'U
MQT27M%SK?K_G_F8KW'RO;I_D=O\ V$W_ $$[_P#[^C_"LXZ0?^$B6'[=>?\
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M\*/[";_H)W__ ']'^%:M% &5_83?]!.__P"_H_PH_L)O^@G?_P#?T?X5JT4
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M"YM=5MO]+L1Y<3R!7#%P=A!_B]JVE3YO>IK3\C-3M[LWK^9W=%%%<YL%%%%
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M^(;ZXDOTC?7==MMZS6-FBC>&<@;9I#A?7DUO^ M$;X7?'8>#=(U?5=1T"_\
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M!O)[BUCL#O,QE27(BV]L;3DXP:^FS&K,K%067H2.13([6&%BT<2(QZE5 )H
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M +\+6I10!E_V;J'_ $%6_P"_"T?V;J'_ $%6_P"_"UJ44 9?]FZA_P!!5O\
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MR?\ &M2B@#+^SZM_S]V__?D_XT?9]6_Y^[?_ +\G_&M2B@#+^SZM_P _=O\
M]^3_ (U%=6^JBVEW7=N5V'($1]/K6S4-Y_QZ3?[C?RH Q-$@U-M'L3%=0)&8
M4VJT1) P,9YJ[]GU;_G[M_\ OR?\:?X=_P"0#IW_ %[I_P"@BM&@#+^SZM_S
M]V__ 'Y/^-'V?5O^?NW_ ._)_P :U** ,O[/JW_/W;_]^3_C1]GU;_G[M_\
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M=O\ ]^3_ (UJ44 9?V?5O^?NW_[\G_&C[/JW_/W;_P#?D_XUJ44 9?V?5O\
MG[M_^_)_QH^SZM_S]V__ 'Y/^-:E% &7]GU;_G[M_P#OR?\ &LWQ%#J*:+=&
M:Y@>(+\RK&03R.^:Z:LGQ7_R+][_ +@_F* '?9]6_P"?NW_[\G_&C[/JW_/W
M;_\ ?D_XUJ44 9?V?5O^?NW_ ._)_P :/L^K?\_=O_WY/^-:E% &7]GU;_G[
MM_\ OR?\:/L^K?\ /W;_ /?D_P"-:E% &7]GU;_G[M_^_)_QH^SZM_S]V_\
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M%%% !1110!\?_M7^ =:^#'Q!T_\ :,^']HT]_ID8M?%ND0# U33N 9"!U>,
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MP?S% &M1110 4444 %%%% !1110 5D>%/^1?L_\ =/\ Z$:UZR/"G_(OV?\
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M;XA\*Z[XV\=:4WAK5;.:".\ETS6+)S)_H]N%9%G#$+D*2,H><9]:]OK@M?\
M@GX9\3:K=7M^E](EVX>YLEO95MISC'SQ@X.>X[T =!X,\4V_B_PGH6M0Q&T3
M5+**[CMI"-R!T#;??&<5YGX-\)Z7X/\ VBM3M-+MO(CE\+Q32NS%WED-W)EG
M8Y+'W/I7I=UX(TF[U_0]8:!H[O18I8+(1.4CC2155AL'!X48STKF+'X%>'M/
M\41^(8[O6'U1-H\V34I6#('+A""<%=Q)V].: /1:0TM(: .,\&W=[#IUZL&G
MFXC_ +0N_G\Y5S^^;L:WO[1U/_H$'_P)2L_P#_R"+S_L(W?_ *.:NFH R?[1
MU/\ Z!!_\"4H_M'4_P#H$'_P)2M:B@#)_M'4_P#H$'_P)2C^T=3_ .@0?_ E
M*UJ* ,G^T=3_ .@0?_ E*X#XY_"BU^/?PUU;P?KVBE8+Q,P7:W"&2TG',<R>
MZG\QD=Z]5HJX3E"2E%V:$TI*S/E#]D'XY>)W;5?@Y\0+7=\2?!H$+2R3A?[3
MLAQ%<H3][C:"1U!4]2<?1!O;_P#X2)7_ +-/F_92/*\]?N[QSGIUXQ7A7[8W
MP2UO6(](^+7PY3R/B;X,S<P+$.=2M!DRVK@?>R-VT=\D=Q4_PI_;>^%/Q+G\
M-W<GB>ST/5M4L%BDTW4"T9M[HN 8&D(V;L@XR>1CUKT*U%XA?6*,=]TNC_R>
MZ^XYH3]F_9S?IY_\$]__ +1U/_H$'_P)2C^T=3_Z!!_\"4K5!R,CI2UYAU&3
M_:.I_P#0(/\ X$I1_:.I_P#0(/\ X$I6M10!D_VCJ?\ T"#_ .!*4?VCJ?\
MT"#_ .!*5K44 9/]HZG_ - @_P#@2E']HZG_ - @_P#@2E:U% ',:Q>W[OI_
MF::8BMTI7]^IW-M;CV^OM6C_ &CJ?_0(/_@2E&O?ZS2O^OU/_06K5'2@#*_M
M'4_^@0?_  )2C^T=3_Z!!_\  E*UJ* ,*_>^U*RGM+C1B\,\;1NOVE.01@U\
MWR?L;QV>M7&IZ=)+'(I,MK#.Z,J2=1NQU%?5M%4G:VB=M5=)ZGGXK+\+CG"6
M)IJ3@[J_1GE7@OXKW[7Z^%_$.DKI_B:W4+L,RI%<@<!XR>#] ?I7?_VCJ?\
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M=8WM^NKZFRZ:7D8Q[T\]1L^3CGOFNGK(TW_D.ZQ_O0_^@4 +_:.I_P#0(/\
MX$I1_:.I_P#0(/\ X$I6M10!D_VCJ?\ T"#_ .!*4?VCJ?\ T"#_ .!*5K4A
M.* ,K^T=3_Z!!_\  E*/[1U/_H$'_P "4K5SFEH R?[1U/\ Z!!_\"4H_M'4
M_P#H$'_P)2M:B@#F+F]OSKMB[::5E$4H6/SU^8?+DY[8_K6C_:.I_P#0(/\
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M *!!_P# E*UJ* ,G^T=3_P"@0?\ P)2C^T=3_P"@0?\ P)2M:B@#)_M'4_\
MH$'_ ,"4H_M'4_\ H$'_ ,"4K6HH R?[1U/_ *!!_P# E*/[1U/_ *!!_P#
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MT445P'0%%%% !1110!DZ]_K-*_Z_4_\ 06K5'2LK7O\ 6:5_U^I_Z"U:HZ4
M+1110 4444 %97B7PQIOB_2)M-U6U2ZM91RK#E3V93V(]:U:*:;3NA-7W/%[
M76M:^!EW%8:Y)-K'@QW"6VJ8+2V>>B2>J^A__57K:WUOJ6D_:K69+BVFB+QR
MQMN5E(X(-37MC;ZE:36MU"EQ;3*4DBD4,K*>H(-?,WQ<U_5/V9+67_A'KDW&
MBZKN%OI]TI=;63/S%6[#&>*V;C-.4G9K5]CAQ.)IY?1E7K/W(J[\CZ/\._\
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M3OL%9/BO_D7[W_<'\Q6M63XK_P"1?O?]P?S%(9K4444 %%%% !1110 4444
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M=_\ ? _QK4HH R_[9E_Z!MW_ -\#_&C^V9?^@;=_]\#_ !K4HH R_P"V9?\
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MC1_;,O\ T#;O_O@?XUJ44 9?]LR_] V[_P"^!_C1_;,O_0-N_P#O@?XUJ44
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MQM5_4Y!_*E-4XP=2^BW[_P#!_ \W,<QAE>&GBL0FXQ[:^6Q];_VS+_T#;O\
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M\_Y&33O^N$W\TK7H **** "BBB@ HHHH *YCXA>'=,U_P]<#4;&"\\I=R&5
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MQ743131K+&PPR.,@UB^"K&VL?#UJ+>". ."6$:A<G)]*WJR/"G_(OV?^Z?\
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M-><K8?"#P[H2G[KZIK9D(]RJJ/YUR_4ZB^)I?]O+_,V]M'I?[F?2G_"0P?\
M/O>?^ [?X5A^+OBSX7\ :5_:?B74TT'3]XC%QJ \I"QZ*,]3P>!S7@W]G_M<
M^(#MEU7X>^&$)/-O:S7+ ?\  F(/Y5X)^T?\%OC;8:WH7B/Q[JW_  LRQM[>
M:W@?0M,V)I<C,"6\A1D[U&/, )&W'0UU87 4ZU:-.I6BD_Z]/Q,:V(E3IN<8
M-M'WQX4^*7AKQUI":KX<U%=<TUV*"ZL!YT>X=5)7H1Z'FMC_ (2&#_GWO/\
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MQ3:"">">P/6N_P"M9.+C:Z+33V,S_A(8/^?>\_\  =O\*/\ A(8/^?>\_P#
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M0 4444 9.O?ZS2O^OU/_ $%JU1TK*U[_ %FE?]?J?^@M6J.E "T444 %%%%
M!28I:* *&JZ#INNVSV^HV%M?0.-K1W,*R*1Z$$&OD+]J#]BVVO=0TGQA\+/"
M^D66K6B30:EIEHB6IO87VE70\()$*'@XR&/-?9E0WG_'I-_N-_*NS"XNK@ZB
MJTGJON,*U&%>#A-:,_/_ .#?[#'B;QUJ$OB/QEJ^N_#N)+/[/I\7AS4EBOY"
MS;F>5U#*$&!M3G)R3Z5ZRO[$OBS2<_V#^T9\1[ #[HO9XKO'UR%SQ7TYX=_Y
M .G?]>Z?^@BM&NJOFF)Q%1U)M:^2M^-S*EA*5&"A%;'RA_PS?^T-HC;M)_:4
MN-1QR%U?P] WOR0Q]A^= \#_ +7FCLS1?$CP%KR#HEYHSPL>.^P#^?:OJ^BN
M?ZY-_%&+_P"W5^B-?8QZ-_>S\A_'OCGQIKWCC7I_B1XDO;#Q?I][+;36]G?2
MV<&GA&(3[,BL,(5 </R6W9)-?2WPD\$_M0_&?X<:%J^I?&2W\':5>P;H%AT*
M-]2:$$JDDK,%&]U"OU_B[5]=>(/A?X1\5ZO;ZIK/AO2]3U&WQY5U=6B22+CI
M\Q&>*Z9$6-%5%"JHP% P *]7%9M"M1ITZ=&,7'K9/[M#BHX.5.I*4YMIGRG'
M^P4WB"7S?'/QH^(OBYF_UD*ZD+.W?_@" D?@:Z?P[^P%\#/#VQCX(AU>=#D3
M:Q=S7C?^/N1^E?0]%>2\9B'ISM>FGY'<J--=#@XO@-\.[;0K[1H/!6A6VFWL
M#VUQ;V]A'&)(V&UE)4 \COG->._#[]AGX>^$_B"VJ/=Z[KEOI$\5QI^EZM>K
M+:V\@&Y&P$#2%#C;YC-C /)&:^GJR--_Y#NL?[T/_H%3#%UZ:E&$VE+?7<)4
M:<VG**T-; I:**Y#8**** "DP*6B@#G_ !)\/O#/C&V^SZ[X?TS5X#SY=[:1
MRC_QX&O#_%G_  3]^"_B%WN;#PY-X5U$DLEYX=OIK-E?LVU6VG\J^D**WIUZ
MM+X)-?,B5.$OB1^.VI?";Q+X2U&[\'Z]X5UC5?$S2RQ.?LDEP^I/N(699L$-
MN&T[BWR^V*^OO _@G]K_ , ^$=$MH?$_@?Q'';6<,:Z?K%M(L\0" ".29-N]
MEQ@MDY()S7UI>#_BI-._ZX3?S2M>O:Q><U,7"$)TX^[Y7_X8\^A@8T)2E&3U
M/E0?&#]J+PUM_MGX*^'?$2_Q-H&NF'/T$F_\JD;]LKQCH;A?$O[/_CC3L??E
ML!%>1K^((/Z5]38HQ7F>WI/XJ2^3:_4[/9R6TG^!\;>/O^"C6D6&A&T\-^$M
M=@\7W<JVUG:^)=-EM+5&()9Y'_B"J"=JG)X&1U'$^"/V_/B!H6M0:=XG\+0>
M.FU1FATZ'PQ;&VN_M.TL(RCNRLA4-\PP1CG-?9?Q:^$/AOXT^$9O#WB2U:6U
M:19HIX'\N>WE4Y62-QRK#_$'BO.O@U^QSX/^#WBM?$L>HZMXDUN%'BM+G6)4
M86BN,-Y:(BKN(X+$$XXKU*.(RR.%G&I2?/TU_72QQU*>+=:+C/W>IP4U]^U7
M\:\I9VOA[X):%)G]].3J.I[3Q_N*<<CY5^M:7A[_ ()^^#[S4%U;XE^)/$?Q
M9UK.YI/$%\ZVH/?; A  ]B37U)C%+7EO&5$K4DH+RW^_?\3L]C'>6OJ8/A/P
M'X<\":>ECX=T/3]$M$^[#86R1+_XZ!4GC""*?P[>+)&DB[0<.H(ZBMJLGQ7_
M ,B_>_[@_F*XFVW=LV22T1J)&D2*B*$51@*HP!7.^+_AQX5\?636GB/P[IFM
MV[9S'?VB2CD8R-PX/N*Z2BFI.+NF#2>C/E[7_P#@GQX 2\?4? >L>)/A=JQY
M6?PSJ<B0Y[9A<LN,]@16'J&A_M2_ K3[R_L?%WAWXP:!8PO,]OK=FUEJ!C12
MS8>,X9L# R6Y[5]>TC*&4JP!!X(/>NQ8RJ]*EI+S5_QW_$Q=&.\=/0_+W_AM
M3XQW+#QJGB2PBM#']N7PX+&,V @QO\@R8\TMMX,F[.>W:OH[2OCK^TQ\0M)L
M]1\,?!GP_H%G>0)<03^(M;:3<C*&5BB!",@CCK7<R?L/?".7Q4=:/A^0(TQN
M&TL7<@L#)NW9,&=N,\XZ>U>]1QK$BHBA548  P *]3'8W!5%#ZM02:6M_P#@
M/7U9QX>AB(.7MJESY1;P1^UQXN.Z]^(?@GP7!)PT.DZ2US(@]FDS_/M0/V-/
MB)XD0#QC^TCXWU!&Y>#1(HM.4>P(W?RKZPHKR_KE1? DO2*_RN=GL8]6W\V?
M%?Q#_P""<NGKI%MJG@WQ3K=_XRLI2ZS^+=3>[ANHF4K)$<#]V3D$.HX(P1@U
M?_91_92\1^$O'UK\0/&-Q8VTMC:SVVFZ7ITQF^:7"R2RR$ ?=7:J =R2>!7V
M+61X4_Y%^S_W3_Z$:Z/[5Q?L)89S]UF/U.C[55;:HUZ***\D[0HHHH ****
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MB#3/^$F63^T;3R_L97=YZXSO''6M;_A'M*_Z!EG_ . Z?X4?\(]I7_0,L_\
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M  H_X1[2O^@99_\ @.G^% #?^$ETG_H)V?\ X$)_C1_PDND_]!.S_P# A/\
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M_ A/\:=_PCVE?] RS_\  =/\*/\ A'M*_P"@99_^ Z?X4 -_X272?^@G9_\
M@0G^-'_"2Z3_ -!.S_\  A/\:=_PCVE?] RS_P# =/\ "C_A'M*_Z!EG_P"
MZ?X4 9-WK^F-X@L)!J-H46&8%O/7 )*8[UJ?\)+I/_03L_\ P(3_ !IW_"/:
M5_T#+/\ [\)_A1_PCVE?] RS_P# =/\ "@!O_"2Z3_T$[/\ \"$_QH_X272?
M^@G9_P#@0G^-._X1[2O^@99_^ Z?X4?\(]I7_0,L_P#P'3_"@!O_  DND_\
M03L__ A/\:/^$ETG_H)V?_@0G^-._P"$>TK_ *!EG_X#I_A1_P (]I7_ $#+
M/_P'3_"@!O\ PDND_P#03L__  (3_&C_ (272?\ H)V?_@0G^-._X1[2O^@9
M9_\ @.G^%'_"/:5_T#+/_P !T_PH ;_PDND_]!.S_P# A/\ &LOQ-X@TR?0[
MM(]1M'<IPJSJ2>1[UK?\(]I7_0,L_P#P'3_"C_A'M*_Z!EG_ -^$_P * &_\
M)+I/_03L_P#P(3_&C_A)=)_Z"=G_ .!"?XT[_A'M*_Z!EG_X#I_A1_PCVE?]
M RS_ / =/\* &_\ "2Z3_P!!.S_\"$_QH_X272?^@G9_^!"?XT[_ (1[2O\
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MJ]7EOPDUJS@\1>(O#,G@[3_!VMV,=O=3Q:8(S#<PR!EB<.BKDC8RX(XKU*@
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M4U>SU,WNK:S=V$+6]@VL7[7(LHV&&6('&,@ 9.3@ 9Q7?444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"-K)TX:!T'W&4\$?CWKLZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LKQ3_ ,B_??\ 7,_S
M%:M97BG_ )%^^_ZYG^8H 9X1_P"1<L?]S^IK8K'\(_\ (N6/^Y_4UL4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY^9O^_AH_M"Z_P"?F;_OX: /3<T9KS+^T+K_ )^9O^_AH_M"Z_Y^9O\ OX:
M/3<T9KS+^T+K_GYF_P"_AH_M"Z_Y^9O^_AH ]-S1FO,O[0NO^?F;_OX:/[0N
MO^?F;_OX: /3<T9KS+^T+K_GYF_[^&C^T+K_ )^9O^_AH ]-S1FO,O[0NO\
MGYF_[^&C^T+K_GYF_P"_AH ]-S1FO,O[0NO^?F;_ +^&C^T+K_GYF_[^&@#T
MW-&:\R_M"Z_Y^9O^_AH_M"Z_Y^9O^_AH ]-S1FO,O[0NO^?F;_OX:/[0NO\
MGYF_[^&@#TW-&:\R_M"Z_P"?F;_OX:/[0NO^?F;_ +^&@#TW-&:\R_M"Z_Y^
M9O\ OX:/[0NO^?F;_OX: /3<T9KS+^T+K_GYF_[^&C^T+K_GYF_[^&@#TW-&
M:\R_M"Z_Y^9O^_AH_M"Z_P"?F;_OX: /3<T9KS+^T+K_ )^9O^_AH_M"Z_Y^
M9O\ OX: /3<T9KS+^T+K_GYF_P"_AH_M"Z_Y^9O^_AH ]-S1FO,O[0NO^?F;
M_OX:/[0NO^?F;_OX: /3<T9KS+^T+K_GYF_[^&C^T+K_ )^9O^_AH ]-S1FO
M,O[0NO\ GYF_[^&C^T+K_GYF_P"_AH ]-S1FO,O[0NO^?F;_ +^&C^T+K_GY
MF_[^&@#TW-&:\R_M"Z_Y^9O^_AH_M"Z_Y^9O^_AH ]-S1FO,O[0NO^?F;_OX
M:/[0NO\ GYF_[^&@#TW-&:\R_M"Z_P"?F;_OX:/[0NO^?F;_ +^&@#TW-&:\
MR_M"Z_Y^9O\ OX:/[0NO^?F;_OX: /3<T9KS+^T+K_GYF_[^&C^T+K_GYF_[
M^&@#TW-&:\R_M"Z_Y^9O^_AH_M"Z_P"?F;_OX: /3<T9KS+^T+K_ )^9O^_A
MH_M"Z_Y^9O\ OX: /3<T9KS+^T+K_GYF_P"_AH_M"Z_Y^9O^_AH ]-S1FO,O
M[0NO^?F;_OX:/[0NO^?F;_OX: /3<T9KS+^T+K_GYF_[^&C^T+K_ )^9O^_A
MH ]-S1FO,O[0NO\ GYF_[^&C^T+K_GYF_P"_AH ]-S1FO,O[0NO^?F;_ +^&
MC^T+K_GYF_[^&@#TW-&:\R_M"Z_Y^9O^_AH_M"Z_Y^9O^_AH ]-S1FO,O[0N
MO^?F;_OX:/[0NO\ GYF_[^&@#TW-&:\R_M"Z_P"?F;_OX:/[0NO^?F;_ +^&
M@#TW-&:\R_M"Z_Y^9O\ OX:/[0NO^?F;_OX: /3<T9KS+^T+K_GYF_[^&C^T
M+K_GYF_[^&@#TW-&:\R_M"Z_Y^9O^_AH_M"Z_P"?F;_OX: /3<T9KS+^T+K_
M )^9O^_AH_M"Z_Y^9O\ OX: /3<T9KS+^T+K_GYF_P"_AH_M"Z_Y^9O^_AH
M]-S1FO,O[0NO^?F;_OX:/[0NO^?F;_OX: /3<UE^*?\ D7[[_KF?YBN&_M"Z
9_P"?F;_OX:CN+VXD@=7GE=2.0SD@T ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tmb-20221231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N X<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !H_MK3O^?\ M?\ O\O^- %VBJ7]M:=_S_VO_?Y?\:/[:T[_ )_[7_O\O^-
M%VBJ7]M:=_S_ -K_ -_E_P :/[:T[_G_ +7_ +_+_C0!=HJE_;6G?\_]K_W^
M7_&C^VM._P"?^U_[_+_C0!=HJE_;6G?\_P#:_P#?Y?\ &C^VM._Y_P"U_P"_
MR_XT 7:*I?VUIW_/_:_]_E_QH_MK3O\ G_M?^_R_XT 7:*I?VUIW_/\ VO\
MW^7_ !H_MK3O^?\ M?\ O\O^- %VBJ7]M:=_S_VO_?Y?\:/[:T[_ )_[7_O\
MO^- %VBJ7]M:=_S_ -K_ -_E_P :/[:T[_G_ +7_ +_+_C0!=HJE_;6G?\_]
MK_W^7_&C^VM._P"?^U_[_+_C0!=HJE_;6G?\_P#:_P#?Y?\ &C^VM._Y_P"U
M_P"_R_XT 7:*I?VUIW_/_:_]_E_QH_MK3O\ G_M?^_R_XT 7:*I?VUIW_/\
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MM/;^))/%MM-F2+5I&MW\Y2>S6\:1D#ID+]2: -RBBB@ HHHH **** "BBB@
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M&G?'?XZ2RK>^&-8U.RL]!E$JI#J\D-NL*-#*3M\IYI&7S2=H$;-G:,T >I^
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M;]J>XC@C2XF\3ZX)950!Y MA#MW'J<9.,],USW[-'_(^?L\?]D.M_P#T+3Z
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M@UC0M,>R@N(+GS0$:"6:<HZM"W/F$,", 8->O_V+IW_/A:_]^5_PKYX_8_\
M$OASQ<WB'Q/=>./"OB7XG^*O+U76=)\/:Y;:A_8]LH"6]F/*=B5A#!6?[K2,
MQ'4$_2E %+^Q=._Y\+7_ +\K_A1_8NG?\^%K_P!^5_PJ[10!2_L73O\ GPM?
M^_*_X4?V+IW_ #X6O_?E?\*NT4 4O[%T[_GPM?\ ORO^%']BZ=_SX6O_ 'Y7
M_"KM% %+^Q=._P"?"U_[\K_A4D&FVEK)OAM887QC='&%/Y@59HH **** "BB
MB@ HHHH **** "BBORF_X*%_%/QK;?M#W&DIJ^HZ5I>DPP2:=#:W#PIEE#&4
M8(RQ;(S_ +-=>%P[Q,^1.QA6JJC'F:/U9HKS']F7Q3K7C7X!^!];\1;VUB\T
MY'GDD&&EP2%D/NZA6_X%7IU<TXN$G%]#6+YDF%%%%24%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!PWC#XS^%O VLQ:7JE[(MXP!=88BXA!Z%R.GK@9/M7:6EU#?6L-S;R+-!,@
MDCD0Y#*1D$>Q%?)G[0_PVUO3_&&I^(5M9+G1[DK*;I.1$< %6'4<]#TKZ%^#
M4L$OPO\ #9MY_/1;1%9CU##[R_@<C\*ZZE*$:<9Q=[G/"I*4W&2.SHHHKD.@
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".
M>+SH)(\XWJ5SZ9%</\"OA;_PI7X3>'?!/]I_VS_9$+Q?;OL_D>;ND=\[-S;?
MOX^\>E=Y10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7R)_P4)T;P)K_PPU9+^Q@F\=6=JMQI]Y%#
MF:!%D5F5G&/E90XVG/7( ZU]=U\G?M/_  EUW5]>U75+:RDO]+O[;8\B8/DG
M;M(8=AT.>E=N#:59-NUCFQ%_9M)7/1OV,?&"^-_V9? =]O#S6]C]@F'</ [1
M<^Y" _C7M=?$O_!+GQ)(?AYXT\)W#GSM'UCST1NJK*@4@>VZ$GZM7VU4XJ'L
MZ\X^9=&7-3BPHHHKD-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *.N:/;^(-'O=-NUW6]U$T3C
MV(QD>XZUXK^SGJMQX<UCQ#X#U-\76GS-+ ">&4'#;?8Y5A[&O>*^??CC:R_#
M_P")/AOQU:*5B>0076WH2 00?]Y"P_X#751]].EW_,PJ^ZU/M^1]!45#:745
M]:PW$+!X94#HP[@C(J:N4W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!/\ ]!*Z_P"^8O\ XBC[!/\ ]!*Z_P"^8O\ XB@"[15+[!/_ -!*Z_[YB_\
MB*/L$_\ T$KK_OF+_P"(H NT52^P3_\ 02NO^^8O_B*/L$__ $$KK_OF+_XB
M@"[15+[!/_T$KK_OF+_XBC[!/_T$KK_OF+_XB@"[15+[!/\ ]!*Z_P"^8O\
MXBC[!/\ ]!*Z_P"^8O\ XB@"[15+[!/_ -!*Z_[YB_\ B*/L$_\ T$KK_OF+
M_P"(H NT52^P3_\ 02NO^^8O_B*/L$__ $$KK_OF+_XB@"[15+[!/_T$KK_O
MF+_XBC[!/_T$KK_OF+_XB@"[15+[!/\ ]!*Z_P"^8O\ XBC[!/\ ]!*Z_P"^
M8O\ XB@"[15+[!/_ -!*Z_[YB_\ B*/L$_\ T$KK_OF+_P"(H NT52^P3_\
M02NO^^8O_B*/L$__ $$KK_OF+_XB@"[15+[!/_T$KK_OF+_XBI(+66&3<]Y-
M.,?<D" ?HH- %FBBB@ HHHH **** "BBB@ HHHH ^)/^"H7A^:+P+X+\7V>8
M[S1=5V"<=4WKN7_QZ,'\*^P?!7B6'QGX/T37K?'DZE9Q7:A3D#>@;'X9Q7D'
M[<GA/_A+OV8/&T:IOFL+==2CXZ>2X=S_ -\;ZS?V!_&G_"7?LX^'XGDWSZ8&
MLWY[*3M_3C\*]&7OX2+_ )6U]^IRKW:[7='T71117G'4%%%% !1110 4444
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M;G/91R:T=-U>QUF&66PO(+V**>6VD>WD#A)8W*21D@\,KJRD=000: +=%%%
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MC_SZVO\ X$M_\;J[10!2\W4?^?6U_P# EO\ XW1YNH_\^MK_ .!+?_&ZNT4
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MQI\/;[X9>.]&M8=1;2;K4([^.>TEQLE2:-5!/(!4 X.1G(( !]!T5\Z?'_\
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M +M%4O[6@_YYW7_@)+_\31_:T'_/.Z_\!)?_ (F@"[15+^UH/^>=U_X"2_\
MQ-']K0?\\[K_ ,!)?_B: +M%4O[6@_YYW7_@)+_\31_:T'_/.Z_\!)?_ (F@
M"[15+^UH/^>=U_X"2_\ Q-']K0?\\[K_ ,!)?_B: +M%4O[6@_YYW7_@)+_\
M31_:T'_/.Z_\!)?_ (F@"[15+^UH/^>=U_X"2_\ Q-']K0?\\[K_ ,!)?_B:
M +M%4O[6@_YYW7_@)+_\31_:T'_/.Z_\!)?_ (F@"[15+^UH/^>=U_X"2_\
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MA1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5F>(/#>F>*M.>PU:RBOK5_X)5S@^H/4'W'-:=%--K5":ON?'OQJ^"$
MG@*^@NM$BO+W2+C.=R^8T#Y^Z2!T/;/IWK4\$O\ &'P3X?MH=*TB=]+<F6*"
M:!)",]>,[USUP<5]745V_6I.*C))^IS?5TI<T78^</\ A:'QF'R_\(EDCO\
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MQ]UT9<%6'K^>0363\%/V>O!7P T6]TWPEI\D(OG5[NYNI3+-.5R%#,>, ,<
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M5-5*_-,XZ(GI&O.!]2>37M-5B*T6E1I?"OQ?<5*F[\\_B?X!1117"= 4444
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M\K_A4%%VBJ7]BZ=_SX6O_?E?\*/[%T[_ )\+7_ORO^% %VBJ7]BZ=_SX6O\
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M3WKUKPK\(O&%WX;TVUU76S:P+"H^S/-)(8ACA2G &!QC/:O:O[%T[_GPM?\
MORO^%']BZ=_SX6O_ 'Y7_"MI8J4HJ-MC*-"*DW<X32?@9HEF0U[/<:@XZKGR
MT/X#G]:?J_P \%:SJ,%Y+ICQ/'C='#,RI*!T##//X$5W']BZ=_SX6O\ WY7_
M  H_L73O^?"U_P"_*_X5A[6I>]S7V<=K$<?AW2H8DB33;18T 55$"X 'X4Y=
M!TQ#E=.M%/M O^%._L73O^?"U_[\K_A1_8NG?\^%K_WY7_"L[LNR,J'X>>&K
M;7O[:BT2SCU/.?M"Q@$'U Z ^^,UT54O[%T[_GPM?^_*_P"%']BZ=_SX6O\
MWY7_  H;;W!)+8NT52_L73O^?"U_[\K_ (4?V+IW_/A:_P#?E?\ "D,NT56@
MTRSMI!)#:01..C)&%/Y@59H **** "O)O%7Q@U'3_C5X:\&Z3:VESILTODZQ
M=S!B\$CP22PQ1X8 -MCW'(/RLOK7K-?/.L?"SQKX<\6>$GL-7TS4EG\276J7
M-Z/#\Y>.26"4&2X9;O:5"[(EP(P,)Z8(!Z9\5_%FM>&(?#%OH3V$-[K.M0Z6
M9]1MGN(XD>*5RVQ)(R3F,?Q#J:ZG08-6M].5-:O;+4+_ ''=/86;VL1'8"-I
M92#[[N?05Q?BCQ%X=\2:'$/%'@;5M4TI=2FM1;WWAYK_ ,N2(.%G\A%D?RW
M8)(%(PPSMW#-;X :%?:#X4U5)K&YTC2+C5KBYT;2[P%9;2Q;;Y:%"<QC.]A&
M<%=V"!T !Z=115:?3XKB0NSS@GLEQ(@_(,!0!9HJE_9,'_/2Z_\  N7_ .*H
M_LF#_GI=?^!<O_Q5 %VBJ7]DP?\ /2Z_\"Y?_BJ/[)@_YZ77_@7+_P#%4 7:
M*I?V3!_STNO_  +E_P#BJ/[)@_YZ77_@7+_\50!=HJE_9,'_ #TNO_ N7_XJ
MC^R8/^>EU_X%R_\ Q5 %VBJ7]DP?\]+K_P "Y?\ XJC^R8/^>EU_X%R__%4
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M0##OXBN#CK+J*C_T&,5\^:5_P3$\7I\7H[6^N["3X?QW8E>^6Z(GEM@V?*"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%07U[!IME<7EU*L%M;QM++
M*Y 5$49))/0  T 3T5R/PO\ B9I?Q9\*IK^D6][:V3S20*E_$(Y24;!.T,<
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M\;J[10!2\W4?^?6U_P# EO\ XW1YNH_\^MK_ .!+?_&ZNT4 4O-U'_GUM?\
MP);_ .-T>;J/_/K:_P#@2W_QNKM% %+S=1_Y];7_ ,"6_P#C='FZC_SZVO\
MX$M_\;J[10!2\W4?^?6U_P# EO\ XW1YNH_\^MK_ .!+?_&ZNT4 4O-U'_GU
MM?\ P);_ .-T>;J/_/K:_P#@2W_QNKM% %+S=1_Y];7_ ,"6_P#C='FZC_SZ
MVO\ X$M_\;J[10!2\W4?^?6U_P# EO\ XW1YNH_\^MK_ .!+?_&ZNT4 4O-U
M'_GUM?\ P);_ .-T>;J/_/K:_P#@2W_QNKM% %+S=1_Y];7_ ,"6_P#C='FZ
MC_SZVO\ X$M_\;J[10!2\W4?^?6U_P# EO\ XW1YNH_\^MK_ .!+?_&ZNT4
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MPMYGB;'F1ALE001\I)(.1DT =I6!XK\=:+X*6R&JW4B3WLABM;6UMI;JXN&
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MB^*?#GC[X,^&]5AT:-M(2\BBGTN\DDDN;=+;8TCQM$@B'^KR SY9^HQS]&4
M<WXD^(WAKPAK&D:3J^KV]GJFK3""RLSEYIF.<$(H)"\$;CA0<#.2*J>)_BSX
M5\':F;#5=2>"X18WG:*TGGBME=MJ-/)&C)"&/ ,A4&N0^.FC:?%J7@O5$L;9
M-3E\0V,$EZL*B9XU+E4+XR5!)(&<<US]_M?1OVAA?'O('W=HO[/39^&,_K0!
M[XCK(H92&5AD$'((KG)/B/X:C\;P>#_[7@?Q+-"UPNG1[G=8U&27(!"<<@,0
M3VS5CP&LZ>"/#ZW)W7 T^#>??RUS7G7BG2K+3_VD/A_/:V<%M-=V>JRW$D,2
MHTSB.%0SD#+'  R>P% '?6WQ'\-7GC6?PC;:Q;W/B*"#[1-8PY=H4SCYR!M5
MN0=I(;!!Q@UTE>1W&D6.D?M'Z+]ALK>R^TZ+?7,_V>)8_-E::+=(V -S' RQ
MY.*]<H YK1OB1X9\1>(]9T'3-8M[[5=' -_#!EA;G)&UG V[@005!R".0*K>
M%_BOX8\8ZN=+TR_F:_\ LXNXX;NQN+4SP$E?-B,J*)4R/O)N'3GD5R_A72+#
M0OCYKUEIME;Z?9IX=M&6WM8EBC4M=7+,0J@ $LS$^I)/>F:*7^)'QI_X22U1
M5\/>%;:YTFWNP!F^O)63S]A[QQ"-5STWE@.AH ]7=UC1G=@J*,EF. !ZUR6C
M?%OPCXA\.ZSKVFZY!>Z/I%Q):W=Y"KE%E158JGR_O#ATQLW;BP"Y/%=5=VD%
M_:S6US#'<6\R&.2&50R.I&"K \$$=C7E7P3L?L3?%&TTQ;>P\OQ5<1VR^3F&
M$BSM0O[M2N5''R@KQQD=: .Y\*>/M$\:R7T6EW%P;FQ94N;6]LI[.>$L,KNB
MF1' (Z'&#6OJFJV6AZ?/?ZC>6^GV-NN^:YNI5CBC7U9F( 'N:\L^')U'3/C+
MXPT_Q!+;ZCKMU86EXNHV$1M[<VRET6(0,SE&5BQR9'W;NV,5ZCJNCV&NV9M-
M2LK;4+4LKF"ZB65"RG*G:P(R" 0>Q% &=X4\;Z'XW\,P>(=%OUN]&F5G2[9&
MB4JI(8D. 0!@]14?@?Q]H/Q)T/\ MCPY?C4M-\UX//$3Q@NAPPPZ@\'OC![5
MX+X>U*XC_9]T?1X;35)K?6=6N;2]NM,TZ>]:UM?M$C2L4A1V^91L''5\]C76
M?LI:G97/A/Q-:64%W!'!XCU%T6XL9K=0C3G: 9$4;@!ROWEZ, : /5/&'C30
M_ &@W&M>(=3@TK3(/OSSGOV50,EF/90"3Z5FZU\4_#F@PZ))<7-W.=:B,UA#
M8:;<W<TZ! Y81PQLX 5@>0*I?&_2K+4OA9XEDN[."ZDM-/N9[=YHE<PR>2Z[
MT)'RMAF&1S@GUKF[/P#J_B'1/AIXBT/6;+2]1T72%5(]0T][N&836Z*<A)HB
MN,=<GZ4 >IZ5J<.L:?!>P)<1PS+N5;JVDMY0/]J.15=3[, :QO&GQ&\-?#R*
MQ?Q#J\&F&_G%M:QON:2>0D#"(H+'!89(&!D9(JM\+/&-SX[\%6>K7MM%:WID
MFMYX[=BT1DBE:-F0GG:2A(SV-<O^T=I5DWPWO]2-G =12?3[=;LQ+YRQ'4+9
MC&'QG:6521G&0#VH [3Q1X]T7P=<6=OJ,URUY>!S;V=A93WMQ(JXWL(H$=]H
MR,MC R.>16W:7*7MK#<1B18Y4611+&T;@$9&Y& 93Z@@$="*\*\0W'BN/X\>
M,[O1+W2+*?3_  Q:O;_VS9R3I+%OG8JNR6/8#(""Y+8V@;3CCUCX<>+6\>>
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M** "N+A^#OA*WUG^TH].F63[7]O%K]ON/L8N>OG"U\SR0^>=VS.>>O-=I10
M4V1!(C(<@,"#M)!_ CD4ZB@#F?#7PYT+PIJD^IV4%W/J<T(MFOM3U"XO[@1!
MMWEK)/([*FXY*J0"<$C(%=-110!R'C#X5>'O'=];W>LKJDTMNRO"MMK-[:QQ
MNN=KK'%,JAQD_-C=[U%JGP<\)ZW?Q7E]I]Q<S+'#%*'U"YV7:Q$&,7*>9MN,
M$#_7!\]\UVE% "*H50   . !VKC=8^$/AO7?%,/B*\75FU> DPSQ:Y?1+""
M&5(TF"(K;1N50 V.0:[.B@#C)?A'X<G\71>)W&KMK43EXY_[=OMB N'*"+SM
M@C) S'MV'&"N.*[.BB@#B+3X-^&K+Q!+K<?]M'5)8_*DGD\0:A)OC^;"%6G*
ME068A2, G( -/\(_"#PWX$:U_L0:O:06H(AM'UV_FMD!ZCR9)FC/4]5KM**
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MT^LWPU_R+FE?]>D7_H K2H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<]E10!B^$=,U;1]#@L]8U"RU.YA C2>QLGM$\L !04:64[N#D[L'/05M444
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(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tmb-20221231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #< ;@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*\%N/V
MMM(M]#\?Z@?#'B".7POJEEHL%A>6HM;K5;N[\M;=8HY,%%=YD4,^ 1ENF*SA
M^UO=75ZGAJP^'VJWOQ(34;S3[KPFM];J;<6UO%<//]I)V-&T=Q;;"!EFF"D#
M!( /HNBOFFS_ &Z/!]WJ.A3&QN[7PQJ.GVU]/K=U-%&;)I[2XNDC>WSO8*EI
M*KNN0'PO/)'O7@C7[OQ5X1TC6;[2+G0;J_MDN7TR](,]KO&X1R8X#@$9'8Y'
M:@#<HIN\<\'CBG4 %%%% !7E'[65W/8?LP_%BYM9Y+6YA\+:E)%/"Y1XV%LY
M#*PY!![BO5ZYWXB^![#XF>!/$'A+56G32M<L)]-NVMG"2B*5"CE&((#88X)!
MH _,G4?C;\0-;_9P_9ET:\\#>*?#VGGQ/X=3_A,KC5(FAU1<LNW"/YI$@);#
MC&%Y[5[EXY_;;^*,5S\5O%O@OP3X9U#X7_#'6GT;6/[5OIHM5OY(F5;AK<*/
M+0*6XW@Y&",G*CW_ %;]E+P=K/PL^'OP_GN-6&A>!K^PU'2GCN4$[2V@80^:
MVS#+\QW  9[8KC_'G[ /PV^('C/7M>N[WQ/IUEXBNXK_ %[PWI6LO;Z3J\Z'
M(>X@"DDD\G:PR<G@G- 'A7Q#_P""H&K^!-+U>(>%],O?$%MXCMQ;V"F8&7PY
M-9"\COF7.X.(V0-_ "?;GZ6_9N_:&U'X_CXC:W:Z?9-X.T;7IM'\/WEFS>;J
M:0H#)*=QVX9F4*1COGI3?%O[%_PV\:?$R^\<:AIUPFJWGAJ7PK);6TJ):BTD
MB:$LJ;,B01N4#!L  <<5VWP:^!WACX$_"K3?A_X9AG.A6*2HIO)!)-+YKL\C
M2, N22YZ <8':@#Y4_9]_;U\9?$WXV6/@_Q9IOA/PG)>3W45QX8U 7UAK6GA
M YB^>=/)NF8*"50J0"3['*\%?M^?$/Q9\9M \%0V/P\U>/Q/-J-E8?V)<W]Q
M%I]S#"[P>?>&,07"LRIN\C)"DG"G KVSPK^P1X \+>,-!UQ]9\6Z_:>'Y+B3
M1="UW6FN]/TYI@0YB4KOZ$XW.<'GD\U7^'__  3^\"?#?Q%X-U;3/$OC2Z7P
M=>37>@Z;J.LB>RT\2[O-BCB,> C[CD_>.!\U 'RG\"/B]X^\1^%/@/J7Q!E'
MB.?6?B5=6UAJ$.L7<=SE7D\WST!".BNH6./E-@Y KU/X.?MZ?$+XD?%U/!FK
M:5X-\)ZO>RWEM'X5U[[?8:K8RHK_ &;=)(ABN=[!=RQ[6 S@9P#[!X/_ &!?
MA]X+GT,V>K^*9[/0_$+>)=,TZ[U-9+:TN&#!XT7R\B)MY) .20"6IWA']A'P
M!X.\<>'/$BZQXNUB#PS=RWVAZ%K.LM=:?IDS\EHE9=_!Y 9SSR<F@#X:^!VJ
M>(K?6O"?C+QI"=7UC7_C(FB?;[;Q)J0:-XWD:4&$OY31(Q4(N/G!(?@"O<?A
M?_P4K\1^/OB=H(?PQI+> ]=UU]%BM;"&^DUC3HMYCBO+A_*^SM&S8W*C94'V
MR?H?2OV*/ 6DV'AZT@N-;,.A^,7\<6OF7:$G4'.2K_N^8O\ 9X/^U5;P;^PS
MX$\ ^/;/Q'HNK^++?3K'4Y=8L?"8UMQHMI=R?>DCMP 1SR%+%>V,<4 ?(OQE
M_:9^*_QV^%'A'QQ!H^B^'?A?J7Q$LM/TV;3]1G36%6*Y= UP.$9),."HP5*C
M@@YK[2_:T^.6K_ KP)IFHZ'<>%;._O\ 4H[$7'BR[EC@B5@26CAA4RW#C _=
MQC.,GG&#PEW_ ,$W/AA<ZJLT>K^,+/2(=;'B&S\.V^MD:797F_>TD,#(0-W0
MY)(!(!%>L?';]G+P[^T!;>'#K.HZUH>J^';_ /M+2]7\/7@M;NUFQ@E6*L,$
M =1V% 'R/X9_X*%?%7QUX9\(6?AWP;X6N_&.M^,M1\'G[4]W;V3-;P02I<A7
MQ+&N)B61QNPG0$X%?Q?_ ,%(/B%X0\;ZWI,GA3PU?_\ "(75MI>O:19IJ$M_
MJ=U\HNWL'2-HHXXV+;1,VYE7/? ^B/ O["?@'P#KFAZK9ZIXFOKO2/$5SXIA
MDU+4UN&EOKB!(9GE<Q[G#+&K')SNR<\XJ3QO^PUX#\:?$#6?%']K^+-#37KJ
M"]US0]#UI[/3M5GA.4DGB49+<#)5ER>>I)H U/VI/C]K/P'^&GAWQ_H^DVFK
M>&O[6L8M>-VLBRVNG3L%:>, C#*60888^;VKQ?Q3^WYXDAMO&EYX8\+Z1K=B
M_CBU\ >"YGN)$CU*_92;B:>0';Y*$+M*8W;L9X)KW+]KOP[XL\:? ?Q#X4\'
M>#K'QG?Z_;R:5+:ZAJ2V4=K')&P^TAF!WF-PA"94DX.>*X_P)^P_X1@_9(\+
M_!OQ9$]S_9PCOI]1TJ<PSQ:GO,CW$$N,@J[LJDCE< B@#RGQ?^W9\3?A&GC3
MPMXX\)^%C\0_#EWI#K)H]Q<2:9>V5[,(RZ[\2)(A9>&/.3QQS]$>#_CIJOB3
M]J?XA_"V;3;.+2?#6CV&I6][&7\^5[@997!.W [8%<A'^P!\-;GP-XQ\/ZM>
M^)O$5_XLFMKC4_$VLZL9]79[=@T!2<KA0A' VX.<'( QUWP5_92\,_ _QOK_
M (OT[7?%'B+Q'KMI#9ZCJ/B;5/MTUPL1^1RQ4'=C"]< *  * /GC]HC_ (*)
M>)_@+X@^(_A:;PII>H>+-#UFR31;)6FQJ&E3VTMP]RP!SNC6(JQ7Y06&1QS@
M>/\ ]K"]^-?C?PC=:1I%E>>"+3XI:+X?\/ZG;ZE=6KW5T]JTTSS>6P62)'9%
MV$88,<BOJOQ]^R=X!^)'QFT[XG:U97,_B2QTB?1%195%O+;RQRQL73:27"SR
M@,&&,CKBN<\+_L,?#GP?X$\ >$],;5X=-\%>)$\5Z?*UTAFGOE9B#.WEX=/F
MQ@!3A5&>* /A?Q+\4_C+K?[*_P 6-8\5ZM!?75E\48;"SDTW4KE9UN8[A$FM
M$+8"6@&P1XP?F<L*^X?@#\>_B!XE^.?COX5_$O0_#VFZ]H6G6FL6MSX:FGDM
MY+>?JC&4 ED)5=P !(;BH+G]@?X?W5AXSTY]7\4KH_BK7HO$EUI:ZFIMK:]2
M8S%[=#&=F]B V<DJJC(P*]6T?X)Z#HWQJU[XHPRWI\2:UI<&D7,;S*;80Q,&
M4JFW(;(Y)8_2@#\Z?CO\3/C'>P?MEV>LZU91:!X>328($T^_N5ET[=/&UJMH
M.%421LQG)P=V ,K7N6E_MI_$#X/ZAX@T3XI^$=#QIOP]7QKI2^'KN9Y'C5TA
M%M/)*,&3<WS.HP,' :O5OB!^PGX#^(_BKXA:WJ&K^*+$>/+6"VUS3=.U-8[.
M<PF(Q3"(QM^\7RA@DD#<^!\U=5XK_93\#^-_&1\1:Y!>:C,_A-_!DME)< 6T
MNGN^]MP"[O,ST<,,8&!D T >+_LE?MK^*_C1\2HO"?BO1=&DBU/1O[8LM6\-
M6U^EO:.""UE<FYC4&4*=V^,E#C )R,;OQ0_:0^*^J_'KQ5\-/@]X6\+ZK=>#
MM(M]5UB;Q1=RP_:FF4-';V^PA5;:P.]SMSG)7'/H'P3_ &2_#?P.\0_VU8>)
M/%_B6]BTU-'LQXFUI[N*PLE8,((8PJJJ@@8R"0!@$9.<[XU?L4^"/C;XTN_%
M-YJOB?PSJ^H:<-(U63PSJQLUU6S!_P!1<KM8.N..V1@'.!@ YJ+]K#Q9'X\^
M*'AV_P#"^F:9/X0^'\'BP6YN3.RWCVYD>VDE0['16!7>G4#(ZUPO@C]L#XR?
M%_X@>!/"W@OPEX/$FL>"M.\8ZK>:K/<(EK%-,8YDC"DEC]W:#W)R<5Z1XS_8
M ^&WB[4;6YMKWQ/X5@C\/P^%[FP\.ZR]K!?Z=$NV.&X&TF0!0!U&[ SFNS^%
M7[+'A#X/>+=,\1Z%/JDFH:=X6M_"$*WMRDD?V&&3S$9@$&9-PY;.,=A0!\HV
M?_!0GXMVOP1D^*NL>"_"%OX9U75#X;T!(KBZ,SZAY[+YUP!NQ;JD<V0H+LR
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M ()X?#OQAK?B>^DU_P 9:99^(=7&OWNBZ=K(CT\ZAN#_ &D1&-LOD'ABP&>
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MY_P42\=>.?BMI)A\,6%WX"U7Q0WAY=-L-+U*35+&W\SRUOY;H(;5ANY:-3N
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M%TFRT^!I'AM($@1IG+N550H+,>IP.3WH N4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX)))->@44 <GXN'_ !5?@?\ ["4__I%<5UE<GXN_Y&OP/_V$I_\ TBN*ZR@
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MM/;+ZR(#N0?[P%7=+U>QURQBO=.O(+^SF&Z.XM95DC<9QE64D'GTH MT444
M%%%% !112'...M #);F*!HUDE2-I&VH&8 L<9P/4TU[R".>*!YXUFE!,<;.
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M** "BBB@ HHHH **** "BBB@#D_%W_(U^!_^PE/_ .D5Q765R?B[_D:_ _\
MV$I__2*XKK* "BBB@ HHHH **** "BBB@ HHHH *\L_:3^,D_P !OA;>>+[?
M2H]9DM[B" 6DLYA5O,<+G<%;IG/2O4Z^:/\ @HC_ ,FQ:Q_U_P!E_P"CEK"O
M)PI2E'=)GN9%AJ6,S7"X:NKPG.*:[IM)['A/_#T_5?\ HG5E_P"#9_\ XS1_
MP]/U3_HG5G_X-G_^,U\*45\Q]>Q'\WX(_K3_ (A]PU_T"_\ DT__ )(^Z_\
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M>>I^&.]?[P_.C<O]X?G7[F?\*E\$?]"9X>_\%<'_ ,31_P *E\$?]";X>_\
M!7!_\37C_P!E_P!_\#]R_P"(N+_H"_\ )_\ [4_#/<O]X?G7TQ_P3MD1?VF=
M.+.H']F7G4C^XM?II_PJ7P1_T)OA[_P5P?\ Q-*OPF\$J<CP?H"'U33(0?\
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MS/\ A4O@CMX,\/\ XZ7!_P#$T?\ "I?!'_0F^'O_  5P?_$UXG]E_P!_\/\
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MYZQ_]]"C[5#_ ,]4_P"^A7.?\*N\&_\ 0J:+_P""^+_XFC_A5W@W_H4]%_\
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M%_\ !?%_\30!T1N(#UEC/_ A2_:8.?WL?/\ M"N<_P"%7>#?^A3T7_P7Q?\
MQ-)_PJ_P:?\ F4]%_P#!?%_\30&AT?GV_P#STC_[Z%*+F$#_ %L?_?0KG/\
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M24N3N+J#G- 'S_H'[5?CKX;:-XMUOQ?I=EXC\+6FL^,%M;FWO674%&FSSO'
M8S&$$96)HE.XL BL<Y(&AIG[8OQ!UB?3O#]MX#TV#Q7J.M:?IEK+JCW^GZ>\
M=U9W=P7Q/;+-F,V;IPA5]RE2.0/HN'X.>"8+6.T7PSI[VJ3WMR(98_,0R7@<
M7;$-D-YHD?=G.=QK,\,?L[_#CP6+,Z+X1L+&2TOHM2@E&]Y$N(H7@B?>S%OD
MBDD15)VJKD #- 'HML)A"GGE/.VC?Y>=H;'.,]LU+110 4444 %?)_[3.M^.
MI?B7=1^'=8\0S^'-'\-K<WFG>!M3LH=5TNZDEE*7L]K<!?M4)2,!4#XS'+E2
M2"/K"O/?B3\ OA[\6]0MK_Q?X4L-;OK>W:U2YF#)(8&.6B9D(+QD\[&RO)XY
M- '@=C^VEJ<GB/P;I^EVVE>+=#U>\T?1SK5M'=Q223WUI'*ES*!";>V^:5#]
ME:4R[22,< \[X/\ VH/B1I/A#P[J.HZ:OBKQ)J/AS2;R9+-Y9+=$N;R]5[D6
MD4/G2R*D W)"&)&,* A8_2DW[.?PTE\4VWB(^#=,&L6UU!>03HA18KB%42&9
M(P0BR(D:('"YVJ%SCBJH_9B^%B::VGIX*TZ.UWQR(L>]6A9)I)D,3AMT162:
M5AL*X\QL<$T ?-5U^T'XS\<_%7PAK<6M16GA9]#T6Z?2O#NJ2"%[NZUT:?.7
M:2W#2!2&4QNJ%0I'RODC4TW_ (*"ZU?:7)K'_"OY3I>JV\[Z#(_VJ",3B]AM
M(([FXD@$+)(9U=GMVD$85@<G!KZ4L/@+\/=+CLDM/"6FVRV=O;VT CC(\N."
MZ^UP@<_PW&9<GDN2222:I0?LU_"^"ZUR9?!&DEM:MY[2^1X=\<L,[^9/&J$E
M8UD<!F"!=S $\@4 9WP$\5^,?$7B/XH6?C1K%-0TC7H;."VTNX,]K#"=/M)1
MY;,JL-QD9BK#(9CSC%>PUR7PZ^%WA7X5Z?>V7A318-&M[VY-W=")G9IYBJJ9
M'9B69MJ*,D] *ZV@ KEOBCH>M^)?AUXCTSPSK$N@>([FQE33=3AVYM[G:3$Y
MW @C>%R".1FNIHH ^'=8_;/UW4?^$9\6:/!+<6>GZ5IVF:IH4*N4?Q'J<XA%
MO.(XWE(M$MYW,<:EV,T8 Y&.FTO]K?XE^,;RST;PQ\/M+D\1QV>MWEY;:U=7
M=BLRZ?+;QJ+='@\T--]JCPLJH4.X'. 3[]<_ WP#<Z!XAT23PIIATGQ#J+ZM
MJMJL.U;N\=E9KAB.1)N1"'!!!4$8-8FK?#7PI\'O!.L^(?"7AZQTC5]#T;4W
ML;E$+.IEQ<3;BQ)<R2Q1NQ;)8J,F@#,^"O[1,?QRT_Q-KND6L-EX2TRULQ;Z
MM-(7,EW):+<W,;I@ + )84;G.\2 XVU\[>"_C/XV^$DFD>(?'GB?6KK^T-$U
M"]CO-1U&RO/"OB>9(#<0O974*B33QA694>([HR%^9QD_3O[,/@[3_!WP+\*V
MUBK-_:%LVKW4DBH&FN;MVN)W(554 O*V   %  X%1Z;^RG\(=+?5);7X?:+'
M_:5M/9W$1@+1>3,<RQHC$K$KGDA O:@#QC2/VG/B-XX\7>'=$M;#2=%EM?&=
MKI&J/)#>P+>VLVE7%V D5S DR8,388J-Q6,@[685E?"O]L'Q?J^E^!M+DT6U
MM+;6=,LHK/6_$E[/*U]>7%FTR_Z1#;^1YBR;$,$GER.-S*,;0?H2P_9H^&.F
M9^S^$+)7:_MM5:9WE>5KNW#K!.9&8L719'4-G.UBIR.*=I/[-/PNT#6M+U73
MO!.EV=]IB0Q6DD2,%C$4;10MLSM9TC9D5R"R@X!% 'R)\*?VL/&?@#PSX/M=
M8DU+QIXJ\7:)X?NX9[VXGO+>*6^74;B606]O;&8$16F/+B# DJ!M52Q['Q-^
MV!\0/'?PP\57'A;PS:>&-1T#0DOM<GU2^D@N;:26[N+9#9QO"-V!:2R_O0I^
M9(R V<?2%U^SC\-+O28M-E\':<;.&VLK.%%5E:&*S+FT$;@[D,1EDVLI!&]N
M>:HZG^RS\)=;TW1["\\!:1+9:3;_ &2S@6(HJ0^;YNQMI'F+YN9,/N^<EOO$
*F@#UJBBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>tmb-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/13/2023 10:39:27 PM-->
<!--Modified on: 3/13/2023 10:39:27 PM-->
<xsd:schema targetNamespace="http://www.virios.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:viri="http://www.virios.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>00200 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40501 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
        <link:definition>41002 - Disclosure - Income Taxes - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesNetDeferredTaxAssetsDetails">
        <link:definition>41003 - Disclosure - Income Taxes - Net deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>30903 - Disclosure - Share-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails" id="DisclosureBackgroundAndOrganizationDetails">
        <link:definition>40101 - Disclosure - Background and Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Equity Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails">
        <link:definition>40203 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureLicenseAgreementDetails" id="DisclosureLicenseAgreementDetails">
        <link:definition>40401 - Disclosure - License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureRelatedPartiesDetails" id="DisclosureRelatedPartiesDetails">
        <link:definition>40701 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>40801 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails" id="DisclosureShareBasedCompensationEquityIncentivePlanDetails">
        <link:definition>40901 - Disclosure - Share-based compensation - Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails" id="DisclosureShareBasedCompensationNarrativeDetails">
        <link:definition>40902 - Disclosure - Share-based compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails" id="DisclosureShareBasedCompensationUnregisteredSecuritiesDetails">
        <link:definition>40903 - Disclosure - Share-based compensation - Unregistered Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails" id="DisclosureShareBasedCompensationUnderwritersWarrantsDetails">
        <link:definition>40904 - Disclosure - Share-based compensation - Underwriters Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/StatementBalanceSheetsParentheticals" id="StatementBalanceSheetsParentheticals">
        <link:definition>00105 - Statement - BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureBackgroundAndOrganization" id="DisclosureBackgroundAndOrganization">
        <link:definition>10101 - Disclosure - Background and Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>10301 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureLicenseAgreement" id="DisclosureLicenseAgreement">
        <link:definition>10401 - Disclosure - License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10501 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10601 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureRelatedParties" id="DisclosureRelatedParties">
        <link:definition>10701 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>10909 - Disclosure - Share-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11001 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30503 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31003 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCashDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>40601 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.virios.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>41001 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:element id="viri_AccountingPoliciesTable" name="AccountingPoliciesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="viri_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="viri_NorthriverPharmLlcMember" name="NorthriverPharmLlcMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock" name="PrepaidExpenseAndOtherAssetsCurrentTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock" name="PrepaidExpenseAndOtherAssetsCurrentTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="viri_PrepaidServices" name="PrepaidServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="viri_LicenseAgreementAbstract" name="LicenseAgreementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="viri_KnowHowLicenseAgreementMember" name="KnowHowLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest" name="CollaborativeArrangementPercentageOfNonVotingMembershipInterest" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="viri_LicenseAgreementExpirationPeriod" name="LicenseAgreementExpirationPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="viri_AccruedResearchAndDevelopmentCosts" name="AccruedResearchAndDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="viri_AccruedInterestOnPreferredMembersInterest" name="AccruedInterestOnPreferredMembersInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="viri_ChiefMedicalOfficerMember" name="ChiefMedicalOfficerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="viri_PercentageOfCashBonusOnSalary" name="PercentageOfCashBonusOnSalary" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="viri_VicePresidentOperationsAndFinanceMember" name="VicePresidentOperationsAndFinanceMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="viri_PrepaidClinicalResearchCosts" name="PrepaidClinicalResearchCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="viri_GendreauConsultingLlcMember" name="GendreauConsultingLlcMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="viri_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="viri_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="viri_StatusOfCompanyPolicyTextBlock" name="StatusOfCompanyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="viri_EquityIncentivePlan2020Member" name="EquityIncentivePlan2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="viri_NonQualifiedStockOptionsMember" name="NonQualifiedStockOptionsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="viri_AccruedDirectorFeesCurrent" name="AccruedDirectorFeesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="viri_TorreyaCapitalLlcMember" name="TorreyaCapitalLlcMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice" name="WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element name="CommonAndPreferredStockSharesAuthorized" id="viri_CommonAndPreferredStockSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightGranted" id="viri_ClassOfWarrantOrRightGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercisable" id="viri_ClassOfWarrantOrRightExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract" id="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" id="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" id="viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" id="viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightRemainingTerm" id="viri_ClassOfWarrantOrRightRemainingTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" id="viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AggregateIntrinsicValueOfWarrantsOutstanding" id="viri_AggregateIntrinsicValueOfWarrantsOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" id="viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsInvestmentInPartnership" id="viri_DeferredTaxAssetsInvestmentInPartnership" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxAssetsAmortization" id="viri_DeferredTaxAssetsAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent" id="viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmploymentAgreementSeverancePaymentPaymentPeriod" id="viri_EmploymentAgreementSeverancePaymentPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmploymentAgreementThresholdTerminationPeriod" id="viri_EmploymentAgreementThresholdTerminationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmploymentAgreementHealthBenefitOfferedPeriodOnTermination" id="viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmploymentAgreementChangeOfControlTerminationPaymentPeriod" id="viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary" id="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus" id="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary" id="viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment" id="viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfVotesPerCommonStock" id="viri_NumberOfVotesPerCommonStock" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" id="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CapitalizedResearchAndDevelopmentExpense" id="viri_CapitalizedResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>tmb-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/13/2023 10:39:27 PM-->
<!--Modified on: 3/13/2023 10:39:27 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementBalanceSheets" roleURI="http://www.virios.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfOperations" roleURI="http://www.virios.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.virios.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.virios.com/role/DisclosureAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" roleURI="http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" />
  <calculationLink xlink:role="http://www.virios.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638143439663425432" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638143439663425432" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638143439663425432" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638143439663425432" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638143439663425432" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638143439663425432" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638143439663425432" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638143439663425432" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638143439663425432" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638143439663425432" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638143439663435443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638143439663435443" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638143439663435443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638143439663435443" xlink:to="us-gaap_LiabilitiesCurrent_638143439663435443" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638143439663435443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638143439663435443" xlink:to="us-gaap_AccountsPayableCurrent_638143439663435443" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638143439663435443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638143439663435443" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638143439663435443" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638143439663435443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638143439663435443" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638143439663435443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638143439663435443" xlink:to="us-gaap_AdditionalPaidInCapital_638143439663435443" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638143439663435443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638143439663435443" xlink:to="us-gaap_CommonStockValue_638143439663435443" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638143439663435443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638143439663435443" xlink:to="us-gaap_PreferredStockValue_638143439663435443" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638143439663435443" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638143439663435443" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638143439663435443" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.virios.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638143439663445424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638143439663445424" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638143439663445424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638143439663445424" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638143439663445424" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_638143439663445424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638143439663445424" xlink:to="us-gaap_InterestIncomeExpenseNet_638143439663445424" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638143439663445424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638143439663445424" xlink:to="us-gaap_OtherNonoperatingIncome_638143439663445424" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638143439663445424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638143439663445424" xlink:to="us-gaap_OtherNonoperatingExpense_638143439663445424" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638143439663445424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638143439663445424" xlink:to="us-gaap_OperatingIncomeLoss_638143439663445424" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638143439663445424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638143439663445424" xlink:to="us-gaap_OperatingExpenses_638143439663445424" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638143439663445424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638143439663445424" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638143439663445424" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638143439663455426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638143439663445424" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638143439663455426" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638143439663455426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638143439663445424" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638143439663455426" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.virios.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638143439663455426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638143439663455426" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638143439663455426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638143439663455426" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638143439663455426" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638143439663455426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638143439663455426" xlink:to="us-gaap_ProceedsFromWarrantExercises_638143439663455426" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638143439663455426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638143439663455426" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638143439663455426" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439663455426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439663455426" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638143439663455426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439663455426" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638143439663455426" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638143439663465424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439663455426" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638143439663465424" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638143439663465424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439663455426" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638143439663465424" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_638143439663465424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439663455426" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries_638143439663465424" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638143439663465424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439663455426" xlink:to="us-gaap_ShareBasedCompensation_638143439663465424" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638143439663465424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439663455426" xlink:to="us-gaap_ProfitLoss_638143439663465424" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638143439663465424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_638143439663465424" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PrepaidClinicalResearchCosts" xlink:label="viri_PrepaidClinicalResearchCosts_638143439663465424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="viri_PrepaidClinicalResearchCosts_638143439663465424" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PrepaidServices" xlink:label="viri_PrepaidServices_638143439663475424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="viri_PrepaidServices_638143439663475424" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent_638143439663475424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousCurrent_638143439663475424" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.virios.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccruedInterestOnPreferredMembersInterest" xlink:label="viri_AccruedInterestOnPreferredMembersInterest_638143439663475424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="viri_AccruedInterestOnPreferredMembersInterest_638143439663475424" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638143439663475424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638143439663475424" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638143439663475424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638143439663475424" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccruedDirectorFeesCurrent" xlink:label="viri_AccruedDirectorFeesCurrent_638143439663475424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="viri_AccruedDirectorFeesCurrent_638143439663475424" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccruedResearchAndDevelopmentCosts" xlink:label="viri_AccruedResearchAndDevelopmentCosts_638143439663475424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="viri_AccruedResearchAndDevelopmentCosts_638143439663475424" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638143439663475424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638143439663475424" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes - Reconciliation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638143439663485425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638143439663485425" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638143439663485425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638143439663485425" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638143439663485425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638143439663485425" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638143439663485425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638143439663485425" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638143439663485425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638143439663485425" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent" xlink:label="viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent_638143439663485425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent_638143439663485425" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Net deferred tax assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638143439663485425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638143439663485425" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638143439663485425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_638143439663485425" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638143439663485425" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638143439663495424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638143439663495424" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638143439663495424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638143439663495424" xlink:to="us-gaap_DeferredTaxAssetsGross_638143439663495424" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638143439663495424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638143439663495424" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638143439663495424" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638143439663495424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638143439663495424" xlink:to="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638143439663495424" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638143439663495424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638143439663495424" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638143439663495424" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_DeferredTaxAssetsInvestmentInPartnership" xlink:label="viri_DeferredTaxAssetsInvestmentInPartnership_638143439663495424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638143439663495424" xlink:to="viri_DeferredTaxAssetsInvestmentInPartnership_638143439663495424" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_DeferredTaxAssetsAmortization" xlink:label="viri_DeferredTaxAssetsAmortization_638143439663495424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638143439663495424" xlink:to="viri_DeferredTaxAssetsAmortization_638143439663495424" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638143439663495424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638143439663495424" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638143439663495424" order="2" use="optional" weight="-1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>tmb-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/13/2023 10:39:27 PM-->
<!--Modified on: 3/13/2023 10:39:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.virios.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBackgroundAndOrganizationDetails" roleURI="http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails" roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseAgreementDetails" roleURI="http://www.virios.com/role/DisclosureLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.virios.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationEquityIncentivePlanDetails" roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationNarrativeDetails" roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationUnregisteredSecuritiesDetails" roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.virios.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tmb-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:role="http://www.virios.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_1" xlink:title="srt_LitigationCaseAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_1" xlink:title="srt_LitigationCaseTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_LitigationCaseAxis_1" xlink:to="srt_LitigationCaseTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_LitigationCaseAxis_1 To srt_LitigationCaseTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_1" xlink:title="srt_EquityMethodInvesteeNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:to="srt_EquityMethodInvesteeNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1 To srt_EquityMethodInvesteeNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:title="us-gaap_DerivativeInstrumentRiskAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_1" xlink:title="us-gaap_DerivativeContractTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:to="us-gaap_DerivativeContractTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DerivativeInstrumentRiskAxis_1 To us-gaap_DerivativeContractTypeDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.virios.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="viri_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="viri_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="viri_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="viri_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="viri_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Background and Organization (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice" xlink:label="viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment" xlink:label="viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Equity Method Investment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccountingPoliciesTable" xlink:label="viri_AccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="viri_AccountingPoliciesTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_NorthriverPharmLlcMember" xlink:label="viri_NorthriverPharmLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="viri_NorthriverPharmLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccountingPoliciesLineItems" xlink:label="viri_AccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="viri_AccountingPoliciesLineItems" xlink:to="viri_AccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="viri_AccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="viri_AccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.virios.com/role/DisclosureLicenseAgreementDetails" xlink:type="extended" xlink:title="40401 - Disclosure - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_KnowHowLicenseAgreementMember" xlink:label="viri_KnowHowLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="viri_KnowHowLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest" xlink:label="viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_LicenseAgreementExpirationPeriod" xlink:label="viri_LicenseAgreementExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="viri_LicenseAgreementExpirationPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.virios.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Related Parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_GendreauConsultingLlcMember" xlink:label="viri_GendreauConsultingLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="viri_GendreauConsultingLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_TorreyaCapitalLlcMember" xlink:label="viri_TorreyaCapitalLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="viri_TorreyaCapitalLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_VicePresidentOperationsAndFinanceMember" xlink:label="viri_VicePresidentOperationsAndFinanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="viri_VicePresidentOperationsAndFinanceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ChiefMedicalOfficerMember" xlink:label="viri_ChiefMedicalOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="viri_ChiefMedicalOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PercentageOfCashBonusOnSalary" xlink:label="viri_PercentageOfCashBonusOnSalary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="viri_PercentageOfCashBonusOnSalary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementSeverancePaymentPaymentPeriod" xlink:label="viri_EmploymentAgreementSeverancePaymentPaymentPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="viri_EmploymentAgreementSeverancePaymentPaymentPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary" xlink:label="viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementThresholdTerminationPeriod" xlink:label="viri_EmploymentAgreementThresholdTerminationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="viri_EmploymentAgreementThresholdTerminationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination" xlink:label="viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Share-based compensation - Equity Incentive Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EquityIncentivePlan2020Member" xlink:label="viri_EquityIncentivePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="viri_EquityIncentivePlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Share-based compensation - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EquityIncentivePlan2020Member" xlink:label="viri_EquityIncentivePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="viri_EquityIncentivePlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Share-based compensation - Unregistered Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EquityIncentivePlan2020Member" xlink:label="viri_EquityIncentivePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="viri_EquityIncentivePlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_NonQualifiedStockOptionsMember" xlink:label="viri_NonQualifiedStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="viri_NonQualifiedStockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>tmb-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/13/2023 10:39:27 PM-->
<!--Modified on: 3/13/2023 10:39:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and members'/stockholders equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 8)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value; 43,000,000 shares authorized, 18,330,390 and 8,330,390 shares issued and outstanding at December 31, 2022 and 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.0001 par value; 2,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (expense) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of shares outstanding - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of shares outstanding - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Statements of Changes of Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common shares in public offering, net of costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common shares in public offering, net of costs (shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="viri_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="viri_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="viri_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="viri_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based and equity compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease (increase) in prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) increase in accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in accrued salaries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from initial public offering, net of costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from public offering of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Background and Organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Background and Organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:label="viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:to="viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entire disclosure of prepaid expense and other assets current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_LicenseAgreementAbstract" xlink:label="viri_LicenseAgreementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_LicenseAgreementAbstract" xlink:to="viri_LicenseAgreementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_LicenseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_LicenseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Interest Entities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investments [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Net Income (Loss) per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_StatusOfCompanyPolicyTextBlock" xlink:label="viri_StatusOfCompanyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_StatusOfCompanyPolicyTextBlock" xlink:to="viri_StatusOfCompanyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_StatusOfCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for change in status of company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_StatusOfCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Status of Company [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_StatusOfCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock" xlink:label="viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock" xlink:to="viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of prepaid expense and other assets current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of underwriters warrants to purchase common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of federal income tax rate to effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice" xlink:label="viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice" xlink:to="viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercise price as percentage of initial public offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price As Percentage Of Initial Public Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercise price percentage of IPO Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercise price</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment" xlink:label="viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment" xlink:to="viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period in which the company has to raise additional capital to complete clinical development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period in Which Company Has to Raise Additional Capital to Complete Clinical Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period in which the company has to raise additional capital to complete clinical development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, FDIC Insured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federally insured limit</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccountingPoliciesTable" xlink:label="viri_AccountingPoliciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_AccountingPoliciesTable" xlink:to="viri_AccountingPoliciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_AccountingPoliciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_AccountingPoliciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_NorthriverPharmLlcMember" xlink:label="viri_NorthriverPharmLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_NorthriverPharmLlcMember" xlink:to="viri_NorthriverPharmLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_NorthriverPharmLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Northriver Pharm, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_NorthriverPharmLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NRP</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccountingPoliciesLineItems" xlink:label="viri_AccountingPoliciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_AccountingPoliciesLineItems" xlink:to="viri_AccountingPoliciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_AccountingPoliciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_AccountingPoliciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity method investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid insurance</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PrepaidClinicalResearchCosts" xlink:label="viri_PrepaidClinicalResearchCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_PrepaidClinicalResearchCosts" xlink:to="viri_PrepaidClinicalResearchCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_PrepaidClinicalResearchCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of consideration paid in advance for clinical research costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_PrepaidClinicalResearchCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Clinical Research Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_PrepaidClinicalResearchCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid clinical research costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PrepaidServices" xlink:label="viri_PrepaidServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_PrepaidServices" xlink:to="viri_PrepaidServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_PrepaidServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents element information pertaining to prepaid services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_PrepaidServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="viri_PrepaidServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Miscellaneous, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other miscellaneous current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_KnowHowLicenseAgreementMember" xlink:label="viri_KnowHowLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_KnowHowLicenseAgreementMember" xlink:to="viri_KnowHowLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_KnowHowLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to know-how license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_KnowHowLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest" xlink:label="viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest" xlink:to="viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents element information pertaining to percentage of non-voting membership interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Percentage of Non Voting Membership Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of non-voting membership interest</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_LicenseAgreementExpirationPeriod" xlink:label="viri_LicenseAgreementExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_LicenseAgreementExpirationPeriod" xlink:to="viri_LicenseAgreementExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_LicenseAgreementExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents element information pertaining to license agreement expiration period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_LicenseAgreementExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="viri_LicenseAgreementExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccruedInterestOnPreferredMembersInterest" xlink:label="viri_AccruedInterestOnPreferredMembersInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_AccruedInterestOnPreferredMembersInterest" xlink:to="viri_AccruedInterestOnPreferredMembersInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_AccruedInterestOnPreferredMembersInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable pertaining to pertaining to accrued interest on preferred member's interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_AccruedInterestOnPreferredMembersInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Interest on Preferred Members Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="viri_AccruedInterestOnPreferredMembersInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest on preferred members' interests</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccruedResearchAndDevelopmentCosts" xlink:label="viri_AccruedResearchAndDevelopmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_AccruedResearchAndDevelopmentCosts" xlink:to="viri_AccruedResearchAndDevelopmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_AccruedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable pertaining to accrued research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_AccruedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="viri_AccruedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued clinical research costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccruedDirectorFeesCurrent" xlink:label="viri_AccruedDirectorFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_AccruedDirectorFeesCurrent" xlink:to="viri_AccruedDirectorFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_AccruedDirectorFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for director fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_AccruedDirectorFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Director Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_AccruedDirectorFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued director fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other miscellaneous accrued expenses</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_CommonAndPreferredStockSharesAuthorized" xlink:label="viri_CommonAndPreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_CommonAndPreferredStockSharesAuthorized" xlink:to="viri_CommonAndPreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_CommonAndPreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of common and preferred shares permitted to be issued by an entity's charter and bylaws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_CommonAndPreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common and Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_CommonAndPreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common and preferred stock authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_NumberOfVotesPerCommonStock" xlink:label="viri_NumberOfVotesPerCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_NumberOfVotesPerCommonStock" xlink:to="viri_NumberOfVotesPerCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_NumberOfVotesPerCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_NumberOfVotesPerCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Votes Per Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_NumberOfVotesPerCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_GendreauConsultingLlcMember" xlink:label="viri_GendreauConsultingLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_GendreauConsultingLlcMember" xlink:to="viri_GendreauConsultingLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_GendreauConsultingLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Gendreau Consulting, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_GendreauConsultingLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gendreau Consulting, LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount paid to the firm</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_TorreyaCapitalLlcMember" xlink:label="viri_TorreyaCapitalLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_TorreyaCapitalLlcMember" xlink:to="viri_TorreyaCapitalLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_TorreyaCapitalLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Torreya Capital LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_TorreyaCapitalLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Torreya Capital LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CEO</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_VicePresidentOperationsAndFinanceMember" xlink:label="viri_VicePresidentOperationsAndFinanceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_VicePresidentOperationsAndFinanceMember" xlink:to="viri_VicePresidentOperationsAndFinanceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_VicePresidentOperationsAndFinanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Vice President Operations and Finance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_VicePresidentOperationsAndFinanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VP of Operations and Finance</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ChiefMedicalOfficerMember" xlink:label="viri_ChiefMedicalOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_ChiefMedicalOfficerMember" xlink:to="viri_ChiefMedicalOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_ChiefMedicalOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Chief Medical Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_ChiefMedicalOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CMO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Damages Sought, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction fee</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PercentageOfCashBonusOnSalary" xlink:label="viri_PercentageOfCashBonusOnSalary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_PercentageOfCashBonusOnSalary" xlink:to="viri_PercentageOfCashBonusOnSalary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_PercentageOfCashBonusOnSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of cash bonus on salary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_PercentageOfCashBonusOnSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Cash Bonus on Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="viri_PercentageOfCashBonusOnSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of cash bonus on salary</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementSeverancePaymentPaymentPeriod" xlink:label="viri_EmploymentAgreementSeverancePaymentPaymentPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_EmploymentAgreementSeverancePaymentPaymentPeriod" xlink:to="viri_EmploymentAgreementSeverancePaymentPaymentPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_EmploymentAgreementSeverancePaymentPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period in which the severance payment is payable in cash to the executive under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_EmploymentAgreementSeverancePaymentPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Severance Payment, Payment Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_EmploymentAgreementSeverancePaymentPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance payment period</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary" xlink:label="viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary" xlink:to="viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The severance payment represented as a percentage of then current annual base salary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Severance Payment As A Percentage Of Then Current Annual Base Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of then current annual base salary.</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementThresholdTerminationPeriod" xlink:label="viri_EmploymentAgreementThresholdTerminationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_EmploymentAgreementThresholdTerminationPeriod" xlink:to="viri_EmploymentAgreementThresholdTerminationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_EmploymentAgreementThresholdTerminationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold termination period under the employment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_EmploymentAgreementThresholdTerminationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Threshold Termination Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_EmploymentAgreementThresholdTerminationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold termination period</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination" xlink:label="viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination" xlink:to="viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of health benefit offered in addition to severance payment when the executive is not eligible for health benefits under another employer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Health Benefit Offered Period On Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment agreement, health benefit offered period on termination</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary" xlink:to="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The termination payment payable as a in ratio of then current annual base salary when the termination occurs due to change of control.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Change Of Control Termination Payment As A Ratio Of Then Current Annual Base Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ratio of current annual base salary</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus" xlink:to="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The termination payment payable as a in ratio of cash bonus for the year, when the termination occurs due to change of control.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Change Of Control Termination Payment As A Ratio Of Cash Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ratio of cash bonus</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod" xlink:to="viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period in which the termination payment is payable in cash, when the termination occurs due to change of control.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Change Of Control Termination Payment Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of termination due to change of control.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EquityIncentivePlan2020Member" xlink:label="viri_EquityIncentivePlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_EquityIncentivePlan2020Member" xlink:to="viri_EquityIncentivePlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Equity incentive plan 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining contractual term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting over one year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting after one year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting in 24 monthly installments thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gendreau</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Director</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonemployee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Employee Director</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:to="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Aggregate Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:to="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair market value assumption that is used in valuing an option on its own shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair market value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value of options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_NonQualifiedStockOptionsMember" xlink:label="viri_NonQualifiedStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_NonQualifiedStockOptionsMember" xlink:to="viri_NonQualifiedStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_NonQualifiedStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to non qualified stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_NonQualifiedStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-qualified stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining contractual term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Note Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightGranted" xlink:label="viri_ClassOfWarrantOrRightGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_ClassOfWarrantOrRightGranted" xlink:to="viri_ClassOfWarrantOrRightGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants or rights  granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants granted</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightExercisable" xlink:label="viri_ClassOfWarrantOrRightExercisable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_ClassOfWarrantOrRightExercisable" xlink:to="viri_ClassOfWarrantOrRightExercisable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants or rights exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract" xlink:label="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract" xlink:to="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:to="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" xlink:label="viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" xlink:to="viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price per share or per unit of warrants or rights granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Granted, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:to="viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price per share or per unit of warrants or rights exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightRemainingTerm" xlink:label="viri_ClassOfWarrantOrRightRemainingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_ClassOfWarrantOrRightRemainingTerm" xlink:to="viri_ClassOfWarrantOrRightRemainingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_ClassOfWarrantOrRightRemainingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining term of warrants and right, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_ClassOfWarrantOrRightRemainingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Remaining Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_ClassOfWarrantOrRightRemainingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining term</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" xlink:label="viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" xlink:to="viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable contractual term</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AggregateIntrinsicValueOfWarrantsOutstanding" xlink:label="viri_AggregateIntrinsicValueOfWarrantsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_AggregateIntrinsicValueOfWarrantsOutstanding" xlink:to="viri_AggregateIntrinsicValueOfWarrantsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_AggregateIntrinsicValueOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of warrants outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_AggregateIntrinsicValueOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value Of Warrants Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_AggregateIntrinsicValueOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value of warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:to="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development expenditures</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_CapitalizedResearchAndDevelopmentExpense" xlink:label="viri_CapitalizedResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_CapitalizedResearchAndDevelopmentExpense" xlink:to="viri_CapitalizedResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_CapitalizedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of research and development expenses capitalized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_CapitalizedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_CapitalizedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of federal income tax rate to effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:to="viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent" xlink:label="viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent" xlink:to="viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax true-ups</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_DeferredTaxAssetsInvestmentInPartnership" xlink:label="viri_DeferredTaxAssetsInvestmentInPartnership" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_DeferredTaxAssetsInvestmentInPartnership" xlink:to="viri_DeferredTaxAssetsInvestmentInPartnership_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_DeferredTaxAssetsInvestmentInPartnership_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investment in partnership.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_DeferredTaxAssetsInvestmentInPartnership_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Investment in Partnership</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_DeferredTaxAssetsInvestmentInPartnership_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment in partnership</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_DeferredTaxAssetsAmortization" xlink:label="viri_DeferredTaxAssetsAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="viri_DeferredTaxAssetsAmortization" xlink:to="viri_DeferredTaxAssetsAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="viri_DeferredTaxAssetsAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="viri_DeferredTaxAssetsAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="viri_DeferredTaxAssetsAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred taxes</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>tmb-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/13/2023 10:39:27 PM-->
<!--Modified on: 3/13/2023 10:39:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.virios.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementBalanceSheets" roleURI="http://www.virios.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementBalanceSheetsParentheticals" roleURI="http://www.virios.com/role/StatementBalanceSheetsParentheticals" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfOperations" roleURI="http://www.virios.com/role/StatementStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.virios.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.virios.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBackgroundAndOrganization" roleURI="http://www.virios.com/role/DisclosureBackgroundAndOrganization" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseAgreement" roleURI="http://www.virios.com/role/DisclosureLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureAccruedExpenses" roleURI="http://www.virios.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquity" roleURI="http://www.virios.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedParties" roleURI="http://www.virios.com/role/DisclosureRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.virios.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensation" roleURI="http://www.virios.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.virios.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.virios.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.virios.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureBackgroundAndOrganizationDetails" roleURI="http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails" roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseAgreementDetails" roleURI="http://www.virios.com/role/DisclosureLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.virios.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.virios.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.virios.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationEquityIncentivePlanDetails" roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationNarrativeDetails" roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationUnregisteredSecuritiesDetails" roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureShareBasedCompensationUnderwritersWarrantsDetails" roleURI="http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.virios.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" roleURI="http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.virios.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638143439663875437" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638143439663875437" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638143439663875437" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638143439663875437" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638143439663875437" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638143439663875437" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638143439663875437" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638143439663875437" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638143439663875437" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638143439663875437" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638143439663875437" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638143439663875437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638143439663875437" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638143439663885444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638143439663885444" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638143439663885444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638143439663885444" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638143439663885444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638143439663885444" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638143439663885444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638143439663885444" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638143439663885444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638143439663885444" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638143439663885444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638143439663885444" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638143439663885444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638143439663885444" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638143439663885444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638143439663885444" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638143439663885444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638143439663885444" order="21" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638143439663885444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638143439663885444" order="22" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638143439663895437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638143439663895437" order="23" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638143439663895437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638143439663895437" order="24" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638143439663895437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638143439663895437" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638143439663895437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638143439663895437" order="26" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638143439663895437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638143439663895437" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638143439663895437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638143439663895437" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638143439663895437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638143439663895437" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638143439663905450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638143439663905450" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638143439663905450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638143439663905450" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638143439663905450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638143439663905450" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638143439663905450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638143439663905450" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638143439663905450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638143439663905450" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638143439663905450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638143439663905450" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638143439663905450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638143439663905450" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638143439663905450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638143439663905450" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638143439663915437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638143439663915437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638143439663915437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638143439663915437" xlink:to="us-gaap_AssetsCurrentAbstract_638143439663915437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638143439663915437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638143439663915437" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638143439663915437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638143439663915437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638143439663915437" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638143439663915437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638143439663915437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638143439663915437" xlink:to="us-gaap_AssetsCurrent_638143439663915437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638143439663915437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638143439663915437" xlink:to="us-gaap_Assets_638143439663915437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638143439663945437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638143439663945437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638143439663945437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638143439663945437" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638143439663945437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638143439663945437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638143439663945437" xlink:to="us-gaap_AccountsPayableCurrent_638143439663945437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638143439663955476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638143439663945437" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638143439663955476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638143439663955476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638143439663945437" xlink:to="us-gaap_LiabilitiesCurrent_638143439663955476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638143439663955476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638143439663945437" xlink:to="us-gaap_Liabilities_638143439663955476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638143439663955476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638143439663945437" xlink:to="us-gaap_CommitmentsAndContingencies_638143439663955476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638143439663955476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638143439663945437" xlink:to="us-gaap_StockholdersEquityAbstract_638143439663955476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638143439663955476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638143439663955476" xlink:to="us-gaap_CommonStockValue_638143439663955476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638143439663955476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638143439663955476" xlink:to="us-gaap_PreferredStockValue_638143439663955476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638143439663955476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638143439663955476" xlink:to="us-gaap_AdditionalPaidInCapital_638143439663955476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638143439663955476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638143439663955476" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638143439663955476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638143439663955476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638143439663955476" xlink:to="us-gaap_StockholdersEquity_638143439663955476" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638143439663955476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638143439663945437" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638143439663955476" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/StatementBalanceSheetsParentheticals" xlink:type="extended" xlink:title="00105 - Statement - BALANCE SHEETS (Parentheticals)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638143439663965439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638143439663965439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638143439663965439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638143439663965439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638143439663965439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638143439663965439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638143439663965439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638143439663965439" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638143439663965439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638143439663965439" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638143439663965439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638143439663965439" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638143439663965439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638143439663965439" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638143439663975440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638143439663975440" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638143439663975440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638143439663975440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638143439663975440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638143439663975440" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638143439663975440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638143439663975440" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638143439663975440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638143439663975440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638143439663975440" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638143439663975440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638143439663975440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638143439663975440" xlink:to="us-gaap_OperatingExpenses_638143439663975440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638143439663975440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638143439663975440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638143439663975440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638143439663975440" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_638143439663975440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638143439663975440" xlink:to="us-gaap_InterestIncomeExpenseNet_638143439663975440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638143439663975440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638143439663975440" xlink:to="us-gaap_OtherNonoperatingIncome_638143439663975440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638143439663985438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638143439663975440" xlink:to="us-gaap_OtherNonoperatingExpense_638143439663985438" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638143439663985438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638143439663975440" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638143439663985438" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638143439663985438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638143439663985438" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638143439663985438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638143439663985438" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638143439663985438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638143439663985438" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638143439663985438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638143439663985438" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638143439663985438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638143439663985438" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638143439663985438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638143439663985438" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638143439663985438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638143439663985438" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638143439663985438" xlink:to="us-gaap_StatementEquityComponentsAxis_638143439663995440" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638143439663995440" xlink:to="us-gaap_CommonStockMember_638143439663995440" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638143439663995440" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638143439663995440" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638143439663995440" xlink:to="us-gaap_RetainedEarningsMember_638143439663995440" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638143439663995440" xlink:to="us-gaap_EquityComponentDomain_638143439663995440" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638143439663985438" xlink:to="us-gaap_StatementLineItems_638143439663995440" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638143439663995440" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638143439663995440" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638143439663995440" xlink:to="us-gaap_StockholdersEquity_638143439663995440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638143439663995440" xlink:to="us-gaap_SharesOutstanding_638143439663995440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638143439663995440" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638143439663995440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638143439663995440" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638143439663995440" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638143439663995440" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638143439663995440" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="viri_StockIssuedDuringPeriodValueWarrantsExercised_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638143439663995440" xlink:to="viri_StockIssuedDuringPeriodValueWarrantsExercised_638143439663995440" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="viri_StockIssuedDuringPeriodSharesWarrantsExercised_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="viri_StockIssuedDuringPeriodValueWarrantsExercised_638143439663995440" xlink:to="viri_StockIssuedDuringPeriodSharesWarrantsExercised_638143439663995440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638143439663995440" xlink:to="us-gaap_NetIncomeLoss_638143439663995440" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6381434396639954401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638143439663995440" xlink:to="us-gaap_StockholdersEquity_6381434396639954401" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_6381434396639954401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638143439663995440" xlink:to="us-gaap_SharesOutstanding_6381434396639954401" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638143439663995440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638143439663995440" xlink:to="us-gaap_ProfitLoss_638143439663995440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638143439663995440" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638143439663995440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638143439663995440" xlink:to="us-gaap_ShareBasedCompensation_638143439663995440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638143439663995440" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638143439663995440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638143439663995440" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638143439663995440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638143439663995440" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638143439663995440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638143439663995440" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638143439663995440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638143439663995440" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries_638143439663995440" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638143439663995440" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439663995440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638143439663995440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638143439663995440" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638143439663995440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638143439663995440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638143439663995440" xlink:to="us-gaap_ProceedsFromWarrantExercises_638143439663995440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638143439664021361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638143439663995440" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638143439664021361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638143439664021361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638143439663995440" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638143439664021361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638143439664021361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638143439664021361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638143439664021361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638143439664021361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638143439664025446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638143439664025446" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureBackgroundAndOrganization" xlink:type="extended" xlink:title="10101 - Disclosure - Background and Organization" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638143439664025446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638143439664025446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638143439664025446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638143439664025446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="10301 - Disclosure - Prepaid Expenses and Other Current Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:label="viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock_638143439664025446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock_638143439664025446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureLicenseAgreement" xlink:type="extended" xlink:title="10401 - Disclosure - License Agreement" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_LicenseAgreementAbstract" xlink:label="viri_LicenseAgreementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638143439664025446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="viri_LicenseAgreementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638143439664025446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10501 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638143439664035445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638143439664035445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10601 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638143439664035445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638143439664035445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureRelatedParties" xlink:type="extended" xlink:title="10701 - Disclosure - Related Parties" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638143439664035445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638143439664035445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10801 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638143439664035445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638143439664035445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="10909 - Disclosure - Share-based compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638143439664045441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638143439664045441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11001 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638143439664045441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638143439664045441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638143439664045441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638143439664045441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638143439664045441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638143439664045441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638143439664045441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638143439664045441" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638143439664045441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638143439664045441" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638143439664045441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638143439664045441" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_638143439664045441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_638143439664045441" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_638143439664045441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_638143439664045441" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638143439664055446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638143439664055446" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638143439664055446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638143439664055446" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638143439664055446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638143439664055446" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638143439664055446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638143439664055446" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_StatusOfCompanyPolicyTextBlock" xlink:label="viri_StatusOfCompanyPolicyTextBlock_638143439664055446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="viri_StatusOfCompanyPolicyTextBlock_638143439664055446" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638143439664055446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638143439664055446" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock" xlink:label="viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock_638143439664055446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock_638143439664055446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638143439664055446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638143439664055446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - Share-based compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638143439664065441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638143439664065441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638143439664065441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638143439664065441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638143439664065441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638143439664065441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638143439664065441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638143439664065441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Background and Organization (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638143439664065441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638143439664065441" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638143439664065441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638143439664065441" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638143439664065441" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638143439664065441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638143439664065441" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638143439664065441" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638143439664065441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638143439664065441" xlink:to="us-gaap_IPOMember_638143439664065441" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638143439664065441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638143439664065441" xlink:to="srt_RangeAxis_638143439664065441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638143439664075436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638143439664065441" xlink:to="srt_RangeMember_638143439664075436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638143439664075436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638143439664075436" xlink:to="srt_MinimumMember_638143439664075436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638143439664075436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638143439664075436" xlink:to="srt_MaximumMember_638143439664075436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638143439664065441" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638143439664075436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638143439664075436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638143439664075436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" xlink:to="us-gaap_SharePrice_638143439664075436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638143439664075436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638143439664075436" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638143439664075436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638143439664075436" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice" xlink:label="viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice_638143439664075436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" xlink:to="viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice_638143439664075436" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638143439664075436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638143439664075436" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638143439664075436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638143439664075436" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638143439664085438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" xlink:to="us-gaap_NetIncomeLoss_638143439664085438" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439664085438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638143439664085438" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638143439664085438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638143439664085438" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment" xlink:label="viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment_638143439664085438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638143439664075436" xlink:to="viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment_638143439664085438" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_638143439664085438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashFDICInsuredAmount_638143439664085438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Equity Method Investment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccountingPoliciesTable" xlink:label="viri_AccountingPoliciesTable_638143439664085438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="viri_AccountingPoliciesTable_638143439664085438" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638143439664085438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="viri_AccountingPoliciesTable_638143439664085438" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638143439664085438" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_638143439664085438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638143439664085438" xlink:to="srt_EquityMethodInvesteeNameDomain_638143439664085438" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_NorthriverPharmLlcMember" xlink:label="viri_NorthriverPharmLlcMember_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_638143439664085438" xlink:to="viri_NorthriverPharmLlcMember_638143439664095434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccountingPoliciesLineItems" xlink:label="viri_AccountingPoliciesLineItems_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="viri_AccountingPoliciesTable_638143439664085438" xlink:to="viri_AccountingPoliciesLineItems_638143439664095434" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="viri_AccountingPoliciesLineItems_638143439664095434" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_638143439664095434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="viri_AccountingPoliciesLineItems_638143439664095434" xlink:to="us-gaap_EquityMethodInvestments_638143439664095434" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638143439664095434" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638143439664095434" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638143439664095434" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638143439664095434" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638143439664095434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638143439664095434" xlink:to="us-gaap_EmployeeStockOptionMember_638143439664095434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638143439664095434" xlink:to="us-gaap_WarrantMember_638143439664095434" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638143439664095434" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638143439664095434" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638143439664095434" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638143439664095434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638143439664095434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance_638143439664095434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PrepaidClinicalResearchCosts" xlink:label="viri_PrepaidClinicalResearchCosts_638143439664107316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="viri_PrepaidClinicalResearchCosts_638143439664107316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PrepaidServices" xlink:label="viri_PrepaidServices_638143439664107316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="viri_PrepaidServices_638143439664107316" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent_638143439664107316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsMiscellaneousCurrent_638143439664107316" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638143439664107316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638143439664107316" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureLicenseAgreementDetails" xlink:type="extended" xlink:title="40401 - Disclosure - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_LicenseAgreementAbstract" xlink:label="viri_LicenseAgreementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638143439664107316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="viri_LicenseAgreementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638143439664107316" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638143439664107316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638143439664107316" xlink:to="us-gaap_TypeOfArrangementAxis_638143439664107316" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638143439664107316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638143439664107316" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638143439664107316" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_KnowHowLicenseAgreementMember" xlink:label="viri_KnowHowLicenseAgreementMember_638143439664107316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638143439664107316" xlink:to="viri_KnowHowLicenseAgreementMember_638143439664107316" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638143439664107316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638143439664107316" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638143439664107316" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest" xlink:label="viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest_638143439664107316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638143439664107316" xlink:to="viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest_638143439664107316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_LicenseAgreementExpirationPeriod" xlink:label="viri_LicenseAgreementExpirationPeriod_638143439664115441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638143439664107316" xlink:to="viri_LicenseAgreementExpirationPeriod_638143439664115441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638143439664115441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638143439664115441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccruedInterestOnPreferredMembersInterest" xlink:label="viri_AccruedInterestOnPreferredMembersInterest_638143439664115441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="viri_AccruedInterestOnPreferredMembersInterest_638143439664115441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccruedResearchAndDevelopmentCosts" xlink:label="viri_AccruedResearchAndDevelopmentCosts_638143439664115441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="viri_AccruedResearchAndDevelopmentCosts_638143439664115441" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AccruedDirectorFeesCurrent" xlink:label="viri_AccruedDirectorFeesCurrent_638143439664115441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="viri_AccruedDirectorFeesCurrent_638143439664115441" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638143439664115441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638143439664115441" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638143439664115441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638143439664115441" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638143439664115441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638143439664115441" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_CommonAndPreferredStockSharesAuthorized" xlink:label="viri_CommonAndPreferredStockSharesAuthorized_638143439664115441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="viri_CommonAndPreferredStockSharesAuthorized_638143439664115441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638143439664115441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638143439664115441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638143439664125502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638143439664125502" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638143439664125502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638143439664125502" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638143439664125502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638143439664125502" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_NumberOfVotesPerCommonStock" xlink:label="viri_NumberOfVotesPerCommonStock_638143439664125502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="viri_NumberOfVotesPerCommonStock_638143439664125502" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Related Parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638143439664125502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638143439664125502" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638143439664125502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638143439664125502" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638143439664125502" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638143439664125502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638143439664125502" xlink:to="us-gaap_RelatedPartyDomain_638143439664125502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_GendreauConsultingLlcMember" xlink:label="viri_GendreauConsultingLlcMember_638143439664125502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638143439664125502" xlink:to="viri_GendreauConsultingLlcMember_638143439664125502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638143439664125502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638143439664125502" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638143439664125502" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638143439664125502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638143439664125502" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638143439664125502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_638143439664125502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638143439664125502" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_638143439664125502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_638143439664135434" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638143439664135434" xlink:to="srt_LitigationCaseAxis_638143439664135434" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638143439664135434" xlink:to="srt_LitigationCaseTypeDomain_638143439664135434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_TorreyaCapitalLlcMember" xlink:label="viri_TorreyaCapitalLlcMember_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638143439664135434" xlink:to="viri_TorreyaCapitalLlcMember_638143439664135434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638143439664135434" xlink:to="srt_RangeAxis_638143439664135434" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638143439664135434" xlink:to="srt_RangeMember_638143439664135434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638143439664135434" xlink:to="srt_MinimumMember_638143439664135434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638143439664135434" xlink:to="srt_TitleOfIndividualAxis_638143439664135434" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638143439664135434" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638143439664135434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638143439664135434" xlink:to="srt_ChiefExecutiveOfficerMember_638143439664135434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_VicePresidentOperationsAndFinanceMember" xlink:label="viri_VicePresidentOperationsAndFinanceMember_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638143439664135434" xlink:to="viri_VicePresidentOperationsAndFinanceMember_638143439664135434" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ChiefMedicalOfficerMember" xlink:label="viri_ChiefMedicalOfficerMember_638143439664135434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638143439664135434" xlink:to="viri_ChiefMedicalOfficerMember_638143439664135434" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638143439664145445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638143439664135434" xlink:to="us-gaap_OtherCommitmentsLineItems_638143439664145445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_638143439664145445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638143439664145445" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_638143439664145445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_PercentageOfCashBonusOnSalary" xlink:label="viri_PercentageOfCashBonusOnSalary_638143439664145445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638143439664145445" xlink:to="viri_PercentageOfCashBonusOnSalary_638143439664145445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementSeverancePaymentPaymentPeriod" xlink:label="viri_EmploymentAgreementSeverancePaymentPaymentPeriod_638143439664145445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638143439664145445" xlink:to="viri_EmploymentAgreementSeverancePaymentPaymentPeriod_638143439664145445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary" xlink:label="viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary_638143439664145445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638143439664145445" xlink:to="viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary_638143439664145445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementThresholdTerminationPeriod" xlink:label="viri_EmploymentAgreementThresholdTerminationPeriod_638143439664145445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638143439664145445" xlink:to="viri_EmploymentAgreementThresholdTerminationPeriod_638143439664145445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination" xlink:label="viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination_638143439664145445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638143439664145445" xlink:to="viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination_638143439664145445" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary_638143439664145445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638143439664145445" xlink:to="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary_638143439664145445" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus_638143439664145445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638143439664145445" xlink:to="viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus_638143439664145445" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod" xlink:label="viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod_638143439664145445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638143439664145445" xlink:to="viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod_638143439664145445" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638143439664155437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638143439664145445" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638143439664155437" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638143439664155437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638143439664145445" xlink:to="us-gaap_OtherNonoperatingIncome_638143439664155437" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Share-based compensation - Equity Incentive Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664155437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664155437" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638143439664155437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664155437" xlink:to="us-gaap_PlanNameAxis_638143439664155437" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638143439664155437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638143439664155437" xlink:to="us-gaap_PlanNameDomain_638143439664155437" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EquityIncentivePlan2020Member" xlink:label="viri_EquityIncentivePlan2020Member_638143439664155437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638143439664155437" xlink:to="viri_EquityIncentivePlan2020Member_638143439664155437" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664155437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664155437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664155437" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638143439664155437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664155437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638143439664155437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638143439664155437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638143439664155437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638143439664155437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638143439664155437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638143439664155437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638143439664155437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638143439664165436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638143439664155437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638143439664165436" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638143439664165436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638143439664155437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638143439664165436" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638143439664165436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638143439664155437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638143439664165436" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638143439664165436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664155437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638143439664165436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638143439664165436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638143439664165436" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638143439664165436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638143439664165436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638143439664165436" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638143439664165436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638143439664165436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638143439664165436" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638143439664165436" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381434396641654361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638143439664165436" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381434396641654361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638143439664165436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638143439664165436" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638143439664165436" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638143439664165436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664155437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638143439664165436" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638143439664175460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638143439664165436" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638143439664175460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638143439664175460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638143439664165436" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638143439664175460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Share-based compensation - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664175460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664175460" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638143439664175460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664175460" xlink:to="us-gaap_PlanNameAxis_638143439664175460" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638143439664175460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638143439664175460" xlink:to="us-gaap_PlanNameDomain_638143439664175460" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EquityIncentivePlan2020Member" xlink:label="viri_EquityIncentivePlan2020Member_638143439664175460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638143439664175460" xlink:to="viri_EquityIncentivePlan2020Member_638143439664175460" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638143439664175460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664175460" xlink:to="us-gaap_AwardTypeAxis_638143439664175460" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638143439664175460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638143439664175460" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638143439664175460" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638143439664175460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638143439664175460" xlink:to="us-gaap_EmployeeStockOptionMember_638143439664175460" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638143439664175460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664175460" xlink:to="us-gaap_VestingAxis_638143439664175460" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638143439664185440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638143439664175460" xlink:to="us-gaap_VestingDomain_638143439664185440" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638143439664185440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638143439664185440" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638143439664185440" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638143439664185440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638143439664185440" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638143439664185440" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638143439664185440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638143439664185440" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638143439664185440" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638143439664185440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664175460" xlink:to="srt_RangeAxis_638143439664185440" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638143439664185440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638143439664185440" xlink:to="srt_RangeMember_638143439664185440" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638143439664185440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638143439664185440" xlink:to="srt_MinimumMember_638143439664185440" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638143439664185440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638143439664185440" xlink:to="srt_MaximumMember_638143439664185440" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638143439664185440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664175460" xlink:to="us-gaap_GranteeStatusAxis_638143439664185440" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638143439664185440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638143439664185440" xlink:to="us-gaap_GranteeStatusDomain_638143439664185440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638143439664185440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638143439664185440" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638143439664185440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638143439664195437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638143439664185440" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638143439664195437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664175460" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638143439664195437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638143439664195437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638143439664195437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638143439664195437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638143439664195437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638143439664195437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638143439664195437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638143439664195437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638143439664195437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638143439664195437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638143439664195437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638143439664195437" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_638143439664195437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_638143439664195437" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_638143439664205451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_638143439664205451" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664205451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664205451" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638143439664205451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664205451" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638143439664205451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638143439664205451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664205451" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638143439664205451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638143439664205451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664205451" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638143439664205451" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_638143439664205451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664205451" xlink:to="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_638143439664205451" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_638143439664205451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664205451" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_638143439664205451" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638143439664205451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664205451" xlink:to="us-gaap_SharePrice_638143439664205451" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638143439664215436" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638143439664215436" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664195437" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638143439664215436" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Share-based compensation - Unregistered Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664215436" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664215436" xlink:to="us-gaap_PlanNameAxis_638143439664215436" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638143439664215436" xlink:to="us-gaap_PlanNameDomain_638143439664215436" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EquityIncentivePlan2020Member" xlink:label="viri_EquityIncentivePlan2020Member_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638143439664215436" xlink:to="viri_EquityIncentivePlan2020Member_638143439664215436" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664215436" xlink:to="us-gaap_AwardTypeAxis_638143439664215436" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638143439664215436" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638143439664215436" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_NonQualifiedStockOptionsMember" xlink:label="viri_NonQualifiedStockOptionsMember_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638143439664215436" xlink:to="viri_NonQualifiedStockOptionsMember_638143439664215436" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638143439664215436" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664215436" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664215436" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638143439664215436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664215436" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638143439664215436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664215436" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638143439664215436" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664215436" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638143439664215436" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664215436" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638143439664215436" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664215436" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638143439664215436" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664215436" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_638143439664215436" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664215436" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638143439664215436" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664215436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638143439664215436" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664215436" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638143439664236761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664215436" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638143439664236761" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638143439664236761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664215436" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638143439664236761" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638143439664236761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664215436" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638143439664236761" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638143439664236761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664215436" xlink:to="us-gaap_SharePrice_638143439664236761" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638143439664236761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664215436" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638143439664236761" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Share-based compensation - Underwriters Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638143439664236761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638143439664236761" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638143439664245439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638143439664245439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:label="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_638143439664245439" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664245439" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664245439" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638143439664245439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664245439" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638143439664245439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664245439" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638143439664245439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664245439" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_638143439664245439" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638143439664245439" xlink:to="us-gaap_SharePrice_638143439664245439" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638143439664245439" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_638143439664245439" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_638143439664245439" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638143439664245439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightGranted" xlink:label="viri_ClassOfWarrantOrRightGranted_638143439664245439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_638143439664245439" xlink:to="viri_ClassOfWarrantOrRightGranted_638143439664245439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638143439664255443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_638143439664245439" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638143439664255443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightExercisable" xlink:label="viri_ClassOfWarrantOrRightExercisable_638143439664255443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_638143439664245439" xlink:to="viri_ClassOfWarrantOrRightExercisable_638143439664255443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract" xlink:label="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract_638143439664255443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract_638143439664255443" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_638143439664255443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract_638143439664255443" xlink:to="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_638143439664255443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" xlink:label="viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_638143439664255443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract_638143439664255443" xlink:to="viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_638143439664255443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_6381434396642554431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract_638143439664255443" xlink:to="viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_6381434396642554431" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_638143439664255443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract_638143439664255443" xlink:to="viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_638143439664255443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightRemainingTerm" xlink:label="viri_ClassOfWarrantOrRightRemainingTerm_638143439664255443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="viri_ClassOfWarrantOrRightRemainingTerm_638143439664255443" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" xlink:label="viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm_638143439664255443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm_638143439664255443" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_AggregateIntrinsicValueOfWarrantsOutstanding" xlink:label="viri_AggregateIntrinsicValueOfWarrantsOutstanding_638143439664255443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="viri_AggregateIntrinsicValueOfWarrantsOutstanding_638143439664255443" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638143439664265474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwards_638143439664265474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638143439664265474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638143439664265474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638143439664265474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638143439664265474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_CapitalizedResearchAndDevelopmentExpense" xlink:label="viri_CapitalizedResearchAndDevelopmentExpense_638143439664265474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="viri_CapitalizedResearchAndDevelopmentExpense_638143439664265474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638143439664265474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638143439664265474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638143439664265474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638143439664265474" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638143439664265474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638143439664265474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638143439664265474" xlink:to="viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638143439664265474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638143439664265474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638143439664265474" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638143439664265474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent" xlink:label="viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent_638143439664275448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638143439664265474" xlink:to="viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent_638143439664275448" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638143439664275448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638143439664265474" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638143439664275448" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638143439664275448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638143439664265474" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638143439664275448" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638143439664275448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638143439664265474" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638143439664275448" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Net deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638143439664275448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638143439664275448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638143439664275448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638143439664275448" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638143439664275448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638143439664275448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638143439664275448" xlink:to="viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638143439664275448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638143439664275448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638143439664275448" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638143439664275448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_DeferredTaxAssetsInvestmentInPartnership" xlink:label="viri_DeferredTaxAssetsInvestmentInPartnership_638143439664275448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638143439664275448" xlink:to="viri_DeferredTaxAssetsInvestmentInPartnership_638143439664275448" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#viri_DeferredTaxAssetsAmortization" xlink:label="viri_DeferredTaxAssetsAmortization_638143439664275448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638143439664275448" xlink:to="viri_DeferredTaxAssetsAmortization_638143439664275448" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638143439664285449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638143439664275448" xlink:to="us-gaap_DeferredTaxAssetsGross_638143439664285449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638143439664285449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638143439664275448" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638143439664285449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638143439664285449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638143439664275448" xlink:to="us-gaap_DeferredTaxAssetsNet_638143439664285449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638143439664285449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638143439664285449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638143439664285449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638143439664285449" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638143439664285449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638143439664285449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638143439664285449" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638143439664285449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638143439664285449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638143439664285449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799601887088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Virios Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-4314201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">44 Milton Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alpharetta<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">GA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">620-8655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VIRI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,229,227.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,330,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">FORVIS, LLP (Formerly, Dixon Hughes Goodman LLP)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Atlanta, Georgia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602966576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 7,030,992<span></span>
</td>
<td class="nump">$ 14,008,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,338,764<span></span>
</td>
<td class="nump">1,768,503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,369,756<span></span>
</td>
<td class="nump">15,776,687<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">8,369,756<span></span>
</td>
<td class="nump">15,776,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">573,164<span></span>
</td>
<td class="nump">353,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">470,098<span></span>
</td>
<td class="nump">921,760<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,043,262<span></span>
</td>
<td class="nump">1,275,623<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,043,262<span></span>
</td>
<td class="nump">1,275,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 43,000,000 shares authorized, 18,330,390 and 8,330,390 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">1,833<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 2,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">63,497,868<span></span>
</td>
<td class="nump">58,425,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(56,173,207)<span></span>
</td>
<td class="num">(43,925,373)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">7,326,494<span></span>
</td>
<td class="nump">14,501,064<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 8,369,756<span></span>
</td>
<td class="nump">$ 15,776,687<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602068224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">43,000,000<span></span>
</td>
<td class="nump">43,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">18,330,390<span></span>
</td>
<td class="nump">8,330,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">18,330,390<span></span>
</td>
<td class="nump">8,330,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799604988064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Condensed Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,069,628<span></span>
</td>
<td class="nump">10,795,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,245,681<span></span>
</td>
<td class="nump">4,845,252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">12,315,309<span></span>
</td>
<td class="nump">15,640,940<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,315,309)<span></span>
</td>
<td class="num">(15,640,940)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">67,475<span></span>
</td>
<td class="nump">5,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(325,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">67,475<span></span>
</td>
<td class="num">(319,328)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(12,247,834)<span></span>
</td>
<td class="num">(15,960,268)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,247,834)<span></span>
</td>
<td class="num">$ (15,960,268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic</a></td>
<td class="nump">11,070,116<span></span>
</td>
<td class="nump">8,329,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted</a></td>
<td class="nump">11,070,116<span></span>
</td>
<td class="nump">8,329,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602106816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 830<span></span>
</td>
<td class="nump">$ 57,905,164<span></span>
</td>
<td class="num">$ (27,965,105)<span></span>
</td>
<td class="nump">$ 29,940,889<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Beginning (in shares) at Dec. 31, 2020</a></td>
<td class="nump">8,305,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">197,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">25,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,960,268)<span></span>
</td>
<td class="num">(15,960,268)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Ending at Dec. 31, 2021</a></td>
<td class="nump">$ 833<span></span>
</td>
<td class="nump">58,425,604<span></span>
</td>
<td class="num">(43,925,373)<span></span>
</td>
<td class="nump">14,501,064<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Ending (in shares) at Dec. 31, 2021</a></td>
<td class="nump">8,330,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares in public offering, net of costs</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">4,489,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,490,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares in public offering, net of costs (shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,247,834)<span></span>
</td>
<td class="num">(12,247,834)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Ending at Dec. 31, 2022</a></td>
<td class="nump">$ 1,833<span></span>
</td>
<td class="nump">$ 63,497,868<span></span>
</td>
<td class="num">$ (56,173,207)<span></span>
</td>
<td class="nump">$ 7,326,494<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Ending (in shares) at Dec. 31, 2022</a></td>
<td class="nump">18,330,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602993168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (12,247,834)<span></span>
</td>
<td class="num">$ (15,960,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based and equity compensation expense</a></td>
<td class="nump">582,659<span></span>
</td>
<td class="nump">322,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in prepaid expenses and other current assets</a></td>
<td class="nump">429,739<span></span>
</td>
<td class="num">(91,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="nump">219,301<span></span>
</td>
<td class="nump">270,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">(Decrease) increase in accrued expenses</a></td>
<td class="num">(451,662)<span></span>
</td>
<td class="nump">147,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedSalaries', window );">Decrease in accrued salaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(378,833)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,467,797)<span></span>
</td>
<td class="num">(15,689,578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of costs</a></td>
<td class="nump">4,490,605<span></span>
</td>
<td class="num">(295,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,562<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">4,490,605<span></span>
</td>
<td class="num">(97,604)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash</a></td>
<td class="num">(6,977,192)<span></span>
</td>
<td class="num">(15,787,182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="nump">14,008,184<span></span>
</td>
<td class="nump">29,795,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="nump">$ 7,030,992<span></span>
</td>
<td class="nump">$ 14,008,184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799604291680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Background and Organization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background and Organization</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;Background and Organization</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Virios Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the State of Delaware on December 16, 2020 through a corporate conversion (the &#8220;Corporate Conversion&#8221;) just prior to the Company&#8217;s initial public offering (&#8220;IPO&#8221;). The Company was originally formed on February&#160;28, 2012 as a limited liability company (&#8220;LLC&#8221;) under the laws of the State of Alabama as Innovative Med Concepts, LLC. On July&#160;23, 2020, the Company changed its name from Innovative Med Concepts, LLC to Virios Therapeutics,&#160;LLC. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company operates in one segment as a pre-revenue, development-stage biotechnology company focused on advancing novel combination antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The Company is developing its initial product candidate, IMC-1, for people who are suffering from fibromyalgia (&#8220;FM&#8221;). Research has shown that the herpes virus could be a potential root cause of FM. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib, both of which are drugs approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for other indications. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication, thereby converting activated herpes virus back to dormancy and/or by keeping the herpes virus in a latent or dormant state. The famciclovir component of IMC-1 inhibits viral DNA replication, thus inhibiting upregulation of the herpes virus. The celecoxib component of IMC-1 inhibits cyclooxegenase-2 (&#8220;COX-2&#8221;) enzymes used by the herpes virus to amplify or accelerate its own replication. IMC-1&#8217;s synergistic antiviral mechanism represents a first-in-class medicine designed specifically to inhibit both herpes virus activation and subsequent replication, with the goal of keeping tissue resident herpes virus in a latent state.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Public Offering</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On September 19, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with ThinkEquity LLC (the &#8220;Underwriter&#8221;) in connection with the issuance and sale by the Company in a public offering of </span><span style="font-weight:normal;">10,000,000</span><span style="font-weight:normal;"> shares of its common stock at a public offering price of </span><span style="font-weight:normal;">$0.50</span><span style="font-weight:normal;"> per share (the &#8220;Offering&#8221;), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-263700). The Offering closed on September 22, 2022 and the gross proceeds from the Offering were </span><span style="font-weight:normal;">$5,000,000</span><span style="font-weight:normal;">. The net proceeds of the Offering were approximately </span><span style="font-weight:normal;">$4,490,605</span><span style="font-weight:normal;white-space:pre-wrap;"> after deducting underwriting discounts, commissions and offering expenses payable by the Company.  In conjunction with the Offering, the Company granted to the Underwriter </span><span style="font-weight:normal;">500,000</span><span style="font-weight:normal;"> warrants to purchase shares of the Company&#8217;s common stock at an exercise price of </span><span style="font-weight:normal;">$0.625</span><span style="font-weight:normal;"> per share, which was </span><span style="font-weight:normal;">125%</span><span style="font-weight:normal;"> of the Offering price.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Material Uncertainty</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its founding, the Company has been engaged in research and development activities as well as organizational activities, including raising capital. The Company has not generated any revenues to date. As such, the Company is subject to all of the risks associated with any development-stage biotechnology company that has substantial expenditures for research and development. Since inception, the Company has incurred losses and negative cash flows from operating activities. The Company has funded its losses primarily through issuance of members&#8217; interests, convertible debt instruments and issuance of equity securities. For the years ended December 31, 2022 and 2021, the Company incurred net losses of $12,247,834 and $15,960,268, respectively, and had net cash flows used in operating activities of $11,467,797 and $15,689,578, respectively. As of December&#160;31, 2022, the Company had an accumulated deficit of $56,173,207.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of the date these financial statements are issued, based on reasonable estimates, current cash is sufficient to fund operating expenses and obligations for at least 12 months. Currently, there are no planned research and development activities for 2023 other than minimal carryover costs associated with completing the final reports for the Company&#8217;s FORTRESS, (Fibromyalgia Outcome Research Trial Evaluating </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Synergistic Suppression of HSV-1), study for the treatment of FM and the chronic toxicology program, regulatory consulting to prepare for the meeting with the FDA, the on-going grant to the Bateman Horne Center for the fully funded investigator-sponsored study in Long-COVID and the purchase of active pharmaceutical ingredients to support the start of a potential Phase 3 program for IMC-1.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses in 2022 primarily related to our FORTRESS study for IMC-1, the Company&#8217;s lead candidate, which was completed in August 2022 and two long-term animal toxicology studies; a 26-week study in rats, which was completed in the first quarter of 2022 and a 39-week study in dogs, which was completed in the second quarter of 2022. Overall, the study for IMC-1, did not achieve statistical significance on the prespecified primary efficacy endpoint of change from baseline to Week 14 in the weekly average of daily self-reported average pain severity scores comparing IMC-1 to placebo (p=0.302). However, management observed a differential response based on the timing of patient enrollment and believe it is highly unlikely due to chance or a random occurrence, thus further analysis of the data was warranted, particularly in the context of the previous IMC-1 Phase 2a study success. Based on the analysis of the data, management believes focusing the forward development of IMC-1 on new fibromyalgia patients remains a viable and manageable path forward. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is scheduled to meet with the FDA in March 2023 to discuss the most appropriate next steps in advancing IMC-1 development as a treatment for FM and hopefully agree on a Phase 3 program. If alignment can be reached, management will consider raising additional capital to fund future research and/or seek a partner to develop or co-develop IMC-1 as a treatment for FM.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company will need to raise additional capital within the next 13 to 18 months to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms. The financial statements do not include any adjustments to reflect this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799606258000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Basis of Presentation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from those estimates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentrations of Credit Risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash is potentially subject to concentrations of credit risk. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i>, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8212; Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8212; Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amount of the Company&#8217;s financial instruments, including cash, accounts payable and accrued expenses approximate their fair values.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cash</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash is maintained in bank deposit accounts, which exceed the federally insured limits of $250,000. The Company does not have any cash equivalents.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Variable Interest Entities</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When determining whether a legal entity should be consolidated, the Company first determines whether it has a variable interest in the legal entity. If a variable interest exists, the Company determines whether the legal entity is a variable interest entity (&#8220;VIE&#8221;) due to either: 1) a lack of sufficient equity to finance its activities, 2) its equity holders lacking the characteristics of a controlling financial interest, or 3) the legal entity being structured with non-substantive voting rights. If the Company concludes that the legal entity is a VIE, the Company next determines whether it is the primary beneficiary due to it possessing both: 1) the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, and 2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE which could be significant to the VIE. If the Company concludes that it is the primary beneficiary, it consolidates the entity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Equity Method Investment</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2017, the Company purchased a 25% ownership in Northriver Pharm, LLC (&#8220;NRP&#8221;) in the amount of $125,000 from existing investors of NRP. NRP is an entity with common ownership with the Company&#8217;s former Chief Executive Officer and Founder, who is also the Founder and sole voting member of NRP. The Company evaluated the ownership under VIE guidance and has determined that the Company does not have the power and economics to control the entity and are not the entity most closely associated with NRP.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company previously accounted for the investment under the equity method of accounting. However, consistent with equity method accounting guidance, the Company has now discontinued applying the equity method accounting as the investment has been reduced to zero and the Company has not committed to provide further financial support and there is no expected return to profitable operations by NRP.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"> <span style="font-style:italic;">Income Taxes</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company operated as an Alabama limited liability company until its Corporate Conversion. Therefore, the Company passed through all income and losses to its members until this point. As of December 31, 2022 and 2021, the Company had a full valuation allowance against deferred tax assets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, <i style="font-style:italic;">Income Taxes</i>. Under ASC 740, consideration is given to the recognition and measurement of tax positions that meet a &#8220;more-likely-than-not&#8221; threshold. A tax position is a position taken in a previously filed tax return or a position expected to be taken in a future that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions include the Company&#8217;s status as a pass-through entity until December 16, 2020 and as a corporation thereafter. The recognition and measurement of tax positions taken for various jurisdictions consider the amounts and probabilities of outcomes that could be realized upon settlement using the facts, circumstances, and information available at the reporting date. The Company has determined that it does not have any material unrecognized tax benefits or obligations as of December&#160;31, 2022 and 2021. The Company recognizes interest and penalties related to uncertain tax positions, if any, in income tax expense. The Company is not currently under examination by the Internal Revenue Service or by state tax authorities and the Company&#8217;s tax year remains subject to examination by the tax authorities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Basic and Diluted Net Income (Loss) per Share</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share (&#8220;EPS&#8221;) is computed in accordance with U.S. GAAP. Basic EPS is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted EPS reflects potential dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if all potential common shares had been issued and were dilutive. However, potentially dilutive securities are excluded from the computation of diluted EPS to the extent that their effect is anti-dilutive. For the&#160;years ended December&#160;31, 2022 and 2021, the Company had 1,924,397 and 1,041,647 options, respectively, and 672,500 and 172,500 warrants, respectively, to purchase common shares outstanding that were anti-dilutive. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development costs are expensed as incurred. The Company arranges and contracts with third-party contract research organizations (&#8220;CROs&#8221;), contract development and manufacturing organizations (&#8220;CMOs&#8221;), contractor laboratories and independent consultants. As part of the process of preparing its financial statements, the Company may be required to estimate some of its expenses resulting from its obligations under these arrangements and contracts. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided. The Company&#8217;s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are rendered. The Company determines any accrual estimates based on account discussions with applicable personnel and outside service providers as to the progress or state of completion. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company&#8217;s estimates are dependent upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record prepaid or accrued expenses related to these costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Share-Based Compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense relating to share-based awards to employees and directors with a performance condition over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and warrants granted using an options pricing model, see Note 9. Expense is recognized within both research and development and general and administrative expenses and forfeitures are recognized as they are incurred.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided by the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recent Accounting Pronouncements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes</i>. The standard eliminates the need for an organization to analyze whether the following apply in a given period: (1) the exception to the incremental approach for intraperiod tax allocation; (2) the exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (3) the exception in interim periods income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also is designed to improve financial statement preparers&#8217; application of income tax-related guidance and simplify U.S. GAAP for (1) franchise taxes that are partially based on income, (2) transactions with a government that result in a step-up in the tax basis of goodwill, (3) separate financial statements of legal entities that are not subject to tax, (4) enacted changes in tax laws in interim periods and (5) certain income tax accounting for employee stock ownership plans and affordable housing projects. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">In August 2020, the FASB issued ASU 2020-06, <i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. Early adoption is permitted. ASU 2020-06 allows companies to adopt the guidance through either a modified retrospective method of transition or a fully retrospective method of transition. The Company is continuing to evaluate the impacts that ASU 2020-06 will have on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799604214000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;Prepaid Expenses and Other Current Assets</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18.7pt;">Prepaid expenses and other current assets consist of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,165,634</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,329,385</p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid clinical research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 154,510</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 422,591</p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 11,329</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,664</p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other miscellaneous current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,291</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 863</p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,338,764</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,768,503</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of prepaid expense and other assets current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799601812128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_LicenseAgreementAbstract', window );"><strong>License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License Agreement</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;License Agreement</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company entered into a Know-How License Agreement (the &#8220;Agreement&#8221;) with the University of Alabama (&#8220;UA&#8221;) in 2012. In consideration for the Agreement, UA received a 10% non-voting membership interest in the Company. Upon the adoption of the May 1, 2020 Second Amended and Restated Operating Agreement, the non-voting membership interest converted to a voting membership interest. Upon the Corporate Conversion, voting membership interest was converted into shares of common stock. The Agreement is in effect for 25&#160;years and will terminate on June&#160;1, 2037.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799604786384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.&#160;&#160;&#160;&#160;Accrued Expenses</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18.7pt;">Accrued expenses consist of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 159,704</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 532,678</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest on preferred members&#8217; interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 188,085</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 188,085</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 78,349</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 138,522</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued director fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 31,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 31,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 11,600</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,100</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other miscellaneous accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,360</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,375</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 470,098</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 921,760</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799705936080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6.</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Stockholders&#8217; Equity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s certificate of incorporation adopted on December 16, 2020, authorizes the issuance of two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock&#8221;. The total number of shares which the Company is authorized to issue is 45,000,000, each with a <span style="-sec-ix-hidden:Hidden_VfwIj3Fs2EKwWsM1T_o8Qw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">par value</span></span> of $0.0001 per share. Of these shares, 43,000,000 shall be Common Stock and 2,000,000 shall be Preferred Stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividends</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of the Common Stock are entitled to receive dividends when and as declared by the Board.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to the holders of Common Stock as to liquidation, upon liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of the Common Stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Voting</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the Common Stock are entitled to one vote for each share of Common Stock held. There is no cumulative voting.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preferred Stock may be issued from time to time by the Board in one or more series.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799608479872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">7</span>.&#160;&#160;&#160;&#160;Related Parties</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company uses Gendreau Consulting, LLC, a consulting firm (&#8220;Gendreau&#8221;), for drug development, clinical trial design, and planning, implementation and execution of contracted activities with CROs. Gendreau&#8217;s managing member became the Company&#8217;s Chief Medical Officer (&#8220;CMO&#8221;) effective January 1, 2021. The Company has and will continue to contract the services of the CMO&#8217;s spouse through the firm to perform certain activities in connect with the Company&#8217;s ongoing clinical development of product candidates. During the years ended December 31, 2022 and 2021, the Company paid Gendreau $356,088 and $326,416, respectively, and had accounts payable of $21,000 and $24,840 to Gendreau as of December 31, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799604291152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">8</span>.&#160;&#160;&#160;&#160;Commitments and Contingencies</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Litigation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#8217;s liquidity, financial condition and cash flows.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 26, 2021, Torreya Capital LLC (&#8220;Torreya&#8221;) filed a demand for arbitration with the American Arbitration Association in New York, New York in connection with a claim by Torreya that it is entitled to a transaction fee of $1,035,000 in connection with the Company&#8217;s IPO, plus the costs of arbitration, based on services Torreya alleged it provided for the Company as a financial advisor to the Company prior to the IPO.&#160;<span style="white-space:pre-wrap;">  On December 20, 2021, in order to avoid the risk, inconvenience and expense of a continued dispute, the Company entered into a release and settlement agreement with Torreya, whereby the Company agreed to pay Torreya </span>$325,000 for the release and discharge of any and all claims, liabilities and costs related to the arbitration. The Company paid the obligation prior to December 31, 2021, the cost of which is included in other expense in the accompanying statements of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreement and Deferred Compensation Plan</p><p style="font-family:'Garamond';font-size:11pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">The Company has employment agreements with its CEO, SVP of Operations, and SVP of Finance (the &#8220;Executives&#8221;), as well as its CMO. Per the terms of the agreements, each Executive and the CMO are entitled to receive a cash bonus with a target amount of no less than </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">50%</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> for the CEO, </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">35%</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> for the CMO and </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">20%</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> for the SVP of Operations and the SVP of Finance, of the then-current base salary. The bonuses are subject to achievement of annual bonus metrics set by the Board. The employment agreements will continue in effect until terminated by either party pursuant to its terms. Upon termination of the agreement by the Company for any reason other than for cause, death or disability or by one of the Executives or CMO for good reason, the Company shall pay to an Executive a &#8220;Severance Payment&#8221; equal to the aggregate of the Executive&#8217;s then-current annual base salary plus an amount equal to a prorated portion of the Executive&#8217;s cash bonus for the year in which the termination occurs. &#160;The Severance Payment to an Executive is payable in cash over a period of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">one year</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. The Company shall pay to the CMO a Severance Payment equal to </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">25%</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> of the then-current annual base salary plus a prorated portion of the CMO&#8217;s cash bonus for the year in which the termination occurs over a period of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">three months</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> and health benefits for a period of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">12 months</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> unless the CMO becomes eligible for health benefits under another employer. If the termination of the agreement is related to a change of control, the Company shall pay to the Executives and the CMO a &#8220;Change of Control Termination Payment&#8221; equal to the aggregate of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">1.0</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> times the then-current annual base salary plus an amount equal to </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">1.0</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> times the Executives&#8217; and CMO&#8217;s cash bonus for year in which the termination occurs. The Change of Control Termination Payments are payable in a single cash lump sum no later than </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">45 days</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> after the triggering event. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799604483936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based compensation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;Share-Based Compensation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Equity Incentive Plan</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 16, 2022, the stockholders of the Company approved the Amended and Restated 2020 Equity Incentive Plan (the &#8220;Plan&#8221;) to increase the total number of shares of common stock reserved for issuance under the Plan by 1,250,000 shares to 2,062,500 total shares issuable under the Plan. As of December&#160;31, 2022 and 2021, 430,603 and 63,353 shares, respectively, were available for future grants.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock awards, options, and other equity-based awards. The amount and terms of grants are determined by the Board. Stock options have a maximum term of <span style="-sec-ix-hidden:Hidden_zpYbTwNkCEuu23buIe0eJQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">10&#160;years</span></span> after date of grant and are exercisable in cash or as otherwise determined by the Board. The maximum aggregate number of shares subject to grant under the Plan to any individual, with the exception of any non-employee director, during any calendar year is limited to 500,000 shares. With respect to any non-employee director, the maximum aggregate number of shares subject to grant under the Plan to any individual during any calendar year is limited to 200,000 shares.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below sets forth the outstanding options to purchase common shares under the Plan:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 519,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.98</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 229,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 749,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.09</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 912,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (29,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,631,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.04</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 665,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.06</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022 and 2021, the aggregate intrinsic value of options outstanding and exercisable was $0.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, the Company granted certain individuals options to purchase 912,500 shares of the Company&#8217;s common stock with an average exercise price of $1.42 per share, contractual terms of 10 years and vesting periods ranging from 100% vesting after one year to 33.333% vesting after one year with the remaining 66.667% vesting in 24 monthly installments, thereafter. The options had an aggregate grant date fair value of $980,075 as calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option pricing model include: (1) discount rates ranging from 3.145% to 3.765% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected lives ranging from 5.5 years to 6.0 years based on the simplified method (vesting plus contractual term divided by two), (3) expected volatility ranging from 90.62% to 93.66% based on the average historical volatility of comparable companies' stock, (4) no expected dividends and (5) fair market value of the Company's stock ranging from $0.2789 to $4.23 per share.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, the Company granted certain individuals options to purchase 229,984 shares of the Company&#8217;s common stock with an average exercise price of $6.85 per share, contractual terms of 10 years and vesting periods ranging from 8.33% monthly over one year to 33.333% vesting after one year with the remaining 66.667% vesting in 24 monthly installments, thereafter. The options had an aggregate grant date fair value of $1,150,284 as calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option pricing model include: (1) discount rates ranging from 0.505% to 1.075% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected lives ranging from 5.27 years to 6.0 years based on the simplified method (vesting plus contractual term divided by two), (3) expected volatility ranging from 89.04% to 90.16% based on the average historical volatility of comparable companies' stock, (4) no expected dividends and (5) fair market value of the Company's stock ranging from $6.50 to $7.51 per share.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2022 and 2021, the Company recognized share-based compensation expense related to stock options of $582,659 and $322,881, respectively. The unrecognized compensation expense for stock options at December 31, 2022 and 2021 was $1,114,073 and $827,402, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock Options for Unregistered Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the stock options issued under the Plan, on December 16, 2020, the Company granted non-qualified stock options to purchase 292,500 shares of common stock as provided for in the employment agreement of the Company&#8217;s President at the time of and in conjunction with the Company&#8217;s IPO (the &#8220;President Options&#8221;). The President Options are exercisable within 10 years of the date of grant at $10.00 per share, were 100% vested at the grant date and have a remaining contractual term of 7.96 years. As of December 31, 2022, there was no unrecognized compensation expense related to these options as they were 100% vested upon issuance. The shares of common stock issuable upon exercise of the President Options will be unregistered, and the option agreement does not include any obligation on the part of the Company to register such shares of common stock. Consequently, the Company has not recognized a contingent liability associated with registering the securities for the arrangement. As of December 31, 2022, the aggregate intrinsic value of the President Options was $0.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Underwriters Warrants</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In conjunction with the IPO, the Company granted the underwriters warrants to purchase 172,500 shares of common stock at an exercise price of $12.50 per share. The warrants have a <span style="-sec-ix-hidden:Hidden_qp_BKBo_iESKd88pDgZH3g;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">five-year</span></span> contractual term and were not exercisable prior to December 21, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">In conjunction with the Offering in September 2022, the Company granted the Underwriter warrants to purchase 500,000 shares of common stock at an exercise price of $0.625 per share. The warrants have a </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">five-year contractual term and are not exercisable prior to March 18, 2023. The Company has accounted for the warrants as equity-based awards issued to a non-employee. The warrants had an aggregate grant date fair value of $178,462 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option pricing model include: (1) discount rate of 3.69% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected life of 5.0 years, (3) expected volatility of 96.46% based on the average historical volatility of comparable companies' stock, (4) no expected dividends and (5) fair market value (Offering price) of the Company's stock of $0.50 per share.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There was no net impact recognized by the Company in the accompanying financial statements as the warrants were equity-based awards issued for services rendered by the Underwriter for the Offering that was offset by the Company recognizing the fair value of the warrants as a direct and incremental costs associated with the Offering by reducing paid-in capital for the same amount. There is no unrecognized compensation expense for these awards as of December 31, 2022. The table below sets forth the outstanding warrants to purchase common shares:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 172,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.96</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 172,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.96</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 672,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.27</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 172,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.96</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">As of December 31, 2022, the aggregate intrinsic value of the warrants outstanding was $0.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799601807984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company has U.S. federal and state net operating loss carryforwards of approximately $22,168,000, which have an indefinite carryforward. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">A reconciliation of the U.S. federal income tax rate to the Company&#8217;s effective tax rate is as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21.00</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (0.57)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4.83</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax true-ups</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.82)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 0.06</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (25.32)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23.47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective Income Tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets are comprised of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,692,533</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,586,488</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,873,211</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,411,624</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,338,234</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Investment in partnership</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 30,771</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,593</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 15,223</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,299</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 9,023,362</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,971,614</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (8,682,497)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,581,599)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 340,865</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 390,015</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (340,865)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (390,015)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (340,865)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (390,015)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For tax years beginning on or after January 1, 2022, the 2017 Tax Cuts and Jobs Act amended Section 174 of the code to eliminate current-year deductibility of research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and fifteen years for research activities performed outside of the United States. For the 2022 tax year, the Company has capitalized $8,099,702<span style="white-space:pre-wrap;"> of research and development expenses.  This has resulted in an increase in the deferred tax asset associated with capitalized research and development by </span>$1,873,211.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company has not generated sufficient positive evidence for future earnings to support a position that it will be able to realize its net deferred tax asset. The Company has significant negative evidence to overcome in the form of cumulative pre-tax losses from continuing operations since its formation, as well as projected losses for the current year. Therefore, it will continue to maintain a full valuation allowance on its U.S. federal and state net deferred tax asset. The change in the valuation allowance offset the income tax benefit related to the pre-tax loss for the year ended December 31, 2022. The Company does not have any material unrecognized tax benefits as of December 31, 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company experienced a net change in valuation allowance of $3,100,898 and $3,745,299 for the years ended December&#160;31, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799603007136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Basis of Presentation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentrations of Credit Risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash is potentially subject to concentrations of credit risk. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i>, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8212; Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8212; Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amount of the Company&#8217;s financial instruments, including cash, accounts payable and accrued expenses approximate their fair values.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cash</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash is maintained in bank deposit accounts, which exceed the federally insured limits of $250,000. The Company does not have any cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Variable Interest Entities</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When determining whether a legal entity should be consolidated, the Company first determines whether it has a variable interest in the legal entity. If a variable interest exists, the Company determines whether the legal entity is a variable interest entity (&#8220;VIE&#8221;) due to either: 1) a lack of sufficient equity to finance its activities, 2) its equity holders lacking the characteristics of a controlling financial interest, or 3) the legal entity being structured with non-substantive voting rights. If the Company concludes that the legal entity is a VIE, the Company next determines whether it is the primary beneficiary due to it possessing both: 1) the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, and 2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE which could be significant to the VIE. If the Company concludes that it is the primary beneficiary, it consolidates the entity.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investment</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Equity Method Investment</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2017, the Company purchased a 25% ownership in Northriver Pharm, LLC (&#8220;NRP&#8221;) in the amount of $125,000 from existing investors of NRP. NRP is an entity with common ownership with the Company&#8217;s former Chief Executive Officer and Founder, who is also the Founder and sole voting member of NRP. The Company evaluated the ownership under VIE guidance and has determined that the Company does not have the power and economics to control the entity and are not the entity most closely associated with NRP.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company previously accounted for the investment under the equity method of accounting. However, consistent with equity method accounting guidance, the Company has now discontinued applying the equity method accounting as the investment has been reduced to zero and the Company has not committed to provide further financial support and there is no expected return to profitable operations by NRP.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company operated as an Alabama limited liability company until its Corporate Conversion. Therefore, the Company passed through all income and losses to its members until this point. As of December 31, 2022 and 2021, the Company had a full valuation allowance against deferred tax assets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, <i style="font-style:italic;">Income Taxes</i>. Under ASC 740, consideration is given to the recognition and measurement of tax positions that meet a &#8220;more-likely-than-not&#8221; threshold. A tax position is a position taken in a previously filed tax return or a position expected to be taken in a future that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions include the Company&#8217;s status as a pass-through entity until December 16, 2020 and as a corporation thereafter. The recognition and measurement of tax positions taken for various jurisdictions consider the amounts and probabilities of outcomes that could be realized upon settlement using the facts, circumstances, and information available at the reporting date. The Company has determined that it does not have any material unrecognized tax benefits or obligations as of December&#160;31, 2022 and 2021. The Company recognizes interest and penalties related to uncertain tax positions, if any, in income tax expense. The Company is not currently under examination by the Internal Revenue Service or by state tax authorities and the Company&#8217;s tax year remains subject to examination by the tax authorities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Basic and Diluted Net Income (Loss) per Share</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share (&#8220;EPS&#8221;) is computed in accordance with U.S. GAAP. Basic EPS is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted EPS reflects potential dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if all potential common shares had been issued and were dilutive. However, potentially dilutive securities are excluded from the computation of diluted EPS to the extent that their effect is anti-dilutive. For the&#160;years ended December&#160;31, 2022 and 2021, the Company had 1,924,397 and 1,041,647 options, respectively, and 672,500 and 172,500 warrants, respectively, to purchase common shares outstanding that were anti-dilutive. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development costs are expensed as incurred. The Company arranges and contracts with third-party contract research organizations (&#8220;CROs&#8221;), contract development and manufacturing organizations (&#8220;CMOs&#8221;), contractor laboratories and independent consultants. As part of the process of preparing its financial statements, the Company may be required to estimate some of its expenses resulting from its obligations under these arrangements and contracts. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided. The Company&#8217;s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are rendered. The Company determines any accrual estimates based on account discussions with applicable personnel and outside service providers as to the progress or state of completion. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company&#8217;s estimates are dependent upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record prepaid or accrued expenses related to these costs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Share-Based Compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense relating to share-based awards to employees and directors with a performance condition over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and warrants granted using an options pricing model, see Note 9. Expense is recognized within both research and development and general and administrative expenses and forfeitures are recognized as they are incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_StatusOfCompanyPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company Status</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided by the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recent Accounting Pronouncements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes</i>. The standard eliminates the need for an organization to analyze whether the following apply in a given period: (1) the exception to the incremental approach for intraperiod tax allocation; (2) the exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (3) the exception in interim periods income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also is designed to improve financial statement preparers&#8217; application of income tax-related guidance and simplify U.S. GAAP for (1) franchise taxes that are partially based on income, (2) transactions with a government that result in a step-up in the tax basis of goodwill, (3) separate financial statements of legal entities that are not subject to tax, (4) enacted changes in tax laws in interim periods and (5) certain income tax accounting for employee stock ownership plans and affordable housing projects. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">In August 2020, the FASB issued ASU 2020-06, <i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. Early adoption is permitted. ASU 2020-06 allows companies to adopt the guidance through either a modified retrospective method of transition or a fully retrospective method of transition. The Company is continuing to evaluate the impacts that ASU 2020-06 will have on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_StatusOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for change in status of company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_StatusOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602194080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,165,634</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,329,385</p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid clinical research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 154,510</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 422,591</p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 11,329</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,664</p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other miscellaneous current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,291</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 863</p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,338,764</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,768,503</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prepaid expense and other assets current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799693025584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 159,704</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 532,678</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest on preferred members&#8217; interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 188,085</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 188,085</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 78,349</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 138,522</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued director fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 31,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 31,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 11,600</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,100</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other miscellaneous accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,360</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,375</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 470,098</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 921,760</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799604343680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 519,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.98</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 229,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 749,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.09</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 912,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (29,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,631,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.04</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 665,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.06</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of underwriters warrants to purchase common shares</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 172,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.96</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 172,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.96</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 672,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.27</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 172,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.96</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799604291680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of federal income tax rate to effective tax rate</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21.00</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (0.57)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4.83</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax true-ups</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.82)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 0.06</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (25.32)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23.47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective Income Tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of net deferred tax assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,692,533</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,586,488</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,873,211</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,411,624</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,338,234</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Investment in partnership</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 30,771</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,593</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 15,223</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,299</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 9,023,362</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,971,614</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (8,682,497)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,581,599)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> 340,865</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 390,015</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (340,865)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (390,015)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (340,865)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (390,015)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799603871776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Organization (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 21, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 4,490,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice', window );">Warrants exercise price percentage of IPO Price</a></td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,247,834<span></span>
</td>
<td class="nump">$ 15,960,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,467,797<span></span>
</td>
<td class="nump">15,689,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,173,207<span></span>
</td>
<td class="nump">$ 43,925,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment', window );">Period in which the company has to raise additional capital to complete clinical development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment', window );">Period in which the company has to raise additional capital to complete clinical development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period in which the company has to raise additional capital to complete clinical development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise price as percentage of initial public offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602194080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federally insured limit</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602182864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Equity Method Investment (Details) - NRP<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=viri_NorthriverPharmLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=viri_NorthriverPharmLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799601888160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Basic and Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">1,924,397<span></span>
</td>
<td class="nump">1,041,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">672,500<span></span>
</td>
<td class="nump">172,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799603947040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 1,165,634<span></span>
</td>
<td class="nump">$ 1,329,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_PrepaidClinicalResearchCosts', window );">Prepaid clinical research costs</a></td>
<td class="nump">154,510<span></span>
</td>
<td class="nump">422,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_PrepaidServices', window );">Prepaid services</a></td>
<td class="nump">11,329<span></span>
</td>
<td class="nump">15,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Other miscellaneous current assets</a></td>
<td class="nump">7,291<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,338,764<span></span>
</td>
<td class="nump">$ 1,768,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_PrepaidClinicalResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for clinical research costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_PrepaidClinicalResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_PrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents element information pertaining to prepaid services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_PrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602953728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement (Details) - Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2012</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest', window );">Percentage of non-voting membership interest</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_LicenseAgreementExpirationPeriod', window );">License agreement expiration period</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents element information pertaining to percentage of non-voting membership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_LicenseAgreementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents element information pertaining to license agreement expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_LicenseAgreementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=viri_KnowHowLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=viri_KnowHowLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799601956032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 159,704<span></span>
</td>
<td class="nump">$ 532,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_AccruedInterestOnPreferredMembersInterest', window );">Accrued interest on preferred members' interests</a></td>
<td class="nump">188,085<span></span>
</td>
<td class="nump">188,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_AccruedResearchAndDevelopmentCosts', window );">Accrued clinical research costs</a></td>
<td class="nump">78,349<span></span>
</td>
<td class="nump">138,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_AccruedDirectorFeesCurrent', window );">Accrued director fees</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">24,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other miscellaneous accrued expenses</a></td>
<td class="nump">1,360<span></span>
</td>
<td class="nump">7,375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 470,098<span></span>
</td>
<td class="nump">$ 921,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_AccruedDirectorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for director fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_AccruedDirectorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_AccruedInterestOnPreferredMembersInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable pertaining to pertaining to accrued interest on preferred member's interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_AccruedInterestOnPreferredMembersInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable pertaining to accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602171712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 16, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_CommonAndPreferredStockSharesAuthorized', window );">Common and preferred stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">43,000,000<span></span>
</td>
<td class="nump">43,000,000<span></span>
</td>
<td class="nump">43,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_NumberOfVotesPerCommonStock', window );">Number of votes per common stock | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_CommonAndPreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common and preferred shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_CommonAndPreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_NumberOfVotesPerCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes per common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_NumberOfVotesPerCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602921824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - Gendreau Consulting, LLC - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Amount paid to the firm</a></td>
<td class="nump">$ 356,088<span></span>
</td>
<td class="nump">$ 326,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 24,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=viri_GendreauConsultingLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=viri_GendreauConsultingLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602766400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th"><div>Aug. 26, 2021</div></th>
<th class="th"><div>Sep. 10, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_EmploymentAgreementSeverancePaymentPaymentPeriod', window );">Severance payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod', window );">Period of termination due to change of control.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_PercentageOfCashBonusOnSalary', window );">Percentage of cash bonus on salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=viri_VicePresidentOperationsAndFinanceMember', window );">VP of Operations and Finance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_PercentageOfCashBonusOnSalary', window );">Percentage of cash bonus on salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=viri_ChiefMedicalOfficerMember', window );">CMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary', window );">Percentage of then current annual base salary.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_EmploymentAgreementThresholdTerminationPeriod', window );">Threshold termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination', window );">Employment agreement, health benefit offered period on termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary', window );">Ratio of current annual base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus', window );">Ratio of cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | CMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_PercentageOfCashBonusOnSalary', window );">Percentage of cash bonus on salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=viri_TorreyaCapitalLlcMember', window );">Torreya Capital LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Transaction fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other (expense) income</a></td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The termination payment payable as a in ratio of cash bonus for the year, when the termination occurs due to change of control.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The termination payment payable as a in ratio of then current annual base salary when the termination occurs due to change of control.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period in which the termination payment is payable in cash, when the termination occurs due to change of control.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of health benefit offered in addition to severance payment when the executive is not eligible for health benefits under another employer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The severance payment represented as a percentage of then current annual base salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_EmploymentAgreementSeverancePaymentPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period in which the severance payment is payable in cash to the executive under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_EmploymentAgreementSeverancePaymentPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_EmploymentAgreementThresholdTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold termination period under the employment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_EmploymentAgreementThresholdTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_PercentageOfCashBonusOnSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash bonus on salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_PercentageOfCashBonusOnSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=viri_VicePresidentOperationsAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=viri_VicePresidentOperationsAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=viri_ChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=viri_ChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=viri_TorreyaCapitalLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=viri_TorreyaCapitalLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799603824960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Equity Incentive Plan (Details) - Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period</a></td>
<td class="nump">749,147<span></span>
</td>
<td class="nump">519,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">912,500<span></span>
</td>
<td class="nump">229,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(29,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period</a></td>
<td class="nump">1,631,897<span></span>
</td>
<td class="nump">749,147<span></span>
</td>
<td class="nump">519,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2022</a></td>
<td class="nump">665,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding the beginning of the period</a></td>
<td class="nump">$ 9.03<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">1.42<span></span>
</td>
<td class="nump">6.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">4.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period</a></td>
<td class="nump">4.85<span></span>
</td>
<td class="nump">$ 9.03<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2022</a></td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (years)</a></td>
<td class="text">9 years 14 days<span></span>
</td>
<td class="text">9 years 1 month 2 days<span></span>
</td>
<td class="text">9 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at December 31, 2022</a></td>
<td class="text">8 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799599332256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Jun. 16, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue', window );">Aggregate grant date fair value</a></td>
<td class="nump">$ 178,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Discount rates</a></td>
<td class="nump">3.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">96.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member', window );">Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,062,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,603<span></span>
</td>
<td class="nump">63,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue', window );">Aggregate grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 980,075<span></span>
</td>
<td class="nump">$ 1,150,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member', window );">Plan | Employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum aggregate number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member', window );">Plan | Non-Employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum aggregate number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member', window );">Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.145%<span></span>
</td>
<td class="nump">0.505%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.62%<span></span>
</td>
<td class="nump">89.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2789<span></span>
</td>
<td class="nump">$ 6.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member', window );">Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.765%<span></span>
</td>
<td class="nump">1.075%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.66%<span></span>
</td>
<td class="nump">90.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.23<span></span>
</td>
<td class="nump">$ 7.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member', window );">Plan | Vesting over one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member', window );">Plan | Vesting after one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.333%<span></span>
</td>
<td class="nump">33.333%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member', window );">Plan | Vesting in 24 monthly installments thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.667%<span></span>
</td>
<td class="nump">66.667%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member', window );">Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 582,659<span></span>
</td>
<td class="nump">$ 322,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,114,073<span></span>
</td>
<td class="nump">$ 827,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair market value assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799599262832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Unregistered Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Jun. 16, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Discount rates</a></td>
<td class="nump">3.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">96.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member', window );">Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">912,500<span></span>
</td>
<td class="nump">229,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.42<span></span>
</td>
<td class="nump">$ 6.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 14 days<span></span>
</td>
<td class="text">9 years 1 month 2 days<span></span>
</td>
<td class="text">9 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member', window );">Plan | Non-qualified stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=viri_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=viri_NonQualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=viri_NonQualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602821136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Underwriters Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 21, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining contractual term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue', window );">Aggregate grant date fair value</a></td>
<td class="nump">$ 178,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Discount rates</a></td>
<td class="nump">3.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">96.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,500<span></span>
</td>
<td class="nump">172,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ClassOfWarrantOrRightGranted', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672,500<span></span>
</td>
<td class="nump">172,500<span></span>
</td>
<td class="nump">172,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ClassOfWarrantOrRightExercisable', window );">Exercisable at December 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.67<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ClassOfWarrantOrRightRemainingTerm', window );">Remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 7 days<span></span>
</td>
<td class="text">3 years 11 months 15 days<span></span>
</td>
<td class="text">4 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm', window );">Exercisable contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_AggregateIntrinsicValueOfWarrantsOutstanding', window );">Intrinsic value of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_AggregateIntrinsicValueOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate intrinsic value of warrants outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_AggregateIntrinsicValueOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share or per unit of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_ClassOfWarrantOrRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights  granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_ClassOfWarrantOrRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share or per unit of warrants or rights granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_ClassOfWarrantOrRightRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining term of warrants and right, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_ClassOfWarrantOrRightRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799604862560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 22,168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in valuation allowance</a></td>
<td class="nump">3,100,898<span></span>
</td>
<td class="nump">$ 3,745,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses', window );">Deferred Tax Assets, Capitalized Research and Development Expenses</a></td>
<td class="nump">1,873,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_CapitalizedResearchAndDevelopmentExpense', window );">Capitalized research and development expenses</a></td>
<td class="nump">$ 8,099,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_CapitalizedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development expenses capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_CapitalizedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799603947552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of federal income tax rate to effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="num">(0.57%)<span></span>
</td>
<td class="num">(0.33%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">4.83%<span></span>
</td>
<td class="nump">4.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent', window );">Deferred tax true-ups</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.82%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="nump">0.06%<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(25.32%)<span></span>
</td>
<td class="num">(23.47%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799602118528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Net deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 5,692,533<span></span>
</td>
<td class="nump">$ 4,586,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses', window );">Capitalized research and development expenditures</a></td>
<td class="nump">1,873,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,411,624<span></span>
</td>
<td class="nump">1,338,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_DeferredTaxAssetsInvestmentInPartnership', window );">Investment in partnership</a></td>
<td class="nump">30,771<span></span>
</td>
<td class="nump">30,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_viri_DeferredTaxAssetsAmortization', window );">Amortization</a></td>
<td class="nump">15,223<span></span>
</td>
<td class="nump">16,299<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">9,023,362<span></span>
</td>
<td class="nump">5,971,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(8,682,497)<span></span>
</td>
<td class="num">(5,581,599)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">340,865<span></span>
</td>
<td class="nump">390,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">340,865<span></span>
</td>
<td class="nump">390,015<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">340,865<span></span>
</td>
<td class="nump">390,015<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_DeferredTaxAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_DeferredTaxAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_viri_DeferredTaxAssetsInvestmentInPartnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investment in partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">viri_DeferredTaxAssetsInvestmentInPartnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>viri_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>tmb-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:viri="http://www.virios.com/20221231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tmb-20221231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_S_a8HrS8Ike_exmqyqXIMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_LDUdwdZQkU2vEFN0QuBgEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_xfm2EfLia0i3nez_VARJng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_07boxe2rbUysaeH7Ihz82A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">viri:ChiefMedicalOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_VicePresidentOperationsAndFinanceMember_X9NqiprFVkeF2f-E51b3HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">viri:VicePresidentOperationsAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_9Fj9-utpbkORtVRzg81GPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2020_To_9_10_2020_RVDodrV4eECIJMPDAPhQBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <startDate>2020-09-10</startDate>
            <endDate>2020-09-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">viri:ChiefMedicalOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2012_To_12_31_2012_us-gaap_TypeOfArrangementAxis_viri_KnowHowLicenseAgreementMember_v_HMShg6JkeIz5pkc4ARKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">viri:KnowHowLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_ujddVzlF9kmGOtaxPWQprg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_19_2022_To_9_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FjS6TDESSkSjA8g43D0JKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-19</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mTuQdj48xkSPPkeT8q6HWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4-H-oXcCNESU_xrftuaLnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZScAQIaW_km0W4UmK9ailg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_585XaE_Qb06wg3yY8VCAnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9rd8UeAZvkiyb61_0b58xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TTmYcU_i-kGxQDW5uKyINw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xSxWfKQTuEmBuKVtKLpaYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_na0T6F0WK0iSAkJB4vdliQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m9xCbfrpkkuZH2FpqooItA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bmANR8woWk2jfaAekf9q_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_f6XxsTWSbk6n_wNrDUfYkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_HfIQGNlGO0GfJuvJzN6shA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_PSW_ICNFWUWC815QcUkHTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_16_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_EKNzGamAM0e5Uudfko5Mbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="Duration_6_16_2022_To_6_16_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Sy6PBJsphU-CRbISsoIF6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="Duration_6_16_2022_To_6_16_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_kJHmoKVpsEyo6AaXVE_bJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ikj9w2rCj0izLrRvksWE6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_qgz0o95s_0aPxtVxKLV_Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ClZ-Zp5G-kmzZkhdCCktbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_jfwr1MSSHkK724vOCV_g2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_16_2022_To_6_16_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_p9GEDysUj0yLr6kbN6USkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">viri:NonQualifiedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yFCbkitpnUybTr1oZGQIXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_iX6ZkNMhbEeXsuVhLuePbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_epi_lHMtoEOuSGGUHTT6cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iwzJfTl-OUiIleLyhau04g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_Qf178jUjQ0m0mIlYgP4eGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_npYg-xxOqkqKwXBoOxfd0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_X5Y3MAAZ80-3sQBqUVtS-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">viri:GendreauConsultingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_uEjU9DNz10qTagf5uNcBwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">viri:GendreauConsultingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <startDate>2022-09-19</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="Duration_12_20_2021_To_12_20_2021_srt_LitigationCaseAxis_viri_TorreyaCapitalLlcMember_593RpFikOES1pICvYkGC7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">viri:TorreyaCapitalLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aWecVCFl10-XycTsN-tb1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nhUquGnkwkWL4lFfC9GfAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_26_2021_To_8_26_2021_srt_LitigationCaseAxis_viri_TorreyaCapitalLlcMember_U8Q3TkmcJkCKXKS_Ao-Drw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">viri:TorreyaCapitalLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-26</startDate>
            <endDate>2021-08-26</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_viri_NorthriverPharmLlcMember_5EL1vFgplUm9u---06s8UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">viri:NorthriverPharmLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_5tEhIARsaEiYoR53c54ELg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">viri:NonQualifiedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_IXFyCqWULkiAGzccCCWCsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_fA7tndkyWEeG7RdGqTIrYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <instant>2020-12-16</instant>
        </period>
    </context>
    <context id="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <instant>2022-09-19</instant>
        </period>
    </context>
    <context id="As_Of_12_21_2021_UH5_wupqpEWPUP_czHBCeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <instant>2021-12-21</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_tCm4u3HF1ESoDqVBr91eXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_J7UBwLt2s02a0dmSAvm0Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_zVHuNo8JJUOL740CgoX5UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_tuCBnQCdJkqjINAChtpNqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aPhBzRC3h0y-kExu1oDuMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_bzvM8doJ10mkpUYJYD_rTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_E57glfgKCUSq3eMsl6w6qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">viri:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fp9m85ab_kqv2G63PG8esw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_13Xq7gMuT0mkNLo5wF0tow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_VktHnKz5PUWL5c7XiyyBUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">viri:GendreauConsultingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_XAqJzIFAPEimuSHD-_p6Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">viri:GendreauConsultingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_6pKaPRrEBEueDT3pVVSG6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_10_2023_gDWxuz6Fxk2oZ4xGHfj6UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818844</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_wR6KQv_y_U6N2ZwjlZ-M-Q">
        <measure>viri:item</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      id="Hidden_lZFub5RiNEaT10GhfCSmMg"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      id="Hidden_nSxxnShqC0ms8I3lL-ScrA"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      id="Hidden_g98_LEx6m0iGYU0oez53mQ"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      id="Hidden_H490oChYRUiWywnG5LXpSQ"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Hidden_fShwsexZgUqxezn77bjtyQ"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      id="Hidden_P2p0tDP4lU2AYmbbheUymA"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="2"
      id="Hidden_MhJuUiG5jEG0ZWPo8EvG4A"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">-1.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="2"
      id="Hidden_WF2qwdt_CEm6Zk4VcPToSw"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">-1.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Hidden_8OtyTsZAIU6iOHmtIfjT1A"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">11070116</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Hidden_pJLaGSLK5USc2kdWUT-cdg"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">8329310</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tc_5_Xy6zwY8k-0WrAHtohZrw_2_1">0001818844</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tc_DVUl0Fm3QUWkMcjaIWjbbQ_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tc_L8mugFSx0UeKqnknKgsZ1w_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tc_LHPwOb2JFkuKkvTGNL1fIg_6_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Hidden_DaqBv8HmyEyA7xikWYGzsw">Virios Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Hidden_Q5qZWOLpJUCZAh_89hTyVw">NASDAQ</dei:SecurityExchangeName>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="INF"
      id="Hidden_oHnHAxEtjkSEk0DF-WTqiA"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">18330390</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="INF"
      id="Hidden_JxC-36GfvUKSaH-OXfQG3A"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="INF"
      id="Hidden_sdXhQbgcvUWsTh4eEyGrAg"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg"
      decimals="INF"
      id="Hidden_VfwIj3Fs2EKwWsM1T_o8Qw"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="INF"
      id="Hidden_VYcd50m3f0yVEciBOooblw"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">8330390</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_6_16_2022_To_6_16_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_p9GEDysUj0yLr6kbN6USkA"
      id="Hidden_zpYbTwNkCEuu23buIe0eJQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_12_21_2021_UH5_wupqpEWPUP_czHBCeA"
      id="Hidden_qp_BKBo_iESKd88pDgZH3g">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_gbct8qp7i0-A4LI14cFoGw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_uZ2UOly8v0aO2A0qW_7qhg">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_BUyQLcbick-CmN7OPJNeBw">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_ldpqV8MhKkezda36-GXwWA">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_OLF2kxDHBkGoX1691aACfw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_3rT7g5MEaUiv_oPODjC15Q">001-39811</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tc_m9Z7_WSSEkq_r6BZuSvZtw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tc_R2tqBK0PB0eBGynG158ffQ_1_1">85-4314201</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_w0h8kTvOYEiNjDzSeOZ2rQ">44 Milton Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_t5avwlTq2kKPp8JavpsEBA">Alpharetta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_2q6Wi1QSU02OO70G05FWVw">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tc_ozGofd8x9k-9c2wRUQBVlw_4_1">30009</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_fZSNkIyFRkq4FkD_T0k9PQ">866</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_WEDj40NKDkehIROcpjDpDA">620-8655</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tc_TDxuqVevZEWMPTpFOImpxw_3_0">Common Stock, $0.0001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tc_luiKQtU0HUC821X2r7oFKw_3_2">VIRI</dei:TradingSymbol>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_P0mp9CHw-kKXMw7tNu-2Pg">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_lxuImP4xiUSTimITbYWX6A">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_c7KNyOmzvU6TmD0XecpoJQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_QgEmPknhwkqPs-A3pdeEzw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_l77-gqvJTU24Yga_JlYgfg">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_rnahE-OcX0KZA1errctwTA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_BEJD6L1u_0CT0IcJy7CQbA">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_dzSv5vdVFEKGFrBayhXzkw">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_ttw9KJnN9EiLo9OR1UE-IA">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_QBH-kAz-H0K-oklN3avkUA">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_6pKaPRrEBEueDT3pVVSG6w"
      decimals="2"
      id="Narr_1gnbtabwYEu0oaSkWRe9Sg"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">31229227.08</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_10_2023_gDWxuz6Fxk2oZ4xGHfj6UA"
      decimals="INF"
      id="Narr_iBQJRVkhgE618CJFURdzeA"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">18330390</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_AIlfJljf1kan1ADGr1-cuA">FORVIS, LLP (Formerly, Dixon Hughes Goodman LLP)</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_xHnzDFZvWE-smkwc-5fiDw">Atlanta, Georgia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_XYZPwqmI80CrOj1oolnMUg_5_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">7030992</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_hDVQrRVCUE-ul2iilTSZUw_5_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">14008184</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_3JX0vflhvkGONL9SpS41Bg_6_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1338764</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_zPOHtVF2vUCwnpNj9E6tXQ_6_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1768503</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_XBOfVVttuEiP7GvbsbR2Uw_7_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">8369756</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_eRAn66-NUEu0QU2bzV31Pw_7_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">15776687</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_ulR25h4D3U-iqN7C1qhhqA_8_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">8369756</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_Zv9sLAElIk2II168uxlpDQ_8_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">15776687</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_AKgcEM6gvky-CwzM3z6yqg_11_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">573164</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_cAatySCcd0Cxv992iOKvMg_11_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">353863</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_UmoU1MSlDUu_u_HRmqRxhg_12_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">470098</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_uCc9nV3Q_kGadoCrEDhzXQ_12_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">921760</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_1VGzqo4iEUWu1mNkSinLKQ_13_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1043262</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_9tHMQyKR_kK7FSqE9kJ2HQ_13_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1275623</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_lCURV5faV0iDV9Ug4rqRRA_14_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1043262</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_gipTcHKLykaM4tEnB6gzYA_14_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1275623</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="INF"
      id="Narr_rZSg5I0p5ECFPTSTY21e8Q"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="INF"
      id="Narr_P6AURPlJmUiz4lz2jG4Ogg"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="INF"
      id="Narr_swwPA3zUYkuI7-Z9fN3yVA"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">43000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="INF"
      id="Narr_qz_CDTeR8EuHq2yqJkt_OQ"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">43000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="INF"
      id="Narr_RGn1Znqk7ke1zXdhicv7mw"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">18330390</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="INF"
      id="Narr_X_bRSqU1p0-nJIkEQFxajg"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">8330390</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_wFButRb3HUqoVBodVK5-CQ_17_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1833</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_4qTSOcYkv0muxcd2_EzY5g_17_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">833</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="INF"
      id="Narr_RREj4tHHCUyupnpg0nYdHQ"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="INF"
      id="Narr_lz4Uws_Vqky4f1ZUmqzzgw"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="INF"
      id="Narr_T3hLjyqe_0CjqqY6brkD7g"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="INF"
      id="Narr_lvNk53GT_UacmDM-h7tgSw"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="INF"
      id="Narr_7qhALSuM8U2MMbkwR9czaQ"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="INF"
      id="Narr_O7wkVMVAg0CdZ_KMSOjH2Q"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_KwTO8TeYk02J4fjoFEXzZg_19_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">63497868</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_Spbs4hzCW0Kl2lFh9HEB4Q_19_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">58425604</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_o35ctKZ10UWjnsjSnbYrBA_20_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-56173207</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_oyxD2liKFkG1KWFhw0tWMw_20_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-43925373</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_E7YgM21RXEKBKMr_5qPI0Q_21_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">7326494</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_EOFu5V0aLUKAjKiVG6oYsA_21_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">14501064</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_S4x8wHr4ykydgFRXnOX3lw_22_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">8369756</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_sGLOogTtKkuv_oukt467hQ_22_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">15776687</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_HXwEnAVT0EqOdMZsrvcgTQ_7_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">8069628</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_8cb3g2A3HUiZhWtf7xdpCA_7_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">10795688</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_Ymo3jREfO0eJc3A63bw2AA_8_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">4245681</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_ZAIkBb43t0iqSDsI14zIxA_8_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">4845252</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_LS1Aqz0CmUWL32MoKIXfeA_9_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">12315309</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_4WBHHRCvx0u1V4sr5hjFQg_9_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">15640940</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_5cStOpNEY0u0aJVpv59N1g_11_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-12315309</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_oBWNCxOe5Ume7g9lfJrByA_11_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-15640940</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_e1hoSmpnwk2pO7kQF66vBg_14_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">67475</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_H10yYDBuyEqrA3mBlLlQMg_14_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">5672</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_AxIJU_pt-ECOWW4cZENN0w_15_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">325000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_zD70wdW2f0ue6uaCf3QFyA_16_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">67475</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_nhk1xRiEdkioHQyeflWHBw_16_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-319328</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_EM0lrNSBg0OhBrL3QaiRww_18_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-12247834</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_eAAknUXXSk6DgaazeBuQ3g_18_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-15960268</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_9pd7FtIaCkC8L_sBJSXOzQ_21_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-12247834</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_WzaP-FOLL0KaAEYKcKIqVQ_21_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-15960268</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="2"
      id="Tc_F78nKKOWBka4UIG7ILGMuQ_22_3"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">-1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="2"
      id="Tc_UVX2VbFrsUmbOgEAmGca7g_22_6"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">-1.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_jyOkpiWlMUSjSbWluZApoA_23_3"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">11070116</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_GiRR1PoZgk28c6sBjmuuxw_23_6"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">8329310</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bmANR8woWk2jfaAekf9q_w"
      decimals="INF"
      id="Tc_MR9JANizikWVcYQS1zEB8Q_5_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">8305075</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bmANR8woWk2jfaAekf9q_w"
      decimals="0"
      id="Tc_YLplOO4cekSHqBHLv9k0HQ_5_5"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">830</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xSxWfKQTuEmBuKVtKLpaYg"
      decimals="0"
      id="Tc_TWj0pAUDrkiNWfs1yKJ4rg_5_8"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">57905164</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TTmYcU_i-kGxQDW5uKyINw"
      decimals="0"
      id="Tc_EQPeH3nfEE2i7RuSPRauJQ_5_11"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-27965105</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_tCm4u3HF1ESoDqVBr91eXw"
      decimals="0"
      id="Tc_U25HiZAn6Eae5Yli8pFnuw_5_14"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">29940889</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_13Xq7gMuT0mkNLo5wF0tow"
      decimals="0"
      id="Tc_Qa0nIZNurUiVDd53eKl_5A_6_8"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">322881</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_TxQyl6uxrkiY2N04K5rPZg_6_14"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">322881</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <viri:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_S_a8HrS8Ike_exmqyqXIMA"
      decimals="INF"
      id="Tc_5S9-n67FPESXnriadTi8zA_7_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">25315</viri:StockIssuedDuringPeriodSharesWarrantsExercised>
    <viri:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_S_a8HrS8Ike_exmqyqXIMA"
      decimals="0"
      id="Tc_1KXbd0JNwUGA7eF9HM65cg_7_5"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">3</viri:StockIssuedDuringPeriodValueWarrantsExercised>
    <viri:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_13Xq7gMuT0mkNLo5wF0tow"
      decimals="0"
      id="Tc_wXSd_AbhPU-5wDxFkQ6Srw_7_8"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">197559</viri:StockIssuedDuringPeriodValueWarrantsExercised>
    <viri:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_fbflZTJhDECa2cebKp445w_7_14"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">197562</viri:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nhUquGnkwkWL4lFfC9GfAQ"
      decimals="0"
      id="Tc_7XA8z7sqh0SAm8iKKTlhIg_8_11"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-15960268</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_e7JJnUONVkyFLH0yc_YCnw_8_14"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-15960268</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m9xCbfrpkkuZH2FpqooItA"
      decimals="INF"
      id="Tc_KnhNz4nM0U-GM3kbJ0NQAw_9_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">8330390</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m9xCbfrpkkuZH2FpqooItA"
      decimals="0"
      id="Tc_Xrg6008BLEutH1tl66orGg_9_5"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">833</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9rd8UeAZvkiyb61_0b58xQ"
      decimals="0"
      id="Tc_4sgSqovgKUSb_gGA0D9vPQ_9_8"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">58425604</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_585XaE_Qb06wg3yY8VCAnw"
      decimals="0"
      id="Tc_7-syKa8gUUCluFOvtKorYw_9_11"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-43925373</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_0u_yxRqBtkSarcbcJng20A_9_14"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">14501064</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mTuQdj48xkSPPkeT8q6HWw"
      decimals="INF"
      id="Tc_UACgrMPar0-M3VroH-CZpw_10_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mTuQdj48xkSPPkeT8q6HWw"
      decimals="0"
      id="Tc_VXGMFYs5TE-Zt7ZIkNLdXQ_10_5"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fp9m85ab_kqv2G63PG8esw"
      decimals="0"
      id="Tc_iZ1-0lK_xkSEPX2DBmmV7A_10_8"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">4489605</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_mqzjoehbcEaAKjWGtD4v_g_10_14"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">4490605</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fp9m85ab_kqv2G63PG8esw"
      decimals="0"
      id="Tc_8WWTOJUWn0OLKShw07KKAQ_11_8"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">582659</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_69-dofRcmUGuXahJ8mxtYw_11_14"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">582659</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aWecVCFl10-XycTsN-tb1Q"
      decimals="0"
      id="Tc_Y3jRrNPfJ0WDjg5v3mYKiw_12_11"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-12247834</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_dMgh6byj70aVOHmU03RjhQ_12_14"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-12247834</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_na0T6F0WK0iSAkJB4vdliQ"
      decimals="INF"
      id="Tc_c5wvUb5Ex0iigK88NKG61A_13_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">18330390</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_na0T6F0WK0iSAkJB4vdliQ"
      decimals="0"
      id="Tc_R_io_gAsMUGo0AFECmoB7w_13_5"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1833</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZScAQIaW_km0W4UmK9ailg"
      decimals="0"
      id="Tc_Gzt8msg96k68Jyti4miEVw_13_8"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">63497868</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4-H-oXcCNESU_xrftuaLnQ"
      decimals="0"
      id="Tc_yjfyFvRgW0uxrkIJHcoG3A_13_11"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-56173207</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_vZe8L4XjkE61ZegBnv7dng_13_14"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">7326494</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_RAUpIdOTNkyxKeVBhpx0fA_5_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-12247834</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_X0c7SjdEHky5tbtNhla6Pg_5_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-15960268</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_FN6X7fS90kyRMyq4eLVMdQ_7_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">582659</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_IlNeM8HRzUqrQvHQUyUZAw_7_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">322881</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_bQz_Y6B1G0yL9CAJHstQSg_9_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-429739</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_eya_Zy4X7kysxDwhnZZ14A_9_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">91138</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_Vka134VeHEKL7negIIG0-A_10_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">219301</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_2YuTgSLW3Uy1Mrc7MM9fug_10_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">270007</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_8MUo4T5Uzk6OUfpPO9OSfQ_11_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-451662</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_t_VaXrkxDEeNBt-fTfcUpw_11_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">147773</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_z1gqYwGWyECTS-rBCjrwig_12_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-378833</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_xXkkeavaa0ei1b_Kct5rpQ_13_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-11467797</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_ddEx60sV0EG5-WTZTYuzQQ_13_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-15689578</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_nAxssqAPqE6v7lLkbMKgjw_15_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">4490605</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_Se-h7Om-PkqBn6UYGqb_Yg_15_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-295166</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_pojKn03tY0Wky5cOjo-aNA_16_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">197562</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_7Qef1Ofb80a7r7UaWED65g_17_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">4490605</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_3nqeGdWeIUieKurN6-OkXQ_17_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-97604</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Tc_9D9i1E2NBkmMRwXHqc8cqA_18_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-6977192</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Tc_VgCmrvSD40SnhwxjRqU3zQ_18_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-15787182</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_RkorXC64r0iBPCNen0Bv6A_19_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">14008184</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_tCm4u3HF1ESoDqVBr91eXw"
      decimals="0"
      id="Tc_2HOnP9iDRk-PYkJVjAxMOg_19_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">29795366</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_KpQmDAAVS0K8ExZoEJK_WQ_20_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">7030992</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_R89ZzOi-hEeb-gd8dsDAhg_20_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">14008184</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_sbT_04F9u06UtASDlg2s5g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1.&#160;&#160;&#160;Background and Organization&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Virios Therapeutics, Inc. (the &#x201c;Company&#x201d;) was incorporated under the laws of the State of Delaware on December 16, 2020 through a corporate conversion (the &#x201c;Corporate Conversion&#x201d;) just prior to the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;). The Company was originally formed on February&#160;28, 2012 as a limited liability company (&#x201c;LLC&#x201d;) under the laws of the State of Alabama as Innovative Med Concepts, LLC. On July&#160;23, 2020, the Company changed its name from Innovative Med Concepts, LLC to Virios Therapeutics,&#160;LLC. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company operates in one segment as a pre-revenue, development-stage biotechnology company focused on advancing novel combination antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The Company is developing its initial product candidate, IMC-1, for people who are suffering from fibromyalgia (&#x201c;FM&#x201d;). Research has shown that the herpes virus could be a potential root cause of FM. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib, both of which are drugs approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for other indications. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication, thereby converting activated herpes virus back to dormancy and/or by keeping the herpes virus in a latent or dormant state. The famciclovir component of IMC-1 inhibits viral DNA replication, thus inhibiting upregulation of the herpes virus. The celecoxib component of IMC-1 inhibits cyclooxegenase-2 (&#x201c;COX-2&#x201d;) enzymes used by the herpes virus to amplify or accelerate its own replication. IMC-1&#x2019;s synergistic antiviral mechanism represents a first-in-class medicine designed specifically to inhibit both herpes virus activation and subsequent replication, with the goal of keeping tissue resident herpes virus in a latent state.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;On September 19, 2022, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with ThinkEquity LLC (the &#x201c;Underwriter&#x201d;) in connection with the issuance and sale by the Company in a public offering of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;10,000,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; shares of its common stock at a public offering price of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$0.50&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; per share (the &#x201c;Offering&#x201d;), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-263700). The Offering closed on September 22, 2022 and the gross proceeds from the Offering were &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$5,000,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;. The net proceeds of the Offering were approximately &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$4,490,605&lt;/span&gt;&lt;span style="font-weight:normal;white-space:pre-wrap;"&gt; after deducting underwriting discounts, commissions and offering expenses payable by the Company.  In conjunction with the Offering, the Company granted to the Underwriter &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;500,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; warrants to purchase shares of the Company&#x2019;s common stock at an exercise price of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$0.625&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; per share, which was &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;125%&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; of the Offering price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Material Uncertainty&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Since its founding, the Company has been engaged in research and development activities as well as organizational activities, including raising capital. The Company has not generated any revenues to date. As such, the Company is subject to all of the risks associated with any development-stage biotechnology company that has substantial expenditures for research and development. Since inception, the Company has incurred losses and negative cash flows from operating activities. The Company has funded its losses primarily through issuance of members&#x2019; interests, convertible debt instruments and issuance of equity securities. For the years ended December 31, 2022 and 2021, the Company incurred net losses of $12,247,834 and $15,960,268, respectively, and had net cash flows used in operating activities of $11,467,797 and $15,689,578, respectively. As of December&#160;31, 2022, the Company had an accumulated deficit of $56,173,207.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of the date these financial statements are issued, based on reasonable estimates, current cash is sufficient to fund operating expenses and obligations for at least 12 months. Currently, there are no planned research and development activities for 2023 other than minimal carryover costs associated with completing the final reports for the Company&#x2019;s FORTRESS, (Fibromyalgia Outcome Research Trial Evaluating &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Synergistic Suppression of HSV-1), study for the treatment of FM and the chronic toxicology program, regulatory consulting to prepare for the meeting with the FDA, the on-going grant to the Bateman Horne Center for the fully funded investigator-sponsored study in Long-COVID and the purchase of active pharmaceutical ingredients to support the start of a potential Phase 3 program for IMC-1.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Our research and development expenses in 2022 primarily related to our FORTRESS study for IMC-1, the Company&#x2019;s lead candidate, which was completed in August 2022 and two long-term animal toxicology studies; a 26-week study in rats, which was completed in the first quarter of 2022 and a 39-week study in dogs, which was completed in the second quarter of 2022. Overall, the study for IMC-1, did not achieve statistical significance on the prespecified primary efficacy endpoint of change from baseline to Week 14 in the weekly average of daily self-reported average pain severity scores comparing IMC-1 to placebo (p=0.302). However, management observed a differential response based on the timing of patient enrollment and believe it is highly unlikely due to chance or a random occurrence, thus further analysis of the data was warranted, particularly in the context of the previous IMC-1 Phase 2a study success. Based on the analysis of the data, management believes focusing the forward development of IMC-1 on new fibromyalgia patients remains a viable and manageable path forward. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is scheduled to meet with the FDA in March 2023 to discuss the most appropriate next steps in advancing IMC-1 development as a treatment for FM and hopefully agree on a Phase 3 program. If alignment can be reached, management will consider raising additional capital to fund future research and/or seek a partner to develop or co-develop IMC-1 as a treatment for FM.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company will need to raise additional capital within the next 13 to 18 months to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms. The financial statements do not include any adjustments to reflect this uncertainty.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FjS6TDESSkSjA8g43D0JKQ"
      decimals="INF"
      id="Narr_iofUl-bh5U2AaPEjD-w7Hw"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg"
      decimals="INF"
      id="Narr_-1wVCgH_70aGrk02hPH6Nw"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.50</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g"
      decimals="0"
      id="Narr_1fMOHVhNGUOjUvCYpTl0MQ"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g"
      decimals="0"
      id="Narr_V208XluLyEWj2WQkqIsbpw"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">4490605</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg"
      decimals="INF"
      id="Narr_4ZaEHX1kVEWukng2VCdHEg"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg"
      decimals="3"
      id="Narr_fqfqGGlLqEC4WTajr6pavg"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <viri:WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice
      contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg"
      decimals="2"
      id="Narr_agErT73GREyj6PXa3drd9A"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">1.25</viri:WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Narr_Bq996NVPY02z4NLqYvcJDQ"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-12247834</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Narr_I4-P5z00okOeGLSXe-GUPQ"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-15960268</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Narr_L2xC1nj25kyFSTQ5ilRXLg"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-11467797</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Narr_IYrDMraJpEmsie-tWIvycg"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-15689578</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Narr_enUBt7pbZUeJnd_K2jkimg"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">-56173207</us-gaap:RetainedEarningsAccumulatedDeficit>
    <viri:PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_LDUdwdZQkU2vEFN0QuBgEQ"
      id="Narr_Fd588vvUj0eYDo_aQr3Ljw">P13M</viri:PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment>
    <viri:PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_xfm2EfLia0i3nez_VARJng"
      id="Narr_3vO7V3a8EE-IXlZBXQdpeQ">P18M</viri:PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_7DCnA2ZllEO3Nz2iddq-1Q">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2.&#160;&#160;&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash is potentially subject to concentrations of credit risk. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt;, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;&#x2014; Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;&#x2014; Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amount of the Company&#x2019;s financial instruments, including cash, accounts payable and accrued expenses approximate their fair values.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash is maintained in bank deposit accounts, which exceed the federally insured limits of $250,000. The Company does not have any cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;When determining whether a legal entity should be consolidated, the Company first determines whether it has a variable interest in the legal entity. If a variable interest exists, the Company determines whether the legal entity is a variable interest entity (&#x201c;VIE&#x201d;) due to either: 1) a lack of sufficient equity to finance its activities, 2) its equity holders lacking the characteristics of a controlling financial interest, or 3) the legal entity being structured with non-substantive voting rights. If the Company concludes that the legal entity is a VIE, the Company next determines whether it is the primary beneficiary due to it possessing both: 1) the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance, and 2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE which could be significant to the VIE. If the Company concludes that it is the primary beneficiary, it consolidates the entity.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Equity Method Investment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2017, the Company purchased a 25% ownership in Northriver Pharm, LLC (&#x201c;NRP&#x201d;) in the amount of $125,000 from existing investors of NRP. NRP is an entity with common ownership with the Company&#x2019;s former Chief Executive Officer and Founder, who is also the Founder and sole voting member of NRP. The Company evaluated the ownership under VIE guidance and has determined that the Company does not have the power and economics to control the entity and are not the entity most closely associated with NRP.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company previously accounted for the investment under the equity method of accounting. However, consistent with equity method accounting guidance, the Company has now discontinued applying the equity method accounting as the investment has been reduced to zero and the Company has not committed to provide further financial support and there is no expected return to profitable operations by NRP.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt; &lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company operated as an Alabama limited liability company until its Corporate Conversion. Therefore, the Company passed through all income and losses to its members until this point. As of December 31, 2022 and 2021, the Company had a full valuation allowance against deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to the provisions of ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;. Under ASC 740, consideration is given to the recognition and measurement of tax positions that meet a &#x201c;more-likely-than-not&#x201d; threshold. A tax position is a position taken in a previously filed tax return or a position expected to be taken in a future that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions include the Company&#x2019;s status as a pass-through entity until December 16, 2020 and as a corporation thereafter. The recognition and measurement of tax positions taken for various jurisdictions consider the amounts and probabilities of outcomes that could be realized upon settlement using the facts, circumstances, and information available at the reporting date. The Company has determined that it does not have any material unrecognized tax benefits or obligations as of December&#160;31, 2022 and 2021. The Company recognizes interest and penalties related to uncertain tax positions, if any, in income tax expense. The Company is not currently under examination by the Internal Revenue Service or by state tax authorities and the Company&#x2019;s tax year remains subject to examination by the tax authorities.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Basic and Diluted Net Income (Loss) per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per common share (&#x201c;EPS&#x201d;) is computed in accordance with U.S. GAAP. Basic EPS is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted EPS reflects potential dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if all potential common shares had been issued and were dilutive. However, potentially dilutive securities are excluded from the computation of diluted EPS to the extent that their effect is anti-dilutive. For the&#160;years ended December&#160;31, 2022 and 2021, the Company had 1,924,397 and 1,041,647 options, respectively, and 672,500 and 172,500 warrants, respectively, to purchase common shares outstanding that were anti-dilutive. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Research and development costs are expensed as incurred. The Company arranges and contracts with third-party contract research organizations (&#x201c;CROs&#x201d;), contract development and manufacturing organizations (&#x201c;CMOs&#x201d;), contractor laboratories and independent consultants. As part of the process of preparing its financial statements, the Company may be required to estimate some of its expenses resulting from its obligations under these arrangements and contracts. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided. The Company&#x2019;s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are rendered. The Company determines any accrual estimates based on account discussions with applicable personnel and outside service providers as to the progress or state of completion. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company&#x2019;s estimates are dependent upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record prepaid or accrued expenses related to these costs.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes compensation expense relating to share-based awards to employees and directors with a performance condition over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and warrants granted using an options pricing model, see Note 9. Expense is recognized within both research and development and general and administrative expenses and forfeitures are recognized as they are incurred.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided by the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. The standard eliminates the need for an organization to analyze whether the following apply in a given period: (1) the exception to the incremental approach for intraperiod tax allocation; (2) the exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (3) the exception in interim periods income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also is designed to improve financial statement preparers&#x2019; application of income tax-related guidance and simplify U.S. GAAP for (1) franchise taxes that are partially based on income, (2) transactions with a government that result in a step-up in the tax basis of goodwill, (3) separate financial statements of legal entities that are not subject to tax, (4) enacted changes in tax laws in interim periods and (5) certain income tax accounting for employee stock ownership plans and affordable housing projects. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;i style="font-style:italic;"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/i&gt;. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. Early adoption is permitted. ASU 2020-06 allows companies to adopt the guidance through either a modified retrospective method of transition or a fully retrospective method of transition. The Company is continuing to evaluate the impacts that ASU 2020-06 will have on its financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_v1HHbe2ejkWP5oAv7vRTYg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_yyMmUWHuOkOZ0nvJMP3VSw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_ICfjdY7DTkWRCFuTK1gGXQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash is potentially subject to concentrations of credit risk. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_9KY8LbfMC0KfCIAAGDyTgA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt;, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;&#x2014; Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;&#x2014; Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amount of the Company&#x2019;s financial instruments, including cash, accounts payable and accrued expenses approximate their fair values.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_oRtdRs3FxUC13yy7SEhtxg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash is maintained in bank deposit accounts, which exceed the federally insured limits of $250,000. The Company does not have any cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Narr_mUEOQHRXgEqifw9HbDxcZw"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_tn8y24CdEkC-Srgv5V_tOQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;When determining whether a legal entity should be consolidated, the Company first determines whether it has a variable interest in the legal entity. If a variable interest exists, the Company determines whether the legal entity is a variable interest entity (&#x201c;VIE&#x201d;) due to either: 1) a lack of sufficient equity to finance its activities, 2) its equity holders lacking the characteristics of a controlling financial interest, or 3) the legal entity being structured with non-substantive voting rights. If the Company concludes that the legal entity is a VIE, the Company next determines whether it is the primary beneficiary due to it possessing both: 1) the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance, and 2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE which could be significant to the VIE. If the Company concludes that it is the primary beneficiary, it consolidates the entity.&lt;/p&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_kEyfkaEOI0-Eoi_t2P_KjA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Equity Method Investment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2017, the Company purchased a 25% ownership in Northriver Pharm, LLC (&#x201c;NRP&#x201d;) in the amount of $125,000 from existing investors of NRP. NRP is an entity with common ownership with the Company&#x2019;s former Chief Executive Officer and Founder, who is also the Founder and sole voting member of NRP. The Company evaluated the ownership under VIE guidance and has determined that the Company does not have the power and economics to control the entity and are not the entity most closely associated with NRP.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company previously accounted for the investment under the equity method of accounting. However, consistent with equity method accounting guidance, the Company has now discontinued applying the equity method accounting as the investment has been reduced to zero and the Company has not committed to provide further financial support and there is no expected return to profitable operations by NRP.&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_viri_NorthriverPharmLlcMember_5EL1vFgplUm9u---06s8UQ"
      decimals="2"
      id="Narr_TQCIt0TUF0Kt7muI3eTQJg"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_viri_NorthriverPharmLlcMember_5EL1vFgplUm9u---06s8UQ"
      decimals="0"
      id="Narr_rAjVzQHxYEK2LekNMExVLQ"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">125000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_brpo-ZcUvE6isq2q3S-dQA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company operated as an Alabama limited liability company until its Corporate Conversion. Therefore, the Company passed through all income and losses to its members until this point. As of December 31, 2022 and 2021, the Company had a full valuation allowance against deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to the provisions of ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;. Under ASC 740, consideration is given to the recognition and measurement of tax positions that meet a &#x201c;more-likely-than-not&#x201d; threshold. A tax position is a position taken in a previously filed tax return or a position expected to be taken in a future that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions include the Company&#x2019;s status as a pass-through entity until December 16, 2020 and as a corporation thereafter. The recognition and measurement of tax positions taken for various jurisdictions consider the amounts and probabilities of outcomes that could be realized upon settlement using the facts, circumstances, and information available at the reporting date. The Company has determined that it does not have any material unrecognized tax benefits or obligations as of December&#160;31, 2022 and 2021. The Company recognizes interest and penalties related to uncertain tax positions, if any, in income tax expense. The Company is not currently under examination by the Internal Revenue Service or by state tax authorities and the Company&#x2019;s tax year remains subject to examination by the tax authorities.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_rUIYudLUAk2GcvhFhcMOPA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Basic and Diluted Net Income (Loss) per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per common share (&#x201c;EPS&#x201d;) is computed in accordance with U.S. GAAP. Basic EPS is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted EPS reflects potential dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if all potential common shares had been issued and were dilutive. However, potentially dilutive securities are excluded from the computation of diluted EPS to the extent that their effect is anti-dilutive. For the&#160;years ended December&#160;31, 2022 and 2021, the Company had 1,924,397 and 1,041,647 options, respectively, and 672,500 and 172,500 warrants, respectively, to purchase common shares outstanding that were anti-dilutive. &lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_zVHuNo8JJUOL740CgoX5UA"
      decimals="INF"
      id="Narr_QXMWpSs4xkeqgtHCN7tyQg"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">1924397</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aPhBzRC3h0y-kExu1oDuMA"
      decimals="INF"
      id="Narr_w_gnMCn2TEOBnBQrkNz_wg"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">1041647</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_J7UBwLt2s02a0dmSAvm0Hg"
      decimals="INF"
      id="Narr_fbrJXfTOFEyZQ0P3u1cblA"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">672500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_tuCBnQCdJkqjINAChtpNqg"
      decimals="INF"
      id="Narr_GdM8JsVf3UqwhtocXzWcsw"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">172500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_nnR3q444eUaIA7vQhG6DmQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Research and development costs are expensed as incurred. The Company arranges and contracts with third-party contract research organizations (&#x201c;CROs&#x201d;), contract development and manufacturing organizations (&#x201c;CMOs&#x201d;), contractor laboratories and independent consultants. As part of the process of preparing its financial statements, the Company may be required to estimate some of its expenses resulting from its obligations under these arrangements and contracts. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided. The Company&#x2019;s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are rendered. The Company determines any accrual estimates based on account discussions with applicable personnel and outside service providers as to the progress or state of completion. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company&#x2019;s estimates are dependent upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record prepaid or accrued expenses related to these costs.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_CmNdkZOXgkuE8t6vYV3fuQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes compensation expense relating to share-based awards to employees and directors with a performance condition over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and warrants granted using an options pricing model, see Note 9. Expense is recognized within both research and development and general and administrative expenses and forfeitures are recognized as they are incurred.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <viri:StatusOfCompanyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_QeL_sLfDCkmCPFhuJhZ2Ww">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided by the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;</viri:StatusOfCompanyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_R45bmCCzkEKTMQUZz0WF6g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. The standard eliminates the need for an organization to analyze whether the following apply in a given period: (1) the exception to the incremental approach for intraperiod tax allocation; (2) the exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (3) the exception in interim periods income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also is designed to improve financial statement preparers&#x2019; application of income tax-related guidance and simplify U.S. GAAP for (1) franchise taxes that are partially based on income, (2) transactions with a government that result in a step-up in the tax basis of goodwill, (3) separate financial statements of legal entities that are not subject to tax, (4) enacted changes in tax laws in interim periods and (5) certain income tax accounting for employee stock ownership plans and affordable housing projects. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;i style="font-style:italic;"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/i&gt;. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. Early adoption is permitted. ASU 2020-06 allows companies to adopt the guidance through either a modified retrospective method of transition or a fully retrospective method of transition. The Company is continuing to evaluate the impacts that ASU 2020-06 will have on its financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <viri:PrepaidExpenseAndOtherAssetsCurrentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_1lzxCRoWf0mQ5MrVr_8Ugg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3.&#160;&#160;&#160;&#160;Prepaid Expenses and Other Current Assets&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18.7pt;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,165,634&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,329,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid clinical research costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 154,510&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 422,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,329&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 15,664&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other miscellaneous current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,291&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,338,764&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,768,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</viri:PrepaidExpenseAndOtherAssetsCurrentTextBlock>
    <viri:PrepaidExpenseAndOtherAssetsCurrentTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_A93SbGaJbEec9fsRT7nWQg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,165,634&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,329,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid clinical research costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 154,510&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 422,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,329&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 15,664&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other miscellaneous current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,291&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,338,764&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,768,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</viri:PrepaidExpenseAndOtherAssetsCurrentTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_DBhf1XwVNEOJpMiUtIf-7w_3_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1165634</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_oAIq56JaNUmAFYz-JJHXLw_3_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1329385</us-gaap:PrepaidInsurance>
    <viri:PrepaidClinicalResearchCosts
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_FwGPFdessEykyS97znj4Mw_4_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">154510</viri:PrepaidClinicalResearchCosts>
    <viri:PrepaidClinicalResearchCosts
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_Y-yhfmflFUKKDAiFCruI_Q_4_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">422591</viri:PrepaidClinicalResearchCosts>
    <viri:PrepaidServices
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_OLXc4Pgt3kuSHCbgHN_w3w_5_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">11329</viri:PrepaidServices>
    <viri:PrepaidServices
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_09vWMQYjdkWZhedO30LlRQ_5_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">15664</viri:PrepaidServices>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_IIfb7HxWP0Wf5hxDIep7KA_6_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">7291</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_Gi2iEhJD5USkB3DasdY0bQ_6_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">863</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_xseEqjeLZUiz-14akJ2hbQ_7_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1338764</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_GB4nNs_Z00eYATcSpGJWEg_7_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1768503</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_oZs6fzJFR0eOeRxVVIJ_8g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4.&#160;&#160;&#160;License Agreement&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company entered into a Know-How License Agreement (the &#x201c;Agreement&#x201d;) with the University of Alabama (&#x201c;UA&#x201d;) in 2012. In consideration for the Agreement, UA received a 10% non-voting membership interest in the Company. Upon the adoption of the May 1, 2020 Second Amended and Restated Operating Agreement, the non-voting membership interest converted to a voting membership interest. Upon the Corporate Conversion, voting membership interest was converted into shares of common stock. The Agreement is in effect for 25&#160;years and will terminate on June&#160;1, 2037.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <viri:CollaborativeArrangementPercentageOfNonVotingMembershipInterest
      contextRef="Duration_1_1_2012_To_12_31_2012_us-gaap_TypeOfArrangementAxis_viri_KnowHowLicenseAgreementMember_v_HMShg6JkeIz5pkc4ARKw"
      decimals="2"
      id="Narr_NGENaWDRjk-ABWTg2EhBiA"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.10</viri:CollaborativeArrangementPercentageOfNonVotingMembershipInterest>
    <viri:LicenseAgreementExpirationPeriod
      contextRef="Duration_1_1_2012_To_12_31_2012_us-gaap_TypeOfArrangementAxis_viri_KnowHowLicenseAgreementMember_v_HMShg6JkeIz5pkc4ARKw"
      id="Narr_-czADAp2XUChjzWLEMfTsg">P25Y</viri:LicenseAgreementExpirationPeriod>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_H10zK1LjI0Ge4nWfe-1MWg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5.&#160;&#160;&#160;&#160;Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18.7pt;"&gt;Accrued expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 159,704&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 532,678&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued interest on preferred members&#x2019; interests&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 188,085&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 188,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical research costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 78,349&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 138,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued director fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,600&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other miscellaneous accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,360&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 470,098&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 921,760&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_zH1unIr4ZEuZtsvxNww2_g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 159,704&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 532,678&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued interest on preferred members&#x2019; interests&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 188,085&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 188,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical research costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 78,349&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 138,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued director fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,600&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other miscellaneous accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,360&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 470,098&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 921,760&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_LJ98zD3mokelwEn7MTe99w_3_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">159704</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_JvD6kNzaA0egbpeTHoaWcg_3_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">532678</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <viri:AccruedInterestOnPreferredMembersInterest
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_nrSJITKs_EGaS8kHSlN3Gw_4_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">188085</viri:AccruedInterestOnPreferredMembersInterest>
    <viri:AccruedInterestOnPreferredMembersInterest
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_IPksdf2CUEinXrvtQl8A9g_4_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">188085</viri:AccruedInterestOnPreferredMembersInterest>
    <viri:AccruedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_K2UnRgzkik2xh02rB8HGDQ_5_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">78349</viri:AccruedResearchAndDevelopmentCosts>
    <viri:AccruedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_ndxi_ViSOkeFkymwE-xkVQ_5_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">138522</viri:AccruedResearchAndDevelopmentCosts>
    <viri:AccruedDirectorFeesCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_J9UwS45rzkC1UkgKWk_t8g_6_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">31000</viri:AccruedDirectorFeesCurrent>
    <viri:AccruedDirectorFeesCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_SZy0uKtmEkyp2F9zrrHqTg_6_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">31000</viri:AccruedDirectorFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_bBI07w4acEGlY0mFfoAO6Q_7_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">11600</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_ANsb6ri_Y0uBLy9Y52lExg_7_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">24100</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_1n4gSKm8OUq96sWg9S58qw_8_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1360</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_3vOv4uTO0kyZEogVr6KZWQ_8_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">7375</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_PmrK0J3dyEq5Il8m1ymTig_9_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">470098</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_WtPtkEb0OU-24YDzzEBZZA_9_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">921760</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_O_CHQ_h3DkWcWRkxFCvtdA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6.&lt;/b&gt;&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s certificate of incorporation adopted on December 16, 2020, authorizes the issuance of two classes of stock to be designated, respectively, &#x201c;Common Stock&#x201d; and &#x201c;Preferred Stock&#x201d;. The total number of shares which the Company is authorized to issue is 45,000,000, each with a &lt;span style="-sec-ix-hidden:Hidden_VfwIj3Fs2EKwWsM1T_o8Qw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;par value&lt;/span&gt;&lt;/span&gt; of $0.0001 per share. Of these shares, 43,000,000 shall be Common Stock and 2,000,000 shall be Preferred Stock.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Dividends&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of the Common Stock are entitled to receive dividends when and as declared by the Board.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to the holders of Common Stock as to liquidation, upon liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of the Common Stock.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Voting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The holders of the Common Stock are entitled to one vote for each share of Common Stock held. There is no cumulative voting.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock may be issued from time to time by the Board in one or more series.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <viri:CommonAndPreferredStockSharesAuthorized
      contextRef="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg"
      decimals="INF"
      id="Narr_E_vPegy0xkqv18IL4eQD2g"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">45000000</viri:CommonAndPreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg"
      decimals="INF"
      id="Narr_VYZHQiZuAE6P0agZgXqqeQ"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg"
      decimals="INF"
      id="Narr_sbh3RDE7wEqskBk1Svd8Rw"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">43000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg"
      decimals="INF"
      id="Narr_lpCz7mMRPkSlyQVHv85ILw"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">2000000</us-gaap:PreferredStockSharesAuthorized>
    <viri:NumberOfVotesPerCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="INF"
      id="Narr_hQb6DGl0h0aoXeCvdCGJIQ"
      unitRef="Unit_Standard_item_wR6KQv_y_U6N2ZwjlZ-M-Q">1</viri:NumberOfVotesPerCommonStock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_8Yve63CYb0m92I3GxXpdPA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;7&lt;/span&gt;.&#160;&#160;&#160;&#160;Related Parties&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company uses Gendreau Consulting, LLC, a consulting firm (&#x201c;Gendreau&#x201d;), for drug development, clinical trial design, and planning, implementation and execution of contracted activities with CROs. Gendreau&#x2019;s managing member became the Company&#x2019;s Chief Medical Officer (&#x201c;CMO&#x201d;) effective January 1, 2021. The Company has and will continue to contract the services of the CMO&#x2019;s spouse through the firm to perform certain activities in connect with the Company&#x2019;s ongoing clinical development of product candidates. During the years ended December 31, 2022 and 2021, the Company paid Gendreau $356,088 and $326,416, respectively, and had accounts payable of $21,000 and $24,840 to Gendreau as of December 31, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_X5Y3MAAZ80-3sQBqUVtS-Q"
      decimals="0"
      id="Narr_1Bb9892rvkyO44M8FALsZg"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">356088</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_uEjU9DNz10qTagf5uNcBwQ"
      decimals="0"
      id="Narr_33iI7HGr-Eq32AyTlm3nCw"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">326416</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_VktHnKz5PUWL5c7XiyyBUQ"
      decimals="0"
      id="Narr_r4gQrkvmD0-OID0ExOsHXw"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">21000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_XAqJzIFAPEimuSHD-_p6Hg"
      decimals="0"
      id="Narr_arVFGeXCWE-HMX-OpndERA"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">24840</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_9PZWmV4D4U-5-kjEXkgxag">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;8&lt;/span&gt;.&#160;&#160;&#160;&#160;Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Litigation&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#x2019;s liquidity, financial condition and cash flows.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 26, 2021, Torreya Capital LLC (&#x201c;Torreya&#x201d;) filed a demand for arbitration with the American Arbitration Association in New York, New York in connection with a claim by Torreya that it is entitled to a transaction fee of $1,035,000 in connection with the Company&#x2019;s IPO, plus the costs of arbitration, based on services Torreya alleged it provided for the Company as a financial advisor to the Company prior to the IPO.&#160;&lt;span style="white-space:pre-wrap;"&gt;  On December 20, 2021, in order to avoid the risk, inconvenience and expense of a continued dispute, the Company entered into a release and settlement agreement with Torreya, whereby the Company agreed to pay Torreya &lt;/span&gt;$325,000 for the release and discharge of any and all claims, liabilities and costs related to the arbitration. The Company paid the obligation prior to December 31, 2021, the cost of which is included in other expense in the accompanying statements of operations.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employment Agreement and Deferred Compensation Plan&lt;/p&gt;&lt;p style="font-family:'Garamond';font-size:11pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 6pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;The Company has employment agreements with its CEO, SVP of Operations, and SVP of Finance (the &#x201c;Executives&#x201d;), as well as its CMO. Per the terms of the agreements, each Executive and the CMO are entitled to receive a cash bonus with a target amount of no less than &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;50%&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt; for the CEO, &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;35%&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt; for the CMO and &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;20%&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt; for the SVP of Operations and the SVP of Finance, of the then-current base salary. The bonuses are subject to achievement of annual bonus metrics set by the Board. The employment agreements will continue in effect until terminated by either party pursuant to its terms. Upon termination of the agreement by the Company for any reason other than for cause, death or disability or by one of the Executives or CMO for good reason, the Company shall pay to an Executive a &#x201c;Severance Payment&#x201d; equal to the aggregate of the Executive&#x2019;s then-current annual base salary plus an amount equal to a prorated portion of the Executive&#x2019;s cash bonus for the year in which the termination occurs. &#160;The Severance Payment to an Executive is payable in cash over a period of &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;one year&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;. The Company shall pay to the CMO a Severance Payment equal to &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt; of the then-current annual base salary plus a prorated portion of the CMO&#x2019;s cash bonus for the year in which the termination occurs over a period of &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;three months&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt; and health benefits for a period of &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;12 months&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt; unless the CMO becomes eligible for health benefits under another employer. If the termination of the agreement is related to a change of control, the Company shall pay to the Executives and the CMO a &#x201c;Change of Control Termination Payment&#x201d; equal to the aggregate of &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;1.0&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt; times the then-current annual base salary plus an amount equal to &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;1.0&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt; times the Executives&#x2019; and CMO&#x2019;s cash bonus for year in which the termination occurs. The Change of Control Termination Payments are payable in a single cash lump sum no later than &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt;45 days&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"&gt; after the triggering event. &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="Duration_8_26_2021_To_8_26_2021_srt_LitigationCaseAxis_viri_TorreyaCapitalLlcMember_U8Q3TkmcJkCKXKS_Ao-Drw"
      decimals="INF"
      id="Narr_qkFJ2ixoNkGoksWaCIogJA"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1035000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_12_20_2021_To_12_20_2021_srt_LitigationCaseAxis_viri_TorreyaCapitalLlcMember_593RpFikOES1pICvYkGC7A"
      decimals="INF"
      id="Narr_pjaYy48ZcEigXnrUA1TSug"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">325000</us-gaap:OtherNonoperatingIncome>
    <viri:PercentageOfCashBonusOnSalary
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_9Fj9-utpbkORtVRzg81GPA"
      decimals="2"
      id="Narr_Wyz-ri6dB0qJrIl-ogypRA"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.50</viri:PercentageOfCashBonusOnSalary>
    <viri:PercentageOfCashBonusOnSalary
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_07boxe2rbUysaeH7Ihz82A"
      decimals="2"
      id="Narr_keQAqX15HEqpR9wjZ6KEHw"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.35</viri:PercentageOfCashBonusOnSalary>
    <viri:PercentageOfCashBonusOnSalary
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_VicePresidentOperationsAndFinanceMember_X9NqiprFVkeF2f-E51b3HA"
      decimals="2"
      id="Narr_Gp2Aw282JEi_RiERrg4zVQ"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.20</viri:PercentageOfCashBonusOnSalary>
    <viri:EmploymentAgreementSeverancePaymentPaymentPeriod
      contextRef="Duration_9_10_2020_To_9_10_2020_RVDodrV4eECIJMPDAPhQBA"
      id="Narr_Z_46h5VCWkuE-K0zBqqDLw">P1Y</viri:EmploymentAgreementSeverancePaymentPaymentPeriod>
    <viri:EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw"
      decimals="2"
      id="Narr_aWKKzO7RvUGUzOWsOMZHQQ"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.25</viri:EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary>
    <viri:EmploymentAgreementThresholdTerminationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw"
      id="Narr_e2tGHS22M0W0k30SZBIDew">P3M</viri:EmploymentAgreementThresholdTerminationPeriod>
    <viri:EmploymentAgreementHealthBenefitOfferedPeriodOnTermination
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw"
      id="Narr_5JsSVCHEVEqabvnoU4r1eg">P12M</viri:EmploymentAgreementHealthBenefitOfferedPeriodOnTermination>
    <viri:EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw"
      decimals="0"
      id="Narr_HcIgylwRX0m2Ej9oGevcmQ"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">1.0</viri:EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary>
    <viri:EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_viri_ChiefMedicalOfficerMember_ZPTgm8WaR0qQFkpldkv8hw"
      decimals="0"
      id="Narr_rQpqe1JT-EyUcRZn1oSllA"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">1.0</viri:EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus>
    <viri:EmploymentAgreementChangeOfControlTerminationPaymentPeriod
      contextRef="Duration_9_10_2020_To_9_10_2020_RVDodrV4eECIJMPDAPhQBA"
      id="Narr_0hOzF7tnok26xF70FB4QOA">P45D</viri:EmploymentAgreementChangeOfControlTerminationPaymentPeriod>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_LPCBZ8JrR0W6uuZGipbM4g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9.&#160;&#160;&#160;Share-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity Incentive Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 16, 2022, the stockholders of the Company approved the Amended and Restated 2020 Equity Incentive Plan (the &#x201c;Plan&#x201d;) to increase the total number of shares of common stock reserved for issuance under the Plan by 1,250,000 shares to 2,062,500 total shares issuable under the Plan. As of December&#160;31, 2022 and 2021, 430,603 and 63,353 shares, respectively, were available for future grants.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock awards, options, and other equity-based awards. The amount and terms of grants are determined by the Board. Stock options have a maximum term of &lt;span style="-sec-ix-hidden:Hidden_zpYbTwNkCEuu23buIe0eJQ;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10&#160;years&lt;/span&gt;&lt;/span&gt; after date of grant and are exercisable in cash or as otherwise determined by the Board. The maximum aggregate number of shares subject to grant under the Plan to any individual, with the exception of any non-employee director, during any calendar year is limited to 500,000 shares. With respect to any non-employee director, the maximum aggregate number of shares subject to grant under the Plan to any individual during any calendar year is limited to 200,000 shares.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below sets forth the outstanding options to purchase common shares under the Plan:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 519,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 229,984&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 749,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.09&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 912,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,750)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,631,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.04&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 665,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.06&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022 and 2021, the aggregate intrinsic value of options outstanding and exercisable was $0.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2022, the Company granted certain individuals options to purchase 912,500 shares of the Company&#x2019;s common stock with an average exercise price of $1.42 per share, contractual terms of 10 years and vesting periods ranging from 100% vesting after one year to 33.333% vesting after one year with the remaining 66.667% vesting in 24 monthly installments, thereafter. The options had an aggregate grant date fair value of $980,075 as calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option pricing model include: (1) discount rates ranging from 3.145% to 3.765% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected lives ranging from 5.5 years to 6.0 years based on the simplified method (vesting plus contractual term divided by two), (3) expected volatility ranging from 90.62% to 93.66% based on the average historical volatility of comparable companies' stock, (4) no expected dividends and (5) fair market value of the Company's stock ranging from $0.2789 to $4.23 per share.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2021, the Company granted certain individuals options to purchase 229,984 shares of the Company&#x2019;s common stock with an average exercise price of $6.85 per share, contractual terms of 10 years and vesting periods ranging from 8.33% monthly over one year to 33.333% vesting after one year with the remaining 66.667% vesting in 24 monthly installments, thereafter. The options had an aggregate grant date fair value of $1,150,284 as calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option pricing model include: (1) discount rates ranging from 0.505% to 1.075% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected lives ranging from 5.27 years to 6.0 years based on the simplified method (vesting plus contractual term divided by two), (3) expected volatility ranging from 89.04% to 90.16% based on the average historical volatility of comparable companies' stock, (4) no expected dividends and (5) fair market value of the Company's stock ranging from $6.50 to $7.51 per share.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the years ended December 31, 2022 and 2021, the Company recognized share-based compensation expense related to stock options of $582,659 and $322,881, respectively. The unrecognized compensation expense for stock options at December 31, 2022 and 2021 was $1,114,073 and $827,402, respectively.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock Options for Unregistered Securities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition to the stock options issued under the Plan, on December 16, 2020, the Company granted non-qualified stock options to purchase 292,500 shares of common stock as provided for in the employment agreement of the Company&#x2019;s President at the time of and in conjunction with the Company&#x2019;s IPO (the &#x201c;President Options&#x201d;). The President Options are exercisable within 10 years of the date of grant at $10.00 per share, were 100% vested at the grant date and have a remaining contractual term of 7.96 years. As of December 31, 2022, there was no unrecognized compensation expense related to these options as they were 100% vested upon issuance. The shares of common stock issuable upon exercise of the President Options will be unregistered, and the option agreement does not include any obligation on the part of the Company to register such shares of common stock. Consequently, the Company has not recognized a contingent liability associated with registering the securities for the arrangement. As of December 31, 2022, the aggregate intrinsic value of the President Options was $0.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Underwriters Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In conjunction with the IPO, the Company granted the underwriters warrants to purchase 172,500 shares of common stock at an exercise price of $12.50 per share. The warrants have a &lt;span style="-sec-ix-hidden:Hidden_qp_BKBo_iESKd88pDgZH3g;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five-year&lt;/span&gt;&lt;/span&gt; contractual term and were not exercisable prior to December 21, 2021.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In conjunction with the Offering in September 2022, the Company granted the Underwriter warrants to purchase 500,000 shares of common stock at an exercise price of $0.625 per share. The warrants have a &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;five-year contractual term and are not exercisable prior to March 18, 2023. The Company has accounted for the warrants as equity-based awards issued to a non-employee. The warrants had an aggregate grant date fair value of $178,462 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option pricing model include: (1) discount rate of 3.69% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected life of 5.0 years, (3) expected volatility of 96.46% based on the average historical volatility of comparable companies' stock, (4) no expected dividends and (5) fair market value (Offering price) of the Company's stock of $0.50 per share.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;There was no net impact recognized by the Company in the accompanying financial statements as the warrants were equity-based awards issued for services rendered by the Underwriter for the Offering that was offset by the Company recognizing the fair value of the warrants as a direct and incremental costs associated with the Offering by reducing paid-in capital for the same amount. There is no unrecognized compensation expense for these awards as of December 31, 2022. The table below sets forth the outstanding warrants to purchase common shares:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 172,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.96&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 172,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.96&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 672,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 172,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.96&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;As of December 31, 2022, the aggregate intrinsic value of the warrants outstanding was $0.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_6_16_2022_To_6_16_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_p9GEDysUj0yLr6kbN6USkA"
      decimals="INF"
      id="Narr_SwRZ00xA3UGkSV2I0k5HGw"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_16_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_EKNzGamAM0e5Uudfko5Mbg"
      decimals="INF"
      id="Narr_5OKnbshnaUK8bGQZwAU8vg"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">2062500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ"
      decimals="INF"
      id="Narr_TTQfQ2Zo-UOaPmeepnu9YA"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">430603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_PSW_ICNFWUWC815QcUkHTQ"
      decimals="INF"
      id="Narr_iKfppuR8hUSiYdh_qQWF5Q"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">63353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="Duration_6_16_2022_To_6_16_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_kJHmoKVpsEyo6AaXVE_bJw"
      decimals="INF"
      id="Narr_oiNfXKdBt0W0sRwK8hu5Jg"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="Duration_6_16_2022_To_6_16_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Sy6PBJsphU-CRbISsoIF6w"
      decimals="INF"
      id="Narr_NO_wNTH1SECMBr1qCgSjqg"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_KyVlE7MiLk-I9GDNp8R44w">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 519,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 229,984&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 749,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.09&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 912,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,750)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,631,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.04&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 665,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.06&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_HfIQGNlGO0GfJuvJzN6shA"
      decimals="INF"
      id="Tc_MbhmHjPY6UukTZMK3B7x5w_7_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">519163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_HfIQGNlGO0GfJuvJzN6shA"
      decimals="2"
      id="Tc_84oC1AcNLEynXDnX2C3A8Q_7_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">10.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_f6XxsTWSbk6n_wNrDUfYkg"
      id="Tc_OuKtyQlQjECTKE43haveKA_7_7">P9Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g"
      decimals="INF"
      id="Tc_Poo-qM78aUa8UimXm6aQ1Q_8_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">229984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g"
      decimals="2"
      id="Tc_88R82zynkEe_35vcmFEozQ_8_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">6.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_PSW_ICNFWUWC815QcUkHTQ"
      decimals="INF"
      id="Tc_IyjwlvRxRU6JOL7HinCUIA_9_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">749147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_PSW_ICNFWUWC815QcUkHTQ"
      decimals="2"
      id="Tc_HGOBqAfMLEG7QYwRp9OTTA_9_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">9.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g"
      id="Tc_h1eRzm0HRESJmKfp79uiiw_9_7">P9Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"
      decimals="INF"
      id="Tc_7m8A100IQ0OO4AZ3MVmsSA_10_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">912500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"
      decimals="2"
      id="Tc_8odWfNuJ6EKRqZiS13sxxQ_10_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">1.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"
      decimals="INF"
      id="Tc_737bJJIR9ku9J6vWYuWA9A_11_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">29750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"
      decimals="2"
      id="Tc_XfSLeMSi40KinM2K7MlmuQ_11_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">4.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ"
      decimals="INF"
      id="Tc_akhSqBmagkCfV_jlT30ruA_12_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">1631897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ"
      decimals="2"
      id="Tc_NT9VJO6GFUWGwAQke6pTXA_12_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">4.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"
      id="Tc_bsvQaBN80k--671Vxxroxg_12_7">P9Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ"
      decimals="INF"
      id="Tc_QX69vOiyz0iaL4UgQW77NA_13_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">665326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ"
      decimals="2"
      id="Tc_FbHOgD2TREyimEbeDrDUiw_13_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">9.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"
      id="Tc_bXBHzfk_mkK7z6EmABfaJQ_13_7">P8Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_PSW_ICNFWUWC815QcUkHTQ"
      decimals="INF"
      id="Narr_f99qLZ67REOZdLoKj_eEQw"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_6tD8fcQE7UeHsKRWwgqESQ"
      decimals="INF"
      id="Narr_Vtzzok8CX0O7nJpTY5C6rg"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"
      decimals="INF"
      id="Narr_bj4uYiNTGUyHOO8q-9eFtg"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">912500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"
      decimals="2"
      id="Narr_GXGtf31fCk-e3OuXDETPrA"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">1.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"
      id="Narr_0QM-WdqzGUqQOotgMg4QOA">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_epi_lHMtoEOuSGGUHTT6cQ"
      decimals="2"
      id="Narr_8HszjneaAUmie03X7FQ6Ww"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yFCbkitpnUybTr1oZGQIXA"
      decimals="5"
      id="Narr_LZACE7R67EidCrRcSAo2Dg"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.33333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_iX6ZkNMhbEeXsuVhLuePbw"
      decimals="5"
      id="Narr_G6z0Rk09h0qKTEWhg12ovw"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.66667</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"
      decimals="0"
      id="Narr__ElvBkcWl0G4AXPzncc8Sw"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">980075</viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ikj9w2rCj0izLrRvksWE6Q"
      decimals="5"
      id="Narr_BRIW5Xo68kqWRU5v16pfsQ"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.03145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_qgz0o95s_0aPxtVxKLV_Pw"
      decimals="5"
      id="Narr_eTwyms9L4k6zomMweKESrQ"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.03765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ikj9w2rCj0izLrRvksWE6Q"
      id="Narr_HByU-K_ozkCpIDdKXJ_5BA">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_qgz0o95s_0aPxtVxKLV_Pw"
      id="Narr_DKgLpdoyHEeGx7DZdzFUxA">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ikj9w2rCj0izLrRvksWE6Q"
      decimals="4"
      id="Narr_3v7w0tloxUK1hPb2zSwkEg"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.9062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_qgz0o95s_0aPxtVxKLV_Pw"
      decimals="4"
      id="Narr_i94HgyOAZkasvh1DQ70omA"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.9366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew"
      decimals="INF"
      id="Narr_sBTUQjMivEq5SjB_WT7d4Q"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ikj9w2rCj0izLrRvksWE6Q"
      decimals="4"
      id="Narr_zHDJoqgZKEuWp39ZOrZi1g"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.2789</viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_qgz0o95s_0aPxtVxKLV_Pw"
      decimals="2"
      id="Narr_mmJp5NrmG0q4ar349ma8Fw"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">4.23</viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g"
      decimals="0"
      id="Narr_uIv--Ahink6X19cTvqCN3w"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">229984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g"
      decimals="INF"
      id="Narr_FDtmqP8tRUOkZ_1ffy26Lw"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">6.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g"
      id="Narr_i53kdZFHMUa7HVMSAW17gg">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_npYg-xxOqkqKwXBoOxfd0A"
      decimals="INF"
      id="Narr_eI9if_wrhEWqNNJoc6BPng"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iwzJfTl-OUiIleLyhau04g"
      decimals="INF"
      id="Narr_3kkLLLzOk0-92HODKydqLQ"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.33333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_Qf178jUjQ0m0mIlYgP4eGg"
      decimals="INF"
      id="Narr_GiTaQokJa0GYBYmG0yPx7Q"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.66667</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g"
      decimals="0"
      id="Narr_TWnIz6GaHE2OrNoi2FJzcQ"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1150284</viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ClZ-Zp5G-kmzZkhdCCktbA"
      decimals="INF"
      id="Narr_1XDWAlRRrE6zYSXvui8m5A"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.00505</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_jfwr1MSSHkK724vOCV_g2A"
      decimals="INF"
      id="Narr_0pDr-q0c3EO_L26lRdRKXQ"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.01075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ClZ-Zp5G-kmzZkhdCCktbA"
      id="Narr_Nii4RmZsYk-DKSO77PVkIw">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_jfwr1MSSHkK724vOCV_g2A"
      id="Narr_IwSbSEzKSkeZCYrHvnPn9w">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ClZ-Zp5G-kmzZkhdCCktbA"
      decimals="INF"
      id="Narr_J_pmuZlM9UWo3f_yRCcDbA"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.8904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_jfwr1MSSHkK724vOCV_g2A"
      decimals="INF"
      id="Narr_iLB7NXkA7ku5R2Kr14tGSg"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.9016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_xRYREUcg_EOM7Y6CpEBj7g"
      decimals="INF"
      id="Narr_vxxKNvTSiE-Ie3NAwS9tGg"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_ClZ-Zp5G-kmzZkhdCCktbA"
      decimals="INF"
      id="Narr_LiongCwnwESBlra8UJ6Wzw"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">6.50</viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_jfwr1MSSHkK724vOCV_g2A"
      decimals="INF"
      id="Narr_o3tlML9f106okZWbA-9PUQ"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">7.51</viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_bzvM8doJ10mkpUYJYD_rTA"
      decimals="0"
      id="Narr_hXAqVJLMaEGudZIerXQUbA"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">582659</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_E57glfgKCUSq3eMsl6w6qQ"
      decimals="0"
      id="Narr_t-tN7roVVUqDf9iq--Jbaw"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">322881</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_IXFyCqWULkiAGzccCCWCsQ"
      decimals="0"
      id="Narr_1O0BVckgAEuwRJI-daIcMA"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1114073</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_fA7tndkyWEeG7RdGqTIrYA"
      decimals="0"
      id="Narr_oHPwJlPqOUWZ4J1FGgdWuQ"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">827402</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow"
      decimals="0"
      id="Narr_M4fezxbNZkuxe4pgWMkDqg"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">292500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow"
      id="Narr_32iQEr7wU0eN7Di1wnMwmg">10 years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow"
      decimals="INF"
      id="Narr_OJWlFWr3HEyxm7WBhrKNAw"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">10.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow"
      decimals="INF"
      id="Narr_D0V76e45EkevYozd_a1SnA"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow"
      id="Narr_4gF90tgd1kWuhYEDXe5DwQ">P7Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_5tEhIARsaEiYoR53c54ELg"
      decimals="0"
      id="Narr_KeKGgt_Mz0GTMkyQlvc9ww"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow"
      decimals="2"
      id="Narr_Vn4phYpmqE-NwCB3AjRluw"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_5tEhIARsaEiYoR53c54ELg"
      decimals="0"
      id="Narr_iDNqyqvCK06212zuNY9gvw"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_21_2021_UH5_wupqpEWPUP_czHBCeA"
      decimals="INF"
      id="Narr_TPcpDUPFjUynvxWCaivgSw"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">172500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_21_2021_UH5_wupqpEWPUP_czHBCeA"
      decimals="INF"
      id="Narr_so3-9-Ro0EGpiPJsb7Axeg"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg"
      decimals="INF"
      id="Narr_phhOuEzKPUO2GyzKUa7eLA"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg"
      decimals="3"
      id="Narr_urIM6Ai8oEOoq3W3lJg1_Q"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg"
      id="Narr_o101VY_9HUqeJHBrSUxJyA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue
      contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g"
      decimals="0"
      id="Narr_jLtYIFWVs0yW1tD42ykSOg"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">178462</viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g"
      decimals="4"
      id="Narr_rkUQzEXN60qdl3F8WWSa_g"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g"
      id="Narr_KXBN-3jX-0GTE5yRPPjmsw">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g"
      decimals="4"
      id="Narr_e24_NDqwXEumsMInfZEdug"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.9646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g"
      decimals="0"
      id="Narr_whcuwFpC60WxwpmhLWnTUg"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:SharePrice
      contextRef="As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg"
      decimals="2"
      id="Narr_VDhLPCYL_ESaTwYdTWgdrA"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.50</us-gaap:SharePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Narr__Pep5TIWpUeO05Iydi7WCw"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_IYHt-HROUEikv7EDoRwKcg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 172,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.96&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 172,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.96&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 672,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 172,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.96&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2020_tCm4u3HF1ESoDqVBr91eXw"
      decimals="INF"
      id="Tc_wTLkP4rzo0OIL-orGDea8Q_7_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">172500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <viri:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_tCm4u3HF1ESoDqVBr91eXw"
      decimals="2"
      id="Tc_mWqyX0ZIBkWTmvvRjD5gaA_7_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">12.50</viri:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice>
    <viri:ClassOfWarrantOrRightRemainingTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_ujddVzlF9kmGOtaxPWQprg"
      id="Tc_Cig-NEiQOUmxUGLGGeBH0g_7_7">P4Y11M15D</viri:ClassOfWarrantOrRightRemainingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="INF"
      id="Tc_Ljh5xUTk6EuHV6FcLSwsPw_9_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">172500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <viri:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="2"
      id="Tc_MMu7DHuSEEuAZYxL2L1v4A_9_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">12.50</viri:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice>
    <viri:ClassOfWarrantOrRightRemainingTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      id="Tc_BIxpXZOrrkW1mqwi9xpUug_9_7">P3Y11M15D</viri:ClassOfWarrantOrRightRemainingTerm>
    <viri:ClassOfWarrantOrRightGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="INF"
      id="Tc_Su3Cp8eOLk6NECkaFseVSg_10_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">500000</viri:ClassOfWarrantOrRightGranted>
    <viri:ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="2"
      id="Tc_gYwsT3jIXk-SI9F3xAypzA_10_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">0.63</viri:ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="INF"
      id="Tc_pyWQGsnRWUmQSdNA_cdKRA_11_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">672500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <viri:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="2"
      id="Tc_9g8OuAWnokiz3MOMCmIHoA_11_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">3.67</viri:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice>
    <viri:ClassOfWarrantOrRightRemainingTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tc_pfIOYRzVmUmYywhaZIypMw_11_7">P4Y3M7D</viri:ClassOfWarrantOrRightRemainingTerm>
    <viri:ClassOfWarrantOrRightExercisable
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="INF"
      id="Tc_zu8o_XOAsEao-MKe-ZEZnw_12_2"
      unitRef="Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA">172500</viri:ClassOfWarrantOrRightExercisable>
    <viri:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="2"
      id="Tc_Boffg-W9DE2nAsbsPyGkfg_12_5"
      unitRef="Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw">12.50</viri:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice>
    <viri:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tc_lZavUJRYP0iA3p5jBmtmeg_12_7">P2Y11M15D</viri:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm>
    <viri:AggregateIntrinsicValueOfWarrantsOutstanding
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="INF"
      id="Narr__DJsghm2LkCnNmzO7BHLIQ"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">0</viri:AggregateIntrinsicValueOfWarrantsOutstanding>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_OUrwLZ9nXUCahssMNtTETg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10.&#160;&#160;&#160;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company has U.S. federal and state net operating loss carryforwards of approximately $22,168,000, which have an indefinite carryforward. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;A reconciliation of the U.S. federal income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 21.00&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (0.57)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4.83&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax true-ups&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.82)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.06&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (25.32)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23.47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective Income Tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets are comprised of the following:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,692,533&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,586,488&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized research and development expenditures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,873,211&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,411,624&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,338,234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Investment in partnership&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 30,771&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 30,593&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 15,223&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,299&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,023,362&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,971,614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (8,682,497)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,581,599)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 340,865&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 390,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (340,865)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (390,015)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (340,865)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (390,015)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For tax years beginning on or after January 1, 2022, the 2017 Tax Cuts and Jobs Act amended Section 174 of the code to eliminate current-year deductibility of research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and fifteen years for research activities performed outside of the United States. For the 2022 tax year, the Company has capitalized $8,099,702&lt;span style="white-space:pre-wrap;"&gt; of research and development expenses.  This has resulted in an increase in the deferred tax asset associated with capitalized research and development by &lt;/span&gt;$1,873,211.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company has not generated sufficient positive evidence for future earnings to support a position that it will be able to realize its net deferred tax asset. The Company has significant negative evidence to overcome in the form of cumulative pre-tax losses from continuing operations since its formation, as well as projected losses for the current year. Therefore, it will continue to maintain a full valuation allowance on its U.S. federal and state net deferred tax asset. The change in the valuation allowance offset the income tax benefit related to the pre-tax loss for the year ended December 31, 2022. The Company does not have any material unrecognized tax benefits as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company experienced a net change in valuation allowance of $3,100,898 and $3,745,299 for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Narr_TOu55wB-V0yVmkZLUgzdYQ"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">22168000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_YwSkWMq-WUOFgcHGKO9rFw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 21.00&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (0.57)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4.83&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax true-ups&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.82)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.06&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (25.32)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23.47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective Income Tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="4"
      id="Tc_7xKbeAs-dUCl9q1GgBuQCQ_4_2"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="4"
      id="Tc_9QlQY0CnUkWGhwe-OA1uQw_4_4"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <viri:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="4"
      id="Tc_biaQoKBD1kKk_pxkR3hnTw_5_2"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">-0.0057</viri:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <viri:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="4"
      id="Tc_saUEOxEn8kKH_zL3A1ogog_5_4"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">-0.0033</viri:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="4"
      id="Tc_fBD6SVu55kW9HCZDuX2peA_6_2"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.0483</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="4"
      id="Tc_6bdp_-D49kmr6FHXlrslYQ_6_4"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.0447</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <viri:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="4"
      id="Tc_QO-JJsU-PEyonS_4I7CVpQ_7_4"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">-0.0182</viri:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="4"
      id="Tc_4ikNKaWBeUeTvXodMBWZqw_8_2"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.0006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="4"
      id="Tc_LRSkWZD1vUKMO_2byB96ug_8_4"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0.0015</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="4"
      id="Tc_IVFdcym7Tk6_hcsG1PeTIw_9_2"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">-0.2532</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="4"
      id="Tc_T4lgGjV7mEKh8HlM8sR3aA_9_4"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">-0.2347</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="4"
      id="Tc_UJK8kBs1S0uQwZNpbe4CQA_10_2"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="4"
      id="Tc_7KAcAPzvNkOKFyPLQXEIrA_10_4"
      unitRef="Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Tb_OCHRYnzKmU2QkSh9Pnd5xA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,692,533&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,586,488&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized research and development expenditures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,873,211&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,411,624&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,338,234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Investment in partnership&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 30,771&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 30,593&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 15,223&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,299&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,023,362&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,971,614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (8,682,497)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,581,599)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 340,865&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 390,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (340,865)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (390,015)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (340,865)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (390,015)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_0ZLTXUKQ_kmSNczqpgHW9g_4_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">5692533</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_4Eav5LwsyE68TiYDAhwS-A_4_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">4586488</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <viri:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_ueh13h5fHUGLRR-qEHpmpA_5_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1873211</viri:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_rP9xob1L1UiXZfc2eCIjqw_6_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1411624</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_-tsSBnIyx0WmnUhax4kzBw_6_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1338234</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <viri:DeferredTaxAssetsInvestmentInPartnership
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_8AV6y0W7jEOtB8miJxTGAA_7_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">30771</viri:DeferredTaxAssetsInvestmentInPartnership>
    <viri:DeferredTaxAssetsInvestmentInPartnership
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_-6pTGGwVm021YgGWBR22eA_7_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">30593</viri:DeferredTaxAssetsInvestmentInPartnership>
    <viri:DeferredTaxAssetsAmortization
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_LDmN3Tjq3EKPhdLT51RsNg_8_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">15223</viri:DeferredTaxAssetsAmortization>
    <viri:DeferredTaxAssetsAmortization
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_LNjzUQtNHEukL5zCK6SYSw_8_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">16299</viri:DeferredTaxAssetsAmortization>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_K0CF6ONJXUydNVXL3A0xzg_9_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">9023362</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_pDLyB3vZqEuOq1be3PjLZg_9_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">5971614</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_-yvxZ27JEkKXZiNv-s8Hsw_10_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">8682497</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_PUvCqFXFD0mYJxjrsuNcDA_10_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">5581599</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_hjO64A_SCUKKd0BCj7yaYw_11_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">340865</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_hXV8luS9VUiNaQKZM-iX8Q_11_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">390015</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_iIryC39zx0SZhs8plGSnZg_14_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">340865</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_NTEzS0PV0EmxGFHZnQ_X0w_14_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">390015</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_2qnUcK3-aECCyxLWHE74yw_15_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">340865</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_XAic98WwSk6s2NtHOc5ZhQ_15_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">390015</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Tc_eSHO9UiWIUSjnv7jJGjgKw_17_3"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg"
      decimals="0"
      id="Tc_dB2FoGTqvUyaFj2PG3GStw_17_6"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <viri:CapitalizedResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Narr_UdmFeKsa10iAhPKcU025NA"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">8099702</viri:CapitalizedResearchAndDevelopmentExpense>
    <viri:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ"
      decimals="0"
      id="Narr_pRkT8lKqSE6ggYSYCs3f_A"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">1873211</viri:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      decimals="0"
      id="Narr__ck3upPZykCxbC1f6mM_1g"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">3100898</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_fQ7NXGRpPUi--QD3Y21-BA"
      decimals="0"
      id="Narr_7BylGIHc3Uqmd7AZd6Z6hg"
      unitRef="Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA">3745299</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA"
      id="Narr_t_lh695HvUe3bx9yDHWVHg">686</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M*4;MR1B]93*^4; ]PG%+.!Y<D,LTY76E)%B1)[(HJ(ULW)OL(,*HM[7[9CC
M<7AD9R<MP.17 $5-NZRT 4QZ;_8C")/X &#?+/%T]D$[0 2[I@1?D'P[6\?:
MEF!_ZT(?>^%AF;,9>CH3O",3BG::*#H![Z]PHE-Q6@P'<78]$0VVH>F,ER53
M6H6I32U.>:58=4>K5&,&[[]R14%L[_W_H[\!JPIX?:!]\EV31'BP$LT53^]S
M7F14R#\ _5DS]60M16BPV[ZT%KU5M'W670M&PSW8++F6R]*0'X%W\!Q"B'1M
M$N"!%#7] 'P\TK?,'Y Y$:9+URKG@OU+LQ% \0AC.,();#9,-]K:,BE-+6D:
M>ZVDTA=Z0P&B@!9TM%SH5O^L"1LCH^Y&6O_+%6T$?/%D70%+4X\Q/LR3OM6N
MT?Z$=7T?#3=^+5J65!>>;&#.O*$IJ_AK)L<Z'8.(7Y)\KP^T/ZN=2D'#,N4R
MRY@YM^DR:23A&:M 2E9,ETTKX;X:";&?1'%XV($LED'L>T$(CVA7U D7-"@3
M3)^LR[H@2B^A/ABRE"DKUJB'X"P(480]&!V"M9CZ./$"'!W;MIWJ0,.R8]."
MI*7&64'WI84&'/K)H02Q&"(_@ B&Q^:WDR%H6(?TFF:3 R<S2'J'%KNPM1@>
M4;;NSC':?,/X0L0=JR0HZ%*[PO-(9X_8?!;8#!1?-2?K!5?ZG-Y<YI1HY,9
M/U]RW5"W W-8;S_.3/\#4$L#!!0    ( -!+;E:B.?0MV0(   <*   8
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULK99K;YLP%(;_BL6FJ9.Z8"#7+D%J
MTDZ=M$U1L\MG%TZ"56,SVTFZ_?K90%E(:$*TY4.PS3DOSVL?@\=;(1]5 J#1
M4\JXFCB)UMF5ZZHH@92HCLB FSM+(5.B35>N7)5)('&>E#+7Q[COIH1R)QSG
M8W,9CL5:,\IA+I%:IRF1OZ; Q';B>,[SP#U=)=H.N.$X(RM8@/Z6S:7IN95*
M3%/@B@J.)"PGSK5W-?.P3<@COE/8JITVLE8>A'BTG8_QQ,&6"!A$VDH0<]G
M#!BS2H;C9RGJ5,^TB;OM9_4/N7ECYH$HF GV@\8ZF3A#!\6P)&NF[\7V#DI#
M/:L7":;R?[0M8GO80=%::9&6R88@I;RXDJ=R(G82O.X+"7Z9X+=-",J$(#=:
MD.6V;H@FX5B*+9(VVJC91CXW>;9Q0[E=QH66YBXU>3J<7G^Z_C*[18N[V]NO
M"W0Q)Q*X3D#3B##U%KU#KY&+5&*&U=C5YHDVSXU*]6FA[K^@?@-1!P7>)?*Q
M[S>DS]JG>_5TU_BLS/J563_7"U[0FPD>FPJ$&$T)(SP"M+ 3UVBL4.HV*]G-
M=:4R$L'$,;M'@=R $[YYY?7Q^R:;_TFL9CJH3 ?'U(WI-#7[Q512]'B),B+1
MAK UH O*42P8(U*A#&2QQF^;IJ+0'^;Z]K6P"7$'8VQ69+-K\F18#;];X7=;
MXR.RUHF0]+=908M?E&4C<R':WX'I!CC_[5&W"*QQ]RKN7GMNJM3Z-'/O ,4;
M!@$.1OO,AX'[<37D?H7<;X]L7OE*$QY3OCK%W6_+?1AXE'M0<0^.<L_-FQ^D
M-!/\#T4^:%?D)\-J#H:5@^$Y#LZH\^'!E/J-97XZK@8^JL!'9X&W*_31 <P^
M[K&(&JB'_W[H\%FH9Q1XJ7P,^&A(0>SN?*7M$>DSD2O*%6*P-#FX,S#;6A:G
MCJ*C199_N!^$-L> O)F8DQI(&V#N+X70SQU[%JC.?N$?4$L#!!0    ( -!+
M;E9%RU[,200  -40   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULK5C;
M;N,V$/T50BV*7:")1.IFI;:!.,FV 9H+XFSWF9;&MK"2Z)*TG?Y]24F6;(M2
MLVA>8EUFCL[AD#R<C/>,?Q=K (G>\JP0$VLMY>;*MD6\AIR*2[:!0KU9,IY3
MJ6[YRA8;#C0ID_+,)HX3V#E-"VLZ+I\]\^F8;666%O#,D=CF.>7_S"!C^XF%
MK<.#EW2UEOJ!/1UOZ KF(+]NGKFZLQN4),VA$"DK$(?EQ+K&5S<XT@EEQ%\I
M[,71-=)2%HQ]US?WR<1R-"/(()8:@JJ?'=Q EFDDQ>/O&M1JOJD3CZ\/Z%]*
M\4K,@@JX8=FW-)'KB36R4 )+NLWD"]O_ ;4@7^/%+!/E7[2O8OW 0O%62);7
MR8I!GA;5+WVK!^(H ?<ED#J!G"=X/0ENG>"60BMFI:Q;*NETS-D><1VMT/1%
M.39EME*3%KJ,<\G5VU3ER>G\]?KU[N'N\76.GKZ@I^>[E^O7^Z?'.;I 7^>W
MZ-//G\>V5-_1T79<8\XJ3-*#B0EZ8(5<"W17))"< MB*8,.2'%C.R"#B+<27
MR,6_(N(08B!T\_YT/$#';0;-+?'<'KP;IG05 A(TEU2"FM52(+9$3QO@5,].
M81JT"M,S8^KE>B4V-(:)I=:C +X#:_K+3SAP?C,)_B"P$_E>(]\;0I^^P Z*
M+9@T#B:::2&3O/^/<Z+,;Y3Y@X6M"UBL$+QM=(7%E4FE_Y&5_""P$[U!HS?X
MCTH*H#Q>(UHD:O/;J5U]HV>S272%%)1(VAQVTY$31 $9C>W=L9YN'';"R ]&
M;> )U[#A&@YR_1T*59RLI$H3M16F0NIB[: IEHEVV*'C$4^QP6>T#7$CSR<^
M,;,>-:Q'@ZQ?F52<66=>F:B.NB-'7.R[3G3&U1#H!YX3>8Z9;-20C0;)_LF$
M0$O.\@/AGITLZGS_HH>I*7*0*G9:XW*&UZI< T=I$;,<T*=Z7#\;UVN-]$$+
M]J/03G4?&38>+-)](4'AREJZ42_N#'L0>J%_5AQ#F!^$/1,>DY8@&218%:8N
MB)'>8/X/EX-TYYA+?,?IFV&MR^-!%SVL7>,\,^IRWS?LW; +%T<NZ=D@<>O+
M>-B8R_6[ '6XAP-A2=_,FTT-=;:(B1>.7.^<L"G4CP*'!'V46\/%@_XV?52=
M2J9H&RE6J>%[*)I"ARFV'HF'37)&11JCHB:*U,Z(Q)IR\]2NH/P3'I?XW&S,
M85'?TFLM$@][Y&V:;:4ZEKZ3;/@^LL:P7K*M,^)A:_Q6MEB*+=TILUD!*K;Y
M0O%5!^F2LCI2;Z60RN^U<5[H;BV-C3H,?JC.' [&P;F4;N3()9&+^_:*UCGQ
ML'7^J)BDJI113M<T^^1T(\UR[*,&,0>^*OMF@6*V+635A35/F][\NNQ(SY[/
M=,]>-IXM3-7P/U"^2@N!,E@J2.<R5/.%5SUT=2/9IFQ#%TRJIK:\7 --@.L
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MO/GYI]G)].43JAX-JAX])?U_5?5I8;.)>$*>^*:]=D%\J967K>JB+L)(?+3
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MAS[42H1%:_+QG%Q>+3>9JR+Y,R^'P#TI2S P'5%2C-EB0[(.81(VWRC%P?3
ME\@D\(@D+X)Z\M8H K%"BLI=;U#:(/%H[:KW;[(GY%A_]_O9??7Y%%Y$&G3(
MTZHS@[/O:Y0.'5S^Y)'%!GJY.U4IBP0<SP>GGE_]>SP?W*KL7YL&\CG3<X#L
M@0#,9 .=5QO"0!9T.M,_'4)YL&-1#H>![,/&*E\AKA &6YH8 H*V4NVVD?)@
MI7V(8VW'A0%98!6B##&U#9 ^HIC_=Z*%X_ZID G=,JCO'>&T!S\3$1E<.:@%
M"(=(T"%TS$"ZI%T_C(H<"I]2,;OJ.055X!H4GHOLB]1![9<"[&;6TY8 MJD
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M4Y@@#>$%M!O\PG&]XW<Z&VGP$K;/3\9KI6ZV.",MPP\/2@&/24-\[P ?? D
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M&K53>5J YRN'&I^_T '#J^,W_P%02P,$%     @ T$MN5L;*[.L6$0  H"T
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M-@P^*Y)D[MPM??E8OCF:$D.F-D5+%#3^;<RUJ6LB!#9^CS2/\I&T<?@Y4?_
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MOU:SMF'WN6YN4T#GPR91-^:N,$9R2&7*6-*!W8ZR10UM2\[]R^SI=#*=3L<
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M(X:&@O7>%M]6D[&D6QY[,]NYZS6D>W9-@>.5 ^G:WE)@<=\AD8>0#CP6\'1
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MN7AZ)-=>Z0N8X7=P@?:M6_''I4'EZ&D!GE<.N2)^H0/R2]EO_P502P,$%
M  @ T$MN5GU$8Y6J @  W 8  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6RU5=MNVS ,_17!&_IDQ+9\29HF 9JVP_90+&BQ[5FQF5BH+7F2W'1_/TIV
MW*278$"Q%TND#@\/=:%G.ZD>= E@R%-="3WW2F.::1#HO(2:Z9%L0.#*1JJ:
M&335-M"- E:XH+H*:!AF0<VX\!8SYUNIQ4RVIN("5HKHMJZ9^K.$2N[F7N3M
M'7=\6QKK"!:SAFWA'LR/9J70"@:6@M<@-)>"*-C,O<MHNDPLW@%^<MCI@SFQ
ME:RE?+#&MV+NA5805) ;R\!P>(0KJ"I+A#)^]YS>D-(&'L[W[%]<[5C+FFFX
MDM4O7IAR[DT\4L"&M96YD[NOT->36KY<5MI]R:[#)M0C>:N-K/M@5%!ST8WL
MJ=^'@X!)^$X [0.HT]TE<BJOF6&+F9([HBP:V>S$E>JB41P7]E#NC<)5CG%F
ML5+0,%Z0FR<\9@V:,%&0[Z8$1:Y:I4 8<JDU&#T+#*:S04'>4R\[:OH.=43)
MK12FU.1&%% <$P2H<Q!+]V*7]"3C->0C$D<^H2&E)_CBH?C8\<7_H_B..GF;
MVKZEJ6Y8#G,/'XL&]0C>XNQ3E(47)X0G@_#D%/O'A)^FCD?DG]D')!PBI4/F
M/9)UR%SB.]:&R W!9;*1%;8#+K93<O9I0L/XXL,C7@ZHUYC97I C8X^PM\9^
MHD$W%[I53.0P8#Z3R(^RU,_BY,@7TW,_GJ1#9([[QG-6$7NX3.4E5JBQSI>J
MHC3QTRA\Y4\H]=/S9R7VAO <G@DBE_. Q\^RI#^%FNL<^Q@3(%O]<J?W$6.?
M(O_>FF3Q*PVNKGCBC[/C6L?9Q$_# ?_6?0T..DX-:NOZJCWE5IBN^0S>H75?
M=AWK&=[U_5NFMG@.I((-AH:C<>H1U?72SC"R<?UK+0UV0S<M\?<#R@)P?2.E
MV1LVP?!#6_P%4$L#!!0    ( -!+;E;CV:25]@(  -\&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;*55;4_;,!#^*Z>@(29!WEI>!&VEMFP"-C0$
MZ_;932Z-16QGMDOHO]_9:4,GH)NT+ZWO?,]SSYWMRZ!1^M&4B!:>127-,"BM
MK<^CR&0E"F9"5:.DG4)IP2R9>A&96B/+/4A441K')Y%@7 :C@??=Z=% +6W%
M)=YI,$LAF%Y-L%+-,$B"C>.>+TKK'-%H4+,%/J"=U7>:K*ACR;E :;B2H+$8
M!N/D?-)W\3[@!\?&;*W!53)7ZM$9U_DPB)T@K#"SCH'1WQ-.L:H<$<GXM>8,
MNI0.N+W>L'_VM5,M<V9PJJJ?/+?E,#@+(,>"+2M[KYHK7-=S[/@R51G_"TT;
MFU!PMC16B368% @NVW_VO.[#%N L?@>0K@&IU]TF\BHOF66C@58-:!=-;&[A
M2_5H$L>E.Y0'JVF7$\Z.OO*,.HPP7FA$:K8=1)9HW6:4K2DF+47Z#D62PJV2
MMC3P2>:8_TD0D9Y.5+H1-4EW,EYB%D(O.80T3M,=?+VNR)[GZ_U/D2U%_VT*
M]S;.3<TR' 9T^0WJ)PQ&^WO)27RQ0V"_$]C?Q?YO G=3]$-XQ0+?2X2I$C63
M*R ;->; I57 X(M4S=$5R7R-.K $V]\[2]/XHO-Z.[GX2/?3EN B9I+>DS;<
MKD 5,*[8G D&!VO@;-PAN*2#3-(0KB5DBMYSCIKY-TE#Q5-U60YA-J:WGB%1
MYZ0RB3^ 5/+H25DN%R!0S"EER6M7!I5CK&.W+V6&,*M5ZV&YJGT64N?L6[:"
M]D[%\( D)(<QY<Q=(EK?$QFS9'RKO3Q*MR7+$?Q%"#%2/QR#;_#[D5L:ITK7
MBK*YE?3=5/)P!Q0:9K82^;,T):,M5V6FA"!B&AK98^@/_^50N7&=PJ*@<>C[
MGA[#"IDVOOB&5Q50"IHP3@R1W"PEMNWJG89O7?%H:^@(U L_6IVXI;3M_.F\
MW?0>MT/K);P=_;=,+[@T4&%!T#@\/0Y M^.T-:RJ_0B;*TL#T2]+^@*A=@&T
M7RAE-X9+T'W31K\!4$L#!!0    ( -!+;E9$$LY RP(  !$'   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;*65WT_;,!#'_Q4K()ZBYG>3EK82!:;M
M 0V!MCV[R:6)2.S,=BG[[SD[C2FT5)-XB>WSW<??R\67V9:+)UD!*/+2-DS.
MG4JI;NIY,J^@I7+$.V"X4W+14H5+L?9D)X 6)JAMO-#WQUY+:^8L9L9V+Q8S
MOE%-S>!>$+EI6RK^+:'AV[D3.(/AH5Y72AN\Q:RC:W@$]:N[%[CR+*6H6V"R
MYHP(*.?.53!=QMK?./RN82OWYD1GLN+\22]^%'/'UX*@@5QI L7A&:ZA:30(
M9?S=,1U[I [<GP_T;R9WS&5%)5SSYD]=J&KN9 XIH*2;1CWP[7?8Y9-H7LX;
M:9YDV_L&J4/RC52\W06C@K9F_4A?=N]A+R#S/PD(=P&AT=T?9%3>4$47,\&W
M1&AOI.F)2=5$H[B:Z:(\*H&[-<:IQ56>BPT4Y/8%RRQ!SCR%5+WGY3O"LB>$
MGQ""D-QQIBI);ED!Q7N AW*LIG#0M Q/$F\@'Y$H<$GHA^$)7F1SC PO^D*.
M/2$^3M W8RH[FL/<P4]?@G@&9W%Q%HS]RQ/Z8JLO/D7_+WVG"<F(?(18 PR&
MG.-5DHKPDJ@*2,D;O)$U6T_)Q5D6^M'EET<L'+0K$*9X[Q:#AZZH?@167LY;
MK8^:.SJXG9,@F;BI'^]9DBATQVEF VNF &N!^3""12E!"+2VYDRIPX+TTCI)
M"PJRS/6SY&!M]>"[K7/:$%UG*O(*%>['#V.:N5$\.3 '4>8FF.. *VJ!_8<+
M4@(<0O#5^+[_F7E@=(*7('4;1%E'.4'@CH]PPM@-T/P3RRVP><@<FQ]EP#<2
MN^&'K\.BW&C\1DK=*$T.N.<D3GW7GV1[EDD8N.E;Y+%KX>VUJ1;$VC1C_5UN
MF.H[EK7:?G_5M[DW]_YG<4?%NF:2-%!BJ#]*$X>(O@'W"\4[T_167&$+-=,*
M_UD@M /NEYRK8:$/L'_!Q2M02P,$%     @ T$MN5O^@QRF[ P  '0D  !D
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MZ;O+I#M!IT&P=7P MS;0<QJ[)7V_H.,-M+ZS%,Q^P Z&+Z+UWU!+ P04
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M(7Y<+C\4==.[!Z*1PN'4BN?@MZC+BF^_8=OA<VK3]0Z/1"*W6)OZ;A^T*LM
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MK10Y:5RM$83H;1EP# IVO(\V\M:I$+I)E@<\\&CCK=67!NKH"*@O8BFM\EZ
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MI9(@.1J ]_.J,NZ&%'3?F%S^"U!+ P04    " #02VY6K\$D2>L&  "S$@
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MAMXASKY8FW>>.9SS\D&)?(93VF(1S*+DJTQ&#0P;(DE!6KSA>.7<8)?CY<_
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M"19\BS)CK:87?U5N4\'W%G9%F/,+<HB%A^2]^@0'7([4SS_?)"CXY7/JX[0
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MYM'/D-HQ96CJ%B':['3]@_1W'VG]H465C*XP@I3(+V($#_R^31G>?KKM4H;
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MSP1/8E0;O(";[-\O8,=->LE+7PP#,V?.86 \W0CYJ"H C;9-S=7,J[1N+X)
MT0H:HLY$"]SLK(1LB#:F7 >JE4!*%]34 0[#+&@(XUXQ=6L+64Q%IVO&82&1
MZIJ&R']SJ,5FYD7>;N&>K2MM%X)BVI(U/(#^U2ZDL8(1I60-<,4$1Q)6,^\J
MNI@GUM\Y_&:P47MS9)4LA7BTQO=RYH66$-1 M44@9GB":ZAK"V1H_!TPO3&E
M#=R?[]"_.NU&RY(HN!;U'U;J:N;E'BIA1;I:WXO--QCTI!:/BEJY+]KTOFGB
M(=HI+9HAV#!H&.]'LAW.82\@#]\)P$, =KS[1([E#=&DF$JQ0=)Z&S0[<5)=
MM"''N"W*@Y9FEYDX72PDM(25Z'9KRJQ (<)+]$-7(-%U)R5PC:Z4 JW0YY]D
M68/Z,@VTR6NC SKDF/<Y\#LY(HSN!->50K>\A/(0(#"$1]9XQWJ.CR+> #U#
M<>0C'&)\!"\>3R%V>/%'3^$M\3UT\C:T?507JB449IYY-0KD$WC%Z4F4A9='
MB"<C\>08>O%@'FG9U8#$"K6#"-@7(9P(.H@@[XHXGN;T),=A?(D^.IJZ0;,T
MA&SM#HR=ARVH_41H5Q/&52<)IS#Z?$*1'V6IG\7)P5J,S_TX3\=(:F0P2FID
MSYU(6B$JE+G)+UE%:>*G4?AJ/<'83\^?F=CB,0K/ )'+N8?C9UDRW)N&*6IZ
M#>$@.O6B &/$Q,<&?V?E6?R*@],5Y_XD.]0ZR7(_#>.WKE"PUPT:D&O7\PP%
MT7'=-X9Q=6RK5WTW>7;O>_(=D6MS_JB&E0D-SR:IAV3?YWI#B];UEJ70IE.Y
M:65^#2"M@]E?":%WADTP_FR*_U!+ P04    " #02VY6X;_(1LD"  #?!@
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M#--F[!F6%_ BRI8TXTO:YB&M)TK2Z2-$KD0T),  H&7GZ[L@)4J.9(WKOA#
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M!INX;EIBUPS**N#^4DJS7=@ 0Q\^^Q=02P,$%     @ T$MN5MVYVZ V!0
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M\+*!NKYA3#X?E!VT_]RP^!=02P,$%     @ T$MN5@-"!$H  @  .P0  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULI511;]L@$/XKB$U3)VW!(4LZ
M9;:E)E&U/4R*&G5[)OALHV+P ,?MOQ]@QXJFM"_S@[F#^[[[SMPY[;5YLC6
M0\^-5#;#M7/MFA#+:VB8G>D6E#\IM6F8\ZZIB&T-L"*"&DEHDJQ(PX3">1KW
M]B9/=>>D4+ WR'9-P\S+!J3N,SS'YXT'4=4N;) \;5D%!W"/[=YXCTPLA6A
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M@>L -;]F3#YU=&$?W_'\#U!+ P04    " #02VY6T#) B&4"  "#!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q]5&MOTS 4_2M6D!!(K'ET'3#2
M2.T&8M(FJDW !\0'-[E-K/D1[-O'_CW73IIU4M<OB:]]S_&YUS[.M\8^N@8
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M#,XOC#+9=+)FHD7MFL%<:--:W+ RS1^D#3#["R'T;F(3=+^3_ ]02P,$%
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MGJ)9EJ>R?I7$-PJ@W/I(8N"I-E,T"%@GVMPB:U 0->:4<_:>98->H:9P5%J
M2F-OR.O3=YC5Y6[?&B&7=Z7@U0/4P;%JT W4_(U*"U!IK*'-]H8J_\ XU05K
MWYZL.]';I]9!D5&S-"HM0*6QAO8>D;LT[=OC]'4BDFR;D7_)H6=6U "-2@M0
M:0R+UO\/6)>A*7*&IJ@9&I46H-(8%JWO3)>AZ<_(T';HT?:@9FA4&J-#&7I\
MX#F5=B&:VD/T@S1S[0LG*YXGVDRVGS^O!G5&#=6HM "5QK!H?3^Z4$V10S5%
M#=6HM "5QK!H?6>Z4$WMH?I!<5'P>J'.&@9?@]L)1WM1T^;[3R+>>.IY7GO3
M-S*C!F(L6E_F+CA3>_Z[T3$H<@+/.8@"/I!$A#(;5GOZ@SYC^J,\*WN#1W^G
M4<,P%JT6V]U;T92!VE1+R0H2RJW0]>*F]FB[7.VR6J3E=J?7:]VNN=HDHB I
MK$VI-YJ;CJIZ^5B]HV5>K8]ZE%K+K-HTN3H"59Y@/E]+J5]WR@;:17S+_P!0
M2P,$%     @ T$MN5A90E:!A!   *!4  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&ULM5AM<Z,V$/XK&MKIW,TT!O%FD]J>24RNO0_79I*V]UF&M<T<
M()\DV\F_KP0*!HRYV$/]P09Y]]$^#RMIV>F!LF]\ R#02Y;F?&9LA-C>FB:/
M-I 1/J);R.4_*\HR(N0M6YM\RX#$A5.6FK9E^69&DMR83XNQ1S:?TIU(DQP>
M&>*[+"/L]1Y2>I@9V'@;>$K6&Z$&S/ET2];P#.*?[2.3=V:%$B<9Y#RA.6*P
MFAEW^#;$8^506/R;P('7KI&BLJ3TF[KY',\,2T4$*41"01#YLX<%I*E"DG%\
MUZ!&-:=RK%^_H7\JR$LR2\)A0=.O22PV,V-BH!A69)>*)WKX S0A3^%%-.7%
M-SJ4MN/ 0-&."YII9QE!EN3E+WG10M0<L'_&P=8.=LO!=LXX.-K!:3N<F\'5
M#FZA3$FET"$D@LRGC!X04]8235T48A;>DGZ2J^?^+)C\-Y%^8OZ\(0QNE'(Q
MBF@FTXF3XH'<H(?ONT2\HL]Y!+EZ..@Q)3GZ$((@2<H_2HMBX ;]C$S$%0Z?
MFD+&I)#-2,]_7\YOGYD?V^@+S<6&HX<\AK@)8$HR%2/[C=&]W8L80C1"#OX5
MV99M=P2T>+\[[G /W^]N];!QJN?C%'C.&;P_=]D2&*(K]'Q6X1+![490&\<M
MWY((9H;<&3BP/1CS7W["OO5;ESI#@H4#@364<ROEW#[T^5\[P07)XR1?(R*0
MV !:PCK)<S4@]50#6V )C;LT+;'] EOMG?OYV VP.YZ:^[I:IV8>#K#O-,W"
MWDBOU,&K=/!Z=?B=D5RT5U9)TCN)/L"V9UDMDJ=FMAT$$[=%LC>,*TGZ%4F_
MEZ0\ U:0G*'IG\1_8P=CKTVS=X9+,W\@L(88XTJ,\:69#WG\XYP?G^@D,QE/
M@G;2G]IUK8WPU*RU-AKD)A6Y22^YAQ=@4<+),@5%3NZW4.R0/3O^_>0D$M_W
M'-MO\>J=^-($& BLH5%0:13T'AI?BVI'GNAW>V"R>D-:-'F$LR2"+HF"(<^0
M(<'"@< :0F+K6!Y9[UY+%QXA&MFK;Z\C2^Z<M4\K [7+N+X$6]M4V!_PM8+4
MZD5\[7&B/3&NAS]R[3;)#C-_-/':/'OCN):G?>1I7W^B:-\&!7=TLE'V3W'I
M0A@*K2G(L1#%O=7:U:>*AFUIU7[<"VUVP6H)M<N9U=*D>:P:<7_9>,WYHB&;
ML3M6_8/;= <J";42_T>!B8\5)O8N.V^>0+4<5*8LY,L=DR_W.Y*BOX%EZ,,K
M$,8_=LHX4 6I%1X2+1P*K:GPL;S%_?5MI3#1"K-*X:BFL/B1POVS!*AP1=A%
M,7GM>M=<O!<!9>JM'MGG@,+W FDDCFRG ZLIY[% QOT5\E6+O!]RH@.V\7GM
M>A$NSLB!T$H)S5H+*0.V+EIQ7";7+A=E[Z4:K=I]=T63JS5^K]J 16OJ"%/V
M$+\0)FLGCE)824AK-)9+BI5MN?)&T&W1J%I2(6A67&Z Q,"4@?Q_1:EXNU$3
M5,W1^7]02P,$%     @ T$MN5ECBS2@!"0  Z5$  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&ULU9Q=;^.X%8;_"N$6Q2ZP$TO4A^UI$B!C<M$IFFFP
MP4PO%KU@+-H61A\N13MQT1]?2E9,4Z9I*SB+8'*1V [/0^D]TA%?BM;U<RF^
M5TO.)7K)LZ*Z&2RE7'T<#JO9DN>LNBI7O%#_F9<B9U*]%8MAM1*<)4U0G@VQ
MY\7#G*7%X/:Z^>Q!W%Z7:YFE!7\0J%KG.1/;3SPKGV\&_N#U@]_2Q5+6'PQO
MKU=LP1^Y_+IZ$.K=<$])TIP755H62/#YS>#._TBCH YH6GQ+^7-U\!K5N_)4
MEM_K-Y^3FX%7;Q'/^$S6"*;^;/B49UE-4MOQGQ8ZV/=9!QZ^?J7_VNR\VIDG
M5O%IF?TK3>3R9C >H(3/V3J3OY7/?^/M#D4U;U9F5?,;/;=MO0&:K2M9YFVP
MVH(\+79_V4LKQ$& 'YX(P&T OC0@: .";L#H1$#8!H2= 'RJAZ@-:'9]N-OW
M1CC")+N]%N4S$G5K1:M?-.HWT4JOM*@/E$<IU']3%2=O'Y=,\ ^UU F:E;DZ
M_BK69/ #^L*$8'4:T4^$2Y9FU<_JTZ^/!/WTYY^OAU+U7C.&L[8GLNL)G^C)
MQ^B^+.2R0K1(>&("AFJS]]N.7[?]$W82'_GJ"OF37Q#V,+9LT-0=_O=UH<+C
MD^'$'4[X[ H%_LEP>GFX[Q CV"<R:'C!!8F<'B;R3F6Q6'!U<DOTM$6'[1[8
MMOGX[IF)!/W^#X5$GR7/JW];]N?3KO_0WG]=T#Y6*S;C-P-5L2HN-GQP^Y<_
M^;'W5UMJ(&$$$D:!8$82PWT20Q?]]FZQ$'S!)$<+E32)DOKEG*4";5BVYK:L
M[("C!EA?%3:W_F@<QNJ(W!SJ[>RWK]Z0, H$,_2.]GI'?^Q)\POZM<[.MSH[
MZ*Y2E]M5'5\A5B3HGLMEF919N=BBW^^>*BG49=%Z:D60IQ8DC$#"*!#,2'6\
M3W7L/+5(6LW*M<J;NJ;QRI:$7;R/#TXE[\H+XDGG5'+VTU=?2!@%@AGZCO;Z
MCISZTI>5&ONI\R-+Y]9"Y0Z/T)8S8<O+U!G85V](& 6"&7J/]WJ/+]-[4V:J
M9F6IW-I4']L.ZDD<QIV#VME97Y$A810(9H@\V8L\N4SD)-VD"2\2:^&8'%V"
MO8ZZSE[ZJ@L)HT P0UW?T^;#<^K;7%?12J0S:\EHHR/CX(TZVKJ[Z"LN*(U"
MT4QY#[R=[Y3W:R'XK%P4Z7^[[HZ_U*_MHCN9?0<CH#32TARG&H7JT)0<:\FQ
M4_*'C!5659UAO56%I!%0&H6BF0G0-MA_;Q_L@QIA4!H!I5$HFIE*;89]MQO^
MLLZ?N$#E'+$D2>LDL@Q5==Z4OUHK;R7JPF9-$:1#G;:T^-!CX\A3/V;M(:#=
M4BB:J;ZVQK[3CNU.I+-"@SK7EG8H-/;B6NJNT*"V%(IF"JV-J>]VIJ]";UB:
ML:>,HWDIT'PMUZ*=!K(*#VD<IZ TTM(.TQ@&7NP%W4OU<;LX""+=S!14.U'?
M[27_V<[!2"YRJW:0)G!Z9F-\[Z2S): ;0J%HINK:C_IN0_J-5S(M%FC%15K:
MBP6D+YR"TLB9G7-DD;XIU!19^U'?;4C?,$'L)O96'=3*^L?6>3+VO%'4K13'
M[7P_\O XM-<*K!TH]GZ(&6 ,Z3NGH#0"2J-0-#/AVA-CMR>^;$K'#>F=#E 3
MW-(.+YM=$^QL8@JGG2UV.]O/A11I4:6S7:FIA^5E>ZB7:UE)=;RK\F\5$]3[
M@M)(2W/-*#B;F&)JEXJ=UJF9)D#_0S1?9>66<T12H8[*4ECE _6;H#0"2J-0
M-#,IVF_B\)VG#C"H+P6E$5 :A:*9J=3F%;O-ZSU[2?-UCMA^O%3L)Q-V,PC6
M]("Z67SL9IM)@ZZ9!>V50M%,X;69Q6XSVQ:V+V7QX;+B!NIC06D$E$:A:&9B
MM"G&H_<N;J"V&I1&0&D4BF:F4CMM[':4;RQNH.Z[I9E3=;;B!GHO&(IF"J_=
M-W:[[[:XW:=%K;]59%"S#4HCH#0*13,7.VK?'OP8OCT ]>V@- )*HU T,^':
MMP=NWWY^_98;T#L5H)Z]I?E!9W&9'W:GNDZT]"(OLIO.0#OXP.W@SR[1<L?W
M5A#4J)_9MW;]&(I1WBPRMQ[!ER&"%H%&*&%;U[QM<+ XV^WW+URMY:;T3@#L
M(NO NI3,ZRXUIO:&XXEW8K(VT 8]<-\0;BIVSL1W+D_/=[L9O34$]=@M;6PH
M@T?C25?"\&CA4WQUZOS7ICAPF^+7X<MN^&C5#M0 @]((*(U"T<Q4:)L<Q#_&
M\ 74?H/2""B-0M',A&O[';AO U\P? &USZ TTM*.AB^C^&CX8F_I'][3,R74
MMC>X<,7SR>$+J,,%I9$S^Q:?OKW\EDA38>UO@PN7.Y\9I8":7% ::6G=44H0
MQ]T#U=[0\V/[<1IJ:QJZ%S5?-$IQ,_IJ"$HCX?&RZ_ *=U?O6%J-KB+_A'K:
MYX5NG]<.4EY7DY2;>EZKX,U1;A42U/6!T@@HC4+1S,1H]QCB=YY #D'M)RB-
M@-(H%,U,I7:CH=N-'BS5FJGTL(6]1(&:45 ::6F3PP5!W?IDM:'>.#BQOC \
M^)*NVX9V2A2;RW,U"M22@M((*(U"T<S,:(<;_L'?YSU?HT =,BB-@-(H%,U,
MI7;(H?M&\H4U"M2_@M)(2^M8H:#^Z9:J"UJ:,FK?&;I]9Z=6I07"X6Y^,]NJ
M=Y5D658?_A622RYX4\NL0H.Z4U : :51*)J9,.URP_%[ES!0FPQ*(Z T"D4S
M4ZGM=.BVTQ>6,% W#4HC+:U3F&+U,^J6L M:FH_HT'XZ<OOIMH0]RG+V_77)
MJ4U(-Z:OD* T DJC4#0S(=JB1_X/,7D=@5I_4!H!I5$HFIEP;?TC]YW1DP\)
M<WR-W(WLG1Q0,Q\=K^B.QCB.NK?A+.T"C,?C$Y-<D3;@D=N O^F+^6YF;T5!
M_7A+,[^@XX?>J#O4M30<XU'HX8ZDPX-'VN5<+)IG"5:HN8>R>T+<_M/]\PKO
MFJ?T=3XG_D>Z>^J@QNP>@GC/Q$*-@%'&YPKI78V4X1&[YPKNWLARU3PX[ZF4
MLLR;ETO.$B[J!NK_\[*4KV_J#O9/=[S]/U!+ P04    " #02VY6,0KP[?\%
M  "0+@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6S%FEUOVS84AO\*
MX0U#"[2V1=N*G24&4DO:,JQ;D*S91;$+1J)MHI+HDG0<#_OQHSXBB:[,6,4I
M>I-(,L]#4B\/3;[FQ8Z+3W)-J4)/29S*R]Y:J<WY8"##-4V([/,-3?4G2RX2
MHO2M6 WD1E 2Y4%)/,##H3M("$M[\XO\V8V87_"MBEE*;P22VR0A8O^.QGQW
MV7-ZSP]NV6JML@>#^<6&K.@=51\V-T+?#2I*Q!*:2L93).CRLG?EG =XD@7D
M)>X9W<G&-<JZ\L#YI^SF.KKL#;,6T9B&*D,0_>^1+F@<9R3=CL\EM%?5F04V
MKY_I0=YYW9D'(NF"QW^S2*TO>],>BNB2;&-URW>_TK)#>0-#'LO\+]J598<]
M%&ZEXDD9K%N0L+3X3Y[*%]$(<,9' G 9@$\-&)4!HX, [!X)&)<!X\. T9&
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MH&BFQ+5?@^T6R5>=Z; S.RL->G2GI-GV(J 5!E T4\#:K,%VL^:O8]D(:M&
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M%,_*(]:1-5790?,U8UPQVFJR2H+ CP:>YXW<5=M8Y]9O--9OC/7_:BS-J5@
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M?S_;"2G0D&[2>""VXW-\[G&N?<<[QI]$"B#1/L^HF%BIE)L;QQ%1"CD6-ML
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M7@<C;-WB&'[\:I@W8&!Y(-/?K36^VWB%[*\#;$_W50@V4[P2L9GB:PV(?]V
MD23^W<;R  /;!:QV(+\_#]24GQ-%L*N8-^P)QI$DP1"H17^-QC&R.C%\_/N#
M/251E"1^!#"_@RC"$'@:<01S !XP)(KJ]^#.^RA<O:?"]7\RA\]02P,$%
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MQ^:P,V57# -,'X'K1<?^THH<W=9BB"Y#')L$S^S0QL3,$KA>B:"8)S8FYI;
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MGW4_XV=?4$L! A0#%     @ T$MN5@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #02VY6R9E"X>X
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ T$MN5J(Y]"W9 @
M!PH  !@              ("!H!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( -!+;E9%RU[,200  -40   8              " @:\7
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #02VY67; 1
MO/$$  #&&0  &               @($N'   >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ T$MN5J)LR.;)!   V1$  !@
M ("!52$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( -!+
M;E9Z2J;=L0P  $8>   8              " @50F  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " #02VY6QLKLZQ81  "@+0  &
M        @($[,P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( -!+;E89!1D@8 ,  (L'   9              "
M@8A1  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ T$MN
M5CLT58]K!@  8!   !D              ("!'U4  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " #02VY6F@8+_ \*  !O(@  &0
M        @('!6P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( -!+;E:OP21)ZP8  +,2   9              " @0=F  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ T$MN5H8S)&GI$0  &#0
M !D              ("!*6T  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " #02VY61GKCL*<"  !X!@  &0              @(%)?P
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( -!+;E;AO\A&
MR0(  -\&   9              " @2>"  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ T$MN5E;-G@I1 P  7@H  !D
M ("!)X4  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #0
M2VY6<+._1"L$  "3"P  &0              @(&OB   >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -!+;E;=N=N@-@4  .@@   9
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M970R-BYX;6Q02P$"% ,4    " #02VY6T#) B&4"  "#!0  &0
M    @($VG0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M -!+;E:6"## W (  /$(   9              " @=*?  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ T$MN5HPD\9D+ P  R0L  !D
M             ("!Y:(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " #02VY6!=>R*H@"  !:!@  &0              @($GI@  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -!+;E8Y _,B0@4
M - G   9              " @>:H  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ T$MN5A90E:!A!   *!4  !D              ("!
M7ZX  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #02VY6
M6.+-* $)  #I40  &0              @('WL@  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( -!+;E8Q"O#M_P4  ) N   9
M      " @2^\  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ T$MN5OQ$>'B'!@  US   !D              ("!9<(  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #02VY6J(ME7.8"  !3"
M&0              @($CR0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( -!+;E8SJ6*S.P,  %(*   9              " @4#,  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ T$MN5BS:Y?&7
M P  Q@P  !D              ("!LL\  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " #02VY6U:IO/DD#  #6%   #0
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:+GAM;%!+!08     +@ N 'D,  !$WP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>73</ContextCount>
  <ElementCount>216</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/StatementBalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/StatementBalanceSheetsParentheticals</Role>
      <ShortName>BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/StatementStatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Background and Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureBackgroundAndOrganization</Role>
      <ShortName>Background and Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureLicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10909 - Disclosure - Share-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Share-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Background and Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails</Role>
      <ShortName>Background and Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosureBackgroundAndOrganization</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Equity Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Equity Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40401 - Disclosure - License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureLicenseAgreementDetails</Role>
      <ShortName>License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosureLicenseAgreement</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureRelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosureRelatedParties</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.virios.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Share-based compensation - Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails</Role>
      <ShortName>Share-based compensation - Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Share-based compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-based compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Share-based compensation - Unregistered Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails</Role>
      <ShortName>Share-based compensation - Unregistered Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Share-based compensation - Underwriters Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails</Role>
      <ShortName>Share-based compensation - Underwriters Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Income Taxes - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails</Role>
      <ShortName>Income Taxes - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Income Taxes - Net deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Net deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 13 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, dei:SecurityExchangeName, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesIssued, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:WarrantsAndRightsOutstandingTerm, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  tmb-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  tmb-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="tmb-20221231x10k.htm">tmb-20221231x10k.htm</File>
    <File>tmb-20221231.xsd</File>
    <File>tmb-20221231_cal.xml</File>
    <File>tmb-20221231_def.xml</File>
    <File>tmb-20221231_lab.xml</File>
    <File>tmb-20221231_pre.xml</File>
    <File>tmb-20221231xex10d6.htm</File>
    <File>tmb-20221231xex23d1.htm</File>
    <File>tmb-20221231xex31d1.htm</File>
    <File>tmb-20221231xex31d2.htm</File>
    <File>tmb-20221231xex32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tmb-20221231x10k001.jpg</File>
    <File>tmb-20221231x10k002.jpg</File>
    <File>tmb-20221231x10k003.jpg</File>
    <File>tmb-20221231x10k004.jpg</File>
    <File>tmb-20221231x10k005.jpg</File>
    <File>tmb-20221231x10k006.jpg</File>
    <File>tmb-20221231x10k007.jpg</File>
    <File>tmb-20221231x10k008.jpg</File>
    <File>tmb-20221231x10k009.jpg</File>
    <File>tmb-20221231x10k011.jpg</File>
    <File>tmb-20221231x10k012.jpg</File>
    <File>tmb-20221231x10k013.jpg</File>
    <File>tmb-20221231x10k014.jpg</File>
    <File>tmb-20221231x10k015.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="301">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tmb-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 301,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 73,
   "dts": {
    "calculationLink": {
     "local": [
      "tmb-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tmb-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 316,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 17,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 23
   },
   "keyCustom": 40,
   "keyStandard": 176,
   "memberCustom": 8,
   "memberStandard": 14,
   "nsprefix": "viri",
   "nsuri": "http://www.virios.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.virios.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - License Agreement",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.virios.com/role/DisclosureLicenseAgreement",
     "shortName": "License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.virios.com/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.virios.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Related Parties",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.virios.com/role/DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.virios.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10909 - Disclosure - Share-based compensation",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.virios.com/role/DisclosureShareBasedCompensation",
     "shortName": "Share-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.virios.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "viri:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "viri:PrepaidExpenseAndOtherAssetsCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "viri:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "viri:PrepaidExpenseAndOtherAssetsCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.virios.com/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.virios.com/role/StatementBalanceSheets",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Share-based compensation (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.virios.com/role/DisclosureShareBasedCompensationTables",
     "shortName": "Share-based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.virios.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Background and Organization (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
     "shortName": "Background and Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EquityMethodInvestmentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_viri_NorthriverPharmLlcMember_5EL1vFgplUm9u---06s8UQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Equity Method Investment (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Equity Method Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EquityMethodInvestmentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_viri_NorthriverPharmLlcMember_5EL1vFgplUm9u---06s8UQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_zVHuNo8JJUOL740CgoX5UA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_zVHuNo8JJUOL740CgoX5UA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "viri:PrepaidExpenseAndOtherAssetsCurrentTableTextBlock",
       "viri:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "viri:PrepaidExpenseAndOtherAssetsCurrentTableTextBlock",
       "viri:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2012_To_12_31_2012_us-gaap_TypeOfArrangementAxis_viri_KnowHowLicenseAgreementMember_v_HMShg6JkeIz5pkc4ARKw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "viri:CollaborativeArrangementPercentageOfNonVotingMembershipInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - License Agreement (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.virios.com/role/DisclosureLicenseAgreementDetails",
     "shortName": "License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2012_To_12_31_2012_us-gaap_TypeOfArrangementAxis_viri_KnowHowLicenseAgreementMember_v_HMShg6JkeIz5pkc4ARKw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "viri:CollaborativeArrangementPercentageOfNonVotingMembershipInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.virios.com/role/DisclosureAccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "viri:CommonAndPreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.virios.com/role/DisclosureStockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_16_2020_7azCuBrxF0enz0Y99PPsIg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "viri:CommonAndPreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_B1eQQYSpM0GUCyOFYBhNWw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - BALANCE SHEETS (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.virios.com/role/StatementBalanceSheetsParentheticals",
     "shortName": "BALANCE SHEETS (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_8qDIf0iS40afQ_D2p7xkYg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_X5Y3MAAZ80-3sQBqUVtS-Q",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Related Parties (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.virios.com/role/DisclosureRelatedPartiesDetails",
     "shortName": "Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_viri_GendreauConsultingLlcMember_X5Y3MAAZ80-3sQBqUVtS-Q",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_9_10_2020_To_9_10_2020_RVDodrV4eECIJMPDAPhQBA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "viri:EmploymentAgreementSeverancePaymentPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_9_10_2020_To_9_10_2020_RVDodrV4eECIJMPDAPhQBA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "viri:EmploymentAgreementSeverancePaymentPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_PSW_ICNFWUWC815QcUkHTQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Share-based compensation - Equity Incentive Plan (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails",
     "shortName": "Share-based compensation - Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_Fr7WrLrJYkaxfkoPmntqew",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_9_19_2022_To_9_19_2022_nGlN-yTkaUWMIYHnuf3o8g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "viri:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Share-based compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
     "shortName": "Share-based compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_6_16_2022_To_6_16_2022_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_p9GEDysUj0yLr6kbN6USkA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Share-based compensation - Unregistered Securities (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails",
     "shortName": "Share-based compensation - Unregistered Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_viri_NonQualifiedStockOptionsMember_us-gaap_PlanNameAxis_viri_EquityIncentivePlan2020Member_V45ENNLZNEul9gBVym8tow",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_qBpUcKDC60WeioEQW7HVCA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - Share-based compensation - Underwriters Warrants (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails",
     "shortName": "Share-based compensation - Underwriters Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_9_19_2022_V-E2tnahU06pAr9iPmFrRg",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.virios.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Income Taxes - Reconciliation (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails",
     "shortName": "Income Taxes - Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_GytwA-nK2EqCaf7T6L5ibA",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Income Taxes - Net deferred tax assets (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Net deferred tax assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_9SjyKyaJf0S1o8FXE-WiEQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.virios.com/role/StatementStatementsOfOperations",
     "shortName": "STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bmANR8woWk2jfaAekf9q_w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.virios.com/role/StatementStatementsOfStockholdersEquity",
     "shortName": "STATEMENTS OF STOCKHOLDERS EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bmANR8woWk2jfaAekf9q_w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.virios.com/role/StatementStatementsOfCashFlows",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_vEQ3w5U6VUetOsjyEtJHWA",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Background and Organization",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.virios.com/role/DisclosureBackgroundAndOrganization",
     "shortName": "Background and Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "viri:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_wWjo_zQvLU-130ASB9DtoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "viri:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 23,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.virios.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CEO"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r185",
      "r276",
      "r293",
      "r300",
      "r301",
      "r308",
      "r309",
      "r316",
      "r346",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r185",
      "r276",
      "r293",
      "r300",
      "r301",
      "r308",
      "r309",
      "r316",
      "r346",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r183",
      "r185",
      "r212",
      "r213",
      "r214",
      "r275",
      "r276",
      "r293",
      "r300",
      "r301",
      "r308",
      "r309",
      "r316",
      "r339",
      "r346",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r183",
      "r185",
      "r212",
      "r213",
      "r214",
      "r275",
      "r276",
      "r293",
      "r300",
      "r301",
      "r308",
      "r309",
      "r316",
      "r339",
      "r346",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r336",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "verboseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r315"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r64",
      "r70",
      "r80",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties.",
        "label": "Accounts Payable, Related Parties",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued expenses",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails",
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r315"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r333",
      "r334",
      "r335",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r50",
      "r51",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r68",
      "r76",
      "r89",
      "r103",
      "r135",
      "r139",
      "r143",
      "r149",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r251",
      "r255",
      "r261",
      "r315",
      "r344",
      "r345",
      "r383"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r86",
      "r90",
      "r103",
      "r149",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r251",
      "r255",
      "r261",
      "r315",
      "r344",
      "r345",
      "r383"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r24",
      "r88",
      "r302"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r20",
      "r24",
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r20",
      "r62"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "verboseLabel": "Federally insured limit"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding at the end of the period",
        "periodStartLabel": "Warrants outstanding at the beginning of the period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r12",
      "r71",
      "r79"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "verboseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r37",
      "r151",
      "r152",
      "r299",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r333",
      "r334",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureStockholdersEquityDetails",
      "http://www.virios.com/role/StatementBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureStockholdersEquityDetails",
      "http://www.virios.com/role/StatementBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r315"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 43,000,000 shares authorized, 18,330,390 and 8,330,390 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r75",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "verboseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r57",
      "r58",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "verboseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "totalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r56",
      "r375"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r56",
      "r375"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r189",
      "r217",
      "r218",
      "r220",
      "r224",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r97",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r118",
      "r120",
      "r122",
      "r123",
      "r124",
      "r126",
      "r259",
      "r260",
      "r290",
      "r292",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r97",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r120",
      "r122",
      "r123",
      "r124",
      "r126",
      "r259",
      "r260",
      "r290",
      "r292",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Income (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Income Tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of federal income tax rate to effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r104",
      "r229",
      "r242"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r373",
      "r376"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r373",
      "r376"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r373",
      "r376"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r38",
      "r84",
      "r94",
      "r95",
      "r96",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r127",
      "r150",
      "r180",
      "r221",
      "r222",
      "r223",
      "r239",
      "r240",
      "r258",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r34",
      "r136",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "verboseLabel": "Equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r19",
      "r36",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "verboseLabel": "Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r186",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r186",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r14",
      "r67",
      "r72",
      "r82",
      "r135",
      "r138",
      "r142",
      "r144",
      "r291",
      "r306"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r230",
      "r231",
      "r237",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r225",
      "r226",
      "r231",
      "r232",
      "r236",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Increase in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "(Decrease) increase in accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedSalaries": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in accrued salaries.",
        "label": "Increase (Decrease) in Accrued Salaries",
        "verboseLabel": "Decrease in accrued salaries"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Decrease (increase) in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r103",
      "r149",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r252",
      "r255",
      "r256",
      "r261",
      "r305",
      "r344",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r69",
      "r78",
      "r315",
      "r331",
      "r337",
      "r380"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and members'/stockholders equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r87",
      "r103",
      "r149",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r252",
      "r255",
      "r256",
      "r261",
      "r315",
      "r344",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r340",
      "r341",
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "verboseLabel": "Transaction fee"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r20",
      "r21",
      "r23"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r15",
      "r23",
      "r73",
      "r81",
      "r85",
      "r91",
      "r92",
      "r96",
      "r103",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r121",
      "r135",
      "r138",
      "r142",
      "r144",
      "r149",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r260",
      "r261",
      "r306",
      "r344"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/StatementStatementsOfOperations",
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r135",
      "r138",
      "r142",
      "r144",
      "r306"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Background and Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Background and Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other miscellaneous accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Current",
        "terseLabel": "Other miscellaneous current assets"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "verboseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureStockholdersEquityDetails",
      "http://www.virios.com/role/StatementBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureStockholdersEquityDetails",
      "http://www.virios.com/role/StatementBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r315"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 2,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Total prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r303",
      "r307",
      "r338"
     ],
     "calculation": {
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Proceeds from public offering of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r85",
      "r91",
      "r92",
      "r99",
      "r103",
      "r108",
      "r116",
      "r117",
      "r135",
      "r138",
      "r142",
      "r144",
      "r149",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r250",
      "r253",
      "r254",
      "r260",
      "r261",
      "r291",
      "r306",
      "r313",
      "r314",
      "r329",
      "r344"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r184",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Amount paid to the firm"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r184",
      "r271",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r270",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r52",
      "r83",
      "r391"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r39",
      "r77",
      "r297",
      "r298",
      "r315"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r84",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r150",
      "r221",
      "r222",
      "r223",
      "r239",
      "r240",
      "r258",
      "r294",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r133",
      "r134",
      "r137",
      "r140",
      "r141",
      "r145",
      "r146",
      "r147",
      "r181",
      "r182",
      "r277"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of net deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of federal income tax rate to effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r65",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r186",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r40",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of underwriters warrants to purchase common shares"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based and equity compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Discount rates"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum aggregate number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period",
        "periodStartLabel": "Outstanding at the beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period",
        "periodStartLabel": "Outstanding the beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Vesting over one year"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Vesting in 24 monthly installments thereafter"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Vesting after one year"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Gendreau",
        "terseLabel": "Employee Director"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r186",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Non-Employee Director"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "verboseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Options term",
        "verboseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (years)",
        "verboseLabel": "Remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balances, Ending (in shares)",
        "periodStartLabel": "Balances, Beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r27",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r13",
      "r38",
      "r84",
      "r94",
      "r95",
      "r96",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r127",
      "r150",
      "r180",
      "r221",
      "r222",
      "r223",
      "r239",
      "r240",
      "r258",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Changes of Shareholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r127",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r38",
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common shares in public offering, net of costs (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails",
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r38",
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common shares in public offering, net of costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r33",
      "r315",
      "r331",
      "r337",
      "r380"
     ],
     "calculation": {
      "http://www.virios.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balances, Ending",
        "periodStartLabel": "Balances, Beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets",
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r41",
      "r102",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r128",
      "r129",
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Remaining contractual term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r119",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r118",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "viri_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "viri_AccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accounting policies.",
        "label": "Accounting Policies [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesTable",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "viri_AccruedDirectorFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for director fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Director Fees, Current",
        "terseLabel": "Accrued director fees"
       }
      }
     },
     "localname": "AccruedDirectorFeesCurrent",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_AccruedInterestOnPreferredMembersInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable pertaining to pertaining to accrued interest on preferred member's interest.",
        "label": "Accrued Interest on Preferred Members Interest",
        "verboseLabel": "Accrued interest on preferred members' interests"
       }
      }
     },
     "localname": "AccruedInterestOnPreferredMembersInterest",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_AccruedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable pertaining to accrued research and development costs.",
        "label": "Accrued Research and Development Costs",
        "verboseLabel": "Accrued clinical research costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCosts",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_AggregateIntrinsicValueOfWarrantsOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate intrinsic value of warrants outstanding",
        "label": "Aggregate Intrinsic Value Of Warrants Outstanding",
        "terseLabel": "Intrinsic value of warrants outstanding"
       }
      }
     },
     "localname": "AggregateIntrinsicValueOfWarrantsOutstanding",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_CapitalizedResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of research and development expenses capitalized.",
        "label": "Capitalized Research and Development Expense",
        "terseLabel": "Capitalized research and development expenses"
       }
      }
     },
     "localname": "CapitalizedResearchAndDevelopmentExpense",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_ChiefMedicalOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Chief Medical Officer.",
        "label": "CMO"
       }
      }
     },
     "localname": "ChiefMedicalOfficerMember",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "viri_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights exercisable.",
        "label": "Class of Warrant or Right, Exercisable",
        "terseLabel": "Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "viri_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share or per unit of warrants or rights exercisable.",
        "label": "Class of Warrant or Right, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "viri_ClassOfWarrantOrRightGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights  granted.",
        "label": "Class of Warrant or Right, Granted",
        "terseLabel": "Warrants granted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightGranted",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "viri_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share or per unit of warrants or rights granted.",
        "label": "Class of Warrant or Right, Granted, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "viri_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period",
        "periodStartLabel": "Outstanding at the beginning of the period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "viri_ClassOfWarrantOrRightRemainingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining term of warrants and right, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Class of Warrant or Right, Remaining Term",
        "terseLabel": "Remaining term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRemainingTerm",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "viri_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Class of Warrant or Right, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "viri_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Right Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable contractual term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "viri_CollaborativeArrangementPercentageOfNonVotingMembershipInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents element information pertaining to percentage of non-voting membership interest.",
        "label": "Collaborative Arrangement Percentage of Non Voting Membership Interest",
        "verboseLabel": "Percentage of non-voting membership interest"
       }
      }
     },
     "localname": "CollaborativeArrangementPercentageOfNonVotingMembershipInterest",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureLicenseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "viri_CommonAndPreferredStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common and preferred shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common and Preferred Stock, Shares Authorized",
        "terseLabel": "Common and preferred stock authorized (in shares)"
       }
      }
     },
     "localname": "CommonAndPreferredStockSharesAuthorized",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "viri_DeferredTaxAssetsAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization.",
        "label": "Deferred Tax Assets, Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsAmortization",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses.",
        "label": "Deferred Tax Assets, Capitalized Research and Development Expenses",
        "terseLabel": "Capitalized research and development expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_DeferredTaxAssetsInvestmentInPartnership": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investment in partnership.",
        "label": "Deferred Tax Assets, Investment in Partnership",
        "terseLabel": "Investment in partnership"
       }
      }
     },
     "localname": "DeferredTaxAssetsInvestmentInPartnership",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Percent",
        "verboseLabel": "Deferred tax true-ups"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "viri_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The termination payment payable as a in ratio of cash bonus for the year, when the termination occurs due to change of control.",
        "label": "Employment Agreement, Change Of Control Termination Payment As A Ratio Of Cash Bonus",
        "terseLabel": "Ratio of cash bonus"
       }
      }
     },
     "localname": "EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfCashBonus",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "viri_EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The termination payment payable as a in ratio of then current annual base salary when the termination occurs due to change of control.",
        "label": "Employment Agreement, Change Of Control Termination Payment As A Ratio Of Then Current Annual Base Salary",
        "terseLabel": "Ratio of current annual base salary"
       }
      }
     },
     "localname": "EmploymentAgreementChangeOfControlTerminationPaymentAsRatioOfThenCurrentAnnualBaseSalary",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "viri_EmploymentAgreementChangeOfControlTerminationPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period in which the termination payment is payable in cash, when the termination occurs due to change of control.",
        "label": "Employment Agreement, Change Of Control Termination Payment Period",
        "terseLabel": "Period of termination due to change of control."
       }
      }
     },
     "localname": "EmploymentAgreementChangeOfControlTerminationPaymentPeriod",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "viri_EmploymentAgreementHealthBenefitOfferedPeriodOnTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of health benefit offered in addition to severance payment when the executive is not eligible for health benefits under another employer.",
        "label": "Employment Agreement, Health Benefit Offered Period On Termination",
        "terseLabel": "Employment agreement, health benefit offered period on termination"
       }
      }
     },
     "localname": "EmploymentAgreementHealthBenefitOfferedPeriodOnTermination",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "viri_EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The severance payment represented as a percentage of then current annual base salary.",
        "label": "Employment Agreement, Severance Payment As A Percentage Of Then Current Annual Base Salary",
        "terseLabel": "Percentage of then current annual base salary."
       }
      }
     },
     "localname": "EmploymentAgreementSeverancePaymentAsPercentageOfThenCurrentAnnualBaseSalary",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "viri_EmploymentAgreementSeverancePaymentPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period in which the severance payment is payable in cash to the executive under the agreement.",
        "label": "Employment Agreement, Severance Payment, Payment Period",
        "terseLabel": "Severance payment period"
       }
      }
     },
     "localname": "EmploymentAgreementSeverancePaymentPaymentPeriod",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "viri_EmploymentAgreementThresholdTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold termination period under the employment agreement.",
        "label": "Employment Agreement, Threshold Termination Period",
        "terseLabel": "Threshold termination period"
       }
      }
     },
     "localname": "EmploymentAgreementThresholdTerminationPeriod",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "viri_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Equity incentive plan 2020.",
        "label": "Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationEquityIncentivePlanDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "viri_GendreauConsultingLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Gendreau Consulting, LLC.",
        "label": "Gendreau Consulting, LLC"
       }
      }
     },
     "localname": "GendreauConsultingLlcMember",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "viri_KnowHowLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to know-how license agreement.",
        "label": "Agreement"
       }
      }
     },
     "localname": "KnowHowLicenseAgreementMember",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "viri_LicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementAbstract",
     "nsuri": "http://www.virios.com/20221231",
     "xbrltype": "stringItemType"
    },
    "viri_LicenseAgreementExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents element information pertaining to license agreement expiration period.",
        "label": "License Agreement Expiration Period",
        "verboseLabel": "License agreement expiration period"
       }
      }
     },
     "localname": "LicenseAgreementExpirationPeriod",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "viri_NonQualifiedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to non qualified stock options.",
        "label": "Non-qualified stock options"
       }
      }
     },
     "localname": "NonQualifiedStockOptionsMember",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnregisteredSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "viri_NorthriverPharmLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Northriver Pharm, LLC.",
        "label": "NRP"
       }
      }
     },
     "localname": "NorthriverPharmLlcMember",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "viri_NumberOfVotesPerCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes per common stock.",
        "label": "Number Of Votes Per Common Stock",
        "terseLabel": "Number of votes per common stock"
       }
      }
     },
     "localname": "NumberOfVotesPerCommonStock",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "viri_PercentageOfCashBonusOnSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of cash bonus on salary.",
        "label": "Percentage of Cash Bonus on Salary",
        "verboseLabel": "Percentage of cash bonus on salary"
       }
      }
     },
     "localname": "PercentageOfCashBonusOnSalary",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "viri_PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period in which the company has to raise additional capital to complete clinical development.",
        "label": "Period in Which Company Has to Raise Additional Capital to Complete Clinical Development",
        "terseLabel": "Period in which the company has to raise additional capital to complete clinical development"
       }
      }
     },
     "localname": "PeriodInWhichCompanyHasToRaiseAdditionalCapitalToCompleteClinicalDevelopment",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "viri_PrepaidClinicalResearchCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration paid in advance for clinical research costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Clinical Research Costs",
        "terseLabel": "Prepaid clinical research costs"
       }
      }
     },
     "localname": "PrepaidClinicalResearchCosts",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_PrepaidExpenseAndOtherAssetsCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of prepaid expense and other assets current.",
        "label": "Prepaid Expense and Other Assets Current [Table Text Block]",
        "verboseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentTableTextBlock",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "viri_PrepaidExpenseAndOtherAssetsCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure of prepaid expense and other assets current.",
        "label": "Prepaid Expense and Other Assets Current [Text Block]",
        "verboseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentTextBlock",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "viri_PrepaidServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents element information pertaining to prepaid services.",
        "label": "Prepaid Services",
        "verboseLabel": "Prepaid services"
       }
      }
     },
     "localname": "PrepaidServices",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair market value assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "terseLabel": "Fair market value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "viri_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Aggregate Grant Date Fair Value",
        "terseLabel": "Aggregate grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.virios.com/role/DisclosureShareBasedCompensationUnderwritersWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_StatusOfCompanyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for change in status of company.",
        "label": "Status of Company [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "StatusOfCompanyPolicyTextBlock",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "viri_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the current period.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "viri_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "viri_TorreyaCapitalLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Torreya Capital LLC.",
        "label": "Torreya Capital LLC"
       }
      }
     },
     "localname": "TorreyaCapitalLlcMember",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "viri_VicePresidentOperationsAndFinanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Vice President Operations and Finance.",
        "label": "VP of Operations and Finance"
       }
      }
     },
     "localname": "VicePresidentOperationsAndFinanceMember",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "viri_WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercise price as percentage of initial public offering price.",
        "label": "Warrants Exercise Price As Percentage Of Initial Public Offering Price",
        "verboseLabel": "Warrants exercise price percentage of IPO Price"
       }
      }
     },
     "localname": "WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice",
     "nsuri": "http://www.virios.com/20221231",
     "presentation": [
      "http://www.virios.com/role/DisclosureBackgroundAndOrganizationDetails"
     ],
     "xbrltype": "percentItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r317": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r318": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r319": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r321": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r322": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r323": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r324": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r325": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r326": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001558370-23-003650-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-003650-xbrl.zip
M4$L#!!0    ( -%+;E8NO/V.U T  (B%   0    =&UB+3(P,C(Q,C,Q+GAS
M9.U=W7/;-A)_OYG['W!ZN=S,R?I*TK,GZ8TLVXVGMN5::M)[ZD D).%"@BH
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M1+_4G)(Y%]I5$R"B#P97-_+E#AS>IZ@C$!6\_)J-^W7^U=&R?>P4-U/'49_
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MIHHJIQ.R%2W;1 QO_.!M'27G9*RKXS45KA^(D$./PYA0K_,^!B9 M)CW((?
MVR'GV&I+"&3N&B2AOJ'J*XK>'**6Z_(09LVNJ+Q.RN;T[&(\'\$3>0?Q"&[
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MW?RZZ^:'!.-U_,*+SU:RO<:DP!!O;AY0SEQ,_5:9&!__/&/$_^G_4$L#!!0
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MQMAO W+-&1O4/'6UOAH/7))2Q;Z9D.-8#HG>[3 +Z:(1%B';O[6=4#I&T]O
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ML<FEYC"(>(HE^[(5]TSKT1)9%E@D\KS  PQ?B6ED(_Z @U<8T8ITE 71!,?
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M/-5FQYE=%ALL$M_^G22RZYBKNI-&C-,=GP8KJ:#5L88__S]02P,$%     @
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M  Y/C:!#'>]G\;!+21!B#$ZLLJ/3'^JT49:(-2Q)?U\G." 9^TF[Y]W6 W@
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M%43W^R\ C"=-6%+&#L6"GVOT4CZ-\ZO'OM<LO4INR,.VN];H&'K+P:IAIM)
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MX:741"T/(0#].)< [9D7,QGF7N-/:@E&SMU:\U/W[.M3<_:53QVO#EF:>5%
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M7&N&VAQ8Y2STH+(7;+#E_\G/BT79K]:[>O98O%90;3&H%2!5T'^-X-FFID/
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M>G 2_.O02^FT)-?Y*N$:2X"GL9%!-^#A;JJX'.==?0 'N+'H0[V9,V#.G+-
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M.9G1Y&FLC1M#:FPNWZ^MUZ<JE4[UMP*&](>,O4-,46)MG\[0L760+D/=O'I
MF1R7-*OV B:^3*#%34>V:%2_D[ SG?QB13LFSFH0194[$Y>8Y0[5U9[B/RNQ
M<1FGZ9I*]4(76[P\3<-L1AV  J.YLO*-*7UKP'>E#(0>?)!;D$:,-JH1GR2$
MZ=3D/FZ_[SBANE\Q73F7*H=,9;]-Y5G"E:&4J-H0AO&31SW^#&]PDN#@SGL^
M35.<K;>LFL-%)*IA:<PV@ SPT!YJ&#G@^]( # .#51D:+25#5')<H8(GHDP1
MY\HJXOH)IEW0FS,L?OK.;>FVV4W%@,7G)(NW3(3AO(*_O7514Q,*D7N2>2$K
M!G>#4TP#;'L:!6?X$8?QGDVG\Y*>S=%_/#6@^&')3.4*:C@IZ.LI"YH-7E'P
MP$/WF(Z]F,>)+T*&SJ05\<,WOX,">S**/1X3&'D9G8??'S*^&9&QU/S@X&>$
M_X9W^SCQDA<4D WMB#D9YB(HR77C1P=!I5U1/W'N$P2'W\,QGJ<K)+%'-[*M
M) F**L8SOSCAVEZR:=K=*"#986 9#<UIA:&2R@U#\[Z04;VO":H3!\..T!&[
MMQXC\9FB;B=8TC54*=3<1Z]SF:,/(KHX#W!AAT['<%/CG8[U= ;P2"?W?KS#
M=(A@SY.R,Q 2L1<&\^V%.$KSCUAAYL@G(1$KAO;R8O:H X79B<Q8J]9NAS3@
MI;IM#0>?U!5R("$(G^0Q?JC.<(6N,56?AJ[K8F=0+%<GRX;!#0XHZY"N[[DE
MV1(D89:DBPY<FKGX*R#D:Q@H^RSTN*5SC .5X:76N->WTI?R(A%OD/FZT:X7
MV<4AW3#MID<Y+T.Y**B4I=FIQ$)( #BO07]^>_NVQ+NT-%0#^>PM;$UTIE_*
MSHOHUW)6;>;D7Y1J0CR>)%"TLFFP<G4\DA[T1;,M]8;&4TZ'99'EEV.K'4ET
MC[,GEKA<9CM+898OI-";>QSA#<F^XTLM7#QCVMJ2O0MS8*WN7Y"WWX<O/'V6
M\:9]THSXW1&>LLG-/L'L]_RC-^S0]#NQB^J7L[+B4)4]\M?<D=T7AI6W86?>
M)G#M +WFX;FU)#$<#4D@3'>M<A^PTVLV(./3*+BD$H1ENZ.C-TLD@0Y1-@W6
M=R:MH[?P*72G6M,C$Q>!CS]<"*F],X "84%AETR8(<*9O%>0#\;SSI3EP['@
MWP]IQA]/'SE7[B(*%(KL&JW7?+F5XFN8,9LI^)]SY@%SYGJB0V5<@-/F:;W
M?'BJYS%4DDP[-+6DLP*QX)GL2EERP">'/=SY\Q4-MD2RPH@!7T$*Z"!EPT!]
MY\E-.@N?'VO5F1YX..OY$,?*9-BZN801I)$*+,(4B;]'*63'.<,C#-R/RRO
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MXD*Y2W+;BW,@JW#+VC87Y/7 _=.[2J9+^A/]8_&GG,(__W]02P,$%     @
MT4MN5KKP+ZBQ,   ')D# !0   !T;6(M,C R,C$R,S%?<')E+GAM;.U=67/C
MN'9^3U7^@])YR,V#N[W(W>VIF:3D;<9UW99C:[IS\S(%DY"$#$4Z7+S,KP_
M12)%8B,!$J14=YF>%@#BG._#P7;.P<__^;9R1B_0#Y#G_O+AZ./AAQ%T+<]&
M[N*7#U%P  (+H0__^1___$\__\O!P7^?/]R.;,^*5M -1Y8/00CMT2L*EZ.9
M]_P,W-$WZ/O(<4;G/K(7<#0Z.OQX_/'PXWAT<)"V<0X"7,=S1W%CQQ^/UK]<
MI.UY[D^CDT]')Y^.#X]/< L_G9S]=/QE=/]M7?(;[N <\8LZR/WS)_)_3_BC
M(RRJ&_ST%J!?/BS#\/FG3Y]>7U\_OIY\]/P%;N#PZ--_?[M]M)9P!0Z0&X3
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M7P25-!?@]N*V FA]7'@OGVR(B'?1,?E##'D,-_Z7/RZ\%^A/GH+0!U:8M>2
M)^C\\F'KMT\Z^Y%I:X9;W.K&]L]_?#[Y>C0^&9^<?<9_^G(Z/OF2ZUR>"A._
MV%'@6UG;^(\E=A35GY;X]!R[@QQ82^2L49_[WJJDG_1+GF"//1];[5\^''T8
M10'NA_=,>@R<EO0\<=T(. _PV?.W8:<5ZY?>N3U/]7_<C?[O(;9$V-C8EWBK
MP@"@4*Y?"/"[GD)PT@T$,[Q0"A#Y)'<8;!?M%Q!"O4^Q&)>P>,8HXK7E>SQ4
MM *33)+7R(%WT>H)^A6 ;!?I!Q!"O4X!.&UW,"1=>XAW4F3C< =65>:HJEB?
M="_0\U3_G[O0/UD8^WAHQMJ*'0$OR&FY_W[AV70XF+7ZA(Z\("E87[H "^]7
M;FQRWD1N-N*#&+:UHI3O$T R(J30?.T"FHEM8[T%Z3_P3A >46&I*-LG2$2[
MG\)QUB$<%_B/4W_FO;H\,#8E>P@%I_/9?N^P0R1BVSKU[WWO!27!-$PXMHKW
M$!,1"3)@6MZ)%_IY[P4A</X'/3,G_*K"/02%W_\,DI8WYV0$3WP(*"#D?RYV
M^^OI>#PV4.W<'F>*;GD+3J(0G?NEY])W>MM%^J%PH5YG2B_OM;4J/;TD>S\Z
M?IJ14^L*I6\7Z8?2A7J=*;WE_?7,!R0.^?%]]>0Y%1HO_-X/=?.[G.FZY;UT
MQH.K-VL)W 6DG&54%>N'YH5[G@'0R?[X!W2<O[MX&?P(08 MH7T3!!%C?TPI
MWP](Y$7(L.ED@_S=<R*L-3\^C/0#*B9;Y?J$A4C7,PPZV16GOI[)63PQI%AS
M$1V*ZN)]0D1"@NQ2KKQ)WEQ#'+5T)!M"(A+Q-P$A2&5@G,56%>\32A(29"B5
M=\QMHQ2/\0N\QU]X_COSOFA=JD^8\#N>05'>*;<-Q>,*.,YY%" 7;_&I4!1*
M%24Z,_KL@M_Q#(KR7KIM**Y6T%]@0_NK[[V&2^(J"%SZZ*@LW2=HQ 7((&+=
M<K<$T=OF5CYQE*#C4RK:*W#$>I\AT\GU]^,2K]]YPR1?J$\ </N=J;Z\6V]O
M4-Q8<W\2V0BW,PE#&"3*NW; H@(/>N%^X"+9_PR?\F8>"Y2XT-XFRJ%V..YM
MK,'V+=U]].0@Z]KQ 'WUG"O3#PC%NITAU\E6GP0*$6\*S_HS#AL(IE%(<NB1
MLSOZ9I-1J4_(2,N10=7-B0 6U ?.C6O#M[]#^A2T5:X@R-GAZ?CTT%Q !+J>
MN8.V?$.>[G2O46 !YQ\0^'2O7%K1?B AU?L,C([\TS>=O,9_4[6?I)3L!Q0R
MG<^0Z,A3/>EBLG07PR)7MH]H\+J?X='RG?D$]]".>UF]*B[\W@^]\[N<Z;KE
MJ_)T=4ZY0,S]VA,]<SJ<:;F\^39\AY$*=HW\U4W5 4KA]UYAQ>ARAE;5?KT/
M:&4IR.EX925ZA1BSTQEF^O;P/W_:#H)M%AI+S?.=TS(U&/;HD 3#KIO ?SZ?
MW$[N+JY&C[]=7<T>/[01_#H'P5/<8!0<+ !X3E@)G3#(_F9#S_0O_EAW>3J_
M1BZ6&^'U@)><7E*B9.6J-AA@=>1) JLY/2\6*O+WJ+MM?AU,R)B4$(L:@RLW
M*K%Q>/(">)L,SDX@SA)(B2"]5=8XP 6 HZ$M(IH6T#<6^:1U!I"\?"07$/X'
MR8?S AQ(L@.%%\#WWY&[^ Z<:'L=*U774(:(@%TF2GV)!T><8C*Z+!==0;D4
MV@C4'!1IZLI+33*@AC+C;F<;D5EF4#00!KS*!T0&\- +@6,,W$R<#06X%K(Z
MQ[ ID-XB\(2<.%D:MF/E_(^<):1H]:(JQ]W3HNXVHI' 6NQ_=X01VV70*QA'
MBD;@,KDB(KGF!66S\[Q:TT62Y3FX!^\D*3QGF5!9V&2*B&!:,;6(RSFX'4::
M,[FL0SHGJLL7U75Z.O[RN?^TD!!U<!L)84KL A?D2#"4S45.:C[V)H.N>.F@
MTP!48]_^2H']DECE226]QM"Y(2NZ(CMASF0AO4L55?GPN"(I.2/M8S^IDO/\
M9=Y[;!4SCA:2.%8;#:Z$BC8<)/.\">#?9[WFXE]1<G@4$!52U=K"$!9,;!LE
M$MP#9-^X%^ 9A6 [^PJG]/#8(".HJIV&(8QX("\+N-"^ KZ+ETX!WGM'JRA^
M)>@2SI&%:.L(?L7A\:2FS(-;252^0"VVV!P>*01EI":Q[OT)1>7:O.8=F7'T
MT'>6(2Y_.]1IQTWV/M;X$H;( HZXT^PITVEV]+=BL_^^]Z)M?T^)(9CZ<2?M
M>#V=O5?*WV;2:A8'PV<\ILZZGBOJ7937E75@>]!2Z/$D"I>X-W_![0@5@1I#
M)(>0C /;DI;$CQ,$"A,B*3U<,C#D&]A.5"(K@TB5X5*")Z2B[:8IO"@>U4FN
M,L0J#X8K#<15M<DPDC6"RPUVI8&R1&;1T32PUF1V,-<=] J#9@5_]=$T;-=D
M1O 7()Q:1<5].1V/.XK2UL$-GIS4UZZ4$D3;J=7Z#\%T/GV&R0MLH@=6QZ4H
M[\?99';U[>IN]CB:7H^F]U</D]G-],[<>._D1>JU")S#*6KIUJ^S7J ;P6O,
M>N(,1/KP X7+BR@(<?_\JS?+B0AC25 +_B]Y89MZOR7=DG'#G8-A\6I+C;A#
MB!M/A[N[2(,:>5D"J.7[3 @YH70\&5UO_ <0JX.$,5]B1CO>,Y$S%8$ZTAEU
MC(-0#I>J@2XKK>;0B]/62?(K=+$.':R!B;U";OS\+4GNSZ8)I];@B%)'7LVQ
M&.U3I:1$T2E@<'00DU!K'$:'\"<3YZU7>K^!4=(X"M29_3GB:,"[;8A)NHH[
MS_6*$F?Y+#@K/Z'*O29"?0FI]Q M(QP_WP.#L-#S.TC?RE87-P[%!M"4<9:2
M>G K0HHJY4;]L DB(_3@0G)+PK.W"K3B165]/1V??!TR0UA2-UTXG"44<>&"
M7&\:$+;)5F6M]<..T84ONRK/!D-V%YNU=7;LBMP(*V)SW7 .YYX/DW(S\ :#
MJS>L8JP&Y +__08OWP*L08L<V'J.$^LPF<:9Q_1:OF@<6246N6VK18-#=\O4
MQ2M#[I:X4*;/]. +HLH]HCM LY"FS$?H' 3(H@!;6;;/ (L+I,'KH6.@+Y$3
MA52_%TKI(8'-$DF##T/+</^ :+'$XDWP9@HLX%VT>H+^=%YRX6"-=ZDV^DR-
MYH*FA"F_E=9WPJ2C1-0Q2K*5 9)&2M3L0*WJ<?=FO&G%/XH>_LGQDSKA^$D]
MSJ87?_]M>GMY]? XNOJOWV]F_S#682KG6U<C*8]0W=;#O-->S4AV1E[7XT+&
M#60I5(IAW5RY&,?@V:'"<7>@)2*2YXT]-\Z/]89H.S5FG:+H9]T?:PL@PX!3
M6$0CT<T% WV#9**A(%HJ9RZ*PH"40163D@JD&<EWF#@RZPP24WF)S?$]+&:'
M80);77B0B$J(2KT5:ON0I"CMI;?"$M".2*K*#A)(<4E-<?U82XVW.# ^I>>M
M@-8%S46PUK*'+1?CPKZ[M0[>@_L0[^,N8?+/&[>\@G_P'.?:\U^!3SO!E&S%
M7-C9"%9>:C46W,@UL++L8P:@JP*DJE$O)+@B-Z[G^%5PS%,_-,!51_2$DG,P
M-UQN",FMR(/+,&H0]24AS9>1CT5/WK./<R/<P=?X%_H"0:#NKE"HMBZTIJQI
MW^>+HHADB-5DU%;EW::4B#(T9U?MX*DH^W^C('G38.91CD-BQ9!+#IMLQZ ;
MQ!1X@%C] 0KA(_1?D 43)3Y RUNX<2NLO-^Z/[LC3.Y$C68E[PE73S&KCXY/
MCF)FDTM$YJSQ _@^P!J[>H.^A8*2.XI\ P-GFR*%:$WK(VTYI7B33 U-B$-I
MP1CF*,)8C#0RRM":EK3]^;:A+^O@;(NXS(J\(<V)\U%[M'0T1%:(2J[(=3(Y
M0;ARRR$^_3Y:&B8WQ 17Y"0I0(U6O-\N0+"\=KQ7T>1@8X[3V\7D\;?1]>WT
MA[G)P7)>56OIQ5W<*JJT/^633MS[W@O"$)V__X[7.C?N.NO!Q K12_)* ULJ
M^8:,6SR(8+FU+% ALN88\BXR2'IS%#+6D)L"QG% $:9ELG!D'MA.HG#V0PYN
M7 LYL+".GGEJ#(^.3^T.+5O3WN R(63Q<<6C2]9"N%38.)JUQ@;*BEE,0X.;
M,,M[D+4^TW-R?M)9P0;VE%.FM<%9M+(^[GWX#!!YTC&6)TMOX=IQR@J2 3>D
MK?'J-68</1MR1(1TM?72U YR,L=\-H" $\OR(I<\EO?.B+SBUMM%6HFH8'!9
M2BO5X$=8CLUSDS(DVJJZHSP2T8(BAR8:E0PQ1D03C\ !?@T>9?5VF$1,%6AV
M7VJ?0>*;]L9GJL9Q2MN!14.=:$W+W/Z2G:*-]$F;YL?WC(:,HYRBXWM9D0>W
M#<0*L2"TXPQPQ#V&/%E]0_SN@',?/3G(FLZQ7*RGH 3K&\<@18RH//QOH)*!
MW0WDE9&Z665>5HP+(VJ5W621D!8&]D!RU2C"MGZ3^D#"(!7JY94W/CP^.OG<
ML5-*JX:(KPK->[M.'!T%]=MXN;0[W&JH$ZTIC3MXQ!NK@OR/>)"] (?<;SQ
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M+%.@2/J!/4RTT4_V%B]63')F@#<A];=>4JT-B6;-!=?Z@M&1_LF'FA[\$H8
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MBIWX+^$<68C^RA2OXC )5%/NQAEC.,SYHBBD.SXDO7%_+)&U3%-?_ :"F?<
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MO^)9V8<@(@]#1P[Q:F3F3&<4-QHOAGJWUFZR$IKBT$YAYRW'29U7S3A4.[#
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MU31MKVO//KT2WE4LRU?-"S:V'2^&?_[/3+MASDL366UD*O+-5:=X,^C?P;\
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M(-:IO-C=XK/@O&^%3H@8:MS!"D(>A6^R,#H <L_6?)>?DJI/T-L$)PW;I@
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M%*03$#856"M4'20:6@V,,=\G@!-!&*1KT/JBES%4+@JJ'=_$X)'O!35UE-3
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M]C'7V^+E_OEHRQ%L>.E_;._\MOB$(SV^WU,V%;O=BM6F<:WKSO;1)@Y7[''
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M):IATC3%Z6+[K,A(7VDP0%8_.MRS"B2*)Q1P8,GHAW+!WCP\?H/[<.Q.&PJ
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M]K-8I>LIR:JR;=D._(#")'$HN7.;JC[0B++FN[$]BR87T&S9?$TQR:7?0SN
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MV3T0[FLS)9X/]=3U6C7#;'[%^10/90$<;;@)%;LK?7;"M-Q":\L9H(Y-7ML
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M_ ?B#H1#$IO-Y^-42O%-SN +09ZD]$2S4'CT-$T&1:!V@#]&>5!DR,E^3H^
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M#;V6GN.":^&(:,^(Z/+=#5+,*5.,(PQ'&(HPWJ4^Z*R/R4@<! GX!Z0B09Z
M#D)Q<HA4TW94XZBF0C6_2W_@!V/20KV'J&/+ "O:#K!B_HX> *SXR4F /9,
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M@_M@= ? /:PU"*D; 4SE#)N?[K"E<*G+.=</@ :;WFFE%P"[&M2R%^(YV&*
MA _*W8-?Q^0ESJWV<4L%L3*!\PS!U-"OJ3S>\B:7,CE1PGRX3MD99%\LE3,L
M%%K=UJ) 4=_.RD.!G^F;TE[7_#)>3;@\0GO=(UJ.GBM:X)<_+%J.CDX]RO4;
MT;)E)EW7F71/KZG<M/VVJGG]"R4/C,118;Q[Q18(%B,'3)^9]OP.2*"TCL$E
M10?("C7J^#%_HW,"WR"/MPQ\\%_:/16+X[]R]F3)$]IGH"BP50TLN3'<'*RR
MB'625P=WEFJ#JLXC7]524:R;3"".>EW[X+.II S&[)%:7C@L]A@CU@Y0X::,
MI+[-RAM2RS4JB:/D17^:3#$H@S]/99 6(4<ON'.3&O,BZEGU.?@)M("ZY\ D
MX"M-H+&\TXL NAD.M?U:*EY*0=%9FR>@J0P*!/.6GU0ZS4X$ A7@5RF*AM8M
MI1I6T:2^+M@-LN1R'8EO-TJVC,GJOV<8LAW(J:0K((^>#S''GF#5(OR5XN#*
MYBXF\ *X/S:\36C*F$8J)]@^Z=EI7\4QNOG2/M[*O3RY1?#>B6^/G-4V7H9@
MOJIHF#4&BM+YRI_J1.^S>R9'B)ZG=0S]:T[,;GCN2W6HROB%#JA][!VO!'-Q
M!P1OZ]Z#^;-E!Z0@N>:6UP7+LF=X<$U\=^H=MY]R:C^LQMK3^;*U*@;\0\-+
MEW<A@.TX_U>TS=\P8 +\:^'/'*@B:/RW:F2%DK!7I=HSL>YSE6&T\.A?C)![
M7N=)A+R6*[D/M[\NEW0E_N%'A7RE.WA]MMB&._A $"[B!EY>O8?E,@N\875"
M*T&_)B!H(UF51X]&7'PE$;5B\II*0"]U8GYLPI8M"39_& \1YKW'@[Y>;TVG
M40O2^,'3..JN@N!<86\_A7%JS"64!M9!@/5QQW9=?JO57A\K;-?6C\Y>D.XW
M+Q6><!9S,:U!,B$,6Z<O#),L'9:SK_JBLY?Z8B&TN[\J8XW6TW9M_45-I<T+
MAJ=83[HT/%6Y"J<N2@;IKM&FVOK3Z.ZU>T$5I7NK*4Y.]E53=!9WOJ>: @NA
MQ<"423L]81E2BY;T_NJ)H].]U!/$'CYW%.RMGFCO;1"JZX)0ZBRX.\BI!XLK
M6DX]/,@H^PU?\YAZR7^.PXA[T74;IND:KQ3$F[Z7>WI"K (V[.NT&MQ-3;\N
MM$/@>%V]CM^3WP,91=(J?)LJS *LB[.FZ,PC^XMS[A2@[Y2_:8A!FDR3(M>C
M'V)NZ*<%1#S) \[&5(W3C _8?*4O6B $PBA)L;<S42,"X$<77_YQ^;[9/D.D
M'ZG:>*N/[?T,"YLOKC/UY]5W\/IT*6<) :26]L8FH$H5,)51<^&VDOZO75CW
M[.H%0M#BVO%3;^5XO@V402W6/E5+W>\K$EO#:72.O=:Q.PYS'#VOU=F%XUAA
MM!U3>\7&>.F%E>*#=3Y/J.1Y305[7Q73:];W@8;X@!IBH8!L$X+F99MR-GG6
M5ZQGS2GO[DX__]IIG;X(-3U53N_N&9/]MA^TU#Y^3$GE"?47WA>;F%=@FW5&
M%S3 HK7_B-&P"Y)V\YMZBH>]JK=.M$_$P:G7^?D)8W\7Q,2.'$6G)0ZPEW/Q
M*-;%")ND>CU"Y3FTOHVWV>[PH-P?(>QMW+<X%0==[^0%J7CS[%XYEL\XB-3?
M8Q$NCL1!&R[&B?!7(/Y-4OJ?*<_]S7&$]X]9+]MXN6W0ST?[*-%/D*B7F6@[
M*M%OPKC N%RVST*=+OW("?77H/]-$OO[T$_3\?,,F.V]S1\C[.W=]QY)\3^G
M4T(IS*:A0I)>@]VR^3VNAQC:XJ#E]9QTWWGI/LNF<IJ%^R/>N^B,[J%X[XF#
MSHL&#S?/[U7*MDJ\]U>.=Y#:6TZ.OP8#;#1GE"!>_=3?IWC+.HA[*_>],IZZ
MHZ+\ @$5G11W4OPU:'_3 70$W4QR&<:_!(C\&<;X$0^N"V/\*).#O9'P:W!#
MMW+?^R;ASW7#V?[*>!=QV0\9_UN43&1:1#Z.>(WTF"[LR1 #N6_R?5^#,2OW
MO:/R_:-&M7/RW<GWEZ?^C9HRD4\F.SPJ3D"\Q]E0IMA!N'_6>PM)?@_C,_?3
MM^X0YFZM>O0)KZN1T^X1]8L\T1_P6!CZI#(]QKI7]1W\A"G@[,P[/5,-H8\B
M&6J&6TXPZR60Q_5"XX1-,Y#:GL!<F1T[\'.?1MWV943=S<,D*,R4W&&2WOGI
MP)[46DYTA4?C".)RDB[.D\:D!_W3Q[&]>*LTL@/>/Y+TG_#=L7XN3K.F4;,9
MSG0O(AYL-9'2ZI/^^/X<.Z$_^6DPIF'&^!6<\5QD/+-CDF2Y\*?3-)G"68(9
M&\,9P5G+*8WD\@>W?AS@AGC5]E9HD$IUSCA.%+\<"KK;"7=$TQCG%,<%RD%#
M;45-(HLB[NT>8";?9WAZ/=(%QZW[/"$55CS$*=!J "X>$6T'CN87>&>& [Y\
MFIP28\MUHA<IX(]!TM3_I5JEER[Z7B;?FKE41VXNU?P=O=)<JH56JM6"Y=J:
M!4TC?TN&^AI.:*KO1L ?0):,_5NI9E7CV& 9CX $!D:.)!IN0(_U*=D(I!JR
M_E?US;&/> S);3A0/Q^"$DKND+]'13A N <S0W&*@/MJ=-)20;GR;3<A/8=E
M8)!,^AAM'0D693+'6N9!DO$409S=;2%$D,"[Q2F-:3'*>/CW,/R.'\ OU,/8
MMX<OXE1!E&0#6#I(2- #<$VC$.4Q+HY&S?,09#U;',X _\*O 1%&;7+BABN3
M_L^_M8];;WNMWD'_\*!SR/^I-8L<(*J&^)@D("UI/CU2R4623?"ZQ3FL1$^-
M_/C^XKR<&'G?PZ<X #IG@6^M-L'97^(S+/:.1F/YN0#> 7V0X8Q'M:+0FGUM
M9II7-L<S1 CU0P] +Z>H(?0'SIF"(Z19Z V4RO!SAON 9T0AS:_"72(PQC@,
MQG-_&O-@3Y'T<Q^X Z?4DD#@D8\*,92);V[?ZAFT=AFC3,]$07/7S>_$M.A'
M80;*28"=!6=/.D:I%G67Y8Q[14%ZIAB1EH(LP0U(&A\!@B5&: ^:@+Z*YDH5
MG?EPV#[]# Y[!,>+UH G_KR'9LCFF(*OPGO!R6]3V..SU\J )B L)*CC6WQ>
M>4"9)* 7G!>&*S%&T)\WX@KX-TC!1$7[P*(3TJK^Y#9,Q0%(KB ,(A &*2R;
MJ.0SD V.H^&W7LA(@IKY+@X"' ^?? _[^HM70Y!DJ1X2KQ?$YX?O0+:%0QVE
M_F3I_2-I#\%^AN61M4$GA3R=I)6MV')'/2^K4"U?%!QQEJ3F5W,K:J!M,> #
MT=/-B'R:YN97'UE5=OI !6S-X0YY1WHC>.O>1C3$.8^T@W,)HD(+$%R@P=@Q
M ^!XA" <0:?5/D%:'<MH@,)&@O&1#)M3_@49JWP[EKV*1%$>/LWJ4X/V\&-]
MYC@";\'._8PSI?LRY>O'EWL(^.,KE""^.93PZL69^7%%916*/7VXSR&)'-ON
MQGOA+7<;UE1:NC0BH1R3?6!IH++PRU'@?"A*M*@'J+%_9& 13_,2X%OAA$S?
M[R'::J.9^C4['.ITX.'C BQJ<?4W]6=:M6$C.DF+_Y1>8^),8E"I*!)SG&F(
M4A>/H"_5Z&3X7 X.>38D:HS<1E/JES>MQA:F29[ 0EGPJPE_&3@7< P)S4&&
M2X/O@1W/ $AFSF+NXPS"@99,D=_/+"VZ&4)'5IP[6.4(TIA'.K2&8#_/QZU(
MV0336 1IDF6(%J,O2R+ 5:,\V*P( I"VPP*G-YI3]I2A UH:Y0'2/%@8W]$P
M*N5(=3T-ONDX(='3)*@JPL_VE8S&>XM1-:"HPR?:&%*9)S[I*9!D[\!CC;EE
M%GLGT3\;^_A,B4,>!XPSQ12:V9X:4B7>6E_F2,=D[=#-,M'\#7\T1-PP_9;-
MW*LV<7FBYM*[4()=F3EGK>8 [A48H!D P0+%SW,D&CM&""4I6T/&=C2'JNPA
M$R;(BNF4!FOBKZ8Y\3K<!!)4D2G^!,%JX@Q&=/ I5[Y4D209*A(P4'_[XTJT
MN^"2@&\\ A6?+A,FO'#Z]!N(!3AK)AP4EP'2\0QI,DP&2T0#:3O25>8]^$[%
M+4,!8CB=)4U@:MR:I5]#2I=EMN1D3L(1MD \MKPB\YU4HS7YO(@-;]#:@0BU
M^<F'?8":P?H3SDZ-5T/)?8OQS];WC>$+3F4X*&B>:473LW8A2ZO]=K6X!:/<
M1)%""N_<AB _X/$\]%51%ZF[E=35*-5;1H0ILYSC2TQ1?I:AK1DE^!F8^? _
M"*Y'&4I\\K=P$,N9WMY,$\WJ%VZ&-2]A61A*0/K6S*'7B'MKTMX4BY0S[,D.
M+FV%"O/>P[$T'A[!"V5DE$V%U8CF,FE^H.EF0#Z3R,+O3=!MZ,#ZN6(93!NH
M#P?)2#_F8H[@)'C6H5(0^G:?0-M@S3R:MA?H&G:]DE8]L3%-.^?TXV4HH<G6
M">I$/;%214.+(>BD0@US+F4WW,5'N/,<W'1Q<%ZD((\;XO(/L&*(/4HY'8\2
M&C8,;Z#H.BNP@_:INL"Y/Y3V$)OI2EVCS9//IM)8!)657, O$: 2U?_ PJOL
M',V_9#,<]YAL"'#EC9SF9%)C]+A#_.;'<0)VG.*W/)F*B*K<;/C/BO8R5N/'
M3\+ <,Z%U$OS%N6DA*,;O'EFCN.'TC ZH(LGI3_2J'VTAF;DSY(B?T/A(COD
MJV.A*MM9R7JHKYWRW^:R:)5%8PPPH\S =0*4#DNF3W#I2U<]GT]! J"DBG6C
M( CP/JU%5),K_^??SHY/SM[.KVLN [. U?<CL5)ZC@8.LZ.GZJ.?_FL^.4+A
M/Z"YBO#7D]3+ >Y@!2?+;*>'!KLW0 Y-L P_I;?<-V@=E0T9V2!088443"87
M,01;7TT ;&@4=A)9>F !6GYZ+AIY5CS5'<Y5@^F&$PH5:$L). /,H%&4]&'-
M8^ *EAMY@6I:,<>V9RUZ+FOQ]*R%$X=[)@ZOR&6P!")+/[0MK!BSC%.X>_8-
ME;)%RT_%G/0/?.6 ,$&!)!N'4RN45A6<0'QHIVH8;_E]'/;#G"8"PVF ^VPE
M9OK@:0[!U;E'.#G"W3/"Q2.X1XES,$91%85[(]")*=4HH"D?%W:);8'VYEPP
M2R@?P$_U@RNO!-- @A_/D7-$;JT1<;8<;6Z4-M&9OH\V*R:A_"[!O<.LLI5%
MRY,(##?E+.J43S64L)K<%N'YD0K:JEYRC15F3XN1ZB"E-8]!)0S#Q3D/RS2&
MBM]0)DV:5+-RZDWNI.+X8S;/9EO6;J8@BEYSBZGIB?]7DN)AZX2YT8@H!"9%
MO#&'^@>+L>8KK<B16794*\JN*#L'_K3*;)&G3DE/_0),''+:U#?/5<E.%4U,
MBFA@;F^N3H#*!/#']Q=EK+4><;&2<*ZV^*$Q1H^J+JSQ8(#70-SG+Z*4?URQ
M:75805GV_1+7\,/[?[@H6#RGX/:%!@8]H8H,9,@WF:O:H,D4'FZP S81PZ4<
MJ)B.?5"L@2SH\@5XXJA7@R)-X1]V!<P*Z=% 5V;D]^&V8G'PQRR%QQR"ZU%$
MR7<4:E(<7,PF\.?<Y\PT;"WV@W":P@T>W/@@(R/\ 8IA&LZ34;3'*'4[C#-O
M0\98_S,A$]3DMK7&\\1[Q)G*)4G8AN"5\>&K]8 D'TD:^4,>&4@"4)T1)Y-H
MV]_#"2P$#N'?VRT!)!91.)LRQK165F=A6AX2YI^X=BE3Z5[]7IJD1 %L_8I_
M[WK'YJG*#/DSIMW<Y#0PB&LQ3NVT&_]:AZ] VZ :N9;#" M]5 ES+-5U31(X
M5%,S1'M7V5XV@>@1^CJQ%D: J32"!Q04/,9C*//%JJ8N4S>546V>+IPA7>2K
MTC%U"&H1NL;P?"+Q)&)Q'OA@HY$Q<#V6!1PQ)WIP>:AMP79+XA&5,Z%U(.,!
MO/,V"6G_R31,T*L%=9Q@;1W&!-6!,X5R!_>(7OL!D]Y4#C5.[JAL)-.52'JM
M8QE-R1].N*IZ*A/,L-/5@9F":^*:9X04%B,R-U,*&XH,ZZ[@8,FP@</VOTG^
MPQ2(-,QRFP+]O%'60.O58.K#"I;BDJPCY9V2IX1ETB6QE0P(C <^P*8JBX(
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M@F3!C?"*(+BKA$AT>-9H';4:/22WCQ9I_3\6*M"*(D5Q,+3JL \;XN+C#5I
MX(DY6G2T^"Q:;)]T&Z?'W4/+WL"T+M:[@(DR7$&@"$FO>Q7(3J32@(_*!P2_
MYR;!HM4 +9Q!BC#&95E^?4BUY2BU-I1ZKQI?M).)>D%S=WKMQFD/R-?^BJW
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M1A CYY#L@AM]]<KD)6!. N(P''(O'-C6JW3CI-8R]!084>BCZH2GF-C>A(U
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MAC8^1DLY105[%\=4[1W'LY )VH5*GV_FZX4]'W Z\M-,.[LGNPV?^$0^@3N
M5HRB\OQW^/-,E_31IQ,7!9D_SI.%#MH(*_2'.(7XY=Q\>W13B&''4/"B\I82
M1[NR;09">I!K;ZUL,(RQQBF^T7WK#@+TG#!!ML/=I\RQ830KAQ#<XM7?TP^2
MT$*P_C)J.1[_+'N22RL%,WLZ'#W5KE-W?\HMI%?-*_,$1-\3+^395=(I&+C?
M^G2ESZ\9_*7@^M+ZH:@=Z^RY5!,U+&JE\W!=EJ7&0X8@4)_JQ#W:"%WF--L+
M/N" _0@@JH:H[^N^^QA9]#;XZIY2B:;8Y(T<Z;R*I(6'P/BL7I]QR,JKF@Q4
MC--V$O^33""OO///]:!(+\N_]F#"$2+-\.EG_.I6P>5PS6I9A)B1S\TWWBZ_
MK9T!:5(JUC.](CJ()-;)W99P$ 3GP,H][KC#YL4KIL9)3Q:QH22K2XSO6$DC
M\CF6D5-!U4[XO6D3QMMH7W4E#UFJ_FMX[$^>\,5#J$)IIU6*W,K<LF<_HG__
MY,G9:[H"H8P/'V=\1B;*(OSP&:94MR:.V FHG99 V!REML>-(EDP'*9"UUC5
MU9E?0B80B'. $J DJTQ2-F;9<1@E$B_^ZK6B>Q9H[NMOX%5\9.%TH>@MYS&R
MI >E-;/H)1+['P_ICIBX"Y<6+) !.3)<0GF35T7P0S0LN*UO'BC'^C8\KO0A
M'EH^ZE4Z^S5^"=G$N43&H&_ I\4R?^*U17*53@Q?G7[+F0J:Q=,-"1G1(7O=
MEWO;H)7J"^-L3(I,"7%W/BS^^!XS'DP&X-8A@G*Z,<>?BT.?;WV%TN8R"<17
MLDI<5XJVR+?/7QBC0AMS7E?B0IV0*U6[&@*,5L#C7>:+U*YV2?-]-HD+SO+P
M^@@!0CG@I6J.)]&75^\(-Y:JE*PA+Z+-I(F*(>X4ST.2&R@IK7E\^NAWT+AW
M-=CD85 0E(@D60 3*:.]ON:.CS#VUB&DZ;<LIXD "'S-)7F;)-F6P>-EG%D'
M(H'A$:P'*9;!?X6;I[#Q&[9:[HUYFT@6BZT_&YGU$F)#="=6 S[<):EVF31>
MONH0T==O2YH34934D$Q2/=TOON!@/:T8I-D=F'K22+M)'I1G3ZI1S4,?'NS+
MZ[IO_-8JQSFTE"9/A_1)F">!'4%2$7GGK/G*-^0EI/A.):"4^[HLNIL"=;J>
MN<&'NS]/)!RB2ED:BN9I_)$H"70AS=L4(A><@P><I@Y.A&)E&W5I99?G.^C5
MT\^'[[L96A",=T6<Y3O( ?S%V=._/!L_2<PZCCT-',C#X"YD-6/=C]S00'!R
M>@]DWH.3X'53%&?8J_%T\KMVQ.<QJ0+! R'<PH3)#14OO$8YN7W7-S#JAW'7
M*=*%BZ,5R4,<'(.&[D?:[B :FK).>'ZD/_LQM,*('YRIKA,V[_B6D^B-X.=Y
M&]OQ?Q&R>V=Q%I,NWEUAD!S5=I"I.U%!'3%'*Z%?C9, <WOW.-@=(PPAXR"7
M'G$V&F&*/<,?V>L>NV8<GTU?.0J/OB)=[.&YE_AP]6L#EP9H7;%1D3T65M$.
MSBH>&./;>"Q#W&_C@/!W?=="U>!J('GY,%E(+2L7:RL(:HZPM]$@-;0'9%=E
MW <.#\^RQ\0]4FYH "*8"XA_IL:G%66CGYYB#33.()KK5N9X#'%5'%AD/M,9
MB,$<DR>6;IK7?LF8=V8X=6ZW9-!H2VN7=;.OT51ST@DVD'8<]FA$^E-HSR$D
M<EV@&<MDOK]/G^A[Z[33JU_WD'PQ!)ULOA<O+A8?63B-'G+9%D9\\^R+Q>L"
M&D BXRI__^*'Q3YLS<6W=7.3![-XM2RV+ JR6OQO62RO2$&]*\KJ8YG*M\!:
M;>2?89NW*R&+9[NBJJ$</D:1Y8@T/L2J^U=SU?W15=T=(0MI,M+QO:1I;($8
MRJ[(F&R%*6Y-Z1&:D<B[$DDH2JAPD++Y<F7VM;FOB[Z[JAOAWC.(RFL#J'@=
ML>ZF)F8CWFI.]=1?XH^DK_'5^:>?/<[IH$<Y,4%5QN?!\OJ*@J+7%ZX6 L(K
MBSQ?]$2I&^Z-/FU(H(C.(KJN1FSWC0)B,I)XC:S%)/GM:K^X4M<51>3XPO9X
MX_G]_M83..V'UOI$=B/RA? >+XAS^& ;X<5K-RB*H%H?B;NO<MO!PCBV"><[
MXW6:$@>#_M"+"^[<3#X:72ZJ]D *3+ ,MMLB\Y/F(R%7Z.((UM@A9*I_.N$K
M<.Z-_UI@D*XCDZBB7[SZYEVV8-:\+.0R8?%6!4./4(A8E2WV%(&VRCPDWN!8
M[KOZK"2CX&'YZY(&:D2NMKUE4>J] %77M6.*DV(:>S)*J:008G4@9GTB&)]X
MIEB!AO<4]&=*C$TL5XS_&7"V=1&*D3FX+]@_Z 4(T Q0)B$*92-A_B!I%?#\
M"UXE84*6<0)-@I8_P?S9[$_OY4^_S<7Z7U]8B@*;2IPI*S:#[XFM'10;XG>F
M ^070K).T8(!HTJH;NV%I\T\&&==D:0MV3BTS];Y%H4V)TT??5F[#/[5?/34
M-C]?_,CQ1:+3G&^#XUEI#3GNXA0.BS30/Z)[PHRK&6X-E>B7N'G"[A:GH#RI
MR67\8?0Z)"<0[<6WL,/=S;]*-:"TD"^%=YI>\'<@9?SDMZ3:BJH?5Z82P7>Y
M:2LMA7RVWP8O5W#)*5Q1V<[2=^T?X9MB.;GTCV ([A[E@Q]LKC*_I'Y2; U&
MT&RF I;0)=1:S>L+KOR$PUPYFT[NFAVO)!<6RL'&864[%(?*]OV9DC5<YBSO
M.A %LYC%'1SAKL/V*B%,NY1Q1NJI"!8XFZ2R?"3%I6\4N!PSB$?0_[0][^9(
MVJ-^0Z5HI"0> R:\@#5'8%B-09<0H&E?^..R@I^H"2G2X$M2YQBU%8_D3QP1
MC7Y)*IU4;$:!1YM)X4Y#(*A%+H>719&69M.XRBY&69Q-P\%1B^9?E>@JADRK
M.D3HL7,\6CCAI X_C=_BJOCT_1UYYA@$:875]YQ';\(0)"F \LC-Y=3W:MK)
M8/ '7NV)5S1<[]PS]=ZR^")OZW)PW>$&B+?GY4KWTR?^^=!(+1#0K>+#,LQG
M.UBYHR]E\(A/GW#U_/BCRD%C?2EIA_P4SIL=7@.1GU9I<R_S%7%>Y:E]TP&)
MG3QD)H'"M#TH5N$R-LV3?P=G^*"OXL+T9#(,QI'<J'/%A<&I10S9Z(23'^0@
MZ(IH9&G^14S4)PFVD_0\ #,/<=V&I$B8>:!L(C?!1+>/Q:M_QYDB<.C?%/1<
M^:\[,?XSW7D^SE+53E=RFXP7H-H7/P/#[QFDH/K.$_.?_HP&F%JLWH %9;ZI
MPM8FGDKV 9+:)1DQM:C7Q1EUIZC;*T25RQ!Z53(/NBK0RF/NDMB"9%Y5^CLH
M&Y,-HP&X9E#%@B9+@OWU+;0PA"@S>@UXW E0[2Y?%4)+^1L^(R'L&FEY)L_'
M!%(\ZDRG"Z^#>^SX!(96H)U!U9.RHABU)% I-\BYA:<D^JFW\&ACMRIH54I!
MHO LS4+O&?;N/_N68:17OL<^8&=VQ,P,,6)&4/[5MH@/U XGFZ=GH3ID.")L
M5-4AONO*=@VV^(. 6%D*^2[O@Z-7MZ+_ZDEZ7=%2<=9UXKA;T"QV*= )^6&^
MK2PNJ!+Q$\3">3AU;/"0Y,_9AC41Y0H*W]7OUD9*?,48FK**KBQU$@-?0ML&
MB1F2,'\0I#/SP^OGX\%1M^?.78P\/KX&'HL4'43O(VRR(;!A?&H[\%+9'C_5
M1WF/I#;,AOT!=JT^?3)WK>[?M<H7Y>K__8]_+/?_H+7^Q]-_/'OR)=UN_ILW
MM";S[&R H3.MFN'^.A8@XHQ#BG_J,WP)RSU&D40"IO-R/Q0PG]I\(_Q6FO0A
MV;2&@GAE L 2HIK[^,5*L.C!J6P:8H2X%SG*/EP])\4@.;G*C<2PV[R2HLZ#
M"8:TNG0[:KY?*2('A3<BWV;1AO*G82:1:P?%&OSK<MU=Q8]E$AAX,H%1G!-.
MUVU=;0CP6Q3">V+U%I8:BD[7G0]L+8(E]L/5/H**$06K08;C4+#OG8\MIKSU
MZ[$163GRNGZOZII4SB/>SA;C/)!'@U*E-GVH29$HVYS.H*AIK%@RX>T@C:\8
M&/VKIS*9KWT9="U&,9)G2D<LDI3T>-%$OJ<@WLO#J0V7(?P0O*5"JZ2*G?;O
M)!\9M_$RP&V*ME.P97*>29PSL!NKZME2362_'PE2U8<,9C=,EAIV[35;;S0R
M5#T^/G=W:M6G-$%Q9L>SS.%R&X,RN^"78Q$KMVO'] ?C3QR4>2,;"Q%9YPW4
M_+HZ,_4'+W>)>E4J))@EM_9K)Z1W2S^Y+_L\![4<43K5?;-\()#:!78"5<RQ
MS)\\S1;/GCQ[!A305;YB'#&1^IXA6"R"OZ@/!>@:H'H+]E_*7*_"DR^B:(W"
MW&[JYKU2\4@N1G_MWU(P(4*O,=5(W_%JP/"X0%FRZBY4MS!Z5)OV%$G5;>--
MB9Q0E*8:"*7H/U&# ^>0D.:15V52C$-*PXG>=%VMF4M3RM61]8\F*8H;I(5X
M'-QH5VS)F?6\.8BYXR#(-1:]8R*U"BNC!<2E4'[AGB/7!H<)N[SKBE]5??$>
MMOHR7]+6*1_(/.\5)OQ8*!\(3=&&926>KT) EVO5T40&P>VGB$2V\='KLL&K
MXR^HHY=3-X2N#75#V@+15 AHI-+,7<6]V#U^X:*JN(]&SBJVGA[@%?Y87(88
MN<!OCR/CIY])9!S_:4T"4O_X](OPCY__FF'SZ>3V7J_Z.VA,$9\AP1[DM93M
M%,'Z;9>:I)N_[4M77;=O_^LO?[FYN3D/)E/6[7G8PS_G2K^^:1Q?5>+9YY/P
MOZ[*57@/@ )\^>S))U_[NQ!+*)ZL/_GR,G_ZC\^?//GB'Y]^4GSYCR_7ZZ_^
M\<FG7SS+\_47^9?/+A/;>=45NZ<7;\OV_4OVO_]X^N67GW_^Z:]I0_>P>[H=
M#HN>7IPOZ+86<E^_91GZ/F=O-:C$T<DH!,\LI7==;Z\Q.H33=570F84IZ_ P
MYXO_K^Z)I8JJ@(1M9NI]4Z_3EBV?BE%RG*X<>\D8*K7@B3VB9P\9M<<2OP8Z
M02+3>OKD[/^>+[YS\EI9HM1<*;5^V*C]5N0PH\(6@RR QJ"@7T8PPBU0/+H5
M>8%\1:-D5"*U4ERY5D@]5RKY>3'2H7*J+6)O^E'?@Q&!.PE2F%@FV$.]?"\_
MOP*15''N-L3?BV:5=_WN@<SY+9[M+94Y.#JBU7YI:_Q&"B%XZF\+B;4N8JM6
MXLU'TH+YL> B04@%>G!;;6M"&H1LBKIZ]#][>QK*V9;EWNK+-Z(B2[995KUJ
M$8?ED(MHI8.@$6U1,) 'H/OSA<CG@>"!?GF0W KJ434NZ5C/H<+*W!\AY67R
M2OX\?.G#E![D.7(?2H>W02%("I5D4LR#D@% =)KR;]Y]1')=MJR."?:[H^\$
MB8#Z!:RC?8X.8?ELV%'_^?19]NS3+[(O/_D4U_S/IY]E7WW^)'OV^9=<=8@\
M4[XHPN4ES43X7S0=P77"?SP- 7^2L*0?LZR%QYUZC*[1]'1!!0"T$_[SL\^S
MIU]\DCU[\@6> 0_,;!\IAMS)C\:588/0E@O%]-<%&:#5)_Q5K)+@KG6^^+Y&
M'U]N%;B>ZYHGPA@OB76V;=UH=LC<NY+R@LLPOO=DPA"S14=H\"CGR)2]93)5
M^=UZ&3\6$&OEQ(QWKV^_.(Q)M-3!]J["#X3SDN1/MTFO72E^A;B03@Z E5CF
MF5W*A,ZS8L@B:Z!?8E0R"QI-&E+$TOSSE,RLI*/.KF+7J9[6FD:[*@Z1?W_E
MY*/Y*=!8C?=,Q0_>479;^RMP<Q3ZEB%>;'!AU:M6?KA5G[**3#U\Y []7E6P
M^3#MZ@['>\O4\[K.;LPMU<UUY3M=H^!-:1.AD%9MMA]FE^;IW*5Y=+-%?JK-
MFKQN$YPO_BIE;^68[L-&I6;^L:@Y;]MZR72D.$P'_!M:.4^\Q@T?TWVE]#AT
M+M'AP4)]='^*AQ5(09R,UZV[8EGKEIFK"0S!.I[KS$(A@LS*#_ TK\XI8&+S
MGH<4?L9%/4X5VH<]"$#MSG ;:/D<\3B(U5?LD?] 0U./5$_I42+\O0SS&YQ2
MGRQ>OD[HWY4E?L :L$[.2X]WL]'?>-+,ZI*SR:G)11P<A,DS#XLVQG.&/'*P
MIE/G1&020LBF!Z%2R^T#'\HAF$SBM<R4'B;#R\@/*>FE#%B/@Z+9@&<#5@/6
MPQ<,@#K7+SPB<*33'2>JSJWK;5G/MC3;DMK2%0WKNLQ:3]EDSC--6@6-6Q6S
M4YH-R0PI_'@LWY/]Q(*5<(SD0@'F>PGMH87P;@1Y![/RM2O[2X_S&,(%\.UM
M7E%/0IA4Q@E-09J#A)]QW71WS0<28J9' 4.-L5?F.AX=>6VD7OLGF(^>=]P]
M=MR2):Z GCH+%D-9-__I&DCY8;1)46C;%MVCT'Z\1U_C)9/>[E!C!(FA!_3I
M3%K$W&2#L)S<@RX/A>%N2>B?;%Q"JS5:'6&.]G]&5G$M7?@#\TAE*$NI>[FG
MRNQ^ BL!)^6SKQ>C)MXWOEAD.L+?%RVG**\391WZX;>QSJQ"3H92"?]\V^\]
M'[K*<_WVA>^4WOCJ_+C/YAH^]*-5L6%*C&4>$JUU>/K3/;COT:R]PT70(+G*
M);,:-?WHGWD2@EO#HN-#76FTTJF?R\C05DA!(?$A@"P%8"VY,2I4\U9]<TQ=
M[DYQ#XQ%&ZL@-C*3+U_;-/5-=Z77LDH9N A2PS:K%&ML,6D_JAV*R4_T%?QT
MX!2SG(STY%OYH+4ZZ*2X%&Q**V5%NPNA/HR5P84PKF+:OYTJYS,)2(3<QA(E
M ^"YJ#@H)+Z@!D")!U[5TQ\RNCMEYY8EF>S(LL ?V-:8$)!MV6GG"0.?OXFI
M!;^M];O@R9E[_A;W3IB=;@J!H!7=6_$/CV6>\D=YQ:K#Z%,,0;F2DFPOAA^!
M'[RO^<VOB>,\?$RJ(G%:36)+<H?3-F"=N2G\[V2Q&[6;A^G;?Y<L 'LXPNST
M!(]-CAUX(E;#)H\X0$:@>SWMHUOR3I/7<CVZH[T^71X^2?-PT%U-.)Q8_;HI
MC'=[H@>*V[S-..RL,,+[0;A?=T(%>_QM2N(A\B"J.MKD99O\)!EA..GKFM1/
MB#Z^;]J>8!1PG32@LY7>_M2:3'L)_A%]& RKTN^S[B9A6#J@CH5G9L<4BX9R
M"@\O<.=5.*8/F<R-T'>CDBIMFV/=_TB0*97'V[*BWZW'_QT:P"U@LE<Y3[K\
MYQ?9DT^>9%]]]0P(YR&4(XFK?=1.9 Z(V__COPT5DLRH''$QHGS'[V8$[C8Q
M8,,3/'VV$.4.VD T?1$%_&0Z<N6H=YYSMA9%SD[ XQ;/%7"4R8PL(Y$LG3WZ
MAF$]# JDNPX/_XE'+P<C*7?83TUS0&>?6_+#AJ4XRLA@@)@6MQH#MI??O?W^
M[8MW[]"649[UPJ:;N_JG<LG((K&[S.][N+)M)TJ5X:7MZ1GUVG10*GD2_]@W
MPE535V>;FOZ)Q]S"=__ZM^?.,= A2&\70$2= :N;LTCSS+<;3H[_K:O-V?/O
M_O[J&W8>?5A1X5"_336SC:*E;UZ99NE  CAXU49&Q:-CTG86WP7=MS@,P6FU
MRZNPK45B O%"(N87;OLUWCQ>+?F"LEWVK2H#M)U76A;@2U?L,20?<2'L"!/#
MH:#>8WL_,&#%LQE8\>B %7=QT7&$G[;"R]?G'HEJ)R72 CFI:30P!]^Q4%J)
MSA.R"Y>!W^XB(ZZ/V:@PCD$>8R?\.<$M]CO1-45"0V$#B[;PC=P$5[<Q)*@"
M@FG(B!,W&U>+YXJB]"2R$,I%]M'! Y' 6,O.FJYHP%,.X!A*(<<V>;DQT3:]
M_+!6.8LZT#C>&<42F4](%Z!9H@" 8>ZNM!IU313_R4?:?WG?\(<HX\^DB_>J
M*^HNHPXXSG- ]QF-E&D8P=-KBMOWZ%*%;HS9M1)R^'WX!8@-54TP(QUWP)2O
M?MB.S!0:J;'LGP;<,=OO_2!%DW#5$$\#^!O1']&\4OCO;%^S?9ULV07SV9A&
MTRY_'\*4^I!OI89,0FKZYQ:=/#0>5.O1!"IPVI;-ZHSJQ0=I4/ 1#>AE)NT"
M"B_X'Q'WV(SR;)6S53JKK'I,ZS/K6$[%I7"U$.$NI5SH1AIX7HK2210&TOZA
M"Z)G"YLM+($J=,MZ5V@H*!5@GE!RY9Z4U80J&0JCS!OESX;&C"\->V:D&"."
MC<7J*5:-8J&M.U^1QZ2XTJS&+_037.+5B!6Y&#.[Z>>&:=F\)>8MD:#791"+
MR\#(EVA:6\#$Q;K@Q!T\U@1[6JI<G&@C+K=Y*? G176./Z\(]RE0)XI&<RPP
MFV6"<$<SF ]^II$A9ZKSOS8#*G/O+DV:#6DVI+%_0[]'AM&XQ34ETZ>=Q;,V
MK$3AI*?AT*P4^R< ,<Y&]HN-S*HTK".9CNEPCN(F=:CHSD :;8=Z@-*I>9M3
M,(4/"R0YA4*0\9!!]UN;$#<.HL" ,7Q2V5K"5ZB_25)FX(?I11]XFR_?<TJ)
M;XX0F9<%90F>'%+!2]"OK'?4T7DL,*6W>=D.VDG:P"'SX&'@5;GMM=PS!!%F
M1N(VL<R:=?22@X08,?Q%>R51FUXOGLR%\MX,#/=A<$D_0)F!2_(E)7[E>L%4
MILRA0/2=CFL\8HL$+&C@+(9K%3+]WUZAPQ?)%4AQ8W=95G:8""*S#F$,G1ZD
MIE9<=A'U==H9Y$V3B]RX("L9"#W -3(]^8;&6[8\X-<ZI#"N["]DK3MIZZ&E
M*-QR,4MDEML*%"M@\UR!)K<AP^(O,ABT6K50<U>[LZ4"<<2$-<KV6^?7->>\
M$KQ%(G8@$NV9E/-)G[:(>$KA\;0<%_?L0#.,AU*8HCP;VI=<&(_D&RBJ/Q#-
M[EA)^:888[L,:^BTH.@X\5:&$6.<KK2NL+3(N"50%.-W5!F[-F)X1=+">P5S
M>7 =.@:*H7Y">T5V*D?MY:27@PV&>UN9F)[TC$WB1(IX0_3G"#;*=V- )/$Z
M(-$=?BB8XS?)'I.A0OI)@M+(8CG@)56IM>N=R=V#G&S$HZE/1>7&"M(\Z#@+
MN8&18 I3C3M*.JJM,PLG;5-5(U8J8"8;&KAO>G]T.Q['S4#K\!&,[8(6/R3>
M^&8XJXG)<V7PZB/PP&/HZ"DODBHM);ZI;H[Y%\'^E,T* '*87I3SEI-D-3A'
MH-U"5GO\0,FF"P>9[F8==F@)G[$[<OY$LG$I$X.NE&W9X!("P8TN*MQ-?P2V
M?LLJQZTY</P>2GEL?00S"1OST$FZ789.VH.EB,[FCC#)#PPP]<D,F'H@P-0O
M"DU_J%H.GS?;^A+Q* Y\E ;#@17BZ*4__6DC\$FN^C,R  /"=,*L+GG7^AA_
MDI%Q".Z(,>WO&[7_7$[@.Z:=--HC2\OK>?"MAR7!/WFUXQ+Q*PBK1A(S=*8T
M)2TK8CR"92W"^1=6:JOC1,'U-_U>3HIX;?"3T;&]HGR7:?SYQ-<OZJ\[HO),
M^2=;%M;">$"DHEX6Z0?,1'CB*#,*'OQK7S%!-OQ>(RQC_@-EM=ZRYVML3B[.
MMQU(?[+OXH^T<6;F9101X-A) DC&<M/MAI<M?[HLNIM"%=5^>-\0JRC_ 6-M
M?=N6.=9Z">6ER746#E)YDS%YPYOB69)6FC=\/&"3Z%A!8@ 2-NMF\:_,O4FM
M@<E715%@>967E=3MBV:C$@A$1UX=.&(Y;AQQ\Q[;M'VK\C5)B,#2?_6.)RZV
M!U-C=3-M8DNZ(JNB@V8!" ?C SI25 "Z:BJF4*&XKUBUN5G<B  %W2Q0#Y3G
MQ)D<G-3T\@>1(O?85B7E%W3U.,\#\5K*++=TP4I DJ1\$D,('H[ ):A.M#W8
M3!MGY=?%;T2D_0L&G_A-WD*K6=7VQZ1\RE*)TSQBIH%LKR"\CF1E1<W/=#N$
M/U>3.8EOKLN'YBF]@1R8DS&A);DL-J0)%4LHP4">/7GZC+&P[N\[)LP41"])
M?3D(:YK!A)\(RR.IA<S19RX&]Q.1PC2%]3]&EVG$5&N'YD]<2L?:'(PL(U<]
MP5OEY&W#2ZK79^'_((6[[U(*TD.1B*EQ#GEL_-F&WJA(UX0P#97X;+$OKYF4
M,;F3[#C94.:J]P679Y3[@XO[)F<B*8P(#47?A)M;A?NK+>0HKO(MM#:,T0MU
M7=>)2AL%?MP/PY8F/FKYR6AP>?%<_28F:H1-CV=^<&*Y32 7I!NR_9",$K9&
MS >JB*OB$">TN)("7EF_C:>FT2-4XDY;_&&V9%**PEE@9>#;2((M#0N'%8T4
MABW05S+B7=F(<Q;]%,M?@59KJ6DT<C9?K7M?D6 #AQW\WVO5]]#I0>@#]IB%
MU8D!QZ3!<\I#JF.;%5C7RU[4YO0C:")P:4AF>X1[0VU_,$_@;,49IX*8<W\S
M.8V&)[SC2:5=DMC?=)KW?@(PF'&(XZ.7?;E=#3*'R >0TA.G>40T%\TH4!#>
M$H<:RL:1X)?&N>BE_:L/#H1',?4_PY6<FE'GM,9B7X)$X M4C>.PPTYH9_G4
M9!&C0RTM$4B_U-N!; V&]F/RPU@-ZKSUI.@D-\1A2,Z#?:*?)+3[8A%4I DV
M"9UKE*H</>%ZHI+*>"2J'SV,J,MOPD+Q>$(R%B_.KTOX994-$HX&.PG6.L,,
MS&V1KV)XH)$7S9=VY'T8G#O-"RT3[)@R<K6FF@ZUNCO5=%1YTL@?J#7=R7J4
M5-6B^YEV+'32_%[.Y&LONF/M$*.1C5J B-M05,28Z\28N)N-M1<RIK:/"QQ6
M6V*RBZ.NMFS3]W^*3F9,[YT.@%L$-?4BUU!Z R6(?YW#'QC.ST\D13AL1"[R
MR#?(BG^H<#Z+*IJ*"K,D.=\G>^&)6U46X)??7'RMXG5;/MA/_*ZR6T@^//W[
M=_CE.P,YB9X9<X G+QK'EGW8*CT?OG.)5BE&[IQKYDAFJ%^,R,%W-XMK+K@L
M-CE&MJ&#<L<)*+8(7#*8IS(U>.;ST5)F.FINFLF.FEV&I<.>$EMHD5MP(8(5
MMJ\Y.J=&]MITL8>/+OTIDYGVSGUM>E^9LKY[7;5ZRVXH7X7 .]PP^IJTK3"C
M3+ZN&I+W2J?(YI/YU.5YZ6>7@W'S3&>8RU5"&$."AP"X(P+T0@$%!9KYDB8S
M@5AN(YT,7PK9YW"WRUZ>W!7WA3"3R[,+[>B,4M6<Y$814TM4T,2CM\>XB).&
M0_[#;3#22?T >Q"?SCV(1S>T38<G+?J>@OF\J1A808XL[PU1P/J(+GS-N+UY
M$.I\94>[[,-R5RV0/V'?GYGU,_L!]7E);<O10/IAYNDFX>G3-9Y^GNG*4_SS
MO29[T3'3R(9LC^[("."1@>MIJB&YRP& 0IK;#AYC_ZP=UX2B9T!3))G'@,+/
M< [<;=>9G<Q8P$#2SY@C58(5?K6$0\^!0>ZRQI&PBT-?S;:->\R?M'6SR2L3
MH([3EO$CP==2P05EI-(*=2/W2\\B1TJXO7(7+*QERQ'/'&?GP.)'LTP5SWKF
M!Q0*IFSJMOCKV%L.&[>Z[27Z0/.Q -RD3A'.<+6%& O'#H2T_/@$8D9#CIYQ
M_NM!V ;?D*]8A@*A!;49PT6H:Y3TSNJFKD*NU81_?O;DZ5=(S8'[^ @<+&=/
MO_I8\RFNJ$G%7-G-CI#W_09K>R]A[]$6!0\M2?<XI(25"&5UI;;MB=LF1.O\
M9F599T)N%KMR&?;0OL1_H3G2=SCWV$%,O(>'6YMH'9,WY@U$K2"+[%S2>I*%
MB)K=LLKHLI6$K&* 1\F,1KM]\/V"SFOR&UME-,8LC;K,VU)0.2?9\R375H /
ME'=1*^IL.I+\3>6X(UWJJ"-E=\P$!O"_J[I%Y[(56#) *]:\X.VI0!8Z8.G!
M%]*/71BU"EHFE%A0&=SRAM,OYGSQCNJ5J*;JK^N[R+6X%;YL;D/HG%V&$!V)
MU#XJ4[I/B?U<,8[WB7\C\1W\7'C"XL&,_U[ZKN1703PCZ,4X5)$O[>C779^9
M)XA(P*LBWQ)W5_#493N]L<:E#<_R=[L?2YK?7)RG((=XKB2T<<QA(YH/YL!D
MD%?LQPU(LVZ_">GLCAAMQ$_ZP:7,U7A)&348E.$5A.^MTB-])+=4K/SC5L5-
MPE%N +<0?30;!([API4.J +-(:X*E?][V<*=7[,;FU$D)/"1E88@]*  [V$G
MTZV5C34EV0=DQ/JH X6/)D1Y/BR1-(6TC<IKGC8NSACO$N'>KN6]*BB 9[^C
M8TGJA@2/6CE;D)K PYR3\5&YCJ[8%#RJFBG#7G>@$(Q:F([45)Z.W!\_#%VF
MK*@6A2Z*/6P(^_-R*V0FK(%+](;D7J!VOF+WG?!^<H'&U/U4$&W0%CEVR!54
M.!P7O41=53NZ9=QZ]-RQ(2*_D#E>%DQ5"( _'/> B6I\SGUW XOH_86W3)'L
M"=%+)R]U&U$I-KY!O9PO]&1DJA.D$PGC)=#,C<"XK,(H77#C%).2.34[">7*
MD&]A@1Q>3>#E&R2_,ISA6=,*WA3DUYA?2>F66OT\/;J,Y)!)P:TJ(2&GS1TA
MFL\7P]U)EG0IZR"*PDGOC3!D [R;K%FL<,U:;W_*0;^?1=X08DO,$PA(36):
M<?I$73(:1444/]CI?_2YYMD,[\%C<K(EI:)N$*UEIS<;SVP\:CP-"2OS(1_G
MG%!M6!)Z+X)610]6()A:<"9>I@A"\K52SIJ>O_U.&/ ' 5E;=CJ,9B-DDDCS
M@>QJ\4@K$5%6Q:86+D<C0[\F1%T*N^&L@*)JA)"X"^X(QM^>-\&\"<8>]%45
M\IBNER&NMTS]]-<Z;U8PYU=O_YHY(9".9<G)GOB?JXC%>-%=$5?9<YF;E0^\
M>)Y^'Z9HR(-1K_R$D7Y@#=//YH;I_1NFLR/ZDSFBD+PW/4\2M[VP35BF2S5Y
M(#?+/=!AE<9S4X,G4K9V'3XF5)S/O=G<HEAJ?NVHJUL_<,&&A7I2US<5ZB(
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M0L@)Z+U<%9[(PD0A13!J ,XR_:A4QI!>.($;A>GF!' \TAHX4H0!)8)22-Z
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M=(>SR<TF-U*+*L-U). 6R E[+/T[]"?V4DXW9?A8A<Q7USG:%Q;#CVN_+,G
M0X[((!DWQ1 "+AOEUWFYY1))^&.^Q]"E4UVK#HLJO#+NJAB'X:6.^DHZP2H1
M6O=NE>L\;IMPK7D7S+O [P+X2^XXI.6R@9 (U76E1T4(_TJFRKTHR1\' ?KE
MC #]DR) 9_?Q2^(V:EN@O*^%+VHKT7'Z)R IF2WGWKDBT95*CUH316T>335P
M@$4CR4V5V[225ZL N-C4>PPPFE_4XGT;(1T37!G9HJ AN"FJ:RXJI^R(&A5>
M%ZPP*I=6/9"PV-3JM_[:@_5FFU_\T,=50MQR"-1'EF,P4H.5"*^-,$E#>;K%
MFTGU$5Z\UO* X0UZXC,9L&&2 6H$3)7@NB:G5F_XR)Y$Q503G+@P"/1$"/L0
M?VRNCM*HA+]"?C)Z@ LOZVB1G+2U+LMZ3]"(X%5Z)D$/KZYON^; V$KJV:+?
M[P!)B[;H*"#BGCFE0\LQ"8U*O"GRU![42Y?Q.H2'7)=;>MGA95&.3Q#5E3P^
M,[/8VZ(V=["(,EINJN036^5MQ-;&RT0"6V\^=NOZ*Y)JT8M#RH;]M*R;ADJC
M-U?$/*,L$;R7%$E"]C5Z 4I5,T54'X5R\NC,2&RL7>RWQ*[$3?6P[&+(RW \
MY'AY#-HM(],]O&7"?#IA9RF9S7',VL-XA)=0YR'-*LJ[P_\W2,&^O]R6[15/
MJ)<[%4X+?OPL+&DA>FA ?H40M22EP>;@WO<4D1K9#E\M?F[X@E3W" ).AD]H
M@-#^IZN4QY.MKACU6<<N322_Z;MP$7%-#ITDI%KTUL<X!Y70:_U8-'\*]WU)
MN.8B5A3(9\4E"+=R9*WP9:#M!'[B'BD/"\0(BVMZIPJL U1HU3>%JTE$0"3
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MI\4%';K4Q_[F^466' .RSO&EBN0<*"3EC6+K%#G*T;34XYO5UVB\C?BK[;;
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MG  D(CAY4=K$Q1H<,B!+QCP&SA@PK80-N<(6W<J/D,9GO;M4F1/&:/K?9YH
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M@?=[>#U:E^26]$ @:K!@(OXE@.5&I.O$0_^ J6)/D)-LC>&\,L $$-6[9#N
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M7WXM(YTG 7Z8ZAJWR'@*G^:#4FURAA!Y$A<&'F+\V/7R98:@VCR6'O:KM:*
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MH3U<=ZB48R<7ERZLBN+9' . =>> 0/V8-XO=-C#UD%OG^E)?K;6207? G%A
M*A=U=_FH9CN['DXF/X6]WX#(ZM(G,7+F<G<&QE,*(U]T,GG+<X,HTO\J[@%4
M\PGR$DXJ3RTV>L/_*X&5N Q$8B&(,<YJ.E/<Z3?9D\T "/2F$/I>/@;AZ<M@
M?HGU&S05;M/3Z4JX7E+C2!<Y#5B/11)KIQ/M^9+W\AA?BRRN:5W>/D2TX5;M
MI1K)7YY>.9*;R:X0X\2.4@B\F845[8 G^4/;7 9[9\6- :_@X-W-UHV/!5ST
M&17V%7&FYRHOS F*; OQ(.H.34?D[Q<QN-<(;AWECOH!E)"FY-1P^[6=\WDI
MZZ[97+=GY)Q>SX6_%=OXLN(L/%U&L']-N\?B1=8+Q[%$*^L0#LC5"-,Y&1#C
M_K,3#NK[[)@Q&URXZ_K=1DC1"P9\LFFC9%L35N:\A, \CY0/&/B*+IOV?0B
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MK@M)$_'HN<0>?#)$VS)6N2H0Y.(E&%)#37KM(DDWT,D*>Q_W+$$SFGG#916
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M"=H-2G($,:6K*4P87>G5\O#VD2Q97J(:)?3=E$6_[]1>9IFE,4]54H2WUR"
M65"H7^,[!G)$C#H3(9QGW[W%C^'\!5>D277<+'$051ND.CCJZ6 8*5ES*GG@
M-%1=AJX4!$PN4R<\NMRYP/)CG$1S^?VXG\#I.%(<Y*\#T&/<U\I[0L2KU6\'
MO%#Q4)0Z#NYP&6LI%(A9I)WT&A ,>\7T XQK'D"']Q)1T:%FAS729PN3/+MN
M!#'JRGE;]CG-%0EG7/*]Y5GJ=2(Y.ITKY"L$QJNFLI*T19^09 Q.S=D.YMI.
MVL>%&%B&V4H!NU,[L.NR[&-POBB+Q8JQFA:26+VT::578&[@G?0NP+Z0<+)B
M8]4V8=;IP5O3$?'5ML6YH*"2#:T>KD<"#SL\HE0=[R\5K#MP":&]8$$Y9J=_
M9_6IQ31)@*9%],-1,J;K@.3GN,QG5*7 H<@P#-!"B:P?CET\2Z\;V;A-R)5?
M%;G6N2XELX94-Q]"):J/LGP'DNN#JMBMT9XS;M])34B2B0]S7.M<9==8TIV*
MS$#T-$G@O.$$#J1)**Z,"[)2\<1(IW\R>1N>,#\7O5L. KR[@L=9AMGI.H^D
MF#\ZO5Q,E$KC<'+YS4ARV>],+'+'N'@SW47MJ;C'<TXP-@P.Z'#WC\;@".S)
M")$CIAGMF,<A(+<A::@NE*^Y7G)B,:^M6D-;(;PS]>W0[7A.O0)(#*KB:(:9
ML/([.SHZ*\F?II5-IR<PCM6?>JZ=IN85U+8AKRAPI _Y%^-UH&TGY3]< ;LH
M0)+(+UB7UQ@7?M'#+5 =:TB.8"=[O2KN0^'T>7L4W#MNPWP;4J-8V'L,&\@0
M J/W+Y?PT$K5,A@^W6^9V^^2V5^2[)XTAV6G4=SU"&C@HJ6U@EVKG<08U=@I
MQTSF9Q^1A;HW'1.D&*Q* %R)UZ,*$(YN@GH^BW9^+HV,<60DA2*^2YC&LNME
M,=MF5ZQ %KUC/XDS![F\&Y(JG'.R^> OY]N4'WYI4O'\%$FT&QA'G50N+:0#
MW%__'0*V<I2#<\.2(%M]9<^:/08\7JTT'.)>2M[_+*ZN?^#&.AT-(L;7?B$:
MJ-)J&WRXYW5-4=V;DC5E:F+364_NG][[#X[&"Y3#)=1RU8PFWYV:(+S".1JY
M8.#3:-V<XW*D&:3#T =";N?6 NP+HYL57=4YT-'M! O>179 \0HA4(R?7=2L
MQ=U#1[ R-YYK.;&_*ZSNK*KE3/L*-',@\I&U3V^"5ZZT!7VF1QG.(+6+4$IU
M<UYT*,JZ.';0II:5<*_@@) J>_*%US8L*'13=9*LO'%0(M9GWP,1QN@NI$B$
M<&EN<$EO'!#Q?3-_CS9[%W/FKHZ&GU]8K>O^L=;U1=2ZUA%\-/">I6+K;PQR
M:X*[MXUTE;.JB<F]J,F%[$WN#ERM<QE\2#S<3&W,D"8=W)I+93^M*\OW4O>0
MA&CFE'$Z.1&7I\IU@1Z"FDU^- -(/*7W1"K<ZQ@.Z1Y#QS/** A+@#$T9LU]
MZKOQ<E8T9G"R.R&P994_OD4E;C;F&'K%ID,3B1]@I%P8_-I]:QENYZU-N%>\
M$@B\>C:IW)Y,5T02"\=!I;C;).#*+\?I%9J, X"1=(X/3?_2R1.;C9]:*KM5
M-%W?C79LT$7E_'9M2N>$_O#SW=0][^#>-5W6WNMI NIW2$^3\])[131I2>$\
M@C?CRCO0^4?BZE"[LN!\=5W+E7@&D.?\^&^(LHF#9INA>*?M;J%:^#2JG@G0
M&R^G98!Q.4^MD7N O*M-T83@F7&T]-4V.\A96%? U9%.UNXZDIY=<@^+N>;[
M,9\S@=R4:\8^0V*[B>&#=_#E*;*!U=<PYT.*!UYHL!XF6#X]ZNTCF?7^&NDN
M?E0VHY\Q:S^"0>=%[&;Z*3AEX27N"%KO^YHA88X>P[->E6>5$N#R%2Q& "8O
MLIWSUNJT+\@=KZ3:;QC<?"N6@^ZUO8T*W"1F&3:^2X "E=W;E=+27DRJQ?_^
MP[OYYAWY&N_NOWOP])2\JN)6XAX:Z-]K=!2\[0WX/\J'PM$A#OZL+&L+GI6<
M ;\>0/YF5#9R-Z6MW876LBT UN!'<MQR$<L/)8QUNX#5-;1=%HG.F-Z,68P1
MVDNJB3"Q3/CJ=O!FZCJX=TA> 3X/W@!W1:]DMLH]([U_/6W4L'6D X/<+/8&
M<->Y%XEM):#?DE2(E5J7[K-@S TS7JRAC4A\.)2D^5__X_Z3TV\?G-X_90_H
MM2B1O$ZKT<])1GX! _J"OO@Y8R7Y[XHPA#53J@GFB:T'?Y3^_/LP<#YT;XAF
MG;H^^9_)<P1D__S%\V"Y28B17+J%7E*NG+72%6?7ZY)<&$<+UTG]@\=#40 ^
MYFB<>)]4%\R_1Z5]CB"31"B.PX*8@S%6'S ME^$,V$)CBXVBI6V!,P=>F>M.
M)F\K\)_T!.0*?\&IG7Q7"27#15BWW[;A6%6R55X$=SCLTTXN]5@PH@M8^KX*
MJ>J*%QLF]V0B*5&VY_Y8Z9&)7VVGB6^K9M-'QK;T]'=5+8Y8^ ZL7\FF^.1F
ML\HD:=L:,=SDO+G4$TF=PF?F^+D%E]>YZ>&ZV;!@GD88=_87V_98$-R<.U.5
M)F>5LAG^9N+J'Z=S:O^F$788$Q>HVH+Y<ZWL@.Q[8K_P()AM\T84J9(TO^V<
MFAZ%CK>CW-<0<<VN P%"XGRC1[+L^O&=*C2SG3(#@2$!&6BAD0'_HJ=U3$DK
M\^.9'D.(RK=5?AN-[<*XXE3*/JO9]6*G$Y$2*NSAOH'."?F:;GQ3'_O 5T&.
M'[E>SG_1IS69'LG/VA)<ZHR!<S666=E?\HGGUV>_Q+IWHDA5PB79EL!,>E4K
M"?I2_:MUV9\W"TI66)*"1N>[:54!)OVH^,TNMSI^-/QL9MZ!,PQ(:YC;05%,
M#(KVL<#)*Z[#OD-X:/UJJ354"@0!7GHL&IH .)>^9N4<K?BG7^IFD=/CE L=
M<,]%61SM%]I/5\E(3)'9R:1ULE@G*5#H"2@[O/-GHU1Z%9GSNEZI0H8G./)&
MS8+)7I?.+D"_GH\C<U>2%Y'8"]6^($>(YII^Z?'<_BPJS'(\ 4=;=.X*.G8R
M$P9GSI#HZ4F/!=GM<,@K%*:4[Q6$$%'_!;@@N<WUFQST+P8D, (.K8C4E+<@
MNH7A@,,'[&CRYB$ 0LXEOC<0+"WZI:%QS=.&YF>%?8HR,,_%=O5>&_Y!QX8@
MD<$U"X24FFW'=.*5]+CKD9CM)JERK(KC*3#/S<B>6N]T_,Z]#AXF!3N9:)4[
M>1X\COT3M^IY> I%JLKCZ?;B%GMO5BUD-S3A/,**"!TK([8OR1QD>RPYZ>H"
M:V^?VB#>:&:$JG9X ^#OO\12QH-C*>/.$6X-:,35&2"47=79#62."3F?Y'1>
M[P[:;'N[=-0GS8SKK=5Y14Z1 -(=&/>6PXMIFIEW>F,_66+R1-V39-9W6>"(
MGB RK3O-#-4[9VQQ\3FB8#&K9474S#"K2O>5V@\N\53B  D[2)AIRM'@-5;5
M^W)5G3=-N!> [RRGG)/MI0#@?!,7A9AD3T&:?GQ!:+B6!C09T2_3$(_?[@D@
MVZ>27,O158H&2/, 0=^Z>DJQ*#:Y#VFD13DP'/X:^7A2M:$H+?\,"<#-7?,M
M#P[(E71TVM2A(QDC48L,4=-#W'(KT#C7NU$$B"U(#$\BKU.*2U>6*@RX4_=B
M6:GXW5WIO_[9I]%3O1JEW_'9WA$0;R:>D9JOI49NN8#&T!N9FA>7T1#S4)AU
M/U[.+F9QG;?#<)X6D'G O!N?D+\:+_;M]2;=8 F&H/?/NP+3(7ONK&V*Q6KG
M%^*C93(2F8<ULWBP%P^;$2?*MUXD<\(/]/M4NS6E6<VZH3+Z;A]:4&KL,L+M
M5"("<A4<HAB!XC4Y[=X:>;[XE7\ZPL3_5?&Y26+B.8GD_8<(HN":WJ+[!9M5
MA4RZ<8 &$V%RA5<ILN$GD(R$!.S"^, -&1WN5%8]:9;+LI5D%V$]^8>MXTSA
MBW"]K>6(3+Z*)X1^IS(NTPE$_O#7&DVWY2R<@J\I\@Z/%X) BNOX7U-0-<B/
MY_+?")M#Q'PN&A?O*PJE"?)7*QBB+2^+=B$@@_"O8!-K[N\2HA7.O84W:[5Z
MZ*-)[03K6?D0)'K3X$[A?[#1A=V,VVL6"BOAU-,97#AAUJ31!D^3&\LX6:0=
MF%@YS;AI;7K!E:'+\V95JH9'L+Y322+N2:>/22.HL+3F'?%QU5TXF3QW\AK8
M%;M(:JIX!D[R,'Z2]LJJ7)R9V]WQ'L2+J<?+>E+TIR('11A"@I.W  (W2@RX
M7E<]2L3R.7B6OUQKS_M,= @B@P<M]7)#S"9VWG*J:6COTZH=L\F40,B<%P(.
MD2A^QCK%L@D$Y4C92*H^:NN2>P3?7N%#1\W@FUCS;_ZEC/DR.%JE<D'!;R)=
MEBBS8KZF.*6IO M_^"6>\8*? <'5<!!?HG!+EF7\)H R3)GJO_#CG.R+_S9V
MB?@CX;E=ORIG(:;C=G?=X=4_/D"QN0S!WZ0OUG_^8_79EU&%>Z;&YA6OC.QR
M#?^(=ZM(<.G%2=2[TE4P*_67)=]@!^H14]TO2Z2R=XI52^-.LO.\N\CU-:&N
MJ1O.NGB/H? H!@.B*P@A.PK_A3R-Y7MAZ^G"D3M+2<\;^USRK3QBYA5/W0T>
M@_U5?"8]ZJ*IT-FMX$" O>8EMJN#\2,H"]<FG9K=%9,W[*3UV11D3R#8))/(
M _<ZB4@6^8*/*^N*');=9(E(\N&[#&$+$DG=H2GD-=^V='BCCB+A")XG0PV_
MU#/YF<\&P6P?G'[+KN!_;:GP"TPJ91SQN_O?LF8,%HO=1^9GL -@O )7K5YZ
M=TO'RWF)*A_+GVC;$<T1:X"A+9JI.91W848503E3YGU24[PKI'(%1"G=Z' )
M_TWXG+PRF+3U%;DI;"8Z@ PNWK.FW=%!.(9[>ST$@6^]JK6)ZS65  7%#SC8
M'"EI_9&@N.Y_\\T3V-N_OGK]7%T!N?6[L6N?3@P_ 3'/F,^P+T@42)3<:H1
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M.'H4"8^906+!N\_W/_A4EA"]C]J?9"3>/8<GQ-7+*N$LOSU^CW&2B8S&.MQ
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M+ Y[?YK4 *)<P(*01YT42-!&7SJ?7IE:*::Q[VLT8*C"66X.1&ZREA0)Z X
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M(@*F[D[@\P1?HC^D!O\5_:"975#^G._<%G1H)5P*EI3\)456HT+.@[P2\:\
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M&?FTJF!<N@$-7HB'.!C5%. S+RXJ_+0%U(\;]+D([&JL'4K0&-__73NJ;62
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M%3E[X&=I '2PI?$3K--#X4=2:\2,, F!4>0(/9DC9LG:N;4(.DVQ:,U>J(;
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M1<&*5!8L!J'61Q*9*X2>D3ERTDZQH:K0E\@8]>2(_?\2&:.(_\'=:*WW3KF
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M7KUR;T:[X/%/P)F%@.8-J(-:(BQY 9S9]U 2>5.N;GV3/@Z;-*)DXT#-(O&
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MX QUWHJ,Y#EYZNHK_;/WOPQ_T730.R_3#3U&8>)L-'2')%]=#H&(BK4)%CL
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M"R!HOF #V5C547$#/?14 Q-NMPOBLN,:)]Y>N!:4"LCPL!2ODQY (A,].2$
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MD^Y\0)K>^N&$I+9G4OORH@--EYZL99>]Y*[W:Q)VZ;H8.L=N;'/N2VP+)6N
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M!HX/UOIWO7G*]%#7_UUC^JW)/Q9T<CO$CV81TO4SXF9G!)<C(,7K2(1AH(E
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MD?OY^ZI9N\\U"S%'$U15:]2?FI!!GOSU#Q^/<EPZRJ?C&SCY>#S,.Q.-9!5
M-49(MQC2DD'@/)0E_W)[-LMI&B@'B[E_TEK9[K4S$V:'7?RIVB^,MPN4M;$
MK !?T_L%%CS:(/3$JP=NTM7ZD\%%Y?8F4Q_5X_QY3TJ"]<)'13$=324WR;PC
MC3X=S%0)D$#87CSDZ/C]R"R9K['TRUWETKXO"I-F;JJ/;I\SA:3] /5M8,=@
M=DY'$YRX=3/FD,:XAU:1)(]O&#9@TBT9-#_2UPI8#"9(0F[_5D_@]N-4#:'W
MY./#>:5[?V_;3D&]2UU,VE:[)F _+P4F3SHJ)C/15"(9!FSV$[ )DLS8NF$4
MN.7^8%OI/:Y'M:R>3,9NFP6'JS:%]LN]R-\!UX-5E(BF4LEH,ITZWNC.1AMH
MR[;/:1HZ2RPK8I;M& Y4=@?.K-GVU=.!%W[:]LL&$>9H-2'1C^?%9DP=WZ9R
M_+C?'V>E]!X-EY.P4H+$\-N\9#HB?CY*XV,#RSY-,M9-MJ"5!D*IQ"?3SDP;
MY0'#9[=6QZ']B[>D\8TJ$T9V&WTL=YZ"[O&T[U3H<!U]HLP>'*H )JJ%I'J$
MR1RG2:H!]VD_FA.O+53*\2;&'TI''#.7!9"E0HH+5 ;]"5#<4;H(K)\A=$*;
M T[BCS2? G8_&QB]'>;('VMHDG'M'67:UV];LM<]I5!.]B:#>2PW?2F++\GY
MN <PO^*O?Q(I,<KO.JOLT/1_FFY4F!,?T #E1QE7R<KVO)Y3.EQN-LED!+5R
M/2D3QDW^^D=,B-%T<ONY8WLV/$P'+5+@C]]R#\[EZ*FE?!U/,L</,T* @WWW
M"*^+L^;0:/+ENI9O.I(C7=:&X]JLWR-S^_5//,5%N4PZO#$-L]M_!),?GTWR
M83YV<DI&OQ>KTN!"[A@YLY#OOSR07B#8+,D(D-;._:A;U#=3VGWQ[A_I+P4L
M;A(D\1;FM9^LW?,A0<G?7[R,C;A::+8<?G@[J*OZS745.B&1@CXN+D:%9 A'
M$&:WG[A@.#);Z4.\G[$OR]7Y=4T:7*>*]7$A,[@2+@GOD\H_(96()H4CCMYL
MM(EV80N=IN$3(%D5AG).SJ39(,^T7+-VG^C*]YR:O\\T>W%S7*N15HW[LV5.
MPG )$.>'X9LC-$DV\&Y/'364R^N;^4 NQ^V"?I[LO3P2WMVI+7)HU^/-;$5C
M.%3M(8!1D<1W."L\&Z0KD K_YZUAHTCZK] 3._K<E]/,)0Y)]0CS-4Z35 /N
MY[ZG2.JO5$S]D-SW0SK!I[;H "0U!V$;3L;5^^%K#!HY?V;51^GP@$]CP'*Q
M1HI&_GC;@\VK$[6#B/]J]6436=(YCZK5Q_JHS%TT<_-*\?&\?]N:?MN-+=T6
M/X,73-9 E.J=;%9,[&C;J$-0@N^068>9KCJXM[)I2N93O9<H<:-$(5>\:]0;
MCP*/TE6\S;O?A(_$X?:S"7?);+-VIUT-F^I+7'L1GB_BE5[OUS_<&<=Q_ ;_
M?N6#R$@V(Q-XS=\?C7^P;1N?CYK*=3Z7Y%I(-0K55NKR/O?]$,B7MXWLD95U
M[+YA8F;I;-PN:SJ]RXHOS<>!4TK%GC+=6W%^GWV/9K:P])U2S(>6/GZ1<OD&
MJJ4+SN58F(^O!K94P>P2%Z.85.#_'Z 6N@$1V7M5=/=4LX>MJSBV!1/%LGKC
MWM4N=/Y)'P]2 \2_/'3ZJC))#:>__N'345'DHF)F?>](B.DG<%3)LIQ72.I!
M:M?JXR8_XF+Z56E0J!9G\G./@.&\MBN,@):T-%9T2DR=Q:B*_GU)_B,9E_IE
M=E:PGP?UPH#+%V.MQEC-;C18OZA)Z:_P'#Q'O#W:4IM<]M&O?U2R 9Z]0/Y#
M3_?]1=P_*IT$-Q2[W/R^H*CG%<-H:],#+,)84/CJ2NR(V_\X(O+1"' <61Z0
M5S2"3VN$%.AZK\U_9+ I8,ENI[8/ 8Q;_>@K7Y]\?ZT1Q[1X[MBUMGC9'!OW
MYT;G_CH1RU4E/D7O?=/BIGNC\-;DR$/18?O2GW K_ 'VCH\;]8KR.)AP0V>F
M= 2I\/*8Z %[)['IMI&YCR=P?V>B+C)-U#GNF(BWC,]'!&JUPG/<OKS,->?.
M2!_U./VQ<WFL89%O[(/V$F].+>E^/)C'N_Q3<SA^>>E-3R8RLKQS'XH0-,3^
MS?-\C"0N]SP>/R;;YB"?ZAUE<.0+J]<FMX.$>-&0FK(RS)=C_93=JV-Z$0(>
M'OD*Z8"S"ALX-<R.A?2/[-Y[(9+4N)^]J3OE=%,HE]N#:2VCO,COBIT#$<\.
MUE])30?WY?MLC\MUGJ3K<KWR?"G@]>O&Q^F&1AIH4[C%Z][VT(__^BV\;SZ=
M^^9UU_K]&%HODY9N"K/DD%,O'IN<@5X2XK"Z[I;O)(#F.OEP%+S LM[#>^_P
MWOOHV>HRGN&,7/^QUE1;\ZE^D;AY&-6K!PA-+WC+'Y<^\HOY+'X^Z'99BT +
MN9BJ1Q1YI-JR]B/#9&$0/0!J/=B!M)\41%]P]QUF[I*>HZR](=AV/6U4T@WT
M.."$JWCWV2@6'EZ>>A*?@5AZ4HS&,ZEH.KEC#)P@<4@84#]Q.7!D ?6/LWI]
MU+;B_9=<B[O6!*W8SUP6SN-58/7DKW\2Z6A<2$23W'$WL,\JBC-T-(C XOWL
MJHIJ'[\?%%9]?T!#GU;5][OVRI_'9;#4D"VK.NH49%/'VVCY^#A/V1@+-+P1
MV%G<(-D,,:'8UT\\UVP]Z]9S76\_FN=9/$^")IR,\BDQ*G#K;92V6TSYPW5W
M6 I^2&[?-4-OVRSY)D//9WE!4Z^+@PO^NE7L3SF[59X"0R=)0G &FRIB:CT3
MX*]CCLILA*]YO?O9#_2] A:E"9*P"W']3C:8XR_G+1#FWR Q"ZG'7EG@:P^%
MZ_/KLBDEQG<EKBH)I*%"*BH*R6@\$[94"'']3EPP'%ETYV.\7RDZB7M.OFE>
M9Y^OU?N+I/%H98'W 4LG'DUP?)3;V$_E2 ([[P'[O=,G]MC]N^#$?\+N]H'L
MAOV3K!T?;%A6[WQ(_M7CL_3TTHS/!_-.KUA[T"L/HH:]12%L?!\VOO]AK'YD
M]LL7N-FZN*D8O89]/7 FDN$,['@RU:\"-X,UDXBF4LEH,KT>S%VQ9OYM0R.K
M_>AF,C"-__A!9MPVU2@('ZBY/,LZ0A%948PA?NL<LG1UP\:6DFU$[#Z*=%5=
MUA65!)AD&Q'0P;/MS>TC^\7O>;_".1WOG BMJSI^B?W[,W.DXSS'5 C,5GY4
M:W?4R3__P?^XWU,T))N@U_HK:Q/A)4RK<=R_=J&;EJ6,$/?Y972%&<$W:?+O
M__P__^07D8.88FB&^=O5K[Y5]:GM*A!5VT.QMHGD04SNXC?_EK6I/+?8*E.9
M,]%5W;\]%0W;$.&Y,S'QKXCO9]B.M;T<RK.8;\>89H]IJ&O_9E]S/R-JV?O0
ML$C&Q6\3:3( #\#37SNCY5=L^J9,%)^$4()+R/&VQ&72"2G.BW%)[G:24EQ,
M"^EX-\,EVBE8A>Q]@ZAQW:XCHO^D3EI6$O$$DA*RDI;BF6Y<:G/MI,2^M!5J
M6',OWE%"]Z5:J5*/-"X+M>Q=H=DHY>K12.DV1U4-70>IES.ZE1$R95B(=<@)
MUQO91J%<N&W4(Y5BI'*'Y]TH56[K 9()[NEWE':*[V###77B4KP3YZ0TZJ0D
M0>';8CPC=#H"MT0OV+2ZO>V>7\W'THR[R%54[MZI2Q5^*F'+;W7D2V*:L<K3
MLE&X3L3R*2X^F9?G/4E8'ZE>7)5N;Q]NRX/6.%.ZG2>*\?PS=KZDQ.K(=+(W
M2$QBXQ*GRL6'EU0[[G!W/4E<?^:S?#-Y/K_H7 [&G<?F]/KRHE8IP\BU9SZ:
M3Q55<D;M0;)82CWUQ[&XC(W%N+2V]E$QE;XH&NWG0E)//U:MN#Q0A1X>N?;V
M65IL7]Q+-PTNI@_'ICD0RL-2%H]<>_O#D$]>9IM7Q>9UNCF87EPY]9'=DY+K
M;T_<CAKS6EFZ*\32,S&E7%JUIY>LE%H?J3[=Y]/%+$H7ZF4N/9HJ\9Z8F$KI
M]9%IJ7@?N] DM7!1;@R<A/@X?92S4F9])/^2Z]\*+W=C;CZ^>^[(N>1UXJ(*
M35O7AO;DVYA<RJ!9(:E*+:WAS*]LA_0(61O*\>F6/+X=-@?R9"Q>-P5S*#Y7
M <)[;>A0Z^D3/G[W5$!WL_2S5$.9_!4>FE@?JF1LN51^UBZ:0O'>N<UJSG"0
M)T/%U:%:7*@E!O/D35.N=0=/8PX-1_>8G#?L?R;73]U</SP-"Q>ZEKM+S2[J
MB1H>NF%;GS*:\IC.W+2X2KLZR,]TL9^8DS2YM:$7K8>Z).LWI8':NQN8"7->
M& ZK+'EV>:C3?IGUN]>7TZ9<Z-BCIVKBGAOV6/+="I=6;QNE6"QI<;DGL:U?
ME9NU@DK"N6L3:&>+R;O!19MKHOSLL7TO=J]S63)TC:KO;A.6UNUJ0M,QBNV7
M^-R^OWN8PM ULHZW,G=Y^?8V46A-"M?/:&*4\YA8L0>V-@&-:\7L#%]4"_4N
M-^3*9@=O'G[J@ER(&^99 -33QMI?DT<6^NW^X!>2$.-E5@"H3Z;EEM6SSQ-G
MNGG=_+%-]ZWL:3P5N1\.<;]9?N?3][['&_B17<V8N@+<_3T&08??U):!FLYW
M;0AFU9$7NT/EMF5HCHUV8>9MV>CWF8 [CJZ%Y["O<WB['#4\ASV=PWNE?.%!
MA(+IM,XA%$R!.(=0,&WU(#Z?DG%PN CO&N10"0N'S]+8VA9@SP@^_.^OQ*\O
M;H>0/DL>-*L]_?XEU9N)"X](-B,%O8,ZD>6K^I U0M8 UA"^RAJ\>!;G=[D?
MWR5]%TZ)YFZ*?'2[&=XA-?P\:@B%8M#8(+VV ^_7<*S_N\;S6R/XX[4,(.WP
M2&1A2 0[) )^"R+PP$4K-31!NH-^9 W.0?/6 U>E<KA,]L!MQ9:1XKKU_M1"
MLZ=><SQ#+WHJU7ZVYS\(@#%(/!VR<,C".V#A.V'$V?F[N-84LH_#=KN/FO-A
M-D L?%SNU8_PGP)L79S:H@^-'QN0;3B-2J^0OH^;OH_1#6;9WWHO@F8CI%O(
M^OTCS>> N<2GM@\!Q!\-R,X$CE-"Q@@9X\ Z\5#X)C5D(=E4^@36I(,F2#-&
M4*%[_";LR?AL^T9K"U*T9Y]@)'F'%@U*O,302!J&'YMDVGHVI)?JY*89XT4N
M6S_/Y&TC^W502\J86;V37[!E@5JL&Z ,+A^F!3U[W^ *XTJG_&29$Z77J$HI
MBDO")3/1I+!C:/U3T-\A9^^'LW?-O/P2\_)2MYJZ?;BHC>Z::BQ6S8N/ A\[
MWQOSII6VV!.RXF53?>JW[&YJUAGEH&038$BX:"J3B";3F[CW:/WP%3/D NG8
M*=>(%2)WAJJN6K9)4J\])_U'>AX!\]&/YLXK1*$](5.("0<L3+-+HN%U>?HX
M-,3G6J%;X="5(F:38GLJ9+-2&HRA>%2(@SC=U/9XB\90D*1,*%3<;0D!:G^.
MD?5YL?"4+0W.VW'1YM1Q/6^5^/A+:09B 9#^HVDL%H2$L&TK:_\F%9\FSZ?0
MM<;:;<?Q^WL'M9H"),V"L"E![V=R2H:2=[/)1*"U00;>U/GL^(7+#9NM&U$H
M&]>EARX")!]L&O%"5.0349'+A(&B'RLG0K'P VVACW!^O'5^>5G+36:<P]_'
M+3/1?RY6>U*&8=TFXUPT$^=^9)")641+?$"'+3">3O3N.V 1J%/;AY]^&?Z#
M..5$&2/D@R]L1+ C!?B1-X9E1;JF,70#!(8>!@9^CL$?=B_^Z&YLO=GI@5S^
MDJX80P1L_5:STX12MRNCV\(CYW#RU?UHDLC<\CU YWW;_0^[%Q^S. B[%Q^A
M)_\QAC;.6[>Y604EFD.4ZF6T[I5Y/L\"0[_MU7^K>_%)6JB!\T="SSWTW$//
M/4 "(FB,$?+!3_3<*W8?F1&56 >1/]FE_E_;*V$\-3D>%B$'@$,/J:E^N'P^
M+'V?)CG_Z!+ZE=3]$F#I(<MF*NE'&I"G[&H%( T_0&DB/SA[S&5D&GABB22W
MR-X0=4)\WZ@/1_IT((PJJ4&UF$Q.SGO0CDW\]4\R%8VG$F%V_<^3!7O(G@\0
MJQ]W1M@GN/F2Y^:/^7-G7AB;67%XKMUHU3+AYN2O?Q+19.H'Y,0G?;XS\YF/
MWX$(K[O#Z^[O&2Q+,)3'S@XG2OWA[>[Q:&6B@&X-W5C)U]Z@E;.STE53&MFQ
M0J[2:L65I\+M+3>%YL18*XM"(HK/XD==Z[Y2O[8QW/TC'8F 11F").."L$\_
MH>+W!X<OUD3KDN>S0<"^Y%/<M-,2NIR#DHZ<ZXK5(J3.),,@1BAJ@G&%'ES)
M\@--L55Y\6K.G=X?\+.:6N@,5..R.D==K75Y/@7! 989GXF*&Y#6OFN9G7S1
MW*F9&V%>0@ N<L.\A!]*WZ=)SJ>4ET JW-H(VP/(#1_8\BS$$?QIEY*GG:#P
MKD]_W.5MBR*8HFD,<W@>JN[@[:UX1:OGA,/IN ;P=V%FFS+VFU1=-N<E&PTM
M;.3#"DQ#TXB93R]&W[+P"V5.,V_KYSVNTC\W;\2JK-:FV,)/LS(Y(9Z*IL7X
MCLOD#LU8P8D/'/5U2L#$Q9&[[0>2""B;'>C-AX?Z()G'\WA!YTY5[(%$H'5V
MF207%9(_P>UWLSI=BRDR,@W@?DPH?[:1CKJJO;WKE],TF((4[0Q3)\+4B3!U
MXO2(>T&_/\7A#TJ@.DAF^RG'!0*P#\'T (*P,X'CE!-EC) /]A4:W^<1WR([
MHF$7^?@-T^#X:2*VYCJ&T]90\!RU/W;IH^U_X:<;[\:,^S'<I\RHDRK:)3DW
MR*5O).O\JOY0>:E* K_7"/4/5UO!DP)_G J3'WF4^L-\W'J1[V+%RLT-=RUG
M"X_7RG5I?$_X>+=QY0/;H.>RI2JTY["J.3;J1'1FLD1&R(Q8?=G\F4@"0<JS
M/;1%X]\7_ 4EILYB=%-^7Y+_2.7^E=-4+Q+/A0ONJ75GI N3BWAVW0;XXG3H
MK_ <O'^8L[6_7[>M]IWL&S2!_"VK*Z].U XBLIJPMB6=\ZA:?:R/RMQ%,S>O
M%!_/^[>MZ;9-+^$3(KL@FSK>4NL.F768(Q%1;XGN8BJM7U]76N<#.=XL7:1*
M-Q=E!XMN@9A@9_QZ@\&?FQX0L#CCH5GILW*N513&TXXMY0K#Y-,@?J_<-8SZ
M=.,F[T34L8^(L&.'<^KR;C\B[?-6Z$Y%6O/^0;AO%TVK.6Q7>H7L\$*14ST0
M:6"-GF76@2".)K\!/[)%B!W;FC*>E]Q#$;QY;6QM&EUJ<%H1P[$M<"R@72*Y
M'^/_CK173=70>SY6[_G R0Z!$G&[*0UEHG!\/FHJU_E<DL,\9Q2JK=3E?>Z@
M@367][.4]6\)YU>Z1"Q:E07;NR)R53(^SRN#D=K2RLWZ<[W=TIRG[,C(2H)(
MC#T^RJ6X*,\G?VC?Q# *OY>$D6 +B#W(@-T&Y;XK R[46HV_,YYZ R&M)*WS
MYZ'CS*8@ [!UE(Z*0B8J\N\V4/RW+>,#W@_+TH$?3W_9'DVI.GX)3;WYZ!Q9
MRHZ;/"4$=MI!F"CE605!ZO(;4_=2I,3T629!EE)'*"(KBC'$LYJ#H:L;-C9]
M;2-B]U&DJ^JRKN#YX)G*-AKB1UIGVYO[]VW2CCKYYS_X'_=[BH9D$\1M?X6
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M'U$0L#G([RZ8<TI<MY=:ND"M>,>%<@=5FZ=&O>]!I_Z\%0>->O>L)+?;AOL
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MTM5I\/_^#8'T.%_J<FH]SLG=JI071JG98,>@D)PCS6>U\;D]J,NFTE:N])[
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MIA[%YYIY>]>]XEKYYUYB(@X?K]4IK(Y@30E1(9Z*IL7U6I,0:^H;@950+)R
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MCH2-UM5A8NOOL\#;&MBF8(H,(1RS(V_ SSE "+,C0Y54.OO/\IR@(.D"7N1
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MZ7A$X'?Q]A/C/J_GH>9\\Q'4'19C#4M])$%?$KM2(MQ 8DY%Z/B"-3 0UUB
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MKT==)R'+T;]ZV0'W%='/+F">?Z3!@C^XV%^D1:$\!@83*.QB@4=(*252D38
M"!;F"W_1V!Q]<(11"**;L)3GB9)'$E LOD=(9*?A8!H@Q5KT9NJ(MW.BX<3_
MVCWH ,$70"J3D"JKW<+T&_4+ZS'QSTWB.2&>;9L >Z.;KTECNO:Z(>LN,#&L
M-J^!9).&W[QFL[1NFGX_0 :I'X2?&9C!3T=*SXG&!^YS G+R+7/!LG")Q4)]
M=QMEPF0SS*$%:<H!W0SD ]X>^QJ[7Z+$0/6!.<$,C46JJ3>1E,C3]ZYK\DAF
MS, VK4&@/IZM1U\;#$_Y[6J#*B*+(<$76-D-@3W-J2$N1P85)]"'#)ZF@N^-
M-=^ZP5>O( )_#E T?9#1X5$$ NT4624:?844)$W6"I@O!,;B:CB6Q'J%CXJF
MUG>$1O_V.;<;'0E_[EPBLZQK)@4&MX;&,05&!4J=8NE-\O?*P* VY3 =>CP\
MBJ5).G6;53/4A^'XLOLI0C6,9R0?&W*H^S5LFXXL3'M6 PK6[G29Y68GQ;O8
MO*1.]>XDZT:C43YE9[K-CW8 >AV=ZPL#RX&1-ETW PIO^--I%BH.W^F6^%LG
M/7$K<=1IWJB@].WV^X'NP715D*KK\W'D@+3QNB?L:JU&L.%J("1R<!7Z%&[P
M(QKZ'H84JJ-;N>?[EV9Y^2C>"G=H7*N*R_L[TDXD&:JC4W9/]!K2?ITL;UI$
MQN KNH)_B,0U//'K56-#E[/U??NE/#O6.J1A65QAI*$A)RZ1[!(5H XJ#*(=
MSTLF:<87(;W<X5VZ364+^P/-JS)U7W&@G6S\+0:M#$33JIB9MMX?70A$FA^O
MH5U!-CP^OL(1;K2L]0'XKB?";98* OI20'A1?P,IDG>"'Q,=@30(A5S:K2IW
M.,_1:[6\^C>:Z\M\75Z]KN8C8&#" ],NJ1>,5N)Z\;% )2$ICK(=6BSEC+:^
M%1I>W6ZC9)@+ZH!C0I:D#*\\37;O@I*]O7>_&Y8%'2%IQ/4%6::?GK?=L8KT
MA718<AZ+,ON%AX'D'%9=S);Q:TC X0231?'[L&)LL$6PPD4L M:7 0*C@]4:
M"<)2=#:3(LXL22=S2=+Y>)(.&T=5UL>IE("A$<NRL4T?S]X1/I2]$]^?O?.J
M5GNP(J0/:+;<FZHM[3_%=2"]]BL+E>A[\6OW>70'UM2,/LG=N9C2[)DPB[>C
M2O- :44_+2%8E@T),E- DCQE;EW:3!,V@AGE*^IME^31%5<,I#?OS3XG6<,R
M4+"R65KN59]#"-++;]F3G$XY,7[)0&*F\[ZW,<8/S_IS=VA_<%K11S.O@Z^&
M#?J,G=C2,,()[3D=.0T5-IC)2Z$)X-HPLGE2BNUDVWY.- +8$_%(+>N)B9=F
M5?,D2$LU#LC'(4GC5K!7HA*R-5JZ:SJLM%G'Z+&9DN_-(O(RF[SA3?LG0H'@
MU8GG*6S$%:NOQ-BS)>.GL".X!S9!2]<]]"+71=T?Q&%C>_T,V:M(BA;IIK#=
M,>NM#H2D:Q;I0Q)Z)9(*=?9.&.".KZIMML2D+A83*C)9/C+DU:43;V;4;?)"
M[1\O[\W_NASL\@UO5;%P,KQW I&JAN:/9PGFA0':88!YDLW+_(+R?\EKTP\(
M'*4(' 4$CF)<9,8A28VRP6V)KW5C)>H']']SI#$RV B.M?XZU'1V8TSO(@ED
M_I>"Q#M P358<3[U7]E>S2T-$M'CD4@C:[D%V5H>>JS9X1Y.<P5P#@#$*V$)
MLYZ C;DV&_F%EXMZE,&,"8K[NR/H:'%$8 *=1OD)IF[0E"AQ?^S:"&R WX,?
M&[IC/&,8V(HFT[_[G0_6ECP].4;(P9K+XG5-VGR+88*\SGVDC(=6@V# .3K=
M2J!;!C9:H=&99LGN!+S),F(%-:\6CZRKC11_SE-0O=\V #%7W0U63;QVOZ[!
MX/;",,OWG$*M=Z"3FO1*WSZ?%6WNQE_97@<)" R1(>D$?H$*(;_T>_.FL%2
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M FS:(99 VB>A'2CR@'Q1OU?,N@29Y@1XO67I/9!A4>O68W@#-HQ_UNEL!"P
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M0YC;ZWT(<0MOCK0W])O&M*%C#WMJH\H\ D, N)J)X9J]XD3O&#87B#RS1OK
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M7OB]C:'0C,XXQD;%=&$HVRFBXV6L]Z>&XJ7QJ#W+3R1U7!C>]Y_U3IRWW!Q
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MP#Z11&53-ZT?'B4$CL7&$@N$*%04I=.'I2%^]0])7T@KVY-RF#UY!O8/GY@
M#AS6M^/)?W.!GP$>.\"<2,MH &2,!O]_>U_6G#JRI?O>$?T?%-7G=-2^UU":
M!;O.K0@F P8S#[9?%$)*0$9(0@.#?_W-3$E8&/ (1F#UB=YEXT3*8:UOC;E6
M0@-#Y[?_M> SR^N5['_X1A?DC4/:?,6N;\(S1_RFZBXF88_(!F*UD<L^I&ZL
M%MGG7?>AJ)J#6W8DHJ&4)]7@-R#1.F^-IO>_H[+J:07A5JU.$N5T,5\S4RV6
M7?COB(S:]V+RAZ1L58>OA0>[66P1TS1%KPD[8Q/&<-OB)1#^$=#J03_ 7YTQ
MM(Q'(PN,) <0*@0/5;<AFLXES07H"88'/801CF'!KX.0:;V0;.)?[[2TD/8S
M+S29!=?E>UW@U.W'5<&Y*?5_X(7$<K#=/;3;+U6=FF19XC"=GE4?>*%5J#\H
M5:/R*()"<[$6?D?:[<LQ:C^VVSWGZ<F8I')W9%W0;\S./9?CK=$?_^Q2*5]\
MD,1\_]U<#A4=Q)"(BY'"00#X+67-]43 \!Z?HQV4]!4Q\BZO$#)4&J'6 +E>
M098)5!GL-;L[!F&ZECR&VQI?JCCFI0I,=X-'UKU7:YUB=U6JUU.S1!I<.Z/]
M-RH(;Z\1/H<.%F=&"'_;<*NG4P.)+$.>$ O5&4/$)B1/4PR &Q FLJ_0(]Z
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MR+$XB\795\29?QW)3R6DS"5A&YJJ$$'IJ[-A!GSYSX[%W)?%W,50!+X;'<O
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MKV,J<(VAE4*V0+];**@?Y"+Y^7;0\/;SCHSEZMFFQ"8EDE)0]#%P [![;0H
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MVA3<RO19 <:/TZ_"BU=4V]2DU6]51]T#$P,-F@9;Q2:\=20X%B[$>X2_#=^
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MC*5/-KYQJ-+Y=*".@2Z^9*O&JUL-]K:/NY[:X %?D^2G9!SR;"H<]I-$RF;
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M-9#2P)S13F;"TGARCWSM&*4([$J)=@G]X')<X_R?01DL$]5Z\@!K$2Q^L++
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ME*EAS5Y[RX5+O X=V<794,=B9=38-E6[%4O^7+P@MZZ278IP@UNDA8(7.&E
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MI#H[5]6W7\AXXOUH;+I\ 8JIAG_O)G!0N%O]J#3 - U F 9AGQ%CJ6_G&VD
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M>>=%L"AQ<--^N$6OF&C&TO_P2-#_XO"L3NL[ZQ[KR(A/GWREU[U>+9PFRY%
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M"GZBZQ37Y0U-9_4)=\1Z!3+OFUG>O#WKT]Z_GIF4[4-(7DK+P'O*2&FT*M,
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M(OR\ICRK?.F]P^O+MWL,?0W(1K"K.,3DZ&UB 2&H"RU+T(LK)TLNAJF8I$U
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MHJ8&B1[U52R#O4'P/Q5="%.0E!R;4E)J<A@R\N:;>]7X:0C3;WT(QH/A=G^
M'2?30M8"[\6]09F,4KA_D2Y#T\0_8?8F^M#_$AE>!05LE]PJ72\&[*64.T7)
MUW$&W0FA#WL9>5 $/UJZD-OC(QBE'1TKUMG<-HO$HTR$LMCG;#JKAMIQFTW]
M916FVAQ$1. @:O.4/V$GQXZYP\ 7]P!<J48,QD<F/K!\11>*<0U>(;::ZM'6
M%V:J-11UWW[.YQX7[5M(<Y1/A<IO_#0%M#\J /,,=)%<'']Z!65Z$Z4Y[7Y8
MDB(!JM0)U&G")=],]=Q;=MWBC!Q FSXHP!%DQ1&<HZS$CA*^&W)!1,3<PN7!
M8_2W4WEU=UF*A#9W^RE!.Z-Z54=#!Y8&BB]8W^[:H[#$LI^RJ2.0(SIACKL[
MLL;""E2HWV=K[4114?Z<-1*;F$4E+[<T%L 8U,H:74)K1^(P,1.5*JPZ=0^H
MN?R!XNR58UR08=ABH&!&GH;N^HDKP2JSK4Y*'!-)Z&18F77> P0=P=U;HN?*
M' IYHF/O_&>U=!LF<EMT0G*31#[7/3?@$E:Q>623/T'S\]&_9W6MQ[1[%8(%
MM(2,W[!UI&XW5'\]R=I1NM(F=E67_W+Z%O("^6L]%,)D[U3\E/;;*?NOV9S1
M\MH63^WS27G<&5LL5Y],JW]R*B@,M;NB-*J;VS*.0['AJG+=E@MI%27Z''E%
M*_#AMD0;N-B#I'R+%;5_)X4N0&1BW9$14&E-PUZ:S1GLG?V@/=DA!DZT,Y3V
MXP<:FQ1M20LP04@7+MJ(1P@FT^7VLD_[-]4LG9Q=N>..=CWO <@J)N6,>T"^
MC1>,UK[DX'$+S_6+2M'\>\!7VBM$0/!G.>.*O]^NH=^)'@7GD#V[%A==LMR>
M-?17$;<U;3D(P/R#UMD$WF ]Z/F?D65(V&8XDJ,,D?E2/Z>E%>J!U4HZ&*+/
M(N^!(_<U*T.G*SC@]^M;KGN V5[ .>U16=8[VQ'^@@+W'V=#$7<$)NBARY_V
M?PU5Q.4>@9Z:?%XI(QBX'@LA!2@)8KL-#U&DHRH9I"_=83),56B>-S<,EPVE
M'-'7FI6Z\.-\W:4.MY >!E71\XEW\_6&!.85!M>C:TCX>!,QS1;1+S4IJ=T\
M(FW-#XFK>X1<64IEX"&$7E\XW\44!7]PR1X?MZHWX?=$-FAD/Z#G^V8W9]IE
M>+Y^GC[QB<JC0(:>*N&_^9-RA/9KA]3W@.$HDY \@E;E<-E7)'&W[N^3,SZ4
MXZE^.OXGW-CY[AG:H:I$O0)MAT1[F3I:IK"O.GG=C:/<G:Y"J7WF1.0C-#$+
M*",08X*;?QV5&JGX6F>1UWU<IW=]YF$=7A[9E3:T7A'N2PZB&A).Y;^H;0J-
M^PZ/_(9$<Y//$\2.;+1-0'^S$4ZAIF)ICC+ZF\F'YL(G7?6FUY:[?^WB3IHF
M]C0]&:E0_DE;?/+'/CKP%9;,6A5%?6;'@SUO7<:O[UP:R\R .77*Y!_(_X/E
MT/%[>4? /^@[5O)$#,FJSA8S\P$_R02$/+Q,1;NA7AYH:!+UI^S\H2ZN;\=<
MTQMRUQO<?)CFK_GI&J\X9CVMBV<^9CU'509O9 I>$/CJU<[RQEM.> G]E'^3
M!:PN9PJ]!]#)4*$<-;:1A2V4Y9>OO/<26BFP\LR_#,OEQNJ+3H >'URVK,PH
M4[#^[XK%_V_;G[-+Q#T@D8OI;TB%_#FKJ2)L*KN)ZC9![1YPQ/= L#FTA[T!
MC(R%% _$RHJ8@R9^NZ@,[EM[#+U]GV_7FI5N5Z>_'[%CU*9&'G@W+ _>RL"]
M--1P"^$Y<EO8#\"X*':GNP>0KKZ^# R->Q$KO5%!'Y-%7N:\_OI,S$,!3ZA8
M5IQ>YZ$GGKE\Q5*11^Y+16(C[B<Y^,&E%\-#L]^2%[XCCDY\[K*WVF2]-ET9
M/BTKUWYLN-%+G-.LBYR#/+/Z/I@-]MV"MP(C& 6^[;>V?YJ$GJET-(<=-;T#
M%_#/OJ GM^%S^5XM%8VO-V4P^%W$[[6&DH>U#RKPYI KQ6:95>;%X0>\5V&>
M%D97PS3E?Q,[9B"G%GM_9*Q*[-?K9<1J["M<"I=?[<QH#AY^-!R^V<"O,BG"
M6DM<-]'DGNLC@2C '!K:+F#^<_39((UUCF5;&M[\HY>+S+X6/ZN(D/> 2VB(
MO7B$2/V+90/QI?RV7J$\M7Q0SXF*KPZ#H1HM5]/$:LQP%K.8PZ[^$^\[JJ%5
M\Q7:;,M&)FG9F\$[_@46RAD":6";6[FJAY5+,;I45I6-[$NDRR\5%>%$ **Y
M*U;9B3"Y>,6N2:!DA8861.MG["%2MUON6L*LT\:UK9=8$F5K]?LR*]\",T7H
MNYR^$=&)Q;7.8%J4)L[D;C.$9^$<I-H#/;.G2IDV!K]$:!Q^M#:C_47C_W'>
MTIHH.-8N.[A=E6$W:"?M\IJMK1EE7+ 2P=8M)IP"(<L@,ED8WC/%$74BM575
MKI^'R#R+%9#2:88RQZJ128Q'>FN!=UIBE-2D_.OAEDV>I..UV-&75^J\]%>D
MA-@7HC(UH*6X'_GULNDJJ(7U2#E.<"5,!_8U815NHF\[>++-7DMVI:,N_9;>
M8^,#G-<G+(@/0F)MS1]3=M!8>%')E[>PJ1PNN8US!4A\-!U\/@'VKS%K%<MQ
ML6)?R)R.:/2&UO%6=[4V;X;-EE!^?<8V5'\ET5-T-+=L[I9Y#QB4M@'=?@SE
M^W2HY\V7\(NJZ="/O2ZK^L=\//J"HO?]DX32QPP4OO1?N 865#2>,^Y2E.LD
MASN>(&8TS\@\5P_;YF3F2L+WY<@#1JR01']#'J2]<H?_]]CD/YG(O#L-@2\!
M1_S9UWR'Y_WN5?),E[+R[XN(VD-R(WE&I?\KY>>P*T'F'4V)>.&)8,NG)I+D
M0M6RBEA!/.%)&]:!;)[FFV,VKFZU6(EL3,JZ /_';:/<WS(\/]G*3F+=D0,#
M _8PF.Z>:-X#!F8>) AG=]?YH[A[P&..>P#BL#.W# YLH^(^<I9'YD+P[@$*
M#W89R>)TQQ^'UI9[^N")\ /0).+W "KC"W)?]2OST39ZHMOGV8_O =.8\K?8
MZ?> J+S_V G,3YEQUF_1M7((XS]W]R#V0\@V3*\!0_> 0+( E,>ZMFI]MB=]
M64WW/: W BGP]Y](K>Z(+G2K_.8K--7=%\%[P,:K]5MCKWGM8\[5,.XC-Q,Z
M-&@S#GNE83(IUT!_]07<\;%C*F/Z,E^< TQ#F8*@J8Q6]Y_S?R7<UP;/,89O
M'SZ"'#9X#Z"W^>KM8N>B6-9-Y';%-K05.8->1^8Z1=#2O]O7XRE"A_9+UK=P
MXH[V$9$QG53?E@EO2:EOG)*!38>0)2]LZ^CX-&Q&;GC;*>5/,F@OBCEB=ZA_
M14#55I5X2H;-5!0IIK?G8I3_?IQ@.Z4TNY6>/FD7W@#AO>[ YC\ZV@K5IG-\
MVVVV<549&<F#>7)B,*?PSXOVO[O@N@]J&K?V9!U=Z5B1HWWPILPDTY8I"43N
M)_;3=%COVZW3/2#B-+P=9S/D3\QE:=/[Y\?DK+Y,4Q2'GQI2XB,OF"%O#)[G
MUO+^<X?#$XM2[?,UMGA+.YCLP1&(8*,V?CU.M$9T,I[)9FHQE4.Q./,A/:J5
M3&_E[%@<(0L-]"-,VO+]>![50LU&6\Z6CE>WC!^P('AW>/<$]I,'$Q <[_U$
M!Z3QIA[*6UC7V1AY K5:9A-^9FF^IU@I_0JI6[-18;+&A_?.,!N_#6$LH.WY
MN=[4T%M2XD%]-Y^SE*VF)E$6_Q.']D_N5RP"P:-F8KNM]DFQ)4L%MU167?8Y
M1C(Z!P7LNP=@RPAP="&D?SRK4?WX)528+?8(K*,]#VWZ"M$O!._V>=*>Q+A<
M5HA=,_,*'7.K76'%*VY1_/ESXW;K,WO'87_M% *1]DEMU4UF3D2<<(R_F_1_
M2W[.K.)-;WFCM\+T^):/*%B.!/Q>/51;2-F<[ >6BC7=R"V\]4#[TCV/RW&<
M]7T:B"]AV=A@P!?$UXXJKQXM8*"W%,K"%D5F']/<X"RAW52@,H8;47](\=["
M7/>:6)V5Z9N2.;5C1Q6O8<NM#S_H/!M//_U!\#?.55QC-<=S;.T)C\CUMJ<C
MU@=EY6XVO2+3U68])EX+'.W7>#.FLQA&E_R):GZKVCS!*W/P4KW/?#[:LF-K
M [ATN"%7=:.,+C6D7&"KG3UB)5TU&3?X'*/>_4%7'OS7F><\>*.K6QX7@C_[
MN0'YM[W*PRVNP8X*V.F-FB;KQE@$\&P]0"#G>O06,B.+_T8EO61M>3A>6+-(
MOV,X.L@?^29>\KRJ!2**(NOKY/>,TE@P:VX!=MGU#TGY69A1^^LLQ&2JBA/5
M1MNH<',;:RZW%9>#"IHS^]_VAZPNYQ;3<#0#0TP9(*RH[P=Y?52S1HWI LE"
M$SCA&;N$/R_>QS; #ZXA/HW)7E8"UVWA:1S7Q,K^5OY3763'\M9,<?".E#Q7
M4X7$'9#0"?@/;JY2[1NBEYA^=4;S-J75R4TJ#=RNZI[6!P04JJK0(QFE(L6
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MF9X2QY1]XS=C9A_N 67W ,NNM2'(YY]_"^'=>]?DXA6 679H>6CS([J8RGM
MZOCIKY-N242(ELPH@](/^*ZZ^8WJK=P\_W&.IJN:>4N\LI.?A[G;TV]'6@"-
MU.A72\>ANXWVM0VHV"A?A&$7D5+Q*_A".8^+:,*P1T2S'@U])7AXPAJBW#C#
MCG:I4BYG[[ID6F0_2S%[\O)%&./:]UM!TQ?H0(ABR:T@VI JE'8;8FXLN39I
MI@ ^OU/Z\ROPC[[84ZQ,=!&N2TEC-NS"V=5EY7I(">49A]!8?0?3Z(J]]!,*
MJ#/!KGTEM"6-,R@<^Y-1&B;[@#TQ:SA(QIJ_J16',P:FO)_T6=2LTH=?.C.^
MIZV. %YE%%<*;X;%WLIO,GU=8PH@!'OU2TVTAVRU1@'KJ:C>K@;?W /J;_M(
MG2:!<XW<IN%RS]5/^&7X-C()N62<$(;.5Z<BCZB 35;+NVLD*X]?YDA:=&]Q
M%+PW@MHKGMFZ+3J</IOG,V]I_,'/MZ/(YMK?DSP?'81]@%U2AM>]1A[<?4<\
M*X)G:P)VO[%LTK<\0--G.V2@X$WV6/9[!@_H%O\_TL\>=T+^-G=M1ZH^N&1[
MX%]LV+3'V>[QP#V [9W\#9Y!P)Y**S)[**PD)&!S&%U_594CPU=BPT3@GHVU
MG]99X5VT9D39U=D0U#>AGNA2HZNZUJ;P/BNTTU=6\V/;7!4OHBGE  YF;=9$
MML_41N@5?LC*6]&KDCC;6QJB&BLYU34A@[4SY1^F^./4QMX#^HD/;OAI^'*S
MM#_KN2LK!?^F_^V"7G I U=IHX79VQ7&V L;V R^B4V_TL4&#YMAC;:<R$LA
M01,9)V8^UASQI(\ \41OB0SBK-=_\V1<RYWVI<A)H5(CVQEJX5"K1-B[AF^E
MA13:D%^34A0[Y6#%$]'C]P;0<ZN6Q&X[ET55\UQ;:*T6LP*Y2.V;%PEF]!N6
MU[ )NG3)E:6+*1%,JTGJ2I\-1-&2K7U<]O"U](<V* @BC!)70?:*W6B:2=36
M!XD)&M9FOSCFN?*[\1S0L"]2O5QD>EW7F#V LVG#-OL3K#VFD9V93 VRQIL3
M/?N\L[OCZ',&C4X*3DJ8WBV0M]JAWYWS>?.^*OR6W05A2/<*%7 ).DJMU@21
MMK'D"-+D:3?):V?HI:)A_51R@FB+ KOK#,^)XH%233O^9XUJZN'/F+$5,+$<
M>29!H$J!RKP@N*0COQ4H@EZAKN4<X*II8V]"#GN TDQ3U7GW@J2_ILL@RZ_B
M<\XTA3]SK\B29^8@$O]$B3V([DMLT[^T#= #J;^3<1MQH=>@-(,^IY)7<HOK
M5A'YWW&^X!J52%R3F @D2B>D"8&W47-9R5I47G>-I,D)%Z')FVTEHE54QGL@
MPFPOQLXHD1K;+@=OOH5'@D\^2#_:G::_H-#H%9-*:?-&9!H"@S29M&E_EW=Z
MQEMG+#_'&A$L91*05\RXJ,)^X-]^^PJB5[2OKK62*C[R];3&RK[#2AJ+CR;%
M;;T8@D"_9=-<V&^ZME8FYQ[&3[A=%H3>+8R^1&-L8Q\&?L$DM,=Z;9#FUG_)
MQW%NAS70FAD:4Q'0J^)A3@>WA>I6!#RM9GHF^";_B>QE] V,*P A*2-JCL+2
MG3T'G_,L=-3'F+4W!>GS_?AV:O93B(?>G1X_BV?H5@,!4AI(6QVL*'Y->^+Z
M2) @LA3S<3$#@/Y3;:V"3 9CYT5NP4JJW%";'?2ZLP7IH_ZKKA/93IE2QELF
M^_7QV'OVSEO78\):^ET:UCF*3?*"[U_P!$VZDR)?SPK^:B'UD@+^^]&TOS7D
M^3T@<6R#Z0:OZ"[*YZ\@ T_4O] 0(O?[GY=7GA_]7Q_B_/?V_#!-M"K</:I#
M[)H]:_: (U)M.>?="_MQ.:+#5'^2A9-.NL/9.A/;4:M9Q_P'*SXF@WQT,C(=
M!RSP.?;N>F G3/5*M(.]CZ%?=G\:B7@C%5>?E;?-5&DU-4M#,'#%5XA]E3%!
MV0Q--4 "GNNY5FG!AJ="#[E,3VJ87MQBLS25B94?C:UPT01Q?7+&8DLS.&.*
M33N^]=%*VLQD<0.5H&-1#I0>-]/]*I8NI_5,DQD6XT<<1Y56M_(!Z(]=E*+K
MU-&-"04J[C&"-VI_QF>)'&Y;JCZ59^."/_7UK#'6S-0O?A7S3 B?]I(K]U.7
MY#PTF-_EMR[LC:Q]&/K/?[T\\3^WJH0NV^RE!Q@]'>P*?[RL!>,];B=D!7+3
M.,)%8KK"VU\+,Y]SQA7X.6MQV1MX,'"YJ;IR4HA^AE A3-$<JW_#0BR;9]J-
M6E/:2)UNZ"\_/;>27]5=49/[&C?:$A>TWI ==4?.C/9&@&>?-'W75PHH9J5Q
MKVO#\B&Z")<*O$XP];Y]A7K328D\'+,)\M/Z!86.,IV.[^*A"8L6]=+L[P$U
M5U]DG*RMQ,./BMI@[W=;%T"5M#25EIQ\[;'84P"2;@R*57J@#"A\P5URE5_/
MQX?A-,2?=@\J-%"^JK;&!OW\]AX OPXD;7EBZ6UQ,M@9J'!K7SY_/@:RUFJI
M:0]QY..WL"F(&%3BHGXV4[!?;7,-J@@I_=;8$&$>H<X6\A9 (PNFL&O?Y5@]
M\6"W^(H&(O5ZNYZZE[41X2VI@QA6!FWST]ZSQ?H2#*$5-G#A*."7>@'J_KSW
MU;'J6SL\S?< +Q><HW?*?5S7M'NVV/C8L@3BDN+C:SF6R7'!_K)WT+5G2 )H
M'?*JC[89NA/2.0F_12%V\)'3T9!:B?T="R1'K3_%/:!'[B*;'FPEVD6!#@42
M&:]591)D>"*\%1R57FO@DV5LN$UQ=.;-R5N:AAHX10O<OH:SKA_HN;8/.!79
MYL:L)PZ'??'>DARRV^]D,%X!>^G,R] $"(\[D .+IIC'-.R&'JF?O+WM>J/W
M$X5+W$# I.MZP\EEDG.&U3NUI+2%U0.,2/,8"KO5,!</G>A-']0(BV$/DPEK
M,E-T\&$:[%PCK_]1R=U@I5_$-['Y]*DE'[GVQS1&%X3\%T8BE%R=7_&*X0%E
M57&\!YV?](>6^J:N[NXS1,R"T59T0J*$9*7%X#IF_2GYK0$RPVW/M2I,I(,4
M@<W/:^GK5*/>*<]GD<BA&WV,10=\?3 T1( C Z2,<RLZA.+(PA9S%@3<(S9K
M4B ;*K6U@2,;I&))TVDC3G#[GFR''Q0>$;P55>E:;0MDK[\OP8TPEVOU/3=<
M55E9L]0JO]]8-8QG,\_8W .>WC+D[,\L&=ILY*X5YL\!77CKQES#>'@3VZ@2
MPFY>13I%R^&B58>DABXKBXHF6Z.4+[TK>04J>=<0 G]VN4)@XZ:?IPPF47I#
MID1[4H5Y!<J@\H.Y_?V[;)>\_21C)?/DX3-CS$=#$C3/7)6M(92H^KK;)S4H
MT7Y8VO[ODTI=M843CLPGLPYPN3-(,\#G7<.KEI-[P.80^,CB]BWZ,_M\_7<'
M?VI#=)):==V-;,%@4B4#_S4,RB&=MXI#O>5]]?X]1.IO9GVQ'$-G',*/!0K5
MOU 7!5>(I)=\NIN(WV 9D*+PZQ;@QQ[AK)#O?M!@:\F5M[+5*,*Z?+MKG5_;
M._!UH+&09\IOXZ/'AASB&KV_5?$FU0:\LIZBL_/ =QJ']B(=U0N\N%$= A\:
M? V+,?R@EN:C&?0OAN4:7#TLZ$3M?1*_T;4HJ:%I-F((1P^@<Z_P&%;GQ6$$
M[..SZJ+]JH*C)Y/ZWWV2IB +7/+6\@"-DA%?CBC6U-8;YT;Q*Z;/L5N>6]Q*
M.]XVVV?)VKJWMJ@\521_$7O%76K5U!/L6F,[2H-79P8&)7M3SXTL8(XNZ^1=
M-!XMS&A1A*S>ZPYP]HW$E).7/;,NX(M.<I@LD;9^T;M#O1+=.%!$U1T>6O4#
M5#3F]:[6CQTH,?LMCZ]4CR1UGXABK],&9'&J0P\EWAWW%-VDDZ[=-<>I418.
MY<FS"G"Q2[7IH'2/5-97N <X,$KLZRMMA<9L+O/) ].6#6%./ZN#_%YJLFJF
M78 H\K#<)[]\ 7+2-PJYZ%Z8PK%Z4VA#&@IR#]*NTITHMI-L6AU@+LM*S/VN
MK]\R_#P;X@Q.&! I+2KH14JM<G;#"4-*.?**;..7C O2]O>F?^F YG]9X!).
M/\+X6<;(B.Q,W=24/7(O4ZYOL+7,&*3Y3N7)NYOHDZCI^O;6!7D!BUQ6:FR$
M\G_U>CQIK$7 ;UT3"<'X)=/C7/3$,@O3FZ5L^6Z:D:IY8791N:PPDWUHB15F
M.<=A++HSN1JT$=/E&[/N)?,Y+S%O57"-+>I&%DW@477,G-MU"_G;=,3Q.Z#Z
MSY^I]$OC.ZVCL\Q,[T/CE-3-&&&5!5%-E=$9LX[Y5<:3M^-ORH/M$G&ZNV5K
MC*9"Y 1M3,10["<Q>8HE:^H6(BE77MEF"7QFR5*#L]48+E. SS\>."+ZFO.K
M1XE(GG7YH?BT"D=KG/(<>_L-FW7>Z[?F;D$N8\02Y/ 2SM$3O&2[&"(Z"!_R
M-&ZGOG6![W/<N[JI)0\^N0-#C6;A>;89H6JLUEVLV3*PU\;ZUUMQB]+EH4(&
MY0O+WQ=T%0;> I4"5-3+;$F4GTV5)[$*/L@SRE#&B*>7>9-P9/XMHS][N4]_
M^:?'9C$NHV2C^$^@!$O+L?QE>-"#$X3XT]P#OGH9A0&3-#5^=:5J_'CL:#Z6
M^"(A1*9F#RPR;P<?O:38]$W3[:H+"P+]:M3GNY ^%EOH3X'+WM5XN)EC8"0T
MKFYS!2X2*QP]]6QU"CHW9NV7BFVS_U1S  ]BTZ-Z,SX^G.V!J8Z;=U,6:!2;
M@+KJDQJL -G3TPYT)&^O6]=!^>M;<JO;DB3PZ,>;)9]M9& >:5K#_>=,"#I;
MPD:,S?9_FS#(-GR>+31\7JE$_COKW0LZYZ$B+=OFA92K)QN-TA-$/5("H0T@
MTW=SO+J3IWK?@#X6GLLB7RR\7WJ&#KT#3$%@G*5W4XR8"[>*)8>NBW9BUUE%
MSU)^VS/87<Z_V3"C_%BHL^$R^P]";JP30UP0541=80T@2?>H*A:>LA@YFRT/
MO*2.[^8?LX*;=SIT<UKF?-H$*_59LA(*#/=\K!I"BM+X*J95F3*%Q]&,E=MU
M3*[J9=^T]2G_0Y6*_\1=G<'_%@8$^WHG(_N&YQY J#H0UN&'9YUC:\)R#P@)
M<"I?2K^A;A=V<S8CK;>L)56AIH_\<W0AVD04*Z/H= D4T&L!UAJ*9E"S7CDW
MK46[3,,J)%H<7 86SP^5-KS/UW%,Y0-!_:VK6TL:N ?BC!_4*JE\");67"4Y
MZ=USU_LZR9%=H8Y5 A!QRC9GF5?7EI]W3FQZ^S)<24+5&.2-8(F%7<5#3[_R
M>#^+[%42+74)-\I(,9':]BJIE-$K-X:GVS;0Y']929^CL\!T@VIEVGDS!0PD
MC[<Q-B&RL<%:>JC)A$*PG_M2/39K:_!;\<0QWA_F+49D38Y$U#34!W8I1<@;
MU2B$7(XY9HI**N87IR#,^%+U[5!"0\F;-7252.J@U,K9@=M(J9%,:QIVE5%"
M>@@#ALO<O@$7ZOT@3E[AMT[6+EK75V:4:V;+OQ*"BJ(38OMGWZ8=T,\<^80F
M;<ICB]P]G>%$]@NO'%Y;9[J4B*Z,L;F:;28H@;!8,X)D2QO#-J8PP%Y]M.SK
MX9]G"_Q>>Z?H>U!VG)%0C!Y_52A0BNV2\SXV,2U"I_;##$+3^6)^G5^U&K'S
MCN-T'",PXG]B=(]LS[<2]0=0H'W6#(TYC3H:0O6$ZK7- ]T6OG [^PT^=TX-
MZ(>,U91L/.<]]O^GN,.9Z$"D7:!9\GR9D.5&O+/B4(6/5H6%>1E89M_'O\ZO
MZN.!"?M')\>&)X*-&<OAN.'Z=Y=:=!)R0>T<RQ^ZYCS #=C6:03J;&>)$'^D
MG/\5:Y6H!,PC1H[G!MBPLLR^':11#!RU=':E":3!DD%%EB@V^2866%DLR'CE
M0J3F'!I\GW^>._;@D]HDI3Z?@<#X VM8)C^;"G@**1KA+S0@@:'MJ@AYO(E<
M6P--V%?'AJ?U*0>3B*WC5]\X1YM5G9*;)]\"[,<O3",Z>6"\>77SHC=C;3:K
MQA;Q56NFK>H8;'&N]N\UT#U5V61[:5EMQ:N'NG#CH:R4@MD76MA;N)A^PZ+T
M21H!_94V*T=Y2*?0=E.G$D70YB!R>1\^3PMN#47HX\^T$>L"7R1T12.Q#*J*
M'WZ.U*^F6%Z^]A=93.E]Q8QXFV["8\Q$30X]BY6&Q?"GSIT"Z$P$D/:-2EZY
MR8K^D&3:VIH^)HOD\/:C1%F@*&4;2F# GW..3&O!XV;YAN)9.+M+?<)T!L"0
M\4]A#O\]((K0)JNH FW8<P] QA_(434BVW7GAG+].D25V[^/<I!@;6J X&[1
M9C!9J\T8C %&PNH'@^D_];JE)0($T\U2WS566<CLK0_$\]9DU,+$HNA6W^)S
M!;W35+_0".U*7(%W]+"Z*3<Y3F8*#AATHJ,0(*"2)N.A86NJAD(IGVMILVDK
M#H LSM7F;6)CSL.^^8&BZ[T'$-73 8EM7P"+#.VN78OK* - OB/T),W #D@Y
ML5ORH*Q]/T_A_!T'N$I_EC#5KVIMU?:7#CZI4'RW^].:YL 333=1YZC(.DOU
MPO/_*GG&_;\A3]R@2V;1_)GD%1K<+1A+4>X7F>5+R)S N6EH8XI43#G4K<?-
M-8I\3Z?1N_S#QB5+!T<D=P'_Y\7$VFJ]'^!#U8[YSA?@QPAIR8*:NIL/B9/A
MKU66 <9#C;YZA3.OK$9/"(P4I]_-**OU_B_N3(F2Y#=^7O-W, 6Y,Y'9TB;_
MRJ#56>-G;?BQA1& PPQ79:Z6ISW/7M+8>A5 =4>Y?V9BJNJ"X*&X$<MAW-RA
M-&UC-NEZ,2374NEU>8+*RMY<#_0)377NJ?*(((7#>7^K,?_H_()A2G]+\S?Q
MC@VB/?.^WX M!4Z8S?&*RJOIG<+<5HE"Y,=*WPS<"]M>T1=CF? I%9=1+0J_
M!;=S54/3XZXH.$$2EZ\?_RQ(\=OY&0Y)SE"C>I5BU82Q^.4K=$\11+EAS@)%
M49%2],NOQ.-Y@VWL8A] [8\2*0[]IRX5&?&BM7T#S&SKXO7&$K\G./17L3EO
M)C'QXJ4L87P^+D%QO)4@+2V]UIH"97(]YNI_%<;,ABB^+P /]<#GE7:H0GLM
M8FM&FW=A.P!8 $N=2H^A!;&"@S7CQ9\M5-NE(;K)%_5D#8@ -RR*&MX#N =W
M_%ZJ_< CU7D#[@4QK0XC6JN1T;].7P_JL"'J]>16T4TH5BVT_H:LGND\_Z<O
MR]V#V+\<:*R&1B.E$UU,6>]ZWZ&K$)S]]P!R]/K'A5-'4(HP_0C;^,P(;QCS
MRZ0OY!C1A"]X)N18_/]5&5UZ<ZFA;'E,GE35)E2=[]BI(,UFWH.[]OFD;*S]
M8M=&!J-PM115A S_$>L\U*-#68:&E=7V-E9>ZNC2N2@L/7C'6EXX^55^N5_)
MFV_"*IMT]O$*GX2##X&Y[4GU?S3NR)EB&H DMC"IQE1[W])%^YD#87#:6;\7
M67J91[JS&DBPEI0,PY::>HL-!N["$IU!6@QD4=\#E.[FYB_HRIJ)TB =M6\8
MO,0D).A1QF)EJ$9*6 ,!:Q\C-?36WJVP*S5 ++ZZH*-NBT.8=U:E@@-;FHS-
MTIJ"?7?(& ^(K,PN6]F_GJ=*"^G3A]L([9^T?CN+K2GGK)0ZF1QW:Z.'663J
M@?#)S5HS.L)".I]!)+I0['%A];*L_08F;> KY)KQ@<K"48&[CD>R3.,9,<43
M"LD#[%-CKY[U)W9K!&A@$=C7('&AX6.BB_32=J^!.D-M2\_0Q&RI[3I=;IC1
MW'D5.=C0$&D$_Q;$0Q>C8Y8(]R92NUUD2]">LH)8_QRI\&-"[(9=J*)DW-3%
MDEPV6W /7MAQLX#G'']],XNW,,]X(;,12V#-[UGA=/@IE=LW2V-S*I11'GD1
M%G*2,U/?M !A<'-/F=8LN=O5;<SH1%"K?F=[-"B.2?,P55=]ZSC@Q#,$9L56
M-KF^_EZJGAA7(7Q?S,O43K"_JKV]]OCMQ_@7Y&:$NZ)PM,! XYT$<B&EQ=;6
MV]H:W&F)XT<<J1(GSW,\TFT^/"7!&FBT\P/5U0N']8^T$Q1-N?B6*^*-B4SW
M:I9;";;*B^>X)"33#$'>NV94EN,H&[X?\7\!(4>EQLD $5]3-9M0!+%YCPL3
MO+T1=%$:?L]!?3P&*H+,G)DKNSD#/ET1[40E=NL8!<A\3*9CW5G6VJ?K)'^B
M:$O^U,P].XL\O/CKXHZG5F3/<XAB&R%*-7?\[+'BTAPXH_K.%W<62Y2_/"TN
M?EZW:"QMZ&B_;%^.?;X*@5SHBF:&,@>F>T54GN=92;UB-1LC66:SIAFF:T6Z
MZ;9;(WE,0ODXEGO72&;/.UY#>WD,@20V=VRM-2D]?8[F+!0<B&?JW/0U,MOX
ML#G9YQ-Z4,ZB6Z8SJKJ(,Y,JI,6@>*=8[);6+$A&WEL$E:DZ(/6Y34BU6(&8
M-Q<D_WDPH66W"<N+NCP.[VZ"ZIHM18ZI$_DYL^PCW/A/L$DS2A,=J?8D!":F
M6+-#B"E<QRJW<&%B:W/=?^QT=M>E<.DB ?QJ@M^%U$VJ6#Z04TWW+C<V5=V6
MV_PUK+*"E-Q*,-%!86R(%=P#\)A,402I82PHO\+6&L&(6PVO_(Z,X0+75ZH.
M"?%^XD0^5\L3'@X7;0PB2Z:O879'_.9-?$\,55Q8S]_Y6E?8?L[Y\,UJ8J6(
M?"$N_2)@J4D7]3D];S\Q1KSW.B!DPS"3E$!*M>5],:E^?D+!T[1G8+CZ:B)0
M@2?@'5(OYB*. G[@=2T;7%CSLS&JC,Y8P[S&=4E8!=<?!7S;3I*AU[S3$C5%
M/V"-(@(B<^H3"MJJ4]!&88\^L#Z%ZU5J^2QPUR7(1##B;3@MP=[..)W+<KY'
MFF2Z@0K>1,-OL[BZ4B13A']+Z5/VCLR%2BM."AO_0,M79@?U]6[HQ[R_>;.:
MM'-W:@U_D^W+X'GC4;G^8,6(3T6Z&&SN*&;=@<?VA\,&)PA]QX%V3^A!C\9V
M&95#%OFC$V7//T7<=3-=;]_&#I\Q8: M^OW)T05;--9S(&OD98N4J7*)JG<$
MBUDZI/!K)?"FI\8D6SW-H/?=CM?GB']_]Q7RY\8E8(0\[JX7FGU-4O7S<'=J
M.>I.+3_@DK+^'C =X[$I'T?T'O<>T)> LCU4?^TSJU?O' *T<H"EQBLDC/!H
ML/Q4"S6N=0EA[$PV:@V%?\0\GQ*5S5R!4CFO+ ]/3^%%L";XE&'$*P-\Q;J0
M44I-R(6)%;'9?:]+<<]IH,/UO%Z=D)J"G(--WDB 0UH58AV YH<'4-M*:396
M.97:4/;N&:^:\-9H#N.G/XXF!$M.-;CZ5 T"20\NJ2C=Q-+)Q<G8^X_M"_OP
M)E@RPCRU4R0O#O6I3&2@3AX,=M?Z6_:9GUB?;F%_P%**!=PQ!B=\?#Y5=E<O
MZBA+<F2"/PWAVR2B6MFK-K1+/)S92QR_CEJIBC]"GE@1'P\#&.F\-DU\D5([
M]@)T4RY./$HR!E9;0RST0M5QSX(7YSWO ?0RAB!+OL2#D;BESD%'R[E-^[ P
MZL79A.8O4FX/K'^K';#QU]B#3Z277X>1U^AE'2L/_HOG*\3*N*1U76]=]71E
MQ?ON6.8[62"BL'P4WVWKMVN=@;)%.W$L<9*V9OP@DR+6#-V4/.3-RP49'42Z
M?GX'BC/\9Z;NNE;S A2*L+FMUBBK91(-O&.4J!*&=7+8KS'7-=9F:6A(XWF_
MFEFR;=0VZ-G!B!\@!@P=ZE9T\J.#8.];YI-%2CQHML]BMJ^-A#3IM@"#1SA:
MLERN&H6!XZV9V:'^%.#/3$2V5/YL+:%P/\UM@<M,3SK,VIB/E:\<\D>[+W[Y
M<75BH'5^'@I[ZTV/>%G+_;S4O6Z!YM2&*A ^"A(JGQ,OWO#1(RF\_0 [7V:J
MI:R>-]<WL+D'U)^C*],X+5*>&S&TR*#>V3!1WJINMGVL.&:K3GC6;/^=]A08
M:1VD(FE!]V+4&IX>H^G0(Y$IEHD\5$A7AB9"<6Z5JQ975E0NM0]LK7D%.3R'
M:\CEO-[$8P_8[]\#<""LUC_W[@'+/@4-F6MYEHYKUUM&D8O+I(0#AKKO+.G-
M,GN;#9DB&-GFCAPK*XY%SLDTGOF]O^%@%6K_L5(F:53R+$MX-J<>75(%MWUA
M>^1^LU@Q/> D>I=)T(_DNB-/F*^-!9_G##H5FW!R"F$7)E#T1Y9_D#HW(S*P
MXB$=5]].2E(W_/'/=F+@[(W[P]OYZ!Y0W1JPUU0U1S+;)=SY;]%]NUMW0T4'
M[IM7\?7:RMZJ9O\WQ3GTJ%!N"/Q[ 'X[]?5"94KKQ$Q;8UWHQ(G_9.79FP1^
M2_BR C_.'^#K8YY!>?MP\^R-><1^4>R,A['H"7NCM3YKN,DKXS[.\>:W6IO#
M@_:O;5_;"ED>4\XL@?7ZY20ZYI=DU#?Y>%[.O7)8MV^ :2X['HG1@=%R;<WG
ME:T'O^DD3/3S/\Y\J.%UZ:81W6!D0,GWW/@"B=FS(R^ I,K\F>++O!X$NO<
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M&?-@XI&5,CH6UHV'&E&#K6^@K,#9@IIZ09&4\2DG#&'R\&J+>,^D1,&TJWL
M7%AC[B(@1"JYL:1L+&>)QMQ6@')48SB5E&M91GWLI4L8#8:MY#-M[M=\JE.W
M@>KU2XOHI,%K\1"1[Z)\*A<LM5D('IM?P SAX4UB_(#Z;NL&^XZ+=IORL\'2
M?H!^]Y.L[$R(ME<!VNG!"V(VE%3),&R.B,20]3>*XY7;/*P:S9:(@JACTC[\
M]&B[8MR1NN?>VV<FZ85@NKXU/G19U4$:?Y*UGX75IB\F<O_%YU$:\16'1')6
M,[.7FU^&&033BE2X[.X!%?+CKT%U>PUM(2>,3Y-I+>G27G17,^9[D)=YX!F)
MX''3?'.TZ2/H]DF 42#O ;U_J4WLLD@;4DVFZP/"B4V5^7/Y( *^?]NM"=)#
M6C(FNQ\^]07_UABWXEN)BG5\U5RT[]8G0]M@393'Q4D%Q-$1IM%:CR),9--;
M.U/SU_^I^+OR%R"FS55A#.Q>687&^?!;KB_R@&8[@369#3S)H!/([3=DIW:R
MD6;+K)[G;3%XKOLT]4!:KW^=* _$<J@_(_.(,0D!LM-\_(<9Q9%:N&)[75"?
MMZ,SKY28^/JX^S/\)M1S(VWO?![)WHLF7=],R;CL(JDXK= \Z[/EU:L>:/%?
M^IM[]#->;QQKG)/W0879@'UE[P%$4]4+&MF&=,VZ.M%CU F!W 6A:@S.LB6@
M$_.V</4G)2+67U#5YG\B_^CV;6:'G<K10( +%]D--O!D:$/Q2_B!OKJ'FY-3
MA_\'!3QOSLS1[T\H1TZ- X[*BI<T."./SCLX^PZ+!G@)1;MPX!.V1::2ND]U
M:7!P6 #BWI8E*T)N Z]*V"GG%NV\;(7W'M"_)>;E_P#QK'\J/RQYGFV=1LD(
M^/WM3/-,+G*,/5C8XAV/5N20<6F+=CLTV?]IXVE",^/@7B%%XF1AC=N#KW'+
MG?>XGEO8A?C[2TM%+AJ2$[J:P\A9'?;GQ1T)W%QBL/>!Z/BAOBQFY'HD*LI>
M,B;ST.*D1V"L^083;C^M$PQ0?,*(J+YU\LY= FOHI/<+*V%&IIQ>EG!*O/V^
MTTF-%#]V0F$,=)'?BF\\>)Z5[CLFPX7ZD,ICG4K^BF#GV1IY+IR_*XQ8/O!,
M+MT8F)*DIN+A_-\GN?&N7/;?%O\5<CLERLG(@ZXI7!JZ&9,GZH>E8E5G#B["
M#C U(<LW:O[SIJ2=V!![7VJ+VNP^4H5$.-S(D&BM\D6_&N%Q]QV#1%7./<"Z
MPNTE"MBW[.>E.A_0P#F?L6)'Q2_("2=:4V'J:_K)^,4']KZ VUF'<<J"0E32
MM3*L4)UVC(ZUV-(\B.@ESRX1X&ZX:'/H&,-M*Y/)('9=(=G*I0![ZCNC@A>'
MC\/(\"F\,]KW>UX"J[>V94!K>3?E->$%GP5M8I"=K";]A_)UA>(3DOP@997%
MHWP>'WJ/DN?EHS)*EPXPD56LWNOLKQ<\X2+W +)]J9AE.[%4H2?)MR,_H!L8
M0<,'??@2&[$+R0@!!K0/,&:-&)5Z6=$ ^PI=.WM)6]MUS5=P)A1??@]P=P04
M'FUQTE29H?3ZG'#0.VJ6**K0^DQ/-7#$!=WS74O&+]5L1':S3@3[ KD!%HT_
M/KO'"8S</&H"LEI?0=I!0XT\>7#5'Z/+/WZW??PM +<VG/-8Q^C;E)5#$"CU
MPU?G<0H_+@\S@GJ5G:1Q78N_4/*#&1MVY:G/Z;JB3"1:H1 !<\:2(K08>[#1
M,BL+."0YN"/TPY<>P?:D['2\%=@L(R7:>I,)8TRDDP$YF) S]J(_T?92L'M2
M%N<M#N-"4]&^IX%R2]#@+)X$GO#W"L0'X_[MC$?122.BVJ4ER\F@ZXB>,;>I
M\X"(UJ[(XW-9I9XUVCKH+4\ KK2=0!E??<KMYG3/KYJ5[\]B^N*5+<&ASS?_
M%LK0UN0.M2EU?2)_E-0A6:4W5U_&QT(5.3B)]SP3KJL!3A&UMDCY!*!/FI_+
M!C8D7DH/-894;KV,<)X)9BDYP/  7.L:[8M;ZO'8ZWK? X9B/EV]0F:ERH9L
M0]]U-EC@J3\)H4DH?/0M83$6NXH%Z=GBO5D53>L-$VVK(LXT_=#24+]0;TI.
MEVXK*0TZ$=FA#E?!%%?-($FTWS\<HP.]%(T]6./YOM!7^B:PV\P5&ZM9]I!C
MJ-N?=O9BJ:%-GLA6-VW\SYD'-6^N1H0PS#W0BZE_H3<WVLB /'>Y9<>4@M?Q
M5A.5U,O()#5989X/+#(Q,EJR39VROVQ\XZ#KSOQERN/9#2S<II,9%=M@[U41
M8+=LZ_^L88%VQO%"@$'=B2%KQ+.@;7^'-!KW41_I1)MT2U6]Y=RQ57OD\7&.
M;_&W?+=ZLU:N?R8!JCGU!2+HC<"^6+J5SI^J&(I)^Y8B*#JZ5<C&T^SO\;8\
MMWPZ@\ZKY:RCX3@[\AQ(CPX;E)-9D!%%Q+"<[) WUD.S1OGX2 (\&M>=]8A@
M[I'+=0-&:"(4_X9=&@Y*(&+;U[<+>PB<:*?'3(E0%%Q_CJ_ UT0SI&BRB9@*
MDV-$26L6&Z%]U3MAI%BQ\+N#2?$TH0^!C2\+4I,6H5A?_$GWIV_%D8-1B&,\
M]873\^^=I@V&0^XUZLT9.1X2,K$JW!WY] SW@,T.G%^V65R;4Q&TG0UY>WK0
M-9;VEL:V)M@O_92-A.?1\M_6;IS%KG5-2AXL%&98+D2DD7:PI$P)D:[H4FIR
MD,65KGEC=$ALLV'XI9(9BW,[FAGB(7J1(<<TP\*"7;\JB_^Z6R7^V2+3J3/6
MH[;KV0-_JIF&"J8;SK>S#D[U%3G^?6X.B8J!TPYF>AC[JDV1OD1+;8Z0&B>$
M -E'@X\V!EV1B-EV5M^JBF]7K4[ADWEN14._DBYM!2)9.:ZZG]QVTSM6YO7
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MI*<#K^=AAL5J60I*8* L1I.M9DYD@D>Y[@;<Y5+4.^IHJ3LJ'6IQT=U]65*
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MC-Z]D=;] D&7:Z3(A;42>Y?BP4LO/(R!4K_O?C\9Q?M9$L(!L='"^HTFDM5
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M;P-JZB2SA'+Y.UDP/EUJ[!=*,YR)]&.>FN"U"-\,\B4<B&JN,=<@Y#4%@BC
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M\MW2GB32M<#HZ>%'.6;?D;5%U;JL SBP",:,N=2.YD@3E+7VHZ<]OBK CI,
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ME^& X!>'#&G/2"#(XN"F)8XG!LRR>:I>3OC!D4;7Q:I'F8#[FJ^-DS7*!"Z
M8\.\-%P/<JNDY[:UOL2.:@L!ND69?SS[[S#;2EJD!\[+,SBF?#/39"/G?I>8
M^@,]HU>?.#$R+VSMDO/,LR.*@>(=6>3=X'];./^OI:SWGSXAV*L:2U+^*3=2
MX2D\!]2#VT/^4IT>_$*46?7Y+2;U4L_[.GB-ECAD:Y&]8E.*^ZW OA>XHE-L
MKF6>$F>:N<SSOF9<YUWJ+\'$QY9 3]-7[7SQ[RFJ B.2P0Z0>.4[K=F' R-'
MG2S>M:X\ZHWWT,M'$O2]QW=JG LD&<TJBW<6QK!9US2(>3RTPQ +U"93T4W%
MT""<GUW?EY]+^'LC$9WDOQ?^@ /S2&<7%QX^<6%FB.1W!-Z3.O0#Y^R= Z26
M3X0WZ CV^1RD^!VFB(5F,$E"Z_2>?LHY0/TH ;4S=[$DUN)_5F*IJSA%Y1P7
M"EZ8^O<#@['1OO 3GA:]<T#XQ>5 Z.:>C]^O:3P'O Q1*.P[CGBS%R;F [E(
M5?_G>LP'\?]A1B160<V+M)38M7"T/7@.2#;:^AVA0"P\IOB_3?%_96KT4U4-
M*-]N1FM$I'3<K[*X@8KJ28[#>D13<3/WE3"_<M(W$G.BBM_?\&:<S.VPOQAY
M[X^ 7-29^W0;]^FMW;2.9L&&770"O.RX< ,*:-DK/%Q^:HEB,A(Q9?78 3=&
M0&YEL:<OJ*>?O56F%/\V>$V^S;<1+U#RX"1Y[4>EPXN7YP _+>XS=XQ+48M;
MUFTS?>^Y?'QB](KJ?VCC\?] >,ZG_@%02P,$%     @ T4MN5K+$QL+<W0
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MP'B91(E4E)3D.G")D824D838!O!?R$E.\K<"_,]"<NE"1@K*RU34-!<=D%>
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MF7!]9&G\@)]^WF(CV3_M4W79G-7[K43PL9&? ZGBLULFH:K1HR!Z.3@%M(+
M1#- -8W+:]G31)?HZ]9;IK;51NJ]S[DTXZ=;<TM0-> NS_."0$_FO\LEH)5H
MQ^9LF)1Z-CQBBCQN2)_ ZT<1^%2PD+/T_T %)9XE8+&;DPK=HO8@Y<)>-42
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MW_/!UYGQO.0TK'H/#AGZ/=J\HZ_8ZK<EN?3:)& I#>NPQ^^U6L_Y_*Z^Z:C
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M;*ZVT1N+F<N$[2@AQB^@J%')?WII?1Y'Q4\$F+7PUZ88SDF\=O%D?[DC%W,
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M,LZV/&0F8.2/['\BKL!XSK^IJD^%AQ^(B[H^ VP<?0VW:ZI$SEI5"[9:0RQ
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MNO4GF5/%][6/$Z)B-POAX>"-4QZE)/<O?_8-.XU#+8QPU@BVA@PME_7C,:=
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M76Z+,Q>]V;NE%T!!.9X4&:'3ZS&L^^Q[I!@%BZ&Y!2+ZH)^[S5\_W%M<@E"
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M(R'WWY(I3>FX\ I=_L$=_4(VP8-!#SX3 &&L=\:QBOD--H[(^]OIYO&8F*N
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MR2<=E0XK%OY4.44<Q64Q![V3[P1T9E'O:*7)'//=$XFHDVR;@Y]];\8EG[
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MTY/(UFAI4QQ(,_A**R'D^9TM^Y.1,T-<\XE:],W%[64:'T7[/#NO5^^SIH1
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M+=N@,]+4B["3;QR4'5'D"CQL>)K-R_^$KK?^N]T/4S*T]YI)>FRNO5':WV_
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M &[S/ )@AH8 .+,[9T3M'E[(L CA?\,)@&K]ANE3OY&LG^[O%:GU;H>$^(V
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M3@=%ZZ 0T3ZVA<MVSO.F]O&VI*P9MIN2VI2?+PRI*N;N#-^E'_)AL2[U.#3
MK#H7>I!VX=G:FB4B<[;3V="W>N.E(MMU@@VM+[22W<DB_7U%H+F@BL2<+ ]E
MQ5:,M[,S4AW26\=3O8-G1LRIZOWQEX\C(1Z@4!DT>'>D>E)6:<O[6)4+X0!9
MC=A:'*K9\[766IA7]'3BH.J)5WCTW6/]=7^_!UO I$Z-_E!ZUD8;.<1*,Y@
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M_8"HYYC#GC=SNXF);CN.^OL=WO,V39Z!F4+1YS_"+C!BT=]6&3K4HWM:^'I
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M:4-9EZ-K4(JH\62WVW6)?RRIRY1^JJ:>P7C \!T!T/H]>M?4Q<G2!2UT!IO
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M-S\W9NCD== :05ME:T>X,ZKO>6IB.>?.<22NFO\FW'\87=_5&\5M,.EC@A2
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M:G@:VO@$(GQ$SYHP)$MMU]ZW+1C]ZX3!S=.86$S##P>N7%K*V*C&:K[#Q1
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M:;O6YV/8EE6;NB4!H+?\$MN//L1&,Q( .-@0 9"5<E)A_&<#7B6]#/0Q#5!
MB8>LGHUOIJC+&)KH%AA^Y_]"<404!62Q6\A@W%\Z[CTF "P&24([OB&&H2<^
MYH?.QWXT&['<R;P/)>^WNYR*G7 0 -7+_L#0,ED!4%CM-Q]E=[OZ)[F)O*A/
MO]HMB4?/:6;%-,CW>@2U9_YJ]NZ^09/#* D LY$-U5R8)2YUG[2!I6'YISGK
M) $ Q(^*IP@@ BSCGZ>O?B9EV%N7_YBSS_JN1YF9Z-#4%=BY3 &U:TR+2LU9
MVCFRG9 5:0EJZB_6B?WYM<=95W2$9'<.D8;+R-ZA6WKES^ W\N' W.6WWN^5
M*T:Y-!G2%.6<'0@#5LY\U?,$=@^C84(A1MIP<$J7?CPL5%O_(5J.!)'OI3L/
MFR-^E=';RC=U"@(NC.1Z! ]]V*R.6N<?^_(T9H8XHZ,"3(/E8SR/+OC''TZ4
M"IULAO7;QQ,'^[_6_500.UXIJ[YRQ2+3F<[8-*%4YERXHZ2;R!<N7$E)'_2@
M#@SKA 0)&KEOX-O*2#R-_KJO *,NZ3J'Q)'+FN.N?TV.?I1N3-'LLQ@'D4<4
MW"3?G6XVW7%Q=16]HF7GB.3JHM?MXR:>L:J#^X$P.1K-M36-J,T2)U=7?#8#
M_SJ9T%4.\W1B)"JI6QH>_L%'#ASIFP\U>: \M__VSH3L'R7PUH'=>* 3QSGG
ML9I"-OJ\]UI56'PD1YL%!$I^3\OX37VV(-F7N4T5X1PE?7E-E,E]O.I&WZ.T
MQ2-EEU'1\LZDL=+1LG_N_%F+L&ZQ@'?<'CT%4L]XQ F8+:VIUWJ6;E16N(>M
M!$3NJ4A&+T>7.=>9WD73YN2(ESG\/[2]=U237_,@'D5 I E*;TH5Z4BO(M+%
M" I(5^F$WDL  >E-0$!!0'H-2 FA)O10I#<)/8!(3Z@!$OCQ^>Z^>_;=>G;W
M_/ZXY^1Y3N;>N3-S[YVYSY0?6T;,'RB@:U)58]2O&ZG2'DN@8,##QP<O-QPP
M,^CUDC#3;NS"[Z6OT,ID[R)S\L"6D*\-],]D6$^JKH_ID\2Z%H3#Q+,V,D("
M;PIQ#R;SV=LP;CLNH8F<XW4YC8]X'32Y?97$$)'^I-"Z8,V@L^->O(;97;$>
MJP63(1M/H;9N<16%%WKH-.U:T:W;BI32+VE]MX0=N)\7W"']T1.<C&>Y J28
MKN2>'VCCY__MGL*L<22">70A._N^GH7>[W_[/(M-VJVX7F=_8J[_)W2]H&(O
MY.!B!&C(&GA,>;L'<21F[F>)_CJ-H\[^F]\FOYS[\2CI'KP-XA?)7^7E?&=T
M?M"!(HO99^?;%NEX6XR6FOEW?O/?A\P"$[L2YARK(M&"7B-D.)>Y#@BSEN3:
MP6*_ N?=)XU[&P]\V!SGP(# P6SB(]?[#J@_J>6++-2[+/;FSVG/Q>^E*!Z^
MWN6$C59IC!Z\[Z@.GD+8VR.CP52HE]"*V;_-SO5ZCCYCD0G6 O'X;V?GS-TM
MA.^_'J68XI#:B%@A%8GM,Z$?G^-D&9?M^/[@Q8R3\8!I<VCCT!J_9\F6V.;G
MSK'/+NO!$2^#]<)3I^N^E(WXZ+].1 85X@,Q+3KH"OE^OGHH?!*^9!=PKF\1
M_\Y:0F04VU$%ZD$P'"7X:F 7:BTLYN<=T;-"/.EC[P_IE5K"W I0I;BL$]_6
M42?FK;EN^H#\N06D74"RJ0X-S/?!37+W![>.3<8R3FRYN@_M]?PF=)K@T)B2
MUE@68^/=5:('.TR"P%,-SCKME"GQMM.B1-C+J5:>E9&HD#O'(;3F6X83OYE<
MA#AK/FK6W46N.QT@] P4Y"]4_#RVU5NADZ@@]M4+0]UG9(D9[#^*&.,II.?=
M$_.;_%HE0XIQ++TF-ND51;@X8#W(2ZL(FERDO['7U8;P\)RD>;48/.Q+C[$T
MZ4%G/][N;C ,<<Y]EBA-^]B*FTSN7N+OHD%=//#\\NN^</1FJSRVHG/):6;/
MF_#ZS:2SZ]ZBL41<PF.F=TVZC>JLP9L$34ET,T<,:138#@39Q$+K?6;"T(]4
M^I\O9#?M(^G^GFOLK A#WA=K*A@7FV[)9<>TU4]81P+EGI(8OZ0B40S1[L Q
M+1.4>RSO.TLXNPSN-C1^T7(:[F/ZPDYVBST?:C'\6/?N6996ME%/;MPB"Y;M
M"A %P4NS#<&37<'>\BN"/,;%MDSMBFXWBK E/?O4H 9+&C0T_6]#FU"+<13,
MAH+&;0[1@IN.ZDV*,'D9NL+&3E 0A5-,[DGR0OUZ5N=5UC;(N6JXA0-69:NL
MNCGJUA=S5[HJ-IF/JQ"T9D@0M[OQ$ G3\ W#8+8@)!W-B8_EC'ZNY.RX'P=Z
M)NS'*)YV\4'CU(\IA2<"7\*&IRQD0__JV'U\,@$Q'H>+X83E=?TE=1: KVO;
MFAJSO00@4K+O;%T;L7W^T>>';^F528X0=_SV52:.J>_9GZ_C)A^&7:AJ9GF0
M;(G/R[!AC3D8+QGX0JOVJC=:&GZFG!P :^R3GX-[/K)S<[,^/J?0&WRI#STE
M[Q?(L1(0T%YG^$#/8R2+>M)>; 0QQHM@IF8Z_/#:J'-5B.),2NF'M"\P>ZE$
M:8Y]KPH.S#"#TIMT$#J;'P]DRYB;4[E]^>Z%';O=PK#\AX:3FBV[OA&V_&9E
M(IPV!\.V<\G\%L8^MJ;N6Q6GOQ87SN#>']L3NA*L\HKW3)?\@B(//.YU/2)\
M!-:4R!#E-O*@X*!DV^A7]>!DEKP9^K^]HCGT#N*ZH WI6T%SG!\ "50UW2%W
MU,9Q8R="U]L3S=]_"U^1TIRVGV53+: 0_]G'-3I1^H-:"N?*XJ?<TWP%"$O[
MNMG0EYF>#AE)NU79L<*Q4Q">]+3=J'!&#LP;LJ)L21M7>:,X6V'.:?MB= 5F
M-\?8XV7@Z="2DE;/PA4]]O4[0%S7']FQ;8B]%9"4Z*IUO46;IHTO*0KMK/J\
M+;!\L=QT++1K$>--C7(NBI;J_&OD6ZPNP-(.9[S6144ZF0UC-@@5.Z]NQ\])
M[2L<QG_WSI-7.R6!2I?FQX;]EWHYF3LTY.P?;;.-V85;G94[46WCK I2*7W4
MC<_L'PM\*PQ^C@=.K>$.+_0<+;Q1/:[E(%!)C\0P'2=,@Z:L?QE0#ERUK(9S
MC%7BY?,VSRUR:;NL[&Z:ML>,Z;TA)A 'BX+OC47%!#^H:PVE;(-,70%^R7R(
M-N5(!!WQK?CNFA?Z@3K2Y32B(2)K;;7QJFP]/XUOE2KM^8H^" W%&2G=B2]_
MG690T73<JFN@5Z%QNS[>Z@I ="2I;(^8K=8E%*?JYY#$:4\?>5T(YY8]IEX:
M/,V133*,MWZT1_9!D;HCA!+.ZW=Z(H>K\+?S=)"L_]S'.26AD\XI4'HAGO,-
MR?_@TICNW!Q#C5X,QS*HI\_H7KP(B(!O9WW=XYS+%5>7#[^ILK8Z78=P")E-
M52'DM8JM#]][B17*Y-@A&+\6C*K.X#LMX"O=G?34N1<%GA\;U]P8\/0;CYIR
M#S[F#^; * N-H<#<N):5D00EZ@8L=>3^K9-Q<-U3'.V<5J)5<J H/GK-W1P2
M+(=3[E6^&V(%C,NXJ^MRXOM95&=7W)87=4F!4=FC-G#O4XZNGAP)NP(P@V6Q
M(QT_09?L3?,R.A7\MP\A/,A'JV?LGSSX]2"[BK/VO^K,BM_2EX^#)XOJ=M>N
M !J3MDT8D4X++JPW,D:2A=_EF-] 8Y_7BED\7J#<BT*>'9GY%\]3:@8$N;\'
M7]I<YHHD"T955L07YF)XN)26IR</B^K%=1ZBHHN^KLK<A'LK0W/#*L'.00IN
MCBFH0<=2\P=/V<:&;Q-W]#(>XRO&8K,-;"!)WUS$[+Y? 3I>M)*]+\61/\/J
MMXHY-GO/S/Y\2YI))O=1+KOR_H7U5!*.US>I<#J8!;3(T)@:^'<FS/Z&0G01
M*==?)N"&A>>%*J[EDF'0+P4G\'OSA/GY.$J%B\3IN?3:ZL>WQ\AW O*79.%!
MW"'W6HU!J>LZA17)>[55U%N@88CN6#=RB,,Y(G?ZX'%-!KXE/3><8'Q.ONI*
MAURNIIK?&I]C*5V>^W+Q0FI+_.F@UI/\1TQKZ>?66(M JPM-A_/UM"^9?%&2
M02[HP,"LC,C^W6_O3?T-93WYOW!Y=#GHJ_I4;2/A-VMPH<4FJ(5YLUDM!V^V
M7>A4'E"<J4#6\,94,CR^T! 8<4GY-Y@N4PNR)TF>%</9'*M5M4$U<A)#K_5V
MY>GP&B,2X$8B,!I77+#O G[]!Q[U<-4U<0FE=!M+O!11;^[Z"M8PH;#I#9*,
M(?Z>\I0[GMB7:J=\X!?-R_G$DMA%K'1WMFDG__*C!V,\,_=,O"+WUNUB*)Z:
M?B,'[S4I\ROVWMB/C=P_"1SCF7"1&%0$68S79PUJ[HI45KI,T>Y:Q:M7[KRJ
MA;??>&3D1B3;XZW$@PNT0>L(T1,%!I;T%[Y(-9DW$2=E>95G2%%9*/Z$"!DL
MZCA7DO\<I<X7%?P$!4(EIB3E;67ZI$'D-0JW9IZ)\&*_/*%.,VL-3#/."$AH
M]^DC!IMB*[0QE@E>2]1;4E6Y+NF,5DT,Z;-+ LXOGMH<?O-]1T\6FH.32>U:
M(O&JIMK*=-HNVX(UR+UNS;1(\Y=K@\:)<HE]#,VZ\ZNB+<M>AA&=/QU,^A<U
M$^MR7"9)J;^TZRLUDR%E>-#[<TCB%F-VS#,<B\8 B\/1$'#OK#5J_^TO7 Q6
MB2-*24FG3?_ >HQSS"8-HO>%C$_Z+I)=^FY>#/BF)A$?]YW!*T!D.6;5Y!EG
M37J0UCYQJ@DRQ/J#D=BW&Q? [#6V@=L&2XT_>P5:L+F=$&JDKZYG65 A\.0U
MB*5#N(MAG]8@V6]E:E6?&J9J')#443A53R91@:#;/N0^>&*F/>)\<62#LK+'
M)PD*R[*\NNL_[)B_:>PI]'RR.B_9\T(+%]QYT>V^\'L!A?JKJ3M_,.1451WQ
M\ 6OI2B)<'F5T7O9LYHAU>+@\7.IJ@IGFT*+I6T1?[J4S6D&PPQEB=B=>-M$
M*T;+A9_*4F\2U45U!_=GD5TFE:,)STX-$+50J%2ZE.=PA--H[[U3CUNT;O?O
M,OTFZF."[(JLJ!5];[BW!#*!0SUM_& _AP(%54'EXC<:9,;<(V57N0]T*<=^
M!JXK1^<R'^5&'F[Z^&+.,HOPNG(HR75HH^8$2W^* PT5.0# G>+'^*>N,L0^
M@?QM\\1.?9NR/APQN3M]^#+42N6D]+;\NJ%(O: U'3@YS(AIGFRSU0:#&NPY
M3T@L;(XX22B?+>AB.\FQ6OP =DU(?^[]6+MLW>/V+1IC" ;X+.-5E'[Z]NM<
MX] 5>TE9%YC9LYHJ!:B3U> [TX#5/_.><[1M:=!YU\QSUI=9%WIS<SB09M-,
MO=2$=_93X./?\#R[.V=BFJ_ZX5IAQ^WDV=T;1*S3DR'UB4F!+!8.Y^S50?F=
M#;5F6S65G(R&R^ H$MW=\"YB4C;_BAH\T?@N[4*E]ZYC)WIJ@_[T53^1PBOM
MB\6EC9BT5-]?Y#<'W",A/CB=/ N' &C%O,6\6@5Y2/VO&9;L7X]OWOV]Y=Z_
M;[C WJEM%7P?=P5X@STNKA,N^M&?G\6F'O@H3I<US$"]79FKAG1&9KO'UWL8
M][K#\/)NT]3B^/D!*$A]LYH2TL6E<2OA%-_ZR$EL@P+8()!?R6-+6$B@VRW5
M4Z,C^E>H!=/_R&-PLXDEE#2O^E.P$I@&2QV!MRMS- QP'BZX5A,FD.X@FM1!
M00^]SK7PW.$V"M:4U!=_JK*TD8FFGV$TM&Y$9=P$T [9I:+##+M0,P:-2Q]
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M$7GG9HMFMT?Z V>29PR)H$DX@ST#G [GO[+ H3=W,L?R"+)^^Z+]L=C'A5Y
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M%\]S$WQAE_2884C>;UR06>$,+."[*"'OS;'P#N"9NMN/U',CKF)P8 OANXF
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M#47XJBHN,UR(LHH@00;<M&\F PZ8D63 8)O/O,1#XAW"K9PF,8(*0(LTAER
M-8D<''D:H,YXMAN\B)CIHW?&K78ES1;,4H,RPT7,EW[^(U>LA8=QGZ\B1"QL
M:VC4_XP(/)W)MNC@67[IS?!A[YE.W@>!LJ]' 9AY6CLU6CSU7%3ASU<-W[V+
MI5JB>YLRQE5]HHE/"*KH,[YT;!/PPK?-_?)I&Y'MVGW"(7='^-&S=E %:U35
MQ1QO?HA'<"_P<S-/^%NOK 7K-1TOF7+)Y,,J:_IUA2T/!^89+9PRAO[M<X*\
M 3_,C1[>R^%$%)8(!>X)V(,(#&3 1&FZQR$86E;>^M9XU69@."IKT.?%7\7+
M8@E^9,!=JTHRP'?^U!.$UH*JGS'LVX9G2ZH3J?$Z'BMN\ LC![]SI%?E\F-U
MJAY&>&IV&;3V:!R&XR0#RC3_["4K7;4E_D A*B+2@>U8KUH3!^_^>RUB*5T!
MI[84?H/G]IC_UK"NGT&ATAM2)PJ_4UAPWC9!_H-:$E-B*^/Q-5D$\3P9L#DT
MP(WN/KFN?I]&&>SM#!Y: ]W:)@/^02L0E]W$ QM,*B8#%N3/4HUHC\-+9^!I
M_=^K#PS[?O4$J/G_[V ZSKK189[1_,L=I4P>\@94AS:2(&G[!IS[5L"BCJ<-
MXN6)?$AQ5P][]M4^N(5QY.F# M?77!#JBVHAL03EGTJ)T0WWK;-LGR258CG9
M*0--M^9\#=8Z6@:HC:!JN&C$UTG?IU.2W.I2*XHGO3ZYE3YL1%[<F<'2)*=M
M69:Q%I0#38CSMO#:+=40YFF#.%-4M1N$JVI]U^Z05BBSEL'__YH2U>Z$JET<
M(?$1)%[BQO.S)^WT!YQNF#74A]"K-C<#'Z[9Y*9$Z#@*E&6!>$E\I%80<P-#
MF;'1I(?C9NN4V^\#K].;]S+O#5#'*7\Z]E<+G. C ^B1>'=2V$ H"G=A8FNO
ML5"I_[GDKON[DW1$P=[9?)+*H[YDL3U6XN-F0[0D X(AA'HRX-YJJQF!RN9/
MT?[ +AQ1A$;%GY(!. ;0N'%' PS'2K)>E"!*K[;-'PNJ\9XYF$_S#\FL\KG>
M/E1^%X4B 6#%M7"/,Z=+$ ?:S0B6 Q&H/5WH_;/0 \/_D%!6^5D;!*=E&(P(
M( ,,7;CQ9YK,CA"1*%P/@A6VEDJ(( , 4< _))\^/<TQW'PWB0P@G"-5K*B>
M99:^J-\@=A@Z44V<#!A2Q+.2SG& _I!.DS/A_X:(\M2RUZN###@'6_&1)@-:
MQ*$F9$"F"T:"2"$#^\^2[(GL?:!!"TSDY P+S7'/ET,XB8(,Z/U7\QG_:3[C
M/\VG5A9,,C@\0\.XGRBU R12DP%)A+XS']7^NX^&_T]]V?Z!,ODTZ9_C4I7X
M81;=@YX89&TF27!P]AT$C]Q[?."6>+*BLNA.B;#K_A^&?!7SJ-FAY\RH9$#S
MW[<JS?\+5]A#GA&NX!>-AC]L2SS!A43L?)A5?#AI.'-OA^&;ZCT;75:UL9.+
M_Z'I*B%.TD&^)^\0MO"O00?[(^A@_SSHJ/\AO%'_$="??<X::74011"727)6
M*"N;?QK> %(GL%PPK K&^=*CIR/![-?!L7U8\5Z7H9%M#M UE>)N_F9 UU[9
MH)V=]Y2K0^9#*?T'1T0P;ZEX48F101RI9(U)[SY?ZG]7;/01XQTP349.IN\U
MRD$]OS5AFPRJ'WM,KSQIC83.2:I2LW'[)_S]A[3_4[5A\N2_ %!+ P04
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MU0;[UM.**%[Y&<<7[K1R<]@L.*<(U_]S_]8P4\483YMKY65-?M'-GW"",09
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M)FA/32]NF9\&C<]A?DD#54]GS7QH$SR^/"FL,Y%-D D%T7E0'F3TDR2&+=,
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MMU/YSD31+K0*Y$.+D,RF8%?F HXEKO$Q[!O?J9M@R.I5WR[MYOVZ$_#NSZ/
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M;=V'Z=JG5L8K,",V/QX$, 1\PI^UYM9F>2)S6(7.*6A3 /M<B>)HTF=V[\.
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M@UKEZR.C6V>VMG.65V;\_2'=V3[T$%LG ^;4^^1-9(/E%]*^34GNTS5^A85
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MTE#T@ES3A,>Q+XZ+]V/J$R_(:!X;<4R\T57/4:W']_G<'4"3^X5Q+BFM\EL
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M5\DK/",L(]=G M&^9TY/7&QCQ5#!M:4U=C(K%.U@N3N&9K$T,B^.9P(-X4Q
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M:S2D@M88P4P G<60FAI%K?#7L;I%/6("I"<KB=!EMADUU/W5%Q>B.13%\MB
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M@0@C8*0YI6@DC'[Z\>.B3-N$?5;:,4&+)9<^<6CS@=GK?!F23(#"QHAXG<L
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M6^4-YX0R/8-MYJ+,=_\&4$L#!!0    ( -%+;E:^[K%TH:T  #;4   7
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MP$W9?#RFB,2KXN;7QA@@M:C]"*@MZD*@^PY6-/1:IFC<I*XWPX\0@UNI=>F
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MT0_=Y1).</MXD?9V*0 U%X-W6;VPZVJ9*3<H6[3IK-)U)X2(6'SYI#>1&3)
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M7#PEN6<OI^]"7NU?VT>-'ZA0>$(ALV.E2H!*P?:'B(!PX(\67SSN4O4K:40
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M%B#$MC[CUM/LJ4XAS*;-\#6J6#BS6+&__0K VL2&K!>A7M WDPYVOG8GE+=
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M&Z@XYIDK4,[R;_#H]BKE4.IX6%[D;B:EB*3:YT^9]=A;VU,KWZ02H989)S#
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MXZ^_#E[G$$W;74"F$L\SLKQ(AA/XDKQ*U-G#"^LD+%!N!2RYY,*$?3I2/3,
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M]^>4O";!R2T;/Q-U:N"*1H2'+&Q,<LWF63);[<C7C*<\]RPY2+C2-*H#G^"
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MTBG:#H"PQP?<-A\=)?2RQ [2>W;:'@@6X=?ZI0)P3O"_L('*,IROWJR_4L:
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M+3(P,C(Q,C,Q>#$P:S P-2YJ<&?LO =<4]VV+[KH'00ITI4B2%,ITHFH@("
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M%JMQ #DPEE$.@O&,X8#U6AS0[("EA[2IYN* (6<<X+>(X2?0#/V) ][':N&
MU'7L13-:&P>0W4S# ?)#%^<0Q'<J&4$Q+)T&".N==H[" 3 5#$\2!',".MG%
M 6W^XAO_Z/T?O?^C]W_T_K^H]W*XB;2R1A=)?D0+]GG^?2)Z[3_3&P,<T..@
M@P/<.%=L-<N%("N2^9!ZF@,;8+3S6G:&_U5ZL_A0X(EVJ!$_WEWE6U;?"?_/
MJJ9<I$6F+^" *3&CY\EPT"G>_U5^!F@KT?^)]"RB,,''MT]>836,7!/-<<"-
M1O6+:4CL4^*4?RG3OX$X[V L+BJOPF@ZO=/(AF JXT)"DR2UX]P-LUQ%H=?B
MHEZ1X(7H,2O$;4,8_&[/^H#0BK[+ S(S\FZ3@A[VPG##ALH4'@MR]UVI:SY'
M$H>@,)^KEDANU"1RZL-^"^-,;G XQROFNZ!H"IZ@>0,"M'[:+S0.T!X#67)^
MP@&D#6I/O!:##5DF7AP,4^1U?)1_4$H)^N6X:3A_#I+' :R@FGH1B' SH>\F
MHK_+$L[9?D'0D3.V0_*L/')CEDQN2.C'>?T/L>.6DN1W@X++.. :QGBBB1;;
MR4%4-YQSKZXKU]KN%=$P\!5/V=(Q5=).!V]'TUM_Z*P["G,7%D4U@PYK S/Y
M@+V1[)1.<RI>O(RQI=P_P=_,"2XR6DO#G8W5^IQ,KI9^$8$QGEA=W.\9E!U^
M3,* &.ILYMPZDXST(_$QD=372[*OM+1/BBARI_YAO_SS5*R:B-=\#"U?R(HJ
M1.=##?U&U LVIO0AOSC(&/$WC >W&4\Y?[[<HF9]=\/SJ%/0,*]IU\LX;]]E
M9B=MP1?[F-UJ$WP=\QI)-=0)GBF$A;QW\57>$A88)#WV;K5]-T*B?'$R4!&.
MW1-GNS3/IJ9=I8KZ0PS^V2\W\*>#BN:JVV$241\Y;B*ZWS<Q:L"M7=037T8O
MC:.D'WWN;OS2[4_&CB>Q@*&ZR'.!AANA,F'UC2PG;5B!L8E4.]&CX!X=!E05
M7E^,:!9!C]Q4/XBLZ>XFA!ADE1::%%F8O353I)_@[H;LSC(FFS<P*;<(>!70
M;724]FN]94$ V=T]Q.!C,N%B&T6Z*:FM*939'/4Z<K @=%93E$&7MX8P56S@
MB42X\91ZLTZ!H)JJ>]F10J\0T6N/]LY[?F2(JF+H%KY>Z9A=5OW7^\ES&;?,
M*QQC \"77N9*)6<(:C(I_"RA&\+@D=#]N9N[U3'7,Z-[EZ*O"S^<:.YNW$MB
MYYGZ1AF-A\O-.^J00G2:T?BB+F+9=("]X^JN;;. 6*GE\OH+!1KG"K91ASDG
M$^*$AM@M7Q-$.=PO&NG=6M7$.\)=%]JVNA)!=W"#S3\S[JW_XRT:+[@"*3H3
M7E6_S'EM%GUROWK41=T:F:U!_^I)T,]7_@^KCJ?I]ZX[V?9"7FD%G7D@XJ.0
M%.?FAMCAVYYV%\DHZ!&;PZWZ_NZ%ED'GJ:3T<Q&/P</'R/7N8DWLWM[9K'J\
M;2GA6+T_=](2["$=TP>"*)M1O7"L!O:18)_DX>-SJ1_TEJ&8WI&F6Q[.\!!4
M?"-2!1X56J'AISJ]B6+A<;I(&I7#SR4GY9:SNP824>69JL80HYNAF/L7"7Y\
M[84VL5OZ,U1QX_?."J6OJEXU+K^YMEW[SG,[4&Q(@GI+Q"2NSZA7R=5-H6ON
M;E('LCM<R </QF[<893T$\5B5__B9]5FTX,"4;?P\+2N)EZT&"*A \P"L3RM
M' ##&9NMB;\DW+5F\8UK?3R2T<_T[6*3S$SE14"D]S,9B85,9#OJSI0KB&X[
M*6LFY#U?3<R"U=X=^X0^G=*YUU>Y(E:<APB2G#1NN:M=^B\5?4Y)AT146OOM
MCV?ZG1!B X]D9?6O1^>+=Y2K'3V=J")[?@'1$UI>6^J [4K4=-C2<4I:@$O4
MQSLV9QUU68@%XPA1=>@1WOGDTT<>VP<$WXYO-ABW>54E+T==VXZ_] 9^W.CF
M5H5[D<B8J=>[#M; CLR5KV^7]TJ Z]]BG_-:.T&W,;U1[3^'1ED$0>V3B^;#
MXM-4AS9O!*UB=TL4;<.O<[SBEA:>0A:3:QA.VSY_EQ%ZBY(_(Q3X6VD R8GQ
MWX=L)Q8+_%;\5Z<)BG9C'WHEG/_  3>+97Z6XH#/"]G8'5!OWF4,YO^._W<2
MS;>*Y@^I_$&HL0F,W<TO_3#/BFA"KX!X^6*^.);=V7HWI]PJJ1)65/_%5[E+
M$Z(W1->WLEB/W]Y+/[^9;TW?>U5AY$#UL"RHNZ]=/KZI,[-8HT*]^O@L\JQZ
M[A3:N5@>#$72H)XAJ@-+*&4L0\7#C#TS#--<;&5NZ$4D.K?J<7-+24D,H2'Z
MZ(M,*U02!883L7JQ6L0U[_II_X9!ED -=1^-=+=4EU:VKZUJP*;>_*SO,:\@
M3ST'[;DFAF>R21A#%*9151KHP&!PD7H@:*R3%VS!:A%YSPP@%%OF^P$505N?
MBZ/KGZ,YD6J+78S*G-?0*7'?U3^9N]\DI"(3RLJ;.V7W,I= :=P4,&J63#L^
MHT]K7_&)/6?WH49"WV.L2]#EW6=OXV7\QY;&A(@Z2GO6),C)6)E_X'>S'.Z#
MC5GNAAI5[:GI*9A<?%.XXE'?@@,XL3>WSQ8^HV04"GFZ^C8&6(5@)>%!> ;1
M!]\.B'QIE^7Q,+HP*@?E2&>;LP]?)L.DF _ZTY\N!MM:TE=2F9*STY7J^^SY
M&M<BJ@,4:#%6",D U[001C!-@Q02G!B-T75V9O7;4YIY1_*S@YKINKF\%%0;
MC8=0[S!RV*F'W\9'A_96R!L_L]V(OAG-^3(./Y/N??AKK[6FA$[V6XVZ6@4_
MXB,D1N9.@U :B)-.2+"VXA*$%JT\.-3.&/-"<V:X2<7MC6P<+7U*2ZG<9ZG=
MI]C!10*,*NPRV/J\NLSS"E6\J5@[G/H9*G*L9H<^K7Z+2;]DK(?FNBLTWU'Y
M5K/G/.J',$."=QHCF@2VW@7^U2>LWEZGXG\$_NA%6:WA:.LQ1=O)]1IO\##Z
M,TF?8NL@M>#,SA&4 UV^Y!!1)*<*2^%[@*3.M'8GBDS(4BLJBB >IS[M.N@,
M=B*^:SKD;VUCM!86ME4D?OHZJTXV%>_\+D8"R1?0;&F;1FU;9VX],P[UT1M9
M59:*E15]_G%]^P5XY_P<A(9J7B0UN"^ET4ZS4SR?S$H1GK36;OE)6M"1>:=K
M]>Q<?](@,UO:>V[!ILW(N'?N- IE,*(@C%$8S41(?I3CL\BQND<[UV TTJC*
MG.TF%)J7M>HNQMY!?;?3D9,>PX[L7R;V3Z5#TK2#J?K]BOP]ZF3SIE[J];YF
MGJOW;P5<^%:/SK7HS4+V97^8[G6+(;K;Z- $L/T0'VF)Q=F<T1VS2N_P*^QQ
M]WDLJW.K!',S0NUJ94MY+5[3:RO=^/!W9&S,3=R7KH%]_\)9(MOPM_)_G%I/
MY!K&@PY8QYOG0TXE .L1[1=SG98.0H=]GUOI$F)4KPED!,2HR@/LVT'#"C(>
MQITLQ=FI7V=2YIBB5F=M5+/F?8/?'!D'<<8[!P5]8W/-='\YJSMLE37@Z=J\
MRP3SWA11BHCZY,J_N\=3Z;GC(^TM9_K:7KO%Y6-^.[Z4N"=)XM8S7?//ZBPU
MA,2 ?SL)DG[K;_:B_ROH_[ZG[@/9[BK#AY:*=ROKY#)UFDO'5B/8;L3<LJ<U
MD>0 7AVL( ^==18Q&DC]=MM]&KY0.<%L:RS3^/[+T9?)C\>3K-_RQ*Y^5&=]
M%*K/;?_TF[X#TABV6MT)PMOR8ZVM]>9V*1B>[TI/6GC]$MF#MUWYA<U]19]6
MLAW$YH$#GB*.3.7&CT [=G1GPBH](V8)/\=%N'# L]'$.]Q/_<S"ZOD(I.B7
M&],@[5IH$"1/W4X6U'SIQ;WYM,%RUG=\E"Y2?=B+7S0%97@DM%<E3,T4M;7K
MQ,O""&,:?CYRN/+@J22WNQ2\T8U=LK,027UVH&':@58\6KE,\1C7=VGG]WBS
M+/>RW]U-:V]TY.!'1'4ZL%E58UG')1PHK8TT,!JVS@76/^;D9Q^T4]/QG=(F
MJC*+3 \]U(7^6CR[3 4V*ZIP0  .(#S" 90>H?V="^QC$HW2/^-9(BK<G\I2
MTD6F)W"7MEY*&S$5LH/A@^U**HU][GR5.ZMBBW\UAI9>8.5$BB%77]#D8.>1
M@X5O6SFD\A+%?C=9Q#[$ ?!"M5@&7N;%F4N8.RQR>-D?#D ^@]A>@MK[]4.8
M$!S0J1?)WPE8_JE*^Z(8=(&_#SK@Q $,1E*9]'@IO]>HH"IPP!%%PZ6-03#/
MK>#A3XG=_U3%^:?NGF>&WKW_CR'\8PC_&,+_[X;@M57.2' NNO-ZF<^2$WUL
M-6H6[R_FHX(#KLLNGJW9JI7_5O8GY\_X,_T68 K_-$$V]O_]^L9_2 22'9 #
M@D8<4/*FHO"W<MZ_.KFHG_.4:@N\UXY)JMC^+;I^IY+YE](0[&^2]#$'40H+
M[>X49]9/0 G$;>\JO'@L)=3BY"E%$(E!OI!L&YHQUIYJT+;.1 =/3I@W?GY(
M-5#PY=>-\_0 ONNIHC)OZK@?9*4/Q@>+%'&+J-0>/:?7?K'6JD3_%.^_ 1$[
M?,0!*R3>..#%@+7>[S_^]>F_Y736DW^='[S/XJ*M!-#_1A[5N[2(6%WDBI=?
M84;&'-@P\R%O_LN<Q[T] EK,)'+N SY'"]>03.WL8)7)8SMJ#^[@3=X(RU,]
M966JBNAO;YIV>?A[E_3\*C,VL3=']\1W'RS(]DM/O8T&7;\,V^P?-TTJ2G7>
M>[+42=L\U?7IW;) D\")XY!7'VD\?)+ \\JR&G+\&71B .$>1I7$-ZDA(0$-
M*N<*Z$0)'$ SI^J866Y']Z.'7.LLOV5+GO6@%0I!@Y&ZZNC$K-/)#F.;.P&H
M9":'5+$M^6<HT&1&,0/#$)69B4R"3]E(2N6EZG)@_\>H+9&YR[/D]C)G!R/Z
M%>+DV51ZE?'L!J9&:-=@2=U1L,CQED+R5\MIEA:$Y8?*Z"(C$QOP56BEK\U<
M\+AXH46E,7<7,^/U5#/ B^YT.;5"6'$CZEE6SX"2NRM[1-847=5TNG+T[#!>
M[!GYZ7F[W?)0*"?E*OJ3];+L/,73AF#;76ZEZJJ HLP/ZIYW!YDI>DR>,;[<
MCIBCOB5IV]1>N5.?]G#D14*; UO4)PB5CS0\BL>X*=^"O>-S?H\*-W7F]!VN
MNIF<;\9/ONR5T&NK)CU4(,,!@2D8&Z3*>]8V+,5P)44*M]:$<$YC4TW%YV[>
M%GW24@>V#VPQ>.N",TWF%Y$*LNCV%A!;PZU<8UNFJ:1[M?F*N>#-:DD:(1VA
MHBM2>GRV^3<"KFTH+DUM)NS>.!?U *.^(.:S@ZN%SMRR7^Z@6+*_Z_(0_6!6
M2V6G)GZV_)F4JPG_(AQ#D^U!@IJM042%"NN<:(]R8*<TD[3B]/9$=$QJ5RH4
M^R(=:S@FCCR,*BS>?Y%V55W$# E4W"S,!RL/37C/LOJJ#1H;U^C %RQN\>B(
MK+[S"A1<3?L$H71U"*S#F HBBD9+XF,LN=?N=:35X("%\*/>,XYWMELM2@\]
M+8G3;24J?ZK*-Q3H/,YBUM,=I]TT91<HB3W8BGJ0+2&QYKA([L<_C=$85NKP
MMCOFOU/MEM@;T:A2D-J-V!*L@<;(.<!\]5%>R..2^O1RA2C9-/Z[O&K'MIX@
M:L4SCN]3PTU7T)6P*&85JWBCXKK%%\J<.Z(]C!92EX.,WM77BVL\\^K$$NKF
M0]R\,\LR8L7?U&H&7$(VYN]$?_SP9PQ],I($&-T24[;"^^]=K?[_".;U!.\Z
M?Q\J\:$?-V6UOJVKU5 Q;EG]GFY4D7YKU)\$Y.RX/%H#XIQ!$^\_1[^]1"$W
M1A(ZG;;CRQ_>"\SC/;^R!LN]>V!^@%:P=)*=&G_T^N51T0!WV\R] /F.LS?1
MYKD:[]PU>+/+'HVFUII]MT3FLK-C]B]\6X6?-Q29;:4*#Q_O.A@@A&3"+3O,
MG]@F"J&J5H*?9-1*=>N.24/9T$I(XW8LX47R;L6 [=/J'U,868M[B>Y9ZM>9
MP%8?RP2$+-?,UNWGJ-W)S]A=ZL7'P4^-'S.>+E^I[(GPF;SO1%\EJNS9Y?B<
M#U$2YEJD5*B19:!1T'&7_2B^9^P[RDF29C"],*<>![3B@+L+ PJ+4QN..*"\
M^?V^#RU"O75&)),V$#NK]5!.>%*:+<%"8:D*1'YDQ%_,<YK\.MOB9='BSIM+
M*!6Q?X$!8V]6Y.4S)U^$+A[17@;SYC <T#&U!MF-RE5%L*+&$-61Q:MQ=@Y)
M0WHQ;_T[NK!*+8,R7UN&.+O!><\O$34#J(7;$*T-:V903DQ0&H^H^$G"1?%A
M-O8H^E*G384C+1K*=6$S1K[K(KRF*9/;NCM6XJW.E$Z=^0MR]NEQ[T,5"5]S
MUNM S"4O"!T@^_#+;$UBM;F,)"JJ(^I7=\M,1<PG^^4?QJRQW]+NX;]Z>Y[B
MCY78B6N7JE'M/)+A.HV)V?+(W97(G3?"B M3=0[\5$;12GT))O^V=+2\-B.V
MOP_FZQ3ZH1;3MA/+31PQ#(L+>2!_",YP/_.M*K20R%ZAG9OYF<T3_)RRB,:,
MRF<;.;2D$ O;IU M\;"?5']3&>L[CJ_\SDS._D6,\EC0T5"VEY0:,A3EM.4(
MOZ6FE<*Q_'W3W9V%(T5X]V++5+["3G1?.T1 DJ9^.ZGY(OQW>=(BF+K7N_V(
M@W9%'2;$#X3MRSS?TD3C@"7ULR#36%,7.(R/T4TI7TG\4BV_B4+\3W+)5E)4
M=D")08:53[#8VSC@JLKO/XR>70:L?[3^H_4?K?\OMSIM[!31H#[ 6@<IH"#T
MKM6($O &'86][]Y\_',R[K?BG_+U/XCAMT5^O93? ]LX7NZ_3"E-S<^?>%!@
M&<$M8#8/SV?RG8.)@K/AD'ZK[D1.K%S0(50SIX8RBS9ZCB6OMTU-_7N2CH88
MC!/-*QFEF;Z4=@W]P)KZ0@8EKT8ZS?9Q7:,$1!*6>VYZ?/+![Y7?SU]H$AQ
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M%FC"X#][&7J6!E]OB2+Q>5L]-M;)*$DWE%N>;-S/^NOM'I<A8'A%_:K@VW>
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MD9)PWJ@@<4ZZN1<VU8=AMK=XQG(C*1)IE R9[_?N?GO3% _U]^$\?XL&PW!
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MVWY[1Y%RD?82$E*?8&N31HM^*__U)<:4)FGK15J,-+*[+54&<3OH;8,E556
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MJUP*&RMZE$4*]M_];6O1IR)0DM;;[+W?P;W9VZH9)I4I*_R#B#XNNZ)T1=F
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MFWVV+90;PH8EZYZ>6I!=P]3MZ^&NLS_>W35Y_FX\T\&K6UYF@M=7Y#+*A>,
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M&MU</\;'?EH26O$#H8I5IM_22[:"5S:'<<B@NWUFM(*+<DK+G"LS*T#2NCA
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MK^P-AVLI:/'C4HGOE1.)LP"8%KUUJ@1B(;ED8\K:-WOK"N] 8X?EC9%@11Q
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MJR[+2VX+2-ZB+9GL403Q9:RSI,$#*D4A@[MO@VM/6VG'M*B-DCHX>,<C=&.
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M9]:J>?#[HU21COA4;E@L3X677FXLSW6F4G7A\OSZQDBY:*ZG*2I\D<8&DW?
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MK[ \Z.?15YX*A[YZ19ZX)V$4)&9FVL7S/]D#2\\DNYQ8;XE6)7WH_WY-[6E
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MCK&<=.FGS*YJT#"GJ>E]C_<A]#RN,#@QG!)V$]>E<W+R1F1$>"<XF[,0Z/D
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MP,CP=Q "0GP?(F(R8F(R!BH**H;_[8+K!-"2$KP&=!(2< -NT!(0TA+@>@%
MO)[$!/\4P/\4@AMX'6^2D)*14^ %ZF@ -P@("6\0$?[5&M\:C&\'$-$2T]V1
M>'B3_IDU";<G@^3;Y"^D/(^JNA@-)A"\4C9>863D3,PLK&Q\_ *"=X6D963E
MY.\KJ#Y64]?0U-)^_L+0R/BEB:FMG;V#HY.SB[>/KY\_." P_%U$9%1T3&Q*
MZH>T](R/F5EY^5\+"HN^%7^OKJFMJV]H;&KN[NGMZQ\8_/%S<FIZ9G;NUSQ\
M;7UC<VM[9W=O'WER^N<,=8Z^N/QK%P& D.#?Y?_3+EJ\73>(B B)2/[:17##
M_Z\ +1'Q'8F;= ^?D5A[TG-+OB5E>)3\I:J+C$?* ,%HXS5!SL0KO<:'_&O:
M/Y;]_S,L[/_(LO_;L/]E%QQ 24B WSQ"6@ (<-F )2?Q7&<-801+]O0P,WNN
M[(?(3OI<\-1U-%:;K*>H&R6:'.$  1Q/WK!FO+_/\=:2?AV6!&("V18A@#UQ
MUUX#_8'?>9E-X_TO@Y>F=!E'KHI2W2 G)0H]M(3>/')#J?&ARB3K*Q@&U=7E
MU'5EXVZNVU:L+U=VY\8\WL!Y1ER>Q*3=UJ&,'O[T1X D_)<Q(0Y ?>,:IJ&K
ML5ZT4;8/PJ1:EGJ50M8+V"1KYFR93;.6'Z["$G  ^MJVP F9H29(T+HR<_^R
M2*V%)*F'*-]#CR)+'0^"&WIB+][GL<RD=0L#)-$N'8@!U !Z!@GJNKQ=I4*N
ML%RQGB/W.$G_BKA'S2Z#24YJA+&O,MNKUNL!('A55E.H[@&TZP'(<=&[&&((
M.F>?AE[PA^, Q(!K&.GM?2O&8-"FW#<<X$07=/@)BKG(6.1:AIWR%*.)KQYB
M]-%)5X\A"BIW9TMK+:C-$>7Y#' .A=?KRR>74_KIRUK<-BLM:>^X]<UN:Z1U
M\<J\ NOU=##60>$\&\R]HJ#><R-+3H1&C(RZJVN;$4J]/5992=I(RP8Z@4G8
MLAIF"2'E3# "(?2IYT^Q82!&$)7',QQ@,\L)!PA[BQU[AP,,ZJP786^= ;%:
M^5<"7*A\\4;E.M"V.#@5-8A>6VT1C^AY7H< -R&-PAW7&9MA3QOKZEJ#HAY(
M3_M]O'BN'N6MJ;HS;/4>H.OBLE(/ZW63ASQYXD3DI+"5#N,J=ONZ9+[7K!P_
ME])];BQ6'9!:S4TU\3J^A&.SF'$L"2W(?'B5*P.,[4 K3G=<\*=BN0BN5!*;
M,_JL,)Q_]U'OBN>>U<FZU9NV-KQ&Z U4'+IHPRH*2BMNZG9KHX>+JQ9QRK.7
MSI:0,%J@O(G:&8WHK?K!H+KMUJ89_'65<Z8"]#HI3D4*.9>H1/_%8M<MB&H@
MUN>;:.TUU^'*7O*O'D73%:6%88^V9!ORSYR'U%;I7W" J-"0L2*LC14C%.'_
MSX[9HX-0L]<?,7S$FPIL$.W).ZVM&?I-B6-&TSSTYC\7"M*JO(=:O/2\=:X$
M@$%!K,$]J&D<X*-_6(=+!7 WA,6# >H$!U<8<-T<#YFJT++_%IS^8WNZJ*$Q
M=WMN^ Y\Z:%DK4OIEMX=O^]GE] C9V1)/Q<0<0EV@XC,93P'Y\SURIGRK?_:
MK\]Z;72BZNE!]D$IQ#G]\47F6R'-735K&%J0^O *!W@H'OL9!_CUK[U]^*^#
MI^-XI;->C ,T+N?C #^D<8!J*>J+4_%&2_S1X\I'AJ]C*[P1. #*"=WT[0=T
MK8-JY+O)OJ508N_HA&F/M]TO^CS*6AUA@/\-@KX XTBHLQ4GFK2K[*4+H3ZB
M*!'+Z_+\EU:IR9*EU8^O&75AU)4++0/U/'=2T=7?_8EX9(K7<("%I%6-&%^G
MV@,JU?6WS9D6'[0J7+0;7X@%7&GD98T"$?IZ\\A.$-R*\::QDFM@$@[ .XG]
M,;"\W&_\!]M"O? <:^V+MT^@5U>@SXI1^L",D_YYG%IU4["@3H&> \K_;K&&
M,\?SWQ\O6E*>W_X1)T^R11)Y@ /4[_2OD*$]NIZ[^"W?BMPPBSTYOWKD:GS%
ML2W\A3+0$WQL<;M1D#*Q:W.A37VJ-JL/F7&4>B6*>3R^H(Y4Z^A-@&HYT]G:
M0TM<)!];L'O)JDS-:!)Q]6>O5BQ0HUZBO0NT"M!&4^MR4;5[ D%%=5-G;NK2
M 3#V36M4KDFEI)[Y<^S@0,>%][^\2"41??I==.R(%1')Z7>\H3%>IB2SKOQZ
MS&Y@N*%%Y^6&.#O 7^G-B*)@UWWVJCX([#-&=])7G-I\\1=&'>G6T%VFVC]+
M5>I\L@^/ORQ/^$IQ?X-N<<F;U\JY.8%C@)ZF@WLG1;ADNL,-.I]D/.L3;'H)
MBO'/*HP_T2FRU"UQ$17-'XR\SR8K=]]@4/N3+U'L#!X'@/-_DO%8*![;H7?4
MI@'#9!9<I^*7'B9Y%8Y?<=NA561#K_?:"I7&.I >?;PP )PWE<(HU$A9:%Q_
M'RM]4E/7_7E!ZCK!+>X"$V'CF6HQU[D2FZN@!T_JIW<:1R<-9+V+,O- JU><
MQ<6I)[D="I.O:+PIG!WGM5$E".>;B^PJ\T"#J0\OP=@I= GLBNJOFVM@E A1
MP:!3.O1WZ/&_83*^!PL9.F9N*,+T=<0!Z=WK]."!/Z=Z5/B0).^P?,[-Y@W&
ME\2H8D]/:W\H?V[(4#[\P7?1K=ZO2JDT (%(WM!VUS58M#$3WA5"Q):<<0 :
MC =3=/N-*=,-@[;V-M=:I'?90+8CNW9$OM@:XZ3H9ZI/H=X6. !&B0(%(4S0
M6/_\UW$*_CH.M*<3Y#CI?5V ?'$)[3UXMH$#\#M#[? _.\/M:U<NT.$W.  C
M5G2_G1^1$7K\9XP%W.3@$<4$0\1PTKD.PG& /F>_9%V&+QJ_O^HS2 ZEP5^>
MSK9W77_@SQWKAW%)OV.9>HVQ$XAY $\V7WRYH.O+EAA^/CKJ.?-5H V"/]#4
M>%]^,(;"HV(%ZA]7EFE!**(6KF'25LR<%%VFT/C/TZTFQ>$@U+LY^J_G7I4W
M':6TT7Z=0XEO +O$3ZI;?7A&A'3%'Q@6=]2&>&.G7^$ /9H071R@\GH.&V%A
M?!BT]IL:/340>!RU#J+<L[Q=D]0#SRVCMQRXDW*W[&AHH"YY;FOQIG%;(/4
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M KNN 0_G-EQ+V%W;O/4%>IB-L**MD:#J18H/N5H&??61AJSZJS7T[T9)^SS
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M&L$YS\ZJ]Z2D4<D[[HH:XO>('.WV(=18N*1G_ P(_7(L7(E6O0)";!%C?3C
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MB+%L1O)ZD#W]67+;4X"(X_@4R+N).1KCSZM#[/0$";O&@55N'6@1#XL2(7&
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M'&"Q*@ 'Z'V&?[3R%+^G>OTX /J)!0Z 9+B.QP$R3BC*=PK..(6'<0!G:QR
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MQ0&&D]4_1X($;3M XH24WI91E+FT#9H&HFS+@FN&FLG2XT0N7[HCNA& ='W
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M2#J .%&3\Z::"\88W1*,Z'A9;X^X/%"0=%(HK H2,8ZAZKY^_^"1>D4/'>^
M\N!]@J?^T#46Q)O6UA8NFCIFXX3F;>O\;P$+SN9-"^GRO':7657?]E189^]4
M1>( /1)6:J\2&+_Z*[Q,=IO(L!6QSM@B?F! 0D3ID_^T,\ _IL-51X_$A5E6
MH2+\]^S)G$ZJ?F/DZ.7=UDRC7XMQZL'?<VW5PNX-L$>JWR_QQDY3%.A\[RD'
MBYVKIH\=>3YRF/Z2(W8L"E^R>_OD833OTF.&(\7$!QQVE\3GD:T\WUV2BE?
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M] XZ7+RAA^$OAZ*S\%[5#=U^@2SZFVF!T74>VKFX&64-"Q1.2%V/J!5NUJ-
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M&A_: R1'.I(T54B,<2 ;\N GX-YXM]E'F%5FS.Q)P9X5-(:XG+V/\_)' (<
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MP24TVOCC^[LS\^;.NW/O>V_76?]4U:G/WG5.[;W6KOO?]ZL TE?*:LH C$<
M ,;# ;A? "@"@(\>_3,>#/-A8.%B86%B8N'CX&#C$N(3$A+@$Q 0$9.3$A&3
M$1,0D%*3DE%04E%1$9+0T%)3TI)34E'^\Q ,X,,<3"P\+"P\2B("(LK_SW;?
M!2##!>P #H$8K(!'9!A ,HS[/@#HP4\LC'\9X-\,X]&#C]@XN'CX! \WU),"
M'F$ @8\P@?]X_7#5_^$Z ),,B_RQD (VA<Y['%8(I7!PTC=<MA?5W52Z$T?L
M(A]<0_#PJ6EHZ>@Y.+FX>9Z(BHE+/).44GRII*RBJO9*[XV^@:&1L8FEE;6-
MK9V]@YN[AZ>7MX]OZ*>P\(C(J.CDE,^I:>E?OF;D?R\H+"HN*?U14UM7W]#8
MU-S2T]O7/P ;'!J>G)J>F9W[/8]80Z[_V=C<VM[911V?G)Z=7Z OK_Z)"P,
MQ/AW^U_&1?80UR-,3" FSC]Q83SR^N<&,DRLQT+8Y HZ..\A%*S"P;B4+Y*^
M57?CL8GH'E%]<)W IV877>- _1/:OR+[?Q=8R/^OR/XCL/\[+@2 $(CQL'A
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MQK'Z$YNB HJ/"J_QR"49K_'YWMLXXBR:;!*^]?15:X8(C&W.3V+1H[^W%-V
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M#6QOF[1X,[5\_%: IV[/1]7?W?:]-V77(#751TD;.H0"-\#R# NJAS)8DY9
MW6W.7MW [>;.E?'>3QZL@27I51>&XU5RH>4:/_K3.+D$@[^,RQ:AFXE;(4=_
MC1-Z QWN9JTT0WJ4XO_ -@6S'MNPX!&:O]-5[24;W)-G\H$[(._H[P$P>&R
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M.[-+7_7_D(__!M#]_/\%4$L#!!0    ( -%+;E;>?&]_@"H  $PL   7
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M&8/D?1E._(ZW [T2\G8N74[K7[$6<=PW],>Z29'./C"VH35FF%Y>L$_%^G@
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MK!KNQL0KW%FB%$,-)K[;^J:I#7:1*[57_;X8XI=K8Y.A+_/ZSAK!V,]X"6\
M59)MM)#C#&N+;64M5"&.4/C/(9-1S5*NT8&T_J_G%[/J_R(\8RH? ,[O?LD@
MA-SUS1OL@JZH%T[,T9 "]*&EM?.>HN32IS>[K8RT^E.Y.AI?2EJ6*QB0%0^
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ME\Y8)D@8K-4RS.>S:I" R%"L^CD5!('U"28!_67_,(#^TU Q[I;/>@6O7KB
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MMFO<WF7_,G';$5!15'P7;?\ZZ2W=4+EFEX3BB*Y(Q+]V'OZ?AGONHG6.2/D
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ME^%!]YNG5/Q\F#+4K2:6?G_N7Z^:2QZR6K^2=*;WRJH^;_:9&1HB @TVP6F
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MWDC<?"7XU;OF[!NR"JRZ1!;%'5IC,%[L/6%09TM4C#>1S4/C66#&V"B$?Z9
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M=7Q\8E_+2QFJM'$=3J@R4LD-4H@'&TTD1G"-N3_N&[JN_];/ZR#C8CXUZY=
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MWZW(Y9K9Z=2P1Y$'RFB!+5Z<1[U1R?(/L;H?/ PVN2'_QJ*.L]#DXH.#I:4
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M=;F>*'EUT$M<62[]07).#^?EA5=A.G_FLZ:V!6%IB=QY.WG%[NKSQ&+_<GS
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MT0C\V;&FG9HY5=?8.S8?4MUMT3!B(C\H<O$1 M(G\J$HG_T]%&5F=:FR8W
MZ'4&0?I:*I[W'&OD(:ZK'F;AUH+_8;>2+<8.KR'"\GO8$!L$%^F1$@]AW&XY
MX$MPA.9BUL &/A3_R;WT!DUEH+IBN'_QE1Z,VH;/S8WR=!GG&=0]2E"%6JJ!
M'^Z90WNBV)V$-O28%UJ:/'P2P%/M@\MZAW[1(Y'5YW93J0*3E5]6^;0_K_*A
MF9KOH0'-'$GB0C#?V<;IY>?&"?IY(V=A/7.:0;C70;G2Y'7Q0I%;9]5SANAM
MIQW#LF5.RMV%Y$(KE1KI*XO]8PQ,NORVV<T&T'?(1M+DY!:OA2U+P:P?9?LZ
MV+KLL&#V;AS)'D))M>(OLAQK;HQ&OE<[%&SR7L@V&-'("='T:-87PYR+&R:L
M1;6ZI[3]P0CXH"2P!%7-?&F_6X;"*GINVX?6=/N@SPGWQ-J4XZ0\,4NQCM9[
MV(K:^JL:-8:\_[BQASFB-6J69MY4\7:]%R)_]*RI?(@<N45]%%C&/_]1]:!K
M6JL9":MYZSECE>QD1>'*=6V2N0<D5ISSTJJMM7*/,"4E.PIT(^6X%$L<2-J3
M9R3,BQFGGC _BBB8N[LD8V]IM V<:A!W$-]U),;8:7&F">B8K%GP!$F9DTK^
M;OO @?\=\3#CWXJ'CK\0#\-EOH74,!CK)O1RA U>@50-<13\R'=TYT)7$C+N
M5X#$'B/54.%U7NQX7"AZ^$@D\.N65 'FV2]AM1WV!*1GVX^D1_DM0>Z9ON+W
MBL^2;K&PAD4=Y"_'LN?9\X]E%[HRN8S[P#&%PAU73M)6$D4K4N&XWVS2SK#W
M%LM9W9U1K)X^[RQX]$7!35'#^*C%YT1=WJ%_&L*&.0B'=SP2*(M3"<P<RF6R
MRCXHTISBA/Z<>*-\0$TR2J]WQEW0T6L^6?6W)RVR"R^BAV/2H=,^8G4J80\\
MS]>_#\\A2O$0I9@"";4JYM7R\:WU9ZF1H^/!N3/[?%0+X3SZ*W,DIG:B_3Q#
M=4WAU?K?&U4\^OTKWYDN:.K(S]>2V[U(T7O8)9[SY]FSJFB'-YN\)X4:(LQF
MF+EQ9_:W'4@XIGW(VU2CB9KG]+O65>$7\G+N=I,&*'48%*+UCSI)0=3%?<T^
M[C0Y!ZL:3Z2(4TQJS/W-FJ8Q!W,MGR>N7U 08?KR-#L=(T]\D/$:<L1,2WB@
M9V2SD1Q=&\N4 T+C?8S;X6%4$ YN )8F,O=V#SWD+WPIMO$YENXGCN63 ]&J
M&[@Q?T/=EE<!HX'D)Y1^29UB07CM#H>Y,*#G.&L,]WI^.A64H Z2W3H8S0BO
M)"SR[ZR,33-*<LZ5/6]GFO9WJ'IECU&4V WA2K<XUEYT&:B5B>.8*?8>N =T
M0MLF>H/9H2"<._%$[C4+$#G^WA#<[GMP9B'A@W7NR$T2G%]VD!Y%O'K8\%EN
M@ET3HV_;"KGF!>J96[,F 2C.;/JF)J%_4I.\Y[ X1X'RH?]*38(^\[,3G]6D
M7Z BGWZG[/N&BC/,--B(84;+^> O=/DC>^W)>T:KKJ=7D$HVY.<M"#%>7NY6
M4!K@X!:2P5(C[>3O^/G+B3@Y^:D[O >Z*NX;HH@G?X?ST@[Z:,8=_)ZRIVWO
M36JM\%L<I A6E7*MT >]Y-'W;^(9;R[>E_P7;=B/5W[5AGD.$G-2V E>E<@9
M&9!CM0>;H\)R_LLVS Z:<26T4^4(DH0&+II.#-2[I'^SDZ,^*#.R.1*3?6/7
M(U<)8BSMU/93]B]WN,Q9T*"\"U:>G@2Q<(M;1YTX/ K1+4'R5BH#;((5B2-G
M&"Y,/[B1EB!-$PI9SY"*.=DY5>CWP>PWO.$^E6,&T\&:2CT79)16-?6%$!)J
M/ZV!(RS' 6477 =H>QL,IH>+!@XT%80,/=E,J,2$W,WD;H2:>\C<B)T&*$W+
M?E>VV&_<_:J51.8F$/'WHQNG>W!WR/1='Z=UR+)02YH2-]KF@-!P^Y<]OF?H
M4]R]EA6NN!$;0+[:+.\X^ _YVWG1V5TT7 4TLP20Q(%GK44+\EH)5R_K$']2
MEN0YZ<4+V8?A(EJ",E=,N% $%6B?+3:HU3IQV!C"SQ"W^J9O2.CR=[*3/_&'
M&;M%<XCXHQ9N=\5@M?L,&K_D .Q SS*E]]Z_B\>5Y6J=V<"ET,^_SO=PQMZ2
M'#<X7[[JR5DS\?,NM:EW^9W8UXU<I'_;B:F#\N+))Y?V821@C_.62EB'RN,_
MH4D/*#]2=BD3Q6#,=87:L/PTZ@Z:#Q+ ;U]1@D1!_9B>_5YLL7M<-%<':FX"
M:7]W-&.\ZF>%9N(O* BU"]K12_P(AS, 9NUU"+8<J&(OF^+NP?$_\8%\#.R0
M9=F[@Q /E2"A;D\8O.:Q&21GI::S=]!0X&<_"4(ZT#,*.X%2\7%FA2LTX43J
M'_L9+VJ$KC4/D&>'#@<1+?IY9&/";=!8@J'QLTMT0_RA$83GG^-K7B_U9RC0
MYPN:L\=C(C\=CP$LY]U'KJE^##"%Y:?C,)K>5<,@T!6(H+J3,CX=AUD-VH6'
MD#2^P)B."E(%?UTV>"%?Z_IQU&UWWTL;PC98ZE1OG5J#/&20)+J$>9>'B)"F
M8:8>H2?292>-Z@I!:@#212._(ULT>5P:\C7;2PY^U=L$>*S"X5V@(?(\7K)
MEFG1[RA =V=F RMGPB7 RI)DUB;=L2=-18?G7,SGMT3)H"/J^Y<=D0^(%T%
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M.6WK-LB[S;]3NJ7]7J;,:W.=5,.'$5@))X*#YT.H1#^R(\6/C4GW$62X7I_
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M3B#!_.B_*/__"&7-!2(0\J5-.@6)%^%,6E&9/V(WSB(C MEP_XR_>]#L(*C
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MNJ4M]KGDS#E_P]-\2"5=D='68 \21]*8'L@Q*P*,><2&(RV#+L[C2.*G-EY
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M[J?9-7@>BLW,,94WFE_Q+7V55!5W](UXT8I0G8J:*'3XP)SP.Y<GVJDF$3F
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ME*UXW%#I9+]#5J1T;N7IM]#^Z^>H'TA:YT1>6DT6Y23-.0S2('+E5PHUWX@
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MSE+TBR9#'^S@[<:(CK3C)^6X7#3GZJ-AV!<7\->W1A8RE*_:Q-R9.,\/7XL
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M9>VKV^Q5B8TJC]_,*+8^$D41@8G694EGA,>ZI6@D[KH78BY0:=1N<E_W M3
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M;#4G6L0#'Z09C#R%Y5L;]:K/3//'4GY_M,3/ 6S0=<]'.%S"3H8/@-=$*8D
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M$3QQ4/<,+SL6#,(;I+2K_%_LO6=45,VV-MH*BA(%R1F)2I*<&E"19$N.$D5
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MG5D_E]L00_P%H.HIU[+[U[(B%;1$6#A*F J2<K/LLG\+D'YCK(H>U0W*9$G
MI^APF0'YRDC4\[,L#[\ =\U6#:@%+:-7-4^S0^ZO'P&Q3$4O[3B/%:SOVKG7
M9KPQ1M'X3ZRTIZZ<VQ1(G/F\Q\N=*O66SF_<-L<Y[X%^'&D\V5*OFRALC#D
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MY\S@ +M8W?VW]$0<(33R<9RB.$7LV[$6ZX!/O:Q!90Y3Z3]3:;%2TZ./*@>
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M@6;S;:[$F8./[=?!"APX!+A\,X(88MU]XCQTASM@3"- YHY/!O2&VB2E^P5
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MOU:8RBW9TFOR,H&"=AM:W[X:34: %TQUT$<QP\V%2GF;^RJ,JUV+6SLB71>
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ME'+Y6'6"HQP^=*3.QC,<38,08.%5B?0IP(7<4'KLCD;,S_YI\^H-DN%ZE.K
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M;<<Y0(TV0>I/P-FN2\U-W-AN))4[GX!X63)-@HH&$*> IU,)53@Q<_;$%E2
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M9+_.M*SW<PW.Y[J?I)LA4'N_D394XR#1%O7=@"K\1KKBK&-JMF&?)6$*)]F
M/*%'<,Q;2]956O65]E;IP2,GA#'^6#T:*JFLJQ;]5$PGC%ZVI,_'3UR5,X[:
MYM2,YI]:N="5]]RRA4_Q) IZ,["V,(N\[*F:'SD:W2..5*\?"46%%EB[JD$+
M+;(@7V2HE$<KV<0H*>X>]/@CH[?[ENS4C<=E+\X0; >TXM]V^4,5W2AL/QFL
MY3(U$$.E0<'//,F6+CF;*ETV+3Z,../W()Z8'OEH,34VU=9,?!Y3XI,K:LS
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M[PCI6$'<<.IV"J#13QSS#H:;=A;BLI]./GU,I9;IT[ ZIB([VV+P2A 56[#
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MM]K B'IY9_E&ELST0%>-V@.Z!*]>2=?C-&*U$"M350)MCOGMLY,VGNY(G9;
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M>(/[B?)24N2'23_N"A''D!,%12VDC3]!BY^O<P60=@)8.BIV.=W:&>!*0<M
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MF0&%(<W<8;OW=_S._<]:]]QF%FNZ^ZUZJYZGJKIJ5J-GT$L Q2,5=14 "QL
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MDM3/WD6&J5IDS.'^]B^A%41-Q*F+W]5?92)-8</3EX=S&W9#:,"JM)H.9^.
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MARZG?[8.%O7JU>"FXAJYH6O-CFTFU38B4_P H='VZ7Q[$$4UC+/GG0R"^5!
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M')VT[(SI#S$STDN'18;ZUN;Q +.;QK)5C"T94,5X'DIY'_?Y=_4/%$6HJX:
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MFY#6':;)^Z1JYT2B[YVD+.22Q.[M$.&[SO4YGH2$/T"]13Q :VII>K<*8CE
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M)2B +<Y@TIM+BKML=L%1R5HJ_77$#TG"6F6>A#O&'3'Q;_K.GS ,YFQD?PK
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MW*R%>\J$?[!52YL^LT4#W[.9GA;/;R4E\&HAFQ<PBNMZBQ),"*;^+P3Z/];
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MQ[;$&^X?=E?)4I*E:,!YT4E&;-H[ 6P\?L(KJ3U9.)X?4Z3>0LVCP*-*_5A
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MJ[A7L/LLD[ML";IB;Y3R'H011@$O;[T:;V]P1@.;A;EG*]<HZ\&1&_<AG.D
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M(DQ<HG1=^.?UN3;BDR]?;Q]6SUT4!77P*:NGV\._\N_KX)?S6!.B,RP H)S
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M[]Z7-]D6[*2(57Y8%YDR1%RI=[^J;9"&FG;5WJ7V('V1GI;AG)<WT5DY[Y+
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M6,<ZTF0E(,2B.;$W96JY\*1"R&SP3I!TH,X7VIGAV)E;GN X:YYH:F\#0RQ
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MD<_!$GQ7*Z_YX?$4S#NOF5':+3YO8%E2#Y3TD>E(N]A875=3':8?UBYZQ&A
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M:9%1 H74[71@>4C+E7V6=&H/NDXL0%[!Q%3!#B 3MK7QFE9FINL?4ZNX+VV
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M;/A/C,YH\H-^D4;]%W(9I *<K>D[(E^P0"UDC]/X3RJ5U@OP"[^P)'\GKT.
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MB!A>?"PP.'4G [Y-TN,)'^P(FR]VOEUO>FD^85BD/?-N"62L4EUO"N=V!"9
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M7B(Z^1UDZ%[3=NO$"\PT%B!WQ%S$?%*2K(K\/F.VYK9D5*'#>X:K4LE2[<I
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M7>__2==;SS*H1C(3UWR[MK?4XV%MO[VYF ;IMK-<O4I_JK>L'^*IJ']PLF@
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M3&)4EC4#?L.JACY[D5NB=.BYL#.M\R!X/$EI] 7WX_%,@Y=KODG>F.!]0_N
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M>&B.!^Q -Q\)TMHJ$-LPX4!C!9$H%E_T$\]N>E^\LFN^C/F5YPSP\0O;6_P
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M1.["MMLLE8;'1 VJ/K!I69AD<X=V)F[:WIE4K)*H&,IQ)&'#@0</)DX,SUC
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M)FCQ_G4\?>)GHDS$J/M/)*.?V1PCV[T!"Q1= >1;[<U5R*8:/YWG8;-6="T
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MWY9-TIH7>'/&FBS/)7ORE][E/9<N5V8J3CBT[KFCRF-5EL@$_J2*V0/+Z.*
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M=C%&9=)S6.J>K<.JD!_L<<"P 8<5NI\D9PSVRW#Z[5#T!<+VOE#\INUP0'7
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M,FD\=!>Z?W )B 689!=!'6R6#J\T]!( 3<%9XQ$3\'7\#/X2((@=O?$_U/<
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MXV4X[8D,Q2]V?OYK.M*B@7PK*Z+SKA9QC]<]5^//WV&5#=&L(3G&"*S;2W1
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M-3$<80X#GOQB/'L2-;+-\J5MY0+F VK!#IIA;ZQ.HBD[9'-L)TP>64V^^33
MP%WD97]7N:'BJPP-BKPS@"**Q$S+1$M;]T:Y(-R;T"*A.$!G1%-DWS11D>=3
M:A*ET?4'3\A6>$*UBP& UP2(Y"C>CQM_:IG<NXN"-FIOD5=HL:S(8RW:NI05
MAK*>VKH0#[')T2T%$HFXZ7']/=;G;]]Q26SI5)J<[/3E:>3B).*Y46)+@1S)
M> -0];Z8:L50.R)*@":?2W^J,T;Q?L[#ETD, _6K6;,5[5 *&2/!R-HT#1N/
M1H?Q:?4,P>ZFS'16C@'=APXNC.EO,2-BDS@YK$LVY-&8Y?B501.L')0VKL?D
M5W@5J;<4%W77O^A'.H?\OE/#_$%8E8U%]I]T1U@_P3M3DN)M;(>>$@,IN;:R
MBU9VH,S+;F!E0<<"5'':?1^K4#,D6ZN5JCY(_]ZM$X?\Z@AIH1J3?SD:S/MK
M2'UYO<_IIY=!PQ2>V71H->M:\V>KB>X[CW0O ?G36ZZYY*=V%+N)-2YF.9-@
M!QD3%1/U1:T<R74EX2EK'"Q:AN42<.,9ZNHW3*  +1=>O)%YKRXF:^?\+1V%
M<0.>_M=RT8C),L&6W0SHG1EBNPM:T[F5?.:9X9%M>^9LP%G9'/]V@8J96(F^
M?^3Z:PN88=]%R27 XH)P->N]TYX["[?Z>(MG:;5"L4^ :@/;(7-ISMJ\Q. U
MA3[;4S!R'4=YWG?2Y#Z#6(_F:[E7S+X;C)ABW/SL5ZT2]]4_<&$_:D>[0S?_
M=X#RR1QN+"3Y/I7:?/^%9$4JR#X6]'Q4-%:Z!YPRS6A/45F?/J\6+Y.[7#ZJ
M^5;6FT%B_8L$J@+KZ05+^^44O=0LJYSH#-5ZW&*%2;H(;W%#&<E/'$<<^U6P
MVHRK#+ABDEW7!AH0P\U9OQW3&GZ]/J9&'3TH+DDN6\KAJE6+(T/AM.JA;YUH
M-\MRYSMH=NB$;!-(RO*#M=&5.L&-+$QS<S1'90$JD'L7GT'6=D[A12O[),;&
MUH^5]#+Y!59V=_<X;E&?;M\NGV?M_J"Y^*E#+N5KP 2P-B5H=W%=#_4%G13:
M."<:KF: (7\Q;>F)7@A[.--1G.A:((HW5X-SO$@W.%-5#+# /;D$!&=[;VN/
M.^R( F_-8M4-HYX("C@:+R3"D"H+=%9MNWV;9GKX@:7:MDCT7(>>T'9J>6*^
M-Y+E:\/X^T[N+!:.2/K?(=>$B9S=C#V<=3>Z,M6?9M-'N:7P&1R94.L1M:XN
MD6%-SV[+@O5K*INR]A3Y/MG[9NW!W(*,'XIG2S&INP5$#<'17$EY7^Q:U:;G
M*1I(N+15, P#Y:!N.+"%$'F;JWFJ1=G!TK&%@8LT.DM>!9!EKDNO9G1/DK-9
M]E84KF4:NEP@)QV^TMJ#S[ S%P]::;1>&>>HO\TQC8P@L_R=_$1R>9>XLKSM
M$H"_I8MFZ@-S32"7.C<RP=)W?W!/FFW7<<80'O>S'F^TU-\MRSX?UHW./<O*
M3LHR7^'GU6UMKJZ:W-D7Y&=RZ&EM[93YD*6L[5JP;9;INQ0%=X S6M<?EL<_
MCLR_R$!8[^Z6.N0>8-)#*1,%7-(=UB=23\$8WWKL5P^TZ:)@Z(%)SZIP(F1C
MK)"DYC33)N57W_DEH"?&+6J<P4OT[8)B008>WZU.\RXA>N9L]*(W&RZCU0V=
M<VH'/BY"AJ&9;8:),NR\&J!S.42@X=2_YOP8%2/R$SN"--2W8S6ZF3:4.:#W
MW*6)0>=3S*J$LQVP4#<%A4C)$3W[0=>=>JR\$4ISNG N= GH4*Q=HL"I2(%Z
M;N_>[WL")WT]^>S)+-\OYN)J*R;RY_5LJZD7)-\F^3V,'CCQE9NWU'Q^VB/;
M$K0:K_6D5()]'BP&D7TNT_@NUF8J5M<[^4'^(,]3)E7V4I="OA]] (+)1!U#
M,R.SN<C=\OL-@4?)W*0%:&:P4*4LQ.'<)0 AE=+!\E0=51_DZ+[9HBQ<<Q;;
M75P/?/,\,'YGF+#^AXIY.V!UC:@*;C,R)PZ>;E&1HX7<I;0SY6G^B#"QG:8X
MS:8:2R"<<%YWAWL )"09&.3HKO37:#.U(!BW3^_=_.(2\'YQM_MPP2 I>9'2
MY\'3V'&A$0%]MU'?L\D'$SFV#1F9@\<!RC1JB47>.N=#9D%+J)=:)':,-V)3
MNG,;QF3DRWX/%1H8?.;+9<FZ]6-+RYD:IJ6 H0MI<4/N1QB*^M:'U9;PNVDF
MYO7$;-\/V?AY7O!S.0JM11;0D45\! N?QM--RHC3-O(0V8BE92TLJ:P7'5H@
MVLD&T\D#W)8#1"X"6Z H-\.4'N UB(UW(O?019*;1# R</UU8D0^<*>?VM]&
M34)M/&#H "X+7[[FL9GWHV*S\8Q$,> I!'Q1!;?6D#:K&6M1*)[W!H'''W'5
MUM08664TA7]D#N_O([RIK&#:G WM4&OCW#X3BXV+1'7R6QC=+5;UHL]$6CD_
M,GY*^9!!9EFHKXQRT(XCMQ3_NM)]SF;^@KDB1>XQM$,>0H,R6K'S?KRN.NE1
M5,9 ]Z*YZBV)K3X1XDO6XJ/K;]^^1E^Y:E9$_>Y7]/*GY:K$=D;C%B$*KH]4
M<@>TC9> -KM0- A');[RNQ=N\W#ZR-]G?^D'?/)WRP=18:K#ZM/H-BWC0-4C
MFCQF_IOJ%]EV8\*V>D6<YX75LP%7*6Z'.MOD/I4\%H2T6Z*V W,/ANUA9C&T
MH,/A!9#/O;/=,PIC^%6F;P&, =;D5Q)'!DAX5^VK5/*WR7(:F")?70)N/8,W
MU0.#G'1'Q##@#J= / 46B(SFEY8?*W78'U]@;YY<#;P=70]PM/J ZZ9*('(6
M,8W5;WGUX+S!>FYHZQ*PS,@CG%EK@FL"WL.^Q),4H$XZH93NEP#*GE+;F2;+
M]P-N9+%>OYL^:P>+]P/X&AGF@C93SPZB>*/*;)-2/5AVG&ZY%*!*;OQ#Y0N8
M:7D_9I$6/5PMD)*WJ#(3=?N^!H4"3UP>R?:1A-Q4:DRJ W^4J^IL=4-V%(_:
MK8-+0%P;+S8>62:N#D..A ![Q+U<FQ:-<Z<;*V/(Z!5=/!PYWG$3DH?VJLB2
M%^K(LQ*>BV%Y3N31P"B/# OD)2 2(EAA.TB=TM3;"LUK,OO&'ZKN+_<N]M;Z
MOC 16Z!)?T7 ?X!\PY-<6P"UMY[!L-HI8$I\V [!Q8XO&H'/U\K'E-H#>+V;
M,<[8'!2PAQ(; D:%?15(^F*F['Z65[5?YVY  #ZDDU9H_W4@,GPGH!!WXR(/
M1W.NL"&T8,WXWMEV@-ZNE?)W>U.=+-YLU0PSP[[A7?&RL2X,LVCD%Y'@S?DB
M0?%^&/C%(P7B0O9:B#DZ#4\"S[,]&\2F($T;N8..IYPD^:(;:BD]?KARCY C
M&WP)3+O1HNA()7C3])##H3*IC5I(JRS88E>-]_ #?A18,[/S99"N&TI>'],B
M0D%RD>,*:5=R%O*Y*ZT*.IQ5!ZH=@V:M,!=IJ_7=!:BP9N2@ Z5=C8_[Z<ZZ
M#0%"V,*Y*S$FHXLP+FE$AD:_9_BQB\E+T;C[=PI;@9\QBM0ZIC[_P] \-&N7
M@!JG;KN1]_#K,F8K0[(ZM7>D1CSJ/P=G@SUB28@+29=7VX1,0_S]G?(-M'R\
M9#SKOK&K\QT^>A4+&'C''0A8%SM%HJEZ,N]?V;\0W!M8.YXLU8\\U)=ZQ6[W
M>7"1' FK"W$)ZS-KGU^5A.F>YH7GJF[J2$/X]H_.TE-VR^:?@Q>AEP#;_0B\
M,':=/ RB4V'B#7L^??_S=Y,;7 C%%QT?@@XJKCLPN_(>%;<8+:?L1**VEVFK
MW4JPMKU[)H;>N*PZ6SHBJUAR785 @,1ZS/E,S43/5)Y>@1CG6YZ[Z?=LFO_"
MP8S8^*]2/OS9T/MW$4.HZM[*;;T(S5A(S[M(N:W$ >. ''2%>3'C6K3="HN
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MA;BF>15$%QT!J[\'.+K="<S\O+">['O5NO J$]*TP6[QY74R*V;$]?#NT7S
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M?V9;B0"'TRG,LC+:ZF^>+$-LMU<;%)XB:SPEM1KMNN>;)%""ENI.@E9U?SQ
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M)\J0"83SO'NA;-#-_)IC9A1]&QJ#&8EN$)[0,;C]P3-,,:NKTO,@K.!8TU#
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M6SA=(U%5H1Q64)7==>/M,'9J-0V(#6V'[G#2@'1+&I"FMT8#8HI7$3L6930
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MI8K"QD25JJ6%M2U?O7MO0,.6FCHMN<.:HAR6%PZNKVUM$GDH14)@<'MYB/$
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M;*7X7W;-_<>N@\@V'^:/7_%AX3$C:E\-Z.YZ7;$/K,I!G)\V3L\EY50YL3P
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ME:J/LX_OWQ^<_MG0(+^<'MRI]FBEC[]&#0^+TANN.5+Y/ X6>RI!)&R-8Q"
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M'FY-IE_5[8[MM(6*A:[("VD6$E)I51RF"]V,>C,BH-WR>6*4.^BOE'0/JD0
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ML7P.'$H]I1/S\O9/ZH5!24=162##3&%Q =(EV$,8BZ(3DR@XB+F/ EQ!M)V
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MR\U4#/T\BC?K5OEJM%/+I#_/;:LB,>AXN_5<W:^),A^6O&Y#2]IJVFO$36_
M?W<82A48.7VHEU?O;54CZ,Y/XO32H+9I=R\SE^FK+7#U"__[:B7U-3KQEB7^
MJA<K(\CH^,J+[NXK0KHF/&$(\%H]:=S"AI-D2+=\LT;/+=&CK9 U;M:X6>-F
MC9LU;FZ F[7E]^UMX\X-6(S>K:W7KUV4O.CV!VM!_UBQLU;":]RL<;/&S1HW
M:]Q\"[CY%BUR Y D!?A[>SK(5!###GZ5\85$-.!N@B3?NN&6O-*1FQ>9_56X
M]F\%CW6!T;("HY?K J.6 J/GW1>#1H&1_G)=8'1O!497I4@;Q-L0,^.E"?Q;
MZ$[ZC4=U@L39*^=SF>&0D*L+<<:K2AP_/J@<O!\>OQV^%0?';\7I\&QT,((/
MV_WMOAC^_>/1Z$^$T/!X=/3[4'SX[>#X4<'*99QOH:Q [W@IME9--L_>G'P8
M'9T<B^'_#D\/C\Z&XMW)Z?L[)H$O*4GLB'\X94S_[(C [;1W&J]_5YE*<SP?
M( OFLH0K<N#U).R* QZP2T4*ISP9,=+TCDWU"[P*&]8N=/7$!CX.J6&[O[^R
MADNR;UWJ=HWL>2:W='L%K6NPOTFM_V:R8S4Z[YK&NXZ(4E,'XOULAY'8%GL'
MZDNF*W3$=_TN;'Z &,'.FA('^4VNP$1]J'>M"Q*/3,&2>?$/ ?_\L]Y5+\0P
M"6.:M8U;H(8CE8OO5MDZYA34W0Q?'9H\,<.V%G^,29'B,!Y_X &U7%XQSF(L
MJ2U)HRAJ'CNM 6H.7Q?O0)H W.Y>IOW5#I8;"EXT<TA _O0,S3UX"-GKUN!E
MLQ'P&@?S7.Z9/^I6F#9KT3S"IE!8;,W8*S+X-[*+\QT!,!"-7_NJ^^I[UX33
M=B=M]\?N<[UI^NL>;:WE-N3RQJ"EC4!WX?)5RV0NT2[?]?F>ATW[K&,MZSC8
M&C=KW-Q;C+)71#?2*[M@/ZU8L=P@..%3UQ=5=J^)[2$%P1I5:U2M4;5&U1I5
M:U2M4;5&U5]&U9=EO+^&./P7YN3N+,U/GD /PTP]BF"]N;/1,JO/,GY)&IXH
M]*Z3\(UE4=1Z'_@U*/3?7F8:'A=N_-C_7FRA%[59>X1M%E["XPY[8JJX?U<>
MV(T* 8P(<0#@X?95HRC@87CD%K4>JZIE<.L%_,(%[[LK"A?PU!Q3M]#O_OBJ
MK6ZA-TZC!?QO6LSB-_\/4$L#!!0    ( -%+;E;Q<C@^EP,   T-   7
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M42;+MAEV./O!<#;\,7 F6"H+>#*!HN6YO( T[NK6;5FD2 F<"#<^QWF58$B
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M,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ T4MN5KKP+ZBQ,   ')D# !0
M             ( !$'P  '1M8BTR,#(R,3(S,5]P<F4N>&UL4$L! A0#%
M  @ T4MN5I4T:*:,TP( \:L7 !0              ( !\ZP  '1M8BTR,#(R
M,3(S,7@Q,&LN:'1M4$L! A0#%     @ T4MN5M]WRH]9V@  'N8  !<
M         ( !L8 # '1M8BTR,#(R,3(S,7@Q,&LP,#$N:G!G4$L! A0#%
M  @ T4MN5K+$QL+<W0  ;^T  !<              ( !/UL$ '1M8BTR,#(R
M,3(S,7@Q,&LP,#(N:G!G4$L! A0#%     @ T4MN5FH^<8_S5P  @X<  !<
M             ( !4#D% '1M8BTR,#(R,3(S,7@Q,&LP,#,N:G!G4$L! A0#
M%     @ T4MN5K[NL72AK0  -M0  !<              ( !>)$% '1M8BTR
M,#(R,3(S,7@Q,&LP,#0N:G!G4$L! A0#%     @ T4MN5NXCDO/??@  &Z\
M !<              ( !3C\& '1M8BTR,#(R,3(S,7@Q,&LP,#4N:G!G4$L!
M A0#%     @ T4MN5LMR8Y,O:0  >6P  !<              ( !8KX& '1M
M8BTR,#(R,3(S,7@Q,&LP,#8N:G!G4$L! A0#%     @ T4MN5H@K5_^9+0
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M,3(N:G!G4$L! A0#%     @ T4MN5BD*A\?OB0  W<(  !<
M ( !#QX) '1M8BTR,#(R,3(S,7@Q,&LP,3,N:G!G4$L! A0#%     @ T4MN
M5I)#Y-/'IP  P\L  !<              ( !,Z@) '1M8BTR,#(R,3(S,7@Q
M,&LP,30N:G!G4$L! A0#%     @ T4MN5IT5ZWPM1@  "$T  !<
M     ( !+U * '1M8BTR,#(R,3(S,7@Q,&LP,34N:G!G4$L! A0#%     @
MT4MN5JOK/ %V(@  \?$  !<              ( !D98* '1M8BTR,#(R,3(S
M,7AE>#$P9#8N:'1M4$L! A0#%     @ T4MN5O%R.#Z7 P  #0T  !<
M         ( !/+D* '1M8BTR,#(R,3(S,7AE>#(S9#$N:'1M4$L! A0#%
M  @ T4MN5O%K^WX,"0   #H  !<              ( !"+T* '1M8BTR,#(R
M,3(S,7AE>#,Q9#$N:'1M4$L! A0#%     @ T4MN5J_40I?_"   )SD  !<
M             ( !2<8* '1M8BTR,#(R,3(S,7AE>#,Q9#(N:'1M4$L! A0#
M%     @ T4MN5E.=.%.7!@  !R@  !4              ( !?<\* '1M8BTR
F,#(R,3(S,7AE>#,R+FAT;5!+!08     &0 9 *4&  !'U@H    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
